bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
beta - catenin is a Gene/protein/RNA, E - cadherin is a Gene/protein/RNA, alpha - catenin is a Individual_protein, beta - catenin is a Individual_protein, E - cadherin is a Individual_protein, E - cadherin is a Individual_protein, catenins is a Individual_protein	82_task1	Sentence: Analyses of beta-catenin or E-cadherin immunoprecipitates from BMMC lysate revealed that alpha-catenin, beta-catenin, and E-cadherin were co-precipitated, suggesting that E-cadherin and catenins form a complex in mast cells. Instructions: please typing these entity words according to sentence: beta - catenin, E - cadherin, alpha - catenin, beta - catenin, E - cadherin, E - cadherin, catenins Options: Gene/protein/RNA, Individual_protein	[ "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O" ]	Analyses of beta-catenin or E-cadherin immunoprecipitates from BMMC lysate revealed that alpha-catenin, beta-catenin, and E-cadherin were co-precipitated, suggesting that E-cadherin and catenins form a complex in mast cells.	[ "Analyses", "of", "beta", "-", "catenin", "or", "E", "-", "cadherin", "immunoprecipitates", "from", "BMMC", "lysate", "revealed", "that", "alpha", "-", "catenin", ",", "beta", "-", "catenin", ",", "and", "E", "-", "cadherin", "were", "co", "-", "precipitated", ",", "suggesting", "that", "E", "-", "cadherin", "and", "catenins", "form", "a", "complex", "in", "mast", "cells", "." ]	[ "Individual_protein", "Gene/protein/RNA" ]
beta - catenin, E - cadherin, alpha - catenin, beta - catenin, E - cadherin, E - cadherin, catenins	82_task2	Sentence: Analyses of beta-catenin or E-cadherin immunoprecipitates from BMMC lysate revealed that alpha-catenin, beta-catenin, and E-cadherin were co-precipitated, suggesting that E-cadherin and catenins form a complex in mast cells. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O" ]	Analyses of beta-catenin or E-cadherin immunoprecipitates from BMMC lysate revealed that alpha-catenin, beta-catenin, and E-cadherin were co-precipitated, suggesting that E-cadherin and catenins form a complex in mast cells.	[ "Analyses", "of", "beta", "-", "catenin", "or", "E", "-", "cadherin", "immunoprecipitates", "from", "BMMC", "lysate", "revealed", "that", "alpha", "-", "catenin", ",", "beta", "-", "catenin", ",", "and", "E", "-", "cadherin", "were", "co", "-", "precipitated", ",", "suggesting", "that", "E", "-", "cadherin", "and", "catenins", "form", "a", "complex", "in", "mast", "cells", "." ]	[ "Individual_protein", "Gene/protein/RNA" ]
Wnt signaling is a process, Brg is a protein, Myc is a protein, Brg is a protein, Myc promoter is a DNA, Wnt signaling is a process	1.0alpha7.train.811_task0	Sentence: A prediction from the hypothesis that Wnt signaling might use Brg to activate Myc is that Brg binds the Myc promoter, a direct target of Wnt signaling (He et al., 1998). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: process, DNA, protein	[ "O", "O", "O", "O", "O", "O", "B-process", "I-process", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "B-DNA", "I-DNA", "O", "O", "O", "O", "O", "B-process", "I-process", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A prediction from the hypothesis that Wnt signaling might use Brg to activate Myc is that Brg binds the Myc promoter, a direct target of Wnt signaling (He et al., 1998).	[ "A", "prediction", "from", "the", "hypothesis", "that", "Wnt", "signaling", "might", "use", "Brg", "to", "activate", "Myc", "is", "that", "Brg", "binds", "the", "Myc", "promoter", ",", "a", "direct", "target", "of", "Wnt", "signaling", "(", "He", "et", "al", ".", ",", "1998", ")", "." ]	[ "process", "DNA", "protein", "protein-family" ]
Wnt signaling is a process, Brg is a protein, Myc is a protein, Brg is a protein, Myc promoter is a DNA, Wnt signaling is a process	1.0alpha7.train.811_task1	Sentence: A prediction from the hypothesis that Wnt signaling might use Brg to activate Myc is that Brg binds the Myc promoter, a direct target of Wnt signaling (He et al., 1998). Instructions: please typing these entity words according to sentence: Wnt signaling, Brg, Myc, Brg, Myc promoter, Wnt signaling Options: process, DNA, protein	[ "O", "O", "O", "O", "O", "O", "B-process", "I-process", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "B-DNA", "I-DNA", "O", "O", "O", "O", "O", "B-process", "I-process", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A prediction from the hypothesis that Wnt signaling might use Brg to activate Myc is that Brg binds the Myc promoter, a direct target of Wnt signaling (He et al., 1998).	[ "A", "prediction", "from", "the", "hypothesis", "that", "Wnt", "signaling", "might", "use", "Brg", "to", "activate", "Myc", "is", "that", "Brg", "binds", "the", "Myc", "promoter", ",", "a", "direct", "target", "of", "Wnt", "signaling", "(", "He", "et", "al", ".", ",", "1998", ")", "." ]	[ "process", "DNA", "protein", "protein-family" ]
Wnt signaling, Brg, Myc, Brg, Myc promoter, Wnt signaling	1.0alpha7.train.811_task2	Sentence: A prediction from the hypothesis that Wnt signaling might use Brg to activate Myc is that Brg binds the Myc promoter, a direct target of Wnt signaling (He et al., 1998). Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-process", "I-process", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "B-DNA", "I-DNA", "O", "O", "O", "O", "O", "B-process", "I-process", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A prediction from the hypothesis that Wnt signaling might use Brg to activate Myc is that Brg binds the Myc promoter, a direct target of Wnt signaling (He et al., 1998).	[ "A", "prediction", "from", "the", "hypothesis", "that", "Wnt", "signaling", "might", "use", "Brg", "to", "activate", "Myc", "is", "that", "Brg", "binds", "the", "Myc", "promoter", ",", "a", "direct", "target", "of", "Wnt", "signaling", "(", "He", "et", "al", ".", ",", "1998", ")", "." ]	[ "process", "DNA", "protein", "protein-family" ]
hypophosphataemic rickets is an umlsterm, familial hypophosphataemias is an umlsterm, diseases is an umlsterm, pathogenesis is an umlsterm, disorder is an umlsterm, care is an umlsterm, patients is an umlsterm, rickets is an umlsterm, hypophosphataemias is an umlsterm, pathophysiology is an umlsterm, diagnosis is an umlsterm, therapeutic is an umlsterm, forms is an umlsterm, hypophosphatemic rickets is an umlsterm	MonatsschriftKinderheilkunde.01480564.eng.abstr_task0	Sentence: Hereditary hypophosphataemic rickets ( familial hypophosphataemias ) form a group of different diseases . Much progress has been made over the last few years in understanding the pathogenesis of the disorder but good medical care of these patients is still a challenge for paediatric nephrologists or endocrinologists . Because X-linked dominant hypophosphataemic ( XLHR ) rickets is the commonest form of inherited hypophosphataemias , it will be described in detail . New aspects of pathophysiology , diagnosis and therapeutic approach will be reviewed . The clinical , biochemical and molecular features of other forms of hypophosphatemic rickets will be described . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]	Hereditary hypophosphataemic rickets ( familial hypophosphataemias ) form a group of different diseases . Much progress has been made over the last few years in understanding the pathogenesis of the disorder but good medical care of these patients is still a challenge for paediatric nephrologists or endocrinologists . Because X-linked dominant hypophosphataemic ( XLHR ) rickets is the commonest form of inherited hypophosphataemias , it will be described in detail . New aspects of pathophysiology , diagnosis and therapeutic approach will be reviewed . The clinical , biochemical and molecular features of other forms of hypophosphatemic rickets will be described .	[ "Hereditary", "hypophosphataemic", "rickets", "(", "familial", "hypophosphataemias", ")", "form", "a", "group", "of", "different", "diseases", ".", "Much", "progress", "has", "been", "made", "over", "the", "last", "few", "years", "in", "understanding", "the", "pathogenesis", "of", "the", "disorder", "but", "good", "medical", "care", "of", "these", "patients", "is", "still", "a", "challenge", "for", "paediatric", "nephrologists", "or", "endocrinologists", ".", "Because", "X", "-", "linked", "dominant", "hypophosphataemic", "(", "XLHR", ")", "rickets", "is", "the", "commonest", "form", "of", "inherited", "hypophosphataemias", ",", "it", "will", "be", "described", "in", "detail", ".", "New", "aspects", "of", "pathophysiology", ",", "diagnosis", "and", "therapeutic", "approach", "will", "be", "reviewed", ".", "The", "clinical", ",", "biochemical", "and", "molecular", "features", "of", "other", "forms", "of", "hypophosphatemic", "rickets", "will", "be", "described", "." ]	[ "umlsterm" ]
hypophosphataemic rickets is an umlsterm, familial hypophosphataemias is an umlsterm, diseases is an umlsterm, pathogenesis is an umlsterm, disorder is an umlsterm, care is an umlsterm, patients is an umlsterm, rickets is an umlsterm, hypophosphataemias is an umlsterm, pathophysiology is an umlsterm, diagnosis is an umlsterm, therapeutic is an umlsterm, forms is an umlsterm, hypophosphatemic rickets is an umlsterm	MonatsschriftKinderheilkunde.01480564.eng.abstr_task1	Sentence: Hereditary hypophosphataemic rickets ( familial hypophosphataemias ) form a group of different diseases . Much progress has been made over the last few years in understanding the pathogenesis of the disorder but good medical care of these patients is still a challenge for paediatric nephrologists or endocrinologists . Because X-linked dominant hypophosphataemic ( XLHR ) rickets is the commonest form of inherited hypophosphataemias , it will be described in detail . New aspects of pathophysiology , diagnosis and therapeutic approach will be reviewed . The clinical , biochemical and molecular features of other forms of hypophosphatemic rickets will be described . Instructions: please typing these entity words according to sentence: hypophosphataemic rickets, familial hypophosphataemias, diseases, pathogenesis, disorder, care, patients, rickets, hypophosphataemias, pathophysiology, diagnosis, therapeutic, forms, hypophosphatemic rickets Options: umlsterm	[ "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]	Hereditary hypophosphataemic rickets ( familial hypophosphataemias ) form a group of different diseases . Much progress has been made over the last few years in understanding the pathogenesis of the disorder but good medical care of these patients is still a challenge for paediatric nephrologists or endocrinologists . Because X-linked dominant hypophosphataemic ( XLHR ) rickets is the commonest form of inherited hypophosphataemias , it will be described in detail . New aspects of pathophysiology , diagnosis and therapeutic approach will be reviewed . The clinical , biochemical and molecular features of other forms of hypophosphatemic rickets will be described .	[ "Hereditary", "hypophosphataemic", "rickets", "(", "familial", "hypophosphataemias", ")", "form", "a", "group", "of", "different", "diseases", ".", "Much", "progress", "has", "been", "made", "over", "the", "last", "few", "years", "in", "understanding", "the", "pathogenesis", "of", "the", "disorder", "but", "good", "medical", "care", "of", "these", "patients", "is", "still", "a", "challenge", "for", "paediatric", "nephrologists", "or", "endocrinologists", ".", "Because", "X", "-", "linked", "dominant", "hypophosphataemic", "(", "XLHR", ")", "rickets", "is", "the", "commonest", "form", "of", "inherited", "hypophosphataemias", ",", "it", "will", "be", "described", "in", "detail", ".", "New", "aspects", "of", "pathophysiology", ",", "diagnosis", "and", "therapeutic", "approach", "will", "be", "reviewed", ".", "The", "clinical", ",", "biochemical", "and", "molecular", "features", "of", "other", "forms", "of", "hypophosphatemic", "rickets", "will", "be", "described", "." ]	[ "umlsterm" ]
hypophosphataemic rickets, familial hypophosphataemias, diseases, pathogenesis, disorder, care, patients, rickets, hypophosphataemias, pathophysiology, diagnosis, therapeutic, forms, hypophosphatemic rickets	MonatsschriftKinderheilkunde.01480564.eng.abstr_task2	Sentence: Hereditary hypophosphataemic rickets ( familial hypophosphataemias ) form a group of different diseases . Much progress has been made over the last few years in understanding the pathogenesis of the disorder but good medical care of these patients is still a challenge for paediatric nephrologists or endocrinologists . Because X-linked dominant hypophosphataemic ( XLHR ) rickets is the commonest form of inherited hypophosphataemias , it will be described in detail . New aspects of pathophysiology , diagnosis and therapeutic approach will be reviewed . The clinical , biochemical and molecular features of other forms of hypophosphatemic rickets will be described . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]	Hereditary hypophosphataemic rickets ( familial hypophosphataemias ) form a group of different diseases . Much progress has been made over the last few years in understanding the pathogenesis of the disorder but good medical care of these patients is still a challenge for paediatric nephrologists or endocrinologists . Because X-linked dominant hypophosphataemic ( XLHR ) rickets is the commonest form of inherited hypophosphataemias , it will be described in detail . New aspects of pathophysiology , diagnosis and therapeutic approach will be reviewed . The clinical , biochemical and molecular features of other forms of hypophosphatemic rickets will be described .	[ "Hereditary", "hypophosphataemic", "rickets", "(", "familial", "hypophosphataemias", ")", "form", "a", "group", "of", "different", "diseases", ".", "Much", "progress", "has", "been", "made", "over", "the", "last", "few", "years", "in", "understanding", "the", "pathogenesis", "of", "the", "disorder", "but", "good", "medical", "care", "of", "these", "patients", "is", "still", "a", "challenge", "for", "paediatric", "nephrologists", "or", "endocrinologists", ".", "Because", "X", "-", "linked", "dominant", "hypophosphataemic", "(", "XLHR", ")", "rickets", "is", "the", "commonest", "form", "of", "inherited", "hypophosphataemias", ",", "it", "will", "be", "described", "in", "detail", ".", "New", "aspects", "of", "pathophysiology", ",", "diagnosis", "and", "therapeutic", "approach", "will", "be", "reviewed", ".", "The", "clinical", ",", "biochemical", "and", "molecular", "features", "of", "other", "forms", "of", "hypophosphatemic", "rickets", "will", "be", "described", "." ]	[ "umlsterm" ]
child is a Person, temperature is a Measurement, > 39.0 ◦ C is a Value, severe is a Qualifier, acute illness is a Condition, as defined by the examining nurse is a Qualifier, child is a Person, mid upper arm circumference is a Measurement, < 110 mm is a Value, is older than 6 months is a Value, child is a Person, severe allergic reaction is a Condition, after previous vaccination , drug or food is a Temporal, RECAMP - MV trial is a Observation, enrolled in RECAMP - OPV is a Observation	NCT03460002_exc_task0	Sentence: the child has temperature > 39.0◦C or a severe acute illness as defined by the examining nurse the child has as a mid upper arm circumference < 110 mm and is older than 6 months (most feasible local indicator of AIDS and chronic immunosuppressive disease) the child has experienced a severe allergic reaction after previous vaccination, drug or food. the child is enrolled in an ongoing study of Bacillus Calmette Guerin vaccine and is < 2 months old For the RECAMP-MV trial: the child is enrolled in RECAMP-OPV Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Value, Person, Observation, Measurement	[ "O", "B-Person", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "B-Person", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Person", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O" ]	the child has temperature > 39.0◦C or a severe acute illness as defined by the examining nurse the child has as a mid upper arm circumference < 110 mm and is older than 6 months (most feasible local indicator of AIDS and chronic immunosuppressive disease) the child has experienced a severe allergic reaction after previous vaccination, drug or food. the child is enrolled in an ongoing study of Bacillus Calmette Guerin vaccine and is < 2 months old For the RECAMP-MV trial: the child is enrolled in RECAMP-OPV	[ "the", "child", "has", "temperature", ">", "39.0", "◦", "C", "or", "a", "severe", "acute", "illness", "as", "defined", "by", "the", "examining", "nurse", "\n", "the", "child", "has", "as", "a", "mid", "upper", "arm", "circumference", "<", "110", "mm", "and", "is", "older", "than", "6", "months", "(", "most", "feasible", "local", "indicator", "of", "AIDS", "and", "chronic", "immunosuppressive", "disease", ")", "\n", "the", "child", "has", "experienced", "a", "severe", "allergic", "reaction", "after", "previous", "vaccination", ",", "drug", "or", "food", ".", "\n", "the", "child", "is", "enrolled", "in", "an", "ongoing", "study", "of", "Bacillus", "Calmette", "Guerin", "vaccine", "and", "is", "<", "2", "months", "old", "\n", "For", "the", "RECAMP", "-", "MV", "trial", ":", "the", "child", "is", "enrolled", "in", "RECAMP", "-", "OPV", "\n" ]	[ "Temporal", "Reference_point", "Qualifier", "Measurement", "Scope", "Condition", "Value", "Observation", "Procedure", "Person" ]
child is a Person, temperature is a Measurement, > 39.0 ◦ C is a Value, severe is a Qualifier, acute illness is a Condition, as defined by the examining nurse is a Qualifier, child is a Person, mid upper arm circumference is a Measurement, < 110 mm is a Value, is older than 6 months is a Value, child is a Person, severe allergic reaction is a Condition, after previous vaccination , drug or food is a Temporal, RECAMP - MV trial is a Observation, enrolled in RECAMP - OPV is a Observation	NCT03460002_exc_task1	Sentence: the child has temperature > 39.0◦C or a severe acute illness as defined by the examining nurse the child has as a mid upper arm circumference < 110 mm and is older than 6 months (most feasible local indicator of AIDS and chronic immunosuppressive disease) the child has experienced a severe allergic reaction after previous vaccination, drug or food. the child is enrolled in an ongoing study of Bacillus Calmette Guerin vaccine and is < 2 months old For the RECAMP-MV trial: the child is enrolled in RECAMP-OPV Instructions: please typing these entity words according to sentence: child, temperature, > 39.0 ◦ C, severe, acute illness, as defined by the examining nurse, child, mid upper arm circumference, < 110 mm, is older than 6 months, child, severe allergic reaction, after previous vaccination , drug or food, RECAMP - MV trial, enrolled in RECAMP - OPV Options: Temporal, Condition, Qualifier, Value, Person, Observation, Measurement	[ "O", "B-Person", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "B-Person", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Person", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O" ]	the child has temperature > 39.0◦C or a severe acute illness as defined by the examining nurse the child has as a mid upper arm circumference < 110 mm and is older than 6 months (most feasible local indicator of AIDS and chronic immunosuppressive disease) the child has experienced a severe allergic reaction after previous vaccination, drug or food. the child is enrolled in an ongoing study of Bacillus Calmette Guerin vaccine and is < 2 months old For the RECAMP-MV trial: the child is enrolled in RECAMP-OPV	[ "the", "child", "has", "temperature", ">", "39.0", "◦", "C", "or", "a", "severe", "acute", "illness", "as", "defined", "by", "the", "examining", "nurse", "\n", "the", "child", "has", "as", "a", "mid", "upper", "arm", "circumference", "<", "110", "mm", "and", "is", "older", "than", "6", "months", "(", "most", "feasible", "local", "indicator", "of", "AIDS", "and", "chronic", "immunosuppressive", "disease", ")", "\n", "the", "child", "has", "experienced", "a", "severe", "allergic", "reaction", "after", "previous", "vaccination", ",", "drug", "or", "food", ".", "\n", "the", "child", "is", "enrolled", "in", "an", "ongoing", "study", "of", "Bacillus", "Calmette", "Guerin", "vaccine", "and", "is", "<", "2", "months", "old", "\n", "For", "the", "RECAMP", "-", "MV", "trial", ":", "the", "child", "is", "enrolled", "in", "RECAMP", "-", "OPV", "\n" ]	[ "Temporal", "Reference_point", "Qualifier", "Measurement", "Scope", "Condition", "Value", "Observation", "Procedure", "Person" ]
child, temperature, > 39.0 ◦ C, severe, acute illness, as defined by the examining nurse, child, mid upper arm circumference, < 110 mm, is older than 6 months, child, severe allergic reaction, after previous vaccination , drug or food, RECAMP - MV trial, enrolled in RECAMP - OPV	NCT03460002_exc_task2	Sentence: the child has temperature > 39.0◦C or a severe acute illness as defined by the examining nurse the child has as a mid upper arm circumference < 110 mm and is older than 6 months (most feasible local indicator of AIDS and chronic immunosuppressive disease) the child has experienced a severe allergic reaction after previous vaccination, drug or food. the child is enrolled in an ongoing study of Bacillus Calmette Guerin vaccine and is < 2 months old For the RECAMP-MV trial: the child is enrolled in RECAMP-OPV Instructions: please extract entity words from the input sentence	[ "O", "B-Person", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "B-Person", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Person", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O" ]	the child has temperature > 39.0◦C or a severe acute illness as defined by the examining nurse the child has as a mid upper arm circumference < 110 mm and is older than 6 months (most feasible local indicator of AIDS and chronic immunosuppressive disease) the child has experienced a severe allergic reaction after previous vaccination, drug or food. the child is enrolled in an ongoing study of Bacillus Calmette Guerin vaccine and is < 2 months old For the RECAMP-MV trial: the child is enrolled in RECAMP-OPV	[ "the", "child", "has", "temperature", ">", "39.0", "◦", "C", "or", "a", "severe", "acute", "illness", "as", "defined", "by", "the", "examining", "nurse", "\n", "the", "child", "has", "as", "a", "mid", "upper", "arm", "circumference", "<", "110", "mm", "and", "is", "older", "than", "6", "months", "(", "most", "feasible", "local", "indicator", "of", "AIDS", "and", "chronic", "immunosuppressive", "disease", ")", "\n", "the", "child", "has", "experienced", "a", "severe", "allergic", "reaction", "after", "previous", "vaccination", ",", "drug", "or", "food", ".", "\n", "the", "child", "is", "enrolled", "in", "an", "ongoing", "study", "of", "Bacillus", "Calmette", "Guerin", "vaccine", "and", "is", "<", "2", "months", "old", "\n", "For", "the", "RECAMP", "-", "MV", "trial", ":", "the", "child", "is", "enrolled", "in", "RECAMP", "-", "OPV", "\n" ]	[ "Temporal", "Reference_point", "Qualifier", "Measurement", "Scope", "Condition", "Value", "Observation", "Procedure", "Person" ]
tumour necrosis factor - alpha is a Protein, tumour necrosis factor - alpha is a Protein, TNF - alpha is a Protein, TNF - alpha is a Protein, IkBalpha is a Protein, TNF - alpha is a Protein, TNF - alpha is a Protein	9224625_task0	Sentence: Role of ascorbate in the activation of NF-kappaB by tumour necrosis factor-alpha in T-cells. The first product of ascorbate oxidation, the ascorbate free radical (AFR), acts in biological systems mainly as an oxidant, and through its role in the plasma membrane redox system exerts different effects on the cell. We have investigated the role of ascorbate, AFR and dehydroascorbate (DHA) in the activation of the NF-kappaB transcription factor in Jurkat T-cells stimulated by tumour necrosis factor-alpha (TNF-alpha). Here we show, by electrophoretic mobility shift assays, that ascorbate increases the binding of NF-kappaB to DNA in TNF-alpha-stimulated Jurkat cells. The ability of ascorbate to enhance cytoplasmic inhibitory IkBalpha protein degradation correlates completely with its capacity to induce NF-kappaB binding to DNA and to potentiate NF-kappaB-mediated transactivation of the HIV-1 long terminal repeat promoter in TNF-alpha-stimulated Jurkat cells but not in cells stimulated with PMA plus ionomycin. AFR behaves like ascorbate, while DHA and ascorbate phosphate do not affect TNF-alpha-mediated NF-kappaB activation. These results provide new evidence for a possible relationship between the activation of the electron-transport system at the plasma membrane by ascorbate or its free radical and redox-dependent gene transcription in T-cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Role of ascorbate in the activation of NF-kappaB by tumour necrosis factor-alpha in T-cells. The first product of ascorbate oxidation, the ascorbate free radical (AFR), acts in biological systems mainly as an oxidant, and through its role in the plasma membrane redox system exerts different effects on the cell. We have investigated the role of ascorbate, AFR and dehydroascorbate (DHA) in the activation of the NF-kappaB transcription factor in Jurkat T-cells stimulated by tumour necrosis factor-alpha (TNF-alpha). Here we show, by electrophoretic mobility shift assays, that ascorbate increases the binding of NF-kappaB to DNA in TNF-alpha-stimulated Jurkat cells. The ability of ascorbate to enhance cytoplasmic inhibitory IkBalpha protein degradation correlates completely with its capacity to induce NF-kappaB binding to DNA and to potentiate NF-kappaB-mediated transactivation of the HIV-1 long terminal repeat promoter in TNF-alpha-stimulated Jurkat cells but not in cells stimulated with PMA plus ionomycin. AFR behaves like ascorbate, while DHA and ascorbate phosphate do not affect TNF-alpha-mediated NF-kappaB activation. These results provide new evidence for a possible relationship between the activation of the electron-transport system at the plasma membrane by ascorbate or its free radical and redox-dependent gene transcription in T-cells.	[ "Role", "of", "ascorbate", "in", "the", "activation", "of", "NF", "-", "kappaB", "by", "tumour", "necrosis", "factor", "-", "alpha", "in", "T", "-", "cells", ".", "\n", "The", "first", "product", "of", "ascorbate", "oxidation", ",", "the", "ascorbate", "free", "radical", "(", "AFR", ")", ",", "acts", "in", "biological", "systems", "mainly", "as", "an", "oxidant", ",", "and", "through", "its", "role", "in", "the", "plasma", "membrane", "redox", "system", "exerts", "different", "effects", "on", "the", "cell", ".", "We", "have", "investigated", "the", "role", "of", "ascorbate", ",", "AFR", "and", "dehydroascorbate", "(", "DHA", ")", "in", "the", "activation", "of", "the", "NF", "-", "kappaB", "transcription", "factor", "in", "Jurkat", "T", "-", "cells", "stimulated", "by", "tumour", "necrosis", "factor", "-", "alpha", "(", "TNF", "-", "alpha", ")", ".", "Here", "we", "show", ",", "by", "electrophoretic", "mobility", "shift", "assays", ",", "that", "ascorbate", "increases", "the", "binding", "of", "NF", "-", "kappaB", "to", "DNA", "in", "TNF", "-", "alpha", "-", "stimulated", "Jurkat", "cells", ".", "The", "ability", "of", "ascorbate", "to", "enhance", "cytoplasmic", "inhibitory", "IkBalpha", "protein", "degradation", "correlates", "completely", "with", "its", "capacity", "to", "induce", "NF", "-", "kappaB", "binding", "to", "DNA", "and", "to", "potentiate", "NF", "-", "kappaB", "-", "mediated", "transactivation", "of", "the", "HIV-1", "long", "terminal", "repeat", "promoter", "in", "TNF", "-", "alpha", "-", "stimulated", "Jurkat", "cells", "but", "not", "in", "cells", "stimulated", "with", "PMA", "plus", "ionomycin", ".", "AFR", "behaves", "like", "ascorbate", ",", "while", "DHA", "and", "ascorbate", "phosphate", "do", "not", "affect", "TNF", "-", "alpha", "-", "mediated", "NF", "-", "kappaB", "activation", ".", "These", "results", "provide", "new", "evidence", "for", "a", "possible", "relationship", "between", "the", "activation", "of", "the", "electron", "-", "transport", "system", "at", "the", "plasma", "membrane", "by", "ascorbate", "or", "its", "free", "radical", "and", "redox", "-", "dependent", "gene", "transcription", "in", "T", "-", "cells", "." ]	[ "Protein" ]
tumour necrosis factor - alpha is a Protein, tumour necrosis factor - alpha is a Protein, TNF - alpha is a Protein, TNF - alpha is a Protein, IkBalpha is a Protein, TNF - alpha is a Protein, TNF - alpha is a Protein	9224625_task1	Sentence: Role of ascorbate in the activation of NF-kappaB by tumour necrosis factor-alpha in T-cells. The first product of ascorbate oxidation, the ascorbate free radical (AFR), acts in biological systems mainly as an oxidant, and through its role in the plasma membrane redox system exerts different effects on the cell. We have investigated the role of ascorbate, AFR and dehydroascorbate (DHA) in the activation of the NF-kappaB transcription factor in Jurkat T-cells stimulated by tumour necrosis factor-alpha (TNF-alpha). Here we show, by electrophoretic mobility shift assays, that ascorbate increases the binding of NF-kappaB to DNA in TNF-alpha-stimulated Jurkat cells. The ability of ascorbate to enhance cytoplasmic inhibitory IkBalpha protein degradation correlates completely with its capacity to induce NF-kappaB binding to DNA and to potentiate NF-kappaB-mediated transactivation of the HIV-1 long terminal repeat promoter in TNF-alpha-stimulated Jurkat cells but not in cells stimulated with PMA plus ionomycin. AFR behaves like ascorbate, while DHA and ascorbate phosphate do not affect TNF-alpha-mediated NF-kappaB activation. These results provide new evidence for a possible relationship between the activation of the electron-transport system at the plasma membrane by ascorbate or its free radical and redox-dependent gene transcription in T-cells. Instructions: please typing these entity words according to sentence: tumour necrosis factor - alpha, tumour necrosis factor - alpha, TNF - alpha, TNF - alpha, IkBalpha, TNF - alpha, TNF - alpha Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Role of ascorbate in the activation of NF-kappaB by tumour necrosis factor-alpha in T-cells. The first product of ascorbate oxidation, the ascorbate free radical (AFR), acts in biological systems mainly as an oxidant, and through its role in the plasma membrane redox system exerts different effects on the cell. We have investigated the role of ascorbate, AFR and dehydroascorbate (DHA) in the activation of the NF-kappaB transcription factor in Jurkat T-cells stimulated by tumour necrosis factor-alpha (TNF-alpha). Here we show, by electrophoretic mobility shift assays, that ascorbate increases the binding of NF-kappaB to DNA in TNF-alpha-stimulated Jurkat cells. The ability of ascorbate to enhance cytoplasmic inhibitory IkBalpha protein degradation correlates completely with its capacity to induce NF-kappaB binding to DNA and to potentiate NF-kappaB-mediated transactivation of the HIV-1 long terminal repeat promoter in TNF-alpha-stimulated Jurkat cells but not in cells stimulated with PMA plus ionomycin. AFR behaves like ascorbate, while DHA and ascorbate phosphate do not affect TNF-alpha-mediated NF-kappaB activation. These results provide new evidence for a possible relationship between the activation of the electron-transport system at the plasma membrane by ascorbate or its free radical and redox-dependent gene transcription in T-cells.	[ "Role", "of", "ascorbate", "in", "the", "activation", "of", "NF", "-", "kappaB", "by", "tumour", "necrosis", "factor", "-", "alpha", "in", "T", "-", "cells", ".", "\n", "The", "first", "product", "of", "ascorbate", "oxidation", ",", "the", "ascorbate", "free", "radical", "(", "AFR", ")", ",", "acts", "in", "biological", "systems", "mainly", "as", "an", "oxidant", ",", "and", "through", "its", "role", "in", "the", "plasma", "membrane", "redox", "system", "exerts", "different", "effects", "on", "the", "cell", ".", "We", "have", "investigated", "the", "role", "of", "ascorbate", ",", "AFR", "and", "dehydroascorbate", "(", "DHA", ")", "in", "the", "activation", "of", "the", "NF", "-", "kappaB", "transcription", "factor", "in", "Jurkat", "T", "-", "cells", "stimulated", "by", "tumour", "necrosis", "factor", "-", "alpha", "(", "TNF", "-", "alpha", ")", ".", "Here", "we", "show", ",", "by", "electrophoretic", "mobility", "shift", "assays", ",", "that", "ascorbate", "increases", "the", "binding", "of", "NF", "-", "kappaB", "to", "DNA", "in", "TNF", "-", "alpha", "-", "stimulated", "Jurkat", "cells", ".", "The", "ability", "of", "ascorbate", "to", "enhance", "cytoplasmic", "inhibitory", "IkBalpha", "protein", "degradation", "correlates", "completely", "with", "its", "capacity", "to", "induce", "NF", "-", "kappaB", "binding", "to", "DNA", "and", "to", "potentiate", "NF", "-", "kappaB", "-", "mediated", "transactivation", "of", "the", "HIV-1", "long", "terminal", "repeat", "promoter", "in", "TNF", "-", "alpha", "-", "stimulated", "Jurkat", "cells", "but", "not", "in", "cells", "stimulated", "with", "PMA", "plus", "ionomycin", ".", "AFR", "behaves", "like", "ascorbate", ",", "while", "DHA", "and", "ascorbate", "phosphate", "do", "not", "affect", "TNF", "-", "alpha", "-", "mediated", "NF", "-", "kappaB", "activation", ".", "These", "results", "provide", "new", "evidence", "for", "a", "possible", "relationship", "between", "the", "activation", "of", "the", "electron", "-", "transport", "system", "at", "the", "plasma", "membrane", "by", "ascorbate", "or", "its", "free", "radical", "and", "redox", "-", "dependent", "gene", "transcription", "in", "T", "-", "cells", "." ]	[ "Protein" ]
tumour necrosis factor - alpha, tumour necrosis factor - alpha, TNF - alpha, TNF - alpha, IkBalpha, TNF - alpha, TNF - alpha	9224625_task2	Sentence: Role of ascorbate in the activation of NF-kappaB by tumour necrosis factor-alpha in T-cells. The first product of ascorbate oxidation, the ascorbate free radical (AFR), acts in biological systems mainly as an oxidant, and through its role in the plasma membrane redox system exerts different effects on the cell. We have investigated the role of ascorbate, AFR and dehydroascorbate (DHA) in the activation of the NF-kappaB transcription factor in Jurkat T-cells stimulated by tumour necrosis factor-alpha (TNF-alpha). Here we show, by electrophoretic mobility shift assays, that ascorbate increases the binding of NF-kappaB to DNA in TNF-alpha-stimulated Jurkat cells. The ability of ascorbate to enhance cytoplasmic inhibitory IkBalpha protein degradation correlates completely with its capacity to induce NF-kappaB binding to DNA and to potentiate NF-kappaB-mediated transactivation of the HIV-1 long terminal repeat promoter in TNF-alpha-stimulated Jurkat cells but not in cells stimulated with PMA plus ionomycin. AFR behaves like ascorbate, while DHA and ascorbate phosphate do not affect TNF-alpha-mediated NF-kappaB activation. These results provide new evidence for a possible relationship between the activation of the electron-transport system at the plasma membrane by ascorbate or its free radical and redox-dependent gene transcription in T-cells. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Role of ascorbate in the activation of NF-kappaB by tumour necrosis factor-alpha in T-cells. The first product of ascorbate oxidation, the ascorbate free radical (AFR), acts in biological systems mainly as an oxidant, and through its role in the plasma membrane redox system exerts different effects on the cell. We have investigated the role of ascorbate, AFR and dehydroascorbate (DHA) in the activation of the NF-kappaB transcription factor in Jurkat T-cells stimulated by tumour necrosis factor-alpha (TNF-alpha). Here we show, by electrophoretic mobility shift assays, that ascorbate increases the binding of NF-kappaB to DNA in TNF-alpha-stimulated Jurkat cells. The ability of ascorbate to enhance cytoplasmic inhibitory IkBalpha protein degradation correlates completely with its capacity to induce NF-kappaB binding to DNA and to potentiate NF-kappaB-mediated transactivation of the HIV-1 long terminal repeat promoter in TNF-alpha-stimulated Jurkat cells but not in cells stimulated with PMA plus ionomycin. AFR behaves like ascorbate, while DHA and ascorbate phosphate do not affect TNF-alpha-mediated NF-kappaB activation. These results provide new evidence for a possible relationship between the activation of the electron-transport system at the plasma membrane by ascorbate or its free radical and redox-dependent gene transcription in T-cells.	[ "Role", "of", "ascorbate", "in", "the", "activation", "of", "NF", "-", "kappaB", "by", "tumour", "necrosis", "factor", "-", "alpha", "in", "T", "-", "cells", ".", "\n", "The", "first", "product", "of", "ascorbate", "oxidation", ",", "the", "ascorbate", "free", "radical", "(", "AFR", ")", ",", "acts", "in", "biological", "systems", "mainly", "as", "an", "oxidant", ",", "and", "through", "its", "role", "in", "the", "plasma", "membrane", "redox", "system", "exerts", "different", "effects", "on", "the", "cell", ".", "We", "have", "investigated", "the", "role", "of", "ascorbate", ",", "AFR", "and", "dehydroascorbate", "(", "DHA", ")", "in", "the", "activation", "of", "the", "NF", "-", "kappaB", "transcription", "factor", "in", "Jurkat", "T", "-", "cells", "stimulated", "by", "tumour", "necrosis", "factor", "-", "alpha", "(", "TNF", "-", "alpha", ")", ".", "Here", "we", "show", ",", "by", "electrophoretic", "mobility", "shift", "assays", ",", "that", "ascorbate", "increases", "the", "binding", "of", "NF", "-", "kappaB", "to", "DNA", "in", "TNF", "-", "alpha", "-", "stimulated", "Jurkat", "cells", ".", "The", "ability", "of", "ascorbate", "to", "enhance", "cytoplasmic", "inhibitory", "IkBalpha", "protein", "degradation", "correlates", "completely", "with", "its", "capacity", "to", "induce", "NF", "-", "kappaB", "binding", "to", "DNA", "and", "to", "potentiate", "NF", "-", "kappaB", "-", "mediated", "transactivation", "of", "the", "HIV-1", "long", "terminal", "repeat", "promoter", "in", "TNF", "-", "alpha", "-", "stimulated", "Jurkat", "cells", "but", "not", "in", "cells", "stimulated", "with", "PMA", "plus", "ionomycin", ".", "AFR", "behaves", "like", "ascorbate", ",", "while", "DHA", "and", "ascorbate", "phosphate", "do", "not", "affect", "TNF", "-", "alpha", "-", "mediated", "NF", "-", "kappaB", "activation", ".", "These", "results", "provide", "new", "evidence", "for", "a", "possible", "relationship", "between", "the", "activation", "of", "the", "electron", "-", "transport", "system", "at", "the", "plasma", "membrane", "by", "ascorbate", "or", "its", "free", "radical", "and", "redox", "-", "dependent", "gene", "transcription", "in", "T", "-", "cells", "." ]	[ "Protein" ]
between 18 and 40 years is a Value, age is a Person, self - reported visual exam is a Procedure, in the last two years is a Temporal, Avaira sphere contact lens is a Device, at least 1 week in Avaira sphere is a Temporal, contact lens is a Device, spherical is a Qualifier, + 2.25 to - 8.00 ( inclusive ) is a Value, spectacle cylinder is a Device, up to 0.75D is a Value, best corrected spectacle distance visual acuity is a Measurement, 20/25 is a Value, 0.10 logMAR is a Value, distance visual acuity is a Measurement, 20/30 is a Value, 0.18 logMAR is a Value, study contact lenses is a Device, clear corneas is a Condition, no is a Negation, active is a Temporal, ocular disease is a Condition	NCT02406495_inc_task0	Sentence: Is between 18 and 40 years of age (inclusive) Has had a self-reported visual exam in the last two years Is an adapted Avaira sphere contact lens wearer (at least 1 week in Avaira sphere) Has a contact lens spherical prescription between + 2.25 to - 8.00 (inclusive) Has a spectacle cylinder up to 0.75D in each eye. Can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logMAR) or better in each eye. Can achieve a distance visual acuity of 20/30 (0.18 logMAR) or better in each eye with the study contact lenses. Has clear corneas and no active ocular disease Has read, understood and signed the information consent letter. Patient contact lens refraction should fit within the available parameters of the study lenses. Is willing to comply with the wear schedule (at least 5 days per week, > 8 hours/day assuming there are no contraindications for doing so). Is willing to comply with the visit schedule Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Measurement, Condition, Qualifier, Value, Person, Procedure, Negation, Device	[ "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Person", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Device", "I-Device", "I-Device", "I-Device", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Device", "I-Device", "B-Qualifier", "O", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "B-Device", "I-Device", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "O", "B-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "O", "B-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "B-Device", "I-Device", "I-Device", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Negation", "B-Temporal", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Is between 18 and 40 years of age (inclusive) Has had a self-reported visual exam in the last two years Is an adapted Avaira sphere contact lens wearer (at least 1 week in Avaira sphere) Has a contact lens spherical prescription between + 2.25 to - 8.00 (inclusive) Has a spectacle cylinder up to 0.75D in each eye. Can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logMAR) or better in each eye. Can achieve a distance visual acuity of 20/30 (0.18 logMAR) or better in each eye with the study contact lenses. Has clear corneas and no active ocular disease Has read, understood and signed the information consent letter. Patient contact lens refraction should fit within the available parameters of the study lenses. Is willing to comply with the wear schedule (at least 5 days per week, > 8 hours/day assuming there are no contraindications for doing so). Is willing to comply with the visit schedule	[ "Is", "between", "18", "and", "40", "years", "of", "age", "(", "inclusive", ")", "\n", "Has", "had", "a", "self", "-", "reported", "visual", "exam", "in", "the", "last", "two", "years", "\n", "Is", "an", "adapted", "Avaira", "sphere", "contact", "lens", "wearer", "(", "at", "least", "1", "week", "in", "Avaira", "sphere", ")", "\n", "Has", "a", "contact", "lens", "spherical", "prescription", "between", "+", "2.25", "to", "-", "8.00", "(", "inclusive", ")", "\n", "Has", "a", "spectacle", "cylinder", "up", "to", "0.75D", "in", "each", "eye", ".", "\n", "Can", "achieve", "best", "corrected", "spectacle", "distance", "visual", "acuity", "of", "20/25", "(", "0.10", "logMAR", ")", "or", "better", "in", "each", "eye", ".", "\n", "Can", "achieve", "a", "distance", "visual", "acuity", "of", "20/30", "(", "0.18", "logMAR", ")", "or", "better", "in", "each", "eye", "with", "the", "study", "contact", "lenses", ".", "\n", "Has", "clear", "corneas", "and", "no", "active", "ocular", "disease", "\n", "Has", "read", ",", "understood", "and", "signed", "the", "information", "consent", "letter", ".", "\n", "Patient", "contact", "lens", "refraction", "should", "fit", "within", "the", "available", "parameters", "of", "the", "study", "lenses", ".", "\n", "Is", "willing", "to", "comply", "with", "the", "wear", "schedule", "(", "at", "least", "5", "days", "per", "week", ",", ">", "8", "hours", "/", "day", "assuming", "there", "are", "no", "contraindications", "for", "doing", "so", ")", ".", "\n", "Is", "willing", "to", "comply", "with", "the", "visit", "schedule", "\n" ]	[ "Measurement", "Temporal", "Value", "Device", "Procedure", "Condition", "Reference_point", "Qualifier", "Person", "Negation" ]
between 18 and 40 years is a Value, age is a Person, self - reported visual exam is a Procedure, in the last two years is a Temporal, Avaira sphere contact lens is a Device, at least 1 week in Avaira sphere is a Temporal, contact lens is a Device, spherical is a Qualifier, + 2.25 to - 8.00 ( inclusive ) is a Value, spectacle cylinder is a Device, up to 0.75D is a Value, best corrected spectacle distance visual acuity is a Measurement, 20/25 is a Value, 0.10 logMAR is a Value, distance visual acuity is a Measurement, 20/30 is a Value, 0.18 logMAR is a Value, study contact lenses is a Device, clear corneas is a Condition, no is a Negation, active is a Temporal, ocular disease is a Condition	NCT02406495_inc_task1	Sentence: Is between 18 and 40 years of age (inclusive) Has had a self-reported visual exam in the last two years Is an adapted Avaira sphere contact lens wearer (at least 1 week in Avaira sphere) Has a contact lens spherical prescription between + 2.25 to - 8.00 (inclusive) Has a spectacle cylinder up to 0.75D in each eye. Can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logMAR) or better in each eye. Can achieve a distance visual acuity of 20/30 (0.18 logMAR) or better in each eye with the study contact lenses. Has clear corneas and no active ocular disease Has read, understood and signed the information consent letter. Patient contact lens refraction should fit within the available parameters of the study lenses. Is willing to comply with the wear schedule (at least 5 days per week, > 8 hours/day assuming there are no contraindications for doing so). Is willing to comply with the visit schedule Instructions: please typing these entity words according to sentence: between 18 and 40 years, age, self - reported visual exam, in the last two years, Avaira sphere contact lens, at least 1 week in Avaira sphere, contact lens, spherical, + 2.25 to - 8.00 ( inclusive ), spectacle cylinder, up to 0.75D, best corrected spectacle distance visual acuity, 20/25, 0.10 logMAR, distance visual acuity, 20/30, 0.18 logMAR, study contact lenses, clear corneas, no, active, ocular disease Options: Temporal, Measurement, Condition, Qualifier, Value, Person, Procedure, Negation, Device	[ "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Person", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Device", "I-Device", "I-Device", "I-Device", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Device", "I-Device", "B-Qualifier", "O", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "B-Device", "I-Device", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "O", "B-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "O", "B-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "B-Device", "I-Device", "I-Device", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Negation", "B-Temporal", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Is between 18 and 40 years of age (inclusive) Has had a self-reported visual exam in the last two years Is an adapted Avaira sphere contact lens wearer (at least 1 week in Avaira sphere) Has a contact lens spherical prescription between + 2.25 to - 8.00 (inclusive) Has a spectacle cylinder up to 0.75D in each eye. Can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logMAR) or better in each eye. Can achieve a distance visual acuity of 20/30 (0.18 logMAR) or better in each eye with the study contact lenses. Has clear corneas and no active ocular disease Has read, understood and signed the information consent letter. Patient contact lens refraction should fit within the available parameters of the study lenses. Is willing to comply with the wear schedule (at least 5 days per week, > 8 hours/day assuming there are no contraindications for doing so). Is willing to comply with the visit schedule	[ "Is", "between", "18", "and", "40", "years", "of", "age", "(", "inclusive", ")", "\n", "Has", "had", "a", "self", "-", "reported", "visual", "exam", "in", "the", "last", "two", "years", "\n", "Is", "an", "adapted", "Avaira", "sphere", "contact", "lens", "wearer", "(", "at", "least", "1", "week", "in", "Avaira", "sphere", ")", "\n", "Has", "a", "contact", "lens", "spherical", "prescription", "between", "+", "2.25", "to", "-", "8.00", "(", "inclusive", ")", "\n", "Has", "a", "spectacle", "cylinder", "up", "to", "0.75D", "in", "each", "eye", ".", "\n", "Can", "achieve", "best", "corrected", "spectacle", "distance", "visual", "acuity", "of", "20/25", "(", "0.10", "logMAR", ")", "or", "better", "in", "each", "eye", ".", "\n", "Can", "achieve", "a", "distance", "visual", "acuity", "of", "20/30", "(", "0.18", "logMAR", ")", "or", "better", "in", "each", "eye", "with", "the", "study", "contact", "lenses", ".", "\n", "Has", "clear", "corneas", "and", "no", "active", "ocular", "disease", "\n", "Has", "read", ",", "understood", "and", "signed", "the", "information", "consent", "letter", ".", "\n", "Patient", "contact", "lens", "refraction", "should", "fit", "within", "the", "available", "parameters", "of", "the", "study", "lenses", ".", "\n", "Is", "willing", "to", "comply", "with", "the", "wear", "schedule", "(", "at", "least", "5", "days", "per", "week", ",", ">", "8", "hours", "/", "day", "assuming", "there", "are", "no", "contraindications", "for", "doing", "so", ")", ".", "\n", "Is", "willing", "to", "comply", "with", "the", "visit", "schedule", "\n" ]	[ "Measurement", "Temporal", "Value", "Device", "Procedure", "Condition", "Reference_point", "Qualifier", "Person", "Negation" ]
between 18 and 40 years, age, self - reported visual exam, in the last two years, Avaira sphere contact lens, at least 1 week in Avaira sphere, contact lens, spherical, + 2.25 to - 8.00 ( inclusive ), spectacle cylinder, up to 0.75D, best corrected spectacle distance visual acuity, 20/25, 0.10 logMAR, distance visual acuity, 20/30, 0.18 logMAR, study contact lenses, clear corneas, no, active, ocular disease	NCT02406495_inc_task2	Sentence: Is between 18 and 40 years of age (inclusive) Has had a self-reported visual exam in the last two years Is an adapted Avaira sphere contact lens wearer (at least 1 week in Avaira sphere) Has a contact lens spherical prescription between + 2.25 to - 8.00 (inclusive) Has a spectacle cylinder up to 0.75D in each eye. Can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logMAR) or better in each eye. Can achieve a distance visual acuity of 20/30 (0.18 logMAR) or better in each eye with the study contact lenses. Has clear corneas and no active ocular disease Has read, understood and signed the information consent letter. Patient contact lens refraction should fit within the available parameters of the study lenses. Is willing to comply with the wear schedule (at least 5 days per week, > 8 hours/day assuming there are no contraindications for doing so). Is willing to comply with the visit schedule Instructions: please extract entity words from the input sentence	[ "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Person", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Device", "I-Device", "I-Device", "I-Device", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Device", "I-Device", "B-Qualifier", "O", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "B-Device", "I-Device", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "O", "B-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "O", "B-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "B-Device", "I-Device", "I-Device", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Negation", "B-Temporal", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Is between 18 and 40 years of age (inclusive) Has had a self-reported visual exam in the last two years Is an adapted Avaira sphere contact lens wearer (at least 1 week in Avaira sphere) Has a contact lens spherical prescription between + 2.25 to - 8.00 (inclusive) Has a spectacle cylinder up to 0.75D in each eye. Can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logMAR) or better in each eye. Can achieve a distance visual acuity of 20/30 (0.18 logMAR) or better in each eye with the study contact lenses. Has clear corneas and no active ocular disease Has read, understood and signed the information consent letter. Patient contact lens refraction should fit within the available parameters of the study lenses. Is willing to comply with the wear schedule (at least 5 days per week, > 8 hours/day assuming there are no contraindications for doing so). Is willing to comply with the visit schedule	[ "Is", "between", "18", "and", "40", "years", "of", "age", "(", "inclusive", ")", "\n", "Has", "had", "a", "self", "-", "reported", "visual", "exam", "in", "the", "last", "two", "years", "\n", "Is", "an", "adapted", "Avaira", "sphere", "contact", "lens", "wearer", "(", "at", "least", "1", "week", "in", "Avaira", "sphere", ")", "\n", "Has", "a", "contact", "lens", "spherical", "prescription", "between", "+", "2.25", "to", "-", "8.00", "(", "inclusive", ")", "\n", "Has", "a", "spectacle", "cylinder", "up", "to", "0.75D", "in", "each", "eye", ".", "\n", "Can", "achieve", "best", "corrected", "spectacle", "distance", "visual", "acuity", "of", "20/25", "(", "0.10", "logMAR", ")", "or", "better", "in", "each", "eye", ".", "\n", "Can", "achieve", "a", "distance", "visual", "acuity", "of", "20/30", "(", "0.18", "logMAR", ")", "or", "better", "in", "each", "eye", "with", "the", "study", "contact", "lenses", ".", "\n", "Has", "clear", "corneas", "and", "no", "active", "ocular", "disease", "\n", "Has", "read", ",", "understood", "and", "signed", "the", "information", "consent", "letter", ".", "\n", "Patient", "contact", "lens", "refraction", "should", "fit", "within", "the", "available", "parameters", "of", "the", "study", "lenses", ".", "\n", "Is", "willing", "to", "comply", "with", "the", "wear", "schedule", "(", "at", "least", "5", "days", "per", "week", ",", ">", "8", "hours", "/", "day", "assuming", "there", "are", "no", "contraindications", "for", "doing", "so", ")", ".", "\n", "Is", "willing", "to", "comply", "with", "the", "visit", "schedule", "\n" ]	[ "Measurement", "Temporal", "Value", "Device", "Procedure", "Condition", "Reference_point", "Qualifier", "Person", "Negation" ]
pulmonale Hypertonie is an umlsterm, Aetiologie is an umlsterm, Beurteilung is an umlsterm, thoraxchirurgische is an umlsterm, Arbeit is an umlsterm, tierexperimentelle is an umlsterm, Biopsietechnik is an umlsterm, Biopsie is an umlsterm, pulmonaler Hypertonie is an umlsterm, Versuchstiere is an umlsterm, Patienten is an umlsterm, Bronchialkarzinom is an umlsterm, Biopsietechnik is an umlsterm, Beurteilung is an umlsterm, Pulmonalarterienwand is an umlsterm, Lungenparenchym is an umlsterm, Komplikationen is an umlsterm, Biopsietechnik is an umlsterm	ZfuerKardiologie.70860622.ger.abstr_task0	Sentence: Die pulmonale Hypertonie stellt eine schwerwiegende therapeutisch schlecht beherrschbare Erkrankung unterschiedlicher Aetiologie dar . Obwohl haemodynamische Parameter weitgehend mit morphologischen Befunden korrelieren , besteht aus differentialdiagnostischer Sicht haeufig die Notwendigkeit zur histologischen Beurteilung . Eine adaequate Materialgewinnung ist aufgrund der hohen Blutungsbereitschaft in der Regel nur ueber thoraxchirurgische Verfahren moeglich . In der vorliegenden Arbeit werden tierexperimentelle und erste klinische Daten einer neuen Biopsietechnik ( perkutane transvasale Biopsie , PTB ) , zur Gewinnung von Gefaesswandproben bei pulmonaler Hypertonie vorgestellt . Bei einem Teil der Versuchstiere wurde der pulmonale Hochdruck experimentell erzeugt . Die klinischen Befunde resultieren von Patienten mit einem Bronchialkarzinom . Die ersten Ergebnisse zeigen , dass mit der vorgestellten Biopsietechnik ausreichendes Material zur histologischen und immunologischen Beurteilung gewonnen werden kann . Neben Anteilen der Pulmonalarterienwand kann haeufig repraesentatives Lungenparenchym nachgewiesen werden . Komplikationen im Zusammenhang mit der Biopsietechnik traten waehrend unserer Untersuchungen nicht auf . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]	Die pulmonale Hypertonie stellt eine schwerwiegende therapeutisch schlecht beherrschbare Erkrankung unterschiedlicher Aetiologie dar . Obwohl haemodynamische Parameter weitgehend mit morphologischen Befunden korrelieren , besteht aus differentialdiagnostischer Sicht haeufig die Notwendigkeit zur histologischen Beurteilung . Eine adaequate Materialgewinnung ist aufgrund der hohen Blutungsbereitschaft in der Regel nur ueber thoraxchirurgische Verfahren moeglich . In der vorliegenden Arbeit werden tierexperimentelle und erste klinische Daten einer neuen Biopsietechnik ( perkutane transvasale Biopsie , PTB ) , zur Gewinnung von Gefaesswandproben bei pulmonaler Hypertonie vorgestellt . Bei einem Teil der Versuchstiere wurde der pulmonale Hochdruck experimentell erzeugt . Die klinischen Befunde resultieren von Patienten mit einem Bronchialkarzinom . Die ersten Ergebnisse zeigen , dass mit der vorgestellten Biopsietechnik ausreichendes Material zur histologischen und immunologischen Beurteilung gewonnen werden kann . Neben Anteilen der Pulmonalarterienwand kann haeufig repraesentatives Lungenparenchym nachgewiesen werden . Komplikationen im Zusammenhang mit der Biopsietechnik traten waehrend unserer Untersuchungen nicht auf .	[ "Die", "pulmonale", "Hypertonie", "stellt", "eine", "schwerwiegende", "therapeutisch", "schlecht", "beherrschbare", "Erkrankung", "unterschiedlicher", "Aetiologie", "dar", ".", "Obwohl", "haemodynamische", "Parameter", "weitgehend", "mit", "morphologischen", "Befunden", "korrelieren", ",", "besteht", "aus", "differentialdiagnostischer", "Sicht", "haeufig", "die", "Notwendigkeit", "zur", "histologischen", "Beurteilung", ".", "Eine", "adaequate", "Materialgewinnung", "ist", "aufgrund", "der", "hohen", "Blutungsbereitschaft", "in", "der", "Regel", "nur", "ueber", "thoraxchirurgische", "Verfahren", "moeglich", ".", "In", "der", "vorliegenden", "Arbeit", "werden", "tierexperimentelle", "und", "erste", "klinische", "Daten", "einer", "neuen", "Biopsietechnik", "(", "perkutane", "transvasale", "Biopsie", ",", "PTB", ")", ",", "zur", "Gewinnung", "von", "Gefaesswandproben", "bei", "pulmonaler", "Hypertonie", "vorgestellt", ".", "Bei", "einem", "Teil", "der", "Versuchstiere", "wurde", "der", "pulmonale", "Hochdruck", "experimentell", "erzeugt", ".", "Die", "klinischen", "Befunde", "resultieren", "von", "Patienten", "mit", "einem", "Bronchialkarzinom", ".", "Die", "ersten", "Ergebnisse", "zeigen", ",", "dass", "mit", "der", "vorgestellten", "Biopsietechnik", "ausreichendes", "Material", "zur", "histologischen", "und", "immunologischen", "Beurteilung", "gewonnen", "werden", "kann", ".", "Neben", "Anteilen", "der", "Pulmonalarterienwand", "kann", "haeufig", "repraesentatives", "Lungenparenchym", "nachgewiesen", "werden", ".", "Komplikationen", "im", "Zusammenhang", "mit", "der", "Biopsietechnik", "traten", "waehrend", "unserer", "Untersuchungen", "nicht", "auf", "." ]	[ "umlsterm" ]
pulmonale Hypertonie is an umlsterm, Aetiologie is an umlsterm, Beurteilung is an umlsterm, thoraxchirurgische is an umlsterm, Arbeit is an umlsterm, tierexperimentelle is an umlsterm, Biopsietechnik is an umlsterm, Biopsie is an umlsterm, pulmonaler Hypertonie is an umlsterm, Versuchstiere is an umlsterm, Patienten is an umlsterm, Bronchialkarzinom is an umlsterm, Biopsietechnik is an umlsterm, Beurteilung is an umlsterm, Pulmonalarterienwand is an umlsterm, Lungenparenchym is an umlsterm, Komplikationen is an umlsterm, Biopsietechnik is an umlsterm	ZfuerKardiologie.70860622.ger.abstr_task1	Sentence: Die pulmonale Hypertonie stellt eine schwerwiegende therapeutisch schlecht beherrschbare Erkrankung unterschiedlicher Aetiologie dar . Obwohl haemodynamische Parameter weitgehend mit morphologischen Befunden korrelieren , besteht aus differentialdiagnostischer Sicht haeufig die Notwendigkeit zur histologischen Beurteilung . Eine adaequate Materialgewinnung ist aufgrund der hohen Blutungsbereitschaft in der Regel nur ueber thoraxchirurgische Verfahren moeglich . In der vorliegenden Arbeit werden tierexperimentelle und erste klinische Daten einer neuen Biopsietechnik ( perkutane transvasale Biopsie , PTB ) , zur Gewinnung von Gefaesswandproben bei pulmonaler Hypertonie vorgestellt . Bei einem Teil der Versuchstiere wurde der pulmonale Hochdruck experimentell erzeugt . Die klinischen Befunde resultieren von Patienten mit einem Bronchialkarzinom . Die ersten Ergebnisse zeigen , dass mit der vorgestellten Biopsietechnik ausreichendes Material zur histologischen und immunologischen Beurteilung gewonnen werden kann . Neben Anteilen der Pulmonalarterienwand kann haeufig repraesentatives Lungenparenchym nachgewiesen werden . Komplikationen im Zusammenhang mit der Biopsietechnik traten waehrend unserer Untersuchungen nicht auf . Instructions: please typing these entity words according to sentence: pulmonale Hypertonie, Aetiologie, Beurteilung, thoraxchirurgische, Arbeit, tierexperimentelle, Biopsietechnik, Biopsie, pulmonaler Hypertonie, Versuchstiere, Patienten, Bronchialkarzinom, Biopsietechnik, Beurteilung, Pulmonalarterienwand, Lungenparenchym, Komplikationen, Biopsietechnik Options: umlsterm	[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]	Die pulmonale Hypertonie stellt eine schwerwiegende therapeutisch schlecht beherrschbare Erkrankung unterschiedlicher Aetiologie dar . Obwohl haemodynamische Parameter weitgehend mit morphologischen Befunden korrelieren , besteht aus differentialdiagnostischer Sicht haeufig die Notwendigkeit zur histologischen Beurteilung . Eine adaequate Materialgewinnung ist aufgrund der hohen Blutungsbereitschaft in der Regel nur ueber thoraxchirurgische Verfahren moeglich . In der vorliegenden Arbeit werden tierexperimentelle und erste klinische Daten einer neuen Biopsietechnik ( perkutane transvasale Biopsie , PTB ) , zur Gewinnung von Gefaesswandproben bei pulmonaler Hypertonie vorgestellt . Bei einem Teil der Versuchstiere wurde der pulmonale Hochdruck experimentell erzeugt . Die klinischen Befunde resultieren von Patienten mit einem Bronchialkarzinom . Die ersten Ergebnisse zeigen , dass mit der vorgestellten Biopsietechnik ausreichendes Material zur histologischen und immunologischen Beurteilung gewonnen werden kann . Neben Anteilen der Pulmonalarterienwand kann haeufig repraesentatives Lungenparenchym nachgewiesen werden . Komplikationen im Zusammenhang mit der Biopsietechnik traten waehrend unserer Untersuchungen nicht auf .	[ "Die", "pulmonale", "Hypertonie", "stellt", "eine", "schwerwiegende", "therapeutisch", "schlecht", "beherrschbare", "Erkrankung", "unterschiedlicher", "Aetiologie", "dar", ".", "Obwohl", "haemodynamische", "Parameter", "weitgehend", "mit", "morphologischen", "Befunden", "korrelieren", ",", "besteht", "aus", "differentialdiagnostischer", "Sicht", "haeufig", "die", "Notwendigkeit", "zur", "histologischen", "Beurteilung", ".", "Eine", "adaequate", "Materialgewinnung", "ist", "aufgrund", "der", "hohen", "Blutungsbereitschaft", "in", "der", "Regel", "nur", "ueber", "thoraxchirurgische", "Verfahren", "moeglich", ".", "In", "der", "vorliegenden", "Arbeit", "werden", "tierexperimentelle", "und", "erste", "klinische", "Daten", "einer", "neuen", "Biopsietechnik", "(", "perkutane", "transvasale", "Biopsie", ",", "PTB", ")", ",", "zur", "Gewinnung", "von", "Gefaesswandproben", "bei", "pulmonaler", "Hypertonie", "vorgestellt", ".", "Bei", "einem", "Teil", "der", "Versuchstiere", "wurde", "der", "pulmonale", "Hochdruck", "experimentell", "erzeugt", ".", "Die", "klinischen", "Befunde", "resultieren", "von", "Patienten", "mit", "einem", "Bronchialkarzinom", ".", "Die", "ersten", "Ergebnisse", "zeigen", ",", "dass", "mit", "der", "vorgestellten", "Biopsietechnik", "ausreichendes", "Material", "zur", "histologischen", "und", "immunologischen", "Beurteilung", "gewonnen", "werden", "kann", ".", "Neben", "Anteilen", "der", "Pulmonalarterienwand", "kann", "haeufig", "repraesentatives", "Lungenparenchym", "nachgewiesen", "werden", ".", "Komplikationen", "im", "Zusammenhang", "mit", "der", "Biopsietechnik", "traten", "waehrend", "unserer", "Untersuchungen", "nicht", "auf", "." ]	[ "umlsterm" ]
pulmonale Hypertonie, Aetiologie, Beurteilung, thoraxchirurgische, Arbeit, tierexperimentelle, Biopsietechnik, Biopsie, pulmonaler Hypertonie, Versuchstiere, Patienten, Bronchialkarzinom, Biopsietechnik, Beurteilung, Pulmonalarterienwand, Lungenparenchym, Komplikationen, Biopsietechnik	ZfuerKardiologie.70860622.ger.abstr_task2	Sentence: Die pulmonale Hypertonie stellt eine schwerwiegende therapeutisch schlecht beherrschbare Erkrankung unterschiedlicher Aetiologie dar . Obwohl haemodynamische Parameter weitgehend mit morphologischen Befunden korrelieren , besteht aus differentialdiagnostischer Sicht haeufig die Notwendigkeit zur histologischen Beurteilung . Eine adaequate Materialgewinnung ist aufgrund der hohen Blutungsbereitschaft in der Regel nur ueber thoraxchirurgische Verfahren moeglich . In der vorliegenden Arbeit werden tierexperimentelle und erste klinische Daten einer neuen Biopsietechnik ( perkutane transvasale Biopsie , PTB ) , zur Gewinnung von Gefaesswandproben bei pulmonaler Hypertonie vorgestellt . Bei einem Teil der Versuchstiere wurde der pulmonale Hochdruck experimentell erzeugt . Die klinischen Befunde resultieren von Patienten mit einem Bronchialkarzinom . Die ersten Ergebnisse zeigen , dass mit der vorgestellten Biopsietechnik ausreichendes Material zur histologischen und immunologischen Beurteilung gewonnen werden kann . Neben Anteilen der Pulmonalarterienwand kann haeufig repraesentatives Lungenparenchym nachgewiesen werden . Komplikationen im Zusammenhang mit der Biopsietechnik traten waehrend unserer Untersuchungen nicht auf . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]	Die pulmonale Hypertonie stellt eine schwerwiegende therapeutisch schlecht beherrschbare Erkrankung unterschiedlicher Aetiologie dar . Obwohl haemodynamische Parameter weitgehend mit morphologischen Befunden korrelieren , besteht aus differentialdiagnostischer Sicht haeufig die Notwendigkeit zur histologischen Beurteilung . Eine adaequate Materialgewinnung ist aufgrund der hohen Blutungsbereitschaft in der Regel nur ueber thoraxchirurgische Verfahren moeglich . In der vorliegenden Arbeit werden tierexperimentelle und erste klinische Daten einer neuen Biopsietechnik ( perkutane transvasale Biopsie , PTB ) , zur Gewinnung von Gefaesswandproben bei pulmonaler Hypertonie vorgestellt . Bei einem Teil der Versuchstiere wurde der pulmonale Hochdruck experimentell erzeugt . Die klinischen Befunde resultieren von Patienten mit einem Bronchialkarzinom . Die ersten Ergebnisse zeigen , dass mit der vorgestellten Biopsietechnik ausreichendes Material zur histologischen und immunologischen Beurteilung gewonnen werden kann . Neben Anteilen der Pulmonalarterienwand kann haeufig repraesentatives Lungenparenchym nachgewiesen werden . Komplikationen im Zusammenhang mit der Biopsietechnik traten waehrend unserer Untersuchungen nicht auf .	[ "Die", "pulmonale", "Hypertonie", "stellt", "eine", "schwerwiegende", "therapeutisch", "schlecht", "beherrschbare", "Erkrankung", "unterschiedlicher", "Aetiologie", "dar", ".", "Obwohl", "haemodynamische", "Parameter", "weitgehend", "mit", "morphologischen", "Befunden", "korrelieren", ",", "besteht", "aus", "differentialdiagnostischer", "Sicht", "haeufig", "die", "Notwendigkeit", "zur", "histologischen", "Beurteilung", ".", "Eine", "adaequate", "Materialgewinnung", "ist", "aufgrund", "der", "hohen", "Blutungsbereitschaft", "in", "der", "Regel", "nur", "ueber", "thoraxchirurgische", "Verfahren", "moeglich", ".", "In", "der", "vorliegenden", "Arbeit", "werden", "tierexperimentelle", "und", "erste", "klinische", "Daten", "einer", "neuen", "Biopsietechnik", "(", "perkutane", "transvasale", "Biopsie", ",", "PTB", ")", ",", "zur", "Gewinnung", "von", "Gefaesswandproben", "bei", "pulmonaler", "Hypertonie", "vorgestellt", ".", "Bei", "einem", "Teil", "der", "Versuchstiere", "wurde", "der", "pulmonale", "Hochdruck", "experimentell", "erzeugt", ".", "Die", "klinischen", "Befunde", "resultieren", "von", "Patienten", "mit", "einem", "Bronchialkarzinom", ".", "Die", "ersten", "Ergebnisse", "zeigen", ",", "dass", "mit", "der", "vorgestellten", "Biopsietechnik", "ausreichendes", "Material", "zur", "histologischen", "und", "immunologischen", "Beurteilung", "gewonnen", "werden", "kann", ".", "Neben", "Anteilen", "der", "Pulmonalarterienwand", "kann", "haeufig", "repraesentatives", "Lungenparenchym", "nachgewiesen", "werden", ".", "Komplikationen", "im", "Zusammenhang", "mit", "der", "Biopsietechnik", "traten", "waehrend", "unserer", "Untersuchungen", "nicht", "auf", "." ]	[ "umlsterm" ]
neuroprotective effects is a Outcome_Adverse-effects, recovery profiles is a Outcome_Other, isoflurane is a Intervention_Pharmacological, sevoflurane is a Intervention_Pharmacological, desflurane is a Intervention_Pharmacological, ischemia / reperfusion cerebral injury is a Participant_Condition, neurosurgery is a Participant_Condition, emergence is a Outcome_Other, intraoperative haemodynamic profiles is a Outcome_Other, postoperative adverse effects is a Outcome_Adverse-effects, hemodynamic stability is a Outcome_Physical, quality of induction and recovery is a Outcome_Other, substantial cerebral vasodilation is a Participant_Condition, Sevoflurane is a Intervention_Pharmacological, airway irritation is a Outcome_Physical, onset and recovery is a Outcome_Other	71481_task0	Sentence: Comparison of the neuroprotective effects and recovery profiles of isoflurane , sevoflurane and desflurane as neurosurgical pre-conditioning on ischemia/reperfusion cerebral injury . BACKGROUND There are a few reports regarding the comparison of these anesthetic agents , but previous studies mainly focus on the veterinary anesthesiology . Less attention has been focused comparing the effectiveness of these inhalational anesthetic agents in neurosurgery . This lack of interest is regretful particularly considering the fact that anesthetics during neurosurgery are an issue of extreme sensitivity and subtlety , where the cerebral oxygenation process plays a significant role in the neuroprotective mechanisms . OBJECTIVE The purpose of this retrospective study is to contribute to the existing knowledge of the comparative studies of the volatile anesthetic agents such as isoflurane , sevoflurane and desflurane by evaluating the maintenance and emergence characteristics after volatile anesthetics-induced preconditioning with isoflurane , sevoflurane or desflurane for inpatient ischemia/reperfusion cerebral injury during cerebral or neural surgeries . METHODS The aim was to investigate their neuroprotective mechanisms and effects by analyzing and comparing the superiority of each agent in a Chinese patient population , in terms of faster emergence , and early and intermediate recovery . The intraoperative haemodynamic profiles and postoperative adverse effects of these three agents were also systematically analyzed . RESULTS We found that sevoflurane , when compared with isoflurane and desflurane , provided anesthesia with similar hemodynamic stability but allowed for a smoother , more rapid emergence and better quality of induction and recovery to surgical patients under clinical conditions , particularly to those who were experiencing substantial cerebral vasodilation . CONCLUSION Sevoflurane offers several advantages , including a relative lack of airway irritation , a more rapid onset and recovery , and greater hemodynamic stability than other potent inhaled agents . These properties would appear to afford sevoflurane significant clinical potential . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Physical, Outcome_Other	[ "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Comparison of the neuroprotective effects and recovery profiles of isoflurane , sevoflurane and desflurane as neurosurgical pre-conditioning on ischemia/reperfusion cerebral injury . BACKGROUND There are a few reports regarding the comparison of these anesthetic agents , but previous studies mainly focus on the veterinary anesthesiology . Less attention has been focused comparing the effectiveness of these inhalational anesthetic agents in neurosurgery . This lack of interest is regretful particularly considering the fact that anesthetics during neurosurgery are an issue of extreme sensitivity and subtlety , where the cerebral oxygenation process plays a significant role in the neuroprotective mechanisms . OBJECTIVE The purpose of this retrospective study is to contribute to the existing knowledge of the comparative studies of the volatile anesthetic agents such as isoflurane , sevoflurane and desflurane by evaluating the maintenance and emergence characteristics after volatile anesthetics-induced preconditioning with isoflurane , sevoflurane or desflurane for inpatient ischemia/reperfusion cerebral injury during cerebral or neural surgeries . METHODS The aim was to investigate their neuroprotective mechanisms and effects by analyzing and comparing the superiority of each agent in a Chinese patient population , in terms of faster emergence , and early and intermediate recovery . The intraoperative haemodynamic profiles and postoperative adverse effects of these three agents were also systematically analyzed . RESULTS We found that sevoflurane , when compared with isoflurane and desflurane , provided anesthesia with similar hemodynamic stability but allowed for a smoother , more rapid emergence and better quality of induction and recovery to surgical patients under clinical conditions , particularly to those who were experiencing substantial cerebral vasodilation . CONCLUSION Sevoflurane offers several advantages , including a relative lack of airway irritation , a more rapid onset and recovery , and greater hemodynamic stability than other potent inhaled agents . These properties would appear to afford sevoflurane significant clinical potential .	[ "Comparison", "of", "the", "neuroprotective", "effects", "and", "recovery", "profiles", "of", "isoflurane", ",", "sevoflurane", "and", "desflurane", "as", "neurosurgical", "pre", "-", "conditioning", "on", "ischemia", "/", "reperfusion", "cerebral", "injury", ".", "BACKGROUND", "There", "are", "a", "few", "reports", "regarding", "the", "comparison", "of", "these", "anesthetic", "agents", ",", "but", "previous", "studies", "mainly", "focus", "on", "the", "veterinary", "anesthesiology", ".", "Less", "attention", "has", "been", "focused", "comparing", "the", "effectiveness", "of", "these", "inhalational", "anesthetic", "agents", "in", "neurosurgery", ".", "This", "lack", "of", "interest", "is", "regretful", "particularly", "considering", "the", "fact", "that", "anesthetics", "during", "neurosurgery", "are", "an", "issue", "of", "extreme", "sensitivity", "and", "subtlety", ",", "where", "the", "cerebral", "oxygenation", "process", "plays", "a", "significant", "role", "in", "the", "neuroprotective", "mechanisms", ".", "OBJECTIVE", "The", "purpose", "of", "this", "retrospective", "study", "is", "to", "contribute", "to", "the", "existing", "knowledge", "of", "the", "comparative", "studies", "of", "the", "volatile", "anesthetic", "agents", "such", "as", "isoflurane", ",", "sevoflurane", "and", "desflurane", "by", "evaluating", "the", "maintenance", "and", "emergence", "characteristics", "after", "volatile", "anesthetics", "-", "induced", "preconditioning", "with", "isoflurane", ",", "sevoflurane", "or", "desflurane", "for", "inpatient", "ischemia", "/", "reperfusion", "cerebral", "injury", "during", "cerebral", "or", "neural", "surgeries", ".", "METHODS", "The", "aim", "was", "to", "investigate", "their", "neuroprotective", "mechanisms", "and", "effects", "by", "analyzing", "and", "comparing", "the", "superiority", "of", "each", "agent", "in", "a", "Chinese", "patient", "population", ",", "in", "terms", "of", "faster", "emergence", ",", "and", "early", "and", "intermediate", "recovery", ".", "The", "intraoperative", "haemodynamic", "profiles", "and", "postoperative", "adverse", "effects", "of", "these", "three", "agents", "were", "also", "systematically", "analyzed", ".", "RESULTS", "We", "found", "that", "sevoflurane", ",", "when", "compared", "with", "isoflurane", "and", "desflurane", ",", "provided", "anesthesia", "with", "similar", "hemodynamic", "stability", "but", "allowed", "for", "a", "smoother", ",", "more", "rapid", "emergence", "and", "better", "quality", "of", "induction", "and", "recovery", "to", "surgical", "patients", "under", "clinical", "conditions", ",", "particularly", "to", "those", "who", "were", "experiencing", "substantial", "cerebral", "vasodilation", ".", "CONCLUSION", "Sevoflurane", "offers", "several", "advantages", ",", "including", "a", "relative", "lack", "of", "airway", "irritation", ",", "a", "more", "rapid", "onset", "and", "recovery", ",", "and", "greater", "hemodynamic", "stability", "than", "other", "potent", "inhaled", "agents", ".", "These", "properties", "would", "appear", "to", "afford", "sevoflurane", "significant", "clinical", "potential", "." ]	[ "Outcome_Other", "Participant_Condition", "Outcome_Adverse-effects", "Outcome_Physical", "Intervention_Pharmacological" ]
neuroprotective effects is a Outcome_Adverse-effects, recovery profiles is a Outcome_Other, isoflurane is a Intervention_Pharmacological, sevoflurane is a Intervention_Pharmacological, desflurane is a Intervention_Pharmacological, ischemia / reperfusion cerebral injury is a Participant_Condition, neurosurgery is a Participant_Condition, emergence is a Outcome_Other, intraoperative haemodynamic profiles is a Outcome_Other, postoperative adverse effects is a Outcome_Adverse-effects, hemodynamic stability is a Outcome_Physical, quality of induction and recovery is a Outcome_Other, substantial cerebral vasodilation is a Participant_Condition, Sevoflurane is a Intervention_Pharmacological, airway irritation is a Outcome_Physical, onset and recovery is a Outcome_Other	71481_task1	Sentence: Comparison of the neuroprotective effects and recovery profiles of isoflurane , sevoflurane and desflurane as neurosurgical pre-conditioning on ischemia/reperfusion cerebral injury . BACKGROUND There are a few reports regarding the comparison of these anesthetic agents , but previous studies mainly focus on the veterinary anesthesiology . Less attention has been focused comparing the effectiveness of these inhalational anesthetic agents in neurosurgery . This lack of interest is regretful particularly considering the fact that anesthetics during neurosurgery are an issue of extreme sensitivity and subtlety , where the cerebral oxygenation process plays a significant role in the neuroprotective mechanisms . OBJECTIVE The purpose of this retrospective study is to contribute to the existing knowledge of the comparative studies of the volatile anesthetic agents such as isoflurane , sevoflurane and desflurane by evaluating the maintenance and emergence characteristics after volatile anesthetics-induced preconditioning with isoflurane , sevoflurane or desflurane for inpatient ischemia/reperfusion cerebral injury during cerebral or neural surgeries . METHODS The aim was to investigate their neuroprotective mechanisms and effects by analyzing and comparing the superiority of each agent in a Chinese patient population , in terms of faster emergence , and early and intermediate recovery . The intraoperative haemodynamic profiles and postoperative adverse effects of these three agents were also systematically analyzed . RESULTS We found that sevoflurane , when compared with isoflurane and desflurane , provided anesthesia with similar hemodynamic stability but allowed for a smoother , more rapid emergence and better quality of induction and recovery to surgical patients under clinical conditions , particularly to those who were experiencing substantial cerebral vasodilation . CONCLUSION Sevoflurane offers several advantages , including a relative lack of airway irritation , a more rapid onset and recovery , and greater hemodynamic stability than other potent inhaled agents . These properties would appear to afford sevoflurane significant clinical potential . Instructions: please typing these entity words according to sentence: neuroprotective effects, recovery profiles, isoflurane, sevoflurane, desflurane, ischemia / reperfusion cerebral injury, neurosurgery, emergence, intraoperative haemodynamic profiles, postoperative adverse effects, hemodynamic stability, quality of induction and recovery, substantial cerebral vasodilation, Sevoflurane, airway irritation, onset and recovery Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Physical, Outcome_Other	[ "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Comparison of the neuroprotective effects and recovery profiles of isoflurane , sevoflurane and desflurane as neurosurgical pre-conditioning on ischemia/reperfusion cerebral injury . BACKGROUND There are a few reports regarding the comparison of these anesthetic agents , but previous studies mainly focus on the veterinary anesthesiology . Less attention has been focused comparing the effectiveness of these inhalational anesthetic agents in neurosurgery . This lack of interest is regretful particularly considering the fact that anesthetics during neurosurgery are an issue of extreme sensitivity and subtlety , where the cerebral oxygenation process plays a significant role in the neuroprotective mechanisms . OBJECTIVE The purpose of this retrospective study is to contribute to the existing knowledge of the comparative studies of the volatile anesthetic agents such as isoflurane , sevoflurane and desflurane by evaluating the maintenance and emergence characteristics after volatile anesthetics-induced preconditioning with isoflurane , sevoflurane or desflurane for inpatient ischemia/reperfusion cerebral injury during cerebral or neural surgeries . METHODS The aim was to investigate their neuroprotective mechanisms and effects by analyzing and comparing the superiority of each agent in a Chinese patient population , in terms of faster emergence , and early and intermediate recovery . The intraoperative haemodynamic profiles and postoperative adverse effects of these three agents were also systematically analyzed . RESULTS We found that sevoflurane , when compared with isoflurane and desflurane , provided anesthesia with similar hemodynamic stability but allowed for a smoother , more rapid emergence and better quality of induction and recovery to surgical patients under clinical conditions , particularly to those who were experiencing substantial cerebral vasodilation . CONCLUSION Sevoflurane offers several advantages , including a relative lack of airway irritation , a more rapid onset and recovery , and greater hemodynamic stability than other potent inhaled agents . These properties would appear to afford sevoflurane significant clinical potential .	[ "Comparison", "of", "the", "neuroprotective", "effects", "and", "recovery", "profiles", "of", "isoflurane", ",", "sevoflurane", "and", "desflurane", "as", "neurosurgical", "pre", "-", "conditioning", "on", "ischemia", "/", "reperfusion", "cerebral", "injury", ".", "BACKGROUND", "There", "are", "a", "few", "reports", "regarding", "the", "comparison", "of", "these", "anesthetic", "agents", ",", "but", "previous", "studies", "mainly", "focus", "on", "the", "veterinary", "anesthesiology", ".", "Less", "attention", "has", "been", "focused", "comparing", "the", "effectiveness", "of", "these", "inhalational", "anesthetic", "agents", "in", "neurosurgery", ".", "This", "lack", "of", "interest", "is", "regretful", "particularly", "considering", "the", "fact", "that", "anesthetics", "during", "neurosurgery", "are", "an", "issue", "of", "extreme", "sensitivity", "and", "subtlety", ",", "where", "the", "cerebral", "oxygenation", "process", "plays", "a", "significant", "role", "in", "the", "neuroprotective", "mechanisms", ".", "OBJECTIVE", "The", "purpose", "of", "this", "retrospective", "study", "is", "to", "contribute", "to", "the", "existing", "knowledge", "of", "the", "comparative", "studies", "of", "the", "volatile", "anesthetic", "agents", "such", "as", "isoflurane", ",", "sevoflurane", "and", "desflurane", "by", "evaluating", "the", "maintenance", "and", "emergence", "characteristics", "after", "volatile", "anesthetics", "-", "induced", "preconditioning", "with", "isoflurane", ",", "sevoflurane", "or", "desflurane", "for", "inpatient", "ischemia", "/", "reperfusion", "cerebral", "injury", "during", "cerebral", "or", "neural", "surgeries", ".", "METHODS", "The", "aim", "was", "to", "investigate", "their", "neuroprotective", "mechanisms", "and", "effects", "by", "analyzing", "and", "comparing", "the", "superiority", "of", "each", "agent", "in", "a", "Chinese", "patient", "population", ",", "in", "terms", "of", "faster", "emergence", ",", "and", "early", "and", "intermediate", "recovery", ".", "The", "intraoperative", "haemodynamic", "profiles", "and", "postoperative", "adverse", "effects", "of", "these", "three", "agents", "were", "also", "systematically", "analyzed", ".", "RESULTS", "We", "found", "that", "sevoflurane", ",", "when", "compared", "with", "isoflurane", "and", "desflurane", ",", "provided", "anesthesia", "with", "similar", "hemodynamic", "stability", "but", "allowed", "for", "a", "smoother", ",", "more", "rapid", "emergence", "and", "better", "quality", "of", "induction", "and", "recovery", "to", "surgical", "patients", "under", "clinical", "conditions", ",", "particularly", "to", "those", "who", "were", "experiencing", "substantial", "cerebral", "vasodilation", ".", "CONCLUSION", "Sevoflurane", "offers", "several", "advantages", ",", "including", "a", "relative", "lack", "of", "airway", "irritation", ",", "a", "more", "rapid", "onset", "and", "recovery", ",", "and", "greater", "hemodynamic", "stability", "than", "other", "potent", "inhaled", "agents", ".", "These", "properties", "would", "appear", "to", "afford", "sevoflurane", "significant", "clinical", "potential", "." ]	[ "Outcome_Other", "Participant_Condition", "Outcome_Adverse-effects", "Outcome_Physical", "Intervention_Pharmacological" ]
neuroprotective effects, recovery profiles, isoflurane, sevoflurane, desflurane, ischemia / reperfusion cerebral injury, neurosurgery, emergence, intraoperative haemodynamic profiles, postoperative adverse effects, hemodynamic stability, quality of induction and recovery, substantial cerebral vasodilation, Sevoflurane, airway irritation, onset and recovery	71481_task2	Sentence: Comparison of the neuroprotective effects and recovery profiles of isoflurane , sevoflurane and desflurane as neurosurgical pre-conditioning on ischemia/reperfusion cerebral injury . BACKGROUND There are a few reports regarding the comparison of these anesthetic agents , but previous studies mainly focus on the veterinary anesthesiology . Less attention has been focused comparing the effectiveness of these inhalational anesthetic agents in neurosurgery . This lack of interest is regretful particularly considering the fact that anesthetics during neurosurgery are an issue of extreme sensitivity and subtlety , where the cerebral oxygenation process plays a significant role in the neuroprotective mechanisms . OBJECTIVE The purpose of this retrospective study is to contribute to the existing knowledge of the comparative studies of the volatile anesthetic agents such as isoflurane , sevoflurane and desflurane by evaluating the maintenance and emergence characteristics after volatile anesthetics-induced preconditioning with isoflurane , sevoflurane or desflurane for inpatient ischemia/reperfusion cerebral injury during cerebral or neural surgeries . METHODS The aim was to investigate their neuroprotective mechanisms and effects by analyzing and comparing the superiority of each agent in a Chinese patient population , in terms of faster emergence , and early and intermediate recovery . The intraoperative haemodynamic profiles and postoperative adverse effects of these three agents were also systematically analyzed . RESULTS We found that sevoflurane , when compared with isoflurane and desflurane , provided anesthesia with similar hemodynamic stability but allowed for a smoother , more rapid emergence and better quality of induction and recovery to surgical patients under clinical conditions , particularly to those who were experiencing substantial cerebral vasodilation . CONCLUSION Sevoflurane offers several advantages , including a relative lack of airway irritation , a more rapid onset and recovery , and greater hemodynamic stability than other potent inhaled agents . These properties would appear to afford sevoflurane significant clinical potential . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Comparison of the neuroprotective effects and recovery profiles of isoflurane , sevoflurane and desflurane as neurosurgical pre-conditioning on ischemia/reperfusion cerebral injury . BACKGROUND There are a few reports regarding the comparison of these anesthetic agents , but previous studies mainly focus on the veterinary anesthesiology . Less attention has been focused comparing the effectiveness of these inhalational anesthetic agents in neurosurgery . This lack of interest is regretful particularly considering the fact that anesthetics during neurosurgery are an issue of extreme sensitivity and subtlety , where the cerebral oxygenation process plays a significant role in the neuroprotective mechanisms . OBJECTIVE The purpose of this retrospective study is to contribute to the existing knowledge of the comparative studies of the volatile anesthetic agents such as isoflurane , sevoflurane and desflurane by evaluating the maintenance and emergence characteristics after volatile anesthetics-induced preconditioning with isoflurane , sevoflurane or desflurane for inpatient ischemia/reperfusion cerebral injury during cerebral or neural surgeries . METHODS The aim was to investigate their neuroprotective mechanisms and effects by analyzing and comparing the superiority of each agent in a Chinese patient population , in terms of faster emergence , and early and intermediate recovery . The intraoperative haemodynamic profiles and postoperative adverse effects of these three agents were also systematically analyzed . RESULTS We found that sevoflurane , when compared with isoflurane and desflurane , provided anesthesia with similar hemodynamic stability but allowed for a smoother , more rapid emergence and better quality of induction and recovery to surgical patients under clinical conditions , particularly to those who were experiencing substantial cerebral vasodilation . CONCLUSION Sevoflurane offers several advantages , including a relative lack of airway irritation , a more rapid onset and recovery , and greater hemodynamic stability than other potent inhaled agents . These properties would appear to afford sevoflurane significant clinical potential .	[ "Comparison", "of", "the", "neuroprotective", "effects", "and", "recovery", "profiles", "of", "isoflurane", ",", "sevoflurane", "and", "desflurane", "as", "neurosurgical", "pre", "-", "conditioning", "on", "ischemia", "/", "reperfusion", "cerebral", "injury", ".", "BACKGROUND", "There", "are", "a", "few", "reports", "regarding", "the", "comparison", "of", "these", "anesthetic", "agents", ",", "but", "previous", "studies", "mainly", "focus", "on", "the", "veterinary", "anesthesiology", ".", "Less", "attention", "has", "been", "focused", "comparing", "the", "effectiveness", "of", "these", "inhalational", "anesthetic", "agents", "in", "neurosurgery", ".", "This", "lack", "of", "interest", "is", "regretful", "particularly", "considering", "the", "fact", "that", "anesthetics", "during", "neurosurgery", "are", "an", "issue", "of", "extreme", "sensitivity", "and", "subtlety", ",", "where", "the", "cerebral", "oxygenation", "process", "plays", "a", "significant", "role", "in", "the", "neuroprotective", "mechanisms", ".", "OBJECTIVE", "The", "purpose", "of", "this", "retrospective", "study", "is", "to", "contribute", "to", "the", "existing", "knowledge", "of", "the", "comparative", "studies", "of", "the", "volatile", "anesthetic", "agents", "such", "as", "isoflurane", ",", "sevoflurane", "and", "desflurane", "by", "evaluating", "the", "maintenance", "and", "emergence", "characteristics", "after", "volatile", "anesthetics", "-", "induced", "preconditioning", "with", "isoflurane", ",", "sevoflurane", "or", "desflurane", "for", "inpatient", "ischemia", "/", "reperfusion", "cerebral", "injury", "during", "cerebral", "or", "neural", "surgeries", ".", "METHODS", "The", "aim", "was", "to", "investigate", "their", "neuroprotective", "mechanisms", "and", "effects", "by", "analyzing", "and", "comparing", "the", "superiority", "of", "each", "agent", "in", "a", "Chinese", "patient", "population", ",", "in", "terms", "of", "faster", "emergence", ",", "and", "early", "and", "intermediate", "recovery", ".", "The", "intraoperative", "haemodynamic", "profiles", "and", "postoperative", "adverse", "effects", "of", "these", "three", "agents", "were", "also", "systematically", "analyzed", ".", "RESULTS", "We", "found", "that", "sevoflurane", ",", "when", "compared", "with", "isoflurane", "and", "desflurane", ",", "provided", "anesthesia", "with", "similar", "hemodynamic", "stability", "but", "allowed", "for", "a", "smoother", ",", "more", "rapid", "emergence", "and", "better", "quality", "of", "induction", "and", "recovery", "to", "surgical", "patients", "under", "clinical", "conditions", ",", "particularly", "to", "those", "who", "were", "experiencing", "substantial", "cerebral", "vasodilation", ".", "CONCLUSION", "Sevoflurane", "offers", "several", "advantages", ",", "including", "a", "relative", "lack", "of", "airway", "irritation", ",", "a", "more", "rapid", "onset", "and", "recovery", ",", "and", "greater", "hemodynamic", "stability", "than", "other", "potent", "inhaled", "agents", ".", "These", "properties", "would", "appear", "to", "afford", "sevoflurane", "significant", "clinical", "potential", "." ]	[ "Outcome_Other", "Participant_Condition", "Outcome_Adverse-effects", "Outcome_Physical", "Intervention_Pharmacological" ]
Vegfrecine is a CHEMICAL, VEGF Receptor Tyrosine Kinases is a GENE-N, VEGF receptor tyrosine kinases is a GENE-N, vegfrecine is a CHEMICAL, vascular endothelial growth factor receptor is a GENE-N, VEGFR is a GENE-N, tyrosine kinases is a GENE-N, platelet - derived growth factor receptors is a GENE-N, PDGFRs is a GENE-N, fibroblast growth factor receptor is a GENE-N, FGFR is a GENE-N, epidermal growth factor receptor is a GENE-Y, EGFR is a GENE-Y, VEGFR is a GENE-N	6312_task0	Sentence: Vegfrecine, an Inhibitor of VEGF Receptor Tyrosine Kinases Isolated from the Culture Broth of Streptomyces sp. A new inhibitor of VEGF receptor tyrosine kinases, vegfrecine (1), was isolated from the culture broth of Streptomyces sp. MK931-CF8. The molecular structure of 1 was determined by NMR and MS analysis combined with synthesis. Compound 1 showed potent inhibitory activity against vascular endothelial growth factor receptor (VEGFR) tyrosine kinases in in vitro enzyme assays, but platelet-derived growth factor receptors (PDGFRs), fibroblast growth factor receptor (FGFR), and epidermal growth factor receptor (EGFR) responded only weakly. Compound 1 is a promising new selective VEGFR inhibitor for investigating new treatments of cancer and inflammatory diseases. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N, CHEMICAL	[ "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Vegfrecine, an Inhibitor of VEGF Receptor Tyrosine Kinases Isolated from the Culture Broth of Streptomyces sp. A new inhibitor of VEGF receptor tyrosine kinases, vegfrecine (1), was isolated from the culture broth of Streptomyces sp. MK931-CF8. The molecular structure of 1 was determined by NMR and MS analysis combined with synthesis. Compound 1 showed potent inhibitory activity against vascular endothelial growth factor receptor (VEGFR) tyrosine kinases in in vitro enzyme assays, but platelet-derived growth factor receptors (PDGFRs), fibroblast growth factor receptor (FGFR), and epidermal growth factor receptor (EGFR) responded only weakly. Compound 1 is a promising new selective VEGFR inhibitor for investigating new treatments of cancer and inflammatory diseases.	[ "Vegfrecine", ",", "an", "Inhibitor", "of", "VEGF", "Receptor", "Tyrosine", "Kinases", "Isolated", "from", "the", "Culture", "Broth", "of", "Streptomyces", "sp", ".", "\n", "A", "new", "inhibitor", "of", "VEGF", "receptor", "tyrosine", "kinases", ",", "vegfrecine", "(", "1", ")", ",", "was", "isolated", "from", "the", "culture", "broth", "of", "Streptomyces", "sp", ".", "MK931-CF8", ".", "The", "molecular", "structure", "of", "1", "was", "determined", "by", "NMR", "and", "MS", "analysis", "combined", "with", "synthesis", ".", "Compound", "1", "showed", "potent", "inhibitory", "activity", "against", "vascular", "endothelial", "growth", "factor", "receptor", "(", "VEGFR", ")", "tyrosine", "kinases", "in", "in", "vitro", "enzyme", "assays", ",", "but", "platelet", "-", "derived", "growth", "factor", "receptors", "(", "PDGFRs", ")", ",", "fibroblast", "growth", "factor", "receptor", "(", "FGFR", ")", ",", "and", "epidermal", "growth", "factor", "receptor", "(", "EGFR", ")", "responded", "only", "weakly", ".", "Compound", "1", "is", "a", "promising", "new", "selective", "VEGFR", "inhibitor", "for", "investigating", "new", "treatments", "of", "cancer", "and", "inflammatory", "diseases", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
Vegfrecine is a CHEMICAL, VEGF Receptor Tyrosine Kinases is a GENE-N, VEGF receptor tyrosine kinases is a GENE-N, vegfrecine is a CHEMICAL, vascular endothelial growth factor receptor is a GENE-N, VEGFR is a GENE-N, tyrosine kinases is a GENE-N, platelet - derived growth factor receptors is a GENE-N, PDGFRs is a GENE-N, fibroblast growth factor receptor is a GENE-N, FGFR is a GENE-N, epidermal growth factor receptor is a GENE-Y, EGFR is a GENE-Y, VEGFR is a GENE-N	6312_task1	Sentence: Vegfrecine, an Inhibitor of VEGF Receptor Tyrosine Kinases Isolated from the Culture Broth of Streptomyces sp. A new inhibitor of VEGF receptor tyrosine kinases, vegfrecine (1), was isolated from the culture broth of Streptomyces sp. MK931-CF8. The molecular structure of 1 was determined by NMR and MS analysis combined with synthesis. Compound 1 showed potent inhibitory activity against vascular endothelial growth factor receptor (VEGFR) tyrosine kinases in in vitro enzyme assays, but platelet-derived growth factor receptors (PDGFRs), fibroblast growth factor receptor (FGFR), and epidermal growth factor receptor (EGFR) responded only weakly. Compound 1 is a promising new selective VEGFR inhibitor for investigating new treatments of cancer and inflammatory diseases. Instructions: please typing these entity words according to sentence: Vegfrecine, VEGF Receptor Tyrosine Kinases, VEGF receptor tyrosine kinases, vegfrecine, vascular endothelial growth factor receptor, VEGFR, tyrosine kinases, platelet - derived growth factor receptors, PDGFRs, fibroblast growth factor receptor, FGFR, epidermal growth factor receptor, EGFR, VEGFR Options: GENE-Y, GENE-N, CHEMICAL	[ "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Vegfrecine, an Inhibitor of VEGF Receptor Tyrosine Kinases Isolated from the Culture Broth of Streptomyces sp. A new inhibitor of VEGF receptor tyrosine kinases, vegfrecine (1), was isolated from the culture broth of Streptomyces sp. MK931-CF8. The molecular structure of 1 was determined by NMR and MS analysis combined with synthesis. Compound 1 showed potent inhibitory activity against vascular endothelial growth factor receptor (VEGFR) tyrosine kinases in in vitro enzyme assays, but platelet-derived growth factor receptors (PDGFRs), fibroblast growth factor receptor (FGFR), and epidermal growth factor receptor (EGFR) responded only weakly. Compound 1 is a promising new selective VEGFR inhibitor for investigating new treatments of cancer and inflammatory diseases.	[ "Vegfrecine", ",", "an", "Inhibitor", "of", "VEGF", "Receptor", "Tyrosine", "Kinases", "Isolated", "from", "the", "Culture", "Broth", "of", "Streptomyces", "sp", ".", "\n", "A", "new", "inhibitor", "of", "VEGF", "receptor", "tyrosine", "kinases", ",", "vegfrecine", "(", "1", ")", ",", "was", "isolated", "from", "the", "culture", "broth", "of", "Streptomyces", "sp", ".", "MK931-CF8", ".", "The", "molecular", "structure", "of", "1", "was", "determined", "by", "NMR", "and", "MS", "analysis", "combined", "with", "synthesis", ".", "Compound", "1", "showed", "potent", "inhibitory", "activity", "against", "vascular", "endothelial", "growth", "factor", "receptor", "(", "VEGFR", ")", "tyrosine", "kinases", "in", "in", "vitro", "enzyme", "assays", ",", "but", "platelet", "-", "derived", "growth", "factor", "receptors", "(", "PDGFRs", ")", ",", "fibroblast", "growth", "factor", "receptor", "(", "FGFR", ")", ",", "and", "epidermal", "growth", "factor", "receptor", "(", "EGFR", ")", "responded", "only", "weakly", ".", "Compound", "1", "is", "a", "promising", "new", "selective", "VEGFR", "inhibitor", "for", "investigating", "new", "treatments", "of", "cancer", "and", "inflammatory", "diseases", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
Vegfrecine, VEGF Receptor Tyrosine Kinases, VEGF receptor tyrosine kinases, vegfrecine, vascular endothelial growth factor receptor, VEGFR, tyrosine kinases, platelet - derived growth factor receptors, PDGFRs, fibroblast growth factor receptor, FGFR, epidermal growth factor receptor, EGFR, VEGFR	6312_task2	Sentence: Vegfrecine, an Inhibitor of VEGF Receptor Tyrosine Kinases Isolated from the Culture Broth of Streptomyces sp. A new inhibitor of VEGF receptor tyrosine kinases, vegfrecine (1), was isolated from the culture broth of Streptomyces sp. MK931-CF8. The molecular structure of 1 was determined by NMR and MS analysis combined with synthesis. Compound 1 showed potent inhibitory activity against vascular endothelial growth factor receptor (VEGFR) tyrosine kinases in in vitro enzyme assays, but platelet-derived growth factor receptors (PDGFRs), fibroblast growth factor receptor (FGFR), and epidermal growth factor receptor (EGFR) responded only weakly. Compound 1 is a promising new selective VEGFR inhibitor for investigating new treatments of cancer and inflammatory diseases. Instructions: please extract entity words from the input sentence	[ "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Vegfrecine, an Inhibitor of VEGF Receptor Tyrosine Kinases Isolated from the Culture Broth of Streptomyces sp. A new inhibitor of VEGF receptor tyrosine kinases, vegfrecine (1), was isolated from the culture broth of Streptomyces sp. MK931-CF8. The molecular structure of 1 was determined by NMR and MS analysis combined with synthesis. Compound 1 showed potent inhibitory activity against vascular endothelial growth factor receptor (VEGFR) tyrosine kinases in in vitro enzyme assays, but platelet-derived growth factor receptors (PDGFRs), fibroblast growth factor receptor (FGFR), and epidermal growth factor receptor (EGFR) responded only weakly. Compound 1 is a promising new selective VEGFR inhibitor for investigating new treatments of cancer and inflammatory diseases.	[ "Vegfrecine", ",", "an", "Inhibitor", "of", "VEGF", "Receptor", "Tyrosine", "Kinases", "Isolated", "from", "the", "Culture", "Broth", "of", "Streptomyces", "sp", ".", "\n", "A", "new", "inhibitor", "of", "VEGF", "receptor", "tyrosine", "kinases", ",", "vegfrecine", "(", "1", ")", ",", "was", "isolated", "from", "the", "culture", "broth", "of", "Streptomyces", "sp", ".", "MK931-CF8", ".", "The", "molecular", "structure", "of", "1", "was", "determined", "by", "NMR", "and", "MS", "analysis", "combined", "with", "synthesis", ".", "Compound", "1", "showed", "potent", "inhibitory", "activity", "against", "vascular", "endothelial", "growth", "factor", "receptor", "(", "VEGFR", ")", "tyrosine", "kinases", "in", "in", "vitro", "enzyme", "assays", ",", "but", "platelet", "-", "derived", "growth", "factor", "receptors", "(", "PDGFRs", ")", ",", "fibroblast", "growth", "factor", "receptor", "(", "FGFR", ")", ",", "and", "epidermal", "growth", "factor", "receptor", "(", "EGFR", ")", "responded", "only", "weakly", ".", "Compound", "1", "is", "a", "promising", "new", "selective", "VEGFR", "inhibitor", "for", "investigating", "new", "treatments", "of", "cancer", "and", "inflammatory", "diseases", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
Skelettsystem is an umlsterm, Polymere is an umlsterm, Knochenersatzstoffe is an umlsterm, Knochenzemente is an umlsterm, Knochenwachstumsfaktoren is an umlsterm, Zeit is an umlsterm, Langzeitergebnissen is an umlsterm	DerChirurg.90700888.ger.abstr_task0	Sentence: Zusammenfassung . Die zunehmende Anzahl unterschiedlicher Biomaterialien zur Anwendung im Skelettsystem erfordert immer mehr eine differenzierte Anwendung in der Klinik . Um ihren sinnvollen therapeutischen Einsatz zu gewaehrleisten , muessen die jeweiligen Biomaterialeigenschaften mit den Implantatlagereigenschaften abgestimmt sein . Weiterentwickelte biodegradierbare Polymere mit langsamer Umbaurate und laenger anhaltender Stabilitaet werden bei deutlich verminderter Komplikationsrate zunehmend erfolgreich eingesetzt . Im Bereich der keramischen Knochenersatzstoffe laesst die Entwicklung neuartiger umbaubarer Knochenzemente neben der Moeglichkeit der Defektauffuellung die Idee der Verbundosteosynthese " " wieder aufleben . Eine weitere vielversprechende Gruppe sind die rekombinant humanen Knochenwachstumsfaktoren , die zur Zeit in der klinischen Erprobung sind . Eine allgemeine erfolgreiche Anwendung mit verwertbaren Langzeitergebnissen steht noch aus . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Zusammenfassung . Die zunehmende Anzahl unterschiedlicher Biomaterialien zur Anwendung im Skelettsystem erfordert immer mehr eine differenzierte Anwendung in der Klinik . Um ihren sinnvollen therapeutischen Einsatz zu gewaehrleisten , muessen die jeweiligen Biomaterialeigenschaften mit den Implantatlagereigenschaften abgestimmt sein . Weiterentwickelte biodegradierbare Polymere mit langsamer Umbaurate und laenger anhaltender Stabilitaet werden bei deutlich verminderter Komplikationsrate zunehmend erfolgreich eingesetzt . Im Bereich der keramischen Knochenersatzstoffe laesst die Entwicklung neuartiger umbaubarer Knochenzemente neben der Moeglichkeit der Defektauffuellung die Idee der Verbundosteosynthese " " wieder aufleben . Eine weitere vielversprechende Gruppe sind die rekombinant humanen Knochenwachstumsfaktoren , die zur Zeit in der klinischen Erprobung sind . Eine allgemeine erfolgreiche Anwendung mit verwertbaren Langzeitergebnissen steht noch aus .	[ "Zusammenfassung", ".", "Die", "zunehmende", "Anzahl", "unterschiedlicher", "Biomaterialien", "zur", "Anwendung", "im", "Skelettsystem", "erfordert", "immer", "mehr", "eine", "differenzierte", "Anwendung", "in", "der", "Klinik", ".", "Um", "ihren", "sinnvollen", "therapeutischen", "Einsatz", "zu", "gewaehrleisten", ",", "muessen", "die", "jeweiligen", "Biomaterialeigenschaften", "mit", "den", "Implantatlagereigenschaften", "abgestimmt", "sein", ".", "Weiterentwickelte", "biodegradierbare", "Polymere", "mit", "langsamer", "Umbaurate", "und", "laenger", "anhaltender", "Stabilitaet", "werden", "bei", "deutlich", "verminderter", "Komplikationsrate", "zunehmend", "erfolgreich", "eingesetzt", ".", "Im", "Bereich", "der", "keramischen", "Knochenersatzstoffe", "laesst", "die", "Entwicklung", "neuartiger", "umbaubarer", "Knochenzemente", "neben", "der", "Moeglichkeit", "der", "Defektauffuellung", "die", "Idee", "der", "Verbundosteosynthese", "\"", "\"", "wieder", "aufleben", ".", "Eine", "weitere", "vielversprechende", "Gruppe", "sind", "die", "rekombinant", "humanen", "Knochenwachstumsfaktoren", ",", "die", "zur", "Zeit", "in", "der", "klinischen", "Erprobung", "sind", ".", "Eine", "allgemeine", "erfolgreiche", "Anwendung", "mit", "verwertbaren", "Langzeitergebnissen", "steht", "noch", "aus", "." ]	[ "umlsterm" ]
Skelettsystem is an umlsterm, Polymere is an umlsterm, Knochenersatzstoffe is an umlsterm, Knochenzemente is an umlsterm, Knochenwachstumsfaktoren is an umlsterm, Zeit is an umlsterm, Langzeitergebnissen is an umlsterm	DerChirurg.90700888.ger.abstr_task1	Sentence: Zusammenfassung . Die zunehmende Anzahl unterschiedlicher Biomaterialien zur Anwendung im Skelettsystem erfordert immer mehr eine differenzierte Anwendung in der Klinik . Um ihren sinnvollen therapeutischen Einsatz zu gewaehrleisten , muessen die jeweiligen Biomaterialeigenschaften mit den Implantatlagereigenschaften abgestimmt sein . Weiterentwickelte biodegradierbare Polymere mit langsamer Umbaurate und laenger anhaltender Stabilitaet werden bei deutlich verminderter Komplikationsrate zunehmend erfolgreich eingesetzt . Im Bereich der keramischen Knochenersatzstoffe laesst die Entwicklung neuartiger umbaubarer Knochenzemente neben der Moeglichkeit der Defektauffuellung die Idee der Verbundosteosynthese " " wieder aufleben . Eine weitere vielversprechende Gruppe sind die rekombinant humanen Knochenwachstumsfaktoren , die zur Zeit in der klinischen Erprobung sind . Eine allgemeine erfolgreiche Anwendung mit verwertbaren Langzeitergebnissen steht noch aus . Instructions: please typing these entity words according to sentence: Skelettsystem, Polymere, Knochenersatzstoffe, Knochenzemente, Knochenwachstumsfaktoren, Zeit, Langzeitergebnissen Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Zusammenfassung . Die zunehmende Anzahl unterschiedlicher Biomaterialien zur Anwendung im Skelettsystem erfordert immer mehr eine differenzierte Anwendung in der Klinik . Um ihren sinnvollen therapeutischen Einsatz zu gewaehrleisten , muessen die jeweiligen Biomaterialeigenschaften mit den Implantatlagereigenschaften abgestimmt sein . Weiterentwickelte biodegradierbare Polymere mit langsamer Umbaurate und laenger anhaltender Stabilitaet werden bei deutlich verminderter Komplikationsrate zunehmend erfolgreich eingesetzt . Im Bereich der keramischen Knochenersatzstoffe laesst die Entwicklung neuartiger umbaubarer Knochenzemente neben der Moeglichkeit der Defektauffuellung die Idee der Verbundosteosynthese " " wieder aufleben . Eine weitere vielversprechende Gruppe sind die rekombinant humanen Knochenwachstumsfaktoren , die zur Zeit in der klinischen Erprobung sind . Eine allgemeine erfolgreiche Anwendung mit verwertbaren Langzeitergebnissen steht noch aus .	[ "Zusammenfassung", ".", "Die", "zunehmende", "Anzahl", "unterschiedlicher", "Biomaterialien", "zur", "Anwendung", "im", "Skelettsystem", "erfordert", "immer", "mehr", "eine", "differenzierte", "Anwendung", "in", "der", "Klinik", ".", "Um", "ihren", "sinnvollen", "therapeutischen", "Einsatz", "zu", "gewaehrleisten", ",", "muessen", "die", "jeweiligen", "Biomaterialeigenschaften", "mit", "den", "Implantatlagereigenschaften", "abgestimmt", "sein", ".", "Weiterentwickelte", "biodegradierbare", "Polymere", "mit", "langsamer", "Umbaurate", "und", "laenger", "anhaltender", "Stabilitaet", "werden", "bei", "deutlich", "verminderter", "Komplikationsrate", "zunehmend", "erfolgreich", "eingesetzt", ".", "Im", "Bereich", "der", "keramischen", "Knochenersatzstoffe", "laesst", "die", "Entwicklung", "neuartiger", "umbaubarer", "Knochenzemente", "neben", "der", "Moeglichkeit", "der", "Defektauffuellung", "die", "Idee", "der", "Verbundosteosynthese", "\"", "\"", "wieder", "aufleben", ".", "Eine", "weitere", "vielversprechende", "Gruppe", "sind", "die", "rekombinant", "humanen", "Knochenwachstumsfaktoren", ",", "die", "zur", "Zeit", "in", "der", "klinischen", "Erprobung", "sind", ".", "Eine", "allgemeine", "erfolgreiche", "Anwendung", "mit", "verwertbaren", "Langzeitergebnissen", "steht", "noch", "aus", "." ]	[ "umlsterm" ]
Skelettsystem, Polymere, Knochenersatzstoffe, Knochenzemente, Knochenwachstumsfaktoren, Zeit, Langzeitergebnissen	DerChirurg.90700888.ger.abstr_task2	Sentence: Zusammenfassung . Die zunehmende Anzahl unterschiedlicher Biomaterialien zur Anwendung im Skelettsystem erfordert immer mehr eine differenzierte Anwendung in der Klinik . Um ihren sinnvollen therapeutischen Einsatz zu gewaehrleisten , muessen die jeweiligen Biomaterialeigenschaften mit den Implantatlagereigenschaften abgestimmt sein . Weiterentwickelte biodegradierbare Polymere mit langsamer Umbaurate und laenger anhaltender Stabilitaet werden bei deutlich verminderter Komplikationsrate zunehmend erfolgreich eingesetzt . Im Bereich der keramischen Knochenersatzstoffe laesst die Entwicklung neuartiger umbaubarer Knochenzemente neben der Moeglichkeit der Defektauffuellung die Idee der Verbundosteosynthese " " wieder aufleben . Eine weitere vielversprechende Gruppe sind die rekombinant humanen Knochenwachstumsfaktoren , die zur Zeit in der klinischen Erprobung sind . Eine allgemeine erfolgreiche Anwendung mit verwertbaren Langzeitergebnissen steht noch aus . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Zusammenfassung . Die zunehmende Anzahl unterschiedlicher Biomaterialien zur Anwendung im Skelettsystem erfordert immer mehr eine differenzierte Anwendung in der Klinik . Um ihren sinnvollen therapeutischen Einsatz zu gewaehrleisten , muessen die jeweiligen Biomaterialeigenschaften mit den Implantatlagereigenschaften abgestimmt sein . Weiterentwickelte biodegradierbare Polymere mit langsamer Umbaurate und laenger anhaltender Stabilitaet werden bei deutlich verminderter Komplikationsrate zunehmend erfolgreich eingesetzt . Im Bereich der keramischen Knochenersatzstoffe laesst die Entwicklung neuartiger umbaubarer Knochenzemente neben der Moeglichkeit der Defektauffuellung die Idee der Verbundosteosynthese " " wieder aufleben . Eine weitere vielversprechende Gruppe sind die rekombinant humanen Knochenwachstumsfaktoren , die zur Zeit in der klinischen Erprobung sind . Eine allgemeine erfolgreiche Anwendung mit verwertbaren Langzeitergebnissen steht noch aus .	[ "Zusammenfassung", ".", "Die", "zunehmende", "Anzahl", "unterschiedlicher", "Biomaterialien", "zur", "Anwendung", "im", "Skelettsystem", "erfordert", "immer", "mehr", "eine", "differenzierte", "Anwendung", "in", "der", "Klinik", ".", "Um", "ihren", "sinnvollen", "therapeutischen", "Einsatz", "zu", "gewaehrleisten", ",", "muessen", "die", "jeweiligen", "Biomaterialeigenschaften", "mit", "den", "Implantatlagereigenschaften", "abgestimmt", "sein", ".", "Weiterentwickelte", "biodegradierbare", "Polymere", "mit", "langsamer", "Umbaurate", "und", "laenger", "anhaltender", "Stabilitaet", "werden", "bei", "deutlich", "verminderter", "Komplikationsrate", "zunehmend", "erfolgreich", "eingesetzt", ".", "Im", "Bereich", "der", "keramischen", "Knochenersatzstoffe", "laesst", "die", "Entwicklung", "neuartiger", "umbaubarer", "Knochenzemente", "neben", "der", "Moeglichkeit", "der", "Defektauffuellung", "die", "Idee", "der", "Verbundosteosynthese", "\"", "\"", "wieder", "aufleben", ".", "Eine", "weitere", "vielversprechende", "Gruppe", "sind", "die", "rekombinant", "humanen", "Knochenwachstumsfaktoren", ",", "die", "zur", "Zeit", "in", "der", "klinischen", "Erprobung", "sind", ".", "Eine", "allgemeine", "erfolgreiche", "Anwendung", "mit", "verwertbaren", "Langzeitergebnissen", "steht", "noch", "aus", "." ]	[ "umlsterm" ]
NF - kappa B activation is an other_name, tumor necrosis factor alpha is a protein_molecule, Jurkat T cell line is a cell_line, protein kinase A is a protein_molecule, protein kinase C is a protein_molecule, Ca(2+)-regulated kinases is a protein_family_or_group	93683_task0	Sentence: NF-kappa B activation by tumor necrosis factor alpha in the Jurkat T cell line is independent of protein kinase A, protein kinase C, and Ca(2+)-regulated kinases. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_family_or_group, cell_line, protein_molecule, other_name	[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O" ]	NF-kappa B activation by tumor necrosis factor alpha in the Jurkat T cell line is independent of protein kinase A, protein kinase C, and Ca(2+)-regulated kinases.	[ "NF", "-", "kappa", "B", "activation", "by", "tumor", "necrosis", "factor", "alpha", "in", "the", "Jurkat", "T", "cell", "line", "is", "independent", "of", "protein", "kinase", "A", ",", "protein", "kinase", "C", ",", "and", "Ca(2+)-regulated", "kinases", "." ]	[ "DNA_family_or_group", "other_name", "protein_molecule", "virus", "protein_family_or_group", "cell_line", "other_organic_compound", "cell_type", "atom", "nucleotide" ]
NF - kappa B activation is an other_name, tumor necrosis factor alpha is a protein_molecule, Jurkat T cell line is a cell_line, protein kinase A is a protein_molecule, protein kinase C is a protein_molecule, Ca(2+)-regulated kinases is a protein_family_or_group	93683_task1	Sentence: NF-kappa B activation by tumor necrosis factor alpha in the Jurkat T cell line is independent of protein kinase A, protein kinase C, and Ca(2+)-regulated kinases. Instructions: please typing these entity words according to sentence: NF - kappa B activation, tumor necrosis factor alpha, Jurkat T cell line, protein kinase A, protein kinase C, Ca(2+)-regulated kinases Options: protein_family_or_group, cell_line, protein_molecule, other_name	[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O" ]	NF-kappa B activation by tumor necrosis factor alpha in the Jurkat T cell line is independent of protein kinase A, protein kinase C, and Ca(2+)-regulated kinases.	[ "NF", "-", "kappa", "B", "activation", "by", "tumor", "necrosis", "factor", "alpha", "in", "the", "Jurkat", "T", "cell", "line", "is", "independent", "of", "protein", "kinase", "A", ",", "protein", "kinase", "C", ",", "and", "Ca(2+)-regulated", "kinases", "." ]	[ "DNA_family_or_group", "other_name", "protein_molecule", "virus", "protein_family_or_group", "cell_line", "other_organic_compound", "cell_type", "atom", "nucleotide" ]
NF - kappa B activation, tumor necrosis factor alpha, Jurkat T cell line, protein kinase A, protein kinase C, Ca(2+)-regulated kinases	93683_task2	Sentence: NF-kappa B activation by tumor necrosis factor alpha in the Jurkat T cell line is independent of protein kinase A, protein kinase C, and Ca(2+)-regulated kinases. Instructions: please extract entity words from the input sentence	[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O" ]	NF-kappa B activation by tumor necrosis factor alpha in the Jurkat T cell line is independent of protein kinase A, protein kinase C, and Ca(2+)-regulated kinases.	[ "NF", "-", "kappa", "B", "activation", "by", "tumor", "necrosis", "factor", "alpha", "in", "the", "Jurkat", "T", "cell", "line", "is", "independent", "of", "protein", "kinase", "A", ",", "protein", "kinase", "C", ",", "and", "Ca(2+)-regulated", "kinases", "." ]	[ "DNA_family_or_group", "other_name", "protein_molecule", "virus", "protein_family_or_group", "cell_line", "other_organic_compound", "cell_type", "atom", "nucleotide" ]
pathologic response is a Outcome_Physical, neoadjuvant chemotherapy and trastuzumab is a Intervention_Pharmacological, Preoperative therapy with chemotherapy is a Intervention_Pharmacological, HER2-targeted monoclonal antibody trastuzumab is a Intervention_Pharmacological, patients with large or locally advanced HER2-positive ( HER2 + ) breast cancers is a Participant_Condition, core biopsy samples from 27 HER2 + breast cancer patients enrolled in a preoperative clinical trial using trastuzumab , nab - paclitaxel and carboplatin combination therapy ( BrUOG BR-211B ( NCT00617942 ) ) is a Participant_Condition, pathologic complete response ( pathCR ) is a Outcome_Physical, Measurement of phospho - HER2 is a Outcome_Physical, in the HER2 or phospho - HER2 levels is a Outcome_Physical, High levels of is a Outcome_Physical, levels of Phospho - HER2 is a Outcome_Physical	65819_task0	Sentence: Quantitative measurements of HER2 and phospho-HER2 expression : correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab . BACKGROUND Preoperative therapy with chemotherapy and the HER2-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER2-positive ( HER2+ ) breast cancers but traditional methods of measuring HER2 expression do not accurately stratify patients for likelihood of response . Quantitative immunofluorescent approaches have the potential to provide a mathematically continuous measure of HER2 . Here we seek to determine whether quantitative measurement of HER2 or phospho-HER2 correlates with likelihood of response to trastuzumab- containing neoadjuvant therapy . METHODS We evaluated core biopsy samples from 27 HER2+ breast cancer patients enrolled in a preoperative clinical trial using trastuzumab , nab-paclitaxel and carboplatin combination therapy ( BrUOG BR-211B ( NCT00617942 ) ) . Tumor core biopsies were taken before initiation of treatment and 9-13 days after patients received " run-in " doses of either single agent trastuzumab or nab-paclitaxel . The AQUA method of quantitative immunofluorescence was used for analysis of in situ protein expression . Patients then received 18 weeks of treatment , followed by surgery to assess pathologic response to the neoadjuvant regimen . RESULTS A HER2 score of 2111 by AQUA analysis has been shown to be equivalent to HER2 3+ by immunohistochemical staining in previous studies . Of 20 evaluable patients , 10 cases who achieved a pathologic complete response ( pathCR ) with neoadjuvant treatment had a mean HER2 level of 10251 compared with 4766 in the patients without pathCR ( p = 0.0021 ) . Measurement of phospho-HER2 showed no difference in pathCR vs non-pathCR groups . In 9 patients who had HER2 levels repeated after a single treatment with trastuzumab there was no evidence of a reduction in the HER2 or phospho-HER2 levels following that exposure . CONCLUSIONS High levels of HER2 are associated with achievement of a pathCR in the preoperative setting , while levels of Phospho-HER2 were not predictive of response . This data suggests that accurate measurement of HER2 may help determine the likelihood of response in the pre-surgical setting . Further validation in larger cohorts is required , but this pilot data shows the feasibility of this approach . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Quantitative measurements of HER2 and phospho-HER2 expression : correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab . BACKGROUND Preoperative therapy with chemotherapy and the HER2-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER2-positive ( HER2+ ) breast cancers but traditional methods of measuring HER2 expression do not accurately stratify patients for likelihood of response . Quantitative immunofluorescent approaches have the potential to provide a mathematically continuous measure of HER2 . Here we seek to determine whether quantitative measurement of HER2 or phospho-HER2 correlates with likelihood of response to trastuzumab- containing neoadjuvant therapy . METHODS We evaluated core biopsy samples from 27 HER2+ breast cancer patients enrolled in a preoperative clinical trial using trastuzumab , nab-paclitaxel and carboplatin combination therapy ( BrUOG BR-211B ( NCT00617942 ) ) . Tumor core biopsies were taken before initiation of treatment and 9-13 days after patients received " run-in " doses of either single agent trastuzumab or nab-paclitaxel . The AQUA method of quantitative immunofluorescence was used for analysis of in situ protein expression . Patients then received 18 weeks of treatment , followed by surgery to assess pathologic response to the neoadjuvant regimen . RESULTS A HER2 score of 2111 by AQUA analysis has been shown to be equivalent to HER2 3+ by immunohistochemical staining in previous studies . Of 20 evaluable patients , 10 cases who achieved a pathologic complete response ( pathCR ) with neoadjuvant treatment had a mean HER2 level of 10251 compared with 4766 in the patients without pathCR ( p = 0.0021 ) . Measurement of phospho-HER2 showed no difference in pathCR vs non-pathCR groups . In 9 patients who had HER2 levels repeated after a single treatment with trastuzumab there was no evidence of a reduction in the HER2 or phospho-HER2 levels following that exposure . CONCLUSIONS High levels of HER2 are associated with achievement of a pathCR in the preoperative setting , while levels of Phospho-HER2 were not predictive of response . This data suggests that accurate measurement of HER2 may help determine the likelihood of response in the pre-surgical setting . Further validation in larger cohorts is required , but this pilot data shows the feasibility of this approach .	[ "Quantitative", "measurements", "of", "HER2", "and", "phospho", "-", "HER2", "expression", ":", "correlation", "with", "pathologic", "response", "to", "neoadjuvant", "chemotherapy", "and", "trastuzumab", ".", "BACKGROUND", "Preoperative", "therapy", "with", "chemotherapy", "and", "the", "HER2-targeted", "monoclonal", "antibody", "trastuzumab", "is", "valuable", "for", "patients", "with", "large", "or", "locally", "advanced", "HER2-positive", "(", "HER2", "+", ")", "breast", "cancers", "but", "traditional", "methods", "of", "measuring", "HER2", "expression", "do", "not", "accurately", "stratify", "patients", "for", "likelihood", "of", "response", ".", "Quantitative", "immunofluorescent", "approaches", "have", "the", "potential", "to", "provide", "a", "mathematically", "continuous", "measure", "of", "HER2", ".", "Here", "we", "seek", "to", "determine", "whether", "quantitative", "measurement", "of", "HER2", "or", "phospho", "-", "HER2", "correlates", "with", "likelihood", "of", "response", "to", "trastuzumab-", "containing", "neoadjuvant", "therapy", ".", "METHODS", "We", "evaluated", "core", "biopsy", "samples", "from", "27", "HER2", "+", "breast", "cancer", "patients", "enrolled", "in", "a", "preoperative", "clinical", "trial", "using", "trastuzumab", ",", "nab", "-", "paclitaxel", "and", "carboplatin", "combination", "therapy", "(", "BrUOG", "BR-211B", "(", "NCT00617942", ")", ")", ".", "Tumor", "core", "biopsies", "were", "taken", "before", "initiation", "of", "treatment", "and", "9", "-", "13", "days", "after", "patients", "received", "\"", "run", "-", "in", "\"", "doses", "of", "either", "single", "agent", "trastuzumab", "or", "nab", "-", "paclitaxel", ".", "The", "AQUA", "method", "of", "quantitative", "immunofluorescence", "was", "used", "for", "analysis", "of", "in", "situ", "protein", "expression", ".", "Patients", "then", "received", "18", "weeks", "of", "treatment", ",", "followed", "by", "surgery", "to", "assess", "pathologic", "response", "to", "the", "neoadjuvant", "regimen", ".", "RESULTS", "A", "HER2", "score", "of", "2111", "by", "AQUA", "analysis", "has", "been", "shown", "to", "be", "equivalent", "to", "HER2", "3", "+", "by", "immunohistochemical", "staining", "in", "previous", "studies", ".", "Of", "20", "evaluable", "patients", ",", "10", "cases", "who", "achieved", "a", "pathologic", "complete", "response", "(", "pathCR", ")", "with", "neoadjuvant", "treatment", "had", "a", "mean", "HER2", "level", "of", "10251", "compared", "with", "4766", "in", "the", "patients", "without", "pathCR", "(", "p", "=", "0.0021", ")", ".", "Measurement", "of", "phospho", "-", "HER2", "showed", "no", "difference", "in", "pathCR", "vs", "non", "-", "pathCR", "groups", ".", "In", "9", "patients", "who", "had", "HER2", "levels", "repeated", "after", "a", "single", "treatment", "with", "trastuzumab", "there", "was", "no", "evidence", "of", "a", "reduction", "in", "the", "HER2", "or", "phospho", "-", "HER2", "levels", "following", "that", "exposure", ".", "CONCLUSIONS", "High", "levels", "of", "HER2", "are", "associated", "with", "achievement", "of", "a", "pathCR", "in", "the", "preoperative", "setting", ",", "while", "levels", "of", "Phospho", "-", "HER2", "were", "not", "predictive", "of", "response", ".", "This", "data", "suggests", "that", "accurate", "measurement", "of", "HER2", "may", "help", "determine", "the", "likelihood", "of", "response", "in", "the", "pre", "-", "surgical", "setting", ".", "Further", "validation", "in", "larger", "cohorts", "is", "required", ",", "but", "this", "pilot", "data", "shows", "the", "feasibility", "of", "this", "approach", "." ]	[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Physical" ]
pathologic response is a Outcome_Physical, neoadjuvant chemotherapy and trastuzumab is a Intervention_Pharmacological, Preoperative therapy with chemotherapy is a Intervention_Pharmacological, HER2-targeted monoclonal antibody trastuzumab is a Intervention_Pharmacological, patients with large or locally advanced HER2-positive ( HER2 + ) breast cancers is a Participant_Condition, core biopsy samples from 27 HER2 + breast cancer patients enrolled in a preoperative clinical trial using trastuzumab , nab - paclitaxel and carboplatin combination therapy ( BrUOG BR-211B ( NCT00617942 ) ) is a Participant_Condition, pathologic complete response ( pathCR ) is a Outcome_Physical, Measurement of phospho - HER2 is a Outcome_Physical, in the HER2 or phospho - HER2 levels is a Outcome_Physical, High levels of is a Outcome_Physical, levels of Phospho - HER2 is a Outcome_Physical	65819_task1	Sentence: Quantitative measurements of HER2 and phospho-HER2 expression : correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab . BACKGROUND Preoperative therapy with chemotherapy and the HER2-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER2-positive ( HER2+ ) breast cancers but traditional methods of measuring HER2 expression do not accurately stratify patients for likelihood of response . Quantitative immunofluorescent approaches have the potential to provide a mathematically continuous measure of HER2 . Here we seek to determine whether quantitative measurement of HER2 or phospho-HER2 correlates with likelihood of response to trastuzumab- containing neoadjuvant therapy . METHODS We evaluated core biopsy samples from 27 HER2+ breast cancer patients enrolled in a preoperative clinical trial using trastuzumab , nab-paclitaxel and carboplatin combination therapy ( BrUOG BR-211B ( NCT00617942 ) ) . Tumor core biopsies were taken before initiation of treatment and 9-13 days after patients received " run-in " doses of either single agent trastuzumab or nab-paclitaxel . The AQUA method of quantitative immunofluorescence was used for analysis of in situ protein expression . Patients then received 18 weeks of treatment , followed by surgery to assess pathologic response to the neoadjuvant regimen . RESULTS A HER2 score of 2111 by AQUA analysis has been shown to be equivalent to HER2 3+ by immunohistochemical staining in previous studies . Of 20 evaluable patients , 10 cases who achieved a pathologic complete response ( pathCR ) with neoadjuvant treatment had a mean HER2 level of 10251 compared with 4766 in the patients without pathCR ( p = 0.0021 ) . Measurement of phospho-HER2 showed no difference in pathCR vs non-pathCR groups . In 9 patients who had HER2 levels repeated after a single treatment with trastuzumab there was no evidence of a reduction in the HER2 or phospho-HER2 levels following that exposure . CONCLUSIONS High levels of HER2 are associated with achievement of a pathCR in the preoperative setting , while levels of Phospho-HER2 were not predictive of response . This data suggests that accurate measurement of HER2 may help determine the likelihood of response in the pre-surgical setting . Further validation in larger cohorts is required , but this pilot data shows the feasibility of this approach . Instructions: please typing these entity words according to sentence: pathologic response, neoadjuvant chemotherapy and trastuzumab, Preoperative therapy with chemotherapy, HER2-targeted monoclonal antibody trastuzumab, patients with large or locally advanced HER2-positive ( HER2 + ) breast cancers, core biopsy samples from 27 HER2 + breast cancer patients enrolled in a preoperative clinical trial using trastuzumab , nab - paclitaxel and carboplatin combination therapy ( BrUOG BR-211B ( NCT00617942 ) ), pathologic complete response ( pathCR ), Measurement of phospho - HER2, in the HER2 or phospho - HER2 levels, High levels of, levels of Phospho - HER2 Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Quantitative measurements of HER2 and phospho-HER2 expression : correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab . BACKGROUND Preoperative therapy with chemotherapy and the HER2-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER2-positive ( HER2+ ) breast cancers but traditional methods of measuring HER2 expression do not accurately stratify patients for likelihood of response . Quantitative immunofluorescent approaches have the potential to provide a mathematically continuous measure of HER2 . Here we seek to determine whether quantitative measurement of HER2 or phospho-HER2 correlates with likelihood of response to trastuzumab- containing neoadjuvant therapy . METHODS We evaluated core biopsy samples from 27 HER2+ breast cancer patients enrolled in a preoperative clinical trial using trastuzumab , nab-paclitaxel and carboplatin combination therapy ( BrUOG BR-211B ( NCT00617942 ) ) . Tumor core biopsies were taken before initiation of treatment and 9-13 days after patients received " run-in " doses of either single agent trastuzumab or nab-paclitaxel . The AQUA method of quantitative immunofluorescence was used for analysis of in situ protein expression . Patients then received 18 weeks of treatment , followed by surgery to assess pathologic response to the neoadjuvant regimen . RESULTS A HER2 score of 2111 by AQUA analysis has been shown to be equivalent to HER2 3+ by immunohistochemical staining in previous studies . Of 20 evaluable patients , 10 cases who achieved a pathologic complete response ( pathCR ) with neoadjuvant treatment had a mean HER2 level of 10251 compared with 4766 in the patients without pathCR ( p = 0.0021 ) . Measurement of phospho-HER2 showed no difference in pathCR vs non-pathCR groups . In 9 patients who had HER2 levels repeated after a single treatment with trastuzumab there was no evidence of a reduction in the HER2 or phospho-HER2 levels following that exposure . CONCLUSIONS High levels of HER2 are associated with achievement of a pathCR in the preoperative setting , while levels of Phospho-HER2 were not predictive of response . This data suggests that accurate measurement of HER2 may help determine the likelihood of response in the pre-surgical setting . Further validation in larger cohorts is required , but this pilot data shows the feasibility of this approach .	[ "Quantitative", "measurements", "of", "HER2", "and", "phospho", "-", "HER2", "expression", ":", "correlation", "with", "pathologic", "response", "to", "neoadjuvant", "chemotherapy", "and", "trastuzumab", ".", "BACKGROUND", "Preoperative", "therapy", "with", "chemotherapy", "and", "the", "HER2-targeted", "monoclonal", "antibody", "trastuzumab", "is", "valuable", "for", "patients", "with", "large", "or", "locally", "advanced", "HER2-positive", "(", "HER2", "+", ")", "breast", "cancers", "but", "traditional", "methods", "of", "measuring", "HER2", "expression", "do", "not", "accurately", "stratify", "patients", "for", "likelihood", "of", "response", ".", "Quantitative", "immunofluorescent", "approaches", "have", "the", "potential", "to", "provide", "a", "mathematically", "continuous", "measure", "of", "HER2", ".", "Here", "we", "seek", "to", "determine", "whether", "quantitative", "measurement", "of", "HER2", "or", "phospho", "-", "HER2", "correlates", "with", "likelihood", "of", "response", "to", "trastuzumab-", "containing", "neoadjuvant", "therapy", ".", "METHODS", "We", "evaluated", "core", "biopsy", "samples", "from", "27", "HER2", "+", "breast", "cancer", "patients", "enrolled", "in", "a", "preoperative", "clinical", "trial", "using", "trastuzumab", ",", "nab", "-", "paclitaxel", "and", "carboplatin", "combination", "therapy", "(", "BrUOG", "BR-211B", "(", "NCT00617942", ")", ")", ".", "Tumor", "core", "biopsies", "were", "taken", "before", "initiation", "of", "treatment", "and", "9", "-", "13", "days", "after", "patients", "received", "\"", "run", "-", "in", "\"", "doses", "of", "either", "single", "agent", "trastuzumab", "or", "nab", "-", "paclitaxel", ".", "The", "AQUA", "method", "of", "quantitative", "immunofluorescence", "was", "used", "for", "analysis", "of", "in", "situ", "protein", "expression", ".", "Patients", "then", "received", "18", "weeks", "of", "treatment", ",", "followed", "by", "surgery", "to", "assess", "pathologic", "response", "to", "the", "neoadjuvant", "regimen", ".", "RESULTS", "A", "HER2", "score", "of", "2111", "by", "AQUA", "analysis", "has", "been", "shown", "to", "be", "equivalent", "to", "HER2", "3", "+", "by", "immunohistochemical", "staining", "in", "previous", "studies", ".", "Of", "20", "evaluable", "patients", ",", "10", "cases", "who", "achieved", "a", "pathologic", "complete", "response", "(", "pathCR", ")", "with", "neoadjuvant", "treatment", "had", "a", "mean", "HER2", "level", "of", "10251", "compared", "with", "4766", "in", "the", "patients", "without", "pathCR", "(", "p", "=", "0.0021", ")", ".", "Measurement", "of", "phospho", "-", "HER2", "showed", "no", "difference", "in", "pathCR", "vs", "non", "-", "pathCR", "groups", ".", "In", "9", "patients", "who", "had", "HER2", "levels", "repeated", "after", "a", "single", "treatment", "with", "trastuzumab", "there", "was", "no", "evidence", "of", "a", "reduction", "in", "the", "HER2", "or", "phospho", "-", "HER2", "levels", "following", "that", "exposure", ".", "CONCLUSIONS", "High", "levels", "of", "HER2", "are", "associated", "with", "achievement", "of", "a", "pathCR", "in", "the", "preoperative", "setting", ",", "while", "levels", "of", "Phospho", "-", "HER2", "were", "not", "predictive", "of", "response", ".", "This", "data", "suggests", "that", "accurate", "measurement", "of", "HER2", "may", "help", "determine", "the", "likelihood", "of", "response", "in", "the", "pre", "-", "surgical", "setting", ".", "Further", "validation", "in", "larger", "cohorts", "is", "required", ",", "but", "this", "pilot", "data", "shows", "the", "feasibility", "of", "this", "approach", "." ]	[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Physical" ]
pathologic response, neoadjuvant chemotherapy and trastuzumab, Preoperative therapy with chemotherapy, HER2-targeted monoclonal antibody trastuzumab, patients with large or locally advanced HER2-positive ( HER2 + ) breast cancers, core biopsy samples from 27 HER2 + breast cancer patients enrolled in a preoperative clinical trial using trastuzumab , nab - paclitaxel and carboplatin combination therapy ( BrUOG BR-211B ( NCT00617942 ) ), pathologic complete response ( pathCR ), Measurement of phospho - HER2, in the HER2 or phospho - HER2 levels, High levels of, levels of Phospho - HER2	65819_task2	Sentence: Quantitative measurements of HER2 and phospho-HER2 expression : correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab . BACKGROUND Preoperative therapy with chemotherapy and the HER2-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER2-positive ( HER2+ ) breast cancers but traditional methods of measuring HER2 expression do not accurately stratify patients for likelihood of response . Quantitative immunofluorescent approaches have the potential to provide a mathematically continuous measure of HER2 . Here we seek to determine whether quantitative measurement of HER2 or phospho-HER2 correlates with likelihood of response to trastuzumab- containing neoadjuvant therapy . METHODS We evaluated core biopsy samples from 27 HER2+ breast cancer patients enrolled in a preoperative clinical trial using trastuzumab , nab-paclitaxel and carboplatin combination therapy ( BrUOG BR-211B ( NCT00617942 ) ) . Tumor core biopsies were taken before initiation of treatment and 9-13 days after patients received " run-in " doses of either single agent trastuzumab or nab-paclitaxel . The AQUA method of quantitative immunofluorescence was used for analysis of in situ protein expression . Patients then received 18 weeks of treatment , followed by surgery to assess pathologic response to the neoadjuvant regimen . RESULTS A HER2 score of 2111 by AQUA analysis has been shown to be equivalent to HER2 3+ by immunohistochemical staining in previous studies . Of 20 evaluable patients , 10 cases who achieved a pathologic complete response ( pathCR ) with neoadjuvant treatment had a mean HER2 level of 10251 compared with 4766 in the patients without pathCR ( p = 0.0021 ) . Measurement of phospho-HER2 showed no difference in pathCR vs non-pathCR groups . In 9 patients who had HER2 levels repeated after a single treatment with trastuzumab there was no evidence of a reduction in the HER2 or phospho-HER2 levels following that exposure . CONCLUSIONS High levels of HER2 are associated with achievement of a pathCR in the preoperative setting , while levels of Phospho-HER2 were not predictive of response . This data suggests that accurate measurement of HER2 may help determine the likelihood of response in the pre-surgical setting . Further validation in larger cohorts is required , but this pilot data shows the feasibility of this approach . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Quantitative measurements of HER2 and phospho-HER2 expression : correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab . BACKGROUND Preoperative therapy with chemotherapy and the HER2-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER2-positive ( HER2+ ) breast cancers but traditional methods of measuring HER2 expression do not accurately stratify patients for likelihood of response . Quantitative immunofluorescent approaches have the potential to provide a mathematically continuous measure of HER2 . Here we seek to determine whether quantitative measurement of HER2 or phospho-HER2 correlates with likelihood of response to trastuzumab- containing neoadjuvant therapy . METHODS We evaluated core biopsy samples from 27 HER2+ breast cancer patients enrolled in a preoperative clinical trial using trastuzumab , nab-paclitaxel and carboplatin combination therapy ( BrUOG BR-211B ( NCT00617942 ) ) . Tumor core biopsies were taken before initiation of treatment and 9-13 days after patients received " run-in " doses of either single agent trastuzumab or nab-paclitaxel . The AQUA method of quantitative immunofluorescence was used for analysis of in situ protein expression . Patients then received 18 weeks of treatment , followed by surgery to assess pathologic response to the neoadjuvant regimen . RESULTS A HER2 score of 2111 by AQUA analysis has been shown to be equivalent to HER2 3+ by immunohistochemical staining in previous studies . Of 20 evaluable patients , 10 cases who achieved a pathologic complete response ( pathCR ) with neoadjuvant treatment had a mean HER2 level of 10251 compared with 4766 in the patients without pathCR ( p = 0.0021 ) . Measurement of phospho-HER2 showed no difference in pathCR vs non-pathCR groups . In 9 patients who had HER2 levels repeated after a single treatment with trastuzumab there was no evidence of a reduction in the HER2 or phospho-HER2 levels following that exposure . CONCLUSIONS High levels of HER2 are associated with achievement of a pathCR in the preoperative setting , while levels of Phospho-HER2 were not predictive of response . This data suggests that accurate measurement of HER2 may help determine the likelihood of response in the pre-surgical setting . Further validation in larger cohorts is required , but this pilot data shows the feasibility of this approach .	[ "Quantitative", "measurements", "of", "HER2", "and", "phospho", "-", "HER2", "expression", ":", "correlation", "with", "pathologic", "response", "to", "neoadjuvant", "chemotherapy", "and", "trastuzumab", ".", "BACKGROUND", "Preoperative", "therapy", "with", "chemotherapy", "and", "the", "HER2-targeted", "monoclonal", "antibody", "trastuzumab", "is", "valuable", "for", "patients", "with", "large", "or", "locally", "advanced", "HER2-positive", "(", "HER2", "+", ")", "breast", "cancers", "but", "traditional", "methods", "of", "measuring", "HER2", "expression", "do", "not", "accurately", "stratify", "patients", "for", "likelihood", "of", "response", ".", "Quantitative", "immunofluorescent", "approaches", "have", "the", "potential", "to", "provide", "a", "mathematically", "continuous", "measure", "of", "HER2", ".", "Here", "we", "seek", "to", "determine", "whether", "quantitative", "measurement", "of", "HER2", "or", "phospho", "-", "HER2", "correlates", "with", "likelihood", "of", "response", "to", "trastuzumab-", "containing", "neoadjuvant", "therapy", ".", "METHODS", "We", "evaluated", "core", "biopsy", "samples", "from", "27", "HER2", "+", "breast", "cancer", "patients", "enrolled", "in", "a", "preoperative", "clinical", "trial", "using", "trastuzumab", ",", "nab", "-", "paclitaxel", "and", "carboplatin", "combination", "therapy", "(", "BrUOG", "BR-211B", "(", "NCT00617942", ")", ")", ".", "Tumor", "core", "biopsies", "were", "taken", "before", "initiation", "of", "treatment", "and", "9", "-", "13", "days", "after", "patients", "received", "\"", "run", "-", "in", "\"", "doses", "of", "either", "single", "agent", "trastuzumab", "or", "nab", "-", "paclitaxel", ".", "The", "AQUA", "method", "of", "quantitative", "immunofluorescence", "was", "used", "for", "analysis", "of", "in", "situ", "protein", "expression", ".", "Patients", "then", "received", "18", "weeks", "of", "treatment", ",", "followed", "by", "surgery", "to", "assess", "pathologic", "response", "to", "the", "neoadjuvant", "regimen", ".", "RESULTS", "A", "HER2", "score", "of", "2111", "by", "AQUA", "analysis", "has", "been", "shown", "to", "be", "equivalent", "to", "HER2", "3", "+", "by", "immunohistochemical", "staining", "in", "previous", "studies", ".", "Of", "20", "evaluable", "patients", ",", "10", "cases", "who", "achieved", "a", "pathologic", "complete", "response", "(", "pathCR", ")", "with", "neoadjuvant", "treatment", "had", "a", "mean", "HER2", "level", "of", "10251", "compared", "with", "4766", "in", "the", "patients", "without", "pathCR", "(", "p", "=", "0.0021", ")", ".", "Measurement", "of", "phospho", "-", "HER2", "showed", "no", "difference", "in", "pathCR", "vs", "non", "-", "pathCR", "groups", ".", "In", "9", "patients", "who", "had", "HER2", "levels", "repeated", "after", "a", "single", "treatment", "with", "trastuzumab", "there", "was", "no", "evidence", "of", "a", "reduction", "in", "the", "HER2", "or", "phospho", "-", "HER2", "levels", "following", "that", "exposure", ".", "CONCLUSIONS", "High", "levels", "of", "HER2", "are", "associated", "with", "achievement", "of", "a", "pathCR", "in", "the", "preoperative", "setting", ",", "while", "levels", "of", "Phospho", "-", "HER2", "were", "not", "predictive", "of", "response", ".", "This", "data", "suggests", "that", "accurate", "measurement", "of", "HER2", "may", "help", "determine", "the", "likelihood", "of", "response", "in", "the", "pre", "-", "surgical", "setting", ".", "Further", "validation", "in", "larger", "cohorts", "is", "required", ",", "but", "this", "pilot", "data", "shows", "the", "feasibility", "of", "this", "approach", "." ]	[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Physical" ]
Eligible patients were children and adolescents with HFA is a participant	370_task0	Sentence: Eligible patients were children and adolescents with HFA . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: participant	[ "B-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "O" ]	Eligible patients were children and adolescents with HFA .	[ "Eligible", "patients", "were", "children", "and", "adolescents", "with", "HFA", "." ]	[ "participant" ]
Eligible patients were children and adolescents with HFA is a participant	370_task1	Sentence: Eligible patients were children and adolescents with HFA . Instructions: please typing these entity words according to sentence: Eligible patients were children and adolescents with HFA Options: participant	[ "B-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "O" ]	Eligible patients were children and adolescents with HFA .	[ "Eligible", "patients", "were", "children", "and", "adolescents", "with", "HFA", "." ]	[ "participant" ]
Eligible patients were children and adolescents with HFA	370_task2	Sentence: Eligible patients were children and adolescents with HFA . Instructions: please extract entity words from the input sentence	[ "B-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "O" ]	Eligible patients were children and adolescents with HFA .	[ "Eligible", "patients", "were", "children", "and", "adolescents", "with", "HFA", "." ]	[ "participant" ]
prospective study is an umlsterm, patients is an umlsterm, posterior is an umlsterm, knee is an umlsterm, all - inside is an umlsterm, technique is an umlsterm, tendon is an umlsterm, grafts is an umlsterm, patients is an umlsterm, patients is an umlsterm, grafts is an umlsterm, infection is an umlsterm, rupture is an umlsterm, posterior is an umlsterm, patients is an umlsterm, patient is an umlsterm, overall is an umlsterm, evaluation is an umlsterm, patients is an umlsterm	Arthroskopie.00130041.eng.abstr_task0	Sentence: In a prospective study , 35 consecutive patients with an isolated posterior knee instability were stabilized arthroscopically in a new all-inside , double bundle technique using the autologous quadrupled semitendinosus and the doubled gracilis tendon . Femoral fixation of the grafts was performed with two Endobuttons . Out of 24 patients , 20 were evaluated with a follow-up of 25.4 months ( 12-47 ) on average ; in 15 cases the follow-up was less than 12 months . Only 18 patients could be evaluated because in two cases the grafts had to be removed ( one infection , one rupture ) . The Lysholm score improved from 67.6 points preoperatively to 88.5 points , the Tegner score from 3.9 to 4.9. The corrected posterior drawer measured with the KT-1000 arthrometer was reduced from 9.1 mm to 4.3 mm postoperatively . Preoperatively , 17 patients belonged to group D and one patient to group C in the IKDC overall evaluation form . After stabilization , eight patients were in group B , seven in group C , and three remained in group D. Damage to neurovascular structures in the popliteal area did not occur . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In a prospective study , 35 consecutive patients with an isolated posterior knee instability were stabilized arthroscopically in a new all-inside , double bundle technique using the autologous quadrupled semitendinosus and the doubled gracilis tendon . Femoral fixation of the grafts was performed with two Endobuttons . Out of 24 patients , 20 were evaluated with a follow-up of 25.4 months ( 12-47 ) on average ; in 15 cases the follow-up was less than 12 months . Only 18 patients could be evaluated because in two cases the grafts had to be removed ( one infection , one rupture ) . The Lysholm score improved from 67.6 points preoperatively to 88.5 points , the Tegner score from 3.9 to 4.9. The corrected posterior drawer measured with the KT-1000 arthrometer was reduced from 9.1 mm to 4.3 mm postoperatively . Preoperatively , 17 patients belonged to group D and one patient to group C in the IKDC overall evaluation form . After stabilization , eight patients were in group B , seven in group C , and three remained in group D. Damage to neurovascular structures in the popliteal area did not occur .	[ "In", "a", "prospective", "study", ",", "35", "consecutive", "patients", "with", "an", "isolated", "posterior", "knee", "instability", "were", "stabilized", "arthroscopically", "in", "a", "new", "all", "-", "inside", ",", "double", "bundle", "technique", "using", "the", "autologous", "quadrupled", "semitendinosus", "and", "the", "doubled", "gracilis", "tendon", ".", "Femoral", "fixation", "of", "the", "grafts", "was", "performed", "with", "two", "Endobuttons", ".", "Out", "of", "24", "patients", ",", "20", "were", "evaluated", "with", "a", "follow", "-", "up", "of", "25.4", "months", "(", "12", "-", "47", ")", "on", "average", ";", "in", "15", "cases", "the", "follow", "-", "up", "was", "less", "than", "12", "months", ".", "Only", "18", "patients", "could", "be", "evaluated", "because", "in", "two", "cases", "the", "grafts", "had", "to", "be", "removed", "(", "one", "infection", ",", "one", "rupture", ")", ".", "The", "Lysholm", "score", "improved", "from", "67.6", "points", "preoperatively", "to", "88.5", "points", ",", "the", "Tegner", "score", "from", "3.9", "to", "4.9", ".", "The", "corrected", "posterior", "drawer", "measured", "with", "the", "KT-1000", "arthrometer", "was", "reduced", "from", "9.1", "mm", "to", "4.3", "mm", "postoperatively", ".", "Preoperatively", ",", "17", "patients", "belonged", "to", "group", "D", "and", "one", "patient", "to", "group", "C", "in", "the", "IKDC", "overall", "evaluation", "form", ".", "After", "stabilization", ",", "eight", "patients", "were", "in", "group", "B", ",", "seven", "in", "group", "C", ",", "and", "three", "remained", "in", "group", "D.", "Damage", "to", "neurovascular", "structures", "in", "the", "popliteal", "area", "did", "not", "occur", "." ]	[ "umlsterm" ]
prospective study is an umlsterm, patients is an umlsterm, posterior is an umlsterm, knee is an umlsterm, all - inside is an umlsterm, technique is an umlsterm, tendon is an umlsterm, grafts is an umlsterm, patients is an umlsterm, patients is an umlsterm, grafts is an umlsterm, infection is an umlsterm, rupture is an umlsterm, posterior is an umlsterm, patients is an umlsterm, patient is an umlsterm, overall is an umlsterm, evaluation is an umlsterm, patients is an umlsterm	Arthroskopie.00130041.eng.abstr_task1	Sentence: In a prospective study , 35 consecutive patients with an isolated posterior knee instability were stabilized arthroscopically in a new all-inside , double bundle technique using the autologous quadrupled semitendinosus and the doubled gracilis tendon . Femoral fixation of the grafts was performed with two Endobuttons . Out of 24 patients , 20 were evaluated with a follow-up of 25.4 months ( 12-47 ) on average ; in 15 cases the follow-up was less than 12 months . Only 18 patients could be evaluated because in two cases the grafts had to be removed ( one infection , one rupture ) . The Lysholm score improved from 67.6 points preoperatively to 88.5 points , the Tegner score from 3.9 to 4.9. The corrected posterior drawer measured with the KT-1000 arthrometer was reduced from 9.1 mm to 4.3 mm postoperatively . Preoperatively , 17 patients belonged to group D and one patient to group C in the IKDC overall evaluation form . After stabilization , eight patients were in group B , seven in group C , and three remained in group D. Damage to neurovascular structures in the popliteal area did not occur . Instructions: please typing these entity words according to sentence: prospective study, patients, posterior, knee, all - inside, technique, tendon, grafts, patients, patients, grafts, infection, rupture, posterior, patients, patient, overall, evaluation, patients Options: umlsterm	[ "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In a prospective study , 35 consecutive patients with an isolated posterior knee instability were stabilized arthroscopically in a new all-inside , double bundle technique using the autologous quadrupled semitendinosus and the doubled gracilis tendon . Femoral fixation of the grafts was performed with two Endobuttons . Out of 24 patients , 20 were evaluated with a follow-up of 25.4 months ( 12-47 ) on average ; in 15 cases the follow-up was less than 12 months . Only 18 patients could be evaluated because in two cases the grafts had to be removed ( one infection , one rupture ) . The Lysholm score improved from 67.6 points preoperatively to 88.5 points , the Tegner score from 3.9 to 4.9. The corrected posterior drawer measured with the KT-1000 arthrometer was reduced from 9.1 mm to 4.3 mm postoperatively . Preoperatively , 17 patients belonged to group D and one patient to group C in the IKDC overall evaluation form . After stabilization , eight patients were in group B , seven in group C , and three remained in group D. Damage to neurovascular structures in the popliteal area did not occur .	[ "In", "a", "prospective", "study", ",", "35", "consecutive", "patients", "with", "an", "isolated", "posterior", "knee", "instability", "were", "stabilized", "arthroscopically", "in", "a", "new", "all", "-", "inside", ",", "double", "bundle", "technique", "using", "the", "autologous", "quadrupled", "semitendinosus", "and", "the", "doubled", "gracilis", "tendon", ".", "Femoral", "fixation", "of", "the", "grafts", "was", "performed", "with", "two", "Endobuttons", ".", "Out", "of", "24", "patients", ",", "20", "were", "evaluated", "with", "a", "follow", "-", "up", "of", "25.4", "months", "(", "12", "-", "47", ")", "on", "average", ";", "in", "15", "cases", "the", "follow", "-", "up", "was", "less", "than", "12", "months", ".", "Only", "18", "patients", "could", "be", "evaluated", "because", "in", "two", "cases", "the", "grafts", "had", "to", "be", "removed", "(", "one", "infection", ",", "one", "rupture", ")", ".", "The", "Lysholm", "score", "improved", "from", "67.6", "points", "preoperatively", "to", "88.5", "points", ",", "the", "Tegner", "score", "from", "3.9", "to", "4.9", ".", "The", "corrected", "posterior", "drawer", "measured", "with", "the", "KT-1000", "arthrometer", "was", "reduced", "from", "9.1", "mm", "to", "4.3", "mm", "postoperatively", ".", "Preoperatively", ",", "17", "patients", "belonged", "to", "group", "D", "and", "one", "patient", "to", "group", "C", "in", "the", "IKDC", "overall", "evaluation", "form", ".", "After", "stabilization", ",", "eight", "patients", "were", "in", "group", "B", ",", "seven", "in", "group", "C", ",", "and", "three", "remained", "in", "group", "D.", "Damage", "to", "neurovascular", "structures", "in", "the", "popliteal", "area", "did", "not", "occur", "." ]	[ "umlsterm" ]
prospective study, patients, posterior, knee, all - inside, technique, tendon, grafts, patients, patients, grafts, infection, rupture, posterior, patients, patient, overall, evaluation, patients	Arthroskopie.00130041.eng.abstr_task2	Sentence: In a prospective study , 35 consecutive patients with an isolated posterior knee instability were stabilized arthroscopically in a new all-inside , double bundle technique using the autologous quadrupled semitendinosus and the doubled gracilis tendon . Femoral fixation of the grafts was performed with two Endobuttons . Out of 24 patients , 20 were evaluated with a follow-up of 25.4 months ( 12-47 ) on average ; in 15 cases the follow-up was less than 12 months . Only 18 patients could be evaluated because in two cases the grafts had to be removed ( one infection , one rupture ) . The Lysholm score improved from 67.6 points preoperatively to 88.5 points , the Tegner score from 3.9 to 4.9. The corrected posterior drawer measured with the KT-1000 arthrometer was reduced from 9.1 mm to 4.3 mm postoperatively . Preoperatively , 17 patients belonged to group D and one patient to group C in the IKDC overall evaluation form . After stabilization , eight patients were in group B , seven in group C , and three remained in group D. Damage to neurovascular structures in the popliteal area did not occur . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In a prospective study , 35 consecutive patients with an isolated posterior knee instability were stabilized arthroscopically in a new all-inside , double bundle technique using the autologous quadrupled semitendinosus and the doubled gracilis tendon . Femoral fixation of the grafts was performed with two Endobuttons . Out of 24 patients , 20 were evaluated with a follow-up of 25.4 months ( 12-47 ) on average ; in 15 cases the follow-up was less than 12 months . Only 18 patients could be evaluated because in two cases the grafts had to be removed ( one infection , one rupture ) . The Lysholm score improved from 67.6 points preoperatively to 88.5 points , the Tegner score from 3.9 to 4.9. The corrected posterior drawer measured with the KT-1000 arthrometer was reduced from 9.1 mm to 4.3 mm postoperatively . Preoperatively , 17 patients belonged to group D and one patient to group C in the IKDC overall evaluation form . After stabilization , eight patients were in group B , seven in group C , and three remained in group D. Damage to neurovascular structures in the popliteal area did not occur .	[ "In", "a", "prospective", "study", ",", "35", "consecutive", "patients", "with", "an", "isolated", "posterior", "knee", "instability", "were", "stabilized", "arthroscopically", "in", "a", "new", "all", "-", "inside", ",", "double", "bundle", "technique", "using", "the", "autologous", "quadrupled", "semitendinosus", "and", "the", "doubled", "gracilis", "tendon", ".", "Femoral", "fixation", "of", "the", "grafts", "was", "performed", "with", "two", "Endobuttons", ".", "Out", "of", "24", "patients", ",", "20", "were", "evaluated", "with", "a", "follow", "-", "up", "of", "25.4", "months", "(", "12", "-", "47", ")", "on", "average", ";", "in", "15", "cases", "the", "follow", "-", "up", "was", "less", "than", "12", "months", ".", "Only", "18", "patients", "could", "be", "evaluated", "because", "in", "two", "cases", "the", "grafts", "had", "to", "be", "removed", "(", "one", "infection", ",", "one", "rupture", ")", ".", "The", "Lysholm", "score", "improved", "from", "67.6", "points", "preoperatively", "to", "88.5", "points", ",", "the", "Tegner", "score", "from", "3.9", "to", "4.9", ".", "The", "corrected", "posterior", "drawer", "measured", "with", "the", "KT-1000", "arthrometer", "was", "reduced", "from", "9.1", "mm", "to", "4.3", "mm", "postoperatively", ".", "Preoperatively", ",", "17", "patients", "belonged", "to", "group", "D", "and", "one", "patient", "to", "group", "C", "in", "the", "IKDC", "overall", "evaluation", "form", ".", "After", "stabilization", ",", "eight", "patients", "were", "in", "group", "B", ",", "seven", "in", "group", "C", ",", "and", "three", "remained", "in", "group", "D.", "Damage", "to", "neurovascular", "structures", "in", "the", "popliteal", "area", "did", "not", "occur", "." ]	[ "umlsterm" ]
PU.1 ( Spi-1 ) is a Gene, myeloid cells is a Cell, PU.1 ( Spi-1 ) is a TranscriptionFactor, Ets transcription factor family is a TranscriptionFactor, myeloid is a Cell, granulocytes is a Cell, monocytes is a Cell, macrophages is a Cell, B cells is a Cell, PU.1 is a Gene, multipotential progenitors is a Cell, myeloid lineages is a Cell, PU.1 is a Gene, function is a Function, human is a Eukaryote, CD34 + progenitors is a Cell, PU.1 is a Gene, PU.1 is a Gene, promoter is a Promoter, murine is a Eukaryote, PU.1 is a Gene, promoter is a Promoter, human is a Eukaryote, promoter is a Promoter, reporter gene is a ReporterGene, myeloid cell lines is a Cell, PU.1 is a Gene, promoter is a Promoter, region is a DNARegion, Oct is a ProteinBindingSiteOfDNA, Sp1 site is a ProteinBindingSiteOfDNA, binding site is a ProteinBindingSiteOfDNA, PU.1 is a TranscriptionFactor, ets family is a TranscriptionFactor, PU.1 site is a ProteinBindingSiteOfDNA, myeloid cells is a Cell, PU.1 site is a ProteinBindingSiteOfDNA, PU.1 is a TranscriptionFactor, promoter is a Promoter, activity is a Function, Oct is a ProteinBindingSiteOfDNA, Sp1 site is a ProteinBindingSiteOfDNA, promoter is a Promoter, activity is a Function, myeloid cells is a Cell, Co - transfection is a ExperimentalMethod, PU.1 is a Gene, Spi - B is a Gene, cells is a Cell, PU.1 is a Gene, Spi - B is a Gene, promoter is a Promoter, PU.1 binding site is a ProteinBindingSiteOfDNA, PU.1 is a TranscriptionFactor, promoter elements is a Promoter, PU.1 is a Gene, promoter is a Promoter, function is a Function, PU.1 is a Gene, myeloid cells is a Cell	103_task0	Sentence: PU.1 (Spi-1) autoregulates its expression in myeloid cells. PU.1 (Spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid (granulocytes, monocytes and macrophages) and B cells. PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation blocks myeloid colony formation. Since PU.1 expression appears to play a role in hematopoietic development, we characterized the PU.1 promoter. Here we report that the murine PU.1 promoter, as well as the human promoter, demonstrate tissue-specific reporter gene expression in myeloid cell lines but not in T cells and HeLa (non-hematopoietic cells) cells. Deletion analysis of the PU.1 promoter indicates that tissue-specific functional elements are encoded in the -61 to -39 bp and -7 to +34 bp regions. The first region contains a functional octamer (Oct) site at -54 bp and an Sp1 site at -39 bp. The second contains a binding site at +20 bp for both PU.1 itself and the related ets family member Spi-B. In vivo footprinting assays demonstrate that a hypersensitive band was detected at the PU.1 site in myeloid cells but not in HeLa. A mutation of the PU.1 site which abolished PU.1 binding caused a significant decrease in promoter activity. Mutation of the Oct and/or Sp1 site results in a lesser decrease of promoter activity in myeloid cells. Co-transfection of PU.1 or Spi-B in cells lacking PU.1 and Spi-B specifically transactivated a minimal promoter containing the PU.1 binding site, indicating that PU.1 can activate its own promoter elements in an autoregulatory loop. Positive autoregulation of the PU.1 promoter may play an important role in the function of PU.1 in myeloid cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TranscriptionFactor, Function, Promoter, ProteinBindingSiteOfDNA, ExperimentalMethod, Gene, ReporterGene, Eukaryote, DNARegion, Cell	[ "B-Gene", "I-Gene", "I-Gene", "I-Gene", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "O", "B-Cell", "O", "B-Cell", "O", "O", "B-Cell", "I-Cell", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "B-Gene", "B-Function", "O", "B-Eukaryote", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "B-Promoter", "O", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Gene", "B-Promoter", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Promoter", "O", "O", "O", "O", "O", "B-ReporterGene", "I-ReporterGene", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "B-Promoter", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DNARegion", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "O", "O", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "O", "O", "O", "B-TranscriptionFactor", "O", "O", "O", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "B-TranscriptionFactor", "O", "O", "O", "O", "O", "O", "B-Promoter", "B-Function", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "O", "O", "O", "O", "B-Promoter", "B-Function", "O", "B-Cell", "I-Cell", "O", "B-ExperimentalMethod", "I-ExperimentalMethod", "I-ExperimentalMethod", "O", "B-Gene", "O", "B-Gene", "I-Gene", "I-Gene", "O", "B-Cell", "O", "B-Gene", "O", "B-Gene", "I-Gene", "I-Gene", "O", "O", "O", "O", "B-Promoter", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "O", "B-TranscriptionFactor", "O", "O", "O", "O", "B-Promoter", "I-Promoter", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "B-Promoter", "O", "O", "O", "O", "O", "O", "O", "B-Function", "O", "B-Gene", "O", "B-Cell", "I-Cell", "O", "O" ]	PU.1 (Spi-1) autoregulates its expression in myeloid cells. PU.1 (Spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid (granulocytes, monocytes and macrophages) and B cells. PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation blocks myeloid colony formation. Since PU.1 expression appears to play a role in hematopoietic development, we characterized the PU.1 promoter. Here we report that the murine PU.1 promoter, as well as the human promoter, demonstrate tissue-specific reporter gene expression in myeloid cell lines but not in T cells and HeLa (non-hematopoietic cells) cells. Deletion analysis of the PU.1 promoter indicates that tissue-specific functional elements are encoded in the -61 to -39 bp and -7 to +34 bp regions. The first region contains a functional octamer (Oct) site at -54 bp and an Sp1 site at -39 bp. The second contains a binding site at +20 bp for both PU.1 itself and the related ets family member Spi-B. In vivo footprinting assays demonstrate that a hypersensitive band was detected at the PU.1 site in myeloid cells but not in HeLa. A mutation of the PU.1 site which abolished PU.1 binding caused a significant decrease in promoter activity. Mutation of the Oct and/or Sp1 site results in a lesser decrease of promoter activity in myeloid cells. Co-transfection of PU.1 or Spi-B in cells lacking PU.1 and Spi-B specifically transactivated a minimal promoter containing the PU.1 binding site, indicating that PU.1 can activate its own promoter elements in an autoregulatory loop. Positive autoregulation of the PU.1 promoter may play an important role in the function of PU.1 in myeloid cells.	[ "PU.1", "(", "Spi-1", ")", "autoregulates", "its", "expression", "in", "myeloid", "cells", ".", "PU.1", "(", "Spi-1", ")", ",", "a", "member", "of", "the", "Ets", "transcription", "factor", "family", ",", "is", "predominantly", "expressed", "in", "myeloid", "(", "granulocytes", ",", "monocytes", "and", "macrophages", ")", "and", "B", "cells", ".", "PU.1", "is", "upregulated", "early", "during", "commitment", "of", "multipotential", "progenitors", "to", "the", "myeloid", "lineages", "and", "inhibition", "of", "PU.1", "function", "in", "human", "CD34", "+", "progenitors", "prior", "to", "this", "upregulation", "blocks", "myeloid", "colony", "formation", ".", "Since", "PU.1", "expression", "appears", "to", "play", "a", "role", "in", "hematopoietic", "development", ",", "we", "characterized", "the", "PU.1", "promoter", ".", "Here", "we", "report", "that", "the", "murine", "PU.1", "promoter", ",", "as", "well", "as", "the", "human", "promoter", ",", "demonstrate", "tissue", "-", "specific", "reporter", "gene", "expression", "in", "myeloid", "cell", "lines", "but", "not", "in", "T", "cells", "and", "HeLa", "(", "non", "-", "hematopoietic", "cells", ")", "cells", ".", "Deletion", "analysis", "of", "the", "PU.1", "promoter", "indicates", "that", "tissue", "-", "specific", "functional", "elements", "are", "encoded", "in", "the", "-61", "to", "-39", "bp", "and", "-7", "to", "+34", "bp", "regions", ".", "The", "first", "region", "contains", "a", "functional", "octamer", "(", "Oct", ")", "site", "at", "-54", "bp", "and", "an", "Sp1", "site", "at", "-39", "bp", ".", "The", "second", "contains", "a", "binding", "site", "at", "+20", "bp", "for", "both", "PU.1", "itself", "and", "the", "related", "ets", "family", "member", "Spi", "-", "B.", "In", "vivo", "footprinting", "assays", "demonstrate", "that", "a", "hypersensitive", "band", "was", "detected", "at", "the", "PU.1", "site", "in", "myeloid", "cells", "but", "not", "in", "HeLa", ".", "A", "mutation", "of", "the", "PU.1", "site", "which", "abolished", "PU.1", "binding", "caused", "a", "significant", "decrease", "in", "promoter", "activity", ".", "Mutation", "of", "the", "Oct", "and", "/", "or", "Sp1", "site", "results", "in", "a", "lesser", "decrease", "of", "promoter", "activity", "in", "myeloid", "cells", ".", "Co", "-", "transfection", "of", "PU.1", "or", "Spi", "-", "B", "in", "cells", "lacking", "PU.1", "and", "Spi", "-", "B", "specifically", "transactivated", "a", "minimal", "promoter", "containing", "the", "PU.1", "binding", "site", ",", "indicating", "that", "PU.1", "can", "activate", "its", "own", "promoter", "elements", "in", "an", "autoregulatory", "loop", ".", "Positive", "autoregulation", "of", "the", "PU.1", "promoter", "may", "play", "an", "important", "role", "in", "the", "function", "of", "PU.1", "in", "myeloid", "cells", ".", "\n" ]	[ "TranscriptionFactor", "Cell", "ProteinBindingSiteOfDNA", "Promoter", "ExperimentalMethod", "ReporterGene", "Gene", "Function", "Eukaryote", "DNARegion" ]
PU.1 ( Spi-1 ) is a Gene, myeloid cells is a Cell, PU.1 ( Spi-1 ) is a TranscriptionFactor, Ets transcription factor family is a TranscriptionFactor, myeloid is a Cell, granulocytes is a Cell, monocytes is a Cell, macrophages is a Cell, B cells is a Cell, PU.1 is a Gene, multipotential progenitors is a Cell, myeloid lineages is a Cell, PU.1 is a Gene, function is a Function, human is a Eukaryote, CD34 + progenitors is a Cell, PU.1 is a Gene, PU.1 is a Gene, promoter is a Promoter, murine is a Eukaryote, PU.1 is a Gene, promoter is a Promoter, human is a Eukaryote, promoter is a Promoter, reporter gene is a ReporterGene, myeloid cell lines is a Cell, PU.1 is a Gene, promoter is a Promoter, region is a DNARegion, Oct is a ProteinBindingSiteOfDNA, Sp1 site is a ProteinBindingSiteOfDNA, binding site is a ProteinBindingSiteOfDNA, PU.1 is a TranscriptionFactor, ets family is a TranscriptionFactor, PU.1 site is a ProteinBindingSiteOfDNA, myeloid cells is a Cell, PU.1 site is a ProteinBindingSiteOfDNA, PU.1 is a TranscriptionFactor, promoter is a Promoter, activity is a Function, Oct is a ProteinBindingSiteOfDNA, Sp1 site is a ProteinBindingSiteOfDNA, promoter is a Promoter, activity is a Function, myeloid cells is a Cell, Co - transfection is a ExperimentalMethod, PU.1 is a Gene, Spi - B is a Gene, cells is a Cell, PU.1 is a Gene, Spi - B is a Gene, promoter is a Promoter, PU.1 binding site is a ProteinBindingSiteOfDNA, PU.1 is a TranscriptionFactor, promoter elements is a Promoter, PU.1 is a Gene, promoter is a Promoter, function is a Function, PU.1 is a Gene, myeloid cells is a Cell	103_task1	Sentence: PU.1 (Spi-1) autoregulates its expression in myeloid cells. PU.1 (Spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid (granulocytes, monocytes and macrophages) and B cells. PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation blocks myeloid colony formation. Since PU.1 expression appears to play a role in hematopoietic development, we characterized the PU.1 promoter. Here we report that the murine PU.1 promoter, as well as the human promoter, demonstrate tissue-specific reporter gene expression in myeloid cell lines but not in T cells and HeLa (non-hematopoietic cells) cells. Deletion analysis of the PU.1 promoter indicates that tissue-specific functional elements are encoded in the -61 to -39 bp and -7 to +34 bp regions. The first region contains a functional octamer (Oct) site at -54 bp and an Sp1 site at -39 bp. The second contains a binding site at +20 bp for both PU.1 itself and the related ets family member Spi-B. In vivo footprinting assays demonstrate that a hypersensitive band was detected at the PU.1 site in myeloid cells but not in HeLa. A mutation of the PU.1 site which abolished PU.1 binding caused a significant decrease in promoter activity. Mutation of the Oct and/or Sp1 site results in a lesser decrease of promoter activity in myeloid cells. Co-transfection of PU.1 or Spi-B in cells lacking PU.1 and Spi-B specifically transactivated a minimal promoter containing the PU.1 binding site, indicating that PU.1 can activate its own promoter elements in an autoregulatory loop. Positive autoregulation of the PU.1 promoter may play an important role in the function of PU.1 in myeloid cells. Instructions: please typing these entity words according to sentence: PU.1 ( Spi-1 ), myeloid cells, PU.1 ( Spi-1 ), Ets transcription factor family, myeloid, granulocytes, monocytes, macrophages, B cells, PU.1, multipotential progenitors, myeloid lineages, PU.1, function, human, CD34 + progenitors, PU.1, PU.1, promoter, murine, PU.1, promoter, human, promoter, reporter gene, myeloid cell lines, PU.1, promoter, region, Oct, Sp1 site, binding site, PU.1, ets family, PU.1 site, myeloid cells, PU.1 site, PU.1, promoter, activity, Oct, Sp1 site, promoter, activity, myeloid cells, Co - transfection, PU.1, Spi - B, cells, PU.1, Spi - B, promoter, PU.1 binding site, PU.1, promoter elements, PU.1, promoter, function, PU.1, myeloid cells Options: TranscriptionFactor, Function, Promoter, ProteinBindingSiteOfDNA, ExperimentalMethod, Gene, ReporterGene, Eukaryote, DNARegion, Cell	[ "B-Gene", "I-Gene", "I-Gene", "I-Gene", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "O", "B-Cell", "O", "B-Cell", "O", "O", "B-Cell", "I-Cell", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "B-Gene", "B-Function", "O", "B-Eukaryote", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "B-Promoter", "O", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Gene", "B-Promoter", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Promoter", "O", "O", "O", "O", "O", "B-ReporterGene", "I-ReporterGene", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "B-Promoter", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DNARegion", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "O", "O", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "O", "O", "O", "B-TranscriptionFactor", "O", "O", "O", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "B-TranscriptionFactor", "O", "O", "O", "O", "O", "O", "B-Promoter", "B-Function", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "O", "O", "O", "O", "B-Promoter", "B-Function", "O", "B-Cell", "I-Cell", "O", "B-ExperimentalMethod", "I-ExperimentalMethod", "I-ExperimentalMethod", "O", "B-Gene", "O", "B-Gene", "I-Gene", "I-Gene", "O", "B-Cell", "O", "B-Gene", "O", "B-Gene", "I-Gene", "I-Gene", "O", "O", "O", "O", "B-Promoter", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "O", "B-TranscriptionFactor", "O", "O", "O", "O", "B-Promoter", "I-Promoter", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "B-Promoter", "O", "O", "O", "O", "O", "O", "O", "B-Function", "O", "B-Gene", "O", "B-Cell", "I-Cell", "O", "O" ]	PU.1 (Spi-1) autoregulates its expression in myeloid cells. PU.1 (Spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid (granulocytes, monocytes and macrophages) and B cells. PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation blocks myeloid colony formation. Since PU.1 expression appears to play a role in hematopoietic development, we characterized the PU.1 promoter. Here we report that the murine PU.1 promoter, as well as the human promoter, demonstrate tissue-specific reporter gene expression in myeloid cell lines but not in T cells and HeLa (non-hematopoietic cells) cells. Deletion analysis of the PU.1 promoter indicates that tissue-specific functional elements are encoded in the -61 to -39 bp and -7 to +34 bp regions. The first region contains a functional octamer (Oct) site at -54 bp and an Sp1 site at -39 bp. The second contains a binding site at +20 bp for both PU.1 itself and the related ets family member Spi-B. In vivo footprinting assays demonstrate that a hypersensitive band was detected at the PU.1 site in myeloid cells but not in HeLa. A mutation of the PU.1 site which abolished PU.1 binding caused a significant decrease in promoter activity. Mutation of the Oct and/or Sp1 site results in a lesser decrease of promoter activity in myeloid cells. Co-transfection of PU.1 or Spi-B in cells lacking PU.1 and Spi-B specifically transactivated a minimal promoter containing the PU.1 binding site, indicating that PU.1 can activate its own promoter elements in an autoregulatory loop. Positive autoregulation of the PU.1 promoter may play an important role in the function of PU.1 in myeloid cells.	[ "PU.1", "(", "Spi-1", ")", "autoregulates", "its", "expression", "in", "myeloid", "cells", ".", "PU.1", "(", "Spi-1", ")", ",", "a", "member", "of", "the", "Ets", "transcription", "factor", "family", ",", "is", "predominantly", "expressed", "in", "myeloid", "(", "granulocytes", ",", "monocytes", "and", "macrophages", ")", "and", "B", "cells", ".", "PU.1", "is", "upregulated", "early", "during", "commitment", "of", "multipotential", "progenitors", "to", "the", "myeloid", "lineages", "and", "inhibition", "of", "PU.1", "function", "in", "human", "CD34", "+", "progenitors", "prior", "to", "this", "upregulation", "blocks", "myeloid", "colony", "formation", ".", "Since", "PU.1", "expression", "appears", "to", "play", "a", "role", "in", "hematopoietic", "development", ",", "we", "characterized", "the", "PU.1", "promoter", ".", "Here", "we", "report", "that", "the", "murine", "PU.1", "promoter", ",", "as", "well", "as", "the", "human", "promoter", ",", "demonstrate", "tissue", "-", "specific", "reporter", "gene", "expression", "in", "myeloid", "cell", "lines", "but", "not", "in", "T", "cells", "and", "HeLa", "(", "non", "-", "hematopoietic", "cells", ")", "cells", ".", "Deletion", "analysis", "of", "the", "PU.1", "promoter", "indicates", "that", "tissue", "-", "specific", "functional", "elements", "are", "encoded", "in", "the", "-61", "to", "-39", "bp", "and", "-7", "to", "+34", "bp", "regions", ".", "The", "first", "region", "contains", "a", "functional", "octamer", "(", "Oct", ")", "site", "at", "-54", "bp", "and", "an", "Sp1", "site", "at", "-39", "bp", ".", "The", "second", "contains", "a", "binding", "site", "at", "+20", "bp", "for", "both", "PU.1", "itself", "and", "the", "related", "ets", "family", "member", "Spi", "-", "B.", "In", "vivo", "footprinting", "assays", "demonstrate", "that", "a", "hypersensitive", "band", "was", "detected", "at", "the", "PU.1", "site", "in", "myeloid", "cells", "but", "not", "in", "HeLa", ".", "A", "mutation", "of", "the", "PU.1", "site", "which", "abolished", "PU.1", "binding", "caused", "a", "significant", "decrease", "in", "promoter", "activity", ".", "Mutation", "of", "the", "Oct", "and", "/", "or", "Sp1", "site", "results", "in", "a", "lesser", "decrease", "of", "promoter", "activity", "in", "myeloid", "cells", ".", "Co", "-", "transfection", "of", "PU.1", "or", "Spi", "-", "B", "in", "cells", "lacking", "PU.1", "and", "Spi", "-", "B", "specifically", "transactivated", "a", "minimal", "promoter", "containing", "the", "PU.1", "binding", "site", ",", "indicating", "that", "PU.1", "can", "activate", "its", "own", "promoter", "elements", "in", "an", "autoregulatory", "loop", ".", "Positive", "autoregulation", "of", "the", "PU.1", "promoter", "may", "play", "an", "important", "role", "in", "the", "function", "of", "PU.1", "in", "myeloid", "cells", ".", "\n" ]	[ "TranscriptionFactor", "Cell", "ProteinBindingSiteOfDNA", "Promoter", "ExperimentalMethod", "ReporterGene", "Gene", "Function", "Eukaryote", "DNARegion" ]
PU.1 ( Spi-1 ), myeloid cells, PU.1 ( Spi-1 ), Ets transcription factor family, myeloid, granulocytes, monocytes, macrophages, B cells, PU.1, multipotential progenitors, myeloid lineages, PU.1, function, human, CD34 + progenitors, PU.1, PU.1, promoter, murine, PU.1, promoter, human, promoter, reporter gene, myeloid cell lines, PU.1, promoter, region, Oct, Sp1 site, binding site, PU.1, ets family, PU.1 site, myeloid cells, PU.1 site, PU.1, promoter, activity, Oct, Sp1 site, promoter, activity, myeloid cells, Co - transfection, PU.1, Spi - B, cells, PU.1, Spi - B, promoter, PU.1 binding site, PU.1, promoter elements, PU.1, promoter, function, PU.1, myeloid cells	103_task2	Sentence: PU.1 (Spi-1) autoregulates its expression in myeloid cells. PU.1 (Spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid (granulocytes, monocytes and macrophages) and B cells. PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation blocks myeloid colony formation. Since PU.1 expression appears to play a role in hematopoietic development, we characterized the PU.1 promoter. Here we report that the murine PU.1 promoter, as well as the human promoter, demonstrate tissue-specific reporter gene expression in myeloid cell lines but not in T cells and HeLa (non-hematopoietic cells) cells. Deletion analysis of the PU.1 promoter indicates that tissue-specific functional elements are encoded in the -61 to -39 bp and -7 to +34 bp regions. The first region contains a functional octamer (Oct) site at -54 bp and an Sp1 site at -39 bp. The second contains a binding site at +20 bp for both PU.1 itself and the related ets family member Spi-B. In vivo footprinting assays demonstrate that a hypersensitive band was detected at the PU.1 site in myeloid cells but not in HeLa. A mutation of the PU.1 site which abolished PU.1 binding caused a significant decrease in promoter activity. Mutation of the Oct and/or Sp1 site results in a lesser decrease of promoter activity in myeloid cells. Co-transfection of PU.1 or Spi-B in cells lacking PU.1 and Spi-B specifically transactivated a minimal promoter containing the PU.1 binding site, indicating that PU.1 can activate its own promoter elements in an autoregulatory loop. Positive autoregulation of the PU.1 promoter may play an important role in the function of PU.1 in myeloid cells. Instructions: please extract entity words from the input sentence	[ "B-Gene", "I-Gene", "I-Gene", "I-Gene", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "O", "B-Cell", "O", "B-Cell", "O", "O", "B-Cell", "I-Cell", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "B-Gene", "B-Function", "O", "B-Eukaryote", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "B-Promoter", "O", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Gene", "B-Promoter", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Promoter", "O", "O", "O", "O", "O", "B-ReporterGene", "I-ReporterGene", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "B-Promoter", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DNARegion", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "O", "O", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "O", "O", "O", "B-TranscriptionFactor", "O", "O", "O", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "B-TranscriptionFactor", "O", "O", "O", "O", "O", "O", "B-Promoter", "B-Function", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "O", "O", "O", "O", "B-Promoter", "B-Function", "O", "B-Cell", "I-Cell", "O", "B-ExperimentalMethod", "I-ExperimentalMethod", "I-ExperimentalMethod", "O", "B-Gene", "O", "B-Gene", "I-Gene", "I-Gene", "O", "B-Cell", "O", "B-Gene", "O", "B-Gene", "I-Gene", "I-Gene", "O", "O", "O", "O", "B-Promoter", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "O", "B-TranscriptionFactor", "O", "O", "O", "O", "B-Promoter", "I-Promoter", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "B-Promoter", "O", "O", "O", "O", "O", "O", "O", "B-Function", "O", "B-Gene", "O", "B-Cell", "I-Cell", "O", "O" ]	PU.1 (Spi-1) autoregulates its expression in myeloid cells. PU.1 (Spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid (granulocytes, monocytes and macrophages) and B cells. PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation blocks myeloid colony formation. Since PU.1 expression appears to play a role in hematopoietic development, we characterized the PU.1 promoter. Here we report that the murine PU.1 promoter, as well as the human promoter, demonstrate tissue-specific reporter gene expression in myeloid cell lines but not in T cells and HeLa (non-hematopoietic cells) cells. Deletion analysis of the PU.1 promoter indicates that tissue-specific functional elements are encoded in the -61 to -39 bp and -7 to +34 bp regions. The first region contains a functional octamer (Oct) site at -54 bp and an Sp1 site at -39 bp. The second contains a binding site at +20 bp for both PU.1 itself and the related ets family member Spi-B. In vivo footprinting assays demonstrate that a hypersensitive band was detected at the PU.1 site in myeloid cells but not in HeLa. A mutation of the PU.1 site which abolished PU.1 binding caused a significant decrease in promoter activity. Mutation of the Oct and/or Sp1 site results in a lesser decrease of promoter activity in myeloid cells. Co-transfection of PU.1 or Spi-B in cells lacking PU.1 and Spi-B specifically transactivated a minimal promoter containing the PU.1 binding site, indicating that PU.1 can activate its own promoter elements in an autoregulatory loop. Positive autoregulation of the PU.1 promoter may play an important role in the function of PU.1 in myeloid cells.	[ "PU.1", "(", "Spi-1", ")", "autoregulates", "its", "expression", "in", "myeloid", "cells", ".", "PU.1", "(", "Spi-1", ")", ",", "a", "member", "of", "the", "Ets", "transcription", "factor", "family", ",", "is", "predominantly", "expressed", "in", "myeloid", "(", "granulocytes", ",", "monocytes", "and", "macrophages", ")", "and", "B", "cells", ".", "PU.1", "is", "upregulated", "early", "during", "commitment", "of", "multipotential", "progenitors", "to", "the", "myeloid", "lineages", "and", "inhibition", "of", "PU.1", "function", "in", "human", "CD34", "+", "progenitors", "prior", "to", "this", "upregulation", "blocks", "myeloid", "colony", "formation", ".", "Since", "PU.1", "expression", "appears", "to", "play", "a", "role", "in", "hematopoietic", "development", ",", "we", "characterized", "the", "PU.1", "promoter", ".", "Here", "we", "report", "that", "the", "murine", "PU.1", "promoter", ",", "as", "well", "as", "the", "human", "promoter", ",", "demonstrate", "tissue", "-", "specific", "reporter", "gene", "expression", "in", "myeloid", "cell", "lines", "but", "not", "in", "T", "cells", "and", "HeLa", "(", "non", "-", "hematopoietic", "cells", ")", "cells", ".", "Deletion", "analysis", "of", "the", "PU.1", "promoter", "indicates", "that", "tissue", "-", "specific", "functional", "elements", "are", "encoded", "in", "the", "-61", "to", "-39", "bp", "and", "-7", "to", "+34", "bp", "regions", ".", "The", "first", "region", "contains", "a", "functional", "octamer", "(", "Oct", ")", "site", "at", "-54", "bp", "and", "an", "Sp1", "site", "at", "-39", "bp", ".", "The", "second", "contains", "a", "binding", "site", "at", "+20", "bp", "for", "both", "PU.1", "itself", "and", "the", "related", "ets", "family", "member", "Spi", "-", "B.", "In", "vivo", "footprinting", "assays", "demonstrate", "that", "a", "hypersensitive", "band", "was", "detected", "at", "the", "PU.1", "site", "in", "myeloid", "cells", "but", "not", "in", "HeLa", ".", "A", "mutation", "of", "the", "PU.1", "site", "which", "abolished", "PU.1", "binding", "caused", "a", "significant", "decrease", "in", "promoter", "activity", ".", "Mutation", "of", "the", "Oct", "and", "/", "or", "Sp1", "site", "results", "in", "a", "lesser", "decrease", "of", "promoter", "activity", "in", "myeloid", "cells", ".", "Co", "-", "transfection", "of", "PU.1", "or", "Spi", "-", "B", "in", "cells", "lacking", "PU.1", "and", "Spi", "-", "B", "specifically", "transactivated", "a", "minimal", "promoter", "containing", "the", "PU.1", "binding", "site", ",", "indicating", "that", "PU.1", "can", "activate", "its", "own", "promoter", "elements", "in", "an", "autoregulatory", "loop", ".", "Positive", "autoregulation", "of", "the", "PU.1", "promoter", "may", "play", "an", "important", "role", "in", "the", "function", "of", "PU.1", "in", "myeloid", "cells", ".", "\n" ]	[ "TranscriptionFactor", "Cell", "ProteinBindingSiteOfDNA", "Promoter", "ExperimentalMethod", "ReporterGene", "Gene", "Function", "Eukaryote", "DNARegion" ]
p53 is a Protein, p53 is a Protein, Tip60 is a Protein, p53 is a Protein, lysine 120 is a Entity, K120 is a Entity, p53 is a Protein, p53 is a Protein, K120 is a Entity, p53 is a Protein	225_task0	Sentence: Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Upon DNA damage and other types of stress, p53 induces either cell-cycle arrest or apoptosis depending on the cellular context. However, the molecular mechanisms that govern the choice between cell-cycle arrest and apoptosis are not well understood. Here, we show that Tip60 is required for both cell growth arrest and apoptosis mediated by p53 and also induces its acetylation specifically at lysine 120 (K120) within the DNA-binding domain. Interestingly, this modification is crucial for p53-dependent apoptosis but is dispensable for its mediated growth arrest. K120 is a recurrent site for p53 mutation in human cancer, and the corresponding acetylation-defective tumor mutant (K120R) abrogates p53-mediated apoptosis, but not growth arrest. Thus, our study demonstrates that Tip60-dependent acetylation of p53 at K120 modulates the decision between cell-cycle arrest and apoptosis, and it reveals that the DNA-binding core domain is an important target for p53 regulation by posttranslational modifications. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]	Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Upon DNA damage and other types of stress, p53 induces either cell-cycle arrest or apoptosis depending on the cellular context. However, the molecular mechanisms that govern the choice between cell-cycle arrest and apoptosis are not well understood. Here, we show that Tip60 is required for both cell growth arrest and apoptosis mediated by p53 and also induces its acetylation specifically at lysine 120 (K120) within the DNA-binding domain. Interestingly, this modification is crucial for p53-dependent apoptosis but is dispensable for its mediated growth arrest. K120 is a recurrent site for p53 mutation in human cancer, and the corresponding acetylation-defective tumor mutant (K120R) abrogates p53-mediated apoptosis, but not growth arrest. Thus, our study demonstrates that Tip60-dependent acetylation of p53 at K120 modulates the decision between cell-cycle arrest and apoptosis, and it reveals that the DNA-binding core domain is an important target for p53 regulation by posttranslational modifications.	[ "Tip60-dependent", "acetylation", "of", "p53", "modulates", "the", "decision", "between", "cell", "-", "cycle", "arrest", "and", "apoptosis", ".", "\n", "Upon", "DNA", "damage", "and", "other", "types", "of", "stress", ",", "p53", "induces", "either", "cell", "-", "cycle", "arrest", "or", "apoptosis", "depending", "on", "the", "cellular", "context", ".", "However", ",", "the", "molecular", "mechanisms", "that", "govern", "the", "choice", "between", "cell", "-", "cycle", "arrest", "and", "apoptosis", "are", "not", "well", "understood", ".", "Here", ",", "we", "show", "that", "Tip60", "is", "required", "for", "both", "cell", "growth", "arrest", "and", "apoptosis", "mediated", "by", "p53", "and", "also", "induces", "its", "acetylation", "specifically", "at", "lysine", "120", "(", "K120", ")", "within", "the", "DNA", "-", "binding", "domain", ".", "Interestingly", ",", "this", "modification", "is", "crucial", "for", "p53-dependent", "apoptosis", "but", "is", "dispensable", "for", "its", "mediated", "growth", "arrest", ".", "K120", "is", "a", "recurrent", "site", "for", "p53", "mutation", "in", "human", "cancer", ",", "and", "the", "corresponding", "acetylation", "-", "defective", "tumor", "mutant", "(", "K120R", ")", "abrogates", "p53-mediated", "apoptosis", ",", "but", "not", "growth", "arrest", ".", "Thus", ",", "our", "study", "demonstrates", "that", "Tip60-dependent", "acetylation", "of", "p53", "at", "K120", "modulates", "the", "decision", "between", "cell", "-", "cycle", "arrest", "and", "apoptosis", ",", "and", "it", "reveals", "that", "the", "DNA", "-", "binding", "core", "domain", "is", "an", "important", "target", "for", "p53", "regulation", "by", "posttranslational", "modifications", ".", "\n" ]	[ "Entity", "Protein" ]
p53 is a Protein, p53 is a Protein, Tip60 is a Protein, p53 is a Protein, lysine 120 is a Entity, K120 is a Entity, p53 is a Protein, p53 is a Protein, K120 is a Entity, p53 is a Protein	225_task1	Sentence: Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Upon DNA damage and other types of stress, p53 induces either cell-cycle arrest or apoptosis depending on the cellular context. However, the molecular mechanisms that govern the choice between cell-cycle arrest and apoptosis are not well understood. Here, we show that Tip60 is required for both cell growth arrest and apoptosis mediated by p53 and also induces its acetylation specifically at lysine 120 (K120) within the DNA-binding domain. Interestingly, this modification is crucial for p53-dependent apoptosis but is dispensable for its mediated growth arrest. K120 is a recurrent site for p53 mutation in human cancer, and the corresponding acetylation-defective tumor mutant (K120R) abrogates p53-mediated apoptosis, but not growth arrest. Thus, our study demonstrates that Tip60-dependent acetylation of p53 at K120 modulates the decision between cell-cycle arrest and apoptosis, and it reveals that the DNA-binding core domain is an important target for p53 regulation by posttranslational modifications. Instructions: please typing these entity words according to sentence: p53, p53, Tip60, p53, lysine 120, K120, p53, p53, K120, p53 Options: Entity, Protein	[ "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]	Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Upon DNA damage and other types of stress, p53 induces either cell-cycle arrest or apoptosis depending on the cellular context. However, the molecular mechanisms that govern the choice between cell-cycle arrest and apoptosis are not well understood. Here, we show that Tip60 is required for both cell growth arrest and apoptosis mediated by p53 and also induces its acetylation specifically at lysine 120 (K120) within the DNA-binding domain. Interestingly, this modification is crucial for p53-dependent apoptosis but is dispensable for its mediated growth arrest. K120 is a recurrent site for p53 mutation in human cancer, and the corresponding acetylation-defective tumor mutant (K120R) abrogates p53-mediated apoptosis, but not growth arrest. Thus, our study demonstrates that Tip60-dependent acetylation of p53 at K120 modulates the decision between cell-cycle arrest and apoptosis, and it reveals that the DNA-binding core domain is an important target for p53 regulation by posttranslational modifications.	[ "Tip60-dependent", "acetylation", "of", "p53", "modulates", "the", "decision", "between", "cell", "-", "cycle", "arrest", "and", "apoptosis", ".", "\n", "Upon", "DNA", "damage", "and", "other", "types", "of", "stress", ",", "p53", "induces", "either", "cell", "-", "cycle", "arrest", "or", "apoptosis", "depending", "on", "the", "cellular", "context", ".", "However", ",", "the", "molecular", "mechanisms", "that", "govern", "the", "choice", "between", "cell", "-", "cycle", "arrest", "and", "apoptosis", "are", "not", "well", "understood", ".", "Here", ",", "we", "show", "that", "Tip60", "is", "required", "for", "both", "cell", "growth", "arrest", "and", "apoptosis", "mediated", "by", "p53", "and", "also", "induces", "its", "acetylation", "specifically", "at", "lysine", "120", "(", "K120", ")", "within", "the", "DNA", "-", "binding", "domain", ".", "Interestingly", ",", "this", "modification", "is", "crucial", "for", "p53-dependent", "apoptosis", "but", "is", "dispensable", "for", "its", "mediated", "growth", "arrest", ".", "K120", "is", "a", "recurrent", "site", "for", "p53", "mutation", "in", "human", "cancer", ",", "and", "the", "corresponding", "acetylation", "-", "defective", "tumor", "mutant", "(", "K120R", ")", "abrogates", "p53-mediated", "apoptosis", ",", "but", "not", "growth", "arrest", ".", "Thus", ",", "our", "study", "demonstrates", "that", "Tip60-dependent", "acetylation", "of", "p53", "at", "K120", "modulates", "the", "decision", "between", "cell", "-", "cycle", "arrest", "and", "apoptosis", ",", "and", "it", "reveals", "that", "the", "DNA", "-", "binding", "core", "domain", "is", "an", "important", "target", "for", "p53", "regulation", "by", "posttranslational", "modifications", ".", "\n" ]	[ "Entity", "Protein" ]
p53, p53, Tip60, p53, lysine 120, K120, p53, p53, K120, p53	225_task2	Sentence: Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Upon DNA damage and other types of stress, p53 induces either cell-cycle arrest or apoptosis depending on the cellular context. However, the molecular mechanisms that govern the choice between cell-cycle arrest and apoptosis are not well understood. Here, we show that Tip60 is required for both cell growth arrest and apoptosis mediated by p53 and also induces its acetylation specifically at lysine 120 (K120) within the DNA-binding domain. Interestingly, this modification is crucial for p53-dependent apoptosis but is dispensable for its mediated growth arrest. K120 is a recurrent site for p53 mutation in human cancer, and the corresponding acetylation-defective tumor mutant (K120R) abrogates p53-mediated apoptosis, but not growth arrest. Thus, our study demonstrates that Tip60-dependent acetylation of p53 at K120 modulates the decision between cell-cycle arrest and apoptosis, and it reveals that the DNA-binding core domain is an important target for p53 regulation by posttranslational modifications. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]	Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Upon DNA damage and other types of stress, p53 induces either cell-cycle arrest or apoptosis depending on the cellular context. However, the molecular mechanisms that govern the choice between cell-cycle arrest and apoptosis are not well understood. Here, we show that Tip60 is required for both cell growth arrest and apoptosis mediated by p53 and also induces its acetylation specifically at lysine 120 (K120) within the DNA-binding domain. Interestingly, this modification is crucial for p53-dependent apoptosis but is dispensable for its mediated growth arrest. K120 is a recurrent site for p53 mutation in human cancer, and the corresponding acetylation-defective tumor mutant (K120R) abrogates p53-mediated apoptosis, but not growth arrest. Thus, our study demonstrates that Tip60-dependent acetylation of p53 at K120 modulates the decision between cell-cycle arrest and apoptosis, and it reveals that the DNA-binding core domain is an important target for p53 regulation by posttranslational modifications.	[ "Tip60-dependent", "acetylation", "of", "p53", "modulates", "the", "decision", "between", "cell", "-", "cycle", "arrest", "and", "apoptosis", ".", "\n", "Upon", "DNA", "damage", "and", "other", "types", "of", "stress", ",", "p53", "induces", "either", "cell", "-", "cycle", "arrest", "or", "apoptosis", "depending", "on", "the", "cellular", "context", ".", "However", ",", "the", "molecular", "mechanisms", "that", "govern", "the", "choice", "between", "cell", "-", "cycle", "arrest", "and", "apoptosis", "are", "not", "well", "understood", ".", "Here", ",", "we", "show", "that", "Tip60", "is", "required", "for", "both", "cell", "growth", "arrest", "and", "apoptosis", "mediated", "by", "p53", "and", "also", "induces", "its", "acetylation", "specifically", "at", "lysine", "120", "(", "K120", ")", "within", "the", "DNA", "-", "binding", "domain", ".", "Interestingly", ",", "this", "modification", "is", "crucial", "for", "p53-dependent", "apoptosis", "but", "is", "dispensable", "for", "its", "mediated", "growth", "arrest", ".", "K120", "is", "a", "recurrent", "site", "for", "p53", "mutation", "in", "human", "cancer", ",", "and", "the", "corresponding", "acetylation", "-", "defective", "tumor", "mutant", "(", "K120R", ")", "abrogates", "p53-mediated", "apoptosis", ",", "but", "not", "growth", "arrest", ".", "Thus", ",", "our", "study", "demonstrates", "that", "Tip60-dependent", "acetylation", "of", "p53", "at", "K120", "modulates", "the", "decision", "between", "cell", "-", "cycle", "arrest", "and", "apoptosis", ",", "and", "it", "reveals", "that", "the", "DNA", "-", "binding", "core", "domain", "is", "an", "important", "target", "for", "p53", "regulation", "by", "posttranslational", "modifications", ".", "\n" ]	[ "Entity", "Protein" ]
Rel - A is a Protein, c - Rel is a Protein, protein complexes is a Entity, Nuclear factor - kappa B is a Entity, cellular genes is a Entity, genes is a Entity, NF - kappa B is a Entity, NF - kappa B is a Entity, p50 is a Protein, p65 is a Protein, p50 is a Protein, c - Rel is a Protein, complexes is a Entity, NF - kappa B is a Entity, p50 / c - Rel is a Entity, p50 / p65 is a Entity, p65 is a Protein, p65 is a Protein, p50 is a Protein, c - Rel is a Protein, p65 is a Protein, c - Rel is a Protein, complexes is a Entity, NF - kappa B is a Entity	314_task0	Sentence: Nuclear Rel-A and c-Rel protein complexes are differentially distributed within human thymocytes. Nuclear factor-kappa B (NF-kappa B)/Rel proteins are inducible transcriptional regulators of numerous cellular genes. They are particularly abundant in lymphoid tissues and are thought to be critical for the transcription of genes involved in immune and inflammatory responses. We have reported previously that a nuclear NF-kappa B activity was present in freshly extracted human thymocytes in the absence of in vitro treatment of these cells. In the present report, we identified NF-kappa B proteins extracted from human thymocyte nuclei as being p50/p65 and p50/c-Rel complexes. Immunochemical and immunofluorescent staining of thymus sections using specific Abs allowed visualization of nuclear NF-kappa B proteins in both thymocytes and nonthymocyte cells. This detection suggested a preferential activation of p50/c-Rel in medullary thymocytes, whereas p50/p65 was present in both cortical and medullary regions of human thymus lobules. However, the intensity of p65 labeling was much higher in several thymocytes from the medulla. p65, p50, and c-Rel activities were found in both CD4- and CD8-positive thymocytes. These observations suggest that p65 and c-Rel complexes play distinct roles in gene expression and that both forms of NF-kappa B play critical roles during late stages of the intrathymic maturation of T cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Nuclear Rel-A and c-Rel protein complexes are differentially distributed within human thymocytes. Nuclear factor-kappa B (NF-kappa B)/Rel proteins are inducible transcriptional regulators of numerous cellular genes. They are particularly abundant in lymphoid tissues and are thought to be critical for the transcription of genes involved in immune and inflammatory responses. We have reported previously that a nuclear NF-kappa B activity was present in freshly extracted human thymocytes in the absence of in vitro treatment of these cells. In the present report, we identified NF-kappa B proteins extracted from human thymocyte nuclei as being p50/p65 and p50/c-Rel complexes. Immunochemical and immunofluorescent staining of thymus sections using specific Abs allowed visualization of nuclear NF-kappa B proteins in both thymocytes and nonthymocyte cells. This detection suggested a preferential activation of p50/c-Rel in medullary thymocytes, whereas p50/p65 was present in both cortical and medullary regions of human thymus lobules. However, the intensity of p65 labeling was much higher in several thymocytes from the medulla. p65, p50, and c-Rel activities were found in both CD4- and CD8-positive thymocytes. These observations suggest that p65 and c-Rel complexes play distinct roles in gene expression and that both forms of NF-kappa B play critical roles during late stages of the intrathymic maturation of T cells.	[ "Nuclear", "Rel", "-", "A", "and", "c", "-", "Rel", "protein", "complexes", "are", "differentially", "distributed", "within", "human", "thymocytes", ".", "\n", "Nuclear", "factor", "-", "kappa", "B", "(", "NF", "-", "kappa", "B)/Rel", "proteins", "are", "inducible", "transcriptional", "regulators", "of", "numerous", "cellular", "genes", ".", "They", "are", "particularly", "abundant", "in", "lymphoid", "tissues", "and", "are", "thought", "to", "be", "critical", "for", "the", "transcription", "of", "genes", "involved", "in", "immune", "and", "inflammatory", "responses", ".", "We", "have", "reported", "previously", "that", "a", "nuclear", "NF", "-", "kappa", "B", "activity", "was", "present", "in", "freshly", "extracted", "human", "thymocytes", "in", "the", "absence", "of", "in", "vitro", "treatment", "of", "these", "cells", ".", "In", "the", "present", "report", ",", "we", "identified", "NF", "-", "kappa", "B", "proteins", "extracted", "from", "human", "thymocyte", "nuclei", "as", "being", "p50", "/", "p65", "and", "p50", "/", "c", "-", "Rel", "complexes", ".", "Immunochemical", "and", "immunofluorescent", "staining", "of", "thymus", "sections", "using", "specific", "Abs", "allowed", "visualization", "of", "nuclear", "NF", "-", "kappa", "B", "proteins", "in", "both", "thymocytes", "and", "nonthymocyte", "cells", ".", "This", "detection", "suggested", "a", "preferential", "activation", "of", "p50", "/", "c", "-", "Rel", "in", "medullary", "thymocytes", ",", "whereas", "p50", "/", "p65", "was", "present", "in", "both", "cortical", "and", "medullary", "regions", "of", "human", "thymus", "lobules", ".", "However", ",", "the", "intensity", "of", "p65", "labeling", "was", "much", "higher", "in", "several", "thymocytes", "from", "the", "medulla", ".", "p65", ",", "p50", ",", "and", "c", "-", "Rel", "activities", "were", "found", "in", "both", "CD4-", "and", "CD8-positive", "thymocytes", ".", "These", "observations", "suggest", "that", "p65", "and", "c", "-", "Rel", "complexes", "play", "distinct", "roles", "in", "gene", "expression", "and", "that", "both", "forms", "of", "NF", "-", "kappa", "B", "play", "critical", "roles", "during", "late", "stages", "of", "the", "intrathymic", "maturation", "of", "T", "cells", ".", "\n" ]	[ "Entity", "Protein" ]
Rel - A is a Protein, c - Rel is a Protein, protein complexes is a Entity, Nuclear factor - kappa B is a Entity, cellular genes is a Entity, genes is a Entity, NF - kappa B is a Entity, NF - kappa B is a Entity, p50 is a Protein, p65 is a Protein, p50 is a Protein, c - Rel is a Protein, complexes is a Entity, NF - kappa B is a Entity, p50 / c - Rel is a Entity, p50 / p65 is a Entity, p65 is a Protein, p65 is a Protein, p50 is a Protein, c - Rel is a Protein, p65 is a Protein, c - Rel is a Protein, complexes is a Entity, NF - kappa B is a Entity	314_task1	Sentence: Nuclear Rel-A and c-Rel protein complexes are differentially distributed within human thymocytes. Nuclear factor-kappa B (NF-kappa B)/Rel proteins are inducible transcriptional regulators of numerous cellular genes. They are particularly abundant in lymphoid tissues and are thought to be critical for the transcription of genes involved in immune and inflammatory responses. We have reported previously that a nuclear NF-kappa B activity was present in freshly extracted human thymocytes in the absence of in vitro treatment of these cells. In the present report, we identified NF-kappa B proteins extracted from human thymocyte nuclei as being p50/p65 and p50/c-Rel complexes. Immunochemical and immunofluorescent staining of thymus sections using specific Abs allowed visualization of nuclear NF-kappa B proteins in both thymocytes and nonthymocyte cells. This detection suggested a preferential activation of p50/c-Rel in medullary thymocytes, whereas p50/p65 was present in both cortical and medullary regions of human thymus lobules. However, the intensity of p65 labeling was much higher in several thymocytes from the medulla. p65, p50, and c-Rel activities were found in both CD4- and CD8-positive thymocytes. These observations suggest that p65 and c-Rel complexes play distinct roles in gene expression and that both forms of NF-kappa B play critical roles during late stages of the intrathymic maturation of T cells. Instructions: please typing these entity words according to sentence: Rel - A, c - Rel, protein complexes, Nuclear factor - kappa B, cellular genes, genes, NF - kappa B, NF - kappa B, p50, p65, p50, c - Rel, complexes, NF - kappa B, p50 / c - Rel, p50 / p65, p65, p65, p50, c - Rel, p65, c - Rel, complexes, NF - kappa B Options: Entity, Protein	[ "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Nuclear Rel-A and c-Rel protein complexes are differentially distributed within human thymocytes. Nuclear factor-kappa B (NF-kappa B)/Rel proteins are inducible transcriptional regulators of numerous cellular genes. They are particularly abundant in lymphoid tissues and are thought to be critical for the transcription of genes involved in immune and inflammatory responses. We have reported previously that a nuclear NF-kappa B activity was present in freshly extracted human thymocytes in the absence of in vitro treatment of these cells. In the present report, we identified NF-kappa B proteins extracted from human thymocyte nuclei as being p50/p65 and p50/c-Rel complexes. Immunochemical and immunofluorescent staining of thymus sections using specific Abs allowed visualization of nuclear NF-kappa B proteins in both thymocytes and nonthymocyte cells. This detection suggested a preferential activation of p50/c-Rel in medullary thymocytes, whereas p50/p65 was present in both cortical and medullary regions of human thymus lobules. However, the intensity of p65 labeling was much higher in several thymocytes from the medulla. p65, p50, and c-Rel activities were found in both CD4- and CD8-positive thymocytes. These observations suggest that p65 and c-Rel complexes play distinct roles in gene expression and that both forms of NF-kappa B play critical roles during late stages of the intrathymic maturation of T cells.	[ "Nuclear", "Rel", "-", "A", "and", "c", "-", "Rel", "protein", "complexes", "are", "differentially", "distributed", "within", "human", "thymocytes", ".", "\n", "Nuclear", "factor", "-", "kappa", "B", "(", "NF", "-", "kappa", "B)/Rel", "proteins", "are", "inducible", "transcriptional", "regulators", "of", "numerous", "cellular", "genes", ".", "They", "are", "particularly", "abundant", "in", "lymphoid", "tissues", "and", "are", "thought", "to", "be", "critical", "for", "the", "transcription", "of", "genes", "involved", "in", "immune", "and", "inflammatory", "responses", ".", "We", "have", "reported", "previously", "that", "a", "nuclear", "NF", "-", "kappa", "B", "activity", "was", "present", "in", "freshly", "extracted", "human", "thymocytes", "in", "the", "absence", "of", "in", "vitro", "treatment", "of", "these", "cells", ".", "In", "the", "present", "report", ",", "we", "identified", "NF", "-", "kappa", "B", "proteins", "extracted", "from", "human", "thymocyte", "nuclei", "as", "being", "p50", "/", "p65", "and", "p50", "/", "c", "-", "Rel", "complexes", ".", "Immunochemical", "and", "immunofluorescent", "staining", "of", "thymus", "sections", "using", "specific", "Abs", "allowed", "visualization", "of", "nuclear", "NF", "-", "kappa", "B", "proteins", "in", "both", "thymocytes", "and", "nonthymocyte", "cells", ".", "This", "detection", "suggested", "a", "preferential", "activation", "of", "p50", "/", "c", "-", "Rel", "in", "medullary", "thymocytes", ",", "whereas", "p50", "/", "p65", "was", "present", "in", "both", "cortical", "and", "medullary", "regions", "of", "human", "thymus", "lobules", ".", "However", ",", "the", "intensity", "of", "p65", "labeling", "was", "much", "higher", "in", "several", "thymocytes", "from", "the", "medulla", ".", "p65", ",", "p50", ",", "and", "c", "-", "Rel", "activities", "were", "found", "in", "both", "CD4-", "and", "CD8-positive", "thymocytes", ".", "These", "observations", "suggest", "that", "p65", "and", "c", "-", "Rel", "complexes", "play", "distinct", "roles", "in", "gene", "expression", "and", "that", "both", "forms", "of", "NF", "-", "kappa", "B", "play", "critical", "roles", "during", "late", "stages", "of", "the", "intrathymic", "maturation", "of", "T", "cells", ".", "\n" ]	[ "Entity", "Protein" ]
Rel - A, c - Rel, protein complexes, Nuclear factor - kappa B, cellular genes, genes, NF - kappa B, NF - kappa B, p50, p65, p50, c - Rel, complexes, NF - kappa B, p50 / c - Rel, p50 / p65, p65, p65, p50, c - Rel, p65, c - Rel, complexes, NF - kappa B	314_task2	Sentence: Nuclear Rel-A and c-Rel protein complexes are differentially distributed within human thymocytes. Nuclear factor-kappa B (NF-kappa B)/Rel proteins are inducible transcriptional regulators of numerous cellular genes. They are particularly abundant in lymphoid tissues and are thought to be critical for the transcription of genes involved in immune and inflammatory responses. We have reported previously that a nuclear NF-kappa B activity was present in freshly extracted human thymocytes in the absence of in vitro treatment of these cells. In the present report, we identified NF-kappa B proteins extracted from human thymocyte nuclei as being p50/p65 and p50/c-Rel complexes. Immunochemical and immunofluorescent staining of thymus sections using specific Abs allowed visualization of nuclear NF-kappa B proteins in both thymocytes and nonthymocyte cells. This detection suggested a preferential activation of p50/c-Rel in medullary thymocytes, whereas p50/p65 was present in both cortical and medullary regions of human thymus lobules. However, the intensity of p65 labeling was much higher in several thymocytes from the medulla. p65, p50, and c-Rel activities were found in both CD4- and CD8-positive thymocytes. These observations suggest that p65 and c-Rel complexes play distinct roles in gene expression and that both forms of NF-kappa B play critical roles during late stages of the intrathymic maturation of T cells. Instructions: please extract entity words from the input sentence	[ "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Nuclear Rel-A and c-Rel protein complexes are differentially distributed within human thymocytes. Nuclear factor-kappa B (NF-kappa B)/Rel proteins are inducible transcriptional regulators of numerous cellular genes. They are particularly abundant in lymphoid tissues and are thought to be critical for the transcription of genes involved in immune and inflammatory responses. We have reported previously that a nuclear NF-kappa B activity was present in freshly extracted human thymocytes in the absence of in vitro treatment of these cells. In the present report, we identified NF-kappa B proteins extracted from human thymocyte nuclei as being p50/p65 and p50/c-Rel complexes. Immunochemical and immunofluorescent staining of thymus sections using specific Abs allowed visualization of nuclear NF-kappa B proteins in both thymocytes and nonthymocyte cells. This detection suggested a preferential activation of p50/c-Rel in medullary thymocytes, whereas p50/p65 was present in both cortical and medullary regions of human thymus lobules. However, the intensity of p65 labeling was much higher in several thymocytes from the medulla. p65, p50, and c-Rel activities were found in both CD4- and CD8-positive thymocytes. These observations suggest that p65 and c-Rel complexes play distinct roles in gene expression and that both forms of NF-kappa B play critical roles during late stages of the intrathymic maturation of T cells.	[ "Nuclear", "Rel", "-", "A", "and", "c", "-", "Rel", "protein", "complexes", "are", "differentially", "distributed", "within", "human", "thymocytes", ".", "\n", "Nuclear", "factor", "-", "kappa", "B", "(", "NF", "-", "kappa", "B)/Rel", "proteins", "are", "inducible", "transcriptional", "regulators", "of", "numerous", "cellular", "genes", ".", "They", "are", "particularly", "abundant", "in", "lymphoid", "tissues", "and", "are", "thought", "to", "be", "critical", "for", "the", "transcription", "of", "genes", "involved", "in", "immune", "and", "inflammatory", "responses", ".", "We", "have", "reported", "previously", "that", "a", "nuclear", "NF", "-", "kappa", "B", "activity", "was", "present", "in", "freshly", "extracted", "human", "thymocytes", "in", "the", "absence", "of", "in", "vitro", "treatment", "of", "these", "cells", ".", "In", "the", "present", "report", ",", "we", "identified", "NF", "-", "kappa", "B", "proteins", "extracted", "from", "human", "thymocyte", "nuclei", "as", "being", "p50", "/", "p65", "and", "p50", "/", "c", "-", "Rel", "complexes", ".", "Immunochemical", "and", "immunofluorescent", "staining", "of", "thymus", "sections", "using", "specific", "Abs", "allowed", "visualization", "of", "nuclear", "NF", "-", "kappa", "B", "proteins", "in", "both", "thymocytes", "and", "nonthymocyte", "cells", ".", "This", "detection", "suggested", "a", "preferential", "activation", "of", "p50", "/", "c", "-", "Rel", "in", "medullary", "thymocytes", ",", "whereas", "p50", "/", "p65", "was", "present", "in", "both", "cortical", "and", "medullary", "regions", "of", "human", "thymus", "lobules", ".", "However", ",", "the", "intensity", "of", "p65", "labeling", "was", "much", "higher", "in", "several", "thymocytes", "from", "the", "medulla", ".", "p65", ",", "p50", ",", "and", "c", "-", "Rel", "activities", "were", "found", "in", "both", "CD4-", "and", "CD8-positive", "thymocytes", ".", "These", "observations", "suggest", "that", "p65", "and", "c", "-", "Rel", "complexes", "play", "distinct", "roles", "in", "gene", "expression", "and", "that", "both", "forms", "of", "NF", "-", "kappa", "B", "play", "critical", "roles", "during", "late", "stages", "of", "the", "intrathymic", "maturation", "of", "T", "cells", ".", "\n" ]	[ "Entity", "Protein" ]
pulmonary toxicity is a ADVERSE, Atrial fibrillation is a ADVERSE, Pulmonary toxicity is a ADVERSE	example-342_task0	Sentence: Amiodarone pulmonary toxicity after lung transplantation. Atrial fibrillation occurs frequently after lung transplantation and is commonly treated with amiodarone. Pulmonary toxicity may result from amiodarone exposure and is characterized by non-specific respiratory manifestations. To our knowledge, there are no reports of this complication occurring after lung transplantation. We present a patient who developed radiologic evidence of amiodarone deposition in the lungs after bilateral lung transplantation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ADVERSE	[ "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Amiodarone pulmonary toxicity after lung transplantation. Atrial fibrillation occurs frequently after lung transplantation and is commonly treated with amiodarone. Pulmonary toxicity may result from amiodarone exposure and is characterized by non-specific respiratory manifestations. To our knowledge, there are no reports of this complication occurring after lung transplantation. We present a patient who developed radiologic evidence of amiodarone deposition in the lungs after bilateral lung transplantation.	[ "Amiodarone", "pulmonary", "toxicity", "after", "lung", "transplantation", ".", " ", "Atrial", "fibrillation", "occurs", "frequently", "after", "lung", "transplantation", "and", "is", "commonly", "treated", "with", "amiodarone", ".", "Pulmonary", "toxicity", "may", "result", "from", "amiodarone", "exposure", "and", "is", "characterized", "by", "non", "-", "specific", "respiratory", "manifestations", ".", "To", "our", "knowledge", ",", "there", "are", "no", "reports", "of", "this", "complication", "occurring", "after", "lung", "transplantation", ".", "We", "present", "a", "patient", "who", "developed", "radiologic", "evidence", "of", "amiodarone", "deposition", "in", "the", "lungs", "after", "bilateral", "lung", "transplantation", "." ]	[ "ADVERSE" ]
pulmonary toxicity is a ADVERSE, Atrial fibrillation is a ADVERSE, Pulmonary toxicity is a ADVERSE	example-342_task1	Sentence: Amiodarone pulmonary toxicity after lung transplantation. Atrial fibrillation occurs frequently after lung transplantation and is commonly treated with amiodarone. Pulmonary toxicity may result from amiodarone exposure and is characterized by non-specific respiratory manifestations. To our knowledge, there are no reports of this complication occurring after lung transplantation. We present a patient who developed radiologic evidence of amiodarone deposition in the lungs after bilateral lung transplantation. Instructions: please typing these entity words according to sentence: pulmonary toxicity, Atrial fibrillation, Pulmonary toxicity Options: ADVERSE	[ "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Amiodarone pulmonary toxicity after lung transplantation. Atrial fibrillation occurs frequently after lung transplantation and is commonly treated with amiodarone. Pulmonary toxicity may result from amiodarone exposure and is characterized by non-specific respiratory manifestations. To our knowledge, there are no reports of this complication occurring after lung transplantation. We present a patient who developed radiologic evidence of amiodarone deposition in the lungs after bilateral lung transplantation.	[ "Amiodarone", "pulmonary", "toxicity", "after", "lung", "transplantation", ".", " ", "Atrial", "fibrillation", "occurs", "frequently", "after", "lung", "transplantation", "and", "is", "commonly", "treated", "with", "amiodarone", ".", "Pulmonary", "toxicity", "may", "result", "from", "amiodarone", "exposure", "and", "is", "characterized", "by", "non", "-", "specific", "respiratory", "manifestations", ".", "To", "our", "knowledge", ",", "there", "are", "no", "reports", "of", "this", "complication", "occurring", "after", "lung", "transplantation", ".", "We", "present", "a", "patient", "who", "developed", "radiologic", "evidence", "of", "amiodarone", "deposition", "in", "the", "lungs", "after", "bilateral", "lung", "transplantation", "." ]	[ "ADVERSE" ]
pulmonary toxicity, Atrial fibrillation, Pulmonary toxicity	example-342_task2	Sentence: Amiodarone pulmonary toxicity after lung transplantation. Atrial fibrillation occurs frequently after lung transplantation and is commonly treated with amiodarone. Pulmonary toxicity may result from amiodarone exposure and is characterized by non-specific respiratory manifestations. To our knowledge, there are no reports of this complication occurring after lung transplantation. We present a patient who developed radiologic evidence of amiodarone deposition in the lungs after bilateral lung transplantation. Instructions: please extract entity words from the input sentence	[ "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Amiodarone pulmonary toxicity after lung transplantation. Atrial fibrillation occurs frequently after lung transplantation and is commonly treated with amiodarone. Pulmonary toxicity may result from amiodarone exposure and is characterized by non-specific respiratory manifestations. To our knowledge, there are no reports of this complication occurring after lung transplantation. We present a patient who developed radiologic evidence of amiodarone deposition in the lungs after bilateral lung transplantation.	[ "Amiodarone", "pulmonary", "toxicity", "after", "lung", "transplantation", ".", " ", "Atrial", "fibrillation", "occurs", "frequently", "after", "lung", "transplantation", "and", "is", "commonly", "treated", "with", "amiodarone", ".", "Pulmonary", "toxicity", "may", "result", "from", "amiodarone", "exposure", "and", "is", "characterized", "by", "non", "-", "specific", "respiratory", "manifestations", ".", "To", "our", "knowledge", ",", "there", "are", "no", "reports", "of", "this", "complication", "occurring", "after", "lung", "transplantation", ".", "We", "present", "a", "patient", "who", "developed", "radiologic", "evidence", "of", "amiodarone", "deposition", "in", "the", "lungs", "after", "bilateral", "lung", "transplantation", "." ]	[ "ADVERSE" ]
Enflurane is a DRUG, Enflurane is a DRUG, halothane is a DRUG, nitrous oxide is a DRUG	Enflurane_ddi_task0	Sentence: The action of nondepolarizing relaxants is augmented by Enflurane. Less than the usual amounts of these medicines should be used. If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of Enflurane than when halothane or nitrous oxide with a balanced technique are used. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DRUG	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O" ]	The action of nondepolarizing relaxants is augmented by Enflurane. Less than the usual amounts of these medicines should be used. If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of Enflurane than when halothane or nitrous oxide with a balanced technique are used.	[ "The", "action", "of", "nondepolarizing", "relaxants", "is", "augmented", "by", "Enflurane", ".", "Less", "than", "the", "usual", "amounts", "of", "these", "medicines", "should", "be", "used", ".", "If", "the", "usual", "amounts", "of", "nondepolarizing", "relaxants", "are", "given", ",", "the", "time", "for", "recovery", "from", "neuromuscular", "blockade", "will", "be", "longer", "in", "the", "presence", "of", "Enflurane", "than", "when", "halothane", "or", "nitrous", "oxide", "with", "a", "balanced", "technique", "are", "used", "." ]	[ "DRUG" ]
Enflurane is a DRUG, Enflurane is a DRUG, halothane is a DRUG, nitrous oxide is a DRUG	Enflurane_ddi_task1	Sentence: The action of nondepolarizing relaxants is augmented by Enflurane. Less than the usual amounts of these medicines should be used. If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of Enflurane than when halothane or nitrous oxide with a balanced technique are used. Instructions: please typing these entity words according to sentence: Enflurane, Enflurane, halothane, nitrous oxide Options: DRUG	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O" ]	The action of nondepolarizing relaxants is augmented by Enflurane. Less than the usual amounts of these medicines should be used. If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of Enflurane than when halothane or nitrous oxide with a balanced technique are used.	[ "The", "action", "of", "nondepolarizing", "relaxants", "is", "augmented", "by", "Enflurane", ".", "Less", "than", "the", "usual", "amounts", "of", "these", "medicines", "should", "be", "used", ".", "If", "the", "usual", "amounts", "of", "nondepolarizing", "relaxants", "are", "given", ",", "the", "time", "for", "recovery", "from", "neuromuscular", "blockade", "will", "be", "longer", "in", "the", "presence", "of", "Enflurane", "than", "when", "halothane", "or", "nitrous", "oxide", "with", "a", "balanced", "technique", "are", "used", "." ]	[ "DRUG" ]
Enflurane, Enflurane, halothane, nitrous oxide	Enflurane_ddi_task2	Sentence: The action of nondepolarizing relaxants is augmented by Enflurane. Less than the usual amounts of these medicines should be used. If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of Enflurane than when halothane or nitrous oxide with a balanced technique are used. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O" ]	The action of nondepolarizing relaxants is augmented by Enflurane. Less than the usual amounts of these medicines should be used. If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of Enflurane than when halothane or nitrous oxide with a balanced technique are used.	[ "The", "action", "of", "nondepolarizing", "relaxants", "is", "augmented", "by", "Enflurane", ".", "Less", "than", "the", "usual", "amounts", "of", "these", "medicines", "should", "be", "used", ".", "If", "the", "usual", "amounts", "of", "nondepolarizing", "relaxants", "are", "given", ",", "the", "time", "for", "recovery", "from", "neuromuscular", "blockade", "will", "be", "longer", "in", "the", "presence", "of", "Enflurane", "than", "when", "halothane", "or", "nitrous", "oxide", "with", "a", "balanced", "technique", "are", "used", "." ]	[ "DRUG" ]
prethrombolytic cyclosporine - A injection is a Intervention_Pharmacological, acute anterior ST - elevation myocardial infarction . is a Participant_Condition, Cyclosporine - A ( CsA ) is a Intervention_Pharmacological, , is a Outcome_Physical, patients with acute anterior STEMI receiving thrombolytic treatment ( TLT ) . is a Participant_Condition, normal saline is a Intervention_Control, Infarct size , occurrence of major arrhythmias , heart failure , left ventricular ejection fraction ( LVEF ) , is a Outcome_Physical, TLT - related complications is a Outcome_Adverse-effects, in - hospital and 6-month mortality rates is a Outcome_Mortality, demographics , myocardial enzyme release , occurrence of major arrhythmias is a Outcome_Physical, LVEF at first day is a Outcome_Physical	56841_task0	Sentence: The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction . INTRODUCTION Reperfusion injury reduces the benefits of early reperfusion therapies after acute ST-elevation myocardial infarction ( STEMI ) . Cyclosporine-A ( CsA ) is a potent inhibitor of opening of the mitochondrial permeability transition pore , which has been shown to play a key role in myocardial reperfusion injury . The impact of this treatment on clinical outcomes of acute STEMI remains unknown . Our aim was to investigate the clinical outcomes of using this drug in patients with acute anterior STEMI receiving thrombolytic treatment ( TLT ) . METHODS In this double-blinded randomized clinical trial , 101 patients with acute anterior STEMI who were candidate for TLT , were enrolled and randomly assigned into treatment or control groups . Patients in the treatment group received an intravenous bolus injection of 2.5 mg/kg of CsA immediately before TLT . The patients in the control group received an equivalent volume of normal saline . Infarct size , occurrence of major arrhythmias , heart failure , left ventricular ejection fraction ( LVEF ) , TLT-related complications , in-hospital and 6-month mortality rates were investigated . RESULTS There were no significant differences among the demographics , myocardial enzyme release , occurrence of major arrhythmias [ 9 ( 18 % ) vs. 12 ( 23.5 % ) , P = 0.80 ] , heart failure [ 18 ( 36 % ) vs. 19 ( 38.3 % ) , P = 0.83 ] , LVEF at first day [ 34.7 ± 9.9 % vs. 33.5 ± 8.1 % , P = 0.50 ] or at discharge [ 37.7 ± 10 % vs. 36.1 ± 8.2 % , P = 0.43 ] , and in-hospital [ 4 ( 8 % ) vs. 6 ( 11.8 % ) , P = 0.74 ] or 6-month mortality rates [ 9 ( 18 % ) vs. 10 ( 19.6 % ) , P = 0.99 ] between the CsA vs. the control group . CONCLUSION In this study , the prethrombolytic administration of CsA was not associated with a reduction in the infarct size or any improvement in clinical outcomes . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Control, Participant_Condition, Outcome_Mortality, Outcome_Physical	[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction . INTRODUCTION Reperfusion injury reduces the benefits of early reperfusion therapies after acute ST-elevation myocardial infarction ( STEMI ) . Cyclosporine-A ( CsA ) is a potent inhibitor of opening of the mitochondrial permeability transition pore , which has been shown to play a key role in myocardial reperfusion injury . The impact of this treatment on clinical outcomes of acute STEMI remains unknown . Our aim was to investigate the clinical outcomes of using this drug in patients with acute anterior STEMI receiving thrombolytic treatment ( TLT ) . METHODS In this double-blinded randomized clinical trial , 101 patients with acute anterior STEMI who were candidate for TLT , were enrolled and randomly assigned into treatment or control groups . Patients in the treatment group received an intravenous bolus injection of 2.5 mg/kg of CsA immediately before TLT . The patients in the control group received an equivalent volume of normal saline . Infarct size , occurrence of major arrhythmias , heart failure , left ventricular ejection fraction ( LVEF ) , TLT-related complications , in-hospital and 6-month mortality rates were investigated . RESULTS There were no significant differences among the demographics , myocardial enzyme release , occurrence of major arrhythmias [ 9 ( 18 % ) vs. 12 ( 23.5 % ) , P = 0.80 ] , heart failure [ 18 ( 36 % ) vs. 19 ( 38.3 % ) , P = 0.83 ] , LVEF at first day [ 34.7 ± 9.9 % vs. 33.5 ± 8.1 % , P = 0.50 ] or at discharge [ 37.7 ± 10 % vs. 36.1 ± 8.2 % , P = 0.43 ] , and in-hospital [ 4 ( 8 % ) vs. 6 ( 11.8 % ) , P = 0.74 ] or 6-month mortality rates [ 9 ( 18 % ) vs. 10 ( 19.6 % ) , P = 0.99 ] between the CsA vs. the control group . CONCLUSION In this study , the prethrombolytic administration of CsA was not associated with a reduction in the infarct size or any improvement in clinical outcomes .	[ "The", "effect", "of", "prethrombolytic", "cyclosporine", "-", "A", "injection", "on", "clinical", "outcome", "of", "acute", "anterior", "ST", "-", "elevation", "myocardial", "infarction", ".", "INTRODUCTION", "Reperfusion", "injury", "reduces", "the", "benefits", "of", "early", "reperfusion", "therapies", "after", "acute", "ST", "-", "elevation", "myocardial", "infarction", "(", "STEMI", ")", ".", "Cyclosporine", "-", "A", "(", "CsA", ")", "is", "a", "potent", "inhibitor", "of", "opening", "of", "the", "mitochondrial", "permeability", "transition", "pore", ",", "which", "has", "been", "shown", "to", "play", "a", "key", "role", "in", "myocardial", "reperfusion", "injury", ".", "The", "impact", "of", "this", "treatment", "on", "clinical", "outcomes", "of", "acute", "STEMI", "remains", "unknown", ".", "Our", "aim", "was", "to", "investigate", "the", "clinical", "outcomes", "of", "using", "this", "drug", "in", "patients", "with", "acute", "anterior", "STEMI", "receiving", "thrombolytic", "treatment", "(", "TLT", ")", ".", "METHODS", "In", "this", "double", "-", "blinded", "randomized", "clinical", "trial", ",", "101", "patients", "with", "acute", "anterior", "STEMI", "who", "were", "candidate", "for", "TLT", ",", "were", "enrolled", "and", "randomly", "assigned", "into", "treatment", "or", "control", "groups", ".", "Patients", "in", "the", "treatment", "group", "received", "an", "intravenous", "bolus", "injection", "of", "2.5", "mg", "/", "kg", "of", "CsA", "immediately", "before", "TLT", ".", "The", "patients", "in", "the", "control", "group", "received", "an", "equivalent", "volume", "of", "normal", "saline", ".", "Infarct", "size", ",", "occurrence", "of", "major", "arrhythmias", ",", "heart", "failure", ",", "left", "ventricular", "ejection", "fraction", "(", "LVEF", ")", ",", "TLT", "-", "related", "complications", ",", "in", "-", "hospital", "and", "6-month", "mortality", "rates", "were", "investigated", ".", "RESULTS", "There", "were", "no", "significant", "differences", "among", "the", "demographics", ",", "myocardial", "enzyme", "release", ",", "occurrence", "of", "major", "arrhythmias", "[", "9", "(", "18", "%", ")", "vs", ".", "12", "(", "23.5", "%", ")", ",", "P", "=", "0.80", "]", ",", "heart", "failure", "[", "18", "(", "36", "%", ")", "vs", ".", "19", "(", "38.3", "%", ")", ",", "P", "=", "0.83", "]", ",", "LVEF", "at", "first", "day", "[", "34.7", "±", "9.9", "%", "vs", ".", "33.5", "±", "8.1", "%", ",", "P", "=", "0.50", "]", "or", "at", "discharge", "[", "37.7", "±", "10", "%", "vs", ".", "36.1", "±", "8.2", "%", ",", "P", "=", "0.43", "]", ",", "and", "in", "-", "hospital", "[", "4", "(", "8", "%", ")", "vs", ".", "6", "(", "11.8", "%", ")", ",", "P", "=", "0.74", "]", "or", "6-month", "mortality", "rates", "[", "9", "(", "18", "%", ")", "vs", ".", "10", "(", "19.6", "%", ")", ",", "P", "=", "0.99", "]", "between", "the", "CsA", "vs", ".", "the", "control", "group", ".", "CONCLUSION", "In", "this", "study", ",", "the", "prethrombolytic", "administration", "of", "CsA", "was", "not", "associated", "with", "a", "reduction", "in", "the", "infarct", "size", "or", "any", "improvement", "in", "clinical", "outcomes", "." ]	[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Outcome_Mortality", "Outcome_Adverse-effects", "Intervention_Control" ]
prethrombolytic cyclosporine - A injection is a Intervention_Pharmacological, acute anterior ST - elevation myocardial infarction . is a Participant_Condition, Cyclosporine - A ( CsA ) is a Intervention_Pharmacological, , is a Outcome_Physical, patients with acute anterior STEMI receiving thrombolytic treatment ( TLT ) . is a Participant_Condition, normal saline is a Intervention_Control, Infarct size , occurrence of major arrhythmias , heart failure , left ventricular ejection fraction ( LVEF ) , is a Outcome_Physical, TLT - related complications is a Outcome_Adverse-effects, in - hospital and 6-month mortality rates is a Outcome_Mortality, demographics , myocardial enzyme release , occurrence of major arrhythmias is a Outcome_Physical, LVEF at first day is a Outcome_Physical	56841_task1	Sentence: The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction . INTRODUCTION Reperfusion injury reduces the benefits of early reperfusion therapies after acute ST-elevation myocardial infarction ( STEMI ) . Cyclosporine-A ( CsA ) is a potent inhibitor of opening of the mitochondrial permeability transition pore , which has been shown to play a key role in myocardial reperfusion injury . The impact of this treatment on clinical outcomes of acute STEMI remains unknown . Our aim was to investigate the clinical outcomes of using this drug in patients with acute anterior STEMI receiving thrombolytic treatment ( TLT ) . METHODS In this double-blinded randomized clinical trial , 101 patients with acute anterior STEMI who were candidate for TLT , were enrolled and randomly assigned into treatment or control groups . Patients in the treatment group received an intravenous bolus injection of 2.5 mg/kg of CsA immediately before TLT . The patients in the control group received an equivalent volume of normal saline . Infarct size , occurrence of major arrhythmias , heart failure , left ventricular ejection fraction ( LVEF ) , TLT-related complications , in-hospital and 6-month mortality rates were investigated . RESULTS There were no significant differences among the demographics , myocardial enzyme release , occurrence of major arrhythmias [ 9 ( 18 % ) vs. 12 ( 23.5 % ) , P = 0.80 ] , heart failure [ 18 ( 36 % ) vs. 19 ( 38.3 % ) , P = 0.83 ] , LVEF at first day [ 34.7 ± 9.9 % vs. 33.5 ± 8.1 % , P = 0.50 ] or at discharge [ 37.7 ± 10 % vs. 36.1 ± 8.2 % , P = 0.43 ] , and in-hospital [ 4 ( 8 % ) vs. 6 ( 11.8 % ) , P = 0.74 ] or 6-month mortality rates [ 9 ( 18 % ) vs. 10 ( 19.6 % ) , P = 0.99 ] between the CsA vs. the control group . CONCLUSION In this study , the prethrombolytic administration of CsA was not associated with a reduction in the infarct size or any improvement in clinical outcomes . Instructions: please typing these entity words according to sentence: prethrombolytic cyclosporine - A injection, acute anterior ST - elevation myocardial infarction ., Cyclosporine - A ( CsA ), ,, patients with acute anterior STEMI receiving thrombolytic treatment ( TLT ) ., normal saline, Infarct size , occurrence of major arrhythmias , heart failure , left ventricular ejection fraction ( LVEF ) ,, TLT - related complications, in - hospital and 6-month mortality rates, demographics , myocardial enzyme release , occurrence of major arrhythmias, LVEF at first day Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Control, Participant_Condition, Outcome_Mortality, Outcome_Physical	[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction . INTRODUCTION Reperfusion injury reduces the benefits of early reperfusion therapies after acute ST-elevation myocardial infarction ( STEMI ) . Cyclosporine-A ( CsA ) is a potent inhibitor of opening of the mitochondrial permeability transition pore , which has been shown to play a key role in myocardial reperfusion injury . The impact of this treatment on clinical outcomes of acute STEMI remains unknown . Our aim was to investigate the clinical outcomes of using this drug in patients with acute anterior STEMI receiving thrombolytic treatment ( TLT ) . METHODS In this double-blinded randomized clinical trial , 101 patients with acute anterior STEMI who were candidate for TLT , were enrolled and randomly assigned into treatment or control groups . Patients in the treatment group received an intravenous bolus injection of 2.5 mg/kg of CsA immediately before TLT . The patients in the control group received an equivalent volume of normal saline . Infarct size , occurrence of major arrhythmias , heart failure , left ventricular ejection fraction ( LVEF ) , TLT-related complications , in-hospital and 6-month mortality rates were investigated . RESULTS There were no significant differences among the demographics , myocardial enzyme release , occurrence of major arrhythmias [ 9 ( 18 % ) vs. 12 ( 23.5 % ) , P = 0.80 ] , heart failure [ 18 ( 36 % ) vs. 19 ( 38.3 % ) , P = 0.83 ] , LVEF at first day [ 34.7 ± 9.9 % vs. 33.5 ± 8.1 % , P = 0.50 ] or at discharge [ 37.7 ± 10 % vs. 36.1 ± 8.2 % , P = 0.43 ] , and in-hospital [ 4 ( 8 % ) vs. 6 ( 11.8 % ) , P = 0.74 ] or 6-month mortality rates [ 9 ( 18 % ) vs. 10 ( 19.6 % ) , P = 0.99 ] between the CsA vs. the control group . CONCLUSION In this study , the prethrombolytic administration of CsA was not associated with a reduction in the infarct size or any improvement in clinical outcomes .	[ "The", "effect", "of", "prethrombolytic", "cyclosporine", "-", "A", "injection", "on", "clinical", "outcome", "of", "acute", "anterior", "ST", "-", "elevation", "myocardial", "infarction", ".", "INTRODUCTION", "Reperfusion", "injury", "reduces", "the", "benefits", "of", "early", "reperfusion", "therapies", "after", "acute", "ST", "-", "elevation", "myocardial", "infarction", "(", "STEMI", ")", ".", "Cyclosporine", "-", "A", "(", "CsA", ")", "is", "a", "potent", "inhibitor", "of", "opening", "of", "the", "mitochondrial", "permeability", "transition", "pore", ",", "which", "has", "been", "shown", "to", "play", "a", "key", "role", "in", "myocardial", "reperfusion", "injury", ".", "The", "impact", "of", "this", "treatment", "on", "clinical", "outcomes", "of", "acute", "STEMI", "remains", "unknown", ".", "Our", "aim", "was", "to", "investigate", "the", "clinical", "outcomes", "of", "using", "this", "drug", "in", "patients", "with", "acute", "anterior", "STEMI", "receiving", "thrombolytic", "treatment", "(", "TLT", ")", ".", "METHODS", "In", "this", "double", "-", "blinded", "randomized", "clinical", "trial", ",", "101", "patients", "with", "acute", "anterior", "STEMI", "who", "were", "candidate", "for", "TLT", ",", "were", "enrolled", "and", "randomly", "assigned", "into", "treatment", "or", "control", "groups", ".", "Patients", "in", "the", "treatment", "group", "received", "an", "intravenous", "bolus", "injection", "of", "2.5", "mg", "/", "kg", "of", "CsA", "immediately", "before", "TLT", ".", "The", "patients", "in", "the", "control", "group", "received", "an", "equivalent", "volume", "of", "normal", "saline", ".", "Infarct", "size", ",", "occurrence", "of", "major", "arrhythmias", ",", "heart", "failure", ",", "left", "ventricular", "ejection", "fraction", "(", "LVEF", ")", ",", "TLT", "-", "related", "complications", ",", "in", "-", "hospital", "and", "6-month", "mortality", "rates", "were", "investigated", ".", "RESULTS", "There", "were", "no", "significant", "differences", "among", "the", "demographics", ",", "myocardial", "enzyme", "release", ",", "occurrence", "of", "major", "arrhythmias", "[", "9", "(", "18", "%", ")", "vs", ".", "12", "(", "23.5", "%", ")", ",", "P", "=", "0.80", "]", ",", "heart", "failure", "[", "18", "(", "36", "%", ")", "vs", ".", "19", "(", "38.3", "%", ")", ",", "P", "=", "0.83", "]", ",", "LVEF", "at", "first", "day", "[", "34.7", "±", "9.9", "%", "vs", ".", "33.5", "±", "8.1", "%", ",", "P", "=", "0.50", "]", "or", "at", "discharge", "[", "37.7", "±", "10", "%", "vs", ".", "36.1", "±", "8.2", "%", ",", "P", "=", "0.43", "]", ",", "and", "in", "-", "hospital", "[", "4", "(", "8", "%", ")", "vs", ".", "6", "(", "11.8", "%", ")", ",", "P", "=", "0.74", "]", "or", "6-month", "mortality", "rates", "[", "9", "(", "18", "%", ")", "vs", ".", "10", "(", "19.6", "%", ")", ",", "P", "=", "0.99", "]", "between", "the", "CsA", "vs", ".", "the", "control", "group", ".", "CONCLUSION", "In", "this", "study", ",", "the", "prethrombolytic", "administration", "of", "CsA", "was", "not", "associated", "with", "a", "reduction", "in", "the", "infarct", "size", "or", "any", "improvement", "in", "clinical", "outcomes", "." ]	[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Outcome_Mortality", "Outcome_Adverse-effects", "Intervention_Control" ]
prethrombolytic cyclosporine - A injection, acute anterior ST - elevation myocardial infarction ., Cyclosporine - A ( CsA ), ,, patients with acute anterior STEMI receiving thrombolytic treatment ( TLT ) ., normal saline, Infarct size , occurrence of major arrhythmias , heart failure , left ventricular ejection fraction ( LVEF ) ,, TLT - related complications, in - hospital and 6-month mortality rates, demographics , myocardial enzyme release , occurrence of major arrhythmias, LVEF at first day	56841_task2	Sentence: The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction . INTRODUCTION Reperfusion injury reduces the benefits of early reperfusion therapies after acute ST-elevation myocardial infarction ( STEMI ) . Cyclosporine-A ( CsA ) is a potent inhibitor of opening of the mitochondrial permeability transition pore , which has been shown to play a key role in myocardial reperfusion injury . The impact of this treatment on clinical outcomes of acute STEMI remains unknown . Our aim was to investigate the clinical outcomes of using this drug in patients with acute anterior STEMI receiving thrombolytic treatment ( TLT ) . METHODS In this double-blinded randomized clinical trial , 101 patients with acute anterior STEMI who were candidate for TLT , were enrolled and randomly assigned into treatment or control groups . Patients in the treatment group received an intravenous bolus injection of 2.5 mg/kg of CsA immediately before TLT . The patients in the control group received an equivalent volume of normal saline . Infarct size , occurrence of major arrhythmias , heart failure , left ventricular ejection fraction ( LVEF ) , TLT-related complications , in-hospital and 6-month mortality rates were investigated . RESULTS There were no significant differences among the demographics , myocardial enzyme release , occurrence of major arrhythmias [ 9 ( 18 % ) vs. 12 ( 23.5 % ) , P = 0.80 ] , heart failure [ 18 ( 36 % ) vs. 19 ( 38.3 % ) , P = 0.83 ] , LVEF at first day [ 34.7 ± 9.9 % vs. 33.5 ± 8.1 % , P = 0.50 ] or at discharge [ 37.7 ± 10 % vs. 36.1 ± 8.2 % , P = 0.43 ] , and in-hospital [ 4 ( 8 % ) vs. 6 ( 11.8 % ) , P = 0.74 ] or 6-month mortality rates [ 9 ( 18 % ) vs. 10 ( 19.6 % ) , P = 0.99 ] between the CsA vs. the control group . CONCLUSION In this study , the prethrombolytic administration of CsA was not associated with a reduction in the infarct size or any improvement in clinical outcomes . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction . INTRODUCTION Reperfusion injury reduces the benefits of early reperfusion therapies after acute ST-elevation myocardial infarction ( STEMI ) . Cyclosporine-A ( CsA ) is a potent inhibitor of opening of the mitochondrial permeability transition pore , which has been shown to play a key role in myocardial reperfusion injury . The impact of this treatment on clinical outcomes of acute STEMI remains unknown . Our aim was to investigate the clinical outcomes of using this drug in patients with acute anterior STEMI receiving thrombolytic treatment ( TLT ) . METHODS In this double-blinded randomized clinical trial , 101 patients with acute anterior STEMI who were candidate for TLT , were enrolled and randomly assigned into treatment or control groups . Patients in the treatment group received an intravenous bolus injection of 2.5 mg/kg of CsA immediately before TLT . The patients in the control group received an equivalent volume of normal saline . Infarct size , occurrence of major arrhythmias , heart failure , left ventricular ejection fraction ( LVEF ) , TLT-related complications , in-hospital and 6-month mortality rates were investigated . RESULTS There were no significant differences among the demographics , myocardial enzyme release , occurrence of major arrhythmias [ 9 ( 18 % ) vs. 12 ( 23.5 % ) , P = 0.80 ] , heart failure [ 18 ( 36 % ) vs. 19 ( 38.3 % ) , P = 0.83 ] , LVEF at first day [ 34.7 ± 9.9 % vs. 33.5 ± 8.1 % , P = 0.50 ] or at discharge [ 37.7 ± 10 % vs. 36.1 ± 8.2 % , P = 0.43 ] , and in-hospital [ 4 ( 8 % ) vs. 6 ( 11.8 % ) , P = 0.74 ] or 6-month mortality rates [ 9 ( 18 % ) vs. 10 ( 19.6 % ) , P = 0.99 ] between the CsA vs. the control group . CONCLUSION In this study , the prethrombolytic administration of CsA was not associated with a reduction in the infarct size or any improvement in clinical outcomes .	[ "The", "effect", "of", "prethrombolytic", "cyclosporine", "-", "A", "injection", "on", "clinical", "outcome", "of", "acute", "anterior", "ST", "-", "elevation", "myocardial", "infarction", ".", "INTRODUCTION", "Reperfusion", "injury", "reduces", "the", "benefits", "of", "early", "reperfusion", "therapies", "after", "acute", "ST", "-", "elevation", "myocardial", "infarction", "(", "STEMI", ")", ".", "Cyclosporine", "-", "A", "(", "CsA", ")", "is", "a", "potent", "inhibitor", "of", "opening", "of", "the", "mitochondrial", "permeability", "transition", "pore", ",", "which", "has", "been", "shown", "to", "play", "a", "key", "role", "in", "myocardial", "reperfusion", "injury", ".", "The", "impact", "of", "this", "treatment", "on", "clinical", "outcomes", "of", "acute", "STEMI", "remains", "unknown", ".", "Our", "aim", "was", "to", "investigate", "the", "clinical", "outcomes", "of", "using", "this", "drug", "in", "patients", "with", "acute", "anterior", "STEMI", "receiving", "thrombolytic", "treatment", "(", "TLT", ")", ".", "METHODS", "In", "this", "double", "-", "blinded", "randomized", "clinical", "trial", ",", "101", "patients", "with", "acute", "anterior", "STEMI", "who", "were", "candidate", "for", "TLT", ",", "were", "enrolled", "and", "randomly", "assigned", "into", "treatment", "or", "control", "groups", ".", "Patients", "in", "the", "treatment", "group", "received", "an", "intravenous", "bolus", "injection", "of", "2.5", "mg", "/", "kg", "of", "CsA", "immediately", "before", "TLT", ".", "The", "patients", "in", "the", "control", "group", "received", "an", "equivalent", "volume", "of", "normal", "saline", ".", "Infarct", "size", ",", "occurrence", "of", "major", "arrhythmias", ",", "heart", "failure", ",", "left", "ventricular", "ejection", "fraction", "(", "LVEF", ")", ",", "TLT", "-", "related", "complications", ",", "in", "-", "hospital", "and", "6-month", "mortality", "rates", "were", "investigated", ".", "RESULTS", "There", "were", "no", "significant", "differences", "among", "the", "demographics", ",", "myocardial", "enzyme", "release", ",", "occurrence", "of", "major", "arrhythmias", "[", "9", "(", "18", "%", ")", "vs", ".", "12", "(", "23.5", "%", ")", ",", "P", "=", "0.80", "]", ",", "heart", "failure", "[", "18", "(", "36", "%", ")", "vs", ".", "19", "(", "38.3", "%", ")", ",", "P", "=", "0.83", "]", ",", "LVEF", "at", "first", "day", "[", "34.7", "±", "9.9", "%", "vs", ".", "33.5", "±", "8.1", "%", ",", "P", "=", "0.50", "]", "or", "at", "discharge", "[", "37.7", "±", "10", "%", "vs", ".", "36.1", "±", "8.2", "%", ",", "P", "=", "0.43", "]", ",", "and", "in", "-", "hospital", "[", "4", "(", "8", "%", ")", "vs", ".", "6", "(", "11.8", "%", ")", ",", "P", "=", "0.74", "]", "or", "6-month", "mortality", "rates", "[", "9", "(", "18", "%", ")", "vs", ".", "10", "(", "19.6", "%", ")", ",", "P", "=", "0.99", "]", "between", "the", "CsA", "vs", ".", "the", "control", "group", ".", "CONCLUSION", "In", "this", "study", ",", "the", "prethrombolytic", "administration", "of", "CsA", "was", "not", "associated", "with", "a", "reduction", "in", "the", "infarct", "size", "or", "any", "improvement", "in", "clinical", "outcomes", "." ]	[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Outcome_Mortality", "Outcome_Adverse-effects", "Intervention_Control" ]
pneumonectomy is an umlsterm, carcinoma is an umlsterm, adjuvant is an umlsterm, radiation is an umlsterm, drainage is an umlsterm, therapy is an umlsterm, empyema is an umlsterm, Dacron is an umlsterm, rupture is an umlsterm, aorta is an umlsterm, emergency is an umlsterm, aorta is an umlsterm, blind is an umlsterm, omentum is an umlsterm, pneumonectomy is an umlsterm, infections is an umlsterm, prostheses is an umlsterm, lung is an umlsterm, graft is an umlsterm, incorporation is an umlsterm, tissue is an umlsterm, complications is an umlsterm, grafting is an umlsterm, graft is an umlsterm, implantation is an umlsterm, procedures is an umlsterm, debridement is an umlsterm, omentum is an umlsterm, thoracoplasty is an umlsterm, postoperative is an umlsterm, infection is an umlsterm, tissue is an umlsterm	Gefaesschirurgie.90040096.eng.abstr_task0	Sentence: Four years after extensive pneumonectomy on the left side with resection of the aortic wall and patch reconstruction for a T4 carcinoma , 2 years after adjuvant radiation and 10 months after drainage therapy of late intrathoracic empyema , destruction of the infected Dacron patch led to rupture of the aorta descendens . Successful primary emergency reconstruction of the aorta descendens was followed by venetian blind plasty ( Heller ) and transposition of the omentum majus for omentoplasty of the aortal wall and reduction of the pneumonectomy cavity . The rate of prosthetic infections is between 0.3 and 2.5% and must be taken into consideration even in cases of intrathoracic vascular reconstruction with alloplastic prostheses . After lung resection it is necessary to cover up the prosthetic graft by using autogenous material to obtain prosthetic incorporation into the protective tissue . In intrathoracic infectious complications , extra-anatomic bypass grafting or autogenous vascular graft implantation should be considered . If there is no possibility of carrying out these procedures , first aggressive local debridement of the infected vascular wall and afterwards coverage with alloplastic prosthetics with omentum transposition and thoracoplasty are essential to minimize postoperative infection and obtain solid anchorage in the surrounding tissue . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Four years after extensive pneumonectomy on the left side with resection of the aortic wall and patch reconstruction for a T4 carcinoma , 2 years after adjuvant radiation and 10 months after drainage therapy of late intrathoracic empyema , destruction of the infected Dacron patch led to rupture of the aorta descendens . Successful primary emergency reconstruction of the aorta descendens was followed by venetian blind plasty ( Heller ) and transposition of the omentum majus for omentoplasty of the aortal wall and reduction of the pneumonectomy cavity . The rate of prosthetic infections is between 0.3 and 2.5% and must be taken into consideration even in cases of intrathoracic vascular reconstruction with alloplastic prostheses . After lung resection it is necessary to cover up the prosthetic graft by using autogenous material to obtain prosthetic incorporation into the protective tissue . In intrathoracic infectious complications , extra-anatomic bypass grafting or autogenous vascular graft implantation should be considered . If there is no possibility of carrying out these procedures , first aggressive local debridement of the infected vascular wall and afterwards coverage with alloplastic prosthetics with omentum transposition and thoracoplasty are essential to minimize postoperative infection and obtain solid anchorage in the surrounding tissue .	[ "Four", "years", "after", "extensive", "pneumonectomy", "on", "the", "left", "side", "with", "resection", "of", "the", "aortic", "wall", "and", "patch", "reconstruction", "for", "a", "T4", "carcinoma", ",", "2", "years", "after", "adjuvant", "radiation", "and", "10", "months", "after", "drainage", "therapy", "of", "late", "intrathoracic", "empyema", ",", "destruction", "of", "the", "infected", "Dacron", "patch", "led", "to", "rupture", "of", "the", "aorta", "descendens", ".", "Successful", "primary", "emergency", "reconstruction", "of", "the", "aorta", "descendens", "was", "followed", "by", "venetian", "blind", "plasty", "(", "Heller", ")", "and", "transposition", "of", "the", "omentum", "majus", "for", "omentoplasty", "of", "the", "aortal", "wall", "and", "reduction", "of", "the", "pneumonectomy", "cavity", ".", "The", "rate", "of", "prosthetic", "infections", "is", "between", "0.3", "and", "2.5", "%", "and", "must", "be", "taken", "into", "consideration", "even", "in", "cases", "of", "intrathoracic", "vascular", "reconstruction", "with", "alloplastic", "prostheses", ".", "After", "lung", "resection", "it", "is", "necessary", "to", "cover", "up", "the", "prosthetic", "graft", "by", "using", "autogenous", "material", "to", "obtain", "prosthetic", "incorporation", "into", "the", "protective", "tissue", ".", "In", "intrathoracic", "infectious", "complications", ",", "extra", "-", "anatomic", "bypass", "grafting", "or", "autogenous", "vascular", "graft", "implantation", "should", "be", "considered", ".", "If", "there", "is", "no", "possibility", "of", "carrying", "out", "these", "procedures", ",", "first", "aggressive", "local", "debridement", "of", "the", "infected", "vascular", "wall", "and", "afterwards", "coverage", "with", "alloplastic", "prosthetics", "with", "omentum", "transposition", "and", "thoracoplasty", "are", "essential", "to", "minimize", "postoperative", "infection", "and", "obtain", "solid", "anchorage", "in", "the", "surrounding", "tissue", "." ]	[ "umlsterm" ]
pneumonectomy is an umlsterm, carcinoma is an umlsterm, adjuvant is an umlsterm, radiation is an umlsterm, drainage is an umlsterm, therapy is an umlsterm, empyema is an umlsterm, Dacron is an umlsterm, rupture is an umlsterm, aorta is an umlsterm, emergency is an umlsterm, aorta is an umlsterm, blind is an umlsterm, omentum is an umlsterm, pneumonectomy is an umlsterm, infections is an umlsterm, prostheses is an umlsterm, lung is an umlsterm, graft is an umlsterm, incorporation is an umlsterm, tissue is an umlsterm, complications is an umlsterm, grafting is an umlsterm, graft is an umlsterm, implantation is an umlsterm, procedures is an umlsterm, debridement is an umlsterm, omentum is an umlsterm, thoracoplasty is an umlsterm, postoperative is an umlsterm, infection is an umlsterm, tissue is an umlsterm	Gefaesschirurgie.90040096.eng.abstr_task1	Sentence: Four years after extensive pneumonectomy on the left side with resection of the aortic wall and patch reconstruction for a T4 carcinoma , 2 years after adjuvant radiation and 10 months after drainage therapy of late intrathoracic empyema , destruction of the infected Dacron patch led to rupture of the aorta descendens . Successful primary emergency reconstruction of the aorta descendens was followed by venetian blind plasty ( Heller ) and transposition of the omentum majus for omentoplasty of the aortal wall and reduction of the pneumonectomy cavity . The rate of prosthetic infections is between 0.3 and 2.5% and must be taken into consideration even in cases of intrathoracic vascular reconstruction with alloplastic prostheses . After lung resection it is necessary to cover up the prosthetic graft by using autogenous material to obtain prosthetic incorporation into the protective tissue . In intrathoracic infectious complications , extra-anatomic bypass grafting or autogenous vascular graft implantation should be considered . If there is no possibility of carrying out these procedures , first aggressive local debridement of the infected vascular wall and afterwards coverage with alloplastic prosthetics with omentum transposition and thoracoplasty are essential to minimize postoperative infection and obtain solid anchorage in the surrounding tissue . Instructions: please typing these entity words according to sentence: pneumonectomy, carcinoma, adjuvant, radiation, drainage, therapy, empyema, Dacron, rupture, aorta, emergency, aorta, blind, omentum, pneumonectomy, infections, prostheses, lung, graft, incorporation, tissue, complications, grafting, graft, implantation, procedures, debridement, omentum, thoracoplasty, postoperative, infection, tissue Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Four years after extensive pneumonectomy on the left side with resection of the aortic wall and patch reconstruction for a T4 carcinoma , 2 years after adjuvant radiation and 10 months after drainage therapy of late intrathoracic empyema , destruction of the infected Dacron patch led to rupture of the aorta descendens . Successful primary emergency reconstruction of the aorta descendens was followed by venetian blind plasty ( Heller ) and transposition of the omentum majus for omentoplasty of the aortal wall and reduction of the pneumonectomy cavity . The rate of prosthetic infections is between 0.3 and 2.5% and must be taken into consideration even in cases of intrathoracic vascular reconstruction with alloplastic prostheses . After lung resection it is necessary to cover up the prosthetic graft by using autogenous material to obtain prosthetic incorporation into the protective tissue . In intrathoracic infectious complications , extra-anatomic bypass grafting or autogenous vascular graft implantation should be considered . If there is no possibility of carrying out these procedures , first aggressive local debridement of the infected vascular wall and afterwards coverage with alloplastic prosthetics with omentum transposition and thoracoplasty are essential to minimize postoperative infection and obtain solid anchorage in the surrounding tissue .	[ "Four", "years", "after", "extensive", "pneumonectomy", "on", "the", "left", "side", "with", "resection", "of", "the", "aortic", "wall", "and", "patch", "reconstruction", "for", "a", "T4", "carcinoma", ",", "2", "years", "after", "adjuvant", "radiation", "and", "10", "months", "after", "drainage", "therapy", "of", "late", "intrathoracic", "empyema", ",", "destruction", "of", "the", "infected", "Dacron", "patch", "led", "to", "rupture", "of", "the", "aorta", "descendens", ".", "Successful", "primary", "emergency", "reconstruction", "of", "the", "aorta", "descendens", "was", "followed", "by", "venetian", "blind", "plasty", "(", "Heller", ")", "and", "transposition", "of", "the", "omentum", "majus", "for", "omentoplasty", "of", "the", "aortal", "wall", "and", "reduction", "of", "the", "pneumonectomy", "cavity", ".", "The", "rate", "of", "prosthetic", "infections", "is", "between", "0.3", "and", "2.5", "%", "and", "must", "be", "taken", "into", "consideration", "even", "in", "cases", "of", "intrathoracic", "vascular", "reconstruction", "with", "alloplastic", "prostheses", ".", "After", "lung", "resection", "it", "is", "necessary", "to", "cover", "up", "the", "prosthetic", "graft", "by", "using", "autogenous", "material", "to", "obtain", "prosthetic", "incorporation", "into", "the", "protective", "tissue", ".", "In", "intrathoracic", "infectious", "complications", ",", "extra", "-", "anatomic", "bypass", "grafting", "or", "autogenous", "vascular", "graft", "implantation", "should", "be", "considered", ".", "If", "there", "is", "no", "possibility", "of", "carrying", "out", "these", "procedures", ",", "first", "aggressive", "local", "debridement", "of", "the", "infected", "vascular", "wall", "and", "afterwards", "coverage", "with", "alloplastic", "prosthetics", "with", "omentum", "transposition", "and", "thoracoplasty", "are", "essential", "to", "minimize", "postoperative", "infection", "and", "obtain", "solid", "anchorage", "in", "the", "surrounding", "tissue", "." ]	[ "umlsterm" ]
pneumonectomy, carcinoma, adjuvant, radiation, drainage, therapy, empyema, Dacron, rupture, aorta, emergency, aorta, blind, omentum, pneumonectomy, infections, prostheses, lung, graft, incorporation, tissue, complications, grafting, graft, implantation, procedures, debridement, omentum, thoracoplasty, postoperative, infection, tissue	Gefaesschirurgie.90040096.eng.abstr_task2	Sentence: Four years after extensive pneumonectomy on the left side with resection of the aortic wall and patch reconstruction for a T4 carcinoma , 2 years after adjuvant radiation and 10 months after drainage therapy of late intrathoracic empyema , destruction of the infected Dacron patch led to rupture of the aorta descendens . Successful primary emergency reconstruction of the aorta descendens was followed by venetian blind plasty ( Heller ) and transposition of the omentum majus for omentoplasty of the aortal wall and reduction of the pneumonectomy cavity . The rate of prosthetic infections is between 0.3 and 2.5% and must be taken into consideration even in cases of intrathoracic vascular reconstruction with alloplastic prostheses . After lung resection it is necessary to cover up the prosthetic graft by using autogenous material to obtain prosthetic incorporation into the protective tissue . In intrathoracic infectious complications , extra-anatomic bypass grafting or autogenous vascular graft implantation should be considered . If there is no possibility of carrying out these procedures , first aggressive local debridement of the infected vascular wall and afterwards coverage with alloplastic prosthetics with omentum transposition and thoracoplasty are essential to minimize postoperative infection and obtain solid anchorage in the surrounding tissue . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Four years after extensive pneumonectomy on the left side with resection of the aortic wall and patch reconstruction for a T4 carcinoma , 2 years after adjuvant radiation and 10 months after drainage therapy of late intrathoracic empyema , destruction of the infected Dacron patch led to rupture of the aorta descendens . Successful primary emergency reconstruction of the aorta descendens was followed by venetian blind plasty ( Heller ) and transposition of the omentum majus for omentoplasty of the aortal wall and reduction of the pneumonectomy cavity . The rate of prosthetic infections is between 0.3 and 2.5% and must be taken into consideration even in cases of intrathoracic vascular reconstruction with alloplastic prostheses . After lung resection it is necessary to cover up the prosthetic graft by using autogenous material to obtain prosthetic incorporation into the protective tissue . In intrathoracic infectious complications , extra-anatomic bypass grafting or autogenous vascular graft implantation should be considered . If there is no possibility of carrying out these procedures , first aggressive local debridement of the infected vascular wall and afterwards coverage with alloplastic prosthetics with omentum transposition and thoracoplasty are essential to minimize postoperative infection and obtain solid anchorage in the surrounding tissue .	[ "Four", "years", "after", "extensive", "pneumonectomy", "on", "the", "left", "side", "with", "resection", "of", "the", "aortic", "wall", "and", "patch", "reconstruction", "for", "a", "T4", "carcinoma", ",", "2", "years", "after", "adjuvant", "radiation", "and", "10", "months", "after", "drainage", "therapy", "of", "late", "intrathoracic", "empyema", ",", "destruction", "of", "the", "infected", "Dacron", "patch", "led", "to", "rupture", "of", "the", "aorta", "descendens", ".", "Successful", "primary", "emergency", "reconstruction", "of", "the", "aorta", "descendens", "was", "followed", "by", "venetian", "blind", "plasty", "(", "Heller", ")", "and", "transposition", "of", "the", "omentum", "majus", "for", "omentoplasty", "of", "the", "aortal", "wall", "and", "reduction", "of", "the", "pneumonectomy", "cavity", ".", "The", "rate", "of", "prosthetic", "infections", "is", "between", "0.3", "and", "2.5", "%", "and", "must", "be", "taken", "into", "consideration", "even", "in", "cases", "of", "intrathoracic", "vascular", "reconstruction", "with", "alloplastic", "prostheses", ".", "After", "lung", "resection", "it", "is", "necessary", "to", "cover", "up", "the", "prosthetic", "graft", "by", "using", "autogenous", "material", "to", "obtain", "prosthetic", "incorporation", "into", "the", "protective", "tissue", ".", "In", "intrathoracic", "infectious", "complications", ",", "extra", "-", "anatomic", "bypass", "grafting", "or", "autogenous", "vascular", "graft", "implantation", "should", "be", "considered", ".", "If", "there", "is", "no", "possibility", "of", "carrying", "out", "these", "procedures", ",", "first", "aggressive", "local", "debridement", "of", "the", "infected", "vascular", "wall", "and", "afterwards", "coverage", "with", "alloplastic", "prosthetics", "with", "omentum", "transposition", "and", "thoracoplasty", "are", "essential", "to", "minimize", "postoperative", "infection", "and", "obtain", "solid", "anchorage", "in", "the", "surrounding", "tissue", "." ]	[ "umlsterm" ]
Intensivpatienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, ueberlebend is an umlsterm, ueberlebend is an umlsterm, Spezifitaet is an umlsterm	DerChirurg.80690077.ger.abstr_task0	Sentence: Zusammenfassung . Im Zeitraum 1. 11. 1993 bis 30. 3. 1997 wurden 1149 allgemeinchirurgische Intensivpatienten prospektiv erfasst , von denen 114 die Kriterien des septischen Schocks erfuellten . Die Letalitaet der Patienten mit einem septischen Schock betrug 47,3 % . Nach Training eines neuronalen Netzes mit 91 ( von insgesamt n = 114 ) Patienten ergab die Testung bei den verbleibenden 23 Patienten bei der Beruecksichtigung von Parameterveraenderungen vom 1. auf den 2. Tag des septischen Schocks folgendes Ergebnis : Alle 10 verstorbenen Patienten wurden korrekt als nicht ueberlebend vorhergesagt , von den 13 Ueberlebenden wurden 12 korrekt als ueberlebend vorhergesagt ( Sensitivitaet 100 % ; Spezifitaet 92,3 % ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Zusammenfassung . Im Zeitraum 1. 11. 1993 bis 30. 3. 1997 wurden 1149 allgemeinchirurgische Intensivpatienten prospektiv erfasst , von denen 114 die Kriterien des septischen Schocks erfuellten . Die Letalitaet der Patienten mit einem septischen Schock betrug 47,3 % . Nach Training eines neuronalen Netzes mit 91 ( von insgesamt n = 114 ) Patienten ergab die Testung bei den verbleibenden 23 Patienten bei der Beruecksichtigung von Parameterveraenderungen vom 1. auf den 2. Tag des septischen Schocks folgendes Ergebnis : Alle 10 verstorbenen Patienten wurden korrekt als nicht ueberlebend vorhergesagt , von den 13 Ueberlebenden wurden 12 korrekt als ueberlebend vorhergesagt ( Sensitivitaet 100 % ; Spezifitaet 92,3 % ) .	[ "Zusammenfassung", ".", "Im", "Zeitraum", "1", ".", "11", ".", "1993", "bis", "30", ".", "3", ".", "1997", "wurden", "1149", "allgemeinchirurgische", "Intensivpatienten", "prospektiv", "erfasst", ",", "von", "denen", "114", "die", "Kriterien", "des", "septischen", "Schocks", "erfuellten", ".", "Die", "Letalitaet", "der", "Patienten", "mit", "einem", "septischen", "Schock", "betrug", "47,3", "%", ".", "Nach", "Training", "eines", "neuronalen", "Netzes", "mit", "91", "(", "von", "insgesamt", "n", "=", "114", ")", "Patienten", "ergab", "die", "Testung", "bei", "den", "verbleibenden", "23", "Patienten", "bei", "der", "Beruecksichtigung", "von", "Parameterveraenderungen", "vom", "1", ".", "auf", "den", "2", ".", "Tag", "des", "septischen", "Schocks", "folgendes", "Ergebnis", ":", "Alle", "10", "verstorbenen", "Patienten", "wurden", "korrekt", "als", "nicht", "ueberlebend", "vorhergesagt", ",", "von", "den", "13", "Ueberlebenden", "wurden", "12", "korrekt", "als", "ueberlebend", "vorhergesagt", "(", "Sensitivitaet", "100", "%", ";", "Spezifitaet", "92,3", "%", ")", "." ]	[ "umlsterm" ]
Intensivpatienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, ueberlebend is an umlsterm, ueberlebend is an umlsterm, Spezifitaet is an umlsterm	DerChirurg.80690077.ger.abstr_task1	Sentence: Zusammenfassung . Im Zeitraum 1. 11. 1993 bis 30. 3. 1997 wurden 1149 allgemeinchirurgische Intensivpatienten prospektiv erfasst , von denen 114 die Kriterien des septischen Schocks erfuellten . Die Letalitaet der Patienten mit einem septischen Schock betrug 47,3 % . Nach Training eines neuronalen Netzes mit 91 ( von insgesamt n = 114 ) Patienten ergab die Testung bei den verbleibenden 23 Patienten bei der Beruecksichtigung von Parameterveraenderungen vom 1. auf den 2. Tag des septischen Schocks folgendes Ergebnis : Alle 10 verstorbenen Patienten wurden korrekt als nicht ueberlebend vorhergesagt , von den 13 Ueberlebenden wurden 12 korrekt als ueberlebend vorhergesagt ( Sensitivitaet 100 % ; Spezifitaet 92,3 % ) . Instructions: please typing these entity words according to sentence: Intensivpatienten, Patienten, Patienten, Patienten, Patienten, ueberlebend, ueberlebend, Spezifitaet Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Zusammenfassung . Im Zeitraum 1. 11. 1993 bis 30. 3. 1997 wurden 1149 allgemeinchirurgische Intensivpatienten prospektiv erfasst , von denen 114 die Kriterien des septischen Schocks erfuellten . Die Letalitaet der Patienten mit einem septischen Schock betrug 47,3 % . Nach Training eines neuronalen Netzes mit 91 ( von insgesamt n = 114 ) Patienten ergab die Testung bei den verbleibenden 23 Patienten bei der Beruecksichtigung von Parameterveraenderungen vom 1. auf den 2. Tag des septischen Schocks folgendes Ergebnis : Alle 10 verstorbenen Patienten wurden korrekt als nicht ueberlebend vorhergesagt , von den 13 Ueberlebenden wurden 12 korrekt als ueberlebend vorhergesagt ( Sensitivitaet 100 % ; Spezifitaet 92,3 % ) .	[ "Zusammenfassung", ".", "Im", "Zeitraum", "1", ".", "11", ".", "1993", "bis", "30", ".", "3", ".", "1997", "wurden", "1149", "allgemeinchirurgische", "Intensivpatienten", "prospektiv", "erfasst", ",", "von", "denen", "114", "die", "Kriterien", "des", "septischen", "Schocks", "erfuellten", ".", "Die", "Letalitaet", "der", "Patienten", "mit", "einem", "septischen", "Schock", "betrug", "47,3", "%", ".", "Nach", "Training", "eines", "neuronalen", "Netzes", "mit", "91", "(", "von", "insgesamt", "n", "=", "114", ")", "Patienten", "ergab", "die", "Testung", "bei", "den", "verbleibenden", "23", "Patienten", "bei", "der", "Beruecksichtigung", "von", "Parameterveraenderungen", "vom", "1", ".", "auf", "den", "2", ".", "Tag", "des", "septischen", "Schocks", "folgendes", "Ergebnis", ":", "Alle", "10", "verstorbenen", "Patienten", "wurden", "korrekt", "als", "nicht", "ueberlebend", "vorhergesagt", ",", "von", "den", "13", "Ueberlebenden", "wurden", "12", "korrekt", "als", "ueberlebend", "vorhergesagt", "(", "Sensitivitaet", "100", "%", ";", "Spezifitaet", "92,3", "%", ")", "." ]	[ "umlsterm" ]
Intensivpatienten, Patienten, Patienten, Patienten, Patienten, ueberlebend, ueberlebend, Spezifitaet	DerChirurg.80690077.ger.abstr_task2	Sentence: Zusammenfassung . Im Zeitraum 1. 11. 1993 bis 30. 3. 1997 wurden 1149 allgemeinchirurgische Intensivpatienten prospektiv erfasst , von denen 114 die Kriterien des septischen Schocks erfuellten . Die Letalitaet der Patienten mit einem septischen Schock betrug 47,3 % . Nach Training eines neuronalen Netzes mit 91 ( von insgesamt n = 114 ) Patienten ergab die Testung bei den verbleibenden 23 Patienten bei der Beruecksichtigung von Parameterveraenderungen vom 1. auf den 2. Tag des septischen Schocks folgendes Ergebnis : Alle 10 verstorbenen Patienten wurden korrekt als nicht ueberlebend vorhergesagt , von den 13 Ueberlebenden wurden 12 korrekt als ueberlebend vorhergesagt ( Sensitivitaet 100 % ; Spezifitaet 92,3 % ) . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Zusammenfassung . Im Zeitraum 1. 11. 1993 bis 30. 3. 1997 wurden 1149 allgemeinchirurgische Intensivpatienten prospektiv erfasst , von denen 114 die Kriterien des septischen Schocks erfuellten . Die Letalitaet der Patienten mit einem septischen Schock betrug 47,3 % . Nach Training eines neuronalen Netzes mit 91 ( von insgesamt n = 114 ) Patienten ergab die Testung bei den verbleibenden 23 Patienten bei der Beruecksichtigung von Parameterveraenderungen vom 1. auf den 2. Tag des septischen Schocks folgendes Ergebnis : Alle 10 verstorbenen Patienten wurden korrekt als nicht ueberlebend vorhergesagt , von den 13 Ueberlebenden wurden 12 korrekt als ueberlebend vorhergesagt ( Sensitivitaet 100 % ; Spezifitaet 92,3 % ) .	[ "Zusammenfassung", ".", "Im", "Zeitraum", "1", ".", "11", ".", "1993", "bis", "30", ".", "3", ".", "1997", "wurden", "1149", "allgemeinchirurgische", "Intensivpatienten", "prospektiv", "erfasst", ",", "von", "denen", "114", "die", "Kriterien", "des", "septischen", "Schocks", "erfuellten", ".", "Die", "Letalitaet", "der", "Patienten", "mit", "einem", "septischen", "Schock", "betrug", "47,3", "%", ".", "Nach", "Training", "eines", "neuronalen", "Netzes", "mit", "91", "(", "von", "insgesamt", "n", "=", "114", ")", "Patienten", "ergab", "die", "Testung", "bei", "den", "verbleibenden", "23", "Patienten", "bei", "der", "Beruecksichtigung", "von", "Parameterveraenderungen", "vom", "1", ".", "auf", "den", "2", ".", "Tag", "des", "septischen", "Schocks", "folgendes", "Ergebnis", ":", "Alle", "10", "verstorbenen", "Patienten", "wurden", "korrekt", "als", "nicht", "ueberlebend", "vorhergesagt", ",", "von", "den", "13", "Ueberlebenden", "wurden", "12", "korrekt", "als", "ueberlebend", "vorhergesagt", "(", "Sensitivitaet", "100", "%", ";", "Spezifitaet", "92,3", "%", ")", "." ]	[ "umlsterm" ]
= 19 or = 75 years is a Value, age is a Person, treatment is a Procedure, type 2 diabetes is a Condition, treatment of statin is a Scope, hypercholesterolemia is a Condition, Fasting LDL - C is a Measurement, = 250mg / dL is a Value, at the screening visit is a Temporal, Fasting LDL - C is a Measurement, = 70mg / dL is a Value, = 160mg / dL is a Value, at the randomization visit is a Temporal	NCT03217409_inc_task0	Sentence: Subjects = 19 or = 75 years of age Subjects undergoing treatment for type 2 diabetes Subjects undergoing treatment of statin for hypercholesterolemia Fasting LDL-C = 250mg/dL at the screening visit Fasting LDL-C =70mg/dL or = 160mg/dL at the randomization visit Fasting TG<500mg/dL Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Value, Person, Procedure, Scope, Measurement	[ "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Person", "O", "O", "O", "B-Procedure", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Value", "I-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O" ]	Subjects = 19 or = 75 years of age Subjects undergoing treatment for type 2 diabetes Subjects undergoing treatment of statin for hypercholesterolemia Fasting LDL-C = 250mg/dL at the screening visit Fasting LDL-C =70mg/dL or = 160mg/dL at the randomization visit Fasting TG<500mg/dL	[ "Subjects", "=", "19", "or", "=", "75", "years", "of", "age", "\n", "Subjects", "undergoing", "treatment", "for", "type", "2", "diabetes", "\n", "Subjects", "undergoing", "treatment", "of", "statin", "for", "hypercholesterolemia", "\n", "Fasting", "LDL", "-", "C", "=", "250mg", "/", "dL", "at", "the", "screening", "visit", "\n", "Fasting", "LDL", "-", "C", "=", "70mg", "/", "dL", "or", "=", "160mg", "/", "dL", "at", "the", "randomization", "visit", "\n", "Fasting", "TG<500mg", "/", "dL", "\n" ]	[ "Temporal", "Scope", "Condition", "Value", "Measurement", "Procedure", "Drug", "Person" ]
= 19 or = 75 years is a Value, age is a Person, treatment is a Procedure, type 2 diabetes is a Condition, treatment of statin is a Scope, hypercholesterolemia is a Condition, Fasting LDL - C is a Measurement, = 250mg / dL is a Value, at the screening visit is a Temporal, Fasting LDL - C is a Measurement, = 70mg / dL is a Value, = 160mg / dL is a Value, at the randomization visit is a Temporal	NCT03217409_inc_task1	Sentence: Subjects = 19 or = 75 years of age Subjects undergoing treatment for type 2 diabetes Subjects undergoing treatment of statin for hypercholesterolemia Fasting LDL-C = 250mg/dL at the screening visit Fasting LDL-C =70mg/dL or = 160mg/dL at the randomization visit Fasting TG<500mg/dL Instructions: please typing these entity words according to sentence: = 19 or = 75 years, age, treatment, type 2 diabetes, treatment of statin, hypercholesterolemia, Fasting LDL - C, = 250mg / dL, at the screening visit, Fasting LDL - C, = 70mg / dL, = 160mg / dL, at the randomization visit Options: Temporal, Condition, Value, Person, Procedure, Scope, Measurement	[ "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Person", "O", "O", "O", "B-Procedure", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Value", "I-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O" ]	Subjects = 19 or = 75 years of age Subjects undergoing treatment for type 2 diabetes Subjects undergoing treatment of statin for hypercholesterolemia Fasting LDL-C = 250mg/dL at the screening visit Fasting LDL-C =70mg/dL or = 160mg/dL at the randomization visit Fasting TG<500mg/dL	[ "Subjects", "=", "19", "or", "=", "75", "years", "of", "age", "\n", "Subjects", "undergoing", "treatment", "for", "type", "2", "diabetes", "\n", "Subjects", "undergoing", "treatment", "of", "statin", "for", "hypercholesterolemia", "\n", "Fasting", "LDL", "-", "C", "=", "250mg", "/", "dL", "at", "the", "screening", "visit", "\n", "Fasting", "LDL", "-", "C", "=", "70mg", "/", "dL", "or", "=", "160mg", "/", "dL", "at", "the", "randomization", "visit", "\n", "Fasting", "TG<500mg", "/", "dL", "\n" ]	[ "Temporal", "Scope", "Condition", "Value", "Measurement", "Procedure", "Drug", "Person" ]
= 19 or = 75 years, age, treatment, type 2 diabetes, treatment of statin, hypercholesterolemia, Fasting LDL - C, = 250mg / dL, at the screening visit, Fasting LDL - C, = 70mg / dL, = 160mg / dL, at the randomization visit	NCT03217409_inc_task2	Sentence: Subjects = 19 or = 75 years of age Subjects undergoing treatment for type 2 diabetes Subjects undergoing treatment of statin for hypercholesterolemia Fasting LDL-C = 250mg/dL at the screening visit Fasting LDL-C =70mg/dL or = 160mg/dL at the randomization visit Fasting TG<500mg/dL Instructions: please extract entity words from the input sentence	[ "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Person", "O", "O", "O", "B-Procedure", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Value", "I-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O" ]	Subjects = 19 or = 75 years of age Subjects undergoing treatment for type 2 diabetes Subjects undergoing treatment of statin for hypercholesterolemia Fasting LDL-C = 250mg/dL at the screening visit Fasting LDL-C =70mg/dL or = 160mg/dL at the randomization visit Fasting TG<500mg/dL	[ "Subjects", "=", "19", "or", "=", "75", "years", "of", "age", "\n", "Subjects", "undergoing", "treatment", "for", "type", "2", "diabetes", "\n", "Subjects", "undergoing", "treatment", "of", "statin", "for", "hypercholesterolemia", "\n", "Fasting", "LDL", "-", "C", "=", "250mg", "/", "dL", "at", "the", "screening", "visit", "\n", "Fasting", "LDL", "-", "C", "=", "70mg", "/", "dL", "or", "=", "160mg", "/", "dL", "at", "the", "randomization", "visit", "\n", "Fasting", "TG<500mg", "/", "dL", "\n" ]	[ "Temporal", "Scope", "Condition", "Value", "Measurement", "Procedure", "Drug", "Person" ]
healthy is a Condition, type 2 diabetes is a Condition	NCT03193684_inc_task0	Sentence: eGFR>60 ml/min healthy volunteers type 2 diabetes patients who otherwise healthy Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition	[ "O", "O", "O", "O", "B-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O" ]	eGFR>60 ml/min healthy volunteers type 2 diabetes patients who otherwise healthy	[ "eGFR>60", "ml", "/", "min", "healthy", "volunteers", "type", "2", "diabetes", "patients", "who", "otherwise", "healthy", "\n" ]	[ "Condition", "Value", "Measurement" ]
healthy is a Condition, type 2 diabetes is a Condition	NCT03193684_inc_task1	Sentence: eGFR>60 ml/min healthy volunteers type 2 diabetes patients who otherwise healthy Instructions: please typing these entity words according to sentence: healthy, type 2 diabetes Options: Condition	[ "O", "O", "O", "O", "B-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O" ]	eGFR>60 ml/min healthy volunteers type 2 diabetes patients who otherwise healthy	[ "eGFR>60", "ml", "/", "min", "healthy", "volunteers", "type", "2", "diabetes", "patients", "who", "otherwise", "healthy", "\n" ]	[ "Condition", "Value", "Measurement" ]
healthy, type 2 diabetes	NCT03193684_inc_task2	Sentence: eGFR>60 ml/min healthy volunteers type 2 diabetes patients who otherwise healthy Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O" ]	eGFR>60 ml/min healthy volunteers type 2 diabetes patients who otherwise healthy	[ "eGFR>60", "ml", "/", "min", "healthy", "volunteers", "type", "2", "diabetes", "patients", "who", "otherwise", "healthy", "\n" ]	[ "Condition", "Value", "Measurement" ]
patients with venous thrombosis is a Participant_Condition	41816_task0	Sentence: Arterial cardiovascular risk factors and venous thrombosis : results from a population-based , prospective study ( the HUNT 2 ) . BACKGROUND An explanation for the increased risk of myocardial infarction and stroke in patients with venous thrombosis is lacking . The objective of this study was to investigate whether risk factors for arterial cardiovascular disease also increase the risk of venous thrombosis . DESIGN AND METHODS Cases who had a first venous thrombosis ( n=515 ) and matched controls ( n=1,505 ) were identified from a population-based , nested , case-cohort study ( the HUNT 2 study ) comprising 71 % ( n=66,140 ) of the adult residents of Nord-Trøndelag County in Norway . RESULTS The age- and sex-adjusted odds ratio of venous thrombosis for subjects with concentrations of C-reactive protein in the highest quintile was 1.6 ( 95 % confidence interval : 1.2-2.2 ) compared to subjects with C-reactive protein in the lowest quintile . This association was strongest in subjects who experienced venous thrombosis within a year after blood sampling with a three-fold increased risk of participants in the highest versus the lowest quintile . Having first degree relatives who had a myocardial infarction before the age of 60 years was positively associated with venous thrombosis compared to not having a positive family history [ odds ratio 1.3 ( 95 % confidence interval : 1.1-1.6 ) ] . Subjects with blood pressure in the highest quintile had half the risk of developing venous thrombosis compared to subjects whose blood pressure was in the lowest quintile . There were no associations between the risk of venous thrombosis and total cholesterol , low density lipoprotein-cholesterol , high density lipoprotein-cholesterol , triglycerides , glucose or smoking . We confirmed the positive association between obesity and venous thrombosis . CONCLUSIONS C-reactive protein and a family history of myocardial infarction were positively associated with subsequent venous thrombosis . Blood pressure was inversely correlated to venous thrombosis . These findings should be confirmed by further investigations . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Arterial cardiovascular risk factors and venous thrombosis : results from a population-based , prospective study ( the HUNT 2 ) . BACKGROUND An explanation for the increased risk of myocardial infarction and stroke in patients with venous thrombosis is lacking . The objective of this study was to investigate whether risk factors for arterial cardiovascular disease also increase the risk of venous thrombosis . DESIGN AND METHODS Cases who had a first venous thrombosis ( n=515 ) and matched controls ( n=1,505 ) were identified from a population-based , nested , case-cohort study ( the HUNT 2 study ) comprising 71 % ( n=66,140 ) of the adult residents of Nord-Trøndelag County in Norway . RESULTS The age- and sex-adjusted odds ratio of venous thrombosis for subjects with concentrations of C-reactive protein in the highest quintile was 1.6 ( 95 % confidence interval : 1.2-2.2 ) compared to subjects with C-reactive protein in the lowest quintile . This association was strongest in subjects who experienced venous thrombosis within a year after blood sampling with a three-fold increased risk of participants in the highest versus the lowest quintile . Having first degree relatives who had a myocardial infarction before the age of 60 years was positively associated with venous thrombosis compared to not having a positive family history [ odds ratio 1.3 ( 95 % confidence interval : 1.1-1.6 ) ] . Subjects with blood pressure in the highest quintile had half the risk of developing venous thrombosis compared to subjects whose blood pressure was in the lowest quintile . There were no associations between the risk of venous thrombosis and total cholesterol , low density lipoprotein-cholesterol , high density lipoprotein-cholesterol , triglycerides , glucose or smoking . We confirmed the positive association between obesity and venous thrombosis . CONCLUSIONS C-reactive protein and a family history of myocardial infarction were positively associated with subsequent venous thrombosis . Blood pressure was inversely correlated to venous thrombosis . These findings should be confirmed by further investigations .	[ "Arterial", "cardiovascular", "risk", "factors", "and", "venous", "thrombosis", ":", "results", "from", "a", "population", "-", "based", ",", "prospective", "study", "(", "the", "HUNT", "2", ")", ".", "BACKGROUND", "An", "explanation", "for", "the", "increased", "risk", "of", "myocardial", "infarction", "and", "stroke", "in", "patients", "with", "venous", "thrombosis", "is", "lacking", ".", "The", "objective", "of", "this", "study", "was", "to", "investigate", "whether", "risk", "factors", "for", "arterial", "cardiovascular", "disease", "also", "increase", "the", "risk", "of", "venous", "thrombosis", ".", "DESIGN", "AND", "METHODS", "Cases", "who", "had", "a", "first", "venous", "thrombosis", "(", "n=515", ")", "and", "matched", "controls", "(", "n=1,505", ")", "were", "identified", "from", "a", "population", "-", "based", ",", "nested", ",", "case", "-", "cohort", "study", "(", "the", "HUNT", "2", "study", ")", "comprising", "71", "%", "(", "n=66,140", ")", "of", "the", "adult", "residents", "of", "Nord", "-", "Trøndelag", "County", "in", "Norway", ".", "RESULTS", "The", "age-", "and", "sex", "-", "adjusted", "odds", "ratio", "of", "venous", "thrombosis", "for", "subjects", "with", "concentrations", "of", "C", "-", "reactive", "protein", "in", "the", "highest", "quintile", "was", "1.6", "(", "95", "%", "confidence", "interval", ":", "1.2", "-", "2.2", ")", "compared", "to", "subjects", "with", "C", "-", "reactive", "protein", "in", "the", "lowest", "quintile", ".", "This", "association", "was", "strongest", "in", "subjects", "who", "experienced", "venous", "thrombosis", "within", "a", "year", "after", "blood", "sampling", "with", "a", "three", "-", "fold", "increased", "risk", "of", "participants", "in", "the", "highest", "versus", "the", "lowest", "quintile", ".", "Having", "first", "degree", "relatives", "who", "had", "a", "myocardial", "infarction", "before", "the", "age", "of", "60", "years", "was", "positively", "associated", "with", "venous", "thrombosis", "compared", "to", "not", "having", "a", "positive", "family", "history", "[", "odds", "ratio", "1.3", "(", "95", "%", "confidence", "interval", ":", "1.1", "-", "1.6", ")", "]", ".", "Subjects", "with", "blood", "pressure", "in", "the", "highest", "quintile", "had", "half", "the", "risk", "of", "developing", "venous", "thrombosis", "compared", "to", "subjects", "whose", "blood", "pressure", "was", "in", "the", "lowest", "quintile", ".", "There", "were", "no", "associations", "between", "the", "risk", "of", "venous", "thrombosis", "and", "total", "cholesterol", ",", "low", "density", "lipoprotein", "-", "cholesterol", ",", "high", "density", "lipoprotein", "-", "cholesterol", ",", "triglycerides", ",", "glucose", "or", "smoking", ".", "We", "confirmed", "the", "positive", "association", "between", "obesity", "and", "venous", "thrombosis", ".", "CONCLUSIONS", "C", "-", "reactive", "protein", "and", "a", "family", "history", "of", "myocardial", "infarction", "were", "positively", "associated", "with", "subsequent", "venous", "thrombosis", ".", "Blood", "pressure", "was", "inversely", "correlated", "to", "venous", "thrombosis", ".", "These", "findings", "should", "be", "confirmed", "by", "further", "investigations", "." ]	[ "Participant_Condition" ]
patients with venous thrombosis is a Participant_Condition	41816_task1	Sentence: Arterial cardiovascular risk factors and venous thrombosis : results from a population-based , prospective study ( the HUNT 2 ) . BACKGROUND An explanation for the increased risk of myocardial infarction and stroke in patients with venous thrombosis is lacking . The objective of this study was to investigate whether risk factors for arterial cardiovascular disease also increase the risk of venous thrombosis . DESIGN AND METHODS Cases who had a first venous thrombosis ( n=515 ) and matched controls ( n=1,505 ) were identified from a population-based , nested , case-cohort study ( the HUNT 2 study ) comprising 71 % ( n=66,140 ) of the adult residents of Nord-Trøndelag County in Norway . RESULTS The age- and sex-adjusted odds ratio of venous thrombosis for subjects with concentrations of C-reactive protein in the highest quintile was 1.6 ( 95 % confidence interval : 1.2-2.2 ) compared to subjects with C-reactive protein in the lowest quintile . This association was strongest in subjects who experienced venous thrombosis within a year after blood sampling with a three-fold increased risk of participants in the highest versus the lowest quintile . Having first degree relatives who had a myocardial infarction before the age of 60 years was positively associated with venous thrombosis compared to not having a positive family history [ odds ratio 1.3 ( 95 % confidence interval : 1.1-1.6 ) ] . Subjects with blood pressure in the highest quintile had half the risk of developing venous thrombosis compared to subjects whose blood pressure was in the lowest quintile . There were no associations between the risk of venous thrombosis and total cholesterol , low density lipoprotein-cholesterol , high density lipoprotein-cholesterol , triglycerides , glucose or smoking . We confirmed the positive association between obesity and venous thrombosis . CONCLUSIONS C-reactive protein and a family history of myocardial infarction were positively associated with subsequent venous thrombosis . Blood pressure was inversely correlated to venous thrombosis . These findings should be confirmed by further investigations . Instructions: please typing these entity words according to sentence: patients with venous thrombosis Options: Participant_Condition	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Arterial cardiovascular risk factors and venous thrombosis : results from a population-based , prospective study ( the HUNT 2 ) . BACKGROUND An explanation for the increased risk of myocardial infarction and stroke in patients with venous thrombosis is lacking . The objective of this study was to investigate whether risk factors for arterial cardiovascular disease also increase the risk of venous thrombosis . DESIGN AND METHODS Cases who had a first venous thrombosis ( n=515 ) and matched controls ( n=1,505 ) were identified from a population-based , nested , case-cohort study ( the HUNT 2 study ) comprising 71 % ( n=66,140 ) of the adult residents of Nord-Trøndelag County in Norway . RESULTS The age- and sex-adjusted odds ratio of venous thrombosis for subjects with concentrations of C-reactive protein in the highest quintile was 1.6 ( 95 % confidence interval : 1.2-2.2 ) compared to subjects with C-reactive protein in the lowest quintile . This association was strongest in subjects who experienced venous thrombosis within a year after blood sampling with a three-fold increased risk of participants in the highest versus the lowest quintile . Having first degree relatives who had a myocardial infarction before the age of 60 years was positively associated with venous thrombosis compared to not having a positive family history [ odds ratio 1.3 ( 95 % confidence interval : 1.1-1.6 ) ] . Subjects with blood pressure in the highest quintile had half the risk of developing venous thrombosis compared to subjects whose blood pressure was in the lowest quintile . There were no associations between the risk of venous thrombosis and total cholesterol , low density lipoprotein-cholesterol , high density lipoprotein-cholesterol , triglycerides , glucose or smoking . We confirmed the positive association between obesity and venous thrombosis . CONCLUSIONS C-reactive protein and a family history of myocardial infarction were positively associated with subsequent venous thrombosis . Blood pressure was inversely correlated to venous thrombosis . These findings should be confirmed by further investigations .	[ "Arterial", "cardiovascular", "risk", "factors", "and", "venous", "thrombosis", ":", "results", "from", "a", "population", "-", "based", ",", "prospective", "study", "(", "the", "HUNT", "2", ")", ".", "BACKGROUND", "An", "explanation", "for", "the", "increased", "risk", "of", "myocardial", "infarction", "and", "stroke", "in", "patients", "with", "venous", "thrombosis", "is", "lacking", ".", "The", "objective", "of", "this", "study", "was", "to", "investigate", "whether", "risk", "factors", "for", "arterial", "cardiovascular", "disease", "also", "increase", "the", "risk", "of", "venous", "thrombosis", ".", "DESIGN", "AND", "METHODS", "Cases", "who", "had", "a", "first", "venous", "thrombosis", "(", "n=515", ")", "and", "matched", "controls", "(", "n=1,505", ")", "were", "identified", "from", "a", "population", "-", "based", ",", "nested", ",", "case", "-", "cohort", "study", "(", "the", "HUNT", "2", "study", ")", "comprising", "71", "%", "(", "n=66,140", ")", "of", "the", "adult", "residents", "of", "Nord", "-", "Trøndelag", "County", "in", "Norway", ".", "RESULTS", "The", "age-", "and", "sex", "-", "adjusted", "odds", "ratio", "of", "venous", "thrombosis", "for", "subjects", "with", "concentrations", "of", "C", "-", "reactive", "protein", "in", "the", "highest", "quintile", "was", "1.6", "(", "95", "%", "confidence", "interval", ":", "1.2", "-", "2.2", ")", "compared", "to", "subjects", "with", "C", "-", "reactive", "protein", "in", "the", "lowest", "quintile", ".", "This", "association", "was", "strongest", "in", "subjects", "who", "experienced", "venous", "thrombosis", "within", "a", "year", "after", "blood", "sampling", "with", "a", "three", "-", "fold", "increased", "risk", "of", "participants", "in", "the", "highest", "versus", "the", "lowest", "quintile", ".", "Having", "first", "degree", "relatives", "who", "had", "a", "myocardial", "infarction", "before", "the", "age", "of", "60", "years", "was", "positively", "associated", "with", "venous", "thrombosis", "compared", "to", "not", "having", "a", "positive", "family", "history", "[", "odds", "ratio", "1.3", "(", "95", "%", "confidence", "interval", ":", "1.1", "-", "1.6", ")", "]", ".", "Subjects", "with", "blood", "pressure", "in", "the", "highest", "quintile", "had", "half", "the", "risk", "of", "developing", "venous", "thrombosis", "compared", "to", "subjects", "whose", "blood", "pressure", "was", "in", "the", "lowest", "quintile", ".", "There", "were", "no", "associations", "between", "the", "risk", "of", "venous", "thrombosis", "and", "total", "cholesterol", ",", "low", "density", "lipoprotein", "-", "cholesterol", ",", "high", "density", "lipoprotein", "-", "cholesterol", ",", "triglycerides", ",", "glucose", "or", "smoking", ".", "We", "confirmed", "the", "positive", "association", "between", "obesity", "and", "venous", "thrombosis", ".", "CONCLUSIONS", "C", "-", "reactive", "protein", "and", "a", "family", "history", "of", "myocardial", "infarction", "were", "positively", "associated", "with", "subsequent", "venous", "thrombosis", ".", "Blood", "pressure", "was", "inversely", "correlated", "to", "venous", "thrombosis", ".", "These", "findings", "should", "be", "confirmed", "by", "further", "investigations", "." ]	[ "Participant_Condition" ]
patients with venous thrombosis	41816_task2	Sentence: Arterial cardiovascular risk factors and venous thrombosis : results from a population-based , prospective study ( the HUNT 2 ) . BACKGROUND An explanation for the increased risk of myocardial infarction and stroke in patients with venous thrombosis is lacking . The objective of this study was to investigate whether risk factors for arterial cardiovascular disease also increase the risk of venous thrombosis . DESIGN AND METHODS Cases who had a first venous thrombosis ( n=515 ) and matched controls ( n=1,505 ) were identified from a population-based , nested , case-cohort study ( the HUNT 2 study ) comprising 71 % ( n=66,140 ) of the adult residents of Nord-Trøndelag County in Norway . RESULTS The age- and sex-adjusted odds ratio of venous thrombosis for subjects with concentrations of C-reactive protein in the highest quintile was 1.6 ( 95 % confidence interval : 1.2-2.2 ) compared to subjects with C-reactive protein in the lowest quintile . This association was strongest in subjects who experienced venous thrombosis within a year after blood sampling with a three-fold increased risk of participants in the highest versus the lowest quintile . Having first degree relatives who had a myocardial infarction before the age of 60 years was positively associated with venous thrombosis compared to not having a positive family history [ odds ratio 1.3 ( 95 % confidence interval : 1.1-1.6 ) ] . Subjects with blood pressure in the highest quintile had half the risk of developing venous thrombosis compared to subjects whose blood pressure was in the lowest quintile . There were no associations between the risk of venous thrombosis and total cholesterol , low density lipoprotein-cholesterol , high density lipoprotein-cholesterol , triglycerides , glucose or smoking . We confirmed the positive association between obesity and venous thrombosis . CONCLUSIONS C-reactive protein and a family history of myocardial infarction were positively associated with subsequent venous thrombosis . Blood pressure was inversely correlated to venous thrombosis . These findings should be confirmed by further investigations . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Arterial cardiovascular risk factors and venous thrombosis : results from a population-based , prospective study ( the HUNT 2 ) . BACKGROUND An explanation for the increased risk of myocardial infarction and stroke in patients with venous thrombosis is lacking . The objective of this study was to investigate whether risk factors for arterial cardiovascular disease also increase the risk of venous thrombosis . DESIGN AND METHODS Cases who had a first venous thrombosis ( n=515 ) and matched controls ( n=1,505 ) were identified from a population-based , nested , case-cohort study ( the HUNT 2 study ) comprising 71 % ( n=66,140 ) of the adult residents of Nord-Trøndelag County in Norway . RESULTS The age- and sex-adjusted odds ratio of venous thrombosis for subjects with concentrations of C-reactive protein in the highest quintile was 1.6 ( 95 % confidence interval : 1.2-2.2 ) compared to subjects with C-reactive protein in the lowest quintile . This association was strongest in subjects who experienced venous thrombosis within a year after blood sampling with a three-fold increased risk of participants in the highest versus the lowest quintile . Having first degree relatives who had a myocardial infarction before the age of 60 years was positively associated with venous thrombosis compared to not having a positive family history [ odds ratio 1.3 ( 95 % confidence interval : 1.1-1.6 ) ] . Subjects with blood pressure in the highest quintile had half the risk of developing venous thrombosis compared to subjects whose blood pressure was in the lowest quintile . There were no associations between the risk of venous thrombosis and total cholesterol , low density lipoprotein-cholesterol , high density lipoprotein-cholesterol , triglycerides , glucose or smoking . We confirmed the positive association between obesity and venous thrombosis . CONCLUSIONS C-reactive protein and a family history of myocardial infarction were positively associated with subsequent venous thrombosis . Blood pressure was inversely correlated to venous thrombosis . These findings should be confirmed by further investigations .	[ "Arterial", "cardiovascular", "risk", "factors", "and", "venous", "thrombosis", ":", "results", "from", "a", "population", "-", "based", ",", "prospective", "study", "(", "the", "HUNT", "2", ")", ".", "BACKGROUND", "An", "explanation", "for", "the", "increased", "risk", "of", "myocardial", "infarction", "and", "stroke", "in", "patients", "with", "venous", "thrombosis", "is", "lacking", ".", "The", "objective", "of", "this", "study", "was", "to", "investigate", "whether", "risk", "factors", "for", "arterial", "cardiovascular", "disease", "also", "increase", "the", "risk", "of", "venous", "thrombosis", ".", "DESIGN", "AND", "METHODS", "Cases", "who", "had", "a", "first", "venous", "thrombosis", "(", "n=515", ")", "and", "matched", "controls", "(", "n=1,505", ")", "were", "identified", "from", "a", "population", "-", "based", ",", "nested", ",", "case", "-", "cohort", "study", "(", "the", "HUNT", "2", "study", ")", "comprising", "71", "%", "(", "n=66,140", ")", "of", "the", "adult", "residents", "of", "Nord", "-", "Trøndelag", "County", "in", "Norway", ".", "RESULTS", "The", "age-", "and", "sex", "-", "adjusted", "odds", "ratio", "of", "venous", "thrombosis", "for", "subjects", "with", "concentrations", "of", "C", "-", "reactive", "protein", "in", "the", "highest", "quintile", "was", "1.6", "(", "95", "%", "confidence", "interval", ":", "1.2", "-", "2.2", ")", "compared", "to", "subjects", "with", "C", "-", "reactive", "protein", "in", "the", "lowest", "quintile", ".", "This", "association", "was", "strongest", "in", "subjects", "who", "experienced", "venous", "thrombosis", "within", "a", "year", "after", "blood", "sampling", "with", "a", "three", "-", "fold", "increased", "risk", "of", "participants", "in", "the", "highest", "versus", "the", "lowest", "quintile", ".", "Having", "first", "degree", "relatives", "who", "had", "a", "myocardial", "infarction", "before", "the", "age", "of", "60", "years", "was", "positively", "associated", "with", "venous", "thrombosis", "compared", "to", "not", "having", "a", "positive", "family", "history", "[", "odds", "ratio", "1.3", "(", "95", "%", "confidence", "interval", ":", "1.1", "-", "1.6", ")", "]", ".", "Subjects", "with", "blood", "pressure", "in", "the", "highest", "quintile", "had", "half", "the", "risk", "of", "developing", "venous", "thrombosis", "compared", "to", "subjects", "whose", "blood", "pressure", "was", "in", "the", "lowest", "quintile", ".", "There", "were", "no", "associations", "between", "the", "risk", "of", "venous", "thrombosis", "and", "total", "cholesterol", ",", "low", "density", "lipoprotein", "-", "cholesterol", ",", "high", "density", "lipoprotein", "-", "cholesterol", ",", "triglycerides", ",", "glucose", "or", "smoking", ".", "We", "confirmed", "the", "positive", "association", "between", "obesity", "and", "venous", "thrombosis", ".", "CONCLUSIONS", "C", "-", "reactive", "protein", "and", "a", "family", "history", "of", "myocardial", "infarction", "were", "positively", "associated", "with", "subsequent", "venous", "thrombosis", ".", "Blood", "pressure", "was", "inversely", "correlated", "to", "venous", "thrombosis", ".", "These", "findings", "should", "be", "confirmed", "by", "further", "investigations", "." ]	[ "Participant_Condition" ]
neoplásico is a MORFOLOGIA_NEOPLASIA, Adenocarcinoma is a MORFOLOGIA_NEOPLASIA, Hemangioma is a MORFOLOGIA_NEOPLASIA, Adenocarcinoma is a MORFOLOGIA_NEOPLASIA, M1 is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, Adenocarcinoma pobremente diferenciado is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA	211_task0	Sentence: Anamnesis Varón de 48 años. ANTECEDENTES PERSONALES: Alergia a Cefuroxima y Septrim (reacción cutánea). Fumador de 15 paquete/año y bebedor de 2 vinos a la semana. VIH + desde 1992 en control por Unidad de Enfermedades Infecciosas (UEI) con estadio C3 del CDC; en 1994 varios ingresos por neumonías de repetición (bacterianas y por Pneumocystis carinii), tuberculosis pulmonar y ganglionar. Tratamiento habitual: Raltegravir 400 1/12h, Maraviroc 150 1/12h, Ritonavir 100 1/24h, Darunavir 400 2/24h, Hierro oral antes del desayuno, Omeprazol 40 mg/24 h. ENFERMEDAD ACTUAL: En Febrero de 2011, acude a revisión en consultas de UEI y comenta la aparición de cierto grado de astenia progresiva con epigastralgia desde hace varios meses, acompañado desde el último mes de deposiciones melénicas, por lo que le realizan un análisis objetivando una hemoglobina (Hb) de 4.7, por lo que deciden ingreso para estudio. Exploración física Estable hemodinámicamente, afebril. Consciente, orientado, bien hidratado y perfundido, eupneico. Palidez cutaneo-mucosa. AC: Rítmica. AP: Murmullo vesicular conservado. Abdomen: Blando, depresible, leve dolor en región epigástrico a la palpación profunda con sensación de masa a dicho nivel. No signos de irritación peritoneal. Peristaltismo presente. Extremidades inferiores: No edemas ni signos de trombosis venosa profunda. Pruebas complementarias - ANÁLISIS (07/02/2011): Albúmina 31.2, PCR 14.4, Hb 4.7, Plaquetas 418000, Leucocitos 9380, Neutrófilos 5720. Coagulación normal. - MARCADORES TUMORALES: Antígeno Carcinoembrionario (CEA); CA 125 y Ca 19.9: Negativos. - GASTROSCOPIA: Gran masa ulcerada en la curvadura menor de aspecto neoplásico, con toma de biopsias de la zona sospechosa. - ANATOMÍA PATOLÓGICA: Biopsia gástrica positiva para Adenocarcinoma. - TAC ABDOMINO-PÉLVICO: Masa a nivel de curvadura menor del estómago, con adenopatías en ligamento gastrohepático, tronco celíaco y espacio portocava. - ECOGRAFÍA ABADOMINAL: Hemangioma hepático en segmento V. - TAC TORÁCICO: Sin evidencia de patología. Diagnóstico Adenocarcinoma gástrico localmente avanzado cT2 (dudosa M1 por adenopatías retroperitoneales por TAC). Tratamiento En el Comité de tumores Gastroesofágicos se decidió que ante la presencia de masa voluminosa y de las adenopatías, se pidiera un PET-TAC para ver el comportamiento de las adenopatías, si captaban se comenzaría con Quimioterapia paliativa por considerarse éstas como metástasis; si no captaban se comenzaría con QT neoadyuvante y tras revalorar el caso se plantearía intervención quirúrgica. - PET-TAC (02/03/2011): Se observa captación a nivel gástrico sin que capten las adenopatías retroperitoneales. El 28/02/2011 comenza tratamiento con el primer ciclo de QT Neoadyuvante con Cisplatino (75 mg/m2), Docetaxel (75 mg/m2) y 5-Fluorouracilo (750 mg/m2). Evolución A los 5 días del primer ciclo de QT presentó una importante toxicidad, con enteritis e insuficiencia renal prerrenal, anemia que precisó trasfusión y mucositis. Se realizó un análisis genético para las mutaciones de las enzimas que catabolizan el 5-Fluorouracilo (5-FU), obteniendo como resultado heterocigoto para MTHFR C677T lo que le produce una intolerancia a la administracion de 5-FU. Ante la toxicidad se cambia el esquema a CPT-11 (Irinotecan 125 mg/m2) semanal administrando 4 dosis del 1 de abril al 22 de Abril, con moderada tolerancia ya que durante la administración comienza con hiperbilirrubinemia y aumento de las enzimas hepáticas sin encontrar otra etiología que el tratamiento quimioterápico. Al mes de finalizar la QT vuelve a consultas de Oncología Médica con Análisis donde sólo se observa leve anemia con Hb de 11.1, mejoría de la función hepática y marcadores tumorales negativos, con un TAC donde se observa la masa en el estómago y las adenopatías retroperitoneales sin cambios; y el PET-TAC donde capta la masa en el estómago y no captan las adenopatías. Por todo esto se define como Enfermedad Estable, relacionando las adenopatías a su antecedente de enfermedad por el VIH y no a la enfermedad tumoral, por lo que se decide intervención quirúrgica. El 13/06/2011 le realizan gastrectomía parcial del 70%, linfadenectomía D2 y omentectomia. Con resultado de anatomía patológica de Adenocarcinoma pobremente diferenciado y áreas de moderadamente diferenciado, afectando a la capa muscular, con bordes de resección libres y con 47 ganglios libres de metástasis. Estadiaje definitivo ypT2 ypN0. Estadio IB. Ante la mala tolerancia al tratamiento quimioterápico se decide no dar quimioterapia adyuvante, y desde entonces pasa a controles. Actualmente sin evidencia de enfermedad a 5 años de la cirugía, en control anual con TAC, análisis y marcadores tumorales. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Varón de 48 años. ANTECEDENTES PERSONALES: Alergia a Cefuroxima y Septrim (reacción cutánea). Fumador de 15 paquete/año y bebedor de 2 vinos a la semana. VIH + desde 1992 en control por Unidad de Enfermedades Infecciosas (UEI) con estadio C3 del CDC; en 1994 varios ingresos por neumonías de repetición (bacterianas y por Pneumocystis carinii), tuberculosis pulmonar y ganglionar. Tratamiento habitual: Raltegravir 400 1/12h, Maraviroc 150 1/12h, Ritonavir 100 1/24h, Darunavir 400 2/24h, Hierro oral antes del desayuno, Omeprazol 40 mg/24 h. ENFERMEDAD ACTUAL: En Febrero de 2011, acude a revisión en consultas de UEI y comenta la aparición de cierto grado de astenia progresiva con epigastralgia desde hace varios meses, acompañado desde el último mes de deposiciones melénicas, por lo que le realizan un análisis objetivando una hemoglobina (Hb) de 4.7, por lo que deciden ingreso para estudio. Exploración física Estable hemodinámicamente, afebril. Consciente, orientado, bien hidratado y perfundido, eupneico. Palidez cutaneo-mucosa. AC: Rítmica. AP: Murmullo vesicular conservado. Abdomen: Blando, depresible, leve dolor en región epigástrico a la palpación profunda con sensación de masa a dicho nivel. No signos de irritación peritoneal. Peristaltismo presente. Extremidades inferiores: No edemas ni signos de trombosis venosa profunda. Pruebas complementarias - ANÁLISIS (07/02/2011): Albúmina 31.2, PCR 14.4, Hb 4.7, Plaquetas 418000, Leucocitos 9380, Neutrófilos 5720. Coagulación normal. - MARCADORES TUMORALES: Antígeno Carcinoembrionario (CEA); CA 125 y Ca 19.9: Negativos. - GASTROSCOPIA: Gran masa ulcerada en la curvadura menor de aspecto neoplásico, con toma de biopsias de la zona sospechosa. - ANATOMÍA PATOLÓGICA: Biopsia gástrica positiva para Adenocarcinoma. - TAC ABDOMINO-PÉLVICO: Masa a nivel de curvadura menor del estómago, con adenopatías en ligamento gastrohepático, tronco celíaco y espacio portocava. - ECOGRAFÍA ABADOMINAL: Hemangioma hepático en segmento V. - TAC TORÁCICO: Sin evidencia de patología. Diagnóstico Adenocarcinoma gástrico localmente avanzado cT2 (dudosa M1 por adenopatías retroperitoneales por TAC). Tratamiento En el Comité de tumores Gastroesofágicos se decidió que ante la presencia de masa voluminosa y de las adenopatías, se pidiera un PET-TAC para ver el comportamiento de las adenopatías, si captaban se comenzaría con Quimioterapia paliativa por considerarse éstas como metástasis; si no captaban se comenzaría con QT neoadyuvante y tras revalorar el caso se plantearía intervención quirúrgica. - PET-TAC (02/03/2011): Se observa captación a nivel gástrico sin que capten las adenopatías retroperitoneales. El 28/02/2011 comenza tratamiento con el primer ciclo de QT Neoadyuvante con Cisplatino (75 mg/m2), Docetaxel (75 mg/m2) y 5-Fluorouracilo (750 mg/m2). Evolución A los 5 días del primer ciclo de QT presentó una importante toxicidad, con enteritis e insuficiencia renal prerrenal, anemia que precisó trasfusión y mucositis. Se realizó un análisis genético para las mutaciones de las enzimas que catabolizan el 5-Fluorouracilo (5-FU), obteniendo como resultado heterocigoto para MTHFR C677T lo que le produce una intolerancia a la administracion de 5-FU. Ante la toxicidad se cambia el esquema a CPT-11 (Irinotecan 125 mg/m2) semanal administrando 4 dosis del 1 de abril al 22 de Abril, con moderada tolerancia ya que durante la administración comienza con hiperbilirrubinemia y aumento de las enzimas hepáticas sin encontrar otra etiología que el tratamiento quimioterápico. Al mes de finalizar la QT vuelve a consultas de Oncología Médica con Análisis donde sólo se observa leve anemia con Hb de 11.1, mejoría de la función hepática y marcadores tumorales negativos, con un TAC donde se observa la masa en el estómago y las adenopatías retroperitoneales sin cambios; y el PET-TAC donde capta la masa en el estómago y no captan las adenopatías. Por todo esto se define como Enfermedad Estable, relacionando las adenopatías a su antecedente de enfermedad por el VIH y no a la enfermedad tumoral, por lo que se decide intervención quirúrgica. El 13/06/2011 le realizan gastrectomía parcial del 70%, linfadenectomía D2 y omentectomia. Con resultado de anatomía patológica de Adenocarcinoma pobremente diferenciado y áreas de moderadamente diferenciado, afectando a la capa muscular, con bordes de resección libres y con 47 ganglios libres de metástasis. Estadiaje definitivo ypT2 ypN0. Estadio IB. Ante la mala tolerancia al tratamiento quimioterápico se decide no dar quimioterapia adyuvante, y desde entonces pasa a controles. Actualmente sin evidencia de enfermedad a 5 años de la cirugía, en control anual con TAC, análisis y marcadores tumorales.	[ "Anamnesis", "\n", "Varón", "de", "48", "años", ".", "\n\n", "ANTECEDENTES", "PERSONALES", ":", "Alergia", "a", "Cefuroxima", "y", "Septrim", "(", "reacción", "cutánea", ")", ".", "Fumador", "de", "15", "paquete", "/", "año", "y", "bebedor", "de", "2", "vinos", "a", "la", "semana", ".", "VIH", "+", "desde", "1992", "en", "control", "por", "Unidad", "de", "Enfermedades", "Infecciosas", "(", "UEI", ")", "con", "estadio", "C3", "del", "CDC", ";", "en", "1994", "varios", "ingresos", "por", "neumonías", "de", "repetición", "(", "bacterianas", "y", "por", "Pneumocystis", "carinii", ")", ",", "tuberculosis", "pulmonar", "y", "ganglionar", ".", "Tratamiento", "habitual", ":", "Raltegravir", "400", "1/12h", ",", "Maraviroc", "150", "1/12h", ",", "Ritonavir", "100", "1/24h", ",", "Darunavir", "400", "2/24h", ",", "Hierro", "oral", "antes", "del", "desayuno", ",", "Omeprazol", "40", "mg/24", "h.", "\n\n", "ENFERMEDAD", "ACTUAL", ":", "\n", "En", "Febrero", "de", "2011", ",", "acude", "a", "revisión", "en", "consultas", "de", "UEI", "y", "comenta", "la", "aparición", "de", "cierto", "grado", "de", "astenia", "progresiva", "con", "epigastralgia", "desde", "hace", "varios", "meses", ",", "acompañado", "desde", "el", "último", "mes", "de", "deposiciones", "melénicas", ",", "por", "lo", "que", "le", "realizan", "un", "análisis", "objetivando", "una", "hemoglobina", "(", "Hb", ")", "de", "4.7", ",", "por", "lo", "que", "deciden", "ingreso", "para", "estudio", ".", "\n\n", "Exploración", "física", "\n", "Estable", "hemodinámicamente", ",", "afebril", ".", "Consciente", ",", "orientado", ",", "bien", "hidratado", "y", "perfundido", ",", "eupneico", ".", "Palidez", "cutaneo", "-", "mucosa", ".", "AC", ":", "Rítmica", ".", "AP", ":", "Murmullo", "vesicular", "conservado", ".", "Abdomen", ":", "Blando", ",", "depresible", ",", "leve", "dolor", "en", "región", "epigástrico", "a", "la", "palpación", "profunda", "con", "sensación", "de", "masa", "a", "dicho", "nivel", ".", "No", "signos", "de", "irritación", "peritoneal", ".", "Peristaltismo", "presente", ".", "Extremidades", "inferiores", ":", "No", "edemas", "ni", "signos", "de", "trombosis", "venosa", "profunda", ".", "\n\n", "Pruebas", "complementarias", "\n", "-", "ANÁLISIS", "(", "07/02/2011", "):", "Albúmina", "31.2", ",", "PCR", "14.4", ",", "Hb", "4.7", ",", "Plaquetas", "418000", ",", "Leucocitos", "9380", ",", "Neutrófilos", "5720", ".", "Coagulación", "normal", ".", "\n", "-", "MARCADORES", "TUMORALES", ":", "Antígeno", "Carcinoembrionario", "(", "CEA", ")", ";", "CA", "125", "y", "Ca", "19.9", ":", "Negativos", ".", "\n", "-", "GASTROSCOPIA", ":", "Gran", "masa", "ulcerada", "en", "la", "curvadura", "menor", "de", "aspecto", "neoplásico", ",", "con", "toma", "de", "biopsias", "de", "la", "zona", "sospechosa", ".", "\n", "-", "ANATOMÍA", "PATOLÓGICA", ":", "Biopsia", "gástrica", "positiva", "para", "Adenocarcinoma", ".", "\n", "-", "TAC", "ABDOMINO", "-", "PÉLVICO", ":", "Masa", "a", "nivel", "de", "curvadura", "menor", "del", "estómago", ",", "con", "adenopatías", "en", "ligamento", "gastrohepático", ",", "tronco", "celíaco", "y", "espacio", "portocava", ".", "\n", "-", "ECOGRAFÍA", "ABADOMINAL", ":", "Hemangioma", "hepático", "en", "segmento", "V.", "\n", "-", "TAC", "TORÁCICO", ":", "Sin", "evidencia", "de", "patología", ".", "\n\n", "Diagnóstico", "\n", "Adenocarcinoma", "gástrico", "localmente", "avanzado", "cT2", "(", "dudosa", "M1", "por", "adenopatías", "retroperitoneales", "por", "TAC", ")", ".", "\n\n", "Tratamiento", "\n", "En", "el", "Comité", "de", "tumores", "Gastroesofágicos", "se", "decidió", "que", "ante", "la", "presencia", "de", "masa", "voluminosa", "y", "de", "las", "adenopatías", ",", "se", "pidiera", "un", "PET", "-", "TAC", "para", "ver", "el", "comportamiento", "de", "las", "adenopatías", ",", "si", "captaban", "se", "comenzaría", "con", "Quimioterapia", "paliativa", "por", "considerarse", "éstas", "como", "metástasis", ";", "si", "no", "captaban", "se", "comenzaría", "con", "QT", "neoadyuvante", "y", "tras", "revalorar", "el", "caso", "se", "plantearía", "intervención", "quirúrgica", ".", "\n", "-", "PET", "-", "TAC", "(", "02/03/2011", "):", "Se", "observa", "captación", "a", "nivel", "gástrico", "sin", "que", "capten", "las", "adenopatías", "retroperitoneales", ".", "\n", "El", "28/02/2011", "comenza", "tratamiento", "con", "el", "primer", "ciclo", "de", "QT", "Neoadyuvante", "con", "Cisplatino", "(", "75", "mg", "/", "m2", ")", ",", "Docetaxel", "(", "75", "mg", "/", "m2", ")", "y", "5-Fluorouracilo", "(", "750", "mg", "/", "m2", ")", ".", "\n\n", "Evolución", "\n", "A", "los", "5", "días", "del", "primer", "ciclo", "de", "QT", "presentó", "una", "importante", "toxicidad", ",", "con", "enteritis", "e", "insuficiencia", "renal", "prerrenal", ",", "anemia", "que", "precisó", "trasfusión", "y", "mucositis", ".", "Se", "realizó", "un", "análisis", "genético", "para", "las", "mutaciones", "de", "las", "enzimas", "que", "catabolizan", "el", "5-Fluorouracilo", "(", "5-FU", ")", ",", "obteniendo", "como", "resultado", "heterocigoto", "para", "MTHFR", "C677", "T", "lo", "que", "le", "produce", "una", "intolerancia", "a", "la", "administracion", "de", "5-FU", ".", "\n", "Ante", "la", "toxicidad", "se", "cambia", "el", "esquema", "a", "CPT-11", "(", "Irinotecan", "125", "mg", "/", "m2", ")", "semanal", "administrando", "4", "dosis", "del", "1", "de", "abril", "al", "22", "de", "Abril", ",", "con", "moderada", "tolerancia", "ya", "que", "durante", "la", "administración", "comienza", "con", "hiperbilirrubinemia", "y", "aumento", "de", "las", "enzimas", "hepáticas", "sin", "encontrar", "otra", "etiología", "que", "el", "tratamiento", "quimioterápico", ".", "\n", "Al", "mes", "de", "finalizar", "la", "QT", "vuelve", "a", "consultas", "de", "Oncología", "Médica", "con", "Análisis", "donde", "sólo", "se", "observa", "leve", "anemia", "con", "Hb", "de", "11.1", ",", "mejoría", "de", "la", "función", "hepática", "y", "marcadores", "tumorales", "negativos", ",", "con", "un", "TAC", "donde", "se", "observa", "la", "masa", "en", "el", "estómago", "y", "las", "adenopatías", "retroperitoneales", "sin", "cambios", ";", "y", "el", "PET", "-", "TAC", "donde", "capta", "la", "masa", "en", "el", "estómago", "y", "no", "captan", "las", "adenopatías", ".", "\n", "Por", "todo", "esto", "se", "define", "como", "Enfermedad", "Estable", ",", "relacionando", "las", "adenopatías", "a", "su", "antecedente", "de", "enfermedad", "por", "el", "VIH", "y", "no", "a", "la", "enfermedad", "tumoral", ",", "por", "lo", "que", "se", "decide", "intervención", "quirúrgica", ".", "\n", "El", "13/06/2011", "le", "realizan", "gastrectomía", "parcial", "del", "70", "%", ",", "linfadenectomía", "D2", "y", "omentectomia", ".", "Con", "resultado", "de", "anatomía", "patológica", "de", "Adenocarcinoma", "pobremente", "diferenciado", "y", "áreas", "de", "moderadamente", "diferenciado", ",", "afectando", "a", "la", "capa", "muscular", ",", "con", "bordes", "de", "resección", "libres", "y", "con", "47", "ganglios", "libres", "de", "metástasis", ".", "Estadiaje", "definitivo", "ypT2", "ypN0", ".", "Estadio", "IB", ".", "\n", "Ante", "la", "mala", "tolerancia", "al", "tratamiento", "quimioterápico", "se", "decide", "no", "dar", "quimioterapia", "adyuvante", ",", "y", "desde", "entonces", "pasa", "a", "controles", ".", "\n", "Actualmente", "sin", "evidencia", "de", "enfermedad", "a", "5", "años", "de", "la", "cirugía", ",", "en", "control", "anual", "con", "TAC", ",", "análisis", "y", "marcadores", "tumorales", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
neoplásico is a MORFOLOGIA_NEOPLASIA, Adenocarcinoma is a MORFOLOGIA_NEOPLASIA, Hemangioma is a MORFOLOGIA_NEOPLASIA, Adenocarcinoma is a MORFOLOGIA_NEOPLASIA, M1 is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, Adenocarcinoma pobremente diferenciado is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA	211_task1	Sentence: Anamnesis Varón de 48 años. ANTECEDENTES PERSONALES: Alergia a Cefuroxima y Septrim (reacción cutánea). Fumador de 15 paquete/año y bebedor de 2 vinos a la semana. VIH + desde 1992 en control por Unidad de Enfermedades Infecciosas (UEI) con estadio C3 del CDC; en 1994 varios ingresos por neumonías de repetición (bacterianas y por Pneumocystis carinii), tuberculosis pulmonar y ganglionar. Tratamiento habitual: Raltegravir 400 1/12h, Maraviroc 150 1/12h, Ritonavir 100 1/24h, Darunavir 400 2/24h, Hierro oral antes del desayuno, Omeprazol 40 mg/24 h. ENFERMEDAD ACTUAL: En Febrero de 2011, acude a revisión en consultas de UEI y comenta la aparición de cierto grado de astenia progresiva con epigastralgia desde hace varios meses, acompañado desde el último mes de deposiciones melénicas, por lo que le realizan un análisis objetivando una hemoglobina (Hb) de 4.7, por lo que deciden ingreso para estudio. Exploración física Estable hemodinámicamente, afebril. Consciente, orientado, bien hidratado y perfundido, eupneico. Palidez cutaneo-mucosa. AC: Rítmica. AP: Murmullo vesicular conservado. Abdomen: Blando, depresible, leve dolor en región epigástrico a la palpación profunda con sensación de masa a dicho nivel. No signos de irritación peritoneal. Peristaltismo presente. Extremidades inferiores: No edemas ni signos de trombosis venosa profunda. Pruebas complementarias - ANÁLISIS (07/02/2011): Albúmina 31.2, PCR 14.4, Hb 4.7, Plaquetas 418000, Leucocitos 9380, Neutrófilos 5720. Coagulación normal. - MARCADORES TUMORALES: Antígeno Carcinoembrionario (CEA); CA 125 y Ca 19.9: Negativos. - GASTROSCOPIA: Gran masa ulcerada en la curvadura menor de aspecto neoplásico, con toma de biopsias de la zona sospechosa. - ANATOMÍA PATOLÓGICA: Biopsia gástrica positiva para Adenocarcinoma. - TAC ABDOMINO-PÉLVICO: Masa a nivel de curvadura menor del estómago, con adenopatías en ligamento gastrohepático, tronco celíaco y espacio portocava. - ECOGRAFÍA ABADOMINAL: Hemangioma hepático en segmento V. - TAC TORÁCICO: Sin evidencia de patología. Diagnóstico Adenocarcinoma gástrico localmente avanzado cT2 (dudosa M1 por adenopatías retroperitoneales por TAC). Tratamiento En el Comité de tumores Gastroesofágicos se decidió que ante la presencia de masa voluminosa y de las adenopatías, se pidiera un PET-TAC para ver el comportamiento de las adenopatías, si captaban se comenzaría con Quimioterapia paliativa por considerarse éstas como metástasis; si no captaban se comenzaría con QT neoadyuvante y tras revalorar el caso se plantearía intervención quirúrgica. - PET-TAC (02/03/2011): Se observa captación a nivel gástrico sin que capten las adenopatías retroperitoneales. El 28/02/2011 comenza tratamiento con el primer ciclo de QT Neoadyuvante con Cisplatino (75 mg/m2), Docetaxel (75 mg/m2) y 5-Fluorouracilo (750 mg/m2). Evolución A los 5 días del primer ciclo de QT presentó una importante toxicidad, con enteritis e insuficiencia renal prerrenal, anemia que precisó trasfusión y mucositis. Se realizó un análisis genético para las mutaciones de las enzimas que catabolizan el 5-Fluorouracilo (5-FU), obteniendo como resultado heterocigoto para MTHFR C677T lo que le produce una intolerancia a la administracion de 5-FU. Ante la toxicidad se cambia el esquema a CPT-11 (Irinotecan 125 mg/m2) semanal administrando 4 dosis del 1 de abril al 22 de Abril, con moderada tolerancia ya que durante la administración comienza con hiperbilirrubinemia y aumento de las enzimas hepáticas sin encontrar otra etiología que el tratamiento quimioterápico. Al mes de finalizar la QT vuelve a consultas de Oncología Médica con Análisis donde sólo se observa leve anemia con Hb de 11.1, mejoría de la función hepática y marcadores tumorales negativos, con un TAC donde se observa la masa en el estómago y las adenopatías retroperitoneales sin cambios; y el PET-TAC donde capta la masa en el estómago y no captan las adenopatías. Por todo esto se define como Enfermedad Estable, relacionando las adenopatías a su antecedente de enfermedad por el VIH y no a la enfermedad tumoral, por lo que se decide intervención quirúrgica. El 13/06/2011 le realizan gastrectomía parcial del 70%, linfadenectomía D2 y omentectomia. Con resultado de anatomía patológica de Adenocarcinoma pobremente diferenciado y áreas de moderadamente diferenciado, afectando a la capa muscular, con bordes de resección libres y con 47 ganglios libres de metástasis. Estadiaje definitivo ypT2 ypN0. Estadio IB. Ante la mala tolerancia al tratamiento quimioterápico se decide no dar quimioterapia adyuvante, y desde entonces pasa a controles. Actualmente sin evidencia de enfermedad a 5 años de la cirugía, en control anual con TAC, análisis y marcadores tumorales. Instructions: please typing these entity words according to sentence: neoplásico, Adenocarcinoma, Hemangioma, Adenocarcinoma, M1, metástasis, tumoral, Adenocarcinoma pobremente diferenciado, metástasis Options: MORFOLOGIA_NEOPLASIA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Varón de 48 años. ANTECEDENTES PERSONALES: Alergia a Cefuroxima y Septrim (reacción cutánea). Fumador de 15 paquete/año y bebedor de 2 vinos a la semana. VIH + desde 1992 en control por Unidad de Enfermedades Infecciosas (UEI) con estadio C3 del CDC; en 1994 varios ingresos por neumonías de repetición (bacterianas y por Pneumocystis carinii), tuberculosis pulmonar y ganglionar. Tratamiento habitual: Raltegravir 400 1/12h, Maraviroc 150 1/12h, Ritonavir 100 1/24h, Darunavir 400 2/24h, Hierro oral antes del desayuno, Omeprazol 40 mg/24 h. ENFERMEDAD ACTUAL: En Febrero de 2011, acude a revisión en consultas de UEI y comenta la aparición de cierto grado de astenia progresiva con epigastralgia desde hace varios meses, acompañado desde el último mes de deposiciones melénicas, por lo que le realizan un análisis objetivando una hemoglobina (Hb) de 4.7, por lo que deciden ingreso para estudio. Exploración física Estable hemodinámicamente, afebril. Consciente, orientado, bien hidratado y perfundido, eupneico. Palidez cutaneo-mucosa. AC: Rítmica. AP: Murmullo vesicular conservado. Abdomen: Blando, depresible, leve dolor en región epigástrico a la palpación profunda con sensación de masa a dicho nivel. No signos de irritación peritoneal. Peristaltismo presente. Extremidades inferiores: No edemas ni signos de trombosis venosa profunda. Pruebas complementarias - ANÁLISIS (07/02/2011): Albúmina 31.2, PCR 14.4, Hb 4.7, Plaquetas 418000, Leucocitos 9380, Neutrófilos 5720. Coagulación normal. - MARCADORES TUMORALES: Antígeno Carcinoembrionario (CEA); CA 125 y Ca 19.9: Negativos. - GASTROSCOPIA: Gran masa ulcerada en la curvadura menor de aspecto neoplásico, con toma de biopsias de la zona sospechosa. - ANATOMÍA PATOLÓGICA: Biopsia gástrica positiva para Adenocarcinoma. - TAC ABDOMINO-PÉLVICO: Masa a nivel de curvadura menor del estómago, con adenopatías en ligamento gastrohepático, tronco celíaco y espacio portocava. - ECOGRAFÍA ABADOMINAL: Hemangioma hepático en segmento V. - TAC TORÁCICO: Sin evidencia de patología. Diagnóstico Adenocarcinoma gástrico localmente avanzado cT2 (dudosa M1 por adenopatías retroperitoneales por TAC). Tratamiento En el Comité de tumores Gastroesofágicos se decidió que ante la presencia de masa voluminosa y de las adenopatías, se pidiera un PET-TAC para ver el comportamiento de las adenopatías, si captaban se comenzaría con Quimioterapia paliativa por considerarse éstas como metástasis; si no captaban se comenzaría con QT neoadyuvante y tras revalorar el caso se plantearía intervención quirúrgica. - PET-TAC (02/03/2011): Se observa captación a nivel gástrico sin que capten las adenopatías retroperitoneales. El 28/02/2011 comenza tratamiento con el primer ciclo de QT Neoadyuvante con Cisplatino (75 mg/m2), Docetaxel (75 mg/m2) y 5-Fluorouracilo (750 mg/m2). Evolución A los 5 días del primer ciclo de QT presentó una importante toxicidad, con enteritis e insuficiencia renal prerrenal, anemia que precisó trasfusión y mucositis. Se realizó un análisis genético para las mutaciones de las enzimas que catabolizan el 5-Fluorouracilo (5-FU), obteniendo como resultado heterocigoto para MTHFR C677T lo que le produce una intolerancia a la administracion de 5-FU. Ante la toxicidad se cambia el esquema a CPT-11 (Irinotecan 125 mg/m2) semanal administrando 4 dosis del 1 de abril al 22 de Abril, con moderada tolerancia ya que durante la administración comienza con hiperbilirrubinemia y aumento de las enzimas hepáticas sin encontrar otra etiología que el tratamiento quimioterápico. Al mes de finalizar la QT vuelve a consultas de Oncología Médica con Análisis donde sólo se observa leve anemia con Hb de 11.1, mejoría de la función hepática y marcadores tumorales negativos, con un TAC donde se observa la masa en el estómago y las adenopatías retroperitoneales sin cambios; y el PET-TAC donde capta la masa en el estómago y no captan las adenopatías. Por todo esto se define como Enfermedad Estable, relacionando las adenopatías a su antecedente de enfermedad por el VIH y no a la enfermedad tumoral, por lo que se decide intervención quirúrgica. El 13/06/2011 le realizan gastrectomía parcial del 70%, linfadenectomía D2 y omentectomia. Con resultado de anatomía patológica de Adenocarcinoma pobremente diferenciado y áreas de moderadamente diferenciado, afectando a la capa muscular, con bordes de resección libres y con 47 ganglios libres de metástasis. Estadiaje definitivo ypT2 ypN0. Estadio IB. Ante la mala tolerancia al tratamiento quimioterápico se decide no dar quimioterapia adyuvante, y desde entonces pasa a controles. Actualmente sin evidencia de enfermedad a 5 años de la cirugía, en control anual con TAC, análisis y marcadores tumorales.	[ "Anamnesis", "\n", "Varón", "de", "48", "años", ".", "\n\n", "ANTECEDENTES", "PERSONALES", ":", "Alergia", "a", "Cefuroxima", "y", "Septrim", "(", "reacción", "cutánea", ")", ".", "Fumador", "de", "15", "paquete", "/", "año", "y", "bebedor", "de", "2", "vinos", "a", "la", "semana", ".", "VIH", "+", "desde", "1992", "en", "control", "por", "Unidad", "de", "Enfermedades", "Infecciosas", "(", "UEI", ")", "con", "estadio", "C3", "del", "CDC", ";", "en", "1994", "varios", "ingresos", "por", "neumonías", "de", "repetición", "(", "bacterianas", "y", "por", "Pneumocystis", "carinii", ")", ",", "tuberculosis", "pulmonar", "y", "ganglionar", ".", "Tratamiento", "habitual", ":", "Raltegravir", "400", "1/12h", ",", "Maraviroc", "150", "1/12h", ",", "Ritonavir", "100", "1/24h", ",", "Darunavir", "400", "2/24h", ",", "Hierro", "oral", "antes", "del", "desayuno", ",", "Omeprazol", "40", "mg/24", "h.", "\n\n", "ENFERMEDAD", "ACTUAL", ":", "\n", "En", "Febrero", "de", "2011", ",", "acude", "a", "revisión", "en", "consultas", "de", "UEI", "y", "comenta", "la", "aparición", "de", "cierto", "grado", "de", "astenia", "progresiva", "con", "epigastralgia", "desde", "hace", "varios", "meses", ",", "acompañado", "desde", "el", "último", "mes", "de", "deposiciones", "melénicas", ",", "por", "lo", "que", "le", "realizan", "un", "análisis", "objetivando", "una", "hemoglobina", "(", "Hb", ")", "de", "4.7", ",", "por", "lo", "que", "deciden", "ingreso", "para", "estudio", ".", "\n\n", "Exploración", "física", "\n", "Estable", "hemodinámicamente", ",", "afebril", ".", "Consciente", ",", "orientado", ",", "bien", "hidratado", "y", "perfundido", ",", "eupneico", ".", "Palidez", "cutaneo", "-", "mucosa", ".", "AC", ":", "Rítmica", ".", "AP", ":", "Murmullo", "vesicular", "conservado", ".", "Abdomen", ":", "Blando", ",", "depresible", ",", "leve", "dolor", "en", "región", "epigástrico", "a", "la", "palpación", "profunda", "con", "sensación", "de", "masa", "a", "dicho", "nivel", ".", "No", "signos", "de", "irritación", "peritoneal", ".", "Peristaltismo", "presente", ".", "Extremidades", "inferiores", ":", "No", "edemas", "ni", "signos", "de", "trombosis", "venosa", "profunda", ".", "\n\n", "Pruebas", "complementarias", "\n", "-", "ANÁLISIS", "(", "07/02/2011", "):", "Albúmina", "31.2", ",", "PCR", "14.4", ",", "Hb", "4.7", ",", "Plaquetas", "418000", ",", "Leucocitos", "9380", ",", "Neutrófilos", "5720", ".", "Coagulación", "normal", ".", "\n", "-", "MARCADORES", "TUMORALES", ":", "Antígeno", "Carcinoembrionario", "(", "CEA", ")", ";", "CA", "125", "y", "Ca", "19.9", ":", "Negativos", ".", "\n", "-", "GASTROSCOPIA", ":", "Gran", "masa", "ulcerada", "en", "la", "curvadura", "menor", "de", "aspecto", "neoplásico", ",", "con", "toma", "de", "biopsias", "de", "la", "zona", "sospechosa", ".", "\n", "-", "ANATOMÍA", "PATOLÓGICA", ":", "Biopsia", "gástrica", "positiva", "para", "Adenocarcinoma", ".", "\n", "-", "TAC", "ABDOMINO", "-", "PÉLVICO", ":", "Masa", "a", "nivel", "de", "curvadura", "menor", "del", "estómago", ",", "con", "adenopatías", "en", "ligamento", "gastrohepático", ",", "tronco", "celíaco", "y", "espacio", "portocava", ".", "\n", "-", "ECOGRAFÍA", "ABADOMINAL", ":", "Hemangioma", "hepático", "en", "segmento", "V.", "\n", "-", "TAC", "TORÁCICO", ":", "Sin", "evidencia", "de", "patología", ".", "\n\n", "Diagnóstico", "\n", "Adenocarcinoma", "gástrico", "localmente", "avanzado", "cT2", "(", "dudosa", "M1", "por", "adenopatías", "retroperitoneales", "por", "TAC", ")", ".", "\n\n", "Tratamiento", "\n", "En", "el", "Comité", "de", "tumores", "Gastroesofágicos", "se", "decidió", "que", "ante", "la", "presencia", "de", "masa", "voluminosa", "y", "de", "las", "adenopatías", ",", "se", "pidiera", "un", "PET", "-", "TAC", "para", "ver", "el", "comportamiento", "de", "las", "adenopatías", ",", "si", "captaban", "se", "comenzaría", "con", "Quimioterapia", "paliativa", "por", "considerarse", "éstas", "como", "metástasis", ";", "si", "no", "captaban", "se", "comenzaría", "con", "QT", "neoadyuvante", "y", "tras", "revalorar", "el", "caso", "se", "plantearía", "intervención", "quirúrgica", ".", "\n", "-", "PET", "-", "TAC", "(", "02/03/2011", "):", "Se", "observa", "captación", "a", "nivel", "gástrico", "sin", "que", "capten", "las", "adenopatías", "retroperitoneales", ".", "\n", "El", "28/02/2011", "comenza", "tratamiento", "con", "el", "primer", "ciclo", "de", "QT", "Neoadyuvante", "con", "Cisplatino", "(", "75", "mg", "/", "m2", ")", ",", "Docetaxel", "(", "75", "mg", "/", "m2", ")", "y", "5-Fluorouracilo", "(", "750", "mg", "/", "m2", ")", ".", "\n\n", "Evolución", "\n", "A", "los", "5", "días", "del", "primer", "ciclo", "de", "QT", "presentó", "una", "importante", "toxicidad", ",", "con", "enteritis", "e", "insuficiencia", "renal", "prerrenal", ",", "anemia", "que", "precisó", "trasfusión", "y", "mucositis", ".", "Se", "realizó", "un", "análisis", "genético", "para", "las", "mutaciones", "de", "las", "enzimas", "que", "catabolizan", "el", "5-Fluorouracilo", "(", "5-FU", ")", ",", "obteniendo", "como", "resultado", "heterocigoto", "para", "MTHFR", "C677", "T", "lo", "que", "le", "produce", "una", "intolerancia", "a", "la", "administracion", "de", "5-FU", ".", "\n", "Ante", "la", "toxicidad", "se", "cambia", "el", "esquema", "a", "CPT-11", "(", "Irinotecan", "125", "mg", "/", "m2", ")", "semanal", "administrando", "4", "dosis", "del", "1", "de", "abril", "al", "22", "de", "Abril", ",", "con", "moderada", "tolerancia", "ya", "que", "durante", "la", "administración", "comienza", "con", "hiperbilirrubinemia", "y", "aumento", "de", "las", "enzimas", "hepáticas", "sin", "encontrar", "otra", "etiología", "que", "el", "tratamiento", "quimioterápico", ".", "\n", "Al", "mes", "de", "finalizar", "la", "QT", "vuelve", "a", "consultas", "de", "Oncología", "Médica", "con", "Análisis", "donde", "sólo", "se", "observa", "leve", "anemia", "con", "Hb", "de", "11.1", ",", "mejoría", "de", "la", "función", "hepática", "y", "marcadores", "tumorales", "negativos", ",", "con", "un", "TAC", "donde", "se", "observa", "la", "masa", "en", "el", "estómago", "y", "las", "adenopatías", "retroperitoneales", "sin", "cambios", ";", "y", "el", "PET", "-", "TAC", "donde", "capta", "la", "masa", "en", "el", "estómago", "y", "no", "captan", "las", "adenopatías", ".", "\n", "Por", "todo", "esto", "se", "define", "como", "Enfermedad", "Estable", ",", "relacionando", "las", "adenopatías", "a", "su", "antecedente", "de", "enfermedad", "por", "el", "VIH", "y", "no", "a", "la", "enfermedad", "tumoral", ",", "por", "lo", "que", "se", "decide", "intervención", "quirúrgica", ".", "\n", "El", "13/06/2011", "le", "realizan", "gastrectomía", "parcial", "del", "70", "%", ",", "linfadenectomía", "D2", "y", "omentectomia", ".", "Con", "resultado", "de", "anatomía", "patológica", "de", "Adenocarcinoma", "pobremente", "diferenciado", "y", "áreas", "de", "moderadamente", "diferenciado", ",", "afectando", "a", "la", "capa", "muscular", ",", "con", "bordes", "de", "resección", "libres", "y", "con", "47", "ganglios", "libres", "de", "metástasis", ".", "Estadiaje", "definitivo", "ypT2", "ypN0", ".", "Estadio", "IB", ".", "\n", "Ante", "la", "mala", "tolerancia", "al", "tratamiento", "quimioterápico", "se", "decide", "no", "dar", "quimioterapia", "adyuvante", ",", "y", "desde", "entonces", "pasa", "a", "controles", ".", "\n", "Actualmente", "sin", "evidencia", "de", "enfermedad", "a", "5", "años", "de", "la", "cirugía", ",", "en", "control", "anual", "con", "TAC", ",", "análisis", "y", "marcadores", "tumorales", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
neoplásico, Adenocarcinoma, Hemangioma, Adenocarcinoma, M1, metástasis, tumoral, Adenocarcinoma pobremente diferenciado, metástasis	211_task2	Sentence: Anamnesis Varón de 48 años. ANTECEDENTES PERSONALES: Alergia a Cefuroxima y Septrim (reacción cutánea). Fumador de 15 paquete/año y bebedor de 2 vinos a la semana. VIH + desde 1992 en control por Unidad de Enfermedades Infecciosas (UEI) con estadio C3 del CDC; en 1994 varios ingresos por neumonías de repetición (bacterianas y por Pneumocystis carinii), tuberculosis pulmonar y ganglionar. Tratamiento habitual: Raltegravir 400 1/12h, Maraviroc 150 1/12h, Ritonavir 100 1/24h, Darunavir 400 2/24h, Hierro oral antes del desayuno, Omeprazol 40 mg/24 h. ENFERMEDAD ACTUAL: En Febrero de 2011, acude a revisión en consultas de UEI y comenta la aparición de cierto grado de astenia progresiva con epigastralgia desde hace varios meses, acompañado desde el último mes de deposiciones melénicas, por lo que le realizan un análisis objetivando una hemoglobina (Hb) de 4.7, por lo que deciden ingreso para estudio. Exploración física Estable hemodinámicamente, afebril. Consciente, orientado, bien hidratado y perfundido, eupneico. Palidez cutaneo-mucosa. AC: Rítmica. AP: Murmullo vesicular conservado. Abdomen: Blando, depresible, leve dolor en región epigástrico a la palpación profunda con sensación de masa a dicho nivel. No signos de irritación peritoneal. Peristaltismo presente. Extremidades inferiores: No edemas ni signos de trombosis venosa profunda. Pruebas complementarias - ANÁLISIS (07/02/2011): Albúmina 31.2, PCR 14.4, Hb 4.7, Plaquetas 418000, Leucocitos 9380, Neutrófilos 5720. Coagulación normal. - MARCADORES TUMORALES: Antígeno Carcinoembrionario (CEA); CA 125 y Ca 19.9: Negativos. - GASTROSCOPIA: Gran masa ulcerada en la curvadura menor de aspecto neoplásico, con toma de biopsias de la zona sospechosa. - ANATOMÍA PATOLÓGICA: Biopsia gástrica positiva para Adenocarcinoma. - TAC ABDOMINO-PÉLVICO: Masa a nivel de curvadura menor del estómago, con adenopatías en ligamento gastrohepático, tronco celíaco y espacio portocava. - ECOGRAFÍA ABADOMINAL: Hemangioma hepático en segmento V. - TAC TORÁCICO: Sin evidencia de patología. Diagnóstico Adenocarcinoma gástrico localmente avanzado cT2 (dudosa M1 por adenopatías retroperitoneales por TAC). Tratamiento En el Comité de tumores Gastroesofágicos se decidió que ante la presencia de masa voluminosa y de las adenopatías, se pidiera un PET-TAC para ver el comportamiento de las adenopatías, si captaban se comenzaría con Quimioterapia paliativa por considerarse éstas como metástasis; si no captaban se comenzaría con QT neoadyuvante y tras revalorar el caso se plantearía intervención quirúrgica. - PET-TAC (02/03/2011): Se observa captación a nivel gástrico sin que capten las adenopatías retroperitoneales. El 28/02/2011 comenza tratamiento con el primer ciclo de QT Neoadyuvante con Cisplatino (75 mg/m2), Docetaxel (75 mg/m2) y 5-Fluorouracilo (750 mg/m2). Evolución A los 5 días del primer ciclo de QT presentó una importante toxicidad, con enteritis e insuficiencia renal prerrenal, anemia que precisó trasfusión y mucositis. Se realizó un análisis genético para las mutaciones de las enzimas que catabolizan el 5-Fluorouracilo (5-FU), obteniendo como resultado heterocigoto para MTHFR C677T lo que le produce una intolerancia a la administracion de 5-FU. Ante la toxicidad se cambia el esquema a CPT-11 (Irinotecan 125 mg/m2) semanal administrando 4 dosis del 1 de abril al 22 de Abril, con moderada tolerancia ya que durante la administración comienza con hiperbilirrubinemia y aumento de las enzimas hepáticas sin encontrar otra etiología que el tratamiento quimioterápico. Al mes de finalizar la QT vuelve a consultas de Oncología Médica con Análisis donde sólo se observa leve anemia con Hb de 11.1, mejoría de la función hepática y marcadores tumorales negativos, con un TAC donde se observa la masa en el estómago y las adenopatías retroperitoneales sin cambios; y el PET-TAC donde capta la masa en el estómago y no captan las adenopatías. Por todo esto se define como Enfermedad Estable, relacionando las adenopatías a su antecedente de enfermedad por el VIH y no a la enfermedad tumoral, por lo que se decide intervención quirúrgica. El 13/06/2011 le realizan gastrectomía parcial del 70%, linfadenectomía D2 y omentectomia. Con resultado de anatomía patológica de Adenocarcinoma pobremente diferenciado y áreas de moderadamente diferenciado, afectando a la capa muscular, con bordes de resección libres y con 47 ganglios libres de metástasis. Estadiaje definitivo ypT2 ypN0. Estadio IB. Ante la mala tolerancia al tratamiento quimioterápico se decide no dar quimioterapia adyuvante, y desde entonces pasa a controles. Actualmente sin evidencia de enfermedad a 5 años de la cirugía, en control anual con TAC, análisis y marcadores tumorales. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Varón de 48 años. ANTECEDENTES PERSONALES: Alergia a Cefuroxima y Septrim (reacción cutánea). Fumador de 15 paquete/año y bebedor de 2 vinos a la semana. VIH + desde 1992 en control por Unidad de Enfermedades Infecciosas (UEI) con estadio C3 del CDC; en 1994 varios ingresos por neumonías de repetición (bacterianas y por Pneumocystis carinii), tuberculosis pulmonar y ganglionar. Tratamiento habitual: Raltegravir 400 1/12h, Maraviroc 150 1/12h, Ritonavir 100 1/24h, Darunavir 400 2/24h, Hierro oral antes del desayuno, Omeprazol 40 mg/24 h. ENFERMEDAD ACTUAL: En Febrero de 2011, acude a revisión en consultas de UEI y comenta la aparición de cierto grado de astenia progresiva con epigastralgia desde hace varios meses, acompañado desde el último mes de deposiciones melénicas, por lo que le realizan un análisis objetivando una hemoglobina (Hb) de 4.7, por lo que deciden ingreso para estudio. Exploración física Estable hemodinámicamente, afebril. Consciente, orientado, bien hidratado y perfundido, eupneico. Palidez cutaneo-mucosa. AC: Rítmica. AP: Murmullo vesicular conservado. Abdomen: Blando, depresible, leve dolor en región epigástrico a la palpación profunda con sensación de masa a dicho nivel. No signos de irritación peritoneal. Peristaltismo presente. Extremidades inferiores: No edemas ni signos de trombosis venosa profunda. Pruebas complementarias - ANÁLISIS (07/02/2011): Albúmina 31.2, PCR 14.4, Hb 4.7, Plaquetas 418000, Leucocitos 9380, Neutrófilos 5720. Coagulación normal. - MARCADORES TUMORALES: Antígeno Carcinoembrionario (CEA); CA 125 y Ca 19.9: Negativos. - GASTROSCOPIA: Gran masa ulcerada en la curvadura menor de aspecto neoplásico, con toma de biopsias de la zona sospechosa. - ANATOMÍA PATOLÓGICA: Biopsia gástrica positiva para Adenocarcinoma. - TAC ABDOMINO-PÉLVICO: Masa a nivel de curvadura menor del estómago, con adenopatías en ligamento gastrohepático, tronco celíaco y espacio portocava. - ECOGRAFÍA ABADOMINAL: Hemangioma hepático en segmento V. - TAC TORÁCICO: Sin evidencia de patología. Diagnóstico Adenocarcinoma gástrico localmente avanzado cT2 (dudosa M1 por adenopatías retroperitoneales por TAC). Tratamiento En el Comité de tumores Gastroesofágicos se decidió que ante la presencia de masa voluminosa y de las adenopatías, se pidiera un PET-TAC para ver el comportamiento de las adenopatías, si captaban se comenzaría con Quimioterapia paliativa por considerarse éstas como metástasis; si no captaban se comenzaría con QT neoadyuvante y tras revalorar el caso se plantearía intervención quirúrgica. - PET-TAC (02/03/2011): Se observa captación a nivel gástrico sin que capten las adenopatías retroperitoneales. El 28/02/2011 comenza tratamiento con el primer ciclo de QT Neoadyuvante con Cisplatino (75 mg/m2), Docetaxel (75 mg/m2) y 5-Fluorouracilo (750 mg/m2). Evolución A los 5 días del primer ciclo de QT presentó una importante toxicidad, con enteritis e insuficiencia renal prerrenal, anemia que precisó trasfusión y mucositis. Se realizó un análisis genético para las mutaciones de las enzimas que catabolizan el 5-Fluorouracilo (5-FU), obteniendo como resultado heterocigoto para MTHFR C677T lo que le produce una intolerancia a la administracion de 5-FU. Ante la toxicidad se cambia el esquema a CPT-11 (Irinotecan 125 mg/m2) semanal administrando 4 dosis del 1 de abril al 22 de Abril, con moderada tolerancia ya que durante la administración comienza con hiperbilirrubinemia y aumento de las enzimas hepáticas sin encontrar otra etiología que el tratamiento quimioterápico. Al mes de finalizar la QT vuelve a consultas de Oncología Médica con Análisis donde sólo se observa leve anemia con Hb de 11.1, mejoría de la función hepática y marcadores tumorales negativos, con un TAC donde se observa la masa en el estómago y las adenopatías retroperitoneales sin cambios; y el PET-TAC donde capta la masa en el estómago y no captan las adenopatías. Por todo esto se define como Enfermedad Estable, relacionando las adenopatías a su antecedente de enfermedad por el VIH y no a la enfermedad tumoral, por lo que se decide intervención quirúrgica. El 13/06/2011 le realizan gastrectomía parcial del 70%, linfadenectomía D2 y omentectomia. Con resultado de anatomía patológica de Adenocarcinoma pobremente diferenciado y áreas de moderadamente diferenciado, afectando a la capa muscular, con bordes de resección libres y con 47 ganglios libres de metástasis. Estadiaje definitivo ypT2 ypN0. Estadio IB. Ante la mala tolerancia al tratamiento quimioterápico se decide no dar quimioterapia adyuvante, y desde entonces pasa a controles. Actualmente sin evidencia de enfermedad a 5 años de la cirugía, en control anual con TAC, análisis y marcadores tumorales.	[ "Anamnesis", "\n", "Varón", "de", "48", "años", ".", "\n\n", "ANTECEDENTES", "PERSONALES", ":", "Alergia", "a", "Cefuroxima", "y", "Septrim", "(", "reacción", "cutánea", ")", ".", "Fumador", "de", "15", "paquete", "/", "año", "y", "bebedor", "de", "2", "vinos", "a", "la", "semana", ".", "VIH", "+", "desde", "1992", "en", "control", "por", "Unidad", "de", "Enfermedades", "Infecciosas", "(", "UEI", ")", "con", "estadio", "C3", "del", "CDC", ";", "en", "1994", "varios", "ingresos", "por", "neumonías", "de", "repetición", "(", "bacterianas", "y", "por", "Pneumocystis", "carinii", ")", ",", "tuberculosis", "pulmonar", "y", "ganglionar", ".", "Tratamiento", "habitual", ":", "Raltegravir", "400", "1/12h", ",", "Maraviroc", "150", "1/12h", ",", "Ritonavir", "100", "1/24h", ",", "Darunavir", "400", "2/24h", ",", "Hierro", "oral", "antes", "del", "desayuno", ",", "Omeprazol", "40", "mg/24", "h.", "\n\n", "ENFERMEDAD", "ACTUAL", ":", "\n", "En", "Febrero", "de", "2011", ",", "acude", "a", "revisión", "en", "consultas", "de", "UEI", "y", "comenta", "la", "aparición", "de", "cierto", "grado", "de", "astenia", "progresiva", "con", "epigastralgia", "desde", "hace", "varios", "meses", ",", "acompañado", "desde", "el", "último", "mes", "de", "deposiciones", "melénicas", ",", "por", "lo", "que", "le", "realizan", "un", "análisis", "objetivando", "una", "hemoglobina", "(", "Hb", ")", "de", "4.7", ",", "por", "lo", "que", "deciden", "ingreso", "para", "estudio", ".", "\n\n", "Exploración", "física", "\n", "Estable", "hemodinámicamente", ",", "afebril", ".", "Consciente", ",", "orientado", ",", "bien", "hidratado", "y", "perfundido", ",", "eupneico", ".", "Palidez", "cutaneo", "-", "mucosa", ".", "AC", ":", "Rítmica", ".", "AP", ":", "Murmullo", "vesicular", "conservado", ".", "Abdomen", ":", "Blando", ",", "depresible", ",", "leve", "dolor", "en", "región", "epigástrico", "a", "la", "palpación", "profunda", "con", "sensación", "de", "masa", "a", "dicho", "nivel", ".", "No", "signos", "de", "irritación", "peritoneal", ".", "Peristaltismo", "presente", ".", "Extremidades", "inferiores", ":", "No", "edemas", "ni", "signos", "de", "trombosis", "venosa", "profunda", ".", "\n\n", "Pruebas", "complementarias", "\n", "-", "ANÁLISIS", "(", "07/02/2011", "):", "Albúmina", "31.2", ",", "PCR", "14.4", ",", "Hb", "4.7", ",", "Plaquetas", "418000", ",", "Leucocitos", "9380", ",", "Neutrófilos", "5720", ".", "Coagulación", "normal", ".", "\n", "-", "MARCADORES", "TUMORALES", ":", "Antígeno", "Carcinoembrionario", "(", "CEA", ")", ";", "CA", "125", "y", "Ca", "19.9", ":", "Negativos", ".", "\n", "-", "GASTROSCOPIA", ":", "Gran", "masa", "ulcerada", "en", "la", "curvadura", "menor", "de", "aspecto", "neoplásico", ",", "con", "toma", "de", "biopsias", "de", "la", "zona", "sospechosa", ".", "\n", "-", "ANATOMÍA", "PATOLÓGICA", ":", "Biopsia", "gástrica", "positiva", "para", "Adenocarcinoma", ".", "\n", "-", "TAC", "ABDOMINO", "-", "PÉLVICO", ":", "Masa", "a", "nivel", "de", "curvadura", "menor", "del", "estómago", ",", "con", "adenopatías", "en", "ligamento", "gastrohepático", ",", "tronco", "celíaco", "y", "espacio", "portocava", ".", "\n", "-", "ECOGRAFÍA", "ABADOMINAL", ":", "Hemangioma", "hepático", "en", "segmento", "V.", "\n", "-", "TAC", "TORÁCICO", ":", "Sin", "evidencia", "de", "patología", ".", "\n\n", "Diagnóstico", "\n", "Adenocarcinoma", "gástrico", "localmente", "avanzado", "cT2", "(", "dudosa", "M1", "por", "adenopatías", "retroperitoneales", "por", "TAC", ")", ".", "\n\n", "Tratamiento", "\n", "En", "el", "Comité", "de", "tumores", "Gastroesofágicos", "se", "decidió", "que", "ante", "la", "presencia", "de", "masa", "voluminosa", "y", "de", "las", "adenopatías", ",", "se", "pidiera", "un", "PET", "-", "TAC", "para", "ver", "el", "comportamiento", "de", "las", "adenopatías", ",", "si", "captaban", "se", "comenzaría", "con", "Quimioterapia", "paliativa", "por", "considerarse", "éstas", "como", "metástasis", ";", "si", "no", "captaban", "se", "comenzaría", "con", "QT", "neoadyuvante", "y", "tras", "revalorar", "el", "caso", "se", "plantearía", "intervención", "quirúrgica", ".", "\n", "-", "PET", "-", "TAC", "(", "02/03/2011", "):", "Se", "observa", "captación", "a", "nivel", "gástrico", "sin", "que", "capten", "las", "adenopatías", "retroperitoneales", ".", "\n", "El", "28/02/2011", "comenza", "tratamiento", "con", "el", "primer", "ciclo", "de", "QT", "Neoadyuvante", "con", "Cisplatino", "(", "75", "mg", "/", "m2", ")", ",", "Docetaxel", "(", "75", "mg", "/", "m2", ")", "y", "5-Fluorouracilo", "(", "750", "mg", "/", "m2", ")", ".", "\n\n", "Evolución", "\n", "A", "los", "5", "días", "del", "primer", "ciclo", "de", "QT", "presentó", "una", "importante", "toxicidad", ",", "con", "enteritis", "e", "insuficiencia", "renal", "prerrenal", ",", "anemia", "que", "precisó", "trasfusión", "y", "mucositis", ".", "Se", "realizó", "un", "análisis", "genético", "para", "las", "mutaciones", "de", "las", "enzimas", "que", "catabolizan", "el", "5-Fluorouracilo", "(", "5-FU", ")", ",", "obteniendo", "como", "resultado", "heterocigoto", "para", "MTHFR", "C677", "T", "lo", "que", "le", "produce", "una", "intolerancia", "a", "la", "administracion", "de", "5-FU", ".", "\n", "Ante", "la", "toxicidad", "se", "cambia", "el", "esquema", "a", "CPT-11", "(", "Irinotecan", "125", "mg", "/", "m2", ")", "semanal", "administrando", "4", "dosis", "del", "1", "de", "abril", "al", "22", "de", "Abril", ",", "con", "moderada", "tolerancia", "ya", "que", "durante", "la", "administración", "comienza", "con", "hiperbilirrubinemia", "y", "aumento", "de", "las", "enzimas", "hepáticas", "sin", "encontrar", "otra", "etiología", "que", "el", "tratamiento", "quimioterápico", ".", "\n", "Al", "mes", "de", "finalizar", "la", "QT", "vuelve", "a", "consultas", "de", "Oncología", "Médica", "con", "Análisis", "donde", "sólo", "se", "observa", "leve", "anemia", "con", "Hb", "de", "11.1", ",", "mejoría", "de", "la", "función", "hepática", "y", "marcadores", "tumorales", "negativos", ",", "con", "un", "TAC", "donde", "se", "observa", "la", "masa", "en", "el", "estómago", "y", "las", "adenopatías", "retroperitoneales", "sin", "cambios", ";", "y", "el", "PET", "-", "TAC", "donde", "capta", "la", "masa", "en", "el", "estómago", "y", "no", "captan", "las", "adenopatías", ".", "\n", "Por", "todo", "esto", "se", "define", "como", "Enfermedad", "Estable", ",", "relacionando", "las", "adenopatías", "a", "su", "antecedente", "de", "enfermedad", "por", "el", "VIH", "y", "no", "a", "la", "enfermedad", "tumoral", ",", "por", "lo", "que", "se", "decide", "intervención", "quirúrgica", ".", "\n", "El", "13/06/2011", "le", "realizan", "gastrectomía", "parcial", "del", "70", "%", ",", "linfadenectomía", "D2", "y", "omentectomia", ".", "Con", "resultado", "de", "anatomía", "patológica", "de", "Adenocarcinoma", "pobremente", "diferenciado", "y", "áreas", "de", "moderadamente", "diferenciado", ",", "afectando", "a", "la", "capa", "muscular", ",", "con", "bordes", "de", "resección", "libres", "y", "con", "47", "ganglios", "libres", "de", "metástasis", ".", "Estadiaje", "definitivo", "ypT2", "ypN0", ".", "Estadio", "IB", ".", "\n", "Ante", "la", "mala", "tolerancia", "al", "tratamiento", "quimioterápico", "se", "decide", "no", "dar", "quimioterapia", "adyuvante", ",", "y", "desde", "entonces", "pasa", "a", "controles", ".", "\n", "Actualmente", "sin", "evidencia", "de", "enfermedad", "a", "5", "años", "de", "la", "cirugía", ",", "en", "control", "anual", "con", "TAC", ",", "análisis", "y", "marcadores", "tumorales", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
dorzolamide is a DRUG, carbonic anhydrase inhibitors is a GROUP, salicylate is a GROUP, dorzolamide is a DRUG	Dorzolamide_ddi_task0	Sentence: Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). Therefore, the potential for such drug interactions should be considered in patients receiving dorzolamide. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, DRUG	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O" ]	Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). Therefore, the potential for such drug interactions should be considered in patients receiving dorzolamide.	[ "Although", "acid", "-", "base", "and", "electrolyte", "disturbances", "were", "not", "reported", "in", "the", "clinical", "trials", "with", "dorzolamide", ",", "these", "disturbances", "have", "been", "reported", "with", "oral", "carbonic", "anhydrase", "inhibitors", "and", "have", ",", "in", "some", "instances", ",", "resulted", "in", "drug", "interactions", "(", "e.g", ".", ",", "toxicity", "associated", "with", "high", "-", "dose", "salicylate", "therapy", ")", ".", "Therefore", ",", "the", "potential", "for", "such", "drug", "interactions", "should", "be", "considered", "in", "patients", "receiving", "dorzolamide", "." ]	[ "GROUP", "DRUG" ]
dorzolamide is a DRUG, carbonic anhydrase inhibitors is a GROUP, salicylate is a GROUP, dorzolamide is a DRUG	Dorzolamide_ddi_task1	Sentence: Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). Therefore, the potential for such drug interactions should be considered in patients receiving dorzolamide. Instructions: please typing these entity words according to sentence: dorzolamide, carbonic anhydrase inhibitors, salicylate, dorzolamide Options: GROUP, DRUG	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O" ]	Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). Therefore, the potential for such drug interactions should be considered in patients receiving dorzolamide.	[ "Although", "acid", "-", "base", "and", "electrolyte", "disturbances", "were", "not", "reported", "in", "the", "clinical", "trials", "with", "dorzolamide", ",", "these", "disturbances", "have", "been", "reported", "with", "oral", "carbonic", "anhydrase", "inhibitors", "and", "have", ",", "in", "some", "instances", ",", "resulted", "in", "drug", "interactions", "(", "e.g", ".", ",", "toxicity", "associated", "with", "high", "-", "dose", "salicylate", "therapy", ")", ".", "Therefore", ",", "the", "potential", "for", "such", "drug", "interactions", "should", "be", "considered", "in", "patients", "receiving", "dorzolamide", "." ]	[ "GROUP", "DRUG" ]
dorzolamide, carbonic anhydrase inhibitors, salicylate, dorzolamide	Dorzolamide_ddi_task2	Sentence: Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). Therefore, the potential for such drug interactions should be considered in patients receiving dorzolamide. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O" ]	Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). Therefore, the potential for such drug interactions should be considered in patients receiving dorzolamide.	[ "Although", "acid", "-", "base", "and", "electrolyte", "disturbances", "were", "not", "reported", "in", "the", "clinical", "trials", "with", "dorzolamide", ",", "these", "disturbances", "have", "been", "reported", "with", "oral", "carbonic", "anhydrase", "inhibitors", "and", "have", ",", "in", "some", "instances", ",", "resulted", "in", "drug", "interactions", "(", "e.g", ".", ",", "toxicity", "associated", "with", "high", "-", "dose", "salicylate", "therapy", ")", ".", "Therefore", ",", "the", "potential", "for", "such", "drug", "interactions", "should", "be", "considered", "in", "patients", "receiving", "dorzolamide", "." ]	[ "GROUP", "DRUG" ]
glycan is a compound, voltage - gated potassium channels is a protein	DS.d1843_task0	Sentence: Atypical sialylated N-glycan structures are attached to neuronal voltage-gated potassium channels. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O" ]	Atypical sialylated N-glycan structures are attached to neuronal voltage-gated potassium channels.	[ "Atypical", "sialylated", "N", "-", "glycan", "structures", "are", "attached", "to", "neuronal", "voltage", "-", "gated", "potassium", "channels", "." ]	[ "protein", "compound" ]
glycan is a compound, voltage - gated potassium channels is a protein	DS.d1843_task1	Sentence: Atypical sialylated N-glycan structures are attached to neuronal voltage-gated potassium channels. Instructions: please typing these entity words according to sentence: glycan, voltage - gated potassium channels Options: compound, protein	[ "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O" ]	Atypical sialylated N-glycan structures are attached to neuronal voltage-gated potassium channels.	[ "Atypical", "sialylated", "N", "-", "glycan", "structures", "are", "attached", "to", "neuronal", "voltage", "-", "gated", "potassium", "channels", "." ]	[ "protein", "compound" ]
glycan, voltage - gated potassium channels	DS.d1843_task2	Sentence: Atypical sialylated N-glycan structures are attached to neuronal voltage-gated potassium channels. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O" ]	Atypical sialylated N-glycan structures are attached to neuronal voltage-gated potassium channels.	[ "Atypical", "sialylated", "N", "-", "glycan", "structures", "are", "attached", "to", "neuronal", "voltage", "-", "gated", "potassium", "channels", "." ]	[ "protein", "compound" ]
antidepressants is a GROUP, antidepressant drugs is a GROUP, hypoglycemic agents is a GROUP, antidepressant agents is a GROUP, antidepressants is a GROUP, Imipramine is a DRUG, moclobemide is a DRUG, clonazepam is a DRUG, fluoxetine is a DRUG, sertraline is a DRUG, glucose is a DRUG, glucose is a DRUG, Imipramine is a DRUG, clonazepam is a DRUG, Fluoxetine is a DRUG, moclobemide is a DRUG, glucose is a DRUG, Sertraline is a DRUG, glucose is a DRUG, glucose is a DRUG, glucose is a DRUG, sertraline is a DRUG, glucose is a DRUG, sertraline is a DRUG, Clonazepam is a DRUG	11151029_task0	Sentence: Acute effect of different antidepressants on glycemia in diabetic and non-diabetic rats. Diabetic patients have a 20% higher risk of depression than the general population. Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents. The treatment of depression in diabetic patients must take into account variations of glycemic levels at different times and a comparison of the available antidepressant agents is important. In the present study we evaluated the interference of antidepressants with blood glucose levels of diabetic and non-diabetic rats. In a first experiment, male adult Wistar rats were fasted for 12 h. Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. After 30 min, fasting glycemia was measured. An oral glucose overload of 1 ml of a 50% glucose solution was given to rats and blood glucose was determined after 30, 60 and 90 min. Imipramine and clonazepam did not change fasting or overload glycemia. Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. Sertraline neutralized the increase of glycemia induced by oral glucose overload. In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of glucose tolerance 30 min after glucose overload. Again, sertraline neutralized the increase in glycemia after glucose overload both in diabetic and non-diabetic rats. These data raise the question of whether sertraline is the best choice for prolonged use for diabetic individuals, because of its antihyperglycemic effects. Clonazepam would be useful in cases with potential risk of hypoglycemia. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, DRUG	[ "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Acute effect of different antidepressants on glycemia in diabetic and non-diabetic rats. Diabetic patients have a 20% higher risk of depression than the general population. Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents. The treatment of depression in diabetic patients must take into account variations of glycemic levels at different times and a comparison of the available antidepressant agents is important. In the present study we evaluated the interference of antidepressants with blood glucose levels of diabetic and non-diabetic rats. In a first experiment, male adult Wistar rats were fasted for 12 h. Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. After 30 min, fasting glycemia was measured. An oral glucose overload of 1 ml of a 50% glucose solution was given to rats and blood glucose was determined after 30, 60 and 90 min. Imipramine and clonazepam did not change fasting or overload glycemia. Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. Sertraline neutralized the increase of glycemia induced by oral glucose overload. In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of glucose tolerance 30 min after glucose overload. Again, sertraline neutralized the increase in glycemia after glucose overload both in diabetic and non-diabetic rats. These data raise the question of whether sertraline is the best choice for prolonged use for diabetic individuals, because of its antihyperglycemic effects. Clonazepam would be useful in cases with potential risk of hypoglycemia.	[ "Acute", "effect", "of", "different", "antidepressants", "on", "glycemia", "in", "diabetic", "and", "non", "-", "diabetic", "rats", ".", "Diabetic", "patients", "have", "a", "20", "%", "higher", "risk", "of", "depression", "than", "the", "general", "population", ".", "Treatment", "with", "antidepressant", "drugs", "can", "directly", "interfere", "with", "blood", "glucose", "levels", "or", "may", "interact", "with", "hypoglycemic", "agents", ".", "The", "treatment", "of", "depression", "in", "diabetic", "patients", "must", "take", "into", "account", "variations", "of", "glycemic", "levels", "at", "different", "times", "and", "a", "comparison", "of", "the", "available", "antidepressant", "agents", "is", "important", ".", "In", "the", "present", "study", "we", "evaluated", "the", "interference", "of", "antidepressants", "with", "blood", "glucose", "levels", "of", "diabetic", "and", "non", "-", "diabetic", "rats", ".", "In", "a", "first", "experiment", ",", "male", "adult", "Wistar", "rats", "were", "fasted", "for", "12", "h.", "Imipramine", "(", "5", "mg", "/", "kg", ")", ",", "moclobemide", "(", "30", "mg", "/", "kg", ")", ",", "clonazepam", "(", "0.25", "mg", "/", "kg", ")", ",", "fluoxetine", "(", "20", "mg", "/", "kg", ")", "sertraline", "(", "30", "mg", "/", "kg", ")", "or", "vehicle", "was", "administered", ".", "After", "30", "min", ",", "fasting", "glycemia", "was", "measured", ".", "An", "oral", "glucose", "overload", "of", "1", "ml", "of", "a", "50", "%", "glucose", "solution", "was", "given", "to", "rats", "and", "blood", "glucose", "was", "determined", "after", "30", ",", "60", "and", "90", "min", ".", "Imipramine", "and", "clonazepam", "did", "not", "change", "fasting", "or", "overload", "glycemia", ".", "Fluoxetine", "and", "moclobemide", "increased", "blood", "glucose", "at", "different", "times", "after", "the", "glucose", "overload", ".", "Sertraline", "neutralized", "the", "increase", "of", "glycemia", "induced", "by", "oral", "glucose", "overload", ".", "In", "the", "second", "experiment", ",", "non", "-", "diabetic", "and", "streptozotocin", "-", "induced", "diabetic", "rats", "were", "fasted", ",", "and", "the", "same", "procedures", "were", "followed", "for", "estimation", "of", "glucose", "tolerance", "30", "min", "after", "glucose", "overload", ".", "Again", ",", "sertraline", "neutralized", "the", "increase", "in", "glycemia", "after", "glucose", "overload", "both", "in", "diabetic", "and", "non", "-", "diabetic", "rats", ".", "These", "data", "raise", "the", "question", "of", "whether", "sertraline", "is", "the", "best", "choice", "for", "prolonged", "use", "for", "diabetic", "individuals", ",", "because", "of", "its", "antihyperglycemic", "effects", ".", "Clonazepam", "would", "be", "useful", "in", "cases", "with", "potential", "risk", "of", "hypoglycemia", "." ]	[ "GROUP", "DRUG" ]
antidepressants is a GROUP, antidepressant drugs is a GROUP, hypoglycemic agents is a GROUP, antidepressant agents is a GROUP, antidepressants is a GROUP, Imipramine is a DRUG, moclobemide is a DRUG, clonazepam is a DRUG, fluoxetine is a DRUG, sertraline is a DRUG, glucose is a DRUG, glucose is a DRUG, Imipramine is a DRUG, clonazepam is a DRUG, Fluoxetine is a DRUG, moclobemide is a DRUG, glucose is a DRUG, Sertraline is a DRUG, glucose is a DRUG, glucose is a DRUG, glucose is a DRUG, sertraline is a DRUG, glucose is a DRUG, sertraline is a DRUG, Clonazepam is a DRUG	11151029_task1	Sentence: Acute effect of different antidepressants on glycemia in diabetic and non-diabetic rats. Diabetic patients have a 20% higher risk of depression than the general population. Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents. The treatment of depression in diabetic patients must take into account variations of glycemic levels at different times and a comparison of the available antidepressant agents is important. In the present study we evaluated the interference of antidepressants with blood glucose levels of diabetic and non-diabetic rats. In a first experiment, male adult Wistar rats were fasted for 12 h. Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. After 30 min, fasting glycemia was measured. An oral glucose overload of 1 ml of a 50% glucose solution was given to rats and blood glucose was determined after 30, 60 and 90 min. Imipramine and clonazepam did not change fasting or overload glycemia. Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. Sertraline neutralized the increase of glycemia induced by oral glucose overload. In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of glucose tolerance 30 min after glucose overload. Again, sertraline neutralized the increase in glycemia after glucose overload both in diabetic and non-diabetic rats. These data raise the question of whether sertraline is the best choice for prolonged use for diabetic individuals, because of its antihyperglycemic effects. Clonazepam would be useful in cases with potential risk of hypoglycemia. Instructions: please typing these entity words according to sentence: antidepressants, antidepressant drugs, hypoglycemic agents, antidepressant agents, antidepressants, Imipramine, moclobemide, clonazepam, fluoxetine, sertraline, glucose, glucose, Imipramine, clonazepam, Fluoxetine, moclobemide, glucose, Sertraline, glucose, glucose, glucose, sertraline, glucose, sertraline, Clonazepam Options: GROUP, DRUG	[ "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Acute effect of different antidepressants on glycemia in diabetic and non-diabetic rats. Diabetic patients have a 20% higher risk of depression than the general population. Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents. The treatment of depression in diabetic patients must take into account variations of glycemic levels at different times and a comparison of the available antidepressant agents is important. In the present study we evaluated the interference of antidepressants with blood glucose levels of diabetic and non-diabetic rats. In a first experiment, male adult Wistar rats were fasted for 12 h. Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. After 30 min, fasting glycemia was measured. An oral glucose overload of 1 ml of a 50% glucose solution was given to rats and blood glucose was determined after 30, 60 and 90 min. Imipramine and clonazepam did not change fasting or overload glycemia. Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. Sertraline neutralized the increase of glycemia induced by oral glucose overload. In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of glucose tolerance 30 min after glucose overload. Again, sertraline neutralized the increase in glycemia after glucose overload both in diabetic and non-diabetic rats. These data raise the question of whether sertraline is the best choice for prolonged use for diabetic individuals, because of its antihyperglycemic effects. Clonazepam would be useful in cases with potential risk of hypoglycemia.	[ "Acute", "effect", "of", "different", "antidepressants", "on", "glycemia", "in", "diabetic", "and", "non", "-", "diabetic", "rats", ".", "Diabetic", "patients", "have", "a", "20", "%", "higher", "risk", "of", "depression", "than", "the", "general", "population", ".", "Treatment", "with", "antidepressant", "drugs", "can", "directly", "interfere", "with", "blood", "glucose", "levels", "or", "may", "interact", "with", "hypoglycemic", "agents", ".", "The", "treatment", "of", "depression", "in", "diabetic", "patients", "must", "take", "into", "account", "variations", "of", "glycemic", "levels", "at", "different", "times", "and", "a", "comparison", "of", "the", "available", "antidepressant", "agents", "is", "important", ".", "In", "the", "present", "study", "we", "evaluated", "the", "interference", "of", "antidepressants", "with", "blood", "glucose", "levels", "of", "diabetic", "and", "non", "-", "diabetic", "rats", ".", "In", "a", "first", "experiment", ",", "male", "adult", "Wistar", "rats", "were", "fasted", "for", "12", "h.", "Imipramine", "(", "5", "mg", "/", "kg", ")", ",", "moclobemide", "(", "30", "mg", "/", "kg", ")", ",", "clonazepam", "(", "0.25", "mg", "/", "kg", ")", ",", "fluoxetine", "(", "20", "mg", "/", "kg", ")", "sertraline", "(", "30", "mg", "/", "kg", ")", "or", "vehicle", "was", "administered", ".", "After", "30", "min", ",", "fasting", "glycemia", "was", "measured", ".", "An", "oral", "glucose", "overload", "of", "1", "ml", "of", "a", "50", "%", "glucose", "solution", "was", "given", "to", "rats", "and", "blood", "glucose", "was", "determined", "after", "30", ",", "60", "and", "90", "min", ".", "Imipramine", "and", "clonazepam", "did", "not", "change", "fasting", "or", "overload", "glycemia", ".", "Fluoxetine", "and", "moclobemide", "increased", "blood", "glucose", "at", "different", "times", "after", "the", "glucose", "overload", ".", "Sertraline", "neutralized", "the", "increase", "of", "glycemia", "induced", "by", "oral", "glucose", "overload", ".", "In", "the", "second", "experiment", ",", "non", "-", "diabetic", "and", "streptozotocin", "-", "induced", "diabetic", "rats", "were", "fasted", ",", "and", "the", "same", "procedures", "were", "followed", "for", "estimation", "of", "glucose", "tolerance", "30", "min", "after", "glucose", "overload", ".", "Again", ",", "sertraline", "neutralized", "the", "increase", "in", "glycemia", "after", "glucose", "overload", "both", "in", "diabetic", "and", "non", "-", "diabetic", "rats", ".", "These", "data", "raise", "the", "question", "of", "whether", "sertraline", "is", "the", "best", "choice", "for", "prolonged", "use", "for", "diabetic", "individuals", ",", "because", "of", "its", "antihyperglycemic", "effects", ".", "Clonazepam", "would", "be", "useful", "in", "cases", "with", "potential", "risk", "of", "hypoglycemia", "." ]	[ "GROUP", "DRUG" ]
antidepressants, antidepressant drugs, hypoglycemic agents, antidepressant agents, antidepressants, Imipramine, moclobemide, clonazepam, fluoxetine, sertraline, glucose, glucose, Imipramine, clonazepam, Fluoxetine, moclobemide, glucose, Sertraline, glucose, glucose, glucose, sertraline, glucose, sertraline, Clonazepam	11151029_task2	Sentence: Acute effect of different antidepressants on glycemia in diabetic and non-diabetic rats. Diabetic patients have a 20% higher risk of depression than the general population. Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents. The treatment of depression in diabetic patients must take into account variations of glycemic levels at different times and a comparison of the available antidepressant agents is important. In the present study we evaluated the interference of antidepressants with blood glucose levels of diabetic and non-diabetic rats. In a first experiment, male adult Wistar rats were fasted for 12 h. Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. After 30 min, fasting glycemia was measured. An oral glucose overload of 1 ml of a 50% glucose solution was given to rats and blood glucose was determined after 30, 60 and 90 min. Imipramine and clonazepam did not change fasting or overload glycemia. Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. Sertraline neutralized the increase of glycemia induced by oral glucose overload. In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of glucose tolerance 30 min after glucose overload. Again, sertraline neutralized the increase in glycemia after glucose overload both in diabetic and non-diabetic rats. These data raise the question of whether sertraline is the best choice for prolonged use for diabetic individuals, because of its antihyperglycemic effects. Clonazepam would be useful in cases with potential risk of hypoglycemia. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Acute effect of different antidepressants on glycemia in diabetic and non-diabetic rats. Diabetic patients have a 20% higher risk of depression than the general population. Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents. The treatment of depression in diabetic patients must take into account variations of glycemic levels at different times and a comparison of the available antidepressant agents is important. In the present study we evaluated the interference of antidepressants with blood glucose levels of diabetic and non-diabetic rats. In a first experiment, male adult Wistar rats were fasted for 12 h. Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. After 30 min, fasting glycemia was measured. An oral glucose overload of 1 ml of a 50% glucose solution was given to rats and blood glucose was determined after 30, 60 and 90 min. Imipramine and clonazepam did not change fasting or overload glycemia. Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. Sertraline neutralized the increase of glycemia induced by oral glucose overload. In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of glucose tolerance 30 min after glucose overload. Again, sertraline neutralized the increase in glycemia after glucose overload both in diabetic and non-diabetic rats. These data raise the question of whether sertraline is the best choice for prolonged use for diabetic individuals, because of its antihyperglycemic effects. Clonazepam would be useful in cases with potential risk of hypoglycemia.	[ "Acute", "effect", "of", "different", "antidepressants", "on", "glycemia", "in", "diabetic", "and", "non", "-", "diabetic", "rats", ".", "Diabetic", "patients", "have", "a", "20", "%", "higher", "risk", "of", "depression", "than", "the", "general", "population", ".", "Treatment", "with", "antidepressant", "drugs", "can", "directly", "interfere", "with", "blood", "glucose", "levels", "or", "may", "interact", "with", "hypoglycemic", "agents", ".", "The", "treatment", "of", "depression", "in", "diabetic", "patients", "must", "take", "into", "account", "variations", "of", "glycemic", "levels", "at", "different", "times", "and", "a", "comparison", "of", "the", "available", "antidepressant", "agents", "is", "important", ".", "In", "the", "present", "study", "we", "evaluated", "the", "interference", "of", "antidepressants", "with", "blood", "glucose", "levels", "of", "diabetic", "and", "non", "-", "diabetic", "rats", ".", "In", "a", "first", "experiment", ",", "male", "adult", "Wistar", "rats", "were", "fasted", "for", "12", "h.", "Imipramine", "(", "5", "mg", "/", "kg", ")", ",", "moclobemide", "(", "30", "mg", "/", "kg", ")", ",", "clonazepam", "(", "0.25", "mg", "/", "kg", ")", ",", "fluoxetine", "(", "20", "mg", "/", "kg", ")", "sertraline", "(", "30", "mg", "/", "kg", ")", "or", "vehicle", "was", "administered", ".", "After", "30", "min", ",", "fasting", "glycemia", "was", "measured", ".", "An", "oral", "glucose", "overload", "of", "1", "ml", "of", "a", "50", "%", "glucose", "solution", "was", "given", "to", "rats", "and", "blood", "glucose", "was", "determined", "after", "30", ",", "60", "and", "90", "min", ".", "Imipramine", "and", "clonazepam", "did", "not", "change", "fasting", "or", "overload", "glycemia", ".", "Fluoxetine", "and", "moclobemide", "increased", "blood", "glucose", "at", "different", "times", "after", "the", "glucose", "overload", ".", "Sertraline", "neutralized", "the", "increase", "of", "glycemia", "induced", "by", "oral", "glucose", "overload", ".", "In", "the", "second", "experiment", ",", "non", "-", "diabetic", "and", "streptozotocin", "-", "induced", "diabetic", "rats", "were", "fasted", ",", "and", "the", "same", "procedures", "were", "followed", "for", "estimation", "of", "glucose", "tolerance", "30", "min", "after", "glucose", "overload", ".", "Again", ",", "sertraline", "neutralized", "the", "increase", "in", "glycemia", "after", "glucose", "overload", "both", "in", "diabetic", "and", "non", "-", "diabetic", "rats", ".", "These", "data", "raise", "the", "question", "of", "whether", "sertraline", "is", "the", "best", "choice", "for", "prolonged", "use", "for", "diabetic", "individuals", ",", "because", "of", "its", "antihyperglycemic", "effects", ".", "Clonazepam", "would", "be", "useful", "in", "cases", "with", "potential", "risk", "of", "hypoglycemia", "." ]	[ "GROUP", "DRUG" ]
ecstasy is a CHEMICAL	23532375_task0	Sentence: ERP evidence suggests executive dysfunction in ecstasy polydrug users. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O" ]	ERP evidence suggests executive dysfunction in ecstasy polydrug users.	[ "ERP", "evidence", "suggests", "executive", "dysfunction", "in", "ecstasy", "polydrug", "users", "." ]	[ "CHEMICAL" ]
ecstasy is a CHEMICAL	23532375_task1	Sentence: ERP evidence suggests executive dysfunction in ecstasy polydrug users. Instructions: please typing these entity words according to sentence: ecstasy Options: CHEMICAL	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O" ]	ERP evidence suggests executive dysfunction in ecstasy polydrug users.	[ "ERP", "evidence", "suggests", "executive", "dysfunction", "in", "ecstasy", "polydrug", "users", "." ]	[ "CHEMICAL" ]
ecstasy	23532375_task2	Sentence: ERP evidence suggests executive dysfunction in ecstasy polydrug users. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O" ]	ERP evidence suggests executive dysfunction in ecstasy polydrug users.	[ "ERP", "evidence", "suggests", "executive", "dysfunction", "in", "ecstasy", "polydrug", "users", "." ]	[ "CHEMICAL" ]
beta - globin is a Protein, locus is a Entity, beta - globin is a Protein, gene cluster is a Entity, upstream regulatory sequences is a Entity, locus control region is a Entity, the individual genes of the cluster is a Entity, locus control region is a Entity, gene - proximal regulatory elements is a Entity	597_task0	Sentence: Regulation of the beta-globin locus. Transcription of the human beta-globin gene cluster depends upon upstream regulatory sequences, which are collectively termed the locus control region. Recent studies have provided new insights into how the individual genes of the cluster are regulated through development. The crux of transcriptional activation is how the locus control region communicates with the gene-proximal regulatory elements. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O" ]	Regulation of the beta-globin locus. Transcription of the human beta-globin gene cluster depends upon upstream regulatory sequences, which are collectively termed the locus control region. Recent studies have provided new insights into how the individual genes of the cluster are regulated through development. The crux of transcriptional activation is how the locus control region communicates with the gene-proximal regulatory elements.	[ "Regulation", "of", "the", "beta", "-", "globin", "locus", ".", "\n", "Transcription", "of", "the", "human", "beta", "-", "globin", "gene", "cluster", "depends", "upon", "upstream", "regulatory", "sequences", ",", "which", "are", "collectively", "termed", "the", "locus", "control", "region", ".", "Recent", "studies", "have", "provided", "new", "insights", "into", "how", "the", "individual", "genes", "of", "the", "cluster", "are", "regulated", "through", "development", ".", "The", "crux", "of", "transcriptional", "activation", "is", "how", "the", "locus", "control", "region", "communicates", "with", "the", "gene", "-", "proximal", "regulatory", "elements", ".", "\n" ]	[ "Entity", "Protein" ]
beta - globin is a Protein, locus is a Entity, beta - globin is a Protein, gene cluster is a Entity, upstream regulatory sequences is a Entity, locus control region is a Entity, the individual genes of the cluster is a Entity, locus control region is a Entity, gene - proximal regulatory elements is a Entity	597_task1	Sentence: Regulation of the beta-globin locus. Transcription of the human beta-globin gene cluster depends upon upstream regulatory sequences, which are collectively termed the locus control region. Recent studies have provided new insights into how the individual genes of the cluster are regulated through development. The crux of transcriptional activation is how the locus control region communicates with the gene-proximal regulatory elements. Instructions: please typing these entity words according to sentence: beta - globin, locus, beta - globin, gene cluster, upstream regulatory sequences, locus control region, the individual genes of the cluster, locus control region, gene - proximal regulatory elements Options: Entity, Protein	[ "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O" ]	Regulation of the beta-globin locus. Transcription of the human beta-globin gene cluster depends upon upstream regulatory sequences, which are collectively termed the locus control region. Recent studies have provided new insights into how the individual genes of the cluster are regulated through development. The crux of transcriptional activation is how the locus control region communicates with the gene-proximal regulatory elements.	[ "Regulation", "of", "the", "beta", "-", "globin", "locus", ".", "\n", "Transcription", "of", "the", "human", "beta", "-", "globin", "gene", "cluster", "depends", "upon", "upstream", "regulatory", "sequences", ",", "which", "are", "collectively", "termed", "the", "locus", "control", "region", ".", "Recent", "studies", "have", "provided", "new", "insights", "into", "how", "the", "individual", "genes", "of", "the", "cluster", "are", "regulated", "through", "development", ".", "The", "crux", "of", "transcriptional", "activation", "is", "how", "the", "locus", "control", "region", "communicates", "with", "the", "gene", "-", "proximal", "regulatory", "elements", ".", "\n" ]	[ "Entity", "Protein" ]
beta - globin, locus, beta - globin, gene cluster, upstream regulatory sequences, locus control region, the individual genes of the cluster, locus control region, gene - proximal regulatory elements	597_task2	Sentence: Regulation of the beta-globin locus. Transcription of the human beta-globin gene cluster depends upon upstream regulatory sequences, which are collectively termed the locus control region. Recent studies have provided new insights into how the individual genes of the cluster are regulated through development. The crux of transcriptional activation is how the locus control region communicates with the gene-proximal regulatory elements. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O" ]	Regulation of the beta-globin locus. Transcription of the human beta-globin gene cluster depends upon upstream regulatory sequences, which are collectively termed the locus control region. Recent studies have provided new insights into how the individual genes of the cluster are regulated through development. The crux of transcriptional activation is how the locus control region communicates with the gene-proximal regulatory elements.	[ "Regulation", "of", "the", "beta", "-", "globin", "locus", ".", "\n", "Transcription", "of", "the", "human", "beta", "-", "globin", "gene", "cluster", "depends", "upon", "upstream", "regulatory", "sequences", ",", "which", "are", "collectively", "termed", "the", "locus", "control", "region", ".", "Recent", "studies", "have", "provided", "new", "insights", "into", "how", "the", "individual", "genes", "of", "the", "cluster", "are", "regulated", "through", "development", ".", "The", "crux", "of", "transcriptional", "activation", "is", "how", "the", "locus", "control", "region", "communicates", "with", "the", "gene", "-", "proximal", "regulatory", "elements", ".", "\n" ]	[ "Entity", "Protein" ]
integrin alpha5beta1 is a Gene_or_gene_product, A5 - 1 is a Gene_or_gene_product, Integrin alpha5beta1 is a Gene_or_gene_product, A5 - 1 is a Gene_or_gene_product, VILVLF is a Gene_or_gene_product, integrin alpha5beta1 is a Gene_or_gene_product, A5 - 1 is a Gene_or_gene_product, integrin is a Gene_or_gene_product, fibronectin is a Gene_or_gene_product, human umbilical vein endothelial cell is a Cell, tubular network is a Multi-tissue_structure, bFGF is a Gene_or_gene_product, chick is a Organism, chorioallantoic membrane is a Multi-tissue_structure, A5 - 1 is a Gene_or_gene_product	284_task0	Sentence: A novel integrin alpha5beta1 antagonistic peptide, A5-1, screened by Protein Chip system as a potent angiogenesis inhibitor. Integrin alpha5beta1 immobilized on a ProteoChip was used to screen new antagonistic peptides from multiple hexapeptide sub-libraries of the positional scanning synthetic peptide combinatorial library (PS-SPCL). The integrin alpha5beta1-Fibronectin interaction was demonstrated on the chip. A novel peptide ligand, A5-1 (VILVLF), with high affinity to integrin alpha5beta1 was identified from the hexapeptide libraries with this chip-based screening method on the basis of a competitive inhibition assay. A5-1 inhibits the integrin-fibronectin interaction in a dose-dependent manner (IC(50); 1.56+/-0.28 microM. In addition, it inhibits human umbilical vein endothelial cell proliferation, migration, adhesion, tubular network formation, and bFGF-induced neovascularization in a chick chorioallantoic membrane. These results suggest that A5-1 will be a potent inhibitor of neovascularization. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Multi-tissue_structure, Organism, Gene_or_gene_product, Cell	[ "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Organism", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A novel integrin alpha5beta1 antagonistic peptide, A5-1, screened by Protein Chip system as a potent angiogenesis inhibitor. Integrin alpha5beta1 immobilized on a ProteoChip was used to screen new antagonistic peptides from multiple hexapeptide sub-libraries of the positional scanning synthetic peptide combinatorial library (PS-SPCL). The integrin alpha5beta1-Fibronectin interaction was demonstrated on the chip. A novel peptide ligand, A5-1 (VILVLF), with high affinity to integrin alpha5beta1 was identified from the hexapeptide libraries with this chip-based screening method on the basis of a competitive inhibition assay. A5-1 inhibits the integrin-fibronectin interaction in a dose-dependent manner (IC(50); 1.56+/-0.28 microM. In addition, it inhibits human umbilical vein endothelial cell proliferation, migration, adhesion, tubular network formation, and bFGF-induced neovascularization in a chick chorioallantoic membrane. These results suggest that A5-1 will be a potent inhibitor of neovascularization.	[ "A", "novel", "integrin", "alpha5beta1", "antagonistic", "peptide", ",", "A5", "-", "1", ",", "screened", "by", "Protein", "Chip", "system", "as", "a", "potent", "angiogenesis", "inhibitor", ".", "\n", "Integrin", "alpha5beta1", "immobilized", "on", "a", "ProteoChip", "was", "used", "to", "screen", "new", "antagonistic", "peptides", "from", "multiple", "hexapeptide", "sub", "-", "libraries", "of", "the", "positional", "scanning", "synthetic", "peptide", "combinatorial", "library", "(", "PS", "-", "SPCL", ")", ".", "The", "integrin", "alpha5beta1-Fibronectin", "interaction", "was", "demonstrated", "on", "the", "chip", ".", "A", "novel", "peptide", "ligand", ",", "A5", "-", "1", "(", "VILVLF", ")", ",", "with", "high", "affinity", "to", "integrin", "alpha5beta1", "was", "identified", "from", "the", "hexapeptide", "libraries", "with", "this", "chip", "-", "based", "screening", "method", "on", "the", "basis", "of", "a", "competitive", "inhibition", "assay", ".", "A5", "-", "1", "inhibits", "the", "integrin", "-", "fibronectin", "interaction", "in", "a", "dose", "-", "dependent", "manner", "(", "IC(50", ")", ";", "1.56+/-0.28", "microM.", "In", "addition", ",", "it", "inhibits", "human", "umbilical", "vein", "endothelial", "cell", "proliferation", ",", "migration", ",", "adhesion", ",", "tubular", "network", "formation", ",", "and", "bFGF", "-", "induced", "neovascularization", "in", "a", "chick", "chorioallantoic", "membrane", ".", "These", "results", "suggest", "that", "A5", "-", "1", "will", "be", "a", "potent", "inhibitor", "of", "neovascularization", ".", "\n" ]	[ "Cell", "Multi-tissue_structure", "Gene_or_gene_product", "Organism" ]
integrin alpha5beta1 is a Gene_or_gene_product, A5 - 1 is a Gene_or_gene_product, Integrin alpha5beta1 is a Gene_or_gene_product, A5 - 1 is a Gene_or_gene_product, VILVLF is a Gene_or_gene_product, integrin alpha5beta1 is a Gene_or_gene_product, A5 - 1 is a Gene_or_gene_product, integrin is a Gene_or_gene_product, fibronectin is a Gene_or_gene_product, human umbilical vein endothelial cell is a Cell, tubular network is a Multi-tissue_structure, bFGF is a Gene_or_gene_product, chick is a Organism, chorioallantoic membrane is a Multi-tissue_structure, A5 - 1 is a Gene_or_gene_product	284_task1	Sentence: A novel integrin alpha5beta1 antagonistic peptide, A5-1, screened by Protein Chip system as a potent angiogenesis inhibitor. Integrin alpha5beta1 immobilized on a ProteoChip was used to screen new antagonistic peptides from multiple hexapeptide sub-libraries of the positional scanning synthetic peptide combinatorial library (PS-SPCL). The integrin alpha5beta1-Fibronectin interaction was demonstrated on the chip. A novel peptide ligand, A5-1 (VILVLF), with high affinity to integrin alpha5beta1 was identified from the hexapeptide libraries with this chip-based screening method on the basis of a competitive inhibition assay. A5-1 inhibits the integrin-fibronectin interaction in a dose-dependent manner (IC(50); 1.56+/-0.28 microM. In addition, it inhibits human umbilical vein endothelial cell proliferation, migration, adhesion, tubular network formation, and bFGF-induced neovascularization in a chick chorioallantoic membrane. These results suggest that A5-1 will be a potent inhibitor of neovascularization. Instructions: please typing these entity words according to sentence: integrin alpha5beta1, A5 - 1, Integrin alpha5beta1, A5 - 1, VILVLF, integrin alpha5beta1, A5 - 1, integrin, fibronectin, human umbilical vein endothelial cell, tubular network, bFGF, chick, chorioallantoic membrane, A5 - 1 Options: Multi-tissue_structure, Organism, Gene_or_gene_product, Cell	[ "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Organism", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A novel integrin alpha5beta1 antagonistic peptide, A5-1, screened by Protein Chip system as a potent angiogenesis inhibitor. Integrin alpha5beta1 immobilized on a ProteoChip was used to screen new antagonistic peptides from multiple hexapeptide sub-libraries of the positional scanning synthetic peptide combinatorial library (PS-SPCL). The integrin alpha5beta1-Fibronectin interaction was demonstrated on the chip. A novel peptide ligand, A5-1 (VILVLF), with high affinity to integrin alpha5beta1 was identified from the hexapeptide libraries with this chip-based screening method on the basis of a competitive inhibition assay. A5-1 inhibits the integrin-fibronectin interaction in a dose-dependent manner (IC(50); 1.56+/-0.28 microM. In addition, it inhibits human umbilical vein endothelial cell proliferation, migration, adhesion, tubular network formation, and bFGF-induced neovascularization in a chick chorioallantoic membrane. These results suggest that A5-1 will be a potent inhibitor of neovascularization.	[ "A", "novel", "integrin", "alpha5beta1", "antagonistic", "peptide", ",", "A5", "-", "1", ",", "screened", "by", "Protein", "Chip", "system", "as", "a", "potent", "angiogenesis", "inhibitor", ".", "\n", "Integrin", "alpha5beta1", "immobilized", "on", "a", "ProteoChip", "was", "used", "to", "screen", "new", "antagonistic", "peptides", "from", "multiple", "hexapeptide", "sub", "-", "libraries", "of", "the", "positional", "scanning", "synthetic", "peptide", "combinatorial", "library", "(", "PS", "-", "SPCL", ")", ".", "The", "integrin", "alpha5beta1-Fibronectin", "interaction", "was", "demonstrated", "on", "the", "chip", ".", "A", "novel", "peptide", "ligand", ",", "A5", "-", "1", "(", "VILVLF", ")", ",", "with", "high", "affinity", "to", "integrin", "alpha5beta1", "was", "identified", "from", "the", "hexapeptide", "libraries", "with", "this", "chip", "-", "based", "screening", "method", "on", "the", "basis", "of", "a", "competitive", "inhibition", "assay", ".", "A5", "-", "1", "inhibits", "the", "integrin", "-", "fibronectin", "interaction", "in", "a", "dose", "-", "dependent", "manner", "(", "IC(50", ")", ";", "1.56+/-0.28", "microM.", "In", "addition", ",", "it", "inhibits", "human", "umbilical", "vein", "endothelial", "cell", "proliferation", ",", "migration", ",", "adhesion", ",", "tubular", "network", "formation", ",", "and", "bFGF", "-", "induced", "neovascularization", "in", "a", "chick", "chorioallantoic", "membrane", ".", "These", "results", "suggest", "that", "A5", "-", "1", "will", "be", "a", "potent", "inhibitor", "of", "neovascularization", ".", "\n" ]	[ "Cell", "Multi-tissue_structure", "Gene_or_gene_product", "Organism" ]
integrin alpha5beta1, A5 - 1, Integrin alpha5beta1, A5 - 1, VILVLF, integrin alpha5beta1, A5 - 1, integrin, fibronectin, human umbilical vein endothelial cell, tubular network, bFGF, chick, chorioallantoic membrane, A5 - 1	284_task2	Sentence: A novel integrin alpha5beta1 antagonistic peptide, A5-1, screened by Protein Chip system as a potent angiogenesis inhibitor. Integrin alpha5beta1 immobilized on a ProteoChip was used to screen new antagonistic peptides from multiple hexapeptide sub-libraries of the positional scanning synthetic peptide combinatorial library (PS-SPCL). The integrin alpha5beta1-Fibronectin interaction was demonstrated on the chip. A novel peptide ligand, A5-1 (VILVLF), with high affinity to integrin alpha5beta1 was identified from the hexapeptide libraries with this chip-based screening method on the basis of a competitive inhibition assay. A5-1 inhibits the integrin-fibronectin interaction in a dose-dependent manner (IC(50); 1.56+/-0.28 microM. In addition, it inhibits human umbilical vein endothelial cell proliferation, migration, adhesion, tubular network formation, and bFGF-induced neovascularization in a chick chorioallantoic membrane. These results suggest that A5-1 will be a potent inhibitor of neovascularization. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Organism", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A novel integrin alpha5beta1 antagonistic peptide, A5-1, screened by Protein Chip system as a potent angiogenesis inhibitor. Integrin alpha5beta1 immobilized on a ProteoChip was used to screen new antagonistic peptides from multiple hexapeptide sub-libraries of the positional scanning synthetic peptide combinatorial library (PS-SPCL). The integrin alpha5beta1-Fibronectin interaction was demonstrated on the chip. A novel peptide ligand, A5-1 (VILVLF), with high affinity to integrin alpha5beta1 was identified from the hexapeptide libraries with this chip-based screening method on the basis of a competitive inhibition assay. A5-1 inhibits the integrin-fibronectin interaction in a dose-dependent manner (IC(50); 1.56+/-0.28 microM. In addition, it inhibits human umbilical vein endothelial cell proliferation, migration, adhesion, tubular network formation, and bFGF-induced neovascularization in a chick chorioallantoic membrane. These results suggest that A5-1 will be a potent inhibitor of neovascularization.	[ "A", "novel", "integrin", "alpha5beta1", "antagonistic", "peptide", ",", "A5", "-", "1", ",", "screened", "by", "Protein", "Chip", "system", "as", "a", "potent", "angiogenesis", "inhibitor", ".", "\n", "Integrin", "alpha5beta1", "immobilized", "on", "a", "ProteoChip", "was", "used", "to", "screen", "new", "antagonistic", "peptides", "from", "multiple", "hexapeptide", "sub", "-", "libraries", "of", "the", "positional", "scanning", "synthetic", "peptide", "combinatorial", "library", "(", "PS", "-", "SPCL", ")", ".", "The", "integrin", "alpha5beta1-Fibronectin", "interaction", "was", "demonstrated", "on", "the", "chip", ".", "A", "novel", "peptide", "ligand", ",", "A5", "-", "1", "(", "VILVLF", ")", ",", "with", "high", "affinity", "to", "integrin", "alpha5beta1", "was", "identified", "from", "the", "hexapeptide", "libraries", "with", "this", "chip", "-", "based", "screening", "method", "on", "the", "basis", "of", "a", "competitive", "inhibition", "assay", ".", "A5", "-", "1", "inhibits", "the", "integrin", "-", "fibronectin", "interaction", "in", "a", "dose", "-", "dependent", "manner", "(", "IC(50", ")", ";", "1.56+/-0.28", "microM.", "In", "addition", ",", "it", "inhibits", "human", "umbilical", "vein", "endothelial", "cell", "proliferation", ",", "migration", ",", "adhesion", ",", "tubular", "network", "formation", ",", "and", "bFGF", "-", "induced", "neovascularization", "in", "a", "chick", "chorioallantoic", "membrane", ".", "These", "results", "suggest", "that", "A5", "-", "1", "will", "be", "a", "potent", "inhibitor", "of", "neovascularization", ".", "\n" ]	[ "Cell", "Multi-tissue_structure", "Gene_or_gene_product", "Organism" ]
monoamine oxidase type A is a GENE-Y	10027835_task0	Sentence: Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y	[ "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.	[ "Inhibition", "of", "monoamine", "oxidase", "type", "A", ",", "but", "not", "type", "B", ",", "is", "an", "effective", "means", "of", "inducing", "anticonvulsant", "activity", "in", "the", "kindling", "model", "of", "epilepsy", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
monoamine oxidase type A is a GENE-Y	10027835_task1	Sentence: Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. Instructions: please typing these entity words according to sentence: monoamine oxidase type A Options: GENE-Y	[ "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.	[ "Inhibition", "of", "monoamine", "oxidase", "type", "A", ",", "but", "not", "type", "B", ",", "is", "an", "effective", "means", "of", "inducing", "anticonvulsant", "activity", "in", "the", "kindling", "model", "of", "epilepsy", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
monoamine oxidase type A	10027835_task2	Sentence: Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.	[ "Inhibition", "of", "monoamine", "oxidase", "type", "A", ",", "but", "not", "type", "B", ",", "is", "an", "effective", "means", "of", "inducing", "anticonvulsant", "activity", "in", "the", "kindling", "model", "of", "epilepsy", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
Fallberichten is an umlsterm, Therapie is an umlsterm, Harnleiterobstruktion is an umlsterm, Harnleiterschiene is an umlsterm, Harnleiters is an umlsterm, Nierenbeckenkelchsystems is an umlsterm, Technik is an umlsterm, Urinfluss is an umlsterm, Urinpassage is an umlsterm, Harnleiterschienen is an umlsterm, Harnleiterkompression is an umlsterm, Schiene is an umlsterm, Therapiealternative is an umlsterm, Patienten is an umlsterm	DerUrologeA.90380150.ger.abstr_task0	Sentence: Anhand von 5 Fallberichten wird ueber die Therapie der extrinsischen Harnleiterobstruktion durch die Einlage von 2 ipsilateralen inneren Doppel-J-Harnleiterschienen berichtet , nachdem die Einlage einer singulaeren inneren Harnleiterschiene trotz korrekter Lage zu keiner suffizienten Entstauung des Harnleiters und Nierenbeckenkelchsystems gefuehrt hatte . Durch die erhoehte Festigkeit von 2 parallelen inneren Schienen konnten Obstruktion und Kinking vermindert und eine Rueckbildung der Stauung des proximalen Hohlsystems erzielt werden . Ferner ermoeglicht diese Technik neben dem Urinfluss innerhalb der Schienen einen vermehrten Fluss zwischen den Schienen , der als entscheidender Mechanismus der Urinpassage bei liegenden Harnleiterschienen angesehen wird . In Faellen extrinsischer Harnleiterkompression , in denen durch die Einlage einer singulaeren inneren Schiene keine suffiziente Rueckbildung der Ektasie des vorgeschalteten intra- und extrarenalen Hohlraumsystems erreicht werden kann , sollte die simultane Einlage von 2 ipsilateralen inneren Doppel-J-Harnleiterschienen als technisch einfache , komplikationsarme Therapiealternative in Betracht gezogen werden , die einigen Patienten die Einlage eines perkutanen Nephrostomiekatheters oder invasivere Massnahmen ersparen kann . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anhand von 5 Fallberichten wird ueber die Therapie der extrinsischen Harnleiterobstruktion durch die Einlage von 2 ipsilateralen inneren Doppel-J-Harnleiterschienen berichtet , nachdem die Einlage einer singulaeren inneren Harnleiterschiene trotz korrekter Lage zu keiner suffizienten Entstauung des Harnleiters und Nierenbeckenkelchsystems gefuehrt hatte . Durch die erhoehte Festigkeit von 2 parallelen inneren Schienen konnten Obstruktion und Kinking vermindert und eine Rueckbildung der Stauung des proximalen Hohlsystems erzielt werden . Ferner ermoeglicht diese Technik neben dem Urinfluss innerhalb der Schienen einen vermehrten Fluss zwischen den Schienen , der als entscheidender Mechanismus der Urinpassage bei liegenden Harnleiterschienen angesehen wird . In Faellen extrinsischer Harnleiterkompression , in denen durch die Einlage einer singulaeren inneren Schiene keine suffiziente Rueckbildung der Ektasie des vorgeschalteten intra- und extrarenalen Hohlraumsystems erreicht werden kann , sollte die simultane Einlage von 2 ipsilateralen inneren Doppel-J-Harnleiterschienen als technisch einfache , komplikationsarme Therapiealternative in Betracht gezogen werden , die einigen Patienten die Einlage eines perkutanen Nephrostomiekatheters oder invasivere Massnahmen ersparen kann .	[ "Anhand", "von", "5", "Fallberichten", "wird", "ueber", "die", "Therapie", "der", "extrinsischen", "Harnleiterobstruktion", "durch", "die", "Einlage", "von", "2", "ipsilateralen", "inneren", "Doppel", "-", "J", "-", "Harnleiterschienen", "berichtet", ",", "nachdem", "die", "Einlage", "einer", "singulaeren", "inneren", "Harnleiterschiene", "trotz", "korrekter", "Lage", "zu", "keiner", "suffizienten", "Entstauung", "des", "Harnleiters", "und", "Nierenbeckenkelchsystems", "gefuehrt", "hatte", ".", "Durch", "die", "erhoehte", "Festigkeit", "von", "2", "parallelen", "inneren", "Schienen", "konnten", "Obstruktion", "und", "Kinking", "vermindert", "und", "eine", "Rueckbildung", "der", "Stauung", "des", "proximalen", "Hohlsystems", "erzielt", "werden", ".", "Ferner", "ermoeglicht", "diese", "Technik", "neben", "dem", "Urinfluss", "innerhalb", "der", "Schienen", "einen", "vermehrten", "Fluss", "zwischen", "den", "Schienen", ",", "der", "als", "entscheidender", "Mechanismus", "der", "Urinpassage", "bei", "liegenden", "Harnleiterschienen", "angesehen", "wird", ".", "In", "Faellen", "extrinsischer", "Harnleiterkompression", ",", "in", "denen", "durch", "die", "Einlage", "einer", "singulaeren", "inneren", "Schiene", "keine", "suffiziente", "Rueckbildung", "der", "Ektasie", "des", "vorgeschalteten", "intra-", "und", "extrarenalen", "Hohlraumsystems", "erreicht", "werden", "kann", ",", "sollte", "die", "simultane", "Einlage", "von", "2", "ipsilateralen", "inneren", "Doppel", "-", "J", "-", "Harnleiterschienen", "als", "technisch", "einfache", ",", "komplikationsarme", "Therapiealternative", "in", "Betracht", "gezogen", "werden", ",", "die", "einigen", "Patienten", "die", "Einlage", "eines", "perkutanen", "Nephrostomiekatheters", "oder", "invasivere", "Massnahmen", "ersparen", "kann", "." ]	[ "umlsterm" ]
Fallberichten is an umlsterm, Therapie is an umlsterm, Harnleiterobstruktion is an umlsterm, Harnleiterschiene is an umlsterm, Harnleiters is an umlsterm, Nierenbeckenkelchsystems is an umlsterm, Technik is an umlsterm, Urinfluss is an umlsterm, Urinpassage is an umlsterm, Harnleiterschienen is an umlsterm, Harnleiterkompression is an umlsterm, Schiene is an umlsterm, Therapiealternative is an umlsterm, Patienten is an umlsterm	DerUrologeA.90380150.ger.abstr_task1	Sentence: Anhand von 5 Fallberichten wird ueber die Therapie der extrinsischen Harnleiterobstruktion durch die Einlage von 2 ipsilateralen inneren Doppel-J-Harnleiterschienen berichtet , nachdem die Einlage einer singulaeren inneren Harnleiterschiene trotz korrekter Lage zu keiner suffizienten Entstauung des Harnleiters und Nierenbeckenkelchsystems gefuehrt hatte . Durch die erhoehte Festigkeit von 2 parallelen inneren Schienen konnten Obstruktion und Kinking vermindert und eine Rueckbildung der Stauung des proximalen Hohlsystems erzielt werden . Ferner ermoeglicht diese Technik neben dem Urinfluss innerhalb der Schienen einen vermehrten Fluss zwischen den Schienen , der als entscheidender Mechanismus der Urinpassage bei liegenden Harnleiterschienen angesehen wird . In Faellen extrinsischer Harnleiterkompression , in denen durch die Einlage einer singulaeren inneren Schiene keine suffiziente Rueckbildung der Ektasie des vorgeschalteten intra- und extrarenalen Hohlraumsystems erreicht werden kann , sollte die simultane Einlage von 2 ipsilateralen inneren Doppel-J-Harnleiterschienen als technisch einfache , komplikationsarme Therapiealternative in Betracht gezogen werden , die einigen Patienten die Einlage eines perkutanen Nephrostomiekatheters oder invasivere Massnahmen ersparen kann . Instructions: please typing these entity words according to sentence: Fallberichten, Therapie, Harnleiterobstruktion, Harnleiterschiene, Harnleiters, Nierenbeckenkelchsystems, Technik, Urinfluss, Urinpassage, Harnleiterschienen, Harnleiterkompression, Schiene, Therapiealternative, Patienten Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anhand von 5 Fallberichten wird ueber die Therapie der extrinsischen Harnleiterobstruktion durch die Einlage von 2 ipsilateralen inneren Doppel-J-Harnleiterschienen berichtet , nachdem die Einlage einer singulaeren inneren Harnleiterschiene trotz korrekter Lage zu keiner suffizienten Entstauung des Harnleiters und Nierenbeckenkelchsystems gefuehrt hatte . Durch die erhoehte Festigkeit von 2 parallelen inneren Schienen konnten Obstruktion und Kinking vermindert und eine Rueckbildung der Stauung des proximalen Hohlsystems erzielt werden . Ferner ermoeglicht diese Technik neben dem Urinfluss innerhalb der Schienen einen vermehrten Fluss zwischen den Schienen , der als entscheidender Mechanismus der Urinpassage bei liegenden Harnleiterschienen angesehen wird . In Faellen extrinsischer Harnleiterkompression , in denen durch die Einlage einer singulaeren inneren Schiene keine suffiziente Rueckbildung der Ektasie des vorgeschalteten intra- und extrarenalen Hohlraumsystems erreicht werden kann , sollte die simultane Einlage von 2 ipsilateralen inneren Doppel-J-Harnleiterschienen als technisch einfache , komplikationsarme Therapiealternative in Betracht gezogen werden , die einigen Patienten die Einlage eines perkutanen Nephrostomiekatheters oder invasivere Massnahmen ersparen kann .	[ "Anhand", "von", "5", "Fallberichten", "wird", "ueber", "die", "Therapie", "der", "extrinsischen", "Harnleiterobstruktion", "durch", "die", "Einlage", "von", "2", "ipsilateralen", "inneren", "Doppel", "-", "J", "-", "Harnleiterschienen", "berichtet", ",", "nachdem", "die", "Einlage", "einer", "singulaeren", "inneren", "Harnleiterschiene", "trotz", "korrekter", "Lage", "zu", "keiner", "suffizienten", "Entstauung", "des", "Harnleiters", "und", "Nierenbeckenkelchsystems", "gefuehrt", "hatte", ".", "Durch", "die", "erhoehte", "Festigkeit", "von", "2", "parallelen", "inneren", "Schienen", "konnten", "Obstruktion", "und", "Kinking", "vermindert", "und", "eine", "Rueckbildung", "der", "Stauung", "des", "proximalen", "Hohlsystems", "erzielt", "werden", ".", "Ferner", "ermoeglicht", "diese", "Technik", "neben", "dem", "Urinfluss", "innerhalb", "der", "Schienen", "einen", "vermehrten", "Fluss", "zwischen", "den", "Schienen", ",", "der", "als", "entscheidender", "Mechanismus", "der", "Urinpassage", "bei", "liegenden", "Harnleiterschienen", "angesehen", "wird", ".", "In", "Faellen", "extrinsischer", "Harnleiterkompression", ",", "in", "denen", "durch", "die", "Einlage", "einer", "singulaeren", "inneren", "Schiene", "keine", "suffiziente", "Rueckbildung", "der", "Ektasie", "des", "vorgeschalteten", "intra-", "und", "extrarenalen", "Hohlraumsystems", "erreicht", "werden", "kann", ",", "sollte", "die", "simultane", "Einlage", "von", "2", "ipsilateralen", "inneren", "Doppel", "-", "J", "-", "Harnleiterschienen", "als", "technisch", "einfache", ",", "komplikationsarme", "Therapiealternative", "in", "Betracht", "gezogen", "werden", ",", "die", "einigen", "Patienten", "die", "Einlage", "eines", "perkutanen", "Nephrostomiekatheters", "oder", "invasivere", "Massnahmen", "ersparen", "kann", "." ]	[ "umlsterm" ]

beta - catenin is a Gene/protein/RNA, E - cadherin is a Gene/protein/RNA, alpha - catenin is a Individual_protein, beta - catenin is a Individual_protein, E - cadherin is a Individual_protein, E - cadherin is a Individual_protein, catenins is a Individual_protein

82_task1

Sentence: Analyses of beta-catenin or E-cadherin immunoprecipitates from BMMC lysate revealed that alpha-catenin, beta-catenin, and E-cadherin were co-precipitated, suggesting that E-cadherin and catenins form a complex in mast cells. Instructions: please typing these entity words according to sentence: beta - catenin, E - cadherin, alpha - catenin, beta - catenin, E - cadherin, E - cadherin, catenins Options: Gene/protein/RNA, Individual_protein

[ "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O" ]

Analyses of beta-catenin or E-cadherin immunoprecipitates from BMMC lysate revealed that alpha-catenin, beta-catenin, and E-cadherin were co-precipitated, suggesting that E-cadherin and catenins form a complex in mast cells.

[ "Analyses", "of", "beta", "-", "catenin", "or", "E", "-", "cadherin", "immunoprecipitates", "from", "BMMC", "lysate", "revealed", "that", "alpha", "-", "catenin", ",", "beta", "-", "catenin", ",", "and", "E", "-", "cadherin", "were", "co", "-", "precipitated", ",", "suggesting", "that", "E", "-", "cadherin", "and", "catenins", "form", "a", "complex", "in", "mast", "cells", "." ]

[ "Individual_protein", "Gene/protein/RNA" ]

beta - catenin, E - cadherin, alpha - catenin, beta - catenin, E - cadherin, E - cadherin, catenins

82_task2

Sentence: Analyses of beta-catenin or E-cadherin immunoprecipitates from BMMC lysate revealed that alpha-catenin, beta-catenin, and E-cadherin were co-precipitated, suggesting that E-cadherin and catenins form a complex in mast cells. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O" ]

Analyses of beta-catenin or E-cadherin immunoprecipitates from BMMC lysate revealed that alpha-catenin, beta-catenin, and E-cadherin were co-precipitated, suggesting that E-cadherin and catenins form a complex in mast cells.

[ "Analyses", "of", "beta", "-", "catenin", "or", "E", "-", "cadherin", "immunoprecipitates", "from", "BMMC", "lysate", "revealed", "that", "alpha", "-", "catenin", ",", "beta", "-", "catenin", ",", "and", "E", "-", "cadherin", "were", "co", "-", "precipitated", ",", "suggesting", "that", "E", "-", "cadherin", "and", "catenins", "form", "a", "complex", "in", "mast", "cells", "." ]

[ "Individual_protein", "Gene/protein/RNA" ]

Wnt signaling is a process, Brg is a protein, Myc is a protein, Brg is a protein, Myc promoter is a DNA, Wnt signaling is a process

1.0alpha7.train.811_task0

Sentence: A prediction from the hypothesis that Wnt signaling might use Brg to activate Myc is that Brg binds the Myc promoter, a direct target of Wnt signaling (He et al., 1998). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: process, DNA, protein

[ "O", "O", "O", "O", "O", "O", "B-process", "I-process", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "B-DNA", "I-DNA", "O", "O", "O", "O", "O", "B-process", "I-process", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A prediction from the hypothesis that Wnt signaling might use Brg to activate Myc is that Brg binds the Myc promoter, a direct target of Wnt signaling (He et al., 1998).

[ "A", "prediction", "from", "the", "hypothesis", "that", "Wnt", "signaling", "might", "use", "Brg", "to", "activate", "Myc", "is", "that", "Brg", "binds", "the", "Myc", "promoter", ",", "a", "direct", "target", "of", "Wnt", "signaling", "(", "He", "et", "al", ".", ",", "1998", ")", "." ]

[ "process", "DNA", "protein", "protein-family" ]

Wnt signaling is a process, Brg is a protein, Myc is a protein, Brg is a protein, Myc promoter is a DNA, Wnt signaling is a process

1.0alpha7.train.811_task1

Sentence: A prediction from the hypothesis that Wnt signaling might use Brg to activate Myc is that Brg binds the Myc promoter, a direct target of Wnt signaling (He et al., 1998). Instructions: please typing these entity words according to sentence: Wnt signaling, Brg, Myc, Brg, Myc promoter, Wnt signaling Options: process, DNA, protein

[ "O", "O", "O", "O", "O", "O", "B-process", "I-process", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "B-DNA", "I-DNA", "O", "O", "O", "O", "O", "B-process", "I-process", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A prediction from the hypothesis that Wnt signaling might use Brg to activate Myc is that Brg binds the Myc promoter, a direct target of Wnt signaling (He et al., 1998).

[ "A", "prediction", "from", "the", "hypothesis", "that", "Wnt", "signaling", "might", "use", "Brg", "to", "activate", "Myc", "is", "that", "Brg", "binds", "the", "Myc", "promoter", ",", "a", "direct", "target", "of", "Wnt", "signaling", "(", "He", "et", "al", ".", ",", "1998", ")", "." ]

[ "process", "DNA", "protein", "protein-family" ]

Wnt signaling, Brg, Myc, Brg, Myc promoter, Wnt signaling

1.0alpha7.train.811_task2

Sentence: A prediction from the hypothesis that Wnt signaling might use Brg to activate Myc is that Brg binds the Myc promoter, a direct target of Wnt signaling (He et al., 1998). Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-process", "I-process", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "B-DNA", "I-DNA", "O", "O", "O", "O", "O", "B-process", "I-process", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A prediction from the hypothesis that Wnt signaling might use Brg to activate Myc is that Brg binds the Myc promoter, a direct target of Wnt signaling (He et al., 1998).

[ "A", "prediction", "from", "the", "hypothesis", "that", "Wnt", "signaling", "might", "use", "Brg", "to", "activate", "Myc", "is", "that", "Brg", "binds", "the", "Myc", "promoter", ",", "a", "direct", "target", "of", "Wnt", "signaling", "(", "He", "et", "al", ".", ",", "1998", ")", "." ]

[ "process", "DNA", "protein", "protein-family" ]

hypophosphataemic rickets is an umlsterm, familial hypophosphataemias is an umlsterm, diseases is an umlsterm, pathogenesis is an umlsterm, disorder is an umlsterm, care is an umlsterm, patients is an umlsterm, rickets is an umlsterm, hypophosphataemias is an umlsterm, pathophysiology is an umlsterm, diagnosis is an umlsterm, therapeutic is an umlsterm, forms is an umlsterm, hypophosphatemic rickets is an umlsterm

MonatsschriftKinderheilkunde.01480564.eng.abstr_task0

Sentence: Hereditary hypophosphataemic rickets ( familial hypophosphataemias ) form a group of different diseases . Much progress has been made over the last few years in understanding the pathogenesis of the disorder but good medical care of these patients is still a challenge for paediatric nephrologists or endocrinologists . Because X-linked dominant hypophosphataemic ( XLHR ) rickets is the commonest form of inherited hypophosphataemias , it will be described in detail . New aspects of pathophysiology , diagnosis and therapeutic approach will be reviewed . The clinical , biochemical and molecular features of other forms of hypophosphatemic rickets will be described . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]

Hereditary hypophosphataemic rickets ( familial hypophosphataemias ) form a group of different diseases . Much progress has been made over the last few years in understanding the pathogenesis of the disorder but good medical care of these patients is still a challenge for paediatric nephrologists or endocrinologists . Because X-linked dominant hypophosphataemic ( XLHR ) rickets is the commonest form of inherited hypophosphataemias , it will be described in detail . New aspects of pathophysiology , diagnosis and therapeutic approach will be reviewed . The clinical , biochemical and molecular features of other forms of hypophosphatemic rickets will be described .

[ "Hereditary", "hypophosphataemic", "rickets", "(", "familial", "hypophosphataemias", ")", "form", "a", "group", "of", "different", "diseases", ".", "Much", "progress", "has", "been", "made", "over", "the", "last", "few", "years", "in", "understanding", "the", "pathogenesis", "of", "the", "disorder", "but", "good", "medical", "care", "of", "these", "patients", "is", "still", "a", "challenge", "for", "paediatric", "nephrologists", "or", "endocrinologists", ".", "Because", "X", "-", "linked", "dominant", "hypophosphataemic", "(", "XLHR", ")", "rickets", "is", "the", "commonest", "form", "of", "inherited", "hypophosphataemias", ",", "it", "will", "be", "described", "in", "detail", ".", "New", "aspects", "of", "pathophysiology", ",", "diagnosis", "and", "therapeutic", "approach", "will", "be", "reviewed", ".", "The", "clinical", ",", "biochemical", "and", "molecular", "features", "of", "other", "forms", "of", "hypophosphatemic", "rickets", "will", "be", "described", "." ]

[ "umlsterm" ]

hypophosphataemic rickets is an umlsterm, familial hypophosphataemias is an umlsterm, diseases is an umlsterm, pathogenesis is an umlsterm, disorder is an umlsterm, care is an umlsterm, patients is an umlsterm, rickets is an umlsterm, hypophosphataemias is an umlsterm, pathophysiology is an umlsterm, diagnosis is an umlsterm, therapeutic is an umlsterm, forms is an umlsterm, hypophosphatemic rickets is an umlsterm

MonatsschriftKinderheilkunde.01480564.eng.abstr_task1

Sentence: Hereditary hypophosphataemic rickets ( familial hypophosphataemias ) form a group of different diseases . Much progress has been made over the last few years in understanding the pathogenesis of the disorder but good medical care of these patients is still a challenge for paediatric nephrologists or endocrinologists . Because X-linked dominant hypophosphataemic ( XLHR ) rickets is the commonest form of inherited hypophosphataemias , it will be described in detail . New aspects of pathophysiology , diagnosis and therapeutic approach will be reviewed . The clinical , biochemical and molecular features of other forms of hypophosphatemic rickets will be described . Instructions: please typing these entity words according to sentence: hypophosphataemic rickets, familial hypophosphataemias, diseases, pathogenesis, disorder, care, patients, rickets, hypophosphataemias, pathophysiology, diagnosis, therapeutic, forms, hypophosphatemic rickets Options: umlsterm

[ "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]

Hereditary hypophosphataemic rickets ( familial hypophosphataemias ) form a group of different diseases . Much progress has been made over the last few years in understanding the pathogenesis of the disorder but good medical care of these patients is still a challenge for paediatric nephrologists or endocrinologists . Because X-linked dominant hypophosphataemic ( XLHR ) rickets is the commonest form of inherited hypophosphataemias , it will be described in detail . New aspects of pathophysiology , diagnosis and therapeutic approach will be reviewed . The clinical , biochemical and molecular features of other forms of hypophosphatemic rickets will be described .

[ "Hereditary", "hypophosphataemic", "rickets", "(", "familial", "hypophosphataemias", ")", "form", "a", "group", "of", "different", "diseases", ".", "Much", "progress", "has", "been", "made", "over", "the", "last", "few", "years", "in", "understanding", "the", "pathogenesis", "of", "the", "disorder", "but", "good", "medical", "care", "of", "these", "patients", "is", "still", "a", "challenge", "for", "paediatric", "nephrologists", "or", "endocrinologists", ".", "Because", "X", "-", "linked", "dominant", "hypophosphataemic", "(", "XLHR", ")", "rickets", "is", "the", "commonest", "form", "of", "inherited", "hypophosphataemias", ",", "it", "will", "be", "described", "in", "detail", ".", "New", "aspects", "of", "pathophysiology", ",", "diagnosis", "and", "therapeutic", "approach", "will", "be", "reviewed", ".", "The", "clinical", ",", "biochemical", "and", "molecular", "features", "of", "other", "forms", "of", "hypophosphatemic", "rickets", "will", "be", "described", "." ]

[ "umlsterm" ]

hypophosphataemic rickets, familial hypophosphataemias, diseases, pathogenesis, disorder, care, patients, rickets, hypophosphataemias, pathophysiology, diagnosis, therapeutic, forms, hypophosphatemic rickets

MonatsschriftKinderheilkunde.01480564.eng.abstr_task2

Sentence: Hereditary hypophosphataemic rickets ( familial hypophosphataemias ) form a group of different diseases . Much progress has been made over the last few years in understanding the pathogenesis of the disorder but good medical care of these patients is still a challenge for paediatric nephrologists or endocrinologists . Because X-linked dominant hypophosphataemic ( XLHR ) rickets is the commonest form of inherited hypophosphataemias , it will be described in detail . New aspects of pathophysiology , diagnosis and therapeutic approach will be reviewed . The clinical , biochemical and molecular features of other forms of hypophosphatemic rickets will be described . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]

Hereditary hypophosphataemic rickets ( familial hypophosphataemias ) form a group of different diseases . Much progress has been made over the last few years in understanding the pathogenesis of the disorder but good medical care of these patients is still a challenge for paediatric nephrologists or endocrinologists . Because X-linked dominant hypophosphataemic ( XLHR ) rickets is the commonest form of inherited hypophosphataemias , it will be described in detail . New aspects of pathophysiology , diagnosis and therapeutic approach will be reviewed . The clinical , biochemical and molecular features of other forms of hypophosphatemic rickets will be described .

[ "Hereditary", "hypophosphataemic", "rickets", "(", "familial", "hypophosphataemias", ")", "form", "a", "group", "of", "different", "diseases", ".", "Much", "progress", "has", "been", "made", "over", "the", "last", "few", "years", "in", "understanding", "the", "pathogenesis", "of", "the", "disorder", "but", "good", "medical", "care", "of", "these", "patients", "is", "still", "a", "challenge", "for", "paediatric", "nephrologists", "or", "endocrinologists", ".", "Because", "X", "-", "linked", "dominant", "hypophosphataemic", "(", "XLHR", ")", "rickets", "is", "the", "commonest", "form", "of", "inherited", "hypophosphataemias", ",", "it", "will", "be", "described", "in", "detail", ".", "New", "aspects", "of", "pathophysiology", ",", "diagnosis", "and", "therapeutic", "approach", "will", "be", "reviewed", ".", "The", "clinical", ",", "biochemical", "and", "molecular", "features", "of", "other", "forms", "of", "hypophosphatemic", "rickets", "will", "be", "described", "." ]

[ "umlsterm" ]

child is a Person, temperature is a Measurement, > 39.0 ◦ C is a Value, severe is a Qualifier, acute illness is a Condition, as defined by the examining nurse is a Qualifier, child is a Person, mid upper arm circumference is a Measurement, < 110 mm is a Value, is older than 6 months is a Value, child is a Person, severe allergic reaction is a Condition, after previous vaccination , drug or food is a Temporal, RECAMP - MV trial is a Observation, enrolled in RECAMP - OPV is a Observation

NCT03460002_exc_task0

Sentence: the child has temperature > 39.0◦C or a severe acute illness as defined by the examining nurse the child has as a mid upper arm circumference < 110 mm and is older than 6 months (most feasible local indicator of AIDS and chronic immunosuppressive disease) the child has experienced a severe allergic reaction after previous vaccination, drug or food. the child is enrolled in an ongoing study of Bacillus Calmette Guerin vaccine and is < 2 months old For the RECAMP-MV trial: the child is enrolled in RECAMP-OPV Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Value, Person, Observation, Measurement

[ "O", "B-Person", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "B-Person", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Person", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O" ]

the child has temperature > 39.0◦C or a severe acute illness as defined by the examining nurse the child has as a mid upper arm circumference < 110 mm and is older than 6 months (most feasible local indicator of AIDS and chronic immunosuppressive disease) the child has experienced a severe allergic reaction after previous vaccination, drug or food. the child is enrolled in an ongoing study of Bacillus Calmette Guerin vaccine and is < 2 months old For the RECAMP-MV trial: the child is enrolled in RECAMP-OPV

[ "the", "child", "has", "temperature", ">", "39.0", "◦", "C", "or", "a", "severe", "acute", "illness", "as", "defined", "by", "the", "examining", "nurse", "\n", "the", "child", "has", "as", "a", "mid", "upper", "arm", "circumference", "<", "110", "mm", "and", "is", "older", "than", "6", "months", "(", "most", "feasible", "local", "indicator", "of", "AIDS", "and", "chronic", "immunosuppressive", "disease", ")", "\n", "the", "child", "has", "experienced", "a", "severe", "allergic", "reaction", "after", "previous", "vaccination", ",", "drug", "or", "food", ".", "\n", "the", "child", "is", "enrolled", "in", "an", "ongoing", "study", "of", "Bacillus", "Calmette", "Guerin", "vaccine", "and", "is", "<", "2", "months", "old", "\n", "For", "the", "RECAMP", "-", "MV", "trial", ":", "the", "child", "is", "enrolled", "in", "RECAMP", "-", "OPV", "\n" ]

[ "Temporal", "Reference_point", "Qualifier", "Measurement", "Scope", "Condition", "Value", "Observation", "Procedure", "Person" ]

child is a Person, temperature is a Measurement, > 39.0 ◦ C is a Value, severe is a Qualifier, acute illness is a Condition, as defined by the examining nurse is a Qualifier, child is a Person, mid upper arm circumference is a Measurement, < 110 mm is a Value, is older than 6 months is a Value, child is a Person, severe allergic reaction is a Condition, after previous vaccination , drug or food is a Temporal, RECAMP - MV trial is a Observation, enrolled in RECAMP - OPV is a Observation

NCT03460002_exc_task1

Sentence: the child has temperature > 39.0◦C or a severe acute illness as defined by the examining nurse the child has as a mid upper arm circumference < 110 mm and is older than 6 months (most feasible local indicator of AIDS and chronic immunosuppressive disease) the child has experienced a severe allergic reaction after previous vaccination, drug or food. the child is enrolled in an ongoing study of Bacillus Calmette Guerin vaccine and is < 2 months old For the RECAMP-MV trial: the child is enrolled in RECAMP-OPV Instructions: please typing these entity words according to sentence: child, temperature, > 39.0 ◦ C, severe, acute illness, as defined by the examining nurse, child, mid upper arm circumference, < 110 mm, is older than 6 months, child, severe allergic reaction, after previous vaccination , drug or food, RECAMP - MV trial, enrolled in RECAMP - OPV Options: Temporal, Condition, Qualifier, Value, Person, Observation, Measurement

[ "O", "B-Person", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "B-Person", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Person", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O" ]

the child has temperature > 39.0◦C or a severe acute illness as defined by the examining nurse the child has as a mid upper arm circumference < 110 mm and is older than 6 months (most feasible local indicator of AIDS and chronic immunosuppressive disease) the child has experienced a severe allergic reaction after previous vaccination, drug or food. the child is enrolled in an ongoing study of Bacillus Calmette Guerin vaccine and is < 2 months old For the RECAMP-MV trial: the child is enrolled in RECAMP-OPV

[ "the", "child", "has", "temperature", ">", "39.0", "◦", "C", "or", "a", "severe", "acute", "illness", "as", "defined", "by", "the", "examining", "nurse", "\n", "the", "child", "has", "as", "a", "mid", "upper", "arm", "circumference", "<", "110", "mm", "and", "is", "older", "than", "6", "months", "(", "most", "feasible", "local", "indicator", "of", "AIDS", "and", "chronic", "immunosuppressive", "disease", ")", "\n", "the", "child", "has", "experienced", "a", "severe", "allergic", "reaction", "after", "previous", "vaccination", ",", "drug", "or", "food", ".", "\n", "the", "child", "is", "enrolled", "in", "an", "ongoing", "study", "of", "Bacillus", "Calmette", "Guerin", "vaccine", "and", "is", "<", "2", "months", "old", "\n", "For", "the", "RECAMP", "-", "MV", "trial", ":", "the", "child", "is", "enrolled", "in", "RECAMP", "-", "OPV", "\n" ]

[ "Temporal", "Reference_point", "Qualifier", "Measurement", "Scope", "Condition", "Value", "Observation", "Procedure", "Person" ]

child, temperature, > 39.0 ◦ C, severe, acute illness, as defined by the examining nurse, child, mid upper arm circumference, < 110 mm, is older than 6 months, child, severe allergic reaction, after previous vaccination , drug or food, RECAMP - MV trial, enrolled in RECAMP - OPV

NCT03460002_exc_task2

Sentence: the child has temperature > 39.0◦C or a severe acute illness as defined by the examining nurse the child has as a mid upper arm circumference < 110 mm and is older than 6 months (most feasible local indicator of AIDS and chronic immunosuppressive disease) the child has experienced a severe allergic reaction after previous vaccination, drug or food. the child is enrolled in an ongoing study of Bacillus Calmette Guerin vaccine and is < 2 months old For the RECAMP-MV trial: the child is enrolled in RECAMP-OPV Instructions: please extract entity words from the input sentence

[ "O", "B-Person", "O", "B-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "B-Person", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Person", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O" ]

the child has temperature > 39.0◦C or a severe acute illness as defined by the examining nurse the child has as a mid upper arm circumference < 110 mm and is older than 6 months (most feasible local indicator of AIDS and chronic immunosuppressive disease) the child has experienced a severe allergic reaction after previous vaccination, drug or food. the child is enrolled in an ongoing study of Bacillus Calmette Guerin vaccine and is < 2 months old For the RECAMP-MV trial: the child is enrolled in RECAMP-OPV

[ "the", "child", "has", "temperature", ">", "39.0", "◦", "C", "or", "a", "severe", "acute", "illness", "as", "defined", "by", "the", "examining", "nurse", "\n", "the", "child", "has", "as", "a", "mid", "upper", "arm", "circumference", "<", "110", "mm", "and", "is", "older", "than", "6", "months", "(", "most", "feasible", "local", "indicator", "of", "AIDS", "and", "chronic", "immunosuppressive", "disease", ")", "\n", "the", "child", "has", "experienced", "a", "severe", "allergic", "reaction", "after", "previous", "vaccination", ",", "drug", "or", "food", ".", "\n", "the", "child", "is", "enrolled", "in", "an", "ongoing", "study", "of", "Bacillus", "Calmette", "Guerin", "vaccine", "and", "is", "<", "2", "months", "old", "\n", "For", "the", "RECAMP", "-", "MV", "trial", ":", "the", "child", "is", "enrolled", "in", "RECAMP", "-", "OPV", "\n" ]

[ "Temporal", "Reference_point", "Qualifier", "Measurement", "Scope", "Condition", "Value", "Observation", "Procedure", "Person" ]

tumour necrosis factor - alpha is a Protein, tumour necrosis factor - alpha is a Protein, TNF - alpha is a Protein, TNF - alpha is a Protein, IkBalpha is a Protein, TNF - alpha is a Protein, TNF - alpha is a Protein

9224625_task0

Sentence: Role of ascorbate in the activation of NF-kappaB by tumour necrosis factor-alpha in T-cells. The first product of ascorbate oxidation, the ascorbate free radical (AFR), acts in biological systems mainly as an oxidant, and through its role in the plasma membrane redox system exerts different effects on the cell. We have investigated the role of ascorbate, AFR and dehydroascorbate (DHA) in the activation of the NF-kappaB transcription factor in Jurkat T-cells stimulated by tumour necrosis factor-alpha (TNF-alpha). Here we show, by electrophoretic mobility shift assays, that ascorbate increases the binding of NF-kappaB to DNA in TNF-alpha-stimulated Jurkat cells. The ability of ascorbate to enhance cytoplasmic inhibitory IkBalpha protein degradation correlates completely with its capacity to induce NF-kappaB binding to DNA and to potentiate NF-kappaB-mediated transactivation of the HIV-1 long terminal repeat promoter in TNF-alpha-stimulated Jurkat cells but not in cells stimulated with PMA plus ionomycin. AFR behaves like ascorbate, while DHA and ascorbate phosphate do not affect TNF-alpha-mediated NF-kappaB activation. These results provide new evidence for a possible relationship between the activation of the electron-transport system at the plasma membrane by ascorbate or its free radical and redox-dependent gene transcription in T-cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Role of ascorbate in the activation of NF-kappaB by tumour necrosis factor-alpha in T-cells. The first product of ascorbate oxidation, the ascorbate free radical (AFR), acts in biological systems mainly as an oxidant, and through its role in the plasma membrane redox system exerts different effects on the cell. We have investigated the role of ascorbate, AFR and dehydroascorbate (DHA) in the activation of the NF-kappaB transcription factor in Jurkat T-cells stimulated by tumour necrosis factor-alpha (TNF-alpha). Here we show, by electrophoretic mobility shift assays, that ascorbate increases the binding of NF-kappaB to DNA in TNF-alpha-stimulated Jurkat cells. The ability of ascorbate to enhance cytoplasmic inhibitory IkBalpha protein degradation correlates completely with its capacity to induce NF-kappaB binding to DNA and to potentiate NF-kappaB-mediated transactivation of the HIV-1 long terminal repeat promoter in TNF-alpha-stimulated Jurkat cells but not in cells stimulated with PMA plus ionomycin. AFR behaves like ascorbate, while DHA and ascorbate phosphate do not affect TNF-alpha-mediated NF-kappaB activation. These results provide new evidence for a possible relationship between the activation of the electron-transport system at the plasma membrane by ascorbate or its free radical and redox-dependent gene transcription in T-cells.

[ "Role", "of", "ascorbate", "in", "the", "activation", "of", "NF", "-", "kappaB", "by", "tumour", "necrosis", "factor", "-", "alpha", "in", "T", "-", "cells", ".", "\n", "The", "first", "product", "of", "ascorbate", "oxidation", ",", "the", "ascorbate", "free", "radical", "(", "AFR", ")", ",", "acts", "in", "biological", "systems", "mainly", "as", "an", "oxidant", ",", "and", "through", "its", "role", "in", "the", "plasma", "membrane", "redox", "system", "exerts", "different", "effects", "on", "the", "cell", ".", "We", "have", "investigated", "the", "role", "of", "ascorbate", ",", "AFR", "and", "dehydroascorbate", "(", "DHA", ")", "in", "the", "activation", "of", "the", "NF", "-", "kappaB", "transcription", "factor", "in", "Jurkat", "T", "-", "cells", "stimulated", "by", "tumour", "necrosis", "factor", "-", "alpha", "(", "TNF", "-", "alpha", ")", ".", "Here", "we", "show", ",", "by", "electrophoretic", "mobility", "shift", "assays", ",", "that", "ascorbate", "increases", "the", "binding", "of", "NF", "-", "kappaB", "to", "DNA", "in", "TNF", "-", "alpha", "-", "stimulated", "Jurkat", "cells", ".", "The", "ability", "of", "ascorbate", "to", "enhance", "cytoplasmic", "inhibitory", "IkBalpha", "protein", "degradation", "correlates", "completely", "with", "its", "capacity", "to", "induce", "NF", "-", "kappaB", "binding", "to", "DNA", "and", "to", "potentiate", "NF", "-", "kappaB", "-", "mediated", "transactivation", "of", "the", "HIV-1", "long", "terminal", "repeat", "promoter", "in", "TNF", "-", "alpha", "-", "stimulated", "Jurkat", "cells", "but", "not", "in", "cells", "stimulated", "with", "PMA", "plus", "ionomycin", ".", "AFR", "behaves", "like", "ascorbate", ",", "while", "DHA", "and", "ascorbate", "phosphate", "do", "not", "affect", "TNF", "-", "alpha", "-", "mediated", "NF", "-", "kappaB", "activation", ".", "These", "results", "provide", "new", "evidence", "for", "a", "possible", "relationship", "between", "the", "activation", "of", "the", "electron", "-", "transport", "system", "at", "the", "plasma", "membrane", "by", "ascorbate", "or", "its", "free", "radical", "and", "redox", "-", "dependent", "gene", "transcription", "in", "T", "-", "cells", "." ]

[ "Protein" ]

tumour necrosis factor - alpha is a Protein, tumour necrosis factor - alpha is a Protein, TNF - alpha is a Protein, TNF - alpha is a Protein, IkBalpha is a Protein, TNF - alpha is a Protein, TNF - alpha is a Protein

9224625_task1

Sentence: Role of ascorbate in the activation of NF-kappaB by tumour necrosis factor-alpha in T-cells. The first product of ascorbate oxidation, the ascorbate free radical (AFR), acts in biological systems mainly as an oxidant, and through its role in the plasma membrane redox system exerts different effects on the cell. We have investigated the role of ascorbate, AFR and dehydroascorbate (DHA) in the activation of the NF-kappaB transcription factor in Jurkat T-cells stimulated by tumour necrosis factor-alpha (TNF-alpha). Here we show, by electrophoretic mobility shift assays, that ascorbate increases the binding of NF-kappaB to DNA in TNF-alpha-stimulated Jurkat cells. The ability of ascorbate to enhance cytoplasmic inhibitory IkBalpha protein degradation correlates completely with its capacity to induce NF-kappaB binding to DNA and to potentiate NF-kappaB-mediated transactivation of the HIV-1 long terminal repeat promoter in TNF-alpha-stimulated Jurkat cells but not in cells stimulated with PMA plus ionomycin. AFR behaves like ascorbate, while DHA and ascorbate phosphate do not affect TNF-alpha-mediated NF-kappaB activation. These results provide new evidence for a possible relationship between the activation of the electron-transport system at the plasma membrane by ascorbate or its free radical and redox-dependent gene transcription in T-cells. Instructions: please typing these entity words according to sentence: tumour necrosis factor - alpha, tumour necrosis factor - alpha, TNF - alpha, TNF - alpha, IkBalpha, TNF - alpha, TNF - alpha Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Role of ascorbate in the activation of NF-kappaB by tumour necrosis factor-alpha in T-cells. The first product of ascorbate oxidation, the ascorbate free radical (AFR), acts in biological systems mainly as an oxidant, and through its role in the plasma membrane redox system exerts different effects on the cell. We have investigated the role of ascorbate, AFR and dehydroascorbate (DHA) in the activation of the NF-kappaB transcription factor in Jurkat T-cells stimulated by tumour necrosis factor-alpha (TNF-alpha). Here we show, by electrophoretic mobility shift assays, that ascorbate increases the binding of NF-kappaB to DNA in TNF-alpha-stimulated Jurkat cells. The ability of ascorbate to enhance cytoplasmic inhibitory IkBalpha protein degradation correlates completely with its capacity to induce NF-kappaB binding to DNA and to potentiate NF-kappaB-mediated transactivation of the HIV-1 long terminal repeat promoter in TNF-alpha-stimulated Jurkat cells but not in cells stimulated with PMA plus ionomycin. AFR behaves like ascorbate, while DHA and ascorbate phosphate do not affect TNF-alpha-mediated NF-kappaB activation. These results provide new evidence for a possible relationship between the activation of the electron-transport system at the plasma membrane by ascorbate or its free radical and redox-dependent gene transcription in T-cells.

[ "Role", "of", "ascorbate", "in", "the", "activation", "of", "NF", "-", "kappaB", "by", "tumour", "necrosis", "factor", "-", "alpha", "in", "T", "-", "cells", ".", "\n", "The", "first", "product", "of", "ascorbate", "oxidation", ",", "the", "ascorbate", "free", "radical", "(", "AFR", ")", ",", "acts", "in", "biological", "systems", "mainly", "as", "an", "oxidant", ",", "and", "through", "its", "role", "in", "the", "plasma", "membrane", "redox", "system", "exerts", "different", "effects", "on", "the", "cell", ".", "We", "have", "investigated", "the", "role", "of", "ascorbate", ",", "AFR", "and", "dehydroascorbate", "(", "DHA", ")", "in", "the", "activation", "of", "the", "NF", "-", "kappaB", "transcription", "factor", "in", "Jurkat", "T", "-", "cells", "stimulated", "by", "tumour", "necrosis", "factor", "-", "alpha", "(", "TNF", "-", "alpha", ")", ".", "Here", "we", "show", ",", "by", "electrophoretic", "mobility", "shift", "assays", ",", "that", "ascorbate", "increases", "the", "binding", "of", "NF", "-", "kappaB", "to", "DNA", "in", "TNF", "-", "alpha", "-", "stimulated", "Jurkat", "cells", ".", "The", "ability", "of", "ascorbate", "to", "enhance", "cytoplasmic", "inhibitory", "IkBalpha", "protein", "degradation", "correlates", "completely", "with", "its", "capacity", "to", "induce", "NF", "-", "kappaB", "binding", "to", "DNA", "and", "to", "potentiate", "NF", "-", "kappaB", "-", "mediated", "transactivation", "of", "the", "HIV-1", "long", "terminal", "repeat", "promoter", "in", "TNF", "-", "alpha", "-", "stimulated", "Jurkat", "cells", "but", "not", "in", "cells", "stimulated", "with", "PMA", "plus", "ionomycin", ".", "AFR", "behaves", "like", "ascorbate", ",", "while", "DHA", "and", "ascorbate", "phosphate", "do", "not", "affect", "TNF", "-", "alpha", "-", "mediated", "NF", "-", "kappaB", "activation", ".", "These", "results", "provide", "new", "evidence", "for", "a", "possible", "relationship", "between", "the", "activation", "of", "the", "electron", "-", "transport", "system", "at", "the", "plasma", "membrane", "by", "ascorbate", "or", "its", "free", "radical", "and", "redox", "-", "dependent", "gene", "transcription", "in", "T", "-", "cells", "." ]

[ "Protein" ]

tumour necrosis factor - alpha, tumour necrosis factor - alpha, TNF - alpha, TNF - alpha, IkBalpha, TNF - alpha, TNF - alpha

9224625_task2

Sentence: Role of ascorbate in the activation of NF-kappaB by tumour necrosis factor-alpha in T-cells. The first product of ascorbate oxidation, the ascorbate free radical (AFR), acts in biological systems mainly as an oxidant, and through its role in the plasma membrane redox system exerts different effects on the cell. We have investigated the role of ascorbate, AFR and dehydroascorbate (DHA) in the activation of the NF-kappaB transcription factor in Jurkat T-cells stimulated by tumour necrosis factor-alpha (TNF-alpha). Here we show, by electrophoretic mobility shift assays, that ascorbate increases the binding of NF-kappaB to DNA in TNF-alpha-stimulated Jurkat cells. The ability of ascorbate to enhance cytoplasmic inhibitory IkBalpha protein degradation correlates completely with its capacity to induce NF-kappaB binding to DNA and to potentiate NF-kappaB-mediated transactivation of the HIV-1 long terminal repeat promoter in TNF-alpha-stimulated Jurkat cells but not in cells stimulated with PMA plus ionomycin. AFR behaves like ascorbate, while DHA and ascorbate phosphate do not affect TNF-alpha-mediated NF-kappaB activation. These results provide new evidence for a possible relationship between the activation of the electron-transport system at the plasma membrane by ascorbate or its free radical and redox-dependent gene transcription in T-cells. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Role of ascorbate in the activation of NF-kappaB by tumour necrosis factor-alpha in T-cells. The first product of ascorbate oxidation, the ascorbate free radical (AFR), acts in biological systems mainly as an oxidant, and through its role in the plasma membrane redox system exerts different effects on the cell. We have investigated the role of ascorbate, AFR and dehydroascorbate (DHA) in the activation of the NF-kappaB transcription factor in Jurkat T-cells stimulated by tumour necrosis factor-alpha (TNF-alpha). Here we show, by electrophoretic mobility shift assays, that ascorbate increases the binding of NF-kappaB to DNA in TNF-alpha-stimulated Jurkat cells. The ability of ascorbate to enhance cytoplasmic inhibitory IkBalpha protein degradation correlates completely with its capacity to induce NF-kappaB binding to DNA and to potentiate NF-kappaB-mediated transactivation of the HIV-1 long terminal repeat promoter in TNF-alpha-stimulated Jurkat cells but not in cells stimulated with PMA plus ionomycin. AFR behaves like ascorbate, while DHA and ascorbate phosphate do not affect TNF-alpha-mediated NF-kappaB activation. These results provide new evidence for a possible relationship between the activation of the electron-transport system at the plasma membrane by ascorbate or its free radical and redox-dependent gene transcription in T-cells.

[ "Role", "of", "ascorbate", "in", "the", "activation", "of", "NF", "-", "kappaB", "by", "tumour", "necrosis", "factor", "-", "alpha", "in", "T", "-", "cells", ".", "\n", "The", "first", "product", "of", "ascorbate", "oxidation", ",", "the", "ascorbate", "free", "radical", "(", "AFR", ")", ",", "acts", "in", "biological", "systems", "mainly", "as", "an", "oxidant", ",", "and", "through", "its", "role", "in", "the", "plasma", "membrane", "redox", "system", "exerts", "different", "effects", "on", "the", "cell", ".", "We", "have", "investigated", "the", "role", "of", "ascorbate", ",", "AFR", "and", "dehydroascorbate", "(", "DHA", ")", "in", "the", "activation", "of", "the", "NF", "-", "kappaB", "transcription", "factor", "in", "Jurkat", "T", "-", "cells", "stimulated", "by", "tumour", "necrosis", "factor", "-", "alpha", "(", "TNF", "-", "alpha", ")", ".", "Here", "we", "show", ",", "by", "electrophoretic", "mobility", "shift", "assays", ",", "that", "ascorbate", "increases", "the", "binding", "of", "NF", "-", "kappaB", "to", "DNA", "in", "TNF", "-", "alpha", "-", "stimulated", "Jurkat", "cells", ".", "The", "ability", "of", "ascorbate", "to", "enhance", "cytoplasmic", "inhibitory", "IkBalpha", "protein", "degradation", "correlates", "completely", "with", "its", "capacity", "to", "induce", "NF", "-", "kappaB", "binding", "to", "DNA", "and", "to", "potentiate", "NF", "-", "kappaB", "-", "mediated", "transactivation", "of", "the", "HIV-1", "long", "terminal", "repeat", "promoter", "in", "TNF", "-", "alpha", "-", "stimulated", "Jurkat", "cells", "but", "not", "in", "cells", "stimulated", "with", "PMA", "plus", "ionomycin", ".", "AFR", "behaves", "like", "ascorbate", ",", "while", "DHA", "and", "ascorbate", "phosphate", "do", "not", "affect", "TNF", "-", "alpha", "-", "mediated", "NF", "-", "kappaB", "activation", ".", "These", "results", "provide", "new", "evidence", "for", "a", "possible", "relationship", "between", "the", "activation", "of", "the", "electron", "-", "transport", "system", "at", "the", "plasma", "membrane", "by", "ascorbate", "or", "its", "free", "radical", "and", "redox", "-", "dependent", "gene", "transcription", "in", "T", "-", "cells", "." ]

[ "Protein" ]

between 18 and 40 years is a Value, age is a Person, self - reported visual exam is a Procedure, in the last two years is a Temporal, Avaira sphere contact lens is a Device, at least 1 week in Avaira sphere is a Temporal, contact lens is a Device, spherical is a Qualifier, + 2.25 to - 8.00 ( inclusive ) is a Value, spectacle cylinder is a Device, up to 0.75D is a Value, best corrected spectacle distance visual acuity is a Measurement, 20/25 is a Value, 0.10 logMAR is a Value, distance visual acuity is a Measurement, 20/30 is a Value, 0.18 logMAR is a Value, study contact lenses is a Device, clear corneas is a Condition, no is a Negation, active is a Temporal, ocular disease is a Condition

NCT02406495_inc_task0

Sentence: Is between 18 and 40 years of age (inclusive) Has had a self-reported visual exam in the last two years Is an adapted Avaira sphere contact lens wearer (at least 1 week in Avaira sphere) Has a contact lens spherical prescription between + 2.25 to - 8.00 (inclusive) Has a spectacle cylinder up to 0.75D in each eye. Can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logMAR) or better in each eye. Can achieve a distance visual acuity of 20/30 (0.18 logMAR) or better in each eye with the study contact lenses. Has clear corneas and no active ocular disease Has read, understood and signed the information consent letter. Patient contact lens refraction should fit within the available parameters of the study lenses. Is willing to comply with the wear schedule (at least 5 days per week, > 8 hours/day assuming there are no contraindications for doing so). Is willing to comply with the visit schedule Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Measurement, Condition, Qualifier, Value, Person, Procedure, Negation, Device

[ "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Person", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Device", "I-Device", "I-Device", "I-Device", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Device", "I-Device", "B-Qualifier", "O", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "B-Device", "I-Device", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "O", "B-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "O", "B-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "B-Device", "I-Device", "I-Device", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Negation", "B-Temporal", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Is between 18 and 40 years of age (inclusive) Has had a self-reported visual exam in the last two years Is an adapted Avaira sphere contact lens wearer (at least 1 week in Avaira sphere) Has a contact lens spherical prescription between + 2.25 to - 8.00 (inclusive) Has a spectacle cylinder up to 0.75D in each eye. Can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logMAR) or better in each eye. Can achieve a distance visual acuity of 20/30 (0.18 logMAR) or better in each eye with the study contact lenses. Has clear corneas and no active ocular disease Has read, understood and signed the information consent letter. Patient contact lens refraction should fit within the available parameters of the study lenses. Is willing to comply with the wear schedule (at least 5 days per week, > 8 hours/day assuming there are no contraindications for doing so). Is willing to comply with the visit schedule

[ "Is", "between", "18", "and", "40", "years", "of", "age", "(", "inclusive", ")", "\n", "Has", "had", "a", "self", "-", "reported", "visual", "exam", "in", "the", "last", "two", "years", "\n", "Is", "an", "adapted", "Avaira", "sphere", "contact", "lens", "wearer", "(", "at", "least", "1", "week", "in", "Avaira", "sphere", ")", "\n", "Has", "a", "contact", "lens", "spherical", "prescription", "between", "+", "2.25", "to", "-", "8.00", "(", "inclusive", ")", "\n", "Has", "a", "spectacle", "cylinder", "up", "to", "0.75D", "in", "each", "eye", ".", "\n", "Can", "achieve", "best", "corrected", "spectacle", "distance", "visual", "acuity", "of", "20/25", "(", "0.10", "logMAR", ")", "or", "better", "in", "each", "eye", ".", "\n", "Can", "achieve", "a", "distance", "visual", "acuity", "of", "20/30", "(", "0.18", "logMAR", ")", "or", "better", "in", "each", "eye", "with", "the", "study", "contact", "lenses", ".", "\n", "Has", "clear", "corneas", "and", "no", "active", "ocular", "disease", "\n", "Has", "read", ",", "understood", "and", "signed", "the", "information", "consent", "letter", ".", "\n", "Patient", "contact", "lens", "refraction", "should", "fit", "within", "the", "available", "parameters", "of", "the", "study", "lenses", ".", "\n", "Is", "willing", "to", "comply", "with", "the", "wear", "schedule", "(", "at", "least", "5", "days", "per", "week", ",", ">", "8", "hours", "/", "day", "assuming", "there", "are", "no", "contraindications", "for", "doing", "so", ")", ".", "\n", "Is", "willing", "to", "comply", "with", "the", "visit", "schedule", "\n" ]

[ "Measurement", "Temporal", "Value", "Device", "Procedure", "Condition", "Reference_point", "Qualifier", "Person", "Negation" ]

between 18 and 40 years is a Value, age is a Person, self - reported visual exam is a Procedure, in the last two years is a Temporal, Avaira sphere contact lens is a Device, at least 1 week in Avaira sphere is a Temporal, contact lens is a Device, spherical is a Qualifier, + 2.25 to - 8.00 ( inclusive ) is a Value, spectacle cylinder is a Device, up to 0.75D is a Value, best corrected spectacle distance visual acuity is a Measurement, 20/25 is a Value, 0.10 logMAR is a Value, distance visual acuity is a Measurement, 20/30 is a Value, 0.18 logMAR is a Value, study contact lenses is a Device, clear corneas is a Condition, no is a Negation, active is a Temporal, ocular disease is a Condition

NCT02406495_inc_task1

Sentence: Is between 18 and 40 years of age (inclusive) Has had a self-reported visual exam in the last two years Is an adapted Avaira sphere contact lens wearer (at least 1 week in Avaira sphere) Has a contact lens spherical prescription between + 2.25 to - 8.00 (inclusive) Has a spectacle cylinder up to 0.75D in each eye. Can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logMAR) or better in each eye. Can achieve a distance visual acuity of 20/30 (0.18 logMAR) or better in each eye with the study contact lenses. Has clear corneas and no active ocular disease Has read, understood and signed the information consent letter. Patient contact lens refraction should fit within the available parameters of the study lenses. Is willing to comply with the wear schedule (at least 5 days per week, > 8 hours/day assuming there are no contraindications for doing so). Is willing to comply with the visit schedule Instructions: please typing these entity words according to sentence: between 18 and 40 years, age, self - reported visual exam, in the last two years, Avaira sphere contact lens, at least 1 week in Avaira sphere, contact lens, spherical, + 2.25 to - 8.00 ( inclusive ), spectacle cylinder, up to 0.75D, best corrected spectacle distance visual acuity, 20/25, 0.10 logMAR, distance visual acuity, 20/30, 0.18 logMAR, study contact lenses, clear corneas, no, active, ocular disease Options: Temporal, Measurement, Condition, Qualifier, Value, Person, Procedure, Negation, Device

[ "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Person", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Device", "I-Device", "I-Device", "I-Device", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Device", "I-Device", "B-Qualifier", "O", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "B-Device", "I-Device", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "O", "B-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "O", "B-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "B-Device", "I-Device", "I-Device", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Negation", "B-Temporal", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Is between 18 and 40 years of age (inclusive) Has had a self-reported visual exam in the last two years Is an adapted Avaira sphere contact lens wearer (at least 1 week in Avaira sphere) Has a contact lens spherical prescription between + 2.25 to - 8.00 (inclusive) Has a spectacle cylinder up to 0.75D in each eye. Can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logMAR) or better in each eye. Can achieve a distance visual acuity of 20/30 (0.18 logMAR) or better in each eye with the study contact lenses. Has clear corneas and no active ocular disease Has read, understood and signed the information consent letter. Patient contact lens refraction should fit within the available parameters of the study lenses. Is willing to comply with the wear schedule (at least 5 days per week, > 8 hours/day assuming there are no contraindications for doing so). Is willing to comply with the visit schedule

[ "Is", "between", "18", "and", "40", "years", "of", "age", "(", "inclusive", ")", "\n", "Has", "had", "a", "self", "-", "reported", "visual", "exam", "in", "the", "last", "two", "years", "\n", "Is", "an", "adapted", "Avaira", "sphere", "contact", "lens", "wearer", "(", "at", "least", "1", "week", "in", "Avaira", "sphere", ")", "\n", "Has", "a", "contact", "lens", "spherical", "prescription", "between", "+", "2.25", "to", "-", "8.00", "(", "inclusive", ")", "\n", "Has", "a", "spectacle", "cylinder", "up", "to", "0.75D", "in", "each", "eye", ".", "\n", "Can", "achieve", "best", "corrected", "spectacle", "distance", "visual", "acuity", "of", "20/25", "(", "0.10", "logMAR", ")", "or", "better", "in", "each", "eye", ".", "\n", "Can", "achieve", "a", "distance", "visual", "acuity", "of", "20/30", "(", "0.18", "logMAR", ")", "or", "better", "in", "each", "eye", "with", "the", "study", "contact", "lenses", ".", "\n", "Has", "clear", "corneas", "and", "no", "active", "ocular", "disease", "\n", "Has", "read", ",", "understood", "and", "signed", "the", "information", "consent", "letter", ".", "\n", "Patient", "contact", "lens", "refraction", "should", "fit", "within", "the", "available", "parameters", "of", "the", "study", "lenses", ".", "\n", "Is", "willing", "to", "comply", "with", "the", "wear", "schedule", "(", "at", "least", "5", "days", "per", "week", ",", ">", "8", "hours", "/", "day", "assuming", "there", "are", "no", "contraindications", "for", "doing", "so", ")", ".", "\n", "Is", "willing", "to", "comply", "with", "the", "visit", "schedule", "\n" ]

[ "Measurement", "Temporal", "Value", "Device", "Procedure", "Condition", "Reference_point", "Qualifier", "Person", "Negation" ]

between 18 and 40 years, age, self - reported visual exam, in the last two years, Avaira sphere contact lens, at least 1 week in Avaira sphere, contact lens, spherical, + 2.25 to - 8.00 ( inclusive ), spectacle cylinder, up to 0.75D, best corrected spectacle distance visual acuity, 20/25, 0.10 logMAR, distance visual acuity, 20/30, 0.18 logMAR, study contact lenses, clear corneas, no, active, ocular disease

NCT02406495_inc_task2

Sentence: Is between 18 and 40 years of age (inclusive) Has had a self-reported visual exam in the last two years Is an adapted Avaira sphere contact lens wearer (at least 1 week in Avaira sphere) Has a contact lens spherical prescription between + 2.25 to - 8.00 (inclusive) Has a spectacle cylinder up to 0.75D in each eye. Can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logMAR) or better in each eye. Can achieve a distance visual acuity of 20/30 (0.18 logMAR) or better in each eye with the study contact lenses. Has clear corneas and no active ocular disease Has read, understood and signed the information consent letter. Patient contact lens refraction should fit within the available parameters of the study lenses. Is willing to comply with the wear schedule (at least 5 days per week, > 8 hours/day assuming there are no contraindications for doing so). Is willing to comply with the visit schedule Instructions: please extract entity words from the input sentence

[ "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Person", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Device", "I-Device", "I-Device", "I-Device", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "B-Device", "I-Device", "B-Qualifier", "O", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "B-Device", "I-Device", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "O", "B-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "O", "B-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "B-Device", "I-Device", "I-Device", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Negation", "B-Temporal", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Is between 18 and 40 years of age (inclusive) Has had a self-reported visual exam in the last two years Is an adapted Avaira sphere contact lens wearer (at least 1 week in Avaira sphere) Has a contact lens spherical prescription between + 2.25 to - 8.00 (inclusive) Has a spectacle cylinder up to 0.75D in each eye. Can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logMAR) or better in each eye. Can achieve a distance visual acuity of 20/30 (0.18 logMAR) or better in each eye with the study contact lenses. Has clear corneas and no active ocular disease Has read, understood and signed the information consent letter. Patient contact lens refraction should fit within the available parameters of the study lenses. Is willing to comply with the wear schedule (at least 5 days per week, > 8 hours/day assuming there are no contraindications for doing so). Is willing to comply with the visit schedule

[ "Is", "between", "18", "and", "40", "years", "of", "age", "(", "inclusive", ")", "\n", "Has", "had", "a", "self", "-", "reported", "visual", "exam", "in", "the", "last", "two", "years", "\n", "Is", "an", "adapted", "Avaira", "sphere", "contact", "lens", "wearer", "(", "at", "least", "1", "week", "in", "Avaira", "sphere", ")", "\n", "Has", "a", "contact", "lens", "spherical", "prescription", "between", "+", "2.25", "to", "-", "8.00", "(", "inclusive", ")", "\n", "Has", "a", "spectacle", "cylinder", "up", "to", "0.75D", "in", "each", "eye", ".", "\n", "Can", "achieve", "best", "corrected", "spectacle", "distance", "visual", "acuity", "of", "20/25", "(", "0.10", "logMAR", ")", "or", "better", "in", "each", "eye", ".", "\n", "Can", "achieve", "a", "distance", "visual", "acuity", "of", "20/30", "(", "0.18", "logMAR", ")", "or", "better", "in", "each", "eye", "with", "the", "study", "contact", "lenses", ".", "\n", "Has", "clear", "corneas", "and", "no", "active", "ocular", "disease", "\n", "Has", "read", ",", "understood", "and", "signed", "the", "information", "consent", "letter", ".", "\n", "Patient", "contact", "lens", "refraction", "should", "fit", "within", "the", "available", "parameters", "of", "the", "study", "lenses", ".", "\n", "Is", "willing", "to", "comply", "with", "the", "wear", "schedule", "(", "at", "least", "5", "days", "per", "week", ",", ">", "8", "hours", "/", "day", "assuming", "there", "are", "no", "contraindications", "for", "doing", "so", ")", ".", "\n", "Is", "willing", "to", "comply", "with", "the", "visit", "schedule", "\n" ]

[ "Measurement", "Temporal", "Value", "Device", "Procedure", "Condition", "Reference_point", "Qualifier", "Person", "Negation" ]

pulmonale Hypertonie is an umlsterm, Aetiologie is an umlsterm, Beurteilung is an umlsterm, thoraxchirurgische is an umlsterm, Arbeit is an umlsterm, tierexperimentelle is an umlsterm, Biopsietechnik is an umlsterm, Biopsie is an umlsterm, pulmonaler Hypertonie is an umlsterm, Versuchstiere is an umlsterm, Patienten is an umlsterm, Bronchialkarzinom is an umlsterm, Biopsietechnik is an umlsterm, Beurteilung is an umlsterm, Pulmonalarterienwand is an umlsterm, Lungenparenchym is an umlsterm, Komplikationen is an umlsterm, Biopsietechnik is an umlsterm

ZfuerKardiologie.70860622.ger.abstr_task0

Sentence: Die pulmonale Hypertonie stellt eine schwerwiegende therapeutisch schlecht beherrschbare Erkrankung unterschiedlicher Aetiologie dar . Obwohl haemodynamische Parameter weitgehend mit morphologischen Befunden korrelieren , besteht aus differentialdiagnostischer Sicht haeufig die Notwendigkeit zur histologischen Beurteilung . Eine adaequate Materialgewinnung ist aufgrund der hohen Blutungsbereitschaft in der Regel nur ueber thoraxchirurgische Verfahren moeglich . In der vorliegenden Arbeit werden tierexperimentelle und erste klinische Daten einer neuen Biopsietechnik ( perkutane transvasale Biopsie , PTB ) , zur Gewinnung von Gefaesswandproben bei pulmonaler Hypertonie vorgestellt . Bei einem Teil der Versuchstiere wurde der pulmonale Hochdruck experimentell erzeugt . Die klinischen Befunde resultieren von Patienten mit einem Bronchialkarzinom . Die ersten Ergebnisse zeigen , dass mit der vorgestellten Biopsietechnik ausreichendes Material zur histologischen und immunologischen Beurteilung gewonnen werden kann . Neben Anteilen der Pulmonalarterienwand kann haeufig repraesentatives Lungenparenchym nachgewiesen werden . Komplikationen im Zusammenhang mit der Biopsietechnik traten waehrend unserer Untersuchungen nicht auf . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]

Die pulmonale Hypertonie stellt eine schwerwiegende therapeutisch schlecht beherrschbare Erkrankung unterschiedlicher Aetiologie dar . Obwohl haemodynamische Parameter weitgehend mit morphologischen Befunden korrelieren , besteht aus differentialdiagnostischer Sicht haeufig die Notwendigkeit zur histologischen Beurteilung . Eine adaequate Materialgewinnung ist aufgrund der hohen Blutungsbereitschaft in der Regel nur ueber thoraxchirurgische Verfahren moeglich . In der vorliegenden Arbeit werden tierexperimentelle und erste klinische Daten einer neuen Biopsietechnik ( perkutane transvasale Biopsie , PTB ) , zur Gewinnung von Gefaesswandproben bei pulmonaler Hypertonie vorgestellt . Bei einem Teil der Versuchstiere wurde der pulmonale Hochdruck experimentell erzeugt . Die klinischen Befunde resultieren von Patienten mit einem Bronchialkarzinom . Die ersten Ergebnisse zeigen , dass mit der vorgestellten Biopsietechnik ausreichendes Material zur histologischen und immunologischen Beurteilung gewonnen werden kann . Neben Anteilen der Pulmonalarterienwand kann haeufig repraesentatives Lungenparenchym nachgewiesen werden . Komplikationen im Zusammenhang mit der Biopsietechnik traten waehrend unserer Untersuchungen nicht auf .

[ "Die", "pulmonale", "Hypertonie", "stellt", "eine", "schwerwiegende", "therapeutisch", "schlecht", "beherrschbare", "Erkrankung", "unterschiedlicher", "Aetiologie", "dar", ".", "Obwohl", "haemodynamische", "Parameter", "weitgehend", "mit", "morphologischen", "Befunden", "korrelieren", ",", "besteht", "aus", "differentialdiagnostischer", "Sicht", "haeufig", "die", "Notwendigkeit", "zur", "histologischen", "Beurteilung", ".", "Eine", "adaequate", "Materialgewinnung", "ist", "aufgrund", "der", "hohen", "Blutungsbereitschaft", "in", "der", "Regel", "nur", "ueber", "thoraxchirurgische", "Verfahren", "moeglich", ".", "In", "der", "vorliegenden", "Arbeit", "werden", "tierexperimentelle", "und", "erste", "klinische", "Daten", "einer", "neuen", "Biopsietechnik", "(", "perkutane", "transvasale", "Biopsie", ",", "PTB", ")", ",", "zur", "Gewinnung", "von", "Gefaesswandproben", "bei", "pulmonaler", "Hypertonie", "vorgestellt", ".", "Bei", "einem", "Teil", "der", "Versuchstiere", "wurde", "der", "pulmonale", "Hochdruck", "experimentell", "erzeugt", ".", "Die", "klinischen", "Befunde", "resultieren", "von", "Patienten", "mit", "einem", "Bronchialkarzinom", ".", "Die", "ersten", "Ergebnisse", "zeigen", ",", "dass", "mit", "der", "vorgestellten", "Biopsietechnik", "ausreichendes", "Material", "zur", "histologischen", "und", "immunologischen", "Beurteilung", "gewonnen", "werden", "kann", ".", "Neben", "Anteilen", "der", "Pulmonalarterienwand", "kann", "haeufig", "repraesentatives", "Lungenparenchym", "nachgewiesen", "werden", ".", "Komplikationen", "im", "Zusammenhang", "mit", "der", "Biopsietechnik", "traten", "waehrend", "unserer", "Untersuchungen", "nicht", "auf", "." ]

[ "umlsterm" ]

pulmonale Hypertonie is an umlsterm, Aetiologie is an umlsterm, Beurteilung is an umlsterm, thoraxchirurgische is an umlsterm, Arbeit is an umlsterm, tierexperimentelle is an umlsterm, Biopsietechnik is an umlsterm, Biopsie is an umlsterm, pulmonaler Hypertonie is an umlsterm, Versuchstiere is an umlsterm, Patienten is an umlsterm, Bronchialkarzinom is an umlsterm, Biopsietechnik is an umlsterm, Beurteilung is an umlsterm, Pulmonalarterienwand is an umlsterm, Lungenparenchym is an umlsterm, Komplikationen is an umlsterm, Biopsietechnik is an umlsterm

ZfuerKardiologie.70860622.ger.abstr_task1

Sentence: Die pulmonale Hypertonie stellt eine schwerwiegende therapeutisch schlecht beherrschbare Erkrankung unterschiedlicher Aetiologie dar . Obwohl haemodynamische Parameter weitgehend mit morphologischen Befunden korrelieren , besteht aus differentialdiagnostischer Sicht haeufig die Notwendigkeit zur histologischen Beurteilung . Eine adaequate Materialgewinnung ist aufgrund der hohen Blutungsbereitschaft in der Regel nur ueber thoraxchirurgische Verfahren moeglich . In der vorliegenden Arbeit werden tierexperimentelle und erste klinische Daten einer neuen Biopsietechnik ( perkutane transvasale Biopsie , PTB ) , zur Gewinnung von Gefaesswandproben bei pulmonaler Hypertonie vorgestellt . Bei einem Teil der Versuchstiere wurde der pulmonale Hochdruck experimentell erzeugt . Die klinischen Befunde resultieren von Patienten mit einem Bronchialkarzinom . Die ersten Ergebnisse zeigen , dass mit der vorgestellten Biopsietechnik ausreichendes Material zur histologischen und immunologischen Beurteilung gewonnen werden kann . Neben Anteilen der Pulmonalarterienwand kann haeufig repraesentatives Lungenparenchym nachgewiesen werden . Komplikationen im Zusammenhang mit der Biopsietechnik traten waehrend unserer Untersuchungen nicht auf . Instructions: please typing these entity words according to sentence: pulmonale Hypertonie, Aetiologie, Beurteilung, thoraxchirurgische, Arbeit, tierexperimentelle, Biopsietechnik, Biopsie, pulmonaler Hypertonie, Versuchstiere, Patienten, Bronchialkarzinom, Biopsietechnik, Beurteilung, Pulmonalarterienwand, Lungenparenchym, Komplikationen, Biopsietechnik Options: umlsterm

[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]

Die pulmonale Hypertonie stellt eine schwerwiegende therapeutisch schlecht beherrschbare Erkrankung unterschiedlicher Aetiologie dar . Obwohl haemodynamische Parameter weitgehend mit morphologischen Befunden korrelieren , besteht aus differentialdiagnostischer Sicht haeufig die Notwendigkeit zur histologischen Beurteilung . Eine adaequate Materialgewinnung ist aufgrund der hohen Blutungsbereitschaft in der Regel nur ueber thoraxchirurgische Verfahren moeglich . In der vorliegenden Arbeit werden tierexperimentelle und erste klinische Daten einer neuen Biopsietechnik ( perkutane transvasale Biopsie , PTB ) , zur Gewinnung von Gefaesswandproben bei pulmonaler Hypertonie vorgestellt . Bei einem Teil der Versuchstiere wurde der pulmonale Hochdruck experimentell erzeugt . Die klinischen Befunde resultieren von Patienten mit einem Bronchialkarzinom . Die ersten Ergebnisse zeigen , dass mit der vorgestellten Biopsietechnik ausreichendes Material zur histologischen und immunologischen Beurteilung gewonnen werden kann . Neben Anteilen der Pulmonalarterienwand kann haeufig repraesentatives Lungenparenchym nachgewiesen werden . Komplikationen im Zusammenhang mit der Biopsietechnik traten waehrend unserer Untersuchungen nicht auf .

[ "Die", "pulmonale", "Hypertonie", "stellt", "eine", "schwerwiegende", "therapeutisch", "schlecht", "beherrschbare", "Erkrankung", "unterschiedlicher", "Aetiologie", "dar", ".", "Obwohl", "haemodynamische", "Parameter", "weitgehend", "mit", "morphologischen", "Befunden", "korrelieren", ",", "besteht", "aus", "differentialdiagnostischer", "Sicht", "haeufig", "die", "Notwendigkeit", "zur", "histologischen", "Beurteilung", ".", "Eine", "adaequate", "Materialgewinnung", "ist", "aufgrund", "der", "hohen", "Blutungsbereitschaft", "in", "der", "Regel", "nur", "ueber", "thoraxchirurgische", "Verfahren", "moeglich", ".", "In", "der", "vorliegenden", "Arbeit", "werden", "tierexperimentelle", "und", "erste", "klinische", "Daten", "einer", "neuen", "Biopsietechnik", "(", "perkutane", "transvasale", "Biopsie", ",", "PTB", ")", ",", "zur", "Gewinnung", "von", "Gefaesswandproben", "bei", "pulmonaler", "Hypertonie", "vorgestellt", ".", "Bei", "einem", "Teil", "der", "Versuchstiere", "wurde", "der", "pulmonale", "Hochdruck", "experimentell", "erzeugt", ".", "Die", "klinischen", "Befunde", "resultieren", "von", "Patienten", "mit", "einem", "Bronchialkarzinom", ".", "Die", "ersten", "Ergebnisse", "zeigen", ",", "dass", "mit", "der", "vorgestellten", "Biopsietechnik", "ausreichendes", "Material", "zur", "histologischen", "und", "immunologischen", "Beurteilung", "gewonnen", "werden", "kann", ".", "Neben", "Anteilen", "der", "Pulmonalarterienwand", "kann", "haeufig", "repraesentatives", "Lungenparenchym", "nachgewiesen", "werden", ".", "Komplikationen", "im", "Zusammenhang", "mit", "der", "Biopsietechnik", "traten", "waehrend", "unserer", "Untersuchungen", "nicht", "auf", "." ]

[ "umlsterm" ]

pulmonale Hypertonie, Aetiologie, Beurteilung, thoraxchirurgische, Arbeit, tierexperimentelle, Biopsietechnik, Biopsie, pulmonaler Hypertonie, Versuchstiere, Patienten, Bronchialkarzinom, Biopsietechnik, Beurteilung, Pulmonalarterienwand, Lungenparenchym, Komplikationen, Biopsietechnik

ZfuerKardiologie.70860622.ger.abstr_task2

Sentence: Die pulmonale Hypertonie stellt eine schwerwiegende therapeutisch schlecht beherrschbare Erkrankung unterschiedlicher Aetiologie dar . Obwohl haemodynamische Parameter weitgehend mit morphologischen Befunden korrelieren , besteht aus differentialdiagnostischer Sicht haeufig die Notwendigkeit zur histologischen Beurteilung . Eine adaequate Materialgewinnung ist aufgrund der hohen Blutungsbereitschaft in der Regel nur ueber thoraxchirurgische Verfahren moeglich . In der vorliegenden Arbeit werden tierexperimentelle und erste klinische Daten einer neuen Biopsietechnik ( perkutane transvasale Biopsie , PTB ) , zur Gewinnung von Gefaesswandproben bei pulmonaler Hypertonie vorgestellt . Bei einem Teil der Versuchstiere wurde der pulmonale Hochdruck experimentell erzeugt . Die klinischen Befunde resultieren von Patienten mit einem Bronchialkarzinom . Die ersten Ergebnisse zeigen , dass mit der vorgestellten Biopsietechnik ausreichendes Material zur histologischen und immunologischen Beurteilung gewonnen werden kann . Neben Anteilen der Pulmonalarterienwand kann haeufig repraesentatives Lungenparenchym nachgewiesen werden . Komplikationen im Zusammenhang mit der Biopsietechnik traten waehrend unserer Untersuchungen nicht auf . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]

Die pulmonale Hypertonie stellt eine schwerwiegende therapeutisch schlecht beherrschbare Erkrankung unterschiedlicher Aetiologie dar . Obwohl haemodynamische Parameter weitgehend mit morphologischen Befunden korrelieren , besteht aus differentialdiagnostischer Sicht haeufig die Notwendigkeit zur histologischen Beurteilung . Eine adaequate Materialgewinnung ist aufgrund der hohen Blutungsbereitschaft in der Regel nur ueber thoraxchirurgische Verfahren moeglich . In der vorliegenden Arbeit werden tierexperimentelle und erste klinische Daten einer neuen Biopsietechnik ( perkutane transvasale Biopsie , PTB ) , zur Gewinnung von Gefaesswandproben bei pulmonaler Hypertonie vorgestellt . Bei einem Teil der Versuchstiere wurde der pulmonale Hochdruck experimentell erzeugt . Die klinischen Befunde resultieren von Patienten mit einem Bronchialkarzinom . Die ersten Ergebnisse zeigen , dass mit der vorgestellten Biopsietechnik ausreichendes Material zur histologischen und immunologischen Beurteilung gewonnen werden kann . Neben Anteilen der Pulmonalarterienwand kann haeufig repraesentatives Lungenparenchym nachgewiesen werden . Komplikationen im Zusammenhang mit der Biopsietechnik traten waehrend unserer Untersuchungen nicht auf .

[ "Die", "pulmonale", "Hypertonie", "stellt", "eine", "schwerwiegende", "therapeutisch", "schlecht", "beherrschbare", "Erkrankung", "unterschiedlicher", "Aetiologie", "dar", ".", "Obwohl", "haemodynamische", "Parameter", "weitgehend", "mit", "morphologischen", "Befunden", "korrelieren", ",", "besteht", "aus", "differentialdiagnostischer", "Sicht", "haeufig", "die", "Notwendigkeit", "zur", "histologischen", "Beurteilung", ".", "Eine", "adaequate", "Materialgewinnung", "ist", "aufgrund", "der", "hohen", "Blutungsbereitschaft", "in", "der", "Regel", "nur", "ueber", "thoraxchirurgische", "Verfahren", "moeglich", ".", "In", "der", "vorliegenden", "Arbeit", "werden", "tierexperimentelle", "und", "erste", "klinische", "Daten", "einer", "neuen", "Biopsietechnik", "(", "perkutane", "transvasale", "Biopsie", ",", "PTB", ")", ",", "zur", "Gewinnung", "von", "Gefaesswandproben", "bei", "pulmonaler", "Hypertonie", "vorgestellt", ".", "Bei", "einem", "Teil", "der", "Versuchstiere", "wurde", "der", "pulmonale", "Hochdruck", "experimentell", "erzeugt", ".", "Die", "klinischen", "Befunde", "resultieren", "von", "Patienten", "mit", "einem", "Bronchialkarzinom", ".", "Die", "ersten", "Ergebnisse", "zeigen", ",", "dass", "mit", "der", "vorgestellten", "Biopsietechnik", "ausreichendes", "Material", "zur", "histologischen", "und", "immunologischen", "Beurteilung", "gewonnen", "werden", "kann", ".", "Neben", "Anteilen", "der", "Pulmonalarterienwand", "kann", "haeufig", "repraesentatives", "Lungenparenchym", "nachgewiesen", "werden", ".", "Komplikationen", "im", "Zusammenhang", "mit", "der", "Biopsietechnik", "traten", "waehrend", "unserer", "Untersuchungen", "nicht", "auf", "." ]

[ "umlsterm" ]

neuroprotective effects is a Outcome_Adverse-effects, recovery profiles is a Outcome_Other, isoflurane is a Intervention_Pharmacological, sevoflurane is a Intervention_Pharmacological, desflurane is a Intervention_Pharmacological, ischemia / reperfusion cerebral injury is a Participant_Condition, neurosurgery is a Participant_Condition, emergence is a Outcome_Other, intraoperative haemodynamic profiles is a Outcome_Other, postoperative adverse effects is a Outcome_Adverse-effects, hemodynamic stability is a Outcome_Physical, quality of induction and recovery is a Outcome_Other, substantial cerebral vasodilation is a Participant_Condition, Sevoflurane is a Intervention_Pharmacological, airway irritation is a Outcome_Physical, onset and recovery is a Outcome_Other

71481_task0

Sentence: Comparison of the neuroprotective effects and recovery profiles of isoflurane , sevoflurane and desflurane as neurosurgical pre-conditioning on ischemia/reperfusion cerebral injury . BACKGROUND There are a few reports regarding the comparison of these anesthetic agents , but previous studies mainly focus on the veterinary anesthesiology . Less attention has been focused comparing the effectiveness of these inhalational anesthetic agents in neurosurgery . This lack of interest is regretful particularly considering the fact that anesthetics during neurosurgery are an issue of extreme sensitivity and subtlety , where the cerebral oxygenation process plays a significant role in the neuroprotective mechanisms . OBJECTIVE The purpose of this retrospective study is to contribute to the existing knowledge of the comparative studies of the volatile anesthetic agents such as isoflurane , sevoflurane and desflurane by evaluating the maintenance and emergence characteristics after volatile anesthetics-induced preconditioning with isoflurane , sevoflurane or desflurane for inpatient ischemia/reperfusion cerebral injury during cerebral or neural surgeries . METHODS The aim was to investigate their neuroprotective mechanisms and effects by analyzing and comparing the superiority of each agent in a Chinese patient population , in terms of faster emergence , and early and intermediate recovery . The intraoperative haemodynamic profiles and postoperative adverse effects of these three agents were also systematically analyzed . RESULTS We found that sevoflurane , when compared with isoflurane and desflurane , provided anesthesia with similar hemodynamic stability but allowed for a smoother , more rapid emergence and better quality of induction and recovery to surgical patients under clinical conditions , particularly to those who were experiencing substantial cerebral vasodilation . CONCLUSION Sevoflurane offers several advantages , including a relative lack of airway irritation , a more rapid onset and recovery , and greater hemodynamic stability than other potent inhaled agents . These properties would appear to afford sevoflurane significant clinical potential . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Physical, Outcome_Other

[ "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Comparison of the neuroprotective effects and recovery profiles of isoflurane , sevoflurane and desflurane as neurosurgical pre-conditioning on ischemia/reperfusion cerebral injury . BACKGROUND There are a few reports regarding the comparison of these anesthetic agents , but previous studies mainly focus on the veterinary anesthesiology . Less attention has been focused comparing the effectiveness of these inhalational anesthetic agents in neurosurgery . This lack of interest is regretful particularly considering the fact that anesthetics during neurosurgery are an issue of extreme sensitivity and subtlety , where the cerebral oxygenation process plays a significant role in the neuroprotective mechanisms . OBJECTIVE The purpose of this retrospective study is to contribute to the existing knowledge of the comparative studies of the volatile anesthetic agents such as isoflurane , sevoflurane and desflurane by evaluating the maintenance and emergence characteristics after volatile anesthetics-induced preconditioning with isoflurane , sevoflurane or desflurane for inpatient ischemia/reperfusion cerebral injury during cerebral or neural surgeries . METHODS The aim was to investigate their neuroprotective mechanisms and effects by analyzing and comparing the superiority of each agent in a Chinese patient population , in terms of faster emergence , and early and intermediate recovery . The intraoperative haemodynamic profiles and postoperative adverse effects of these three agents were also systematically analyzed . RESULTS We found that sevoflurane , when compared with isoflurane and desflurane , provided anesthesia with similar hemodynamic stability but allowed for a smoother , more rapid emergence and better quality of induction and recovery to surgical patients under clinical conditions , particularly to those who were experiencing substantial cerebral vasodilation . CONCLUSION Sevoflurane offers several advantages , including a relative lack of airway irritation , a more rapid onset and recovery , and greater hemodynamic stability than other potent inhaled agents . These properties would appear to afford sevoflurane significant clinical potential .

[ "Comparison", "of", "the", "neuroprotective", "effects", "and", "recovery", "profiles", "of", "isoflurane", ",", "sevoflurane", "and", "desflurane", "as", "neurosurgical", "pre", "-", "conditioning", "on", "ischemia", "/", "reperfusion", "cerebral", "injury", ".", "BACKGROUND", "There", "are", "a", "few", "reports", "regarding", "the", "comparison", "of", "these", "anesthetic", "agents", ",", "but", "previous", "studies", "mainly", "focus", "on", "the", "veterinary", "anesthesiology", ".", "Less", "attention", "has", "been", "focused", "comparing", "the", "effectiveness", "of", "these", "inhalational", "anesthetic", "agents", "in", "neurosurgery", ".", "This", "lack", "of", "interest", "is", "regretful", "particularly", "considering", "the", "fact", "that", "anesthetics", "during", "neurosurgery", "are", "an", "issue", "of", "extreme", "sensitivity", "and", "subtlety", ",", "where", "the", "cerebral", "oxygenation", "process", "plays", "a", "significant", "role", "in", "the", "neuroprotective", "mechanisms", ".", "OBJECTIVE", "The", "purpose", "of", "this", "retrospective", "study", "is", "to", "contribute", "to", "the", "existing", "knowledge", "of", "the", "comparative", "studies", "of", "the", "volatile", "anesthetic", "agents", "such", "as", "isoflurane", ",", "sevoflurane", "and", "desflurane", "by", "evaluating", "the", "maintenance", "and", "emergence", "characteristics", "after", "volatile", "anesthetics", "-", "induced", "preconditioning", "with", "isoflurane", ",", "sevoflurane", "or", "desflurane", "for", "inpatient", "ischemia", "/", "reperfusion", "cerebral", "injury", "during", "cerebral", "or", "neural", "surgeries", ".", "METHODS", "The", "aim", "was", "to", "investigate", "their", "neuroprotective", "mechanisms", "and", "effects", "by", "analyzing", "and", "comparing", "the", "superiority", "of", "each", "agent", "in", "a", "Chinese", "patient", "population", ",", "in", "terms", "of", "faster", "emergence", ",", "and", "early", "and", "intermediate", "recovery", ".", "The", "intraoperative", "haemodynamic", "profiles", "and", "postoperative", "adverse", "effects", "of", "these", "three", "agents", "were", "also", "systematically", "analyzed", ".", "RESULTS", "We", "found", "that", "sevoflurane", ",", "when", "compared", "with", "isoflurane", "and", "desflurane", ",", "provided", "anesthesia", "with", "similar", "hemodynamic", "stability", "but", "allowed", "for", "a", "smoother", ",", "more", "rapid", "emergence", "and", "better", "quality", "of", "induction", "and", "recovery", "to", "surgical", "patients", "under", "clinical", "conditions", ",", "particularly", "to", "those", "who", "were", "experiencing", "substantial", "cerebral", "vasodilation", ".", "CONCLUSION", "Sevoflurane", "offers", "several", "advantages", ",", "including", "a", "relative", "lack", "of", "airway", "irritation", ",", "a", "more", "rapid", "onset", "and", "recovery", ",", "and", "greater", "hemodynamic", "stability", "than", "other", "potent", "inhaled", "agents", ".", "These", "properties", "would", "appear", "to", "afford", "sevoflurane", "significant", "clinical", "potential", "." ]

[ "Outcome_Other", "Participant_Condition", "Outcome_Adverse-effects", "Outcome_Physical", "Intervention_Pharmacological" ]

neuroprotective effects is a Outcome_Adverse-effects, recovery profiles is a Outcome_Other, isoflurane is a Intervention_Pharmacological, sevoflurane is a Intervention_Pharmacological, desflurane is a Intervention_Pharmacological, ischemia / reperfusion cerebral injury is a Participant_Condition, neurosurgery is a Participant_Condition, emergence is a Outcome_Other, intraoperative haemodynamic profiles is a Outcome_Other, postoperative adverse effects is a Outcome_Adverse-effects, hemodynamic stability is a Outcome_Physical, quality of induction and recovery is a Outcome_Other, substantial cerebral vasodilation is a Participant_Condition, Sevoflurane is a Intervention_Pharmacological, airway irritation is a Outcome_Physical, onset and recovery is a Outcome_Other

71481_task1

Sentence: Comparison of the neuroprotective effects and recovery profiles of isoflurane , sevoflurane and desflurane as neurosurgical pre-conditioning on ischemia/reperfusion cerebral injury . BACKGROUND There are a few reports regarding the comparison of these anesthetic agents , but previous studies mainly focus on the veterinary anesthesiology . Less attention has been focused comparing the effectiveness of these inhalational anesthetic agents in neurosurgery . This lack of interest is regretful particularly considering the fact that anesthetics during neurosurgery are an issue of extreme sensitivity and subtlety , where the cerebral oxygenation process plays a significant role in the neuroprotective mechanisms . OBJECTIVE The purpose of this retrospective study is to contribute to the existing knowledge of the comparative studies of the volatile anesthetic agents such as isoflurane , sevoflurane and desflurane by evaluating the maintenance and emergence characteristics after volatile anesthetics-induced preconditioning with isoflurane , sevoflurane or desflurane for inpatient ischemia/reperfusion cerebral injury during cerebral or neural surgeries . METHODS The aim was to investigate their neuroprotective mechanisms and effects by analyzing and comparing the superiority of each agent in a Chinese patient population , in terms of faster emergence , and early and intermediate recovery . The intraoperative haemodynamic profiles and postoperative adverse effects of these three agents were also systematically analyzed . RESULTS We found that sevoflurane , when compared with isoflurane and desflurane , provided anesthesia with similar hemodynamic stability but allowed for a smoother , more rapid emergence and better quality of induction and recovery to surgical patients under clinical conditions , particularly to those who were experiencing substantial cerebral vasodilation . CONCLUSION Sevoflurane offers several advantages , including a relative lack of airway irritation , a more rapid onset and recovery , and greater hemodynamic stability than other potent inhaled agents . These properties would appear to afford sevoflurane significant clinical potential . Instructions: please typing these entity words according to sentence: neuroprotective effects, recovery profiles, isoflurane, sevoflurane, desflurane, ischemia / reperfusion cerebral injury, neurosurgery, emergence, intraoperative haemodynamic profiles, postoperative adverse effects, hemodynamic stability, quality of induction and recovery, substantial cerebral vasodilation, Sevoflurane, airway irritation, onset and recovery Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Physical, Outcome_Other

[ "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Comparison of the neuroprotective effects and recovery profiles of isoflurane , sevoflurane and desflurane as neurosurgical pre-conditioning on ischemia/reperfusion cerebral injury . BACKGROUND There are a few reports regarding the comparison of these anesthetic agents , but previous studies mainly focus on the veterinary anesthesiology . Less attention has been focused comparing the effectiveness of these inhalational anesthetic agents in neurosurgery . This lack of interest is regretful particularly considering the fact that anesthetics during neurosurgery are an issue of extreme sensitivity and subtlety , where the cerebral oxygenation process plays a significant role in the neuroprotective mechanisms . OBJECTIVE The purpose of this retrospective study is to contribute to the existing knowledge of the comparative studies of the volatile anesthetic agents such as isoflurane , sevoflurane and desflurane by evaluating the maintenance and emergence characteristics after volatile anesthetics-induced preconditioning with isoflurane , sevoflurane or desflurane for inpatient ischemia/reperfusion cerebral injury during cerebral or neural surgeries . METHODS The aim was to investigate their neuroprotective mechanisms and effects by analyzing and comparing the superiority of each agent in a Chinese patient population , in terms of faster emergence , and early and intermediate recovery . The intraoperative haemodynamic profiles and postoperative adverse effects of these three agents were also systematically analyzed . RESULTS We found that sevoflurane , when compared with isoflurane and desflurane , provided anesthesia with similar hemodynamic stability but allowed for a smoother , more rapid emergence and better quality of induction and recovery to surgical patients under clinical conditions , particularly to those who were experiencing substantial cerebral vasodilation . CONCLUSION Sevoflurane offers several advantages , including a relative lack of airway irritation , a more rapid onset and recovery , and greater hemodynamic stability than other potent inhaled agents . These properties would appear to afford sevoflurane significant clinical potential .

[ "Comparison", "of", "the", "neuroprotective", "effects", "and", "recovery", "profiles", "of", "isoflurane", ",", "sevoflurane", "and", "desflurane", "as", "neurosurgical", "pre", "-", "conditioning", "on", "ischemia", "/", "reperfusion", "cerebral", "injury", ".", "BACKGROUND", "There", "are", "a", "few", "reports", "regarding", "the", "comparison", "of", "these", "anesthetic", "agents", ",", "but", "previous", "studies", "mainly", "focus", "on", "the", "veterinary", "anesthesiology", ".", "Less", "attention", "has", "been", "focused", "comparing", "the", "effectiveness", "of", "these", "inhalational", "anesthetic", "agents", "in", "neurosurgery", ".", "This", "lack", "of", "interest", "is", "regretful", "particularly", "considering", "the", "fact", "that", "anesthetics", "during", "neurosurgery", "are", "an", "issue", "of", "extreme", "sensitivity", "and", "subtlety", ",", "where", "the", "cerebral", "oxygenation", "process", "plays", "a", "significant", "role", "in", "the", "neuroprotective", "mechanisms", ".", "OBJECTIVE", "The", "purpose", "of", "this", "retrospective", "study", "is", "to", "contribute", "to", "the", "existing", "knowledge", "of", "the", "comparative", "studies", "of", "the", "volatile", "anesthetic", "agents", "such", "as", "isoflurane", ",", "sevoflurane", "and", "desflurane", "by", "evaluating", "the", "maintenance", "and", "emergence", "characteristics", "after", "volatile", "anesthetics", "-", "induced", "preconditioning", "with", "isoflurane", ",", "sevoflurane", "or", "desflurane", "for", "inpatient", "ischemia", "/", "reperfusion", "cerebral", "injury", "during", "cerebral", "or", "neural", "surgeries", ".", "METHODS", "The", "aim", "was", "to", "investigate", "their", "neuroprotective", "mechanisms", "and", "effects", "by", "analyzing", "and", "comparing", "the", "superiority", "of", "each", "agent", "in", "a", "Chinese", "patient", "population", ",", "in", "terms", "of", "faster", "emergence", ",", "and", "early", "and", "intermediate", "recovery", ".", "The", "intraoperative", "haemodynamic", "profiles", "and", "postoperative", "adverse", "effects", "of", "these", "three", "agents", "were", "also", "systematically", "analyzed", ".", "RESULTS", "We", "found", "that", "sevoflurane", ",", "when", "compared", "with", "isoflurane", "and", "desflurane", ",", "provided", "anesthesia", "with", "similar", "hemodynamic", "stability", "but", "allowed", "for", "a", "smoother", ",", "more", "rapid", "emergence", "and", "better", "quality", "of", "induction", "and", "recovery", "to", "surgical", "patients", "under", "clinical", "conditions", ",", "particularly", "to", "those", "who", "were", "experiencing", "substantial", "cerebral", "vasodilation", ".", "CONCLUSION", "Sevoflurane", "offers", "several", "advantages", ",", "including", "a", "relative", "lack", "of", "airway", "irritation", ",", "a", "more", "rapid", "onset", "and", "recovery", ",", "and", "greater", "hemodynamic", "stability", "than", "other", "potent", "inhaled", "agents", ".", "These", "properties", "would", "appear", "to", "afford", "sevoflurane", "significant", "clinical", "potential", "." ]

[ "Outcome_Other", "Participant_Condition", "Outcome_Adverse-effects", "Outcome_Physical", "Intervention_Pharmacological" ]

neuroprotective effects, recovery profiles, isoflurane, sevoflurane, desflurane, ischemia / reperfusion cerebral injury, neurosurgery, emergence, intraoperative haemodynamic profiles, postoperative adverse effects, hemodynamic stability, quality of induction and recovery, substantial cerebral vasodilation, Sevoflurane, airway irritation, onset and recovery

71481_task2

Sentence: Comparison of the neuroprotective effects and recovery profiles of isoflurane , sevoflurane and desflurane as neurosurgical pre-conditioning on ischemia/reperfusion cerebral injury . BACKGROUND There are a few reports regarding the comparison of these anesthetic agents , but previous studies mainly focus on the veterinary anesthesiology . Less attention has been focused comparing the effectiveness of these inhalational anesthetic agents in neurosurgery . This lack of interest is regretful particularly considering the fact that anesthetics during neurosurgery are an issue of extreme sensitivity and subtlety , where the cerebral oxygenation process plays a significant role in the neuroprotective mechanisms . OBJECTIVE The purpose of this retrospective study is to contribute to the existing knowledge of the comparative studies of the volatile anesthetic agents such as isoflurane , sevoflurane and desflurane by evaluating the maintenance and emergence characteristics after volatile anesthetics-induced preconditioning with isoflurane , sevoflurane or desflurane for inpatient ischemia/reperfusion cerebral injury during cerebral or neural surgeries . METHODS The aim was to investigate their neuroprotective mechanisms and effects by analyzing and comparing the superiority of each agent in a Chinese patient population , in terms of faster emergence , and early and intermediate recovery . The intraoperative haemodynamic profiles and postoperative adverse effects of these three agents were also systematically analyzed . RESULTS We found that sevoflurane , when compared with isoflurane and desflurane , provided anesthesia with similar hemodynamic stability but allowed for a smoother , more rapid emergence and better quality of induction and recovery to surgical patients under clinical conditions , particularly to those who were experiencing substantial cerebral vasodilation . CONCLUSION Sevoflurane offers several advantages , including a relative lack of airway irritation , a more rapid onset and recovery , and greater hemodynamic stability than other potent inhaled agents . These properties would appear to afford sevoflurane significant clinical potential . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Comparison of the neuroprotective effects and recovery profiles of isoflurane , sevoflurane and desflurane as neurosurgical pre-conditioning on ischemia/reperfusion cerebral injury . BACKGROUND There are a few reports regarding the comparison of these anesthetic agents , but previous studies mainly focus on the veterinary anesthesiology . Less attention has been focused comparing the effectiveness of these inhalational anesthetic agents in neurosurgery . This lack of interest is regretful particularly considering the fact that anesthetics during neurosurgery are an issue of extreme sensitivity and subtlety , where the cerebral oxygenation process plays a significant role in the neuroprotective mechanisms . OBJECTIVE The purpose of this retrospective study is to contribute to the existing knowledge of the comparative studies of the volatile anesthetic agents such as isoflurane , sevoflurane and desflurane by evaluating the maintenance and emergence characteristics after volatile anesthetics-induced preconditioning with isoflurane , sevoflurane or desflurane for inpatient ischemia/reperfusion cerebral injury during cerebral or neural surgeries . METHODS The aim was to investigate their neuroprotective mechanisms and effects by analyzing and comparing the superiority of each agent in a Chinese patient population , in terms of faster emergence , and early and intermediate recovery . The intraoperative haemodynamic profiles and postoperative adverse effects of these three agents were also systematically analyzed . RESULTS We found that sevoflurane , when compared with isoflurane and desflurane , provided anesthesia with similar hemodynamic stability but allowed for a smoother , more rapid emergence and better quality of induction and recovery to surgical patients under clinical conditions , particularly to those who were experiencing substantial cerebral vasodilation . CONCLUSION Sevoflurane offers several advantages , including a relative lack of airway irritation , a more rapid onset and recovery , and greater hemodynamic stability than other potent inhaled agents . These properties would appear to afford sevoflurane significant clinical potential .

[ "Comparison", "of", "the", "neuroprotective", "effects", "and", "recovery", "profiles", "of", "isoflurane", ",", "sevoflurane", "and", "desflurane", "as", "neurosurgical", "pre", "-", "conditioning", "on", "ischemia", "/", "reperfusion", "cerebral", "injury", ".", "BACKGROUND", "There", "are", "a", "few", "reports", "regarding", "the", "comparison", "of", "these", "anesthetic", "agents", ",", "but", "previous", "studies", "mainly", "focus", "on", "the", "veterinary", "anesthesiology", ".", "Less", "attention", "has", "been", "focused", "comparing", "the", "effectiveness", "of", "these", "inhalational", "anesthetic", "agents", "in", "neurosurgery", ".", "This", "lack", "of", "interest", "is", "regretful", "particularly", "considering", "the", "fact", "that", "anesthetics", "during", "neurosurgery", "are", "an", "issue", "of", "extreme", "sensitivity", "and", "subtlety", ",", "where", "the", "cerebral", "oxygenation", "process", "plays", "a", "significant", "role", "in", "the", "neuroprotective", "mechanisms", ".", "OBJECTIVE", "The", "purpose", "of", "this", "retrospective", "study", "is", "to", "contribute", "to", "the", "existing", "knowledge", "of", "the", "comparative", "studies", "of", "the", "volatile", "anesthetic", "agents", "such", "as", "isoflurane", ",", "sevoflurane", "and", "desflurane", "by", "evaluating", "the", "maintenance", "and", "emergence", "characteristics", "after", "volatile", "anesthetics", "-", "induced", "preconditioning", "with", "isoflurane", ",", "sevoflurane", "or", "desflurane", "for", "inpatient", "ischemia", "/", "reperfusion", "cerebral", "injury", "during", "cerebral", "or", "neural", "surgeries", ".", "METHODS", "The", "aim", "was", "to", "investigate", "their", "neuroprotective", "mechanisms", "and", "effects", "by", "analyzing", "and", "comparing", "the", "superiority", "of", "each", "agent", "in", "a", "Chinese", "patient", "population", ",", "in", "terms", "of", "faster", "emergence", ",", "and", "early", "and", "intermediate", "recovery", ".", "The", "intraoperative", "haemodynamic", "profiles", "and", "postoperative", "adverse", "effects", "of", "these", "three", "agents", "were", "also", "systematically", "analyzed", ".", "RESULTS", "We", "found", "that", "sevoflurane", ",", "when", "compared", "with", "isoflurane", "and", "desflurane", ",", "provided", "anesthesia", "with", "similar", "hemodynamic", "stability", "but", "allowed", "for", "a", "smoother", ",", "more", "rapid", "emergence", "and", "better", "quality", "of", "induction", "and", "recovery", "to", "surgical", "patients", "under", "clinical", "conditions", ",", "particularly", "to", "those", "who", "were", "experiencing", "substantial", "cerebral", "vasodilation", ".", "CONCLUSION", "Sevoflurane", "offers", "several", "advantages", ",", "including", "a", "relative", "lack", "of", "airway", "irritation", ",", "a", "more", "rapid", "onset", "and", "recovery", ",", "and", "greater", "hemodynamic", "stability", "than", "other", "potent", "inhaled", "agents", ".", "These", "properties", "would", "appear", "to", "afford", "sevoflurane", "significant", "clinical", "potential", "." ]

[ "Outcome_Other", "Participant_Condition", "Outcome_Adverse-effects", "Outcome_Physical", "Intervention_Pharmacological" ]

Vegfrecine is a CHEMICAL, VEGF Receptor Tyrosine Kinases is a GENE-N, VEGF receptor tyrosine kinases is a GENE-N, vegfrecine is a CHEMICAL, vascular endothelial growth factor receptor is a GENE-N, VEGFR is a GENE-N, tyrosine kinases is a GENE-N, platelet - derived growth factor receptors is a GENE-N, PDGFRs is a GENE-N, fibroblast growth factor receptor is a GENE-N, FGFR is a GENE-N, epidermal growth factor receptor is a GENE-Y, EGFR is a GENE-Y, VEGFR is a GENE-N

6312_task0

Sentence: Vegfrecine, an Inhibitor of VEGF Receptor Tyrosine Kinases Isolated from the Culture Broth of Streptomyces sp. A new inhibitor of VEGF receptor tyrosine kinases, vegfrecine (1), was isolated from the culture broth of Streptomyces sp. MK931-CF8. The molecular structure of 1 was determined by NMR and MS analysis combined with synthesis. Compound 1 showed potent inhibitory activity against vascular endothelial growth factor receptor (VEGFR) tyrosine kinases in in vitro enzyme assays, but platelet-derived growth factor receptors (PDGFRs), fibroblast growth factor receptor (FGFR), and epidermal growth factor receptor (EGFR) responded only weakly. Compound 1 is a promising new selective VEGFR inhibitor for investigating new treatments of cancer and inflammatory diseases. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N, CHEMICAL

[ "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Vegfrecine, an Inhibitor of VEGF Receptor Tyrosine Kinases Isolated from the Culture Broth of Streptomyces sp. A new inhibitor of VEGF receptor tyrosine kinases, vegfrecine (1), was isolated from the culture broth of Streptomyces sp. MK931-CF8. The molecular structure of 1 was determined by NMR and MS analysis combined with synthesis. Compound 1 showed potent inhibitory activity against vascular endothelial growth factor receptor (VEGFR) tyrosine kinases in in vitro enzyme assays, but platelet-derived growth factor receptors (PDGFRs), fibroblast growth factor receptor (FGFR), and epidermal growth factor receptor (EGFR) responded only weakly. Compound 1 is a promising new selective VEGFR inhibitor for investigating new treatments of cancer and inflammatory diseases.

[ "Vegfrecine", ",", "an", "Inhibitor", "of", "VEGF", "Receptor", "Tyrosine", "Kinases", "Isolated", "from", "the", "Culture", "Broth", "of", "Streptomyces", "sp", ".", "\n", "A", "new", "inhibitor", "of", "VEGF", "receptor", "tyrosine", "kinases", ",", "vegfrecine", "(", "1", ")", ",", "was", "isolated", "from", "the", "culture", "broth", "of", "Streptomyces", "sp", ".", "MK931-CF8", ".", "The", "molecular", "structure", "of", "1", "was", "determined", "by", "NMR", "and", "MS", "analysis", "combined", "with", "synthesis", ".", "Compound", "1", "showed", "potent", "inhibitory", "activity", "against", "vascular", "endothelial", "growth", "factor", "receptor", "(", "VEGFR", ")", "tyrosine", "kinases", "in", "in", "vitro", "enzyme", "assays", ",", "but", "platelet", "-", "derived", "growth", "factor", "receptors", "(", "PDGFRs", ")", ",", "fibroblast", "growth", "factor", "receptor", "(", "FGFR", ")", ",", "and", "epidermal", "growth", "factor", "receptor", "(", "EGFR", ")", "responded", "only", "weakly", ".", "Compound", "1", "is", "a", "promising", "new", "selective", "VEGFR", "inhibitor", "for", "investigating", "new", "treatments", "of", "cancer", "and", "inflammatory", "diseases", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

Vegfrecine is a CHEMICAL, VEGF Receptor Tyrosine Kinases is a GENE-N, VEGF receptor tyrosine kinases is a GENE-N, vegfrecine is a CHEMICAL, vascular endothelial growth factor receptor is a GENE-N, VEGFR is a GENE-N, tyrosine kinases is a GENE-N, platelet - derived growth factor receptors is a GENE-N, PDGFRs is a GENE-N, fibroblast growth factor receptor is a GENE-N, FGFR is a GENE-N, epidermal growth factor receptor is a GENE-Y, EGFR is a GENE-Y, VEGFR is a GENE-N

6312_task1

Sentence: Vegfrecine, an Inhibitor of VEGF Receptor Tyrosine Kinases Isolated from the Culture Broth of Streptomyces sp. A new inhibitor of VEGF receptor tyrosine kinases, vegfrecine (1), was isolated from the culture broth of Streptomyces sp. MK931-CF8. The molecular structure of 1 was determined by NMR and MS analysis combined with synthesis. Compound 1 showed potent inhibitory activity against vascular endothelial growth factor receptor (VEGFR) tyrosine kinases in in vitro enzyme assays, but platelet-derived growth factor receptors (PDGFRs), fibroblast growth factor receptor (FGFR), and epidermal growth factor receptor (EGFR) responded only weakly. Compound 1 is a promising new selective VEGFR inhibitor for investigating new treatments of cancer and inflammatory diseases. Instructions: please typing these entity words according to sentence: Vegfrecine, VEGF Receptor Tyrosine Kinases, VEGF receptor tyrosine kinases, vegfrecine, vascular endothelial growth factor receptor, VEGFR, tyrosine kinases, platelet - derived growth factor receptors, PDGFRs, fibroblast growth factor receptor, FGFR, epidermal growth factor receptor, EGFR, VEGFR Options: GENE-Y, GENE-N, CHEMICAL

[ "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Vegfrecine, an Inhibitor of VEGF Receptor Tyrosine Kinases Isolated from the Culture Broth of Streptomyces sp. A new inhibitor of VEGF receptor tyrosine kinases, vegfrecine (1), was isolated from the culture broth of Streptomyces sp. MK931-CF8. The molecular structure of 1 was determined by NMR and MS analysis combined with synthesis. Compound 1 showed potent inhibitory activity against vascular endothelial growth factor receptor (VEGFR) tyrosine kinases in in vitro enzyme assays, but platelet-derived growth factor receptors (PDGFRs), fibroblast growth factor receptor (FGFR), and epidermal growth factor receptor (EGFR) responded only weakly. Compound 1 is a promising new selective VEGFR inhibitor for investigating new treatments of cancer and inflammatory diseases.

[ "Vegfrecine", ",", "an", "Inhibitor", "of", "VEGF", "Receptor", "Tyrosine", "Kinases", "Isolated", "from", "the", "Culture", "Broth", "of", "Streptomyces", "sp", ".", "\n", "A", "new", "inhibitor", "of", "VEGF", "receptor", "tyrosine", "kinases", ",", "vegfrecine", "(", "1", ")", ",", "was", "isolated", "from", "the", "culture", "broth", "of", "Streptomyces", "sp", ".", "MK931-CF8", ".", "The", "molecular", "structure", "of", "1", "was", "determined", "by", "NMR", "and", "MS", "analysis", "combined", "with", "synthesis", ".", "Compound", "1", "showed", "potent", "inhibitory", "activity", "against", "vascular", "endothelial", "growth", "factor", "receptor", "(", "VEGFR", ")", "tyrosine", "kinases", "in", "in", "vitro", "enzyme", "assays", ",", "but", "platelet", "-", "derived", "growth", "factor", "receptors", "(", "PDGFRs", ")", ",", "fibroblast", "growth", "factor", "receptor", "(", "FGFR", ")", ",", "and", "epidermal", "growth", "factor", "receptor", "(", "EGFR", ")", "responded", "only", "weakly", ".", "Compound", "1", "is", "a", "promising", "new", "selective", "VEGFR", "inhibitor", "for", "investigating", "new", "treatments", "of", "cancer", "and", "inflammatory", "diseases", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

Vegfrecine, VEGF Receptor Tyrosine Kinases, VEGF receptor tyrosine kinases, vegfrecine, vascular endothelial growth factor receptor, VEGFR, tyrosine kinases, platelet - derived growth factor receptors, PDGFRs, fibroblast growth factor receptor, FGFR, epidermal growth factor receptor, EGFR, VEGFR

6312_task2

Sentence: Vegfrecine, an Inhibitor of VEGF Receptor Tyrosine Kinases Isolated from the Culture Broth of Streptomyces sp. A new inhibitor of VEGF receptor tyrosine kinases, vegfrecine (1), was isolated from the culture broth of Streptomyces sp. MK931-CF8. The molecular structure of 1 was determined by NMR and MS analysis combined with synthesis. Compound 1 showed potent inhibitory activity against vascular endothelial growth factor receptor (VEGFR) tyrosine kinases in in vitro enzyme assays, but platelet-derived growth factor receptors (PDGFRs), fibroblast growth factor receptor (FGFR), and epidermal growth factor receptor (EGFR) responded only weakly. Compound 1 is a promising new selective VEGFR inhibitor for investigating new treatments of cancer and inflammatory diseases. Instructions: please extract entity words from the input sentence

[ "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Vegfrecine, an Inhibitor of VEGF Receptor Tyrosine Kinases Isolated from the Culture Broth of Streptomyces sp. A new inhibitor of VEGF receptor tyrosine kinases, vegfrecine (1), was isolated from the culture broth of Streptomyces sp. MK931-CF8. The molecular structure of 1 was determined by NMR and MS analysis combined with synthesis. Compound 1 showed potent inhibitory activity against vascular endothelial growth factor receptor (VEGFR) tyrosine kinases in in vitro enzyme assays, but platelet-derived growth factor receptors (PDGFRs), fibroblast growth factor receptor (FGFR), and epidermal growth factor receptor (EGFR) responded only weakly. Compound 1 is a promising new selective VEGFR inhibitor for investigating new treatments of cancer and inflammatory diseases.

[ "Vegfrecine", ",", "an", "Inhibitor", "of", "VEGF", "Receptor", "Tyrosine", "Kinases", "Isolated", "from", "the", "Culture", "Broth", "of", "Streptomyces", "sp", ".", "\n", "A", "new", "inhibitor", "of", "VEGF", "receptor", "tyrosine", "kinases", ",", "vegfrecine", "(", "1", ")", ",", "was", "isolated", "from", "the", "culture", "broth", "of", "Streptomyces", "sp", ".", "MK931-CF8", ".", "The", "molecular", "structure", "of", "1", "was", "determined", "by", "NMR", "and", "MS", "analysis", "combined", "with", "synthesis", ".", "Compound", "1", "showed", "potent", "inhibitory", "activity", "against", "vascular", "endothelial", "growth", "factor", "receptor", "(", "VEGFR", ")", "tyrosine", "kinases", "in", "in", "vitro", "enzyme", "assays", ",", "but", "platelet", "-", "derived", "growth", "factor", "receptors", "(", "PDGFRs", ")", ",", "fibroblast", "growth", "factor", "receptor", "(", "FGFR", ")", ",", "and", "epidermal", "growth", "factor", "receptor", "(", "EGFR", ")", "responded", "only", "weakly", ".", "Compound", "1", "is", "a", "promising", "new", "selective", "VEGFR", "inhibitor", "for", "investigating", "new", "treatments", "of", "cancer", "and", "inflammatory", "diseases", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

Skelettsystem is an umlsterm, Polymere is an umlsterm, Knochenersatzstoffe is an umlsterm, Knochenzemente is an umlsterm, Knochenwachstumsfaktoren is an umlsterm, Zeit is an umlsterm, Langzeitergebnissen is an umlsterm

DerChirurg.90700888.ger.abstr_task0

Sentence: Zusammenfassung . Die zunehmende Anzahl unterschiedlicher Biomaterialien zur Anwendung im Skelettsystem erfordert immer mehr eine differenzierte Anwendung in der Klinik . Um ihren sinnvollen therapeutischen Einsatz zu gewaehrleisten , muessen die jeweiligen Biomaterialeigenschaften mit den Implantatlagereigenschaften abgestimmt sein . Weiterentwickelte biodegradierbare Polymere mit langsamer Umbaurate und laenger anhaltender Stabilitaet werden bei deutlich verminderter Komplikationsrate zunehmend erfolgreich eingesetzt . Im Bereich der keramischen Knochenersatzstoffe laesst die Entwicklung neuartiger umbaubarer Knochenzemente neben der Moeglichkeit der Defektauffuellung die Idee der Verbundosteosynthese " " wieder aufleben . Eine weitere vielversprechende Gruppe sind die rekombinant humanen Knochenwachstumsfaktoren , die zur Zeit in der klinischen Erprobung sind . Eine allgemeine erfolgreiche Anwendung mit verwertbaren Langzeitergebnissen steht noch aus . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Zusammenfassung . Die zunehmende Anzahl unterschiedlicher Biomaterialien zur Anwendung im Skelettsystem erfordert immer mehr eine differenzierte Anwendung in der Klinik . Um ihren sinnvollen therapeutischen Einsatz zu gewaehrleisten , muessen die jeweiligen Biomaterialeigenschaften mit den Implantatlagereigenschaften abgestimmt sein . Weiterentwickelte biodegradierbare Polymere mit langsamer Umbaurate und laenger anhaltender Stabilitaet werden bei deutlich verminderter Komplikationsrate zunehmend erfolgreich eingesetzt . Im Bereich der keramischen Knochenersatzstoffe laesst die Entwicklung neuartiger umbaubarer Knochenzemente neben der Moeglichkeit der Defektauffuellung die Idee der Verbundosteosynthese " " wieder aufleben . Eine weitere vielversprechende Gruppe sind die rekombinant humanen Knochenwachstumsfaktoren , die zur Zeit in der klinischen Erprobung sind . Eine allgemeine erfolgreiche Anwendung mit verwertbaren Langzeitergebnissen steht noch aus .

[ "Zusammenfassung", ".", "Die", "zunehmende", "Anzahl", "unterschiedlicher", "Biomaterialien", "zur", "Anwendung", "im", "Skelettsystem", "erfordert", "immer", "mehr", "eine", "differenzierte", "Anwendung", "in", "der", "Klinik", ".", "Um", "ihren", "sinnvollen", "therapeutischen", "Einsatz", "zu", "gewaehrleisten", ",", "muessen", "die", "jeweiligen", "Biomaterialeigenschaften", "mit", "den", "Implantatlagereigenschaften", "abgestimmt", "sein", ".", "Weiterentwickelte", "biodegradierbare", "Polymere", "mit", "langsamer", "Umbaurate", "und", "laenger", "anhaltender", "Stabilitaet", "werden", "bei", "deutlich", "verminderter", "Komplikationsrate", "zunehmend", "erfolgreich", "eingesetzt", ".", "Im", "Bereich", "der", "keramischen", "Knochenersatzstoffe", "laesst", "die", "Entwicklung", "neuartiger", "umbaubarer", "Knochenzemente", "neben", "der", "Moeglichkeit", "der", "Defektauffuellung", "die", "Idee", "der", "Verbundosteosynthese", "\"", "\"", "wieder", "aufleben", ".", "Eine", "weitere", "vielversprechende", "Gruppe", "sind", "die", "rekombinant", "humanen", "Knochenwachstumsfaktoren", ",", "die", "zur", "Zeit", "in", "der", "klinischen", "Erprobung", "sind", ".", "Eine", "allgemeine", "erfolgreiche", "Anwendung", "mit", "verwertbaren", "Langzeitergebnissen", "steht", "noch", "aus", "." ]

[ "umlsterm" ]

Skelettsystem is an umlsterm, Polymere is an umlsterm, Knochenersatzstoffe is an umlsterm, Knochenzemente is an umlsterm, Knochenwachstumsfaktoren is an umlsterm, Zeit is an umlsterm, Langzeitergebnissen is an umlsterm

DerChirurg.90700888.ger.abstr_task1

Sentence: Zusammenfassung . Die zunehmende Anzahl unterschiedlicher Biomaterialien zur Anwendung im Skelettsystem erfordert immer mehr eine differenzierte Anwendung in der Klinik . Um ihren sinnvollen therapeutischen Einsatz zu gewaehrleisten , muessen die jeweiligen Biomaterialeigenschaften mit den Implantatlagereigenschaften abgestimmt sein . Weiterentwickelte biodegradierbare Polymere mit langsamer Umbaurate und laenger anhaltender Stabilitaet werden bei deutlich verminderter Komplikationsrate zunehmend erfolgreich eingesetzt . Im Bereich der keramischen Knochenersatzstoffe laesst die Entwicklung neuartiger umbaubarer Knochenzemente neben der Moeglichkeit der Defektauffuellung die Idee der Verbundosteosynthese " " wieder aufleben . Eine weitere vielversprechende Gruppe sind die rekombinant humanen Knochenwachstumsfaktoren , die zur Zeit in der klinischen Erprobung sind . Eine allgemeine erfolgreiche Anwendung mit verwertbaren Langzeitergebnissen steht noch aus . Instructions: please typing these entity words according to sentence: Skelettsystem, Polymere, Knochenersatzstoffe, Knochenzemente, Knochenwachstumsfaktoren, Zeit, Langzeitergebnissen Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Zusammenfassung . Die zunehmende Anzahl unterschiedlicher Biomaterialien zur Anwendung im Skelettsystem erfordert immer mehr eine differenzierte Anwendung in der Klinik . Um ihren sinnvollen therapeutischen Einsatz zu gewaehrleisten , muessen die jeweiligen Biomaterialeigenschaften mit den Implantatlagereigenschaften abgestimmt sein . Weiterentwickelte biodegradierbare Polymere mit langsamer Umbaurate und laenger anhaltender Stabilitaet werden bei deutlich verminderter Komplikationsrate zunehmend erfolgreich eingesetzt . Im Bereich der keramischen Knochenersatzstoffe laesst die Entwicklung neuartiger umbaubarer Knochenzemente neben der Moeglichkeit der Defektauffuellung die Idee der Verbundosteosynthese " " wieder aufleben . Eine weitere vielversprechende Gruppe sind die rekombinant humanen Knochenwachstumsfaktoren , die zur Zeit in der klinischen Erprobung sind . Eine allgemeine erfolgreiche Anwendung mit verwertbaren Langzeitergebnissen steht noch aus .

[ "Zusammenfassung", ".", "Die", "zunehmende", "Anzahl", "unterschiedlicher", "Biomaterialien", "zur", "Anwendung", "im", "Skelettsystem", "erfordert", "immer", "mehr", "eine", "differenzierte", "Anwendung", "in", "der", "Klinik", ".", "Um", "ihren", "sinnvollen", "therapeutischen", "Einsatz", "zu", "gewaehrleisten", ",", "muessen", "die", "jeweiligen", "Biomaterialeigenschaften", "mit", "den", "Implantatlagereigenschaften", "abgestimmt", "sein", ".", "Weiterentwickelte", "biodegradierbare", "Polymere", "mit", "langsamer", "Umbaurate", "und", "laenger", "anhaltender", "Stabilitaet", "werden", "bei", "deutlich", "verminderter", "Komplikationsrate", "zunehmend", "erfolgreich", "eingesetzt", ".", "Im", "Bereich", "der", "keramischen", "Knochenersatzstoffe", "laesst", "die", "Entwicklung", "neuartiger", "umbaubarer", "Knochenzemente", "neben", "der", "Moeglichkeit", "der", "Defektauffuellung", "die", "Idee", "der", "Verbundosteosynthese", "\"", "\"", "wieder", "aufleben", ".", "Eine", "weitere", "vielversprechende", "Gruppe", "sind", "die", "rekombinant", "humanen", "Knochenwachstumsfaktoren", ",", "die", "zur", "Zeit", "in", "der", "klinischen", "Erprobung", "sind", ".", "Eine", "allgemeine", "erfolgreiche", "Anwendung", "mit", "verwertbaren", "Langzeitergebnissen", "steht", "noch", "aus", "." ]

[ "umlsterm" ]

Skelettsystem, Polymere, Knochenersatzstoffe, Knochenzemente, Knochenwachstumsfaktoren, Zeit, Langzeitergebnissen

DerChirurg.90700888.ger.abstr_task2

Sentence: Zusammenfassung . Die zunehmende Anzahl unterschiedlicher Biomaterialien zur Anwendung im Skelettsystem erfordert immer mehr eine differenzierte Anwendung in der Klinik . Um ihren sinnvollen therapeutischen Einsatz zu gewaehrleisten , muessen die jeweiligen Biomaterialeigenschaften mit den Implantatlagereigenschaften abgestimmt sein . Weiterentwickelte biodegradierbare Polymere mit langsamer Umbaurate und laenger anhaltender Stabilitaet werden bei deutlich verminderter Komplikationsrate zunehmend erfolgreich eingesetzt . Im Bereich der keramischen Knochenersatzstoffe laesst die Entwicklung neuartiger umbaubarer Knochenzemente neben der Moeglichkeit der Defektauffuellung die Idee der Verbundosteosynthese " " wieder aufleben . Eine weitere vielversprechende Gruppe sind die rekombinant humanen Knochenwachstumsfaktoren , die zur Zeit in der klinischen Erprobung sind . Eine allgemeine erfolgreiche Anwendung mit verwertbaren Langzeitergebnissen steht noch aus . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Zusammenfassung . Die zunehmende Anzahl unterschiedlicher Biomaterialien zur Anwendung im Skelettsystem erfordert immer mehr eine differenzierte Anwendung in der Klinik . Um ihren sinnvollen therapeutischen Einsatz zu gewaehrleisten , muessen die jeweiligen Biomaterialeigenschaften mit den Implantatlagereigenschaften abgestimmt sein . Weiterentwickelte biodegradierbare Polymere mit langsamer Umbaurate und laenger anhaltender Stabilitaet werden bei deutlich verminderter Komplikationsrate zunehmend erfolgreich eingesetzt . Im Bereich der keramischen Knochenersatzstoffe laesst die Entwicklung neuartiger umbaubarer Knochenzemente neben der Moeglichkeit der Defektauffuellung die Idee der Verbundosteosynthese " " wieder aufleben . Eine weitere vielversprechende Gruppe sind die rekombinant humanen Knochenwachstumsfaktoren , die zur Zeit in der klinischen Erprobung sind . Eine allgemeine erfolgreiche Anwendung mit verwertbaren Langzeitergebnissen steht noch aus .

[ "Zusammenfassung", ".", "Die", "zunehmende", "Anzahl", "unterschiedlicher", "Biomaterialien", "zur", "Anwendung", "im", "Skelettsystem", "erfordert", "immer", "mehr", "eine", "differenzierte", "Anwendung", "in", "der", "Klinik", ".", "Um", "ihren", "sinnvollen", "therapeutischen", "Einsatz", "zu", "gewaehrleisten", ",", "muessen", "die", "jeweiligen", "Biomaterialeigenschaften", "mit", "den", "Implantatlagereigenschaften", "abgestimmt", "sein", ".", "Weiterentwickelte", "biodegradierbare", "Polymere", "mit", "langsamer", "Umbaurate", "und", "laenger", "anhaltender", "Stabilitaet", "werden", "bei", "deutlich", "verminderter", "Komplikationsrate", "zunehmend", "erfolgreich", "eingesetzt", ".", "Im", "Bereich", "der", "keramischen", "Knochenersatzstoffe", "laesst", "die", "Entwicklung", "neuartiger", "umbaubarer", "Knochenzemente", "neben", "der", "Moeglichkeit", "der", "Defektauffuellung", "die", "Idee", "der", "Verbundosteosynthese", "\"", "\"", "wieder", "aufleben", ".", "Eine", "weitere", "vielversprechende", "Gruppe", "sind", "die", "rekombinant", "humanen", "Knochenwachstumsfaktoren", ",", "die", "zur", "Zeit", "in", "der", "klinischen", "Erprobung", "sind", ".", "Eine", "allgemeine", "erfolgreiche", "Anwendung", "mit", "verwertbaren", "Langzeitergebnissen", "steht", "noch", "aus", "." ]

[ "umlsterm" ]

NF - kappa B activation is an other_name, tumor necrosis factor alpha is a protein_molecule, Jurkat T cell line is a cell_line, protein kinase A is a protein_molecule, protein kinase C is a protein_molecule, Ca(2+)-regulated kinases is a protein_family_or_group

93683_task0

Sentence: NF-kappa B activation by tumor necrosis factor alpha in the Jurkat T cell line is independent of protein kinase A, protein kinase C, and Ca(2+)-regulated kinases. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_family_or_group, cell_line, protein_molecule, other_name

[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O" ]

NF-kappa B activation by tumor necrosis factor alpha in the Jurkat T cell line is independent of protein kinase A, protein kinase C, and Ca(2+)-regulated kinases.

[ "NF", "-", "kappa", "B", "activation", "by", "tumor", "necrosis", "factor", "alpha", "in", "the", "Jurkat", "T", "cell", "line", "is", "independent", "of", "protein", "kinase", "A", ",", "protein", "kinase", "C", ",", "and", "Ca(2+)-regulated", "kinases", "." ]

[ "DNA_family_or_group", "other_name", "protein_molecule", "virus", "protein_family_or_group", "cell_line", "other_organic_compound", "cell_type", "atom", "nucleotide" ]

NF - kappa B activation is an other_name, tumor necrosis factor alpha is a protein_molecule, Jurkat T cell line is a cell_line, protein kinase A is a protein_molecule, protein kinase C is a protein_molecule, Ca(2+)-regulated kinases is a protein_family_or_group

93683_task1

Sentence: NF-kappa B activation by tumor necrosis factor alpha in the Jurkat T cell line is independent of protein kinase A, protein kinase C, and Ca(2+)-regulated kinases. Instructions: please typing these entity words according to sentence: NF - kappa B activation, tumor necrosis factor alpha, Jurkat T cell line, protein kinase A, protein kinase C, Ca(2+)-regulated kinases Options: protein_family_or_group, cell_line, protein_molecule, other_name

[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O" ]

NF-kappa B activation by tumor necrosis factor alpha in the Jurkat T cell line is independent of protein kinase A, protein kinase C, and Ca(2+)-regulated kinases.

[ "NF", "-", "kappa", "B", "activation", "by", "tumor", "necrosis", "factor", "alpha", "in", "the", "Jurkat", "T", "cell", "line", "is", "independent", "of", "protein", "kinase", "A", ",", "protein", "kinase", "C", ",", "and", "Ca(2+)-regulated", "kinases", "." ]

[ "DNA_family_or_group", "other_name", "protein_molecule", "virus", "protein_family_or_group", "cell_line", "other_organic_compound", "cell_type", "atom", "nucleotide" ]

NF - kappa B activation, tumor necrosis factor alpha, Jurkat T cell line, protein kinase A, protein kinase C, Ca(2+)-regulated kinases

93683_task2

Sentence: NF-kappa B activation by tumor necrosis factor alpha in the Jurkat T cell line is independent of protein kinase A, protein kinase C, and Ca(2+)-regulated kinases. Instructions: please extract entity words from the input sentence

[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O" ]

NF-kappa B activation by tumor necrosis factor alpha in the Jurkat T cell line is independent of protein kinase A, protein kinase C, and Ca(2+)-regulated kinases.

[ "NF", "-", "kappa", "B", "activation", "by", "tumor", "necrosis", "factor", "alpha", "in", "the", "Jurkat", "T", "cell", "line", "is", "independent", "of", "protein", "kinase", "A", ",", "protein", "kinase", "C", ",", "and", "Ca(2+)-regulated", "kinases", "." ]

[ "DNA_family_or_group", "other_name", "protein_molecule", "virus", "protein_family_or_group", "cell_line", "other_organic_compound", "cell_type", "atom", "nucleotide" ]

pathologic response is a Outcome_Physical, neoadjuvant chemotherapy and trastuzumab is a Intervention_Pharmacological, Preoperative therapy with chemotherapy is a Intervention_Pharmacological, HER2-targeted monoclonal antibody trastuzumab is a Intervention_Pharmacological, patients with large or locally advanced HER2-positive ( HER2 + ) breast cancers is a Participant_Condition, core biopsy samples from 27 HER2 + breast cancer patients enrolled in a preoperative clinical trial using trastuzumab , nab - paclitaxel and carboplatin combination therapy ( BrUOG BR-211B ( NCT00617942 ) ) is a Participant_Condition, pathologic complete response ( pathCR ) is a Outcome_Physical, Measurement of phospho - HER2 is a Outcome_Physical, in the HER2 or phospho - HER2 levels is a Outcome_Physical, High levels of is a Outcome_Physical, levels of Phospho - HER2 is a Outcome_Physical

65819_task0

Sentence: Quantitative measurements of HER2 and phospho-HER2 expression : correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab . BACKGROUND Preoperative therapy with chemotherapy and the HER2-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER2-positive ( HER2+ ) breast cancers but traditional methods of measuring HER2 expression do not accurately stratify patients for likelihood of response . Quantitative immunofluorescent approaches have the potential to provide a mathematically continuous measure of HER2 . Here we seek to determine whether quantitative measurement of HER2 or phospho-HER2 correlates with likelihood of response to trastuzumab- containing neoadjuvant therapy . METHODS We evaluated core biopsy samples from 27 HER2+ breast cancer patients enrolled in a preoperative clinical trial using trastuzumab , nab-paclitaxel and carboplatin combination therapy ( BrUOG BR-211B ( NCT00617942 ) ) . Tumor core biopsies were taken before initiation of treatment and 9-13 days after patients received " run-in " doses of either single agent trastuzumab or nab-paclitaxel . The AQUA method of quantitative immunofluorescence was used for analysis of in situ protein expression . Patients then received 18 weeks of treatment , followed by surgery to assess pathologic response to the neoadjuvant regimen . RESULTS A HER2 score of 2111 by AQUA analysis has been shown to be equivalent to HER2 3+ by immunohistochemical staining in previous studies . Of 20 evaluable patients , 10 cases who achieved a pathologic complete response ( pathCR ) with neoadjuvant treatment had a mean HER2 level of 10251 compared with 4766 in the patients without pathCR ( p = 0.0021 ) . Measurement of phospho-HER2 showed no difference in pathCR vs non-pathCR groups . In 9 patients who had HER2 levels repeated after a single treatment with trastuzumab there was no evidence of a reduction in the HER2 or phospho-HER2 levels following that exposure . CONCLUSIONS High levels of HER2 are associated with achievement of a pathCR in the preoperative setting , while levels of Phospho-HER2 were not predictive of response . This data suggests that accurate measurement of HER2 may help determine the likelihood of response in the pre-surgical setting . Further validation in larger cohorts is required , but this pilot data shows the feasibility of this approach . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Quantitative measurements of HER2 and phospho-HER2 expression : correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab . BACKGROUND Preoperative therapy with chemotherapy and the HER2-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER2-positive ( HER2+ ) breast cancers but traditional methods of measuring HER2 expression do not accurately stratify patients for likelihood of response . Quantitative immunofluorescent approaches have the potential to provide a mathematically continuous measure of HER2 . Here we seek to determine whether quantitative measurement of HER2 or phospho-HER2 correlates with likelihood of response to trastuzumab- containing neoadjuvant therapy . METHODS We evaluated core biopsy samples from 27 HER2+ breast cancer patients enrolled in a preoperative clinical trial using trastuzumab , nab-paclitaxel and carboplatin combination therapy ( BrUOG BR-211B ( NCT00617942 ) ) . Tumor core biopsies were taken before initiation of treatment and 9-13 days after patients received " run-in " doses of either single agent trastuzumab or nab-paclitaxel . The AQUA method of quantitative immunofluorescence was used for analysis of in situ protein expression . Patients then received 18 weeks of treatment , followed by surgery to assess pathologic response to the neoadjuvant regimen . RESULTS A HER2 score of 2111 by AQUA analysis has been shown to be equivalent to HER2 3+ by immunohistochemical staining in previous studies . Of 20 evaluable patients , 10 cases who achieved a pathologic complete response ( pathCR ) with neoadjuvant treatment had a mean HER2 level of 10251 compared with 4766 in the patients without pathCR ( p = 0.0021 ) . Measurement of phospho-HER2 showed no difference in pathCR vs non-pathCR groups . In 9 patients who had HER2 levels repeated after a single treatment with trastuzumab there was no evidence of a reduction in the HER2 or phospho-HER2 levels following that exposure . CONCLUSIONS High levels of HER2 are associated with achievement of a pathCR in the preoperative setting , while levels of Phospho-HER2 were not predictive of response . This data suggests that accurate measurement of HER2 may help determine the likelihood of response in the pre-surgical setting . Further validation in larger cohorts is required , but this pilot data shows the feasibility of this approach .

[ "Quantitative", "measurements", "of", "HER2", "and", "phospho", "-", "HER2", "expression", ":", "correlation", "with", "pathologic", "response", "to", "neoadjuvant", "chemotherapy", "and", "trastuzumab", ".", "BACKGROUND", "Preoperative", "therapy", "with", "chemotherapy", "and", "the", "HER2-targeted", "monoclonal", "antibody", "trastuzumab", "is", "valuable", "for", "patients", "with", "large", "or", "locally", "advanced", "HER2-positive", "(", "HER2", "+", ")", "breast", "cancers", "but", "traditional", "methods", "of", "measuring", "HER2", "expression", "do", "not", "accurately", "stratify", "patients", "for", "likelihood", "of", "response", ".", "Quantitative", "immunofluorescent", "approaches", "have", "the", "potential", "to", "provide", "a", "mathematically", "continuous", "measure", "of", "HER2", ".", "Here", "we", "seek", "to", "determine", "whether", "quantitative", "measurement", "of", "HER2", "or", "phospho", "-", "HER2", "correlates", "with", "likelihood", "of", "response", "to", "trastuzumab-", "containing", "neoadjuvant", "therapy", ".", "METHODS", "We", "evaluated", "core", "biopsy", "samples", "from", "27", "HER2", "+", "breast", "cancer", "patients", "enrolled", "in", "a", "preoperative", "clinical", "trial", "using", "trastuzumab", ",", "nab", "-", "paclitaxel", "and", "carboplatin", "combination", "therapy", "(", "BrUOG", "BR-211B", "(", "NCT00617942", ")", ")", ".", "Tumor", "core", "biopsies", "were", "taken", "before", "initiation", "of", "treatment", "and", "9", "-", "13", "days", "after", "patients", "received", "\"", "run", "-", "in", "\"", "doses", "of", "either", "single", "agent", "trastuzumab", "or", "nab", "-", "paclitaxel", ".", "The", "AQUA", "method", "of", "quantitative", "immunofluorescence", "was", "used", "for", "analysis", "of", "in", "situ", "protein", "expression", ".", "Patients", "then", "received", "18", "weeks", "of", "treatment", ",", "followed", "by", "surgery", "to", "assess", "pathologic", "response", "to", "the", "neoadjuvant", "regimen", ".", "RESULTS", "A", "HER2", "score", "of", "2111", "by", "AQUA", "analysis", "has", "been", "shown", "to", "be", "equivalent", "to", "HER2", "3", "+", "by", "immunohistochemical", "staining", "in", "previous", "studies", ".", "Of", "20", "evaluable", "patients", ",", "10", "cases", "who", "achieved", "a", "pathologic", "complete", "response", "(", "pathCR", ")", "with", "neoadjuvant", "treatment", "had", "a", "mean", "HER2", "level", "of", "10251", "compared", "with", "4766", "in", "the", "patients", "without", "pathCR", "(", "p", "=", "0.0021", ")", ".", "Measurement", "of", "phospho", "-", "HER2", "showed", "no", "difference", "in", "pathCR", "vs", "non", "-", "pathCR", "groups", ".", "In", "9", "patients", "who", "had", "HER2", "levels", "repeated", "after", "a", "single", "treatment", "with", "trastuzumab", "there", "was", "no", "evidence", "of", "a", "reduction", "in", "the", "HER2", "or", "phospho", "-", "HER2", "levels", "following", "that", "exposure", ".", "CONCLUSIONS", "High", "levels", "of", "HER2", "are", "associated", "with", "achievement", "of", "a", "pathCR", "in", "the", "preoperative", "setting", ",", "while", "levels", "of", "Phospho", "-", "HER2", "were", "not", "predictive", "of", "response", ".", "This", "data", "suggests", "that", "accurate", "measurement", "of", "HER2", "may", "help", "determine", "the", "likelihood", "of", "response", "in", "the", "pre", "-", "surgical", "setting", ".", "Further", "validation", "in", "larger", "cohorts", "is", "required", ",", "but", "this", "pilot", "data", "shows", "the", "feasibility", "of", "this", "approach", "." ]

[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Physical" ]

pathologic response is a Outcome_Physical, neoadjuvant chemotherapy and trastuzumab is a Intervention_Pharmacological, Preoperative therapy with chemotherapy is a Intervention_Pharmacological, HER2-targeted monoclonal antibody trastuzumab is a Intervention_Pharmacological, patients with large or locally advanced HER2-positive ( HER2 + ) breast cancers is a Participant_Condition, core biopsy samples from 27 HER2 + breast cancer patients enrolled in a preoperative clinical trial using trastuzumab , nab - paclitaxel and carboplatin combination therapy ( BrUOG BR-211B ( NCT00617942 ) ) is a Participant_Condition, pathologic complete response ( pathCR ) is a Outcome_Physical, Measurement of phospho - HER2 is a Outcome_Physical, in the HER2 or phospho - HER2 levels is a Outcome_Physical, High levels of is a Outcome_Physical, levels of Phospho - HER2 is a Outcome_Physical

65819_task1

Sentence: Quantitative measurements of HER2 and phospho-HER2 expression : correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab . BACKGROUND Preoperative therapy with chemotherapy and the HER2-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER2-positive ( HER2+ ) breast cancers but traditional methods of measuring HER2 expression do not accurately stratify patients for likelihood of response . Quantitative immunofluorescent approaches have the potential to provide a mathematically continuous measure of HER2 . Here we seek to determine whether quantitative measurement of HER2 or phospho-HER2 correlates with likelihood of response to trastuzumab- containing neoadjuvant therapy . METHODS We evaluated core biopsy samples from 27 HER2+ breast cancer patients enrolled in a preoperative clinical trial using trastuzumab , nab-paclitaxel and carboplatin combination therapy ( BrUOG BR-211B ( NCT00617942 ) ) . Tumor core biopsies were taken before initiation of treatment and 9-13 days after patients received " run-in " doses of either single agent trastuzumab or nab-paclitaxel . The AQUA method of quantitative immunofluorescence was used for analysis of in situ protein expression . Patients then received 18 weeks of treatment , followed by surgery to assess pathologic response to the neoadjuvant regimen . RESULTS A HER2 score of 2111 by AQUA analysis has been shown to be equivalent to HER2 3+ by immunohistochemical staining in previous studies . Of 20 evaluable patients , 10 cases who achieved a pathologic complete response ( pathCR ) with neoadjuvant treatment had a mean HER2 level of 10251 compared with 4766 in the patients without pathCR ( p = 0.0021 ) . Measurement of phospho-HER2 showed no difference in pathCR vs non-pathCR groups . In 9 patients who had HER2 levels repeated after a single treatment with trastuzumab there was no evidence of a reduction in the HER2 or phospho-HER2 levels following that exposure . CONCLUSIONS High levels of HER2 are associated with achievement of a pathCR in the preoperative setting , while levels of Phospho-HER2 were not predictive of response . This data suggests that accurate measurement of HER2 may help determine the likelihood of response in the pre-surgical setting . Further validation in larger cohorts is required , but this pilot data shows the feasibility of this approach . Instructions: please typing these entity words according to sentence: pathologic response, neoadjuvant chemotherapy and trastuzumab, Preoperative therapy with chemotherapy, HER2-targeted monoclonal antibody trastuzumab, patients with large or locally advanced HER2-positive ( HER2 + ) breast cancers, core biopsy samples from 27 HER2 + breast cancer patients enrolled in a preoperative clinical trial using trastuzumab , nab - paclitaxel and carboplatin combination therapy ( BrUOG BR-211B ( NCT00617942 ) ), pathologic complete response ( pathCR ), Measurement of phospho - HER2, in the HER2 or phospho - HER2 levels, High levels of, levels of Phospho - HER2 Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Quantitative measurements of HER2 and phospho-HER2 expression : correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab . BACKGROUND Preoperative therapy with chemotherapy and the HER2-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER2-positive ( HER2+ ) breast cancers but traditional methods of measuring HER2 expression do not accurately stratify patients for likelihood of response . Quantitative immunofluorescent approaches have the potential to provide a mathematically continuous measure of HER2 . Here we seek to determine whether quantitative measurement of HER2 or phospho-HER2 correlates with likelihood of response to trastuzumab- containing neoadjuvant therapy . METHODS We evaluated core biopsy samples from 27 HER2+ breast cancer patients enrolled in a preoperative clinical trial using trastuzumab , nab-paclitaxel and carboplatin combination therapy ( BrUOG BR-211B ( NCT00617942 ) ) . Tumor core biopsies were taken before initiation of treatment and 9-13 days after patients received " run-in " doses of either single agent trastuzumab or nab-paclitaxel . The AQUA method of quantitative immunofluorescence was used for analysis of in situ protein expression . Patients then received 18 weeks of treatment , followed by surgery to assess pathologic response to the neoadjuvant regimen . RESULTS A HER2 score of 2111 by AQUA analysis has been shown to be equivalent to HER2 3+ by immunohistochemical staining in previous studies . Of 20 evaluable patients , 10 cases who achieved a pathologic complete response ( pathCR ) with neoadjuvant treatment had a mean HER2 level of 10251 compared with 4766 in the patients without pathCR ( p = 0.0021 ) . Measurement of phospho-HER2 showed no difference in pathCR vs non-pathCR groups . In 9 patients who had HER2 levels repeated after a single treatment with trastuzumab there was no evidence of a reduction in the HER2 or phospho-HER2 levels following that exposure . CONCLUSIONS High levels of HER2 are associated with achievement of a pathCR in the preoperative setting , while levels of Phospho-HER2 were not predictive of response . This data suggests that accurate measurement of HER2 may help determine the likelihood of response in the pre-surgical setting . Further validation in larger cohorts is required , but this pilot data shows the feasibility of this approach .

[ "Quantitative", "measurements", "of", "HER2", "and", "phospho", "-", "HER2", "expression", ":", "correlation", "with", "pathologic", "response", "to", "neoadjuvant", "chemotherapy", "and", "trastuzumab", ".", "BACKGROUND", "Preoperative", "therapy", "with", "chemotherapy", "and", "the", "HER2-targeted", "monoclonal", "antibody", "trastuzumab", "is", "valuable", "for", "patients", "with", "large", "or", "locally", "advanced", "HER2-positive", "(", "HER2", "+", ")", "breast", "cancers", "but", "traditional", "methods", "of", "measuring", "HER2", "expression", "do", "not", "accurately", "stratify", "patients", "for", "likelihood", "of", "response", ".", "Quantitative", "immunofluorescent", "approaches", "have", "the", "potential", "to", "provide", "a", "mathematically", "continuous", "measure", "of", "HER2", ".", "Here", "we", "seek", "to", "determine", "whether", "quantitative", "measurement", "of", "HER2", "or", "phospho", "-", "HER2", "correlates", "with", "likelihood", "of", "response", "to", "trastuzumab-", "containing", "neoadjuvant", "therapy", ".", "METHODS", "We", "evaluated", "core", "biopsy", "samples", "from", "27", "HER2", "+", "breast", "cancer", "patients", "enrolled", "in", "a", "preoperative", "clinical", "trial", "using", "trastuzumab", ",", "nab", "-", "paclitaxel", "and", "carboplatin", "combination", "therapy", "(", "BrUOG", "BR-211B", "(", "NCT00617942", ")", ")", ".", "Tumor", "core", "biopsies", "were", "taken", "before", "initiation", "of", "treatment", "and", "9", "-", "13", "days", "after", "patients", "received", "\"", "run", "-", "in", "\"", "doses", "of", "either", "single", "agent", "trastuzumab", "or", "nab", "-", "paclitaxel", ".", "The", "AQUA", "method", "of", "quantitative", "immunofluorescence", "was", "used", "for", "analysis", "of", "in", "situ", "protein", "expression", ".", "Patients", "then", "received", "18", "weeks", "of", "treatment", ",", "followed", "by", "surgery", "to", "assess", "pathologic", "response", "to", "the", "neoadjuvant", "regimen", ".", "RESULTS", "A", "HER2", "score", "of", "2111", "by", "AQUA", "analysis", "has", "been", "shown", "to", "be", "equivalent", "to", "HER2", "3", "+", "by", "immunohistochemical", "staining", "in", "previous", "studies", ".", "Of", "20", "evaluable", "patients", ",", "10", "cases", "who", "achieved", "a", "pathologic", "complete", "response", "(", "pathCR", ")", "with", "neoadjuvant", "treatment", "had", "a", "mean", "HER2", "level", "of", "10251", "compared", "with", "4766", "in", "the", "patients", "without", "pathCR", "(", "p", "=", "0.0021", ")", ".", "Measurement", "of", "phospho", "-", "HER2", "showed", "no", "difference", "in", "pathCR", "vs", "non", "-", "pathCR", "groups", ".", "In", "9", "patients", "who", "had", "HER2", "levels", "repeated", "after", "a", "single", "treatment", "with", "trastuzumab", "there", "was", "no", "evidence", "of", "a", "reduction", "in", "the", "HER2", "or", "phospho", "-", "HER2", "levels", "following", "that", "exposure", ".", "CONCLUSIONS", "High", "levels", "of", "HER2", "are", "associated", "with", "achievement", "of", "a", "pathCR", "in", "the", "preoperative", "setting", ",", "while", "levels", "of", "Phospho", "-", "HER2", "were", "not", "predictive", "of", "response", ".", "This", "data", "suggests", "that", "accurate", "measurement", "of", "HER2", "may", "help", "determine", "the", "likelihood", "of", "response", "in", "the", "pre", "-", "surgical", "setting", ".", "Further", "validation", "in", "larger", "cohorts", "is", "required", ",", "but", "this", "pilot", "data", "shows", "the", "feasibility", "of", "this", "approach", "." ]

[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Physical" ]

pathologic response, neoadjuvant chemotherapy and trastuzumab, Preoperative therapy with chemotherapy, HER2-targeted monoclonal antibody trastuzumab, patients with large or locally advanced HER2-positive ( HER2 + ) breast cancers, core biopsy samples from 27 HER2 + breast cancer patients enrolled in a preoperative clinical trial using trastuzumab , nab - paclitaxel and carboplatin combination therapy ( BrUOG BR-211B ( NCT00617942 ) ), pathologic complete response ( pathCR ), Measurement of phospho - HER2, in the HER2 or phospho - HER2 levels, High levels of, levels of Phospho - HER2

65819_task2

Sentence: Quantitative measurements of HER2 and phospho-HER2 expression : correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab . BACKGROUND Preoperative therapy with chemotherapy and the HER2-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER2-positive ( HER2+ ) breast cancers but traditional methods of measuring HER2 expression do not accurately stratify patients for likelihood of response . Quantitative immunofluorescent approaches have the potential to provide a mathematically continuous measure of HER2 . Here we seek to determine whether quantitative measurement of HER2 or phospho-HER2 correlates with likelihood of response to trastuzumab- containing neoadjuvant therapy . METHODS We evaluated core biopsy samples from 27 HER2+ breast cancer patients enrolled in a preoperative clinical trial using trastuzumab , nab-paclitaxel and carboplatin combination therapy ( BrUOG BR-211B ( NCT00617942 ) ) . Tumor core biopsies were taken before initiation of treatment and 9-13 days after patients received " run-in " doses of either single agent trastuzumab or nab-paclitaxel . The AQUA method of quantitative immunofluorescence was used for analysis of in situ protein expression . Patients then received 18 weeks of treatment , followed by surgery to assess pathologic response to the neoadjuvant regimen . RESULTS A HER2 score of 2111 by AQUA analysis has been shown to be equivalent to HER2 3+ by immunohistochemical staining in previous studies . Of 20 evaluable patients , 10 cases who achieved a pathologic complete response ( pathCR ) with neoadjuvant treatment had a mean HER2 level of 10251 compared with 4766 in the patients without pathCR ( p = 0.0021 ) . Measurement of phospho-HER2 showed no difference in pathCR vs non-pathCR groups . In 9 patients who had HER2 levels repeated after a single treatment with trastuzumab there was no evidence of a reduction in the HER2 or phospho-HER2 levels following that exposure . CONCLUSIONS High levels of HER2 are associated with achievement of a pathCR in the preoperative setting , while levels of Phospho-HER2 were not predictive of response . This data suggests that accurate measurement of HER2 may help determine the likelihood of response in the pre-surgical setting . Further validation in larger cohorts is required , but this pilot data shows the feasibility of this approach . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Quantitative measurements of HER2 and phospho-HER2 expression : correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab . BACKGROUND Preoperative therapy with chemotherapy and the HER2-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER2-positive ( HER2+ ) breast cancers but traditional methods of measuring HER2 expression do not accurately stratify patients for likelihood of response . Quantitative immunofluorescent approaches have the potential to provide a mathematically continuous measure of HER2 . Here we seek to determine whether quantitative measurement of HER2 or phospho-HER2 correlates with likelihood of response to trastuzumab- containing neoadjuvant therapy . METHODS We evaluated core biopsy samples from 27 HER2+ breast cancer patients enrolled in a preoperative clinical trial using trastuzumab , nab-paclitaxel and carboplatin combination therapy ( BrUOG BR-211B ( NCT00617942 ) ) . Tumor core biopsies were taken before initiation of treatment and 9-13 days after patients received " run-in " doses of either single agent trastuzumab or nab-paclitaxel . The AQUA method of quantitative immunofluorescence was used for analysis of in situ protein expression . Patients then received 18 weeks of treatment , followed by surgery to assess pathologic response to the neoadjuvant regimen . RESULTS A HER2 score of 2111 by AQUA analysis has been shown to be equivalent to HER2 3+ by immunohistochemical staining in previous studies . Of 20 evaluable patients , 10 cases who achieved a pathologic complete response ( pathCR ) with neoadjuvant treatment had a mean HER2 level of 10251 compared with 4766 in the patients without pathCR ( p = 0.0021 ) . Measurement of phospho-HER2 showed no difference in pathCR vs non-pathCR groups . In 9 patients who had HER2 levels repeated after a single treatment with trastuzumab there was no evidence of a reduction in the HER2 or phospho-HER2 levels following that exposure . CONCLUSIONS High levels of HER2 are associated with achievement of a pathCR in the preoperative setting , while levels of Phospho-HER2 were not predictive of response . This data suggests that accurate measurement of HER2 may help determine the likelihood of response in the pre-surgical setting . Further validation in larger cohorts is required , but this pilot data shows the feasibility of this approach .

[ "Quantitative", "measurements", "of", "HER2", "and", "phospho", "-", "HER2", "expression", ":", "correlation", "with", "pathologic", "response", "to", "neoadjuvant", "chemotherapy", "and", "trastuzumab", ".", "BACKGROUND", "Preoperative", "therapy", "with", "chemotherapy", "and", "the", "HER2-targeted", "monoclonal", "antibody", "trastuzumab", "is", "valuable", "for", "patients", "with", "large", "or", "locally", "advanced", "HER2-positive", "(", "HER2", "+", ")", "breast", "cancers", "but", "traditional", "methods", "of", "measuring", "HER2", "expression", "do", "not", "accurately", "stratify", "patients", "for", "likelihood", "of", "response", ".", "Quantitative", "immunofluorescent", "approaches", "have", "the", "potential", "to", "provide", "a", "mathematically", "continuous", "measure", "of", "HER2", ".", "Here", "we", "seek", "to", "determine", "whether", "quantitative", "measurement", "of", "HER2", "or", "phospho", "-", "HER2", "correlates", "with", "likelihood", "of", "response", "to", "trastuzumab-", "containing", "neoadjuvant", "therapy", ".", "METHODS", "We", "evaluated", "core", "biopsy", "samples", "from", "27", "HER2", "+", "breast", "cancer", "patients", "enrolled", "in", "a", "preoperative", "clinical", "trial", "using", "trastuzumab", ",", "nab", "-", "paclitaxel", "and", "carboplatin", "combination", "therapy", "(", "BrUOG", "BR-211B", "(", "NCT00617942", ")", ")", ".", "Tumor", "core", "biopsies", "were", "taken", "before", "initiation", "of", "treatment", "and", "9", "-", "13", "days", "after", "patients", "received", "\"", "run", "-", "in", "\"", "doses", "of", "either", "single", "agent", "trastuzumab", "or", "nab", "-", "paclitaxel", ".", "The", "AQUA", "method", "of", "quantitative", "immunofluorescence", "was", "used", "for", "analysis", "of", "in", "situ", "protein", "expression", ".", "Patients", "then", "received", "18", "weeks", "of", "treatment", ",", "followed", "by", "surgery", "to", "assess", "pathologic", "response", "to", "the", "neoadjuvant", "regimen", ".", "RESULTS", "A", "HER2", "score", "of", "2111", "by", "AQUA", "analysis", "has", "been", "shown", "to", "be", "equivalent", "to", "HER2", "3", "+", "by", "immunohistochemical", "staining", "in", "previous", "studies", ".", "Of", "20", "evaluable", "patients", ",", "10", "cases", "who", "achieved", "a", "pathologic", "complete", "response", "(", "pathCR", ")", "with", "neoadjuvant", "treatment", "had", "a", "mean", "HER2", "level", "of", "10251", "compared", "with", "4766", "in", "the", "patients", "without", "pathCR", "(", "p", "=", "0.0021", ")", ".", "Measurement", "of", "phospho", "-", "HER2", "showed", "no", "difference", "in", "pathCR", "vs", "non", "-", "pathCR", "groups", ".", "In", "9", "patients", "who", "had", "HER2", "levels", "repeated", "after", "a", "single", "treatment", "with", "trastuzumab", "there", "was", "no", "evidence", "of", "a", "reduction", "in", "the", "HER2", "or", "phospho", "-", "HER2", "levels", "following", "that", "exposure", ".", "CONCLUSIONS", "High", "levels", "of", "HER2", "are", "associated", "with", "achievement", "of", "a", "pathCR", "in", "the", "preoperative", "setting", ",", "while", "levels", "of", "Phospho", "-", "HER2", "were", "not", "predictive", "of", "response", ".", "This", "data", "suggests", "that", "accurate", "measurement", "of", "HER2", "may", "help", "determine", "the", "likelihood", "of", "response", "in", "the", "pre", "-", "surgical", "setting", ".", "Further", "validation", "in", "larger", "cohorts", "is", "required", ",", "but", "this", "pilot", "data", "shows", "the", "feasibility", "of", "this", "approach", "." ]

[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Physical" ]

Eligible patients were children and adolescents with HFA is a participant

370_task0

Sentence: Eligible patients were children and adolescents with HFA . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: participant

[ "B-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "O" ]

Eligible patients were children and adolescents with HFA .

[ "Eligible", "patients", "were", "children", "and", "adolescents", "with", "HFA", "." ]

[ "participant" ]

Eligible patients were children and adolescents with HFA is a participant

370_task1

Sentence: Eligible patients were children and adolescents with HFA . Instructions: please typing these entity words according to sentence: Eligible patients were children and adolescents with HFA Options: participant

[ "B-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "O" ]

Eligible patients were children and adolescents with HFA .

[ "Eligible", "patients", "were", "children", "and", "adolescents", "with", "HFA", "." ]

[ "participant" ]

Eligible patients were children and adolescents with HFA

370_task2

Sentence: Eligible patients were children and adolescents with HFA . Instructions: please extract entity words from the input sentence

[ "B-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "I-participant", "O" ]

Eligible patients were children and adolescents with HFA .

[ "Eligible", "patients", "were", "children", "and", "adolescents", "with", "HFA", "." ]

[ "participant" ]

prospective study is an umlsterm, patients is an umlsterm, posterior is an umlsterm, knee is an umlsterm, all - inside is an umlsterm, technique is an umlsterm, tendon is an umlsterm, grafts is an umlsterm, patients is an umlsterm, patients is an umlsterm, grafts is an umlsterm, infection is an umlsterm, rupture is an umlsterm, posterior is an umlsterm, patients is an umlsterm, patient is an umlsterm, overall is an umlsterm, evaluation is an umlsterm, patients is an umlsterm

Arthroskopie.00130041.eng.abstr_task0

Sentence: In a prospective study , 35 consecutive patients with an isolated posterior knee instability were stabilized arthroscopically in a new all-inside , double bundle technique using the autologous quadrupled semitendinosus and the doubled gracilis tendon . Femoral fixation of the grafts was performed with two Endobuttons . Out of 24 patients , 20 were evaluated with a follow-up of 25.4 months ( 12-47 ) on average ; in 15 cases the follow-up was less than 12 months . Only 18 patients could be evaluated because in two cases the grafts had to be removed ( one infection , one rupture ) . The Lysholm score improved from 67.6 points preoperatively to 88.5 points , the Tegner score from 3.9 to 4.9. The corrected posterior drawer measured with the KT-1000 arthrometer was reduced from 9.1 mm to 4.3 mm postoperatively . Preoperatively , 17 patients belonged to group D and one patient to group C in the IKDC overall evaluation form . After stabilization , eight patients were in group B , seven in group C , and three remained in group D. Damage to neurovascular structures in the popliteal area did not occur . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In a prospective study , 35 consecutive patients with an isolated posterior knee instability were stabilized arthroscopically in a new all-inside , double bundle technique using the autologous quadrupled semitendinosus and the doubled gracilis tendon . Femoral fixation of the grafts was performed with two Endobuttons . Out of 24 patients , 20 were evaluated with a follow-up of 25.4 months ( 12-47 ) on average ; in 15 cases the follow-up was less than 12 months . Only 18 patients could be evaluated because in two cases the grafts had to be removed ( one infection , one rupture ) . The Lysholm score improved from 67.6 points preoperatively to 88.5 points , the Tegner score from 3.9 to 4.9. The corrected posterior drawer measured with the KT-1000 arthrometer was reduced from 9.1 mm to 4.3 mm postoperatively . Preoperatively , 17 patients belonged to group D and one patient to group C in the IKDC overall evaluation form . After stabilization , eight patients were in group B , seven in group C , and three remained in group D. Damage to neurovascular structures in the popliteal area did not occur .

[ "In", "a", "prospective", "study", ",", "35", "consecutive", "patients", "with", "an", "isolated", "posterior", "knee", "instability", "were", "stabilized", "arthroscopically", "in", "a", "new", "all", "-", "inside", ",", "double", "bundle", "technique", "using", "the", "autologous", "quadrupled", "semitendinosus", "and", "the", "doubled", "gracilis", "tendon", ".", "Femoral", "fixation", "of", "the", "grafts", "was", "performed", "with", "two", "Endobuttons", ".", "Out", "of", "24", "patients", ",", "20", "were", "evaluated", "with", "a", "follow", "-", "up", "of", "25.4", "months", "(", "12", "-", "47", ")", "on", "average", ";", "in", "15", "cases", "the", "follow", "-", "up", "was", "less", "than", "12", "months", ".", "Only", "18", "patients", "could", "be", "evaluated", "because", "in", "two", "cases", "the", "grafts", "had", "to", "be", "removed", "(", "one", "infection", ",", "one", "rupture", ")", ".", "The", "Lysholm", "score", "improved", "from", "67.6", "points", "preoperatively", "to", "88.5", "points", ",", "the", "Tegner", "score", "from", "3.9", "to", "4.9", ".", "The", "corrected", "posterior", "drawer", "measured", "with", "the", "KT-1000", "arthrometer", "was", "reduced", "from", "9.1", "mm", "to", "4.3", "mm", "postoperatively", ".", "Preoperatively", ",", "17", "patients", "belonged", "to", "group", "D", "and", "one", "patient", "to", "group", "C", "in", "the", "IKDC", "overall", "evaluation", "form", ".", "After", "stabilization", ",", "eight", "patients", "were", "in", "group", "B", ",", "seven", "in", "group", "C", ",", "and", "three", "remained", "in", "group", "D.", "Damage", "to", "neurovascular", "structures", "in", "the", "popliteal", "area", "did", "not", "occur", "." ]

[ "umlsterm" ]

prospective study is an umlsterm, patients is an umlsterm, posterior is an umlsterm, knee is an umlsterm, all - inside is an umlsterm, technique is an umlsterm, tendon is an umlsterm, grafts is an umlsterm, patients is an umlsterm, patients is an umlsterm, grafts is an umlsterm, infection is an umlsterm, rupture is an umlsterm, posterior is an umlsterm, patients is an umlsterm, patient is an umlsterm, overall is an umlsterm, evaluation is an umlsterm, patients is an umlsterm

Arthroskopie.00130041.eng.abstr_task1

Sentence: In a prospective study , 35 consecutive patients with an isolated posterior knee instability were stabilized arthroscopically in a new all-inside , double bundle technique using the autologous quadrupled semitendinosus and the doubled gracilis tendon . Femoral fixation of the grafts was performed with two Endobuttons . Out of 24 patients , 20 were evaluated with a follow-up of 25.4 months ( 12-47 ) on average ; in 15 cases the follow-up was less than 12 months . Only 18 patients could be evaluated because in two cases the grafts had to be removed ( one infection , one rupture ) . The Lysholm score improved from 67.6 points preoperatively to 88.5 points , the Tegner score from 3.9 to 4.9. The corrected posterior drawer measured with the KT-1000 arthrometer was reduced from 9.1 mm to 4.3 mm postoperatively . Preoperatively , 17 patients belonged to group D and one patient to group C in the IKDC overall evaluation form . After stabilization , eight patients were in group B , seven in group C , and three remained in group D. Damage to neurovascular structures in the popliteal area did not occur . Instructions: please typing these entity words according to sentence: prospective study, patients, posterior, knee, all - inside, technique, tendon, grafts, patients, patients, grafts, infection, rupture, posterior, patients, patient, overall, evaluation, patients Options: umlsterm

[ "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In a prospective study , 35 consecutive patients with an isolated posterior knee instability were stabilized arthroscopically in a new all-inside , double bundle technique using the autologous quadrupled semitendinosus and the doubled gracilis tendon . Femoral fixation of the grafts was performed with two Endobuttons . Out of 24 patients , 20 were evaluated with a follow-up of 25.4 months ( 12-47 ) on average ; in 15 cases the follow-up was less than 12 months . Only 18 patients could be evaluated because in two cases the grafts had to be removed ( one infection , one rupture ) . The Lysholm score improved from 67.6 points preoperatively to 88.5 points , the Tegner score from 3.9 to 4.9. The corrected posterior drawer measured with the KT-1000 arthrometer was reduced from 9.1 mm to 4.3 mm postoperatively . Preoperatively , 17 patients belonged to group D and one patient to group C in the IKDC overall evaluation form . After stabilization , eight patients were in group B , seven in group C , and three remained in group D. Damage to neurovascular structures in the popliteal area did not occur .

[ "In", "a", "prospective", "study", ",", "35", "consecutive", "patients", "with", "an", "isolated", "posterior", "knee", "instability", "were", "stabilized", "arthroscopically", "in", "a", "new", "all", "-", "inside", ",", "double", "bundle", "technique", "using", "the", "autologous", "quadrupled", "semitendinosus", "and", "the", "doubled", "gracilis", "tendon", ".", "Femoral", "fixation", "of", "the", "grafts", "was", "performed", "with", "two", "Endobuttons", ".", "Out", "of", "24", "patients", ",", "20", "were", "evaluated", "with", "a", "follow", "-", "up", "of", "25.4", "months", "(", "12", "-", "47", ")", "on", "average", ";", "in", "15", "cases", "the", "follow", "-", "up", "was", "less", "than", "12", "months", ".", "Only", "18", "patients", "could", "be", "evaluated", "because", "in", "two", "cases", "the", "grafts", "had", "to", "be", "removed", "(", "one", "infection", ",", "one", "rupture", ")", ".", "The", "Lysholm", "score", "improved", "from", "67.6", "points", "preoperatively", "to", "88.5", "points", ",", "the", "Tegner", "score", "from", "3.9", "to", "4.9", ".", "The", "corrected", "posterior", "drawer", "measured", "with", "the", "KT-1000", "arthrometer", "was", "reduced", "from", "9.1", "mm", "to", "4.3", "mm", "postoperatively", ".", "Preoperatively", ",", "17", "patients", "belonged", "to", "group", "D", "and", "one", "patient", "to", "group", "C", "in", "the", "IKDC", "overall", "evaluation", "form", ".", "After", "stabilization", ",", "eight", "patients", "were", "in", "group", "B", ",", "seven", "in", "group", "C", ",", "and", "three", "remained", "in", "group", "D.", "Damage", "to", "neurovascular", "structures", "in", "the", "popliteal", "area", "did", "not", "occur", "." ]

[ "umlsterm" ]

prospective study, patients, posterior, knee, all - inside, technique, tendon, grafts, patients, patients, grafts, infection, rupture, posterior, patients, patient, overall, evaluation, patients

Arthroskopie.00130041.eng.abstr_task2

Sentence: In a prospective study , 35 consecutive patients with an isolated posterior knee instability were stabilized arthroscopically in a new all-inside , double bundle technique using the autologous quadrupled semitendinosus and the doubled gracilis tendon . Femoral fixation of the grafts was performed with two Endobuttons . Out of 24 patients , 20 were evaluated with a follow-up of 25.4 months ( 12-47 ) on average ; in 15 cases the follow-up was less than 12 months . Only 18 patients could be evaluated because in two cases the grafts had to be removed ( one infection , one rupture ) . The Lysholm score improved from 67.6 points preoperatively to 88.5 points , the Tegner score from 3.9 to 4.9. The corrected posterior drawer measured with the KT-1000 arthrometer was reduced from 9.1 mm to 4.3 mm postoperatively . Preoperatively , 17 patients belonged to group D and one patient to group C in the IKDC overall evaluation form . After stabilization , eight patients were in group B , seven in group C , and three remained in group D. Damage to neurovascular structures in the popliteal area did not occur . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In a prospective study , 35 consecutive patients with an isolated posterior knee instability were stabilized arthroscopically in a new all-inside , double bundle technique using the autologous quadrupled semitendinosus and the doubled gracilis tendon . Femoral fixation of the grafts was performed with two Endobuttons . Out of 24 patients , 20 were evaluated with a follow-up of 25.4 months ( 12-47 ) on average ; in 15 cases the follow-up was less than 12 months . Only 18 patients could be evaluated because in two cases the grafts had to be removed ( one infection , one rupture ) . The Lysholm score improved from 67.6 points preoperatively to 88.5 points , the Tegner score from 3.9 to 4.9. The corrected posterior drawer measured with the KT-1000 arthrometer was reduced from 9.1 mm to 4.3 mm postoperatively . Preoperatively , 17 patients belonged to group D and one patient to group C in the IKDC overall evaluation form . After stabilization , eight patients were in group B , seven in group C , and three remained in group D. Damage to neurovascular structures in the popliteal area did not occur .

[ "In", "a", "prospective", "study", ",", "35", "consecutive", "patients", "with", "an", "isolated", "posterior", "knee", "instability", "were", "stabilized", "arthroscopically", "in", "a", "new", "all", "-", "inside", ",", "double", "bundle", "technique", "using", "the", "autologous", "quadrupled", "semitendinosus", "and", "the", "doubled", "gracilis", "tendon", ".", "Femoral", "fixation", "of", "the", "grafts", "was", "performed", "with", "two", "Endobuttons", ".", "Out", "of", "24", "patients", ",", "20", "were", "evaluated", "with", "a", "follow", "-", "up", "of", "25.4", "months", "(", "12", "-", "47", ")", "on", "average", ";", "in", "15", "cases", "the", "follow", "-", "up", "was", "less", "than", "12", "months", ".", "Only", "18", "patients", "could", "be", "evaluated", "because", "in", "two", "cases", "the", "grafts", "had", "to", "be", "removed", "(", "one", "infection", ",", "one", "rupture", ")", ".", "The", "Lysholm", "score", "improved", "from", "67.6", "points", "preoperatively", "to", "88.5", "points", ",", "the", "Tegner", "score", "from", "3.9", "to", "4.9", ".", "The", "corrected", "posterior", "drawer", "measured", "with", "the", "KT-1000", "arthrometer", "was", "reduced", "from", "9.1", "mm", "to", "4.3", "mm", "postoperatively", ".", "Preoperatively", ",", "17", "patients", "belonged", "to", "group", "D", "and", "one", "patient", "to", "group", "C", "in", "the", "IKDC", "overall", "evaluation", "form", ".", "After", "stabilization", ",", "eight", "patients", "were", "in", "group", "B", ",", "seven", "in", "group", "C", ",", "and", "three", "remained", "in", "group", "D.", "Damage", "to", "neurovascular", "structures", "in", "the", "popliteal", "area", "did", "not", "occur", "." ]

[ "umlsterm" ]

PU.1 ( Spi-1 ) is a Gene, myeloid cells is a Cell, PU.1 ( Spi-1 ) is a TranscriptionFactor, Ets transcription factor family is a TranscriptionFactor, myeloid is a Cell, granulocytes is a Cell, monocytes is a Cell, macrophages is a Cell, B cells is a Cell, PU.1 is a Gene, multipotential progenitors is a Cell, myeloid lineages is a Cell, PU.1 is a Gene, function is a Function, human is a Eukaryote, CD34 + progenitors is a Cell, PU.1 is a Gene, PU.1 is a Gene, promoter is a Promoter, murine is a Eukaryote, PU.1 is a Gene, promoter is a Promoter, human is a Eukaryote, promoter is a Promoter, reporter gene is a ReporterGene, myeloid cell lines is a Cell, PU.1 is a Gene, promoter is a Promoter, region is a DNARegion, Oct is a ProteinBindingSiteOfDNA, Sp1 site is a ProteinBindingSiteOfDNA, binding site is a ProteinBindingSiteOfDNA, PU.1 is a TranscriptionFactor, ets family is a TranscriptionFactor, PU.1 site is a ProteinBindingSiteOfDNA, myeloid cells is a Cell, PU.1 site is a ProteinBindingSiteOfDNA, PU.1 is a TranscriptionFactor, promoter is a Promoter, activity is a Function, Oct is a ProteinBindingSiteOfDNA, Sp1 site is a ProteinBindingSiteOfDNA, promoter is a Promoter, activity is a Function, myeloid cells is a Cell, Co - transfection is a ExperimentalMethod, PU.1 is a Gene, Spi - B is a Gene, cells is a Cell, PU.1 is a Gene, Spi - B is a Gene, promoter is a Promoter, PU.1 binding site is a ProteinBindingSiteOfDNA, PU.1 is a TranscriptionFactor, promoter elements is a Promoter, PU.1 is a Gene, promoter is a Promoter, function is a Function, PU.1 is a Gene, myeloid cells is a Cell

103_task0

Sentence: PU.1 (Spi-1) autoregulates its expression in myeloid cells. PU.1 (Spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid (granulocytes, monocytes and macrophages) and B cells. PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation blocks myeloid colony formation. Since PU.1 expression appears to play a role in hematopoietic development, we characterized the PU.1 promoter. Here we report that the murine PU.1 promoter, as well as the human promoter, demonstrate tissue-specific reporter gene expression in myeloid cell lines but not in T cells and HeLa (non-hematopoietic cells) cells. Deletion analysis of the PU.1 promoter indicates that tissue-specific functional elements are encoded in the -61 to -39 bp and -7 to +34 bp regions. The first region contains a functional octamer (Oct) site at -54 bp and an Sp1 site at -39 bp. The second contains a binding site at +20 bp for both PU.1 itself and the related ets family member Spi-B. In vivo footprinting assays demonstrate that a hypersensitive band was detected at the PU.1 site in myeloid cells but not in HeLa. A mutation of the PU.1 site which abolished PU.1 binding caused a significant decrease in promoter activity. Mutation of the Oct and/or Sp1 site results in a lesser decrease of promoter activity in myeloid cells. Co-transfection of PU.1 or Spi-B in cells lacking PU.1 and Spi-B specifically transactivated a minimal promoter containing the PU.1 binding site, indicating that PU.1 can activate its own promoter elements in an autoregulatory loop. Positive autoregulation of the PU.1 promoter may play an important role in the function of PU.1 in myeloid cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TranscriptionFactor, Function, Promoter, ProteinBindingSiteOfDNA, ExperimentalMethod, Gene, ReporterGene, Eukaryote, DNARegion, Cell

[ "B-Gene", "I-Gene", "I-Gene", "I-Gene", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "O", "B-Cell", "O", "B-Cell", "O", "O", "B-Cell", "I-Cell", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "B-Gene", "B-Function", "O", "B-Eukaryote", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "B-Promoter", "O", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Gene", "B-Promoter", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Promoter", "O", "O", "O", "O", "O", "B-ReporterGene", "I-ReporterGene", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "B-Promoter", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DNARegion", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "O", "O", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "O", "O", "O", "B-TranscriptionFactor", "O", "O", "O", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "B-TranscriptionFactor", "O", "O", "O", "O", "O", "O", "B-Promoter", "B-Function", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "O", "O", "O", "O", "B-Promoter", "B-Function", "O", "B-Cell", "I-Cell", "O", "B-ExperimentalMethod", "I-ExperimentalMethod", "I-ExperimentalMethod", "O", "B-Gene", "O", "B-Gene", "I-Gene", "I-Gene", "O", "B-Cell", "O", "B-Gene", "O", "B-Gene", "I-Gene", "I-Gene", "O", "O", "O", "O", "B-Promoter", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "O", "B-TranscriptionFactor", "O", "O", "O", "O", "B-Promoter", "I-Promoter", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "B-Promoter", "O", "O", "O", "O", "O", "O", "O", "B-Function", "O", "B-Gene", "O", "B-Cell", "I-Cell", "O", "O" ]

PU.1 (Spi-1) autoregulates its expression in myeloid cells. PU.1 (Spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid (granulocytes, monocytes and macrophages) and B cells. PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation blocks myeloid colony formation. Since PU.1 expression appears to play a role in hematopoietic development, we characterized the PU.1 promoter. Here we report that the murine PU.1 promoter, as well as the human promoter, demonstrate tissue-specific reporter gene expression in myeloid cell lines but not in T cells and HeLa (non-hematopoietic cells) cells. Deletion analysis of the PU.1 promoter indicates that tissue-specific functional elements are encoded in the -61 to -39 bp and -7 to +34 bp regions. The first region contains a functional octamer (Oct) site at -54 bp and an Sp1 site at -39 bp. The second contains a binding site at +20 bp for both PU.1 itself and the related ets family member Spi-B. In vivo footprinting assays demonstrate that a hypersensitive band was detected at the PU.1 site in myeloid cells but not in HeLa. A mutation of the PU.1 site which abolished PU.1 binding caused a significant decrease in promoter activity. Mutation of the Oct and/or Sp1 site results in a lesser decrease of promoter activity in myeloid cells. Co-transfection of PU.1 or Spi-B in cells lacking PU.1 and Spi-B specifically transactivated a minimal promoter containing the PU.1 binding site, indicating that PU.1 can activate its own promoter elements in an autoregulatory loop. Positive autoregulation of the PU.1 promoter may play an important role in the function of PU.1 in myeloid cells.

[ "PU.1", "(", "Spi-1", ")", "autoregulates", "its", "expression", "in", "myeloid", "cells", ".", "PU.1", "(", "Spi-1", ")", ",", "a", "member", "of", "the", "Ets", "transcription", "factor", "family", ",", "is", "predominantly", "expressed", "in", "myeloid", "(", "granulocytes", ",", "monocytes", "and", "macrophages", ")", "and", "B", "cells", ".", "PU.1", "is", "upregulated", "early", "during", "commitment", "of", "multipotential", "progenitors", "to", "the", "myeloid", "lineages", "and", "inhibition", "of", "PU.1", "function", "in", "human", "CD34", "+", "progenitors", "prior", "to", "this", "upregulation", "blocks", "myeloid", "colony", "formation", ".", "Since", "PU.1", "expression", "appears", "to", "play", "a", "role", "in", "hematopoietic", "development", ",", "we", "characterized", "the", "PU.1", "promoter", ".", "Here", "we", "report", "that", "the", "murine", "PU.1", "promoter", ",", "as", "well", "as", "the", "human", "promoter", ",", "demonstrate", "tissue", "-", "specific", "reporter", "gene", "expression", "in", "myeloid", "cell", "lines", "but", "not", "in", "T", "cells", "and", "HeLa", "(", "non", "-", "hematopoietic", "cells", ")", "cells", ".", "Deletion", "analysis", "of", "the", "PU.1", "promoter", "indicates", "that", "tissue", "-", "specific", "functional", "elements", "are", "encoded", "in", "the", "-61", "to", "-39", "bp", "and", "-7", "to", "+34", "bp", "regions", ".", "The", "first", "region", "contains", "a", "functional", "octamer", "(", "Oct", ")", "site", "at", "-54", "bp", "and", "an", "Sp1", "site", "at", "-39", "bp", ".", "The", "second", "contains", "a", "binding", "site", "at", "+20", "bp", "for", "both", "PU.1", "itself", "and", "the", "related", "ets", "family", "member", "Spi", "-", "B.", "In", "vivo", "footprinting", "assays", "demonstrate", "that", "a", "hypersensitive", "band", "was", "detected", "at", "the", "PU.1", "site", "in", "myeloid", "cells", "but", "not", "in", "HeLa", ".", "A", "mutation", "of", "the", "PU.1", "site", "which", "abolished", "PU.1", "binding", "caused", "a", "significant", "decrease", "in", "promoter", "activity", ".", "Mutation", "of", "the", "Oct", "and", "/", "or", "Sp1", "site", "results", "in", "a", "lesser", "decrease", "of", "promoter", "activity", "in", "myeloid", "cells", ".", "Co", "-", "transfection", "of", "PU.1", "or", "Spi", "-", "B", "in", "cells", "lacking", "PU.1", "and", "Spi", "-", "B", "specifically", "transactivated", "a", "minimal", "promoter", "containing", "the", "PU.1", "binding", "site", ",", "indicating", "that", "PU.1", "can", "activate", "its", "own", "promoter", "elements", "in", "an", "autoregulatory", "loop", ".", "Positive", "autoregulation", "of", "the", "PU.1", "promoter", "may", "play", "an", "important", "role", "in", "the", "function", "of", "PU.1", "in", "myeloid", "cells", ".", "\n" ]

[ "TranscriptionFactor", "Cell", "ProteinBindingSiteOfDNA", "Promoter", "ExperimentalMethod", "ReporterGene", "Gene", "Function", "Eukaryote", "DNARegion" ]

PU.1 ( Spi-1 ) is a Gene, myeloid cells is a Cell, PU.1 ( Spi-1 ) is a TranscriptionFactor, Ets transcription factor family is a TranscriptionFactor, myeloid is a Cell, granulocytes is a Cell, monocytes is a Cell, macrophages is a Cell, B cells is a Cell, PU.1 is a Gene, multipotential progenitors is a Cell, myeloid lineages is a Cell, PU.1 is a Gene, function is a Function, human is a Eukaryote, CD34 + progenitors is a Cell, PU.1 is a Gene, PU.1 is a Gene, promoter is a Promoter, murine is a Eukaryote, PU.1 is a Gene, promoter is a Promoter, human is a Eukaryote, promoter is a Promoter, reporter gene is a ReporterGene, myeloid cell lines is a Cell, PU.1 is a Gene, promoter is a Promoter, region is a DNARegion, Oct is a ProteinBindingSiteOfDNA, Sp1 site is a ProteinBindingSiteOfDNA, binding site is a ProteinBindingSiteOfDNA, PU.1 is a TranscriptionFactor, ets family is a TranscriptionFactor, PU.1 site is a ProteinBindingSiteOfDNA, myeloid cells is a Cell, PU.1 site is a ProteinBindingSiteOfDNA, PU.1 is a TranscriptionFactor, promoter is a Promoter, activity is a Function, Oct is a ProteinBindingSiteOfDNA, Sp1 site is a ProteinBindingSiteOfDNA, promoter is a Promoter, activity is a Function, myeloid cells is a Cell, Co - transfection is a ExperimentalMethod, PU.1 is a Gene, Spi - B is a Gene, cells is a Cell, PU.1 is a Gene, Spi - B is a Gene, promoter is a Promoter, PU.1 binding site is a ProteinBindingSiteOfDNA, PU.1 is a TranscriptionFactor, promoter elements is a Promoter, PU.1 is a Gene, promoter is a Promoter, function is a Function, PU.1 is a Gene, myeloid cells is a Cell

103_task1

Sentence: PU.1 (Spi-1) autoregulates its expression in myeloid cells. PU.1 (Spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid (granulocytes, monocytes and macrophages) and B cells. PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation blocks myeloid colony formation. Since PU.1 expression appears to play a role in hematopoietic development, we characterized the PU.1 promoter. Here we report that the murine PU.1 promoter, as well as the human promoter, demonstrate tissue-specific reporter gene expression in myeloid cell lines but not in T cells and HeLa (non-hematopoietic cells) cells. Deletion analysis of the PU.1 promoter indicates that tissue-specific functional elements are encoded in the -61 to -39 bp and -7 to +34 bp regions. The first region contains a functional octamer (Oct) site at -54 bp and an Sp1 site at -39 bp. The second contains a binding site at +20 bp for both PU.1 itself and the related ets family member Spi-B. In vivo footprinting assays demonstrate that a hypersensitive band was detected at the PU.1 site in myeloid cells but not in HeLa. A mutation of the PU.1 site which abolished PU.1 binding caused a significant decrease in promoter activity. Mutation of the Oct and/or Sp1 site results in a lesser decrease of promoter activity in myeloid cells. Co-transfection of PU.1 or Spi-B in cells lacking PU.1 and Spi-B specifically transactivated a minimal promoter containing the PU.1 binding site, indicating that PU.1 can activate its own promoter elements in an autoregulatory loop. Positive autoregulation of the PU.1 promoter may play an important role in the function of PU.1 in myeloid cells. Instructions: please typing these entity words according to sentence: PU.1 ( Spi-1 ), myeloid cells, PU.1 ( Spi-1 ), Ets transcription factor family, myeloid, granulocytes, monocytes, macrophages, B cells, PU.1, multipotential progenitors, myeloid lineages, PU.1, function, human, CD34 + progenitors, PU.1, PU.1, promoter, murine, PU.1, promoter, human, promoter, reporter gene, myeloid cell lines, PU.1, promoter, region, Oct, Sp1 site, binding site, PU.1, ets family, PU.1 site, myeloid cells, PU.1 site, PU.1, promoter, activity, Oct, Sp1 site, promoter, activity, myeloid cells, Co - transfection, PU.1, Spi - B, cells, PU.1, Spi - B, promoter, PU.1 binding site, PU.1, promoter elements, PU.1, promoter, function, PU.1, myeloid cells Options: TranscriptionFactor, Function, Promoter, ProteinBindingSiteOfDNA, ExperimentalMethod, Gene, ReporterGene, Eukaryote, DNARegion, Cell

[ "B-Gene", "I-Gene", "I-Gene", "I-Gene", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "O", "B-Cell", "O", "B-Cell", "O", "O", "B-Cell", "I-Cell", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "B-Gene", "B-Function", "O", "B-Eukaryote", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "B-Promoter", "O", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Gene", "B-Promoter", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Promoter", "O", "O", "O", "O", "O", "B-ReporterGene", "I-ReporterGene", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "B-Promoter", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DNARegion", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "O", "O", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "O", "O", "O", "B-TranscriptionFactor", "O", "O", "O", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "B-TranscriptionFactor", "O", "O", "O", "O", "O", "O", "B-Promoter", "B-Function", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "O", "O", "O", "O", "B-Promoter", "B-Function", "O", "B-Cell", "I-Cell", "O", "B-ExperimentalMethod", "I-ExperimentalMethod", "I-ExperimentalMethod", "O", "B-Gene", "O", "B-Gene", "I-Gene", "I-Gene", "O", "B-Cell", "O", "B-Gene", "O", "B-Gene", "I-Gene", "I-Gene", "O", "O", "O", "O", "B-Promoter", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "O", "B-TranscriptionFactor", "O", "O", "O", "O", "B-Promoter", "I-Promoter", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "B-Promoter", "O", "O", "O", "O", "O", "O", "O", "B-Function", "O", "B-Gene", "O", "B-Cell", "I-Cell", "O", "O" ]

PU.1 (Spi-1) autoregulates its expression in myeloid cells. PU.1 (Spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid (granulocytes, monocytes and macrophages) and B cells. PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation blocks myeloid colony formation. Since PU.1 expression appears to play a role in hematopoietic development, we characterized the PU.1 promoter. Here we report that the murine PU.1 promoter, as well as the human promoter, demonstrate tissue-specific reporter gene expression in myeloid cell lines but not in T cells and HeLa (non-hematopoietic cells) cells. Deletion analysis of the PU.1 promoter indicates that tissue-specific functional elements are encoded in the -61 to -39 bp and -7 to +34 bp regions. The first region contains a functional octamer (Oct) site at -54 bp and an Sp1 site at -39 bp. The second contains a binding site at +20 bp for both PU.1 itself and the related ets family member Spi-B. In vivo footprinting assays demonstrate that a hypersensitive band was detected at the PU.1 site in myeloid cells but not in HeLa. A mutation of the PU.1 site which abolished PU.1 binding caused a significant decrease in promoter activity. Mutation of the Oct and/or Sp1 site results in a lesser decrease of promoter activity in myeloid cells. Co-transfection of PU.1 or Spi-B in cells lacking PU.1 and Spi-B specifically transactivated a minimal promoter containing the PU.1 binding site, indicating that PU.1 can activate its own promoter elements in an autoregulatory loop. Positive autoregulation of the PU.1 promoter may play an important role in the function of PU.1 in myeloid cells.

[ "PU.1", "(", "Spi-1", ")", "autoregulates", "its", "expression", "in", "myeloid", "cells", ".", "PU.1", "(", "Spi-1", ")", ",", "a", "member", "of", "the", "Ets", "transcription", "factor", "family", ",", "is", "predominantly", "expressed", "in", "myeloid", "(", "granulocytes", ",", "monocytes", "and", "macrophages", ")", "and", "B", "cells", ".", "PU.1", "is", "upregulated", "early", "during", "commitment", "of", "multipotential", "progenitors", "to", "the", "myeloid", "lineages", "and", "inhibition", "of", "PU.1", "function", "in", "human", "CD34", "+", "progenitors", "prior", "to", "this", "upregulation", "blocks", "myeloid", "colony", "formation", ".", "Since", "PU.1", "expression", "appears", "to", "play", "a", "role", "in", "hematopoietic", "development", ",", "we", "characterized", "the", "PU.1", "promoter", ".", "Here", "we", "report", "that", "the", "murine", "PU.1", "promoter", ",", "as", "well", "as", "the", "human", "promoter", ",", "demonstrate", "tissue", "-", "specific", "reporter", "gene", "expression", "in", "myeloid", "cell", "lines", "but", "not", "in", "T", "cells", "and", "HeLa", "(", "non", "-", "hematopoietic", "cells", ")", "cells", ".", "Deletion", "analysis", "of", "the", "PU.1", "promoter", "indicates", "that", "tissue", "-", "specific", "functional", "elements", "are", "encoded", "in", "the", "-61", "to", "-39", "bp", "and", "-7", "to", "+34", "bp", "regions", ".", "The", "first", "region", "contains", "a", "functional", "octamer", "(", "Oct", ")", "site", "at", "-54", "bp", "and", "an", "Sp1", "site", "at", "-39", "bp", ".", "The", "second", "contains", "a", "binding", "site", "at", "+20", "bp", "for", "both", "PU.1", "itself", "and", "the", "related", "ets", "family", "member", "Spi", "-", "B.", "In", "vivo", "footprinting", "assays", "demonstrate", "that", "a", "hypersensitive", "band", "was", "detected", "at", "the", "PU.1", "site", "in", "myeloid", "cells", "but", "not", "in", "HeLa", ".", "A", "mutation", "of", "the", "PU.1", "site", "which", "abolished", "PU.1", "binding", "caused", "a", "significant", "decrease", "in", "promoter", "activity", ".", "Mutation", "of", "the", "Oct", "and", "/", "or", "Sp1", "site", "results", "in", "a", "lesser", "decrease", "of", "promoter", "activity", "in", "myeloid", "cells", ".", "Co", "-", "transfection", "of", "PU.1", "or", "Spi", "-", "B", "in", "cells", "lacking", "PU.1", "and", "Spi", "-", "B", "specifically", "transactivated", "a", "minimal", "promoter", "containing", "the", "PU.1", "binding", "site", ",", "indicating", "that", "PU.1", "can", "activate", "its", "own", "promoter", "elements", "in", "an", "autoregulatory", "loop", ".", "Positive", "autoregulation", "of", "the", "PU.1", "promoter", "may", "play", "an", "important", "role", "in", "the", "function", "of", "PU.1", "in", "myeloid", "cells", ".", "\n" ]

[ "TranscriptionFactor", "Cell", "ProteinBindingSiteOfDNA", "Promoter", "ExperimentalMethod", "ReporterGene", "Gene", "Function", "Eukaryote", "DNARegion" ]

PU.1 ( Spi-1 ), myeloid cells, PU.1 ( Spi-1 ), Ets transcription factor family, myeloid, granulocytes, monocytes, macrophages, B cells, PU.1, multipotential progenitors, myeloid lineages, PU.1, function, human, CD34 + progenitors, PU.1, PU.1, promoter, murine, PU.1, promoter, human, promoter, reporter gene, myeloid cell lines, PU.1, promoter, region, Oct, Sp1 site, binding site, PU.1, ets family, PU.1 site, myeloid cells, PU.1 site, PU.1, promoter, activity, Oct, Sp1 site, promoter, activity, myeloid cells, Co - transfection, PU.1, Spi - B, cells, PU.1, Spi - B, promoter, PU.1 binding site, PU.1, promoter elements, PU.1, promoter, function, PU.1, myeloid cells

103_task2

Sentence: PU.1 (Spi-1) autoregulates its expression in myeloid cells. PU.1 (Spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid (granulocytes, monocytes and macrophages) and B cells. PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation blocks myeloid colony formation. Since PU.1 expression appears to play a role in hematopoietic development, we characterized the PU.1 promoter. Here we report that the murine PU.1 promoter, as well as the human promoter, demonstrate tissue-specific reporter gene expression in myeloid cell lines but not in T cells and HeLa (non-hematopoietic cells) cells. Deletion analysis of the PU.1 promoter indicates that tissue-specific functional elements are encoded in the -61 to -39 bp and -7 to +34 bp regions. The first region contains a functional octamer (Oct) site at -54 bp and an Sp1 site at -39 bp. The second contains a binding site at +20 bp for both PU.1 itself and the related ets family member Spi-B. In vivo footprinting assays demonstrate that a hypersensitive band was detected at the PU.1 site in myeloid cells but not in HeLa. A mutation of the PU.1 site which abolished PU.1 binding caused a significant decrease in promoter activity. Mutation of the Oct and/or Sp1 site results in a lesser decrease of promoter activity in myeloid cells. Co-transfection of PU.1 or Spi-B in cells lacking PU.1 and Spi-B specifically transactivated a minimal promoter containing the PU.1 binding site, indicating that PU.1 can activate its own promoter elements in an autoregulatory loop. Positive autoregulation of the PU.1 promoter may play an important role in the function of PU.1 in myeloid cells. Instructions: please extract entity words from the input sentence

[ "B-Gene", "I-Gene", "I-Gene", "I-Gene", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "O", "B-Cell", "O", "B-Cell", "O", "O", "B-Cell", "I-Cell", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "B-Gene", "B-Function", "O", "B-Eukaryote", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "B-Promoter", "O", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Gene", "B-Promoter", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Promoter", "O", "O", "O", "O", "O", "B-ReporterGene", "I-ReporterGene", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "B-Promoter", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DNARegion", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "O", "O", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "O", "O", "O", "B-TranscriptionFactor", "O", "O", "O", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "B-TranscriptionFactor", "O", "O", "O", "O", "O", "O", "B-Promoter", "B-Function", "O", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "O", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "O", "O", "O", "O", "B-Promoter", "B-Function", "O", "B-Cell", "I-Cell", "O", "B-ExperimentalMethod", "I-ExperimentalMethod", "I-ExperimentalMethod", "O", "B-Gene", "O", "B-Gene", "I-Gene", "I-Gene", "O", "B-Cell", "O", "B-Gene", "O", "B-Gene", "I-Gene", "I-Gene", "O", "O", "O", "O", "B-Promoter", "O", "O", "B-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "I-ProteinBindingSiteOfDNA", "O", "O", "O", "B-TranscriptionFactor", "O", "O", "O", "O", "B-Promoter", "I-Promoter", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "B-Promoter", "O", "O", "O", "O", "O", "O", "O", "B-Function", "O", "B-Gene", "O", "B-Cell", "I-Cell", "O", "O" ]

PU.1 (Spi-1) autoregulates its expression in myeloid cells. PU.1 (Spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid (granulocytes, monocytes and macrophages) and B cells. PU.1 is upregulated early during commitment of multipotential progenitors to the myeloid lineages and inhibition of PU.1 function in human CD34+ progenitors prior to this upregulation blocks myeloid colony formation. Since PU.1 expression appears to play a role in hematopoietic development, we characterized the PU.1 promoter. Here we report that the murine PU.1 promoter, as well as the human promoter, demonstrate tissue-specific reporter gene expression in myeloid cell lines but not in T cells and HeLa (non-hematopoietic cells) cells. Deletion analysis of the PU.1 promoter indicates that tissue-specific functional elements are encoded in the -61 to -39 bp and -7 to +34 bp regions. The first region contains a functional octamer (Oct) site at -54 bp and an Sp1 site at -39 bp. The second contains a binding site at +20 bp for both PU.1 itself and the related ets family member Spi-B. In vivo footprinting assays demonstrate that a hypersensitive band was detected at the PU.1 site in myeloid cells but not in HeLa. A mutation of the PU.1 site which abolished PU.1 binding caused a significant decrease in promoter activity. Mutation of the Oct and/or Sp1 site results in a lesser decrease of promoter activity in myeloid cells. Co-transfection of PU.1 or Spi-B in cells lacking PU.1 and Spi-B specifically transactivated a minimal promoter containing the PU.1 binding site, indicating that PU.1 can activate its own promoter elements in an autoregulatory loop. Positive autoregulation of the PU.1 promoter may play an important role in the function of PU.1 in myeloid cells.

[ "PU.1", "(", "Spi-1", ")", "autoregulates", "its", "expression", "in", "myeloid", "cells", ".", "PU.1", "(", "Spi-1", ")", ",", "a", "member", "of", "the", "Ets", "transcription", "factor", "family", ",", "is", "predominantly", "expressed", "in", "myeloid", "(", "granulocytes", ",", "monocytes", "and", "macrophages", ")", "and", "B", "cells", ".", "PU.1", "is", "upregulated", "early", "during", "commitment", "of", "multipotential", "progenitors", "to", "the", "myeloid", "lineages", "and", "inhibition", "of", "PU.1", "function", "in", "human", "CD34", "+", "progenitors", "prior", "to", "this", "upregulation", "blocks", "myeloid", "colony", "formation", ".", "Since", "PU.1", "expression", "appears", "to", "play", "a", "role", "in", "hematopoietic", "development", ",", "we", "characterized", "the", "PU.1", "promoter", ".", "Here", "we", "report", "that", "the", "murine", "PU.1", "promoter", ",", "as", "well", "as", "the", "human", "promoter", ",", "demonstrate", "tissue", "-", "specific", "reporter", "gene", "expression", "in", "myeloid", "cell", "lines", "but", "not", "in", "T", "cells", "and", "HeLa", "(", "non", "-", "hematopoietic", "cells", ")", "cells", ".", "Deletion", "analysis", "of", "the", "PU.1", "promoter", "indicates", "that", "tissue", "-", "specific", "functional", "elements", "are", "encoded", "in", "the", "-61", "to", "-39", "bp", "and", "-7", "to", "+34", "bp", "regions", ".", "The", "first", "region", "contains", "a", "functional", "octamer", "(", "Oct", ")", "site", "at", "-54", "bp", "and", "an", "Sp1", "site", "at", "-39", "bp", ".", "The", "second", "contains", "a", "binding", "site", "at", "+20", "bp", "for", "both", "PU.1", "itself", "and", "the", "related", "ets", "family", "member", "Spi", "-", "B.", "In", "vivo", "footprinting", "assays", "demonstrate", "that", "a", "hypersensitive", "band", "was", "detected", "at", "the", "PU.1", "site", "in", "myeloid", "cells", "but", "not", "in", "HeLa", ".", "A", "mutation", "of", "the", "PU.1", "site", "which", "abolished", "PU.1", "binding", "caused", "a", "significant", "decrease", "in", "promoter", "activity", ".", "Mutation", "of", "the", "Oct", "and", "/", "or", "Sp1", "site", "results", "in", "a", "lesser", "decrease", "of", "promoter", "activity", "in", "myeloid", "cells", ".", "Co", "-", "transfection", "of", "PU.1", "or", "Spi", "-", "B", "in", "cells", "lacking", "PU.1", "and", "Spi", "-", "B", "specifically", "transactivated", "a", "minimal", "promoter", "containing", "the", "PU.1", "binding", "site", ",", "indicating", "that", "PU.1", "can", "activate", "its", "own", "promoter", "elements", "in", "an", "autoregulatory", "loop", ".", "Positive", "autoregulation", "of", "the", "PU.1", "promoter", "may", "play", "an", "important", "role", "in", "the", "function", "of", "PU.1", "in", "myeloid", "cells", ".", "\n" ]

[ "TranscriptionFactor", "Cell", "ProteinBindingSiteOfDNA", "Promoter", "ExperimentalMethod", "ReporterGene", "Gene", "Function", "Eukaryote", "DNARegion" ]

p53 is a Protein, p53 is a Protein, Tip60 is a Protein, p53 is a Protein, lysine 120 is a Entity, K120 is a Entity, p53 is a Protein, p53 is a Protein, K120 is a Entity, p53 is a Protein

225_task0

Sentence: Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Upon DNA damage and other types of stress, p53 induces either cell-cycle arrest or apoptosis depending on the cellular context. However, the molecular mechanisms that govern the choice between cell-cycle arrest and apoptosis are not well understood. Here, we show that Tip60 is required for both cell growth arrest and apoptosis mediated by p53 and also induces its acetylation specifically at lysine 120 (K120) within the DNA-binding domain. Interestingly, this modification is crucial for p53-dependent apoptosis but is dispensable for its mediated growth arrest. K120 is a recurrent site for p53 mutation in human cancer, and the corresponding acetylation-defective tumor mutant (K120R) abrogates p53-mediated apoptosis, but not growth arrest. Thus, our study demonstrates that Tip60-dependent acetylation of p53 at K120 modulates the decision between cell-cycle arrest and apoptosis, and it reveals that the DNA-binding core domain is an important target for p53 regulation by posttranslational modifications. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]

Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Upon DNA damage and other types of stress, p53 induces either cell-cycle arrest or apoptosis depending on the cellular context. However, the molecular mechanisms that govern the choice between cell-cycle arrest and apoptosis are not well understood. Here, we show that Tip60 is required for both cell growth arrest and apoptosis mediated by p53 and also induces its acetylation specifically at lysine 120 (K120) within the DNA-binding domain. Interestingly, this modification is crucial for p53-dependent apoptosis but is dispensable for its mediated growth arrest. K120 is a recurrent site for p53 mutation in human cancer, and the corresponding acetylation-defective tumor mutant (K120R) abrogates p53-mediated apoptosis, but not growth arrest. Thus, our study demonstrates that Tip60-dependent acetylation of p53 at K120 modulates the decision between cell-cycle arrest and apoptosis, and it reveals that the DNA-binding core domain is an important target for p53 regulation by posttranslational modifications.

[ "Tip60-dependent", "acetylation", "of", "p53", "modulates", "the", "decision", "between", "cell", "-", "cycle", "arrest", "and", "apoptosis", ".", "\n", "Upon", "DNA", "damage", "and", "other", "types", "of", "stress", ",", "p53", "induces", "either", "cell", "-", "cycle", "arrest", "or", "apoptosis", "depending", "on", "the", "cellular", "context", ".", "However", ",", "the", "molecular", "mechanisms", "that", "govern", "the", "choice", "between", "cell", "-", "cycle", "arrest", "and", "apoptosis", "are", "not", "well", "understood", ".", "Here", ",", "we", "show", "that", "Tip60", "is", "required", "for", "both", "cell", "growth", "arrest", "and", "apoptosis", "mediated", "by", "p53", "and", "also", "induces", "its", "acetylation", "specifically", "at", "lysine", "120", "(", "K120", ")", "within", "the", "DNA", "-", "binding", "domain", ".", "Interestingly", ",", "this", "modification", "is", "crucial", "for", "p53-dependent", "apoptosis", "but", "is", "dispensable", "for", "its", "mediated", "growth", "arrest", ".", "K120", "is", "a", "recurrent", "site", "for", "p53", "mutation", "in", "human", "cancer", ",", "and", "the", "corresponding", "acetylation", "-", "defective", "tumor", "mutant", "(", "K120R", ")", "abrogates", "p53-mediated", "apoptosis", ",", "but", "not", "growth", "arrest", ".", "Thus", ",", "our", "study", "demonstrates", "that", "Tip60-dependent", "acetylation", "of", "p53", "at", "K120", "modulates", "the", "decision", "between", "cell", "-", "cycle", "arrest", "and", "apoptosis", ",", "and", "it", "reveals", "that", "the", "DNA", "-", "binding", "core", "domain", "is", "an", "important", "target", "for", "p53", "regulation", "by", "posttranslational", "modifications", ".", "\n" ]

[ "Entity", "Protein" ]

p53 is a Protein, p53 is a Protein, Tip60 is a Protein, p53 is a Protein, lysine 120 is a Entity, K120 is a Entity, p53 is a Protein, p53 is a Protein, K120 is a Entity, p53 is a Protein

225_task1

Sentence: Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Upon DNA damage and other types of stress, p53 induces either cell-cycle arrest or apoptosis depending on the cellular context. However, the molecular mechanisms that govern the choice between cell-cycle arrest and apoptosis are not well understood. Here, we show that Tip60 is required for both cell growth arrest and apoptosis mediated by p53 and also induces its acetylation specifically at lysine 120 (K120) within the DNA-binding domain. Interestingly, this modification is crucial for p53-dependent apoptosis but is dispensable for its mediated growth arrest. K120 is a recurrent site for p53 mutation in human cancer, and the corresponding acetylation-defective tumor mutant (K120R) abrogates p53-mediated apoptosis, but not growth arrest. Thus, our study demonstrates that Tip60-dependent acetylation of p53 at K120 modulates the decision between cell-cycle arrest and apoptosis, and it reveals that the DNA-binding core domain is an important target for p53 regulation by posttranslational modifications. Instructions: please typing these entity words according to sentence: p53, p53, Tip60, p53, lysine 120, K120, p53, p53, K120, p53 Options: Entity, Protein

[ "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]

Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Upon DNA damage and other types of stress, p53 induces either cell-cycle arrest or apoptosis depending on the cellular context. However, the molecular mechanisms that govern the choice between cell-cycle arrest and apoptosis are not well understood. Here, we show that Tip60 is required for both cell growth arrest and apoptosis mediated by p53 and also induces its acetylation specifically at lysine 120 (K120) within the DNA-binding domain. Interestingly, this modification is crucial for p53-dependent apoptosis but is dispensable for its mediated growth arrest. K120 is a recurrent site for p53 mutation in human cancer, and the corresponding acetylation-defective tumor mutant (K120R) abrogates p53-mediated apoptosis, but not growth arrest. Thus, our study demonstrates that Tip60-dependent acetylation of p53 at K120 modulates the decision between cell-cycle arrest and apoptosis, and it reveals that the DNA-binding core domain is an important target for p53 regulation by posttranslational modifications.

[ "Tip60-dependent", "acetylation", "of", "p53", "modulates", "the", "decision", "between", "cell", "-", "cycle", "arrest", "and", "apoptosis", ".", "\n", "Upon", "DNA", "damage", "and", "other", "types", "of", "stress", ",", "p53", "induces", "either", "cell", "-", "cycle", "arrest", "or", "apoptosis", "depending", "on", "the", "cellular", "context", ".", "However", ",", "the", "molecular", "mechanisms", "that", "govern", "the", "choice", "between", "cell", "-", "cycle", "arrest", "and", "apoptosis", "are", "not", "well", "understood", ".", "Here", ",", "we", "show", "that", "Tip60", "is", "required", "for", "both", "cell", "growth", "arrest", "and", "apoptosis", "mediated", "by", "p53", "and", "also", "induces", "its", "acetylation", "specifically", "at", "lysine", "120", "(", "K120", ")", "within", "the", "DNA", "-", "binding", "domain", ".", "Interestingly", ",", "this", "modification", "is", "crucial", "for", "p53-dependent", "apoptosis", "but", "is", "dispensable", "for", "its", "mediated", "growth", "arrest", ".", "K120", "is", "a", "recurrent", "site", "for", "p53", "mutation", "in", "human", "cancer", ",", "and", "the", "corresponding", "acetylation", "-", "defective", "tumor", "mutant", "(", "K120R", ")", "abrogates", "p53-mediated", "apoptosis", ",", "but", "not", "growth", "arrest", ".", "Thus", ",", "our", "study", "demonstrates", "that", "Tip60-dependent", "acetylation", "of", "p53", "at", "K120", "modulates", "the", "decision", "between", "cell", "-", "cycle", "arrest", "and", "apoptosis", ",", "and", "it", "reveals", "that", "the", "DNA", "-", "binding", "core", "domain", "is", "an", "important", "target", "for", "p53", "regulation", "by", "posttranslational", "modifications", ".", "\n" ]

[ "Entity", "Protein" ]

p53, p53, Tip60, p53, lysine 120, K120, p53, p53, K120, p53

225_task2

Sentence: Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Upon DNA damage and other types of stress, p53 induces either cell-cycle arrest or apoptosis depending on the cellular context. However, the molecular mechanisms that govern the choice between cell-cycle arrest and apoptosis are not well understood. Here, we show that Tip60 is required for both cell growth arrest and apoptosis mediated by p53 and also induces its acetylation specifically at lysine 120 (K120) within the DNA-binding domain. Interestingly, this modification is crucial for p53-dependent apoptosis but is dispensable for its mediated growth arrest. K120 is a recurrent site for p53 mutation in human cancer, and the corresponding acetylation-defective tumor mutant (K120R) abrogates p53-mediated apoptosis, but not growth arrest. Thus, our study demonstrates that Tip60-dependent acetylation of p53 at K120 modulates the decision between cell-cycle arrest and apoptosis, and it reveals that the DNA-binding core domain is an important target for p53 regulation by posttranslational modifications. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]

Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Upon DNA damage and other types of stress, p53 induces either cell-cycle arrest or apoptosis depending on the cellular context. However, the molecular mechanisms that govern the choice between cell-cycle arrest and apoptosis are not well understood. Here, we show that Tip60 is required for both cell growth arrest and apoptosis mediated by p53 and also induces its acetylation specifically at lysine 120 (K120) within the DNA-binding domain. Interestingly, this modification is crucial for p53-dependent apoptosis but is dispensable for its mediated growth arrest. K120 is a recurrent site for p53 mutation in human cancer, and the corresponding acetylation-defective tumor mutant (K120R) abrogates p53-mediated apoptosis, but not growth arrest. Thus, our study demonstrates that Tip60-dependent acetylation of p53 at K120 modulates the decision between cell-cycle arrest and apoptosis, and it reveals that the DNA-binding core domain is an important target for p53 regulation by posttranslational modifications.

[ "Tip60-dependent", "acetylation", "of", "p53", "modulates", "the", "decision", "between", "cell", "-", "cycle", "arrest", "and", "apoptosis", ".", "\n", "Upon", "DNA", "damage", "and", "other", "types", "of", "stress", ",", "p53", "induces", "either", "cell", "-", "cycle", "arrest", "or", "apoptosis", "depending", "on", "the", "cellular", "context", ".", "However", ",", "the", "molecular", "mechanisms", "that", "govern", "the", "choice", "between", "cell", "-", "cycle", "arrest", "and", "apoptosis", "are", "not", "well", "understood", ".", "Here", ",", "we", "show", "that", "Tip60", "is", "required", "for", "both", "cell", "growth", "arrest", "and", "apoptosis", "mediated", "by", "p53", "and", "also", "induces", "its", "acetylation", "specifically", "at", "lysine", "120", "(", "K120", ")", "within", "the", "DNA", "-", "binding", "domain", ".", "Interestingly", ",", "this", "modification", "is", "crucial", "for", "p53-dependent", "apoptosis", "but", "is", "dispensable", "for", "its", "mediated", "growth", "arrest", ".", "K120", "is", "a", "recurrent", "site", "for", "p53", "mutation", "in", "human", "cancer", ",", "and", "the", "corresponding", "acetylation", "-", "defective", "tumor", "mutant", "(", "K120R", ")", "abrogates", "p53-mediated", "apoptosis", ",", "but", "not", "growth", "arrest", ".", "Thus", ",", "our", "study", "demonstrates", "that", "Tip60-dependent", "acetylation", "of", "p53", "at", "K120", "modulates", "the", "decision", "between", "cell", "-", "cycle", "arrest", "and", "apoptosis", ",", "and", "it", "reveals", "that", "the", "DNA", "-", "binding", "core", "domain", "is", "an", "important", "target", "for", "p53", "regulation", "by", "posttranslational", "modifications", ".", "\n" ]

[ "Entity", "Protein" ]

Rel - A is a Protein, c - Rel is a Protein, protein complexes is a Entity, Nuclear factor - kappa B is a Entity, cellular genes is a Entity, genes is a Entity, NF - kappa B is a Entity, NF - kappa B is a Entity, p50 is a Protein, p65 is a Protein, p50 is a Protein, c - Rel is a Protein, complexes is a Entity, NF - kappa B is a Entity, p50 / c - Rel is a Entity, p50 / p65 is a Entity, p65 is a Protein, p65 is a Protein, p50 is a Protein, c - Rel is a Protein, p65 is a Protein, c - Rel is a Protein, complexes is a Entity, NF - kappa B is a Entity

314_task0

Sentence: Nuclear Rel-A and c-Rel protein complexes are differentially distributed within human thymocytes. Nuclear factor-kappa B (NF-kappa B)/Rel proteins are inducible transcriptional regulators of numerous cellular genes. They are particularly abundant in lymphoid tissues and are thought to be critical for the transcription of genes involved in immune and inflammatory responses. We have reported previously that a nuclear NF-kappa B activity was present in freshly extracted human thymocytes in the absence of in vitro treatment of these cells. In the present report, we identified NF-kappa B proteins extracted from human thymocyte nuclei as being p50/p65 and p50/c-Rel complexes. Immunochemical and immunofluorescent staining of thymus sections using specific Abs allowed visualization of nuclear NF-kappa B proteins in both thymocytes and nonthymocyte cells. This detection suggested a preferential activation of p50/c-Rel in medullary thymocytes, whereas p50/p65 was present in both cortical and medullary regions of human thymus lobules. However, the intensity of p65 labeling was much higher in several thymocytes from the medulla. p65, p50, and c-Rel activities were found in both CD4- and CD8-positive thymocytes. These observations suggest that p65 and c-Rel complexes play distinct roles in gene expression and that both forms of NF-kappa B play critical roles during late stages of the intrathymic maturation of T cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Nuclear Rel-A and c-Rel protein complexes are differentially distributed within human thymocytes. Nuclear factor-kappa B (NF-kappa B)/Rel proteins are inducible transcriptional regulators of numerous cellular genes. They are particularly abundant in lymphoid tissues and are thought to be critical for the transcription of genes involved in immune and inflammatory responses. We have reported previously that a nuclear NF-kappa B activity was present in freshly extracted human thymocytes in the absence of in vitro treatment of these cells. In the present report, we identified NF-kappa B proteins extracted from human thymocyte nuclei as being p50/p65 and p50/c-Rel complexes. Immunochemical and immunofluorescent staining of thymus sections using specific Abs allowed visualization of nuclear NF-kappa B proteins in both thymocytes and nonthymocyte cells. This detection suggested a preferential activation of p50/c-Rel in medullary thymocytes, whereas p50/p65 was present in both cortical and medullary regions of human thymus lobules. However, the intensity of p65 labeling was much higher in several thymocytes from the medulla. p65, p50, and c-Rel activities were found in both CD4- and CD8-positive thymocytes. These observations suggest that p65 and c-Rel complexes play distinct roles in gene expression and that both forms of NF-kappa B play critical roles during late stages of the intrathymic maturation of T cells.

[ "Nuclear", "Rel", "-", "A", "and", "c", "-", "Rel", "protein", "complexes", "are", "differentially", "distributed", "within", "human", "thymocytes", ".", "\n", "Nuclear", "factor", "-", "kappa", "B", "(", "NF", "-", "kappa", "B)/Rel", "proteins", "are", "inducible", "transcriptional", "regulators", "of", "numerous", "cellular", "genes", ".", "They", "are", "particularly", "abundant", "in", "lymphoid", "tissues", "and", "are", "thought", "to", "be", "critical", "for", "the", "transcription", "of", "genes", "involved", "in", "immune", "and", "inflammatory", "responses", ".", "We", "have", "reported", "previously", "that", "a", "nuclear", "NF", "-", "kappa", "B", "activity", "was", "present", "in", "freshly", "extracted", "human", "thymocytes", "in", "the", "absence", "of", "in", "vitro", "treatment", "of", "these", "cells", ".", "In", "the", "present", "report", ",", "we", "identified", "NF", "-", "kappa", "B", "proteins", "extracted", "from", "human", "thymocyte", "nuclei", "as", "being", "p50", "/", "p65", "and", "p50", "/", "c", "-", "Rel", "complexes", ".", "Immunochemical", "and", "immunofluorescent", "staining", "of", "thymus", "sections", "using", "specific", "Abs", "allowed", "visualization", "of", "nuclear", "NF", "-", "kappa", "B", "proteins", "in", "both", "thymocytes", "and", "nonthymocyte", "cells", ".", "This", "detection", "suggested", "a", "preferential", "activation", "of", "p50", "/", "c", "-", "Rel", "in", "medullary", "thymocytes", ",", "whereas", "p50", "/", "p65", "was", "present", "in", "both", "cortical", "and", "medullary", "regions", "of", "human", "thymus", "lobules", ".", "However", ",", "the", "intensity", "of", "p65", "labeling", "was", "much", "higher", "in", "several", "thymocytes", "from", "the", "medulla", ".", "p65", ",", "p50", ",", "and", "c", "-", "Rel", "activities", "were", "found", "in", "both", "CD4-", "and", "CD8-positive", "thymocytes", ".", "These", "observations", "suggest", "that", "p65", "and", "c", "-", "Rel", "complexes", "play", "distinct", "roles", "in", "gene", "expression", "and", "that", "both", "forms", "of", "NF", "-", "kappa", "B", "play", "critical", "roles", "during", "late", "stages", "of", "the", "intrathymic", "maturation", "of", "T", "cells", ".", "\n" ]

[ "Entity", "Protein" ]

Rel - A is a Protein, c - Rel is a Protein, protein complexes is a Entity, Nuclear factor - kappa B is a Entity, cellular genes is a Entity, genes is a Entity, NF - kappa B is a Entity, NF - kappa B is a Entity, p50 is a Protein, p65 is a Protein, p50 is a Protein, c - Rel is a Protein, complexes is a Entity, NF - kappa B is a Entity, p50 / c - Rel is a Entity, p50 / p65 is a Entity, p65 is a Protein, p65 is a Protein, p50 is a Protein, c - Rel is a Protein, p65 is a Protein, c - Rel is a Protein, complexes is a Entity, NF - kappa B is a Entity

314_task1

Sentence: Nuclear Rel-A and c-Rel protein complexes are differentially distributed within human thymocytes. Nuclear factor-kappa B (NF-kappa B)/Rel proteins are inducible transcriptional regulators of numerous cellular genes. They are particularly abundant in lymphoid tissues and are thought to be critical for the transcription of genes involved in immune and inflammatory responses. We have reported previously that a nuclear NF-kappa B activity was present in freshly extracted human thymocytes in the absence of in vitro treatment of these cells. In the present report, we identified NF-kappa B proteins extracted from human thymocyte nuclei as being p50/p65 and p50/c-Rel complexes. Immunochemical and immunofluorescent staining of thymus sections using specific Abs allowed visualization of nuclear NF-kappa B proteins in both thymocytes and nonthymocyte cells. This detection suggested a preferential activation of p50/c-Rel in medullary thymocytes, whereas p50/p65 was present in both cortical and medullary regions of human thymus lobules. However, the intensity of p65 labeling was much higher in several thymocytes from the medulla. p65, p50, and c-Rel activities were found in both CD4- and CD8-positive thymocytes. These observations suggest that p65 and c-Rel complexes play distinct roles in gene expression and that both forms of NF-kappa B play critical roles during late stages of the intrathymic maturation of T cells. Instructions: please typing these entity words according to sentence: Rel - A, c - Rel, protein complexes, Nuclear factor - kappa B, cellular genes, genes, NF - kappa B, NF - kappa B, p50, p65, p50, c - Rel, complexes, NF - kappa B, p50 / c - Rel, p50 / p65, p65, p65, p50, c - Rel, p65, c - Rel, complexes, NF - kappa B Options: Entity, Protein

[ "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Nuclear Rel-A and c-Rel protein complexes are differentially distributed within human thymocytes. Nuclear factor-kappa B (NF-kappa B)/Rel proteins are inducible transcriptional regulators of numerous cellular genes. They are particularly abundant in lymphoid tissues and are thought to be critical for the transcription of genes involved in immune and inflammatory responses. We have reported previously that a nuclear NF-kappa B activity was present in freshly extracted human thymocytes in the absence of in vitro treatment of these cells. In the present report, we identified NF-kappa B proteins extracted from human thymocyte nuclei as being p50/p65 and p50/c-Rel complexes. Immunochemical and immunofluorescent staining of thymus sections using specific Abs allowed visualization of nuclear NF-kappa B proteins in both thymocytes and nonthymocyte cells. This detection suggested a preferential activation of p50/c-Rel in medullary thymocytes, whereas p50/p65 was present in both cortical and medullary regions of human thymus lobules. However, the intensity of p65 labeling was much higher in several thymocytes from the medulla. p65, p50, and c-Rel activities were found in both CD4- and CD8-positive thymocytes. These observations suggest that p65 and c-Rel complexes play distinct roles in gene expression and that both forms of NF-kappa B play critical roles during late stages of the intrathymic maturation of T cells.

[ "Nuclear", "Rel", "-", "A", "and", "c", "-", "Rel", "protein", "complexes", "are", "differentially", "distributed", "within", "human", "thymocytes", ".", "\n", "Nuclear", "factor", "-", "kappa", "B", "(", "NF", "-", "kappa", "B)/Rel", "proteins", "are", "inducible", "transcriptional", "regulators", "of", "numerous", "cellular", "genes", ".", "They", "are", "particularly", "abundant", "in", "lymphoid", "tissues", "and", "are", "thought", "to", "be", "critical", "for", "the", "transcription", "of", "genes", "involved", "in", "immune", "and", "inflammatory", "responses", ".", "We", "have", "reported", "previously", "that", "a", "nuclear", "NF", "-", "kappa", "B", "activity", "was", "present", "in", "freshly", "extracted", "human", "thymocytes", "in", "the", "absence", "of", "in", "vitro", "treatment", "of", "these", "cells", ".", "In", "the", "present", "report", ",", "we", "identified", "NF", "-", "kappa", "B", "proteins", "extracted", "from", "human", "thymocyte", "nuclei", "as", "being", "p50", "/", "p65", "and", "p50", "/", "c", "-", "Rel", "complexes", ".", "Immunochemical", "and", "immunofluorescent", "staining", "of", "thymus", "sections", "using", "specific", "Abs", "allowed", "visualization", "of", "nuclear", "NF", "-", "kappa", "B", "proteins", "in", "both", "thymocytes", "and", "nonthymocyte", "cells", ".", "This", "detection", "suggested", "a", "preferential", "activation", "of", "p50", "/", "c", "-", "Rel", "in", "medullary", "thymocytes", ",", "whereas", "p50", "/", "p65", "was", "present", "in", "both", "cortical", "and", "medullary", "regions", "of", "human", "thymus", "lobules", ".", "However", ",", "the", "intensity", "of", "p65", "labeling", "was", "much", "higher", "in", "several", "thymocytes", "from", "the", "medulla", ".", "p65", ",", "p50", ",", "and", "c", "-", "Rel", "activities", "were", "found", "in", "both", "CD4-", "and", "CD8-positive", "thymocytes", ".", "These", "observations", "suggest", "that", "p65", "and", "c", "-", "Rel", "complexes", "play", "distinct", "roles", "in", "gene", "expression", "and", "that", "both", "forms", "of", "NF", "-", "kappa", "B", "play", "critical", "roles", "during", "late", "stages", "of", "the", "intrathymic", "maturation", "of", "T", "cells", ".", "\n" ]

[ "Entity", "Protein" ]

Rel - A, c - Rel, protein complexes, Nuclear factor - kappa B, cellular genes, genes, NF - kappa B, NF - kappa B, p50, p65, p50, c - Rel, complexes, NF - kappa B, p50 / c - Rel, p50 / p65, p65, p65, p50, c - Rel, p65, c - Rel, complexes, NF - kappa B

314_task2

Sentence: Nuclear Rel-A and c-Rel protein complexes are differentially distributed within human thymocytes. Nuclear factor-kappa B (NF-kappa B)/Rel proteins are inducible transcriptional regulators of numerous cellular genes. They are particularly abundant in lymphoid tissues and are thought to be critical for the transcription of genes involved in immune and inflammatory responses. We have reported previously that a nuclear NF-kappa B activity was present in freshly extracted human thymocytes in the absence of in vitro treatment of these cells. In the present report, we identified NF-kappa B proteins extracted from human thymocyte nuclei as being p50/p65 and p50/c-Rel complexes. Immunochemical and immunofluorescent staining of thymus sections using specific Abs allowed visualization of nuclear NF-kappa B proteins in both thymocytes and nonthymocyte cells. This detection suggested a preferential activation of p50/c-Rel in medullary thymocytes, whereas p50/p65 was present in both cortical and medullary regions of human thymus lobules. However, the intensity of p65 labeling was much higher in several thymocytes from the medulla. p65, p50, and c-Rel activities were found in both CD4- and CD8-positive thymocytes. These observations suggest that p65 and c-Rel complexes play distinct roles in gene expression and that both forms of NF-kappa B play critical roles during late stages of the intrathymic maturation of T cells. Instructions: please extract entity words from the input sentence

[ "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Nuclear Rel-A and c-Rel protein complexes are differentially distributed within human thymocytes. Nuclear factor-kappa B (NF-kappa B)/Rel proteins are inducible transcriptional regulators of numerous cellular genes. They are particularly abundant in lymphoid tissues and are thought to be critical for the transcription of genes involved in immune and inflammatory responses. We have reported previously that a nuclear NF-kappa B activity was present in freshly extracted human thymocytes in the absence of in vitro treatment of these cells. In the present report, we identified NF-kappa B proteins extracted from human thymocyte nuclei as being p50/p65 and p50/c-Rel complexes. Immunochemical and immunofluorescent staining of thymus sections using specific Abs allowed visualization of nuclear NF-kappa B proteins in both thymocytes and nonthymocyte cells. This detection suggested a preferential activation of p50/c-Rel in medullary thymocytes, whereas p50/p65 was present in both cortical and medullary regions of human thymus lobules. However, the intensity of p65 labeling was much higher in several thymocytes from the medulla. p65, p50, and c-Rel activities were found in both CD4- and CD8-positive thymocytes. These observations suggest that p65 and c-Rel complexes play distinct roles in gene expression and that both forms of NF-kappa B play critical roles during late stages of the intrathymic maturation of T cells.

[ "Nuclear", "Rel", "-", "A", "and", "c", "-", "Rel", "protein", "complexes", "are", "differentially", "distributed", "within", "human", "thymocytes", ".", "\n", "Nuclear", "factor", "-", "kappa", "B", "(", "NF", "-", "kappa", "B)/Rel", "proteins", "are", "inducible", "transcriptional", "regulators", "of", "numerous", "cellular", "genes", ".", "They", "are", "particularly", "abundant", "in", "lymphoid", "tissues", "and", "are", "thought", "to", "be", "critical", "for", "the", "transcription", "of", "genes", "involved", "in", "immune", "and", "inflammatory", "responses", ".", "We", "have", "reported", "previously", "that", "a", "nuclear", "NF", "-", "kappa", "B", "activity", "was", "present", "in", "freshly", "extracted", "human", "thymocytes", "in", "the", "absence", "of", "in", "vitro", "treatment", "of", "these", "cells", ".", "In", "the", "present", "report", ",", "we", "identified", "NF", "-", "kappa", "B", "proteins", "extracted", "from", "human", "thymocyte", "nuclei", "as", "being", "p50", "/", "p65", "and", "p50", "/", "c", "-", "Rel", "complexes", ".", "Immunochemical", "and", "immunofluorescent", "staining", "of", "thymus", "sections", "using", "specific", "Abs", "allowed", "visualization", "of", "nuclear", "NF", "-", "kappa", "B", "proteins", "in", "both", "thymocytes", "and", "nonthymocyte", "cells", ".", "This", "detection", "suggested", "a", "preferential", "activation", "of", "p50", "/", "c", "-", "Rel", "in", "medullary", "thymocytes", ",", "whereas", "p50", "/", "p65", "was", "present", "in", "both", "cortical", "and", "medullary", "regions", "of", "human", "thymus", "lobules", ".", "However", ",", "the", "intensity", "of", "p65", "labeling", "was", "much", "higher", "in", "several", "thymocytes", "from", "the", "medulla", ".", "p65", ",", "p50", ",", "and", "c", "-", "Rel", "activities", "were", "found", "in", "both", "CD4-", "and", "CD8-positive", "thymocytes", ".", "These", "observations", "suggest", "that", "p65", "and", "c", "-", "Rel", "complexes", "play", "distinct", "roles", "in", "gene", "expression", "and", "that", "both", "forms", "of", "NF", "-", "kappa", "B", "play", "critical", "roles", "during", "late", "stages", "of", "the", "intrathymic", "maturation", "of", "T", "cells", ".", "\n" ]

[ "Entity", "Protein" ]

pulmonary toxicity is a ADVERSE, Atrial fibrillation is a ADVERSE, Pulmonary toxicity is a ADVERSE

example-342_task0

Sentence: Amiodarone pulmonary toxicity after lung transplantation. Atrial fibrillation occurs frequently after lung transplantation and is commonly treated with amiodarone. Pulmonary toxicity may result from amiodarone exposure and is characterized by non-specific respiratory manifestations. To our knowledge, there are no reports of this complication occurring after lung transplantation. We present a patient who developed radiologic evidence of amiodarone deposition in the lungs after bilateral lung transplantation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ADVERSE

[ "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Amiodarone pulmonary toxicity after lung transplantation. Atrial fibrillation occurs frequently after lung transplantation and is commonly treated with amiodarone. Pulmonary toxicity may result from amiodarone exposure and is characterized by non-specific respiratory manifestations. To our knowledge, there are no reports of this complication occurring after lung transplantation. We present a patient who developed radiologic evidence of amiodarone deposition in the lungs after bilateral lung transplantation.

[ "Amiodarone", "pulmonary", "toxicity", "after", "lung", "transplantation", ".", " ", "Atrial", "fibrillation", "occurs", "frequently", "after", "lung", "transplantation", "and", "is", "commonly", "treated", "with", "amiodarone", ".", "Pulmonary", "toxicity", "may", "result", "from", "amiodarone", "exposure", "and", "is", "characterized", "by", "non", "-", "specific", "respiratory", "manifestations", ".", "To", "our", "knowledge", ",", "there", "are", "no", "reports", "of", "this", "complication", "occurring", "after", "lung", "transplantation", ".", "We", "present", "a", "patient", "who", "developed", "radiologic", "evidence", "of", "amiodarone", "deposition", "in", "the", "lungs", "after", "bilateral", "lung", "transplantation", "." ]

[ "ADVERSE" ]

pulmonary toxicity is a ADVERSE, Atrial fibrillation is a ADVERSE, Pulmonary toxicity is a ADVERSE

example-342_task1

Sentence: Amiodarone pulmonary toxicity after lung transplantation. Atrial fibrillation occurs frequently after lung transplantation and is commonly treated with amiodarone. Pulmonary toxicity may result from amiodarone exposure and is characterized by non-specific respiratory manifestations. To our knowledge, there are no reports of this complication occurring after lung transplantation. We present a patient who developed radiologic evidence of amiodarone deposition in the lungs after bilateral lung transplantation. Instructions: please typing these entity words according to sentence: pulmonary toxicity, Atrial fibrillation, Pulmonary toxicity Options: ADVERSE

[ "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Amiodarone pulmonary toxicity after lung transplantation. Atrial fibrillation occurs frequently after lung transplantation and is commonly treated with amiodarone. Pulmonary toxicity may result from amiodarone exposure and is characterized by non-specific respiratory manifestations. To our knowledge, there are no reports of this complication occurring after lung transplantation. We present a patient who developed radiologic evidence of amiodarone deposition in the lungs after bilateral lung transplantation.

[ "Amiodarone", "pulmonary", "toxicity", "after", "lung", "transplantation", ".", " ", "Atrial", "fibrillation", "occurs", "frequently", "after", "lung", "transplantation", "and", "is", "commonly", "treated", "with", "amiodarone", ".", "Pulmonary", "toxicity", "may", "result", "from", "amiodarone", "exposure", "and", "is", "characterized", "by", "non", "-", "specific", "respiratory", "manifestations", ".", "To", "our", "knowledge", ",", "there", "are", "no", "reports", "of", "this", "complication", "occurring", "after", "lung", "transplantation", ".", "We", "present", "a", "patient", "who", "developed", "radiologic", "evidence", "of", "amiodarone", "deposition", "in", "the", "lungs", "after", "bilateral", "lung", "transplantation", "." ]

[ "ADVERSE" ]

pulmonary toxicity, Atrial fibrillation, Pulmonary toxicity

example-342_task2

Sentence: Amiodarone pulmonary toxicity after lung transplantation. Atrial fibrillation occurs frequently after lung transplantation and is commonly treated with amiodarone. Pulmonary toxicity may result from amiodarone exposure and is characterized by non-specific respiratory manifestations. To our knowledge, there are no reports of this complication occurring after lung transplantation. We present a patient who developed radiologic evidence of amiodarone deposition in the lungs after bilateral lung transplantation. Instructions: please extract entity words from the input sentence

[ "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Amiodarone pulmonary toxicity after lung transplantation. Atrial fibrillation occurs frequently after lung transplantation and is commonly treated with amiodarone. Pulmonary toxicity may result from amiodarone exposure and is characterized by non-specific respiratory manifestations. To our knowledge, there are no reports of this complication occurring after lung transplantation. We present a patient who developed radiologic evidence of amiodarone deposition in the lungs after bilateral lung transplantation.

[ "Amiodarone", "pulmonary", "toxicity", "after", "lung", "transplantation", ".", " ", "Atrial", "fibrillation", "occurs", "frequently", "after", "lung", "transplantation", "and", "is", "commonly", "treated", "with", "amiodarone", ".", "Pulmonary", "toxicity", "may", "result", "from", "amiodarone", "exposure", "and", "is", "characterized", "by", "non", "-", "specific", "respiratory", "manifestations", ".", "To", "our", "knowledge", ",", "there", "are", "no", "reports", "of", "this", "complication", "occurring", "after", "lung", "transplantation", ".", "We", "present", "a", "patient", "who", "developed", "radiologic", "evidence", "of", "amiodarone", "deposition", "in", "the", "lungs", "after", "bilateral", "lung", "transplantation", "." ]

[ "ADVERSE" ]

Enflurane is a DRUG, Enflurane is a DRUG, halothane is a DRUG, nitrous oxide is a DRUG

Enflurane_ddi_task0

Sentence: The action of nondepolarizing relaxants is augmented by Enflurane. Less than the usual amounts of these medicines should be used. If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of Enflurane than when halothane or nitrous oxide with a balanced technique are used. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DRUG

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O" ]

The action of nondepolarizing relaxants is augmented by Enflurane. Less than the usual amounts of these medicines should be used. If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of Enflurane than when halothane or nitrous oxide with a balanced technique are used.

[ "The", "action", "of", "nondepolarizing", "relaxants", "is", "augmented", "by", "Enflurane", ".", "Less", "than", "the", "usual", "amounts", "of", "these", "medicines", "should", "be", "used", ".", "If", "the", "usual", "amounts", "of", "nondepolarizing", "relaxants", "are", "given", ",", "the", "time", "for", "recovery", "from", "neuromuscular", "blockade", "will", "be", "longer", "in", "the", "presence", "of", "Enflurane", "than", "when", "halothane", "or", "nitrous", "oxide", "with", "a", "balanced", "technique", "are", "used", "." ]

[ "DRUG" ]

Enflurane is a DRUG, Enflurane is a DRUG, halothane is a DRUG, nitrous oxide is a DRUG

Enflurane_ddi_task1

Sentence: The action of nondepolarizing relaxants is augmented by Enflurane. Less than the usual amounts of these medicines should be used. If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of Enflurane than when halothane or nitrous oxide with a balanced technique are used. Instructions: please typing these entity words according to sentence: Enflurane, Enflurane, halothane, nitrous oxide Options: DRUG

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O" ]

The action of nondepolarizing relaxants is augmented by Enflurane. Less than the usual amounts of these medicines should be used. If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of Enflurane than when halothane or nitrous oxide with a balanced technique are used.

[ "The", "action", "of", "nondepolarizing", "relaxants", "is", "augmented", "by", "Enflurane", ".", "Less", "than", "the", "usual", "amounts", "of", "these", "medicines", "should", "be", "used", ".", "If", "the", "usual", "amounts", "of", "nondepolarizing", "relaxants", "are", "given", ",", "the", "time", "for", "recovery", "from", "neuromuscular", "blockade", "will", "be", "longer", "in", "the", "presence", "of", "Enflurane", "than", "when", "halothane", "or", "nitrous", "oxide", "with", "a", "balanced", "technique", "are", "used", "." ]

[ "DRUG" ]

Enflurane, Enflurane, halothane, nitrous oxide

Enflurane_ddi_task2

Sentence: The action of nondepolarizing relaxants is augmented by Enflurane. Less than the usual amounts of these medicines should be used. If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of Enflurane than when halothane or nitrous oxide with a balanced technique are used. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O" ]

The action of nondepolarizing relaxants is augmented by Enflurane. Less than the usual amounts of these medicines should be used. If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of Enflurane than when halothane or nitrous oxide with a balanced technique are used.

[ "The", "action", "of", "nondepolarizing", "relaxants", "is", "augmented", "by", "Enflurane", ".", "Less", "than", "the", "usual", "amounts", "of", "these", "medicines", "should", "be", "used", ".", "If", "the", "usual", "amounts", "of", "nondepolarizing", "relaxants", "are", "given", ",", "the", "time", "for", "recovery", "from", "neuromuscular", "blockade", "will", "be", "longer", "in", "the", "presence", "of", "Enflurane", "than", "when", "halothane", "or", "nitrous", "oxide", "with", "a", "balanced", "technique", "are", "used", "." ]

[ "DRUG" ]

prethrombolytic cyclosporine - A injection is a Intervention_Pharmacological, acute anterior ST - elevation myocardial infarction . is a Participant_Condition, Cyclosporine - A ( CsA ) is a Intervention_Pharmacological, , is a Outcome_Physical, patients with acute anterior STEMI receiving thrombolytic treatment ( TLT ) . is a Participant_Condition, normal saline is a Intervention_Control, Infarct size , occurrence of major arrhythmias , heart failure , left ventricular ejection fraction ( LVEF ) , is a Outcome_Physical, TLT - related complications is a Outcome_Adverse-effects, in - hospital and 6-month mortality rates is a Outcome_Mortality, demographics , myocardial enzyme release , occurrence of major arrhythmias is a Outcome_Physical, LVEF at first day is a Outcome_Physical

56841_task0

Sentence: The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction . INTRODUCTION Reperfusion injury reduces the benefits of early reperfusion therapies after acute ST-elevation myocardial infarction ( STEMI ) . Cyclosporine-A ( CsA ) is a potent inhibitor of opening of the mitochondrial permeability transition pore , which has been shown to play a key role in myocardial reperfusion injury . The impact of this treatment on clinical outcomes of acute STEMI remains unknown . Our aim was to investigate the clinical outcomes of using this drug in patients with acute anterior STEMI receiving thrombolytic treatment ( TLT ) . METHODS In this double-blinded randomized clinical trial , 101 patients with acute anterior STEMI who were candidate for TLT , were enrolled and randomly assigned into treatment or control groups . Patients in the treatment group received an intravenous bolus injection of 2.5 mg/kg of CsA immediately before TLT . The patients in the control group received an equivalent volume of normal saline . Infarct size , occurrence of major arrhythmias , heart failure , left ventricular ejection fraction ( LVEF ) , TLT-related complications , in-hospital and 6-month mortality rates were investigated . RESULTS There were no significant differences among the demographics , myocardial enzyme release , occurrence of major arrhythmias [ 9 ( 18 % ) vs. 12 ( 23.5 % ) , P = 0.80 ] , heart failure [ 18 ( 36 % ) vs. 19 ( 38.3 % ) , P = 0.83 ] , LVEF at first day [ 34.7 ± 9.9 % vs. 33.5 ± 8.1 % , P = 0.50 ] or at discharge [ 37.7 ± 10 % vs. 36.1 ± 8.2 % , P = 0.43 ] , and in-hospital [ 4 ( 8 % ) vs. 6 ( 11.8 % ) , P = 0.74 ] or 6-month mortality rates [ 9 ( 18 % ) vs. 10 ( 19.6 % ) , P = 0.99 ] between the CsA vs. the control group . CONCLUSION In this study , the prethrombolytic administration of CsA was not associated with a reduction in the infarct size or any improvement in clinical outcomes . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Control, Participant_Condition, Outcome_Mortality, Outcome_Physical

[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction . INTRODUCTION Reperfusion injury reduces the benefits of early reperfusion therapies after acute ST-elevation myocardial infarction ( STEMI ) . Cyclosporine-A ( CsA ) is a potent inhibitor of opening of the mitochondrial permeability transition pore , which has been shown to play a key role in myocardial reperfusion injury . The impact of this treatment on clinical outcomes of acute STEMI remains unknown . Our aim was to investigate the clinical outcomes of using this drug in patients with acute anterior STEMI receiving thrombolytic treatment ( TLT ) . METHODS In this double-blinded randomized clinical trial , 101 patients with acute anterior STEMI who were candidate for TLT , were enrolled and randomly assigned into treatment or control groups . Patients in the treatment group received an intravenous bolus injection of 2.5 mg/kg of CsA immediately before TLT . The patients in the control group received an equivalent volume of normal saline . Infarct size , occurrence of major arrhythmias , heart failure , left ventricular ejection fraction ( LVEF ) , TLT-related complications , in-hospital and 6-month mortality rates were investigated . RESULTS There were no significant differences among the demographics , myocardial enzyme release , occurrence of major arrhythmias [ 9 ( 18 % ) vs. 12 ( 23.5 % ) , P = 0.80 ] , heart failure [ 18 ( 36 % ) vs. 19 ( 38.3 % ) , P = 0.83 ] , LVEF at first day [ 34.7 ± 9.9 % vs. 33.5 ± 8.1 % , P = 0.50 ] or at discharge [ 37.7 ± 10 % vs. 36.1 ± 8.2 % , P = 0.43 ] , and in-hospital [ 4 ( 8 % ) vs. 6 ( 11.8 % ) , P = 0.74 ] or 6-month mortality rates [ 9 ( 18 % ) vs. 10 ( 19.6 % ) , P = 0.99 ] between the CsA vs. the control group . CONCLUSION In this study , the prethrombolytic administration of CsA was not associated with a reduction in the infarct size or any improvement in clinical outcomes .

[ "The", "effect", "of", "prethrombolytic", "cyclosporine", "-", "A", "injection", "on", "clinical", "outcome", "of", "acute", "anterior", "ST", "-", "elevation", "myocardial", "infarction", ".", "INTRODUCTION", "Reperfusion", "injury", "reduces", "the", "benefits", "of", "early", "reperfusion", "therapies", "after", "acute", "ST", "-", "elevation", "myocardial", "infarction", "(", "STEMI", ")", ".", "Cyclosporine", "-", "A", "(", "CsA", ")", "is", "a", "potent", "inhibitor", "of", "opening", "of", "the", "mitochondrial", "permeability", "transition", "pore", ",", "which", "has", "been", "shown", "to", "play", "a", "key", "role", "in", "myocardial", "reperfusion", "injury", ".", "The", "impact", "of", "this", "treatment", "on", "clinical", "outcomes", "of", "acute", "STEMI", "remains", "unknown", ".", "Our", "aim", "was", "to", "investigate", "the", "clinical", "outcomes", "of", "using", "this", "drug", "in", "patients", "with", "acute", "anterior", "STEMI", "receiving", "thrombolytic", "treatment", "(", "TLT", ")", ".", "METHODS", "In", "this", "double", "-", "blinded", "randomized", "clinical", "trial", ",", "101", "patients", "with", "acute", "anterior", "STEMI", "who", "were", "candidate", "for", "TLT", ",", "were", "enrolled", "and", "randomly", "assigned", "into", "treatment", "or", "control", "groups", ".", "Patients", "in", "the", "treatment", "group", "received", "an", "intravenous", "bolus", "injection", "of", "2.5", "mg", "/", "kg", "of", "CsA", "immediately", "before", "TLT", ".", "The", "patients", "in", "the", "control", "group", "received", "an", "equivalent", "volume", "of", "normal", "saline", ".", "Infarct", "size", ",", "occurrence", "of", "major", "arrhythmias", ",", "heart", "failure", ",", "left", "ventricular", "ejection", "fraction", "(", "LVEF", ")", ",", "TLT", "-", "related", "complications", ",", "in", "-", "hospital", "and", "6-month", "mortality", "rates", "were", "investigated", ".", "RESULTS", "There", "were", "no", "significant", "differences", "among", "the", "demographics", ",", "myocardial", "enzyme", "release", ",", "occurrence", "of", "major", "arrhythmias", "[", "9", "(", "18", "%", ")", "vs", ".", "12", "(", "23.5", "%", ")", ",", "P", "=", "0.80", "]", ",", "heart", "failure", "[", "18", "(", "36", "%", ")", "vs", ".", "19", "(", "38.3", "%", ")", ",", "P", "=", "0.83", "]", ",", "LVEF", "at", "first", "day", "[", "34.7", "±", "9.9", "%", "vs", ".", "33.5", "±", "8.1", "%", ",", "P", "=", "0.50", "]", "or", "at", "discharge", "[", "37.7", "±", "10", "%", "vs", ".", "36.1", "±", "8.2", "%", ",", "P", "=", "0.43", "]", ",", "and", "in", "-", "hospital", "[", "4", "(", "8", "%", ")", "vs", ".", "6", "(", "11.8", "%", ")", ",", "P", "=", "0.74", "]", "or", "6-month", "mortality", "rates", "[", "9", "(", "18", "%", ")", "vs", ".", "10", "(", "19.6", "%", ")", ",", "P", "=", "0.99", "]", "between", "the", "CsA", "vs", ".", "the", "control", "group", ".", "CONCLUSION", "In", "this", "study", ",", "the", "prethrombolytic", "administration", "of", "CsA", "was", "not", "associated", "with", "a", "reduction", "in", "the", "infarct", "size", "or", "any", "improvement", "in", "clinical", "outcomes", "." ]

[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Outcome_Mortality", "Outcome_Adverse-effects", "Intervention_Control" ]

prethrombolytic cyclosporine - A injection is a Intervention_Pharmacological, acute anterior ST - elevation myocardial infarction . is a Participant_Condition, Cyclosporine - A ( CsA ) is a Intervention_Pharmacological, , is a Outcome_Physical, patients with acute anterior STEMI receiving thrombolytic treatment ( TLT ) . is a Participant_Condition, normal saline is a Intervention_Control, Infarct size , occurrence of major arrhythmias , heart failure , left ventricular ejection fraction ( LVEF ) , is a Outcome_Physical, TLT - related complications is a Outcome_Adverse-effects, in - hospital and 6-month mortality rates is a Outcome_Mortality, demographics , myocardial enzyme release , occurrence of major arrhythmias is a Outcome_Physical, LVEF at first day is a Outcome_Physical

56841_task1

Sentence: The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction . INTRODUCTION Reperfusion injury reduces the benefits of early reperfusion therapies after acute ST-elevation myocardial infarction ( STEMI ) . Cyclosporine-A ( CsA ) is a potent inhibitor of opening of the mitochondrial permeability transition pore , which has been shown to play a key role in myocardial reperfusion injury . The impact of this treatment on clinical outcomes of acute STEMI remains unknown . Our aim was to investigate the clinical outcomes of using this drug in patients with acute anterior STEMI receiving thrombolytic treatment ( TLT ) . METHODS In this double-blinded randomized clinical trial , 101 patients with acute anterior STEMI who were candidate for TLT , were enrolled and randomly assigned into treatment or control groups . Patients in the treatment group received an intravenous bolus injection of 2.5 mg/kg of CsA immediately before TLT . The patients in the control group received an equivalent volume of normal saline . Infarct size , occurrence of major arrhythmias , heart failure , left ventricular ejection fraction ( LVEF ) , TLT-related complications , in-hospital and 6-month mortality rates were investigated . RESULTS There were no significant differences among the demographics , myocardial enzyme release , occurrence of major arrhythmias [ 9 ( 18 % ) vs. 12 ( 23.5 % ) , P = 0.80 ] , heart failure [ 18 ( 36 % ) vs. 19 ( 38.3 % ) , P = 0.83 ] , LVEF at first day [ 34.7 ± 9.9 % vs. 33.5 ± 8.1 % , P = 0.50 ] or at discharge [ 37.7 ± 10 % vs. 36.1 ± 8.2 % , P = 0.43 ] , and in-hospital [ 4 ( 8 % ) vs. 6 ( 11.8 % ) , P = 0.74 ] or 6-month mortality rates [ 9 ( 18 % ) vs. 10 ( 19.6 % ) , P = 0.99 ] between the CsA vs. the control group . CONCLUSION In this study , the prethrombolytic administration of CsA was not associated with a reduction in the infarct size or any improvement in clinical outcomes . Instructions: please typing these entity words according to sentence: prethrombolytic cyclosporine - A injection, acute anterior ST - elevation myocardial infarction ., Cyclosporine - A ( CsA ), ,, patients with acute anterior STEMI receiving thrombolytic treatment ( TLT ) ., normal saline, Infarct size , occurrence of major arrhythmias , heart failure , left ventricular ejection fraction ( LVEF ) ,, TLT - related complications, in - hospital and 6-month mortality rates, demographics , myocardial enzyme release , occurrence of major arrhythmias, LVEF at first day Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Control, Participant_Condition, Outcome_Mortality, Outcome_Physical

[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction . INTRODUCTION Reperfusion injury reduces the benefits of early reperfusion therapies after acute ST-elevation myocardial infarction ( STEMI ) . Cyclosporine-A ( CsA ) is a potent inhibitor of opening of the mitochondrial permeability transition pore , which has been shown to play a key role in myocardial reperfusion injury . The impact of this treatment on clinical outcomes of acute STEMI remains unknown . Our aim was to investigate the clinical outcomes of using this drug in patients with acute anterior STEMI receiving thrombolytic treatment ( TLT ) . METHODS In this double-blinded randomized clinical trial , 101 patients with acute anterior STEMI who were candidate for TLT , were enrolled and randomly assigned into treatment or control groups . Patients in the treatment group received an intravenous bolus injection of 2.5 mg/kg of CsA immediately before TLT . The patients in the control group received an equivalent volume of normal saline . Infarct size , occurrence of major arrhythmias , heart failure , left ventricular ejection fraction ( LVEF ) , TLT-related complications , in-hospital and 6-month mortality rates were investigated . RESULTS There were no significant differences among the demographics , myocardial enzyme release , occurrence of major arrhythmias [ 9 ( 18 % ) vs. 12 ( 23.5 % ) , P = 0.80 ] , heart failure [ 18 ( 36 % ) vs. 19 ( 38.3 % ) , P = 0.83 ] , LVEF at first day [ 34.7 ± 9.9 % vs. 33.5 ± 8.1 % , P = 0.50 ] or at discharge [ 37.7 ± 10 % vs. 36.1 ± 8.2 % , P = 0.43 ] , and in-hospital [ 4 ( 8 % ) vs. 6 ( 11.8 % ) , P = 0.74 ] or 6-month mortality rates [ 9 ( 18 % ) vs. 10 ( 19.6 % ) , P = 0.99 ] between the CsA vs. the control group . CONCLUSION In this study , the prethrombolytic administration of CsA was not associated with a reduction in the infarct size or any improvement in clinical outcomes .

[ "The", "effect", "of", "prethrombolytic", "cyclosporine", "-", "A", "injection", "on", "clinical", "outcome", "of", "acute", "anterior", "ST", "-", "elevation", "myocardial", "infarction", ".", "INTRODUCTION", "Reperfusion", "injury", "reduces", "the", "benefits", "of", "early", "reperfusion", "therapies", "after", "acute", "ST", "-", "elevation", "myocardial", "infarction", "(", "STEMI", ")", ".", "Cyclosporine", "-", "A", "(", "CsA", ")", "is", "a", "potent", "inhibitor", "of", "opening", "of", "the", "mitochondrial", "permeability", "transition", "pore", ",", "which", "has", "been", "shown", "to", "play", "a", "key", "role", "in", "myocardial", "reperfusion", "injury", ".", "The", "impact", "of", "this", "treatment", "on", "clinical", "outcomes", "of", "acute", "STEMI", "remains", "unknown", ".", "Our", "aim", "was", "to", "investigate", "the", "clinical", "outcomes", "of", "using", "this", "drug", "in", "patients", "with", "acute", "anterior", "STEMI", "receiving", "thrombolytic", "treatment", "(", "TLT", ")", ".", "METHODS", "In", "this", "double", "-", "blinded", "randomized", "clinical", "trial", ",", "101", "patients", "with", "acute", "anterior", "STEMI", "who", "were", "candidate", "for", "TLT", ",", "were", "enrolled", "and", "randomly", "assigned", "into", "treatment", "or", "control", "groups", ".", "Patients", "in", "the", "treatment", "group", "received", "an", "intravenous", "bolus", "injection", "of", "2.5", "mg", "/", "kg", "of", "CsA", "immediately", "before", "TLT", ".", "The", "patients", "in", "the", "control", "group", "received", "an", "equivalent", "volume", "of", "normal", "saline", ".", "Infarct", "size", ",", "occurrence", "of", "major", "arrhythmias", ",", "heart", "failure", ",", "left", "ventricular", "ejection", "fraction", "(", "LVEF", ")", ",", "TLT", "-", "related", "complications", ",", "in", "-", "hospital", "and", "6-month", "mortality", "rates", "were", "investigated", ".", "RESULTS", "There", "were", "no", "significant", "differences", "among", "the", "demographics", ",", "myocardial", "enzyme", "release", ",", "occurrence", "of", "major", "arrhythmias", "[", "9", "(", "18", "%", ")", "vs", ".", "12", "(", "23.5", "%", ")", ",", "P", "=", "0.80", "]", ",", "heart", "failure", "[", "18", "(", "36", "%", ")", "vs", ".", "19", "(", "38.3", "%", ")", ",", "P", "=", "0.83", "]", ",", "LVEF", "at", "first", "day", "[", "34.7", "±", "9.9", "%", "vs", ".", "33.5", "±", "8.1", "%", ",", "P", "=", "0.50", "]", "or", "at", "discharge", "[", "37.7", "±", "10", "%", "vs", ".", "36.1", "±", "8.2", "%", ",", "P", "=", "0.43", "]", ",", "and", "in", "-", "hospital", "[", "4", "(", "8", "%", ")", "vs", ".", "6", "(", "11.8", "%", ")", ",", "P", "=", "0.74", "]", "or", "6-month", "mortality", "rates", "[", "9", "(", "18", "%", ")", "vs", ".", "10", "(", "19.6", "%", ")", ",", "P", "=", "0.99", "]", "between", "the", "CsA", "vs", ".", "the", "control", "group", ".", "CONCLUSION", "In", "this", "study", ",", "the", "prethrombolytic", "administration", "of", "CsA", "was", "not", "associated", "with", "a", "reduction", "in", "the", "infarct", "size", "or", "any", "improvement", "in", "clinical", "outcomes", "." ]

[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Outcome_Mortality", "Outcome_Adverse-effects", "Intervention_Control" ]

prethrombolytic cyclosporine - A injection, acute anterior ST - elevation myocardial infarction ., Cyclosporine - A ( CsA ), ,, patients with acute anterior STEMI receiving thrombolytic treatment ( TLT ) ., normal saline, Infarct size , occurrence of major arrhythmias , heart failure , left ventricular ejection fraction ( LVEF ) ,, TLT - related complications, in - hospital and 6-month mortality rates, demographics , myocardial enzyme release , occurrence of major arrhythmias, LVEF at first day

56841_task2

Sentence: The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction . INTRODUCTION Reperfusion injury reduces the benefits of early reperfusion therapies after acute ST-elevation myocardial infarction ( STEMI ) . Cyclosporine-A ( CsA ) is a potent inhibitor of opening of the mitochondrial permeability transition pore , which has been shown to play a key role in myocardial reperfusion injury . The impact of this treatment on clinical outcomes of acute STEMI remains unknown . Our aim was to investigate the clinical outcomes of using this drug in patients with acute anterior STEMI receiving thrombolytic treatment ( TLT ) . METHODS In this double-blinded randomized clinical trial , 101 patients with acute anterior STEMI who were candidate for TLT , were enrolled and randomly assigned into treatment or control groups . Patients in the treatment group received an intravenous bolus injection of 2.5 mg/kg of CsA immediately before TLT . The patients in the control group received an equivalent volume of normal saline . Infarct size , occurrence of major arrhythmias , heart failure , left ventricular ejection fraction ( LVEF ) , TLT-related complications , in-hospital and 6-month mortality rates were investigated . RESULTS There were no significant differences among the demographics , myocardial enzyme release , occurrence of major arrhythmias [ 9 ( 18 % ) vs. 12 ( 23.5 % ) , P = 0.80 ] , heart failure [ 18 ( 36 % ) vs. 19 ( 38.3 % ) , P = 0.83 ] , LVEF at first day [ 34.7 ± 9.9 % vs. 33.5 ± 8.1 % , P = 0.50 ] or at discharge [ 37.7 ± 10 % vs. 36.1 ± 8.2 % , P = 0.43 ] , and in-hospital [ 4 ( 8 % ) vs. 6 ( 11.8 % ) , P = 0.74 ] or 6-month mortality rates [ 9 ( 18 % ) vs. 10 ( 19.6 % ) , P = 0.99 ] between the CsA vs. the control group . CONCLUSION In this study , the prethrombolytic administration of CsA was not associated with a reduction in the infarct size or any improvement in clinical outcomes . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction . INTRODUCTION Reperfusion injury reduces the benefits of early reperfusion therapies after acute ST-elevation myocardial infarction ( STEMI ) . Cyclosporine-A ( CsA ) is a potent inhibitor of opening of the mitochondrial permeability transition pore , which has been shown to play a key role in myocardial reperfusion injury . The impact of this treatment on clinical outcomes of acute STEMI remains unknown . Our aim was to investigate the clinical outcomes of using this drug in patients with acute anterior STEMI receiving thrombolytic treatment ( TLT ) . METHODS In this double-blinded randomized clinical trial , 101 patients with acute anterior STEMI who were candidate for TLT , were enrolled and randomly assigned into treatment or control groups . Patients in the treatment group received an intravenous bolus injection of 2.5 mg/kg of CsA immediately before TLT . The patients in the control group received an equivalent volume of normal saline . Infarct size , occurrence of major arrhythmias , heart failure , left ventricular ejection fraction ( LVEF ) , TLT-related complications , in-hospital and 6-month mortality rates were investigated . RESULTS There were no significant differences among the demographics , myocardial enzyme release , occurrence of major arrhythmias [ 9 ( 18 % ) vs. 12 ( 23.5 % ) , P = 0.80 ] , heart failure [ 18 ( 36 % ) vs. 19 ( 38.3 % ) , P = 0.83 ] , LVEF at first day [ 34.7 ± 9.9 % vs. 33.5 ± 8.1 % , P = 0.50 ] or at discharge [ 37.7 ± 10 % vs. 36.1 ± 8.2 % , P = 0.43 ] , and in-hospital [ 4 ( 8 % ) vs. 6 ( 11.8 % ) , P = 0.74 ] or 6-month mortality rates [ 9 ( 18 % ) vs. 10 ( 19.6 % ) , P = 0.99 ] between the CsA vs. the control group . CONCLUSION In this study , the prethrombolytic administration of CsA was not associated with a reduction in the infarct size or any improvement in clinical outcomes .

[ "The", "effect", "of", "prethrombolytic", "cyclosporine", "-", "A", "injection", "on", "clinical", "outcome", "of", "acute", "anterior", "ST", "-", "elevation", "myocardial", "infarction", ".", "INTRODUCTION", "Reperfusion", "injury", "reduces", "the", "benefits", "of", "early", "reperfusion", "therapies", "after", "acute", "ST", "-", "elevation", "myocardial", "infarction", "(", "STEMI", ")", ".", "Cyclosporine", "-", "A", "(", "CsA", ")", "is", "a", "potent", "inhibitor", "of", "opening", "of", "the", "mitochondrial", "permeability", "transition", "pore", ",", "which", "has", "been", "shown", "to", "play", "a", "key", "role", "in", "myocardial", "reperfusion", "injury", ".", "The", "impact", "of", "this", "treatment", "on", "clinical", "outcomes", "of", "acute", "STEMI", "remains", "unknown", ".", "Our", "aim", "was", "to", "investigate", "the", "clinical", "outcomes", "of", "using", "this", "drug", "in", "patients", "with", "acute", "anterior", "STEMI", "receiving", "thrombolytic", "treatment", "(", "TLT", ")", ".", "METHODS", "In", "this", "double", "-", "blinded", "randomized", "clinical", "trial", ",", "101", "patients", "with", "acute", "anterior", "STEMI", "who", "were", "candidate", "for", "TLT", ",", "were", "enrolled", "and", "randomly", "assigned", "into", "treatment", "or", "control", "groups", ".", "Patients", "in", "the", "treatment", "group", "received", "an", "intravenous", "bolus", "injection", "of", "2.5", "mg", "/", "kg", "of", "CsA", "immediately", "before", "TLT", ".", "The", "patients", "in", "the", "control", "group", "received", "an", "equivalent", "volume", "of", "normal", "saline", ".", "Infarct", "size", ",", "occurrence", "of", "major", "arrhythmias", ",", "heart", "failure", ",", "left", "ventricular", "ejection", "fraction", "(", "LVEF", ")", ",", "TLT", "-", "related", "complications", ",", "in", "-", "hospital", "and", "6-month", "mortality", "rates", "were", "investigated", ".", "RESULTS", "There", "were", "no", "significant", "differences", "among", "the", "demographics", ",", "myocardial", "enzyme", "release", ",", "occurrence", "of", "major", "arrhythmias", "[", "9", "(", "18", "%", ")", "vs", ".", "12", "(", "23.5", "%", ")", ",", "P", "=", "0.80", "]", ",", "heart", "failure", "[", "18", "(", "36", "%", ")", "vs", ".", "19", "(", "38.3", "%", ")", ",", "P", "=", "0.83", "]", ",", "LVEF", "at", "first", "day", "[", "34.7", "±", "9.9", "%", "vs", ".", "33.5", "±", "8.1", "%", ",", "P", "=", "0.50", "]", "or", "at", "discharge", "[", "37.7", "±", "10", "%", "vs", ".", "36.1", "±", "8.2", "%", ",", "P", "=", "0.43", "]", ",", "and", "in", "-", "hospital", "[", "4", "(", "8", "%", ")", "vs", ".", "6", "(", "11.8", "%", ")", ",", "P", "=", "0.74", "]", "or", "6-month", "mortality", "rates", "[", "9", "(", "18", "%", ")", "vs", ".", "10", "(", "19.6", "%", ")", ",", "P", "=", "0.99", "]", "between", "the", "CsA", "vs", ".", "the", "control", "group", ".", "CONCLUSION", "In", "this", "study", ",", "the", "prethrombolytic", "administration", "of", "CsA", "was", "not", "associated", "with", "a", "reduction", "in", "the", "infarct", "size", "or", "any", "improvement", "in", "clinical", "outcomes", "." ]

[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Outcome_Mortality", "Outcome_Adverse-effects", "Intervention_Control" ]

pneumonectomy is an umlsterm, carcinoma is an umlsterm, adjuvant is an umlsterm, radiation is an umlsterm, drainage is an umlsterm, therapy is an umlsterm, empyema is an umlsterm, Dacron is an umlsterm, rupture is an umlsterm, aorta is an umlsterm, emergency is an umlsterm, aorta is an umlsterm, blind is an umlsterm, omentum is an umlsterm, pneumonectomy is an umlsterm, infections is an umlsterm, prostheses is an umlsterm, lung is an umlsterm, graft is an umlsterm, incorporation is an umlsterm, tissue is an umlsterm, complications is an umlsterm, grafting is an umlsterm, graft is an umlsterm, implantation is an umlsterm, procedures is an umlsterm, debridement is an umlsterm, omentum is an umlsterm, thoracoplasty is an umlsterm, postoperative is an umlsterm, infection is an umlsterm, tissue is an umlsterm

Gefaesschirurgie.90040096.eng.abstr_task0

Sentence: Four years after extensive pneumonectomy on the left side with resection of the aortic wall and patch reconstruction for a T4 carcinoma , 2 years after adjuvant radiation and 10 months after drainage therapy of late intrathoracic empyema , destruction of the infected Dacron patch led to rupture of the aorta descendens . Successful primary emergency reconstruction of the aorta descendens was followed by venetian blind plasty ( Heller ) and transposition of the omentum majus for omentoplasty of the aortal wall and reduction of the pneumonectomy cavity . The rate of prosthetic infections is between 0.3 and 2.5% and must be taken into consideration even in cases of intrathoracic vascular reconstruction with alloplastic prostheses . After lung resection it is necessary to cover up the prosthetic graft by using autogenous material to obtain prosthetic incorporation into the protective tissue . In intrathoracic infectious complications , extra-anatomic bypass grafting or autogenous vascular graft implantation should be considered . If there is no possibility of carrying out these procedures , first aggressive local debridement of the infected vascular wall and afterwards coverage with alloplastic prosthetics with omentum transposition and thoracoplasty are essential to minimize postoperative infection and obtain solid anchorage in the surrounding tissue . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Four years after extensive pneumonectomy on the left side with resection of the aortic wall and patch reconstruction for a T4 carcinoma , 2 years after adjuvant radiation and 10 months after drainage therapy of late intrathoracic empyema , destruction of the infected Dacron patch led to rupture of the aorta descendens . Successful primary emergency reconstruction of the aorta descendens was followed by venetian blind plasty ( Heller ) and transposition of the omentum majus for omentoplasty of the aortal wall and reduction of the pneumonectomy cavity . The rate of prosthetic infections is between 0.3 and 2.5% and must be taken into consideration even in cases of intrathoracic vascular reconstruction with alloplastic prostheses . After lung resection it is necessary to cover up the prosthetic graft by using autogenous material to obtain prosthetic incorporation into the protective tissue . In intrathoracic infectious complications , extra-anatomic bypass grafting or autogenous vascular graft implantation should be considered . If there is no possibility of carrying out these procedures , first aggressive local debridement of the infected vascular wall and afterwards coverage with alloplastic prosthetics with omentum transposition and thoracoplasty are essential to minimize postoperative infection and obtain solid anchorage in the surrounding tissue .

[ "Four", "years", "after", "extensive", "pneumonectomy", "on", "the", "left", "side", "with", "resection", "of", "the", "aortic", "wall", "and", "patch", "reconstruction", "for", "a", "T4", "carcinoma", ",", "2", "years", "after", "adjuvant", "radiation", "and", "10", "months", "after", "drainage", "therapy", "of", "late", "intrathoracic", "empyema", ",", "destruction", "of", "the", "infected", "Dacron", "patch", "led", "to", "rupture", "of", "the", "aorta", "descendens", ".", "Successful", "primary", "emergency", "reconstruction", "of", "the", "aorta", "descendens", "was", "followed", "by", "venetian", "blind", "plasty", "(", "Heller", ")", "and", "transposition", "of", "the", "omentum", "majus", "for", "omentoplasty", "of", "the", "aortal", "wall", "and", "reduction", "of", "the", "pneumonectomy", "cavity", ".", "The", "rate", "of", "prosthetic", "infections", "is", "between", "0.3", "and", "2.5", "%", "and", "must", "be", "taken", "into", "consideration", "even", "in", "cases", "of", "intrathoracic", "vascular", "reconstruction", "with", "alloplastic", "prostheses", ".", "After", "lung", "resection", "it", "is", "necessary", "to", "cover", "up", "the", "prosthetic", "graft", "by", "using", "autogenous", "material", "to", "obtain", "prosthetic", "incorporation", "into", "the", "protective", "tissue", ".", "In", "intrathoracic", "infectious", "complications", ",", "extra", "-", "anatomic", "bypass", "grafting", "or", "autogenous", "vascular", "graft", "implantation", "should", "be", "considered", ".", "If", "there", "is", "no", "possibility", "of", "carrying", "out", "these", "procedures", ",", "first", "aggressive", "local", "debridement", "of", "the", "infected", "vascular", "wall", "and", "afterwards", "coverage", "with", "alloplastic", "prosthetics", "with", "omentum", "transposition", "and", "thoracoplasty", "are", "essential", "to", "minimize", "postoperative", "infection", "and", "obtain", "solid", "anchorage", "in", "the", "surrounding", "tissue", "." ]

[ "umlsterm" ]

pneumonectomy is an umlsterm, carcinoma is an umlsterm, adjuvant is an umlsterm, radiation is an umlsterm, drainage is an umlsterm, therapy is an umlsterm, empyema is an umlsterm, Dacron is an umlsterm, rupture is an umlsterm, aorta is an umlsterm, emergency is an umlsterm, aorta is an umlsterm, blind is an umlsterm, omentum is an umlsterm, pneumonectomy is an umlsterm, infections is an umlsterm, prostheses is an umlsterm, lung is an umlsterm, graft is an umlsterm, incorporation is an umlsterm, tissue is an umlsterm, complications is an umlsterm, grafting is an umlsterm, graft is an umlsterm, implantation is an umlsterm, procedures is an umlsterm, debridement is an umlsterm, omentum is an umlsterm, thoracoplasty is an umlsterm, postoperative is an umlsterm, infection is an umlsterm, tissue is an umlsterm

Gefaesschirurgie.90040096.eng.abstr_task1

Sentence: Four years after extensive pneumonectomy on the left side with resection of the aortic wall and patch reconstruction for a T4 carcinoma , 2 years after adjuvant radiation and 10 months after drainage therapy of late intrathoracic empyema , destruction of the infected Dacron patch led to rupture of the aorta descendens . Successful primary emergency reconstruction of the aorta descendens was followed by venetian blind plasty ( Heller ) and transposition of the omentum majus for omentoplasty of the aortal wall and reduction of the pneumonectomy cavity . The rate of prosthetic infections is between 0.3 and 2.5% and must be taken into consideration even in cases of intrathoracic vascular reconstruction with alloplastic prostheses . After lung resection it is necessary to cover up the prosthetic graft by using autogenous material to obtain prosthetic incorporation into the protective tissue . In intrathoracic infectious complications , extra-anatomic bypass grafting or autogenous vascular graft implantation should be considered . If there is no possibility of carrying out these procedures , first aggressive local debridement of the infected vascular wall and afterwards coverage with alloplastic prosthetics with omentum transposition and thoracoplasty are essential to minimize postoperative infection and obtain solid anchorage in the surrounding tissue . Instructions: please typing these entity words according to sentence: pneumonectomy, carcinoma, adjuvant, radiation, drainage, therapy, empyema, Dacron, rupture, aorta, emergency, aorta, blind, omentum, pneumonectomy, infections, prostheses, lung, graft, incorporation, tissue, complications, grafting, graft, implantation, procedures, debridement, omentum, thoracoplasty, postoperative, infection, tissue Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Four years after extensive pneumonectomy on the left side with resection of the aortic wall and patch reconstruction for a T4 carcinoma , 2 years after adjuvant radiation and 10 months after drainage therapy of late intrathoracic empyema , destruction of the infected Dacron patch led to rupture of the aorta descendens . Successful primary emergency reconstruction of the aorta descendens was followed by venetian blind plasty ( Heller ) and transposition of the omentum majus for omentoplasty of the aortal wall and reduction of the pneumonectomy cavity . The rate of prosthetic infections is between 0.3 and 2.5% and must be taken into consideration even in cases of intrathoracic vascular reconstruction with alloplastic prostheses . After lung resection it is necessary to cover up the prosthetic graft by using autogenous material to obtain prosthetic incorporation into the protective tissue . In intrathoracic infectious complications , extra-anatomic bypass grafting or autogenous vascular graft implantation should be considered . If there is no possibility of carrying out these procedures , first aggressive local debridement of the infected vascular wall and afterwards coverage with alloplastic prosthetics with omentum transposition and thoracoplasty are essential to minimize postoperative infection and obtain solid anchorage in the surrounding tissue .

[ "Four", "years", "after", "extensive", "pneumonectomy", "on", "the", "left", "side", "with", "resection", "of", "the", "aortic", "wall", "and", "patch", "reconstruction", "for", "a", "T4", "carcinoma", ",", "2", "years", "after", "adjuvant", "radiation", "and", "10", "months", "after", "drainage", "therapy", "of", "late", "intrathoracic", "empyema", ",", "destruction", "of", "the", "infected", "Dacron", "patch", "led", "to", "rupture", "of", "the", "aorta", "descendens", ".", "Successful", "primary", "emergency", "reconstruction", "of", "the", "aorta", "descendens", "was", "followed", "by", "venetian", "blind", "plasty", "(", "Heller", ")", "and", "transposition", "of", "the", "omentum", "majus", "for", "omentoplasty", "of", "the", "aortal", "wall", "and", "reduction", "of", "the", "pneumonectomy", "cavity", ".", "The", "rate", "of", "prosthetic", "infections", "is", "between", "0.3", "and", "2.5", "%", "and", "must", "be", "taken", "into", "consideration", "even", "in", "cases", "of", "intrathoracic", "vascular", "reconstruction", "with", "alloplastic", "prostheses", ".", "After", "lung", "resection", "it", "is", "necessary", "to", "cover", "up", "the", "prosthetic", "graft", "by", "using", "autogenous", "material", "to", "obtain", "prosthetic", "incorporation", "into", "the", "protective", "tissue", ".", "In", "intrathoracic", "infectious", "complications", ",", "extra", "-", "anatomic", "bypass", "grafting", "or", "autogenous", "vascular", "graft", "implantation", "should", "be", "considered", ".", "If", "there", "is", "no", "possibility", "of", "carrying", "out", "these", "procedures", ",", "first", "aggressive", "local", "debridement", "of", "the", "infected", "vascular", "wall", "and", "afterwards", "coverage", "with", "alloplastic", "prosthetics", "with", "omentum", "transposition", "and", "thoracoplasty", "are", "essential", "to", "minimize", "postoperative", "infection", "and", "obtain", "solid", "anchorage", "in", "the", "surrounding", "tissue", "." ]

[ "umlsterm" ]

pneumonectomy, carcinoma, adjuvant, radiation, drainage, therapy, empyema, Dacron, rupture, aorta, emergency, aorta, blind, omentum, pneumonectomy, infections, prostheses, lung, graft, incorporation, tissue, complications, grafting, graft, implantation, procedures, debridement, omentum, thoracoplasty, postoperative, infection, tissue

Gefaesschirurgie.90040096.eng.abstr_task2

Sentence: Four years after extensive pneumonectomy on the left side with resection of the aortic wall and patch reconstruction for a T4 carcinoma , 2 years after adjuvant radiation and 10 months after drainage therapy of late intrathoracic empyema , destruction of the infected Dacron patch led to rupture of the aorta descendens . Successful primary emergency reconstruction of the aorta descendens was followed by venetian blind plasty ( Heller ) and transposition of the omentum majus for omentoplasty of the aortal wall and reduction of the pneumonectomy cavity . The rate of prosthetic infections is between 0.3 and 2.5% and must be taken into consideration even in cases of intrathoracic vascular reconstruction with alloplastic prostheses . After lung resection it is necessary to cover up the prosthetic graft by using autogenous material to obtain prosthetic incorporation into the protective tissue . In intrathoracic infectious complications , extra-anatomic bypass grafting or autogenous vascular graft implantation should be considered . If there is no possibility of carrying out these procedures , first aggressive local debridement of the infected vascular wall and afterwards coverage with alloplastic prosthetics with omentum transposition and thoracoplasty are essential to minimize postoperative infection and obtain solid anchorage in the surrounding tissue . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Four years after extensive pneumonectomy on the left side with resection of the aortic wall and patch reconstruction for a T4 carcinoma , 2 years after adjuvant radiation and 10 months after drainage therapy of late intrathoracic empyema , destruction of the infected Dacron patch led to rupture of the aorta descendens . Successful primary emergency reconstruction of the aorta descendens was followed by venetian blind plasty ( Heller ) and transposition of the omentum majus for omentoplasty of the aortal wall and reduction of the pneumonectomy cavity . The rate of prosthetic infections is between 0.3 and 2.5% and must be taken into consideration even in cases of intrathoracic vascular reconstruction with alloplastic prostheses . After lung resection it is necessary to cover up the prosthetic graft by using autogenous material to obtain prosthetic incorporation into the protective tissue . In intrathoracic infectious complications , extra-anatomic bypass grafting or autogenous vascular graft implantation should be considered . If there is no possibility of carrying out these procedures , first aggressive local debridement of the infected vascular wall and afterwards coverage with alloplastic prosthetics with omentum transposition and thoracoplasty are essential to minimize postoperative infection and obtain solid anchorage in the surrounding tissue .

[ "Four", "years", "after", "extensive", "pneumonectomy", "on", "the", "left", "side", "with", "resection", "of", "the", "aortic", "wall", "and", "patch", "reconstruction", "for", "a", "T4", "carcinoma", ",", "2", "years", "after", "adjuvant", "radiation", "and", "10", "months", "after", "drainage", "therapy", "of", "late", "intrathoracic", "empyema", ",", "destruction", "of", "the", "infected", "Dacron", "patch", "led", "to", "rupture", "of", "the", "aorta", "descendens", ".", "Successful", "primary", "emergency", "reconstruction", "of", "the", "aorta", "descendens", "was", "followed", "by", "venetian", "blind", "plasty", "(", "Heller", ")", "and", "transposition", "of", "the", "omentum", "majus", "for", "omentoplasty", "of", "the", "aortal", "wall", "and", "reduction", "of", "the", "pneumonectomy", "cavity", ".", "The", "rate", "of", "prosthetic", "infections", "is", "between", "0.3", "and", "2.5", "%", "and", "must", "be", "taken", "into", "consideration", "even", "in", "cases", "of", "intrathoracic", "vascular", "reconstruction", "with", "alloplastic", "prostheses", ".", "After", "lung", "resection", "it", "is", "necessary", "to", "cover", "up", "the", "prosthetic", "graft", "by", "using", "autogenous", "material", "to", "obtain", "prosthetic", "incorporation", "into", "the", "protective", "tissue", ".", "In", "intrathoracic", "infectious", "complications", ",", "extra", "-", "anatomic", "bypass", "grafting", "or", "autogenous", "vascular", "graft", "implantation", "should", "be", "considered", ".", "If", "there", "is", "no", "possibility", "of", "carrying", "out", "these", "procedures", ",", "first", "aggressive", "local", "debridement", "of", "the", "infected", "vascular", "wall", "and", "afterwards", "coverage", "with", "alloplastic", "prosthetics", "with", "omentum", "transposition", "and", "thoracoplasty", "are", "essential", "to", "minimize", "postoperative", "infection", "and", "obtain", "solid", "anchorage", "in", "the", "surrounding", "tissue", "." ]

[ "umlsterm" ]

Intensivpatienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, ueberlebend is an umlsterm, ueberlebend is an umlsterm, Spezifitaet is an umlsterm

DerChirurg.80690077.ger.abstr_task0

Sentence: Zusammenfassung . Im Zeitraum 1. 11. 1993 bis 30. 3. 1997 wurden 1149 allgemeinchirurgische Intensivpatienten prospektiv erfasst , von denen 114 die Kriterien des septischen Schocks erfuellten . Die Letalitaet der Patienten mit einem septischen Schock betrug 47,3 % . Nach Training eines neuronalen Netzes mit 91 ( von insgesamt n = 114 ) Patienten ergab die Testung bei den verbleibenden 23 Patienten bei der Beruecksichtigung von Parameterveraenderungen vom 1. auf den 2. Tag des septischen Schocks folgendes Ergebnis : Alle 10 verstorbenen Patienten wurden korrekt als nicht ueberlebend vorhergesagt , von den 13 Ueberlebenden wurden 12 korrekt als ueberlebend vorhergesagt ( Sensitivitaet 100 % ; Spezifitaet 92,3 % ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Zusammenfassung . Im Zeitraum 1. 11. 1993 bis 30. 3. 1997 wurden 1149 allgemeinchirurgische Intensivpatienten prospektiv erfasst , von denen 114 die Kriterien des septischen Schocks erfuellten . Die Letalitaet der Patienten mit einem septischen Schock betrug 47,3 % . Nach Training eines neuronalen Netzes mit 91 ( von insgesamt n = 114 ) Patienten ergab die Testung bei den verbleibenden 23 Patienten bei der Beruecksichtigung von Parameterveraenderungen vom 1. auf den 2. Tag des septischen Schocks folgendes Ergebnis : Alle 10 verstorbenen Patienten wurden korrekt als nicht ueberlebend vorhergesagt , von den 13 Ueberlebenden wurden 12 korrekt als ueberlebend vorhergesagt ( Sensitivitaet 100 % ; Spezifitaet 92,3 % ) .

[ "Zusammenfassung", ".", "Im", "Zeitraum", "1", ".", "11", ".", "1993", "bis", "30", ".", "3", ".", "1997", "wurden", "1149", "allgemeinchirurgische", "Intensivpatienten", "prospektiv", "erfasst", ",", "von", "denen", "114", "die", "Kriterien", "des", "septischen", "Schocks", "erfuellten", ".", "Die", "Letalitaet", "der", "Patienten", "mit", "einem", "septischen", "Schock", "betrug", "47,3", "%", ".", "Nach", "Training", "eines", "neuronalen", "Netzes", "mit", "91", "(", "von", "insgesamt", "n", "=", "114", ")", "Patienten", "ergab", "die", "Testung", "bei", "den", "verbleibenden", "23", "Patienten", "bei", "der", "Beruecksichtigung", "von", "Parameterveraenderungen", "vom", "1", ".", "auf", "den", "2", ".", "Tag", "des", "septischen", "Schocks", "folgendes", "Ergebnis", ":", "Alle", "10", "verstorbenen", "Patienten", "wurden", "korrekt", "als", "nicht", "ueberlebend", "vorhergesagt", ",", "von", "den", "13", "Ueberlebenden", "wurden", "12", "korrekt", "als", "ueberlebend", "vorhergesagt", "(", "Sensitivitaet", "100", "%", ";", "Spezifitaet", "92,3", "%", ")", "." ]

[ "umlsterm" ]

Intensivpatienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, ueberlebend is an umlsterm, ueberlebend is an umlsterm, Spezifitaet is an umlsterm

DerChirurg.80690077.ger.abstr_task1

Sentence: Zusammenfassung . Im Zeitraum 1. 11. 1993 bis 30. 3. 1997 wurden 1149 allgemeinchirurgische Intensivpatienten prospektiv erfasst , von denen 114 die Kriterien des septischen Schocks erfuellten . Die Letalitaet der Patienten mit einem septischen Schock betrug 47,3 % . Nach Training eines neuronalen Netzes mit 91 ( von insgesamt n = 114 ) Patienten ergab die Testung bei den verbleibenden 23 Patienten bei der Beruecksichtigung von Parameterveraenderungen vom 1. auf den 2. Tag des septischen Schocks folgendes Ergebnis : Alle 10 verstorbenen Patienten wurden korrekt als nicht ueberlebend vorhergesagt , von den 13 Ueberlebenden wurden 12 korrekt als ueberlebend vorhergesagt ( Sensitivitaet 100 % ; Spezifitaet 92,3 % ) . Instructions: please typing these entity words according to sentence: Intensivpatienten, Patienten, Patienten, Patienten, Patienten, ueberlebend, ueberlebend, Spezifitaet Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Zusammenfassung . Im Zeitraum 1. 11. 1993 bis 30. 3. 1997 wurden 1149 allgemeinchirurgische Intensivpatienten prospektiv erfasst , von denen 114 die Kriterien des septischen Schocks erfuellten . Die Letalitaet der Patienten mit einem septischen Schock betrug 47,3 % . Nach Training eines neuronalen Netzes mit 91 ( von insgesamt n = 114 ) Patienten ergab die Testung bei den verbleibenden 23 Patienten bei der Beruecksichtigung von Parameterveraenderungen vom 1. auf den 2. Tag des septischen Schocks folgendes Ergebnis : Alle 10 verstorbenen Patienten wurden korrekt als nicht ueberlebend vorhergesagt , von den 13 Ueberlebenden wurden 12 korrekt als ueberlebend vorhergesagt ( Sensitivitaet 100 % ; Spezifitaet 92,3 % ) .

[ "Zusammenfassung", ".", "Im", "Zeitraum", "1", ".", "11", ".", "1993", "bis", "30", ".", "3", ".", "1997", "wurden", "1149", "allgemeinchirurgische", "Intensivpatienten", "prospektiv", "erfasst", ",", "von", "denen", "114", "die", "Kriterien", "des", "septischen", "Schocks", "erfuellten", ".", "Die", "Letalitaet", "der", "Patienten", "mit", "einem", "septischen", "Schock", "betrug", "47,3", "%", ".", "Nach", "Training", "eines", "neuronalen", "Netzes", "mit", "91", "(", "von", "insgesamt", "n", "=", "114", ")", "Patienten", "ergab", "die", "Testung", "bei", "den", "verbleibenden", "23", "Patienten", "bei", "der", "Beruecksichtigung", "von", "Parameterveraenderungen", "vom", "1", ".", "auf", "den", "2", ".", "Tag", "des", "septischen", "Schocks", "folgendes", "Ergebnis", ":", "Alle", "10", "verstorbenen", "Patienten", "wurden", "korrekt", "als", "nicht", "ueberlebend", "vorhergesagt", ",", "von", "den", "13", "Ueberlebenden", "wurden", "12", "korrekt", "als", "ueberlebend", "vorhergesagt", "(", "Sensitivitaet", "100", "%", ";", "Spezifitaet", "92,3", "%", ")", "." ]

[ "umlsterm" ]

Intensivpatienten, Patienten, Patienten, Patienten, Patienten, ueberlebend, ueberlebend, Spezifitaet

DerChirurg.80690077.ger.abstr_task2

Sentence: Zusammenfassung . Im Zeitraum 1. 11. 1993 bis 30. 3. 1997 wurden 1149 allgemeinchirurgische Intensivpatienten prospektiv erfasst , von denen 114 die Kriterien des septischen Schocks erfuellten . Die Letalitaet der Patienten mit einem septischen Schock betrug 47,3 % . Nach Training eines neuronalen Netzes mit 91 ( von insgesamt n = 114 ) Patienten ergab die Testung bei den verbleibenden 23 Patienten bei der Beruecksichtigung von Parameterveraenderungen vom 1. auf den 2. Tag des septischen Schocks folgendes Ergebnis : Alle 10 verstorbenen Patienten wurden korrekt als nicht ueberlebend vorhergesagt , von den 13 Ueberlebenden wurden 12 korrekt als ueberlebend vorhergesagt ( Sensitivitaet 100 % ; Spezifitaet 92,3 % ) . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Zusammenfassung . Im Zeitraum 1. 11. 1993 bis 30. 3. 1997 wurden 1149 allgemeinchirurgische Intensivpatienten prospektiv erfasst , von denen 114 die Kriterien des septischen Schocks erfuellten . Die Letalitaet der Patienten mit einem septischen Schock betrug 47,3 % . Nach Training eines neuronalen Netzes mit 91 ( von insgesamt n = 114 ) Patienten ergab die Testung bei den verbleibenden 23 Patienten bei der Beruecksichtigung von Parameterveraenderungen vom 1. auf den 2. Tag des septischen Schocks folgendes Ergebnis : Alle 10 verstorbenen Patienten wurden korrekt als nicht ueberlebend vorhergesagt , von den 13 Ueberlebenden wurden 12 korrekt als ueberlebend vorhergesagt ( Sensitivitaet 100 % ; Spezifitaet 92,3 % ) .

[ "Zusammenfassung", ".", "Im", "Zeitraum", "1", ".", "11", ".", "1993", "bis", "30", ".", "3", ".", "1997", "wurden", "1149", "allgemeinchirurgische", "Intensivpatienten", "prospektiv", "erfasst", ",", "von", "denen", "114", "die", "Kriterien", "des", "septischen", "Schocks", "erfuellten", ".", "Die", "Letalitaet", "der", "Patienten", "mit", "einem", "septischen", "Schock", "betrug", "47,3", "%", ".", "Nach", "Training", "eines", "neuronalen", "Netzes", "mit", "91", "(", "von", "insgesamt", "n", "=", "114", ")", "Patienten", "ergab", "die", "Testung", "bei", "den", "verbleibenden", "23", "Patienten", "bei", "der", "Beruecksichtigung", "von", "Parameterveraenderungen", "vom", "1", ".", "auf", "den", "2", ".", "Tag", "des", "septischen", "Schocks", "folgendes", "Ergebnis", ":", "Alle", "10", "verstorbenen", "Patienten", "wurden", "korrekt", "als", "nicht", "ueberlebend", "vorhergesagt", ",", "von", "den", "13", "Ueberlebenden", "wurden", "12", "korrekt", "als", "ueberlebend", "vorhergesagt", "(", "Sensitivitaet", "100", "%", ";", "Spezifitaet", "92,3", "%", ")", "." ]

[ "umlsterm" ]

= 19 or = 75 years is a Value, age is a Person, treatment is a Procedure, type 2 diabetes is a Condition, treatment of statin is a Scope, hypercholesterolemia is a Condition, Fasting LDL - C is a Measurement, = 250mg / dL is a Value, at the screening visit is a Temporal, Fasting LDL - C is a Measurement, = 70mg / dL is a Value, = 160mg / dL is a Value, at the randomization visit is a Temporal

NCT03217409_inc_task0

Sentence: Subjects = 19 or = 75 years of age Subjects undergoing treatment for type 2 diabetes Subjects undergoing treatment of statin for hypercholesterolemia Fasting LDL-C = 250mg/dL at the screening visit Fasting LDL-C =70mg/dL or = 160mg/dL at the randomization visit Fasting TG<500mg/dL Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Value, Person, Procedure, Scope, Measurement

[ "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Person", "O", "O", "O", "B-Procedure", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Value", "I-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O" ]

Subjects = 19 or = 75 years of age Subjects undergoing treatment for type 2 diabetes Subjects undergoing treatment of statin for hypercholesterolemia Fasting LDL-C = 250mg/dL at the screening visit Fasting LDL-C =70mg/dL or = 160mg/dL at the randomization visit Fasting TG<500mg/dL

[ "Subjects", "=", "19", "or", "=", "75", "years", "of", "age", "\n", "Subjects", "undergoing", "treatment", "for", "type", "2", "diabetes", "\n", "Subjects", "undergoing", "treatment", "of", "statin", "for", "hypercholesterolemia", "\n", "Fasting", "LDL", "-", "C", "=", "250mg", "/", "dL", "at", "the", "screening", "visit", "\n", "Fasting", "LDL", "-", "C", "=", "70mg", "/", "dL", "or", "=", "160mg", "/", "dL", "at", "the", "randomization", "visit", "\n", "Fasting", "TG<500mg", "/", "dL", "\n" ]

[ "Temporal", "Scope", "Condition", "Value", "Measurement", "Procedure", "Drug", "Person" ]

= 19 or = 75 years is a Value, age is a Person, treatment is a Procedure, type 2 diabetes is a Condition, treatment of statin is a Scope, hypercholesterolemia is a Condition, Fasting LDL - C is a Measurement, = 250mg / dL is a Value, at the screening visit is a Temporal, Fasting LDL - C is a Measurement, = 70mg / dL is a Value, = 160mg / dL is a Value, at the randomization visit is a Temporal

NCT03217409_inc_task1

Sentence: Subjects = 19 or = 75 years of age Subjects undergoing treatment for type 2 diabetes Subjects undergoing treatment of statin for hypercholesterolemia Fasting LDL-C = 250mg/dL at the screening visit Fasting LDL-C =70mg/dL or = 160mg/dL at the randomization visit Fasting TG<500mg/dL Instructions: please typing these entity words according to sentence: = 19 or = 75 years, age, treatment, type 2 diabetes, treatment of statin, hypercholesterolemia, Fasting LDL - C, = 250mg / dL, at the screening visit, Fasting LDL - C, = 70mg / dL, = 160mg / dL, at the randomization visit Options: Temporal, Condition, Value, Person, Procedure, Scope, Measurement

[ "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Person", "O", "O", "O", "B-Procedure", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Value", "I-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O" ]

Subjects = 19 or = 75 years of age Subjects undergoing treatment for type 2 diabetes Subjects undergoing treatment of statin for hypercholesterolemia Fasting LDL-C = 250mg/dL at the screening visit Fasting LDL-C =70mg/dL or = 160mg/dL at the randomization visit Fasting TG<500mg/dL

[ "Subjects", "=", "19", "or", "=", "75", "years", "of", "age", "\n", "Subjects", "undergoing", "treatment", "for", "type", "2", "diabetes", "\n", "Subjects", "undergoing", "treatment", "of", "statin", "for", "hypercholesterolemia", "\n", "Fasting", "LDL", "-", "C", "=", "250mg", "/", "dL", "at", "the", "screening", "visit", "\n", "Fasting", "LDL", "-", "C", "=", "70mg", "/", "dL", "or", "=", "160mg", "/", "dL", "at", "the", "randomization", "visit", "\n", "Fasting", "TG<500mg", "/", "dL", "\n" ]

[ "Temporal", "Scope", "Condition", "Value", "Measurement", "Procedure", "Drug", "Person" ]

= 19 or = 75 years, age, treatment, type 2 diabetes, treatment of statin, hypercholesterolemia, Fasting LDL - C, = 250mg / dL, at the screening visit, Fasting LDL - C, = 70mg / dL, = 160mg / dL, at the randomization visit

NCT03217409_inc_task2

Sentence: Subjects = 19 or = 75 years of age Subjects undergoing treatment for type 2 diabetes Subjects undergoing treatment of statin for hypercholesterolemia Fasting LDL-C = 250mg/dL at the screening visit Fasting LDL-C =70mg/dL or = 160mg/dL at the randomization visit Fasting TG<500mg/dL Instructions: please extract entity words from the input sentence

[ "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Person", "O", "O", "O", "B-Procedure", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Value", "I-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O" ]

Subjects = 19 or = 75 years of age Subjects undergoing treatment for type 2 diabetes Subjects undergoing treatment of statin for hypercholesterolemia Fasting LDL-C = 250mg/dL at the screening visit Fasting LDL-C =70mg/dL or = 160mg/dL at the randomization visit Fasting TG<500mg/dL

[ "Subjects", "=", "19", "or", "=", "75", "years", "of", "age", "\n", "Subjects", "undergoing", "treatment", "for", "type", "2", "diabetes", "\n", "Subjects", "undergoing", "treatment", "of", "statin", "for", "hypercholesterolemia", "\n", "Fasting", "LDL", "-", "C", "=", "250mg", "/", "dL", "at", "the", "screening", "visit", "\n", "Fasting", "LDL", "-", "C", "=", "70mg", "/", "dL", "or", "=", "160mg", "/", "dL", "at", "the", "randomization", "visit", "\n", "Fasting", "TG<500mg", "/", "dL", "\n" ]

[ "Temporal", "Scope", "Condition", "Value", "Measurement", "Procedure", "Drug", "Person" ]

healthy is a Condition, type 2 diabetes is a Condition

NCT03193684_inc_task0

Sentence: eGFR>60 ml/min healthy volunteers type 2 diabetes patients who otherwise healthy Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition

[ "O", "O", "O", "O", "B-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O" ]

eGFR>60 ml/min healthy volunteers type 2 diabetes patients who otherwise healthy

[ "eGFR>60", "ml", "/", "min", "healthy", "volunteers", "type", "2", "diabetes", "patients", "who", "otherwise", "healthy", "\n" ]

[ "Condition", "Value", "Measurement" ]

healthy is a Condition, type 2 diabetes is a Condition

NCT03193684_inc_task1

Sentence: eGFR>60 ml/min healthy volunteers type 2 diabetes patients who otherwise healthy Instructions: please typing these entity words according to sentence: healthy, type 2 diabetes Options: Condition

[ "O", "O", "O", "O", "B-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O" ]

eGFR>60 ml/min healthy volunteers type 2 diabetes patients who otherwise healthy

[ "eGFR>60", "ml", "/", "min", "healthy", "volunteers", "type", "2", "diabetes", "patients", "who", "otherwise", "healthy", "\n" ]

[ "Condition", "Value", "Measurement" ]

healthy, type 2 diabetes

NCT03193684_inc_task2

Sentence: eGFR>60 ml/min healthy volunteers type 2 diabetes patients who otherwise healthy Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O" ]

eGFR>60 ml/min healthy volunteers type 2 diabetes patients who otherwise healthy

[ "eGFR>60", "ml", "/", "min", "healthy", "volunteers", "type", "2", "diabetes", "patients", "who", "otherwise", "healthy", "\n" ]

[ "Condition", "Value", "Measurement" ]

patients with venous thrombosis is a Participant_Condition

41816_task0

Sentence: Arterial cardiovascular risk factors and venous thrombosis : results from a population-based , prospective study ( the HUNT 2 ) . BACKGROUND An explanation for the increased risk of myocardial infarction and stroke in patients with venous thrombosis is lacking . The objective of this study was to investigate whether risk factors for arterial cardiovascular disease also increase the risk of venous thrombosis . DESIGN AND METHODS Cases who had a first venous thrombosis ( n=515 ) and matched controls ( n=1,505 ) were identified from a population-based , nested , case-cohort study ( the HUNT 2 study ) comprising 71 % ( n=66,140 ) of the adult residents of Nord-Trøndelag County in Norway . RESULTS The age- and sex-adjusted odds ratio of venous thrombosis for subjects with concentrations of C-reactive protein in the highest quintile was 1.6 ( 95 % confidence interval : 1.2-2.2 ) compared to subjects with C-reactive protein in the lowest quintile . This association was strongest in subjects who experienced venous thrombosis within a year after blood sampling with a three-fold increased risk of participants in the highest versus the lowest quintile . Having first degree relatives who had a myocardial infarction before the age of 60 years was positively associated with venous thrombosis compared to not having a positive family history [ odds ratio 1.3 ( 95 % confidence interval : 1.1-1.6 ) ] . Subjects with blood pressure in the highest quintile had half the risk of developing venous thrombosis compared to subjects whose blood pressure was in the lowest quintile . There were no associations between the risk of venous thrombosis and total cholesterol , low density lipoprotein-cholesterol , high density lipoprotein-cholesterol , triglycerides , glucose or smoking . We confirmed the positive association between obesity and venous thrombosis . CONCLUSIONS C-reactive protein and a family history of myocardial infarction were positively associated with subsequent venous thrombosis . Blood pressure was inversely correlated to venous thrombosis . These findings should be confirmed by further investigations . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Arterial cardiovascular risk factors and venous thrombosis : results from a population-based , prospective study ( the HUNT 2 ) . BACKGROUND An explanation for the increased risk of myocardial infarction and stroke in patients with venous thrombosis is lacking . The objective of this study was to investigate whether risk factors for arterial cardiovascular disease also increase the risk of venous thrombosis . DESIGN AND METHODS Cases who had a first venous thrombosis ( n=515 ) and matched controls ( n=1,505 ) were identified from a population-based , nested , case-cohort study ( the HUNT 2 study ) comprising 71 % ( n=66,140 ) of the adult residents of Nord-Trøndelag County in Norway . RESULTS The age- and sex-adjusted odds ratio of venous thrombosis for subjects with concentrations of C-reactive protein in the highest quintile was 1.6 ( 95 % confidence interval : 1.2-2.2 ) compared to subjects with C-reactive protein in the lowest quintile . This association was strongest in subjects who experienced venous thrombosis within a year after blood sampling with a three-fold increased risk of participants in the highest versus the lowest quintile . Having first degree relatives who had a myocardial infarction before the age of 60 years was positively associated with venous thrombosis compared to not having a positive family history [ odds ratio 1.3 ( 95 % confidence interval : 1.1-1.6 ) ] . Subjects with blood pressure in the highest quintile had half the risk of developing venous thrombosis compared to subjects whose blood pressure was in the lowest quintile . There were no associations between the risk of venous thrombosis and total cholesterol , low density lipoprotein-cholesterol , high density lipoprotein-cholesterol , triglycerides , glucose or smoking . We confirmed the positive association between obesity and venous thrombosis . CONCLUSIONS C-reactive protein and a family history of myocardial infarction were positively associated with subsequent venous thrombosis . Blood pressure was inversely correlated to venous thrombosis . These findings should be confirmed by further investigations .

[ "Arterial", "cardiovascular", "risk", "factors", "and", "venous", "thrombosis", ":", "results", "from", "a", "population", "-", "based", ",", "prospective", "study", "(", "the", "HUNT", "2", ")", ".", "BACKGROUND", "An", "explanation", "for", "the", "increased", "risk", "of", "myocardial", "infarction", "and", "stroke", "in", "patients", "with", "venous", "thrombosis", "is", "lacking", ".", "The", "objective", "of", "this", "study", "was", "to", "investigate", "whether", "risk", "factors", "for", "arterial", "cardiovascular", "disease", "also", "increase", "the", "risk", "of", "venous", "thrombosis", ".", "DESIGN", "AND", "METHODS", "Cases", "who", "had", "a", "first", "venous", "thrombosis", "(", "n=515", ")", "and", "matched", "controls", "(", "n=1,505", ")", "were", "identified", "from", "a", "population", "-", "based", ",", "nested", ",", "case", "-", "cohort", "study", "(", "the", "HUNT", "2", "study", ")", "comprising", "71", "%", "(", "n=66,140", ")", "of", "the", "adult", "residents", "of", "Nord", "-", "Trøndelag", "County", "in", "Norway", ".", "RESULTS", "The", "age-", "and", "sex", "-", "adjusted", "odds", "ratio", "of", "venous", "thrombosis", "for", "subjects", "with", "concentrations", "of", "C", "-", "reactive", "protein", "in", "the", "highest", "quintile", "was", "1.6", "(", "95", "%", "confidence", "interval", ":", "1.2", "-", "2.2", ")", "compared", "to", "subjects", "with", "C", "-", "reactive", "protein", "in", "the", "lowest", "quintile", ".", "This", "association", "was", "strongest", "in", "subjects", "who", "experienced", "venous", "thrombosis", "within", "a", "year", "after", "blood", "sampling", "with", "a", "three", "-", "fold", "increased", "risk", "of", "participants", "in", "the", "highest", "versus", "the", "lowest", "quintile", ".", "Having", "first", "degree", "relatives", "who", "had", "a", "myocardial", "infarction", "before", "the", "age", "of", "60", "years", "was", "positively", "associated", "with", "venous", "thrombosis", "compared", "to", "not", "having", "a", "positive", "family", "history", "[", "odds", "ratio", "1.3", "(", "95", "%", "confidence", "interval", ":", "1.1", "-", "1.6", ")", "]", ".", "Subjects", "with", "blood", "pressure", "in", "the", "highest", "quintile", "had", "half", "the", "risk", "of", "developing", "venous", "thrombosis", "compared", "to", "subjects", "whose", "blood", "pressure", "was", "in", "the", "lowest", "quintile", ".", "There", "were", "no", "associations", "between", "the", "risk", "of", "venous", "thrombosis", "and", "total", "cholesterol", ",", "low", "density", "lipoprotein", "-", "cholesterol", ",", "high", "density", "lipoprotein", "-", "cholesterol", ",", "triglycerides", ",", "glucose", "or", "smoking", ".", "We", "confirmed", "the", "positive", "association", "between", "obesity", "and", "venous", "thrombosis", ".", "CONCLUSIONS", "C", "-", "reactive", "protein", "and", "a", "family", "history", "of", "myocardial", "infarction", "were", "positively", "associated", "with", "subsequent", "venous", "thrombosis", ".", "Blood", "pressure", "was", "inversely", "correlated", "to", "venous", "thrombosis", ".", "These", "findings", "should", "be", "confirmed", "by", "further", "investigations", "." ]

[ "Participant_Condition" ]

patients with venous thrombosis is a Participant_Condition

41816_task1

Sentence: Arterial cardiovascular risk factors and venous thrombosis : results from a population-based , prospective study ( the HUNT 2 ) . BACKGROUND An explanation for the increased risk of myocardial infarction and stroke in patients with venous thrombosis is lacking . The objective of this study was to investigate whether risk factors for arterial cardiovascular disease also increase the risk of venous thrombosis . DESIGN AND METHODS Cases who had a first venous thrombosis ( n=515 ) and matched controls ( n=1,505 ) were identified from a population-based , nested , case-cohort study ( the HUNT 2 study ) comprising 71 % ( n=66,140 ) of the adult residents of Nord-Trøndelag County in Norway . RESULTS The age- and sex-adjusted odds ratio of venous thrombosis for subjects with concentrations of C-reactive protein in the highest quintile was 1.6 ( 95 % confidence interval : 1.2-2.2 ) compared to subjects with C-reactive protein in the lowest quintile . This association was strongest in subjects who experienced venous thrombosis within a year after blood sampling with a three-fold increased risk of participants in the highest versus the lowest quintile . Having first degree relatives who had a myocardial infarction before the age of 60 years was positively associated with venous thrombosis compared to not having a positive family history [ odds ratio 1.3 ( 95 % confidence interval : 1.1-1.6 ) ] . Subjects with blood pressure in the highest quintile had half the risk of developing venous thrombosis compared to subjects whose blood pressure was in the lowest quintile . There were no associations between the risk of venous thrombosis and total cholesterol , low density lipoprotein-cholesterol , high density lipoprotein-cholesterol , triglycerides , glucose or smoking . We confirmed the positive association between obesity and venous thrombosis . CONCLUSIONS C-reactive protein and a family history of myocardial infarction were positively associated with subsequent venous thrombosis . Blood pressure was inversely correlated to venous thrombosis . These findings should be confirmed by further investigations . Instructions: please typing these entity words according to sentence: patients with venous thrombosis Options: Participant_Condition

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Arterial cardiovascular risk factors and venous thrombosis : results from a population-based , prospective study ( the HUNT 2 ) . BACKGROUND An explanation for the increased risk of myocardial infarction and stroke in patients with venous thrombosis is lacking . The objective of this study was to investigate whether risk factors for arterial cardiovascular disease also increase the risk of venous thrombosis . DESIGN AND METHODS Cases who had a first venous thrombosis ( n=515 ) and matched controls ( n=1,505 ) were identified from a population-based , nested , case-cohort study ( the HUNT 2 study ) comprising 71 % ( n=66,140 ) of the adult residents of Nord-Trøndelag County in Norway . RESULTS The age- and sex-adjusted odds ratio of venous thrombosis for subjects with concentrations of C-reactive protein in the highest quintile was 1.6 ( 95 % confidence interval : 1.2-2.2 ) compared to subjects with C-reactive protein in the lowest quintile . This association was strongest in subjects who experienced venous thrombosis within a year after blood sampling with a three-fold increased risk of participants in the highest versus the lowest quintile . Having first degree relatives who had a myocardial infarction before the age of 60 years was positively associated with venous thrombosis compared to not having a positive family history [ odds ratio 1.3 ( 95 % confidence interval : 1.1-1.6 ) ] . Subjects with blood pressure in the highest quintile had half the risk of developing venous thrombosis compared to subjects whose blood pressure was in the lowest quintile . There were no associations between the risk of venous thrombosis and total cholesterol , low density lipoprotein-cholesterol , high density lipoprotein-cholesterol , triglycerides , glucose or smoking . We confirmed the positive association between obesity and venous thrombosis . CONCLUSIONS C-reactive protein and a family history of myocardial infarction were positively associated with subsequent venous thrombosis . Blood pressure was inversely correlated to venous thrombosis . These findings should be confirmed by further investigations .

[ "Arterial", "cardiovascular", "risk", "factors", "and", "venous", "thrombosis", ":", "results", "from", "a", "population", "-", "based", ",", "prospective", "study", "(", "the", "HUNT", "2", ")", ".", "BACKGROUND", "An", "explanation", "for", "the", "increased", "risk", "of", "myocardial", "infarction", "and", "stroke", "in", "patients", "with", "venous", "thrombosis", "is", "lacking", ".", "The", "objective", "of", "this", "study", "was", "to", "investigate", "whether", "risk", "factors", "for", "arterial", "cardiovascular", "disease", "also", "increase", "the", "risk", "of", "venous", "thrombosis", ".", "DESIGN", "AND", "METHODS", "Cases", "who", "had", "a", "first", "venous", "thrombosis", "(", "n=515", ")", "and", "matched", "controls", "(", "n=1,505", ")", "were", "identified", "from", "a", "population", "-", "based", ",", "nested", ",", "case", "-", "cohort", "study", "(", "the", "HUNT", "2", "study", ")", "comprising", "71", "%", "(", "n=66,140", ")", "of", "the", "adult", "residents", "of", "Nord", "-", "Trøndelag", "County", "in", "Norway", ".", "RESULTS", "The", "age-", "and", "sex", "-", "adjusted", "odds", "ratio", "of", "venous", "thrombosis", "for", "subjects", "with", "concentrations", "of", "C", "-", "reactive", "protein", "in", "the", "highest", "quintile", "was", "1.6", "(", "95", "%", "confidence", "interval", ":", "1.2", "-", "2.2", ")", "compared", "to", "subjects", "with", "C", "-", "reactive", "protein", "in", "the", "lowest", "quintile", ".", "This", "association", "was", "strongest", "in", "subjects", "who", "experienced", "venous", "thrombosis", "within", "a", "year", "after", "blood", "sampling", "with", "a", "three", "-", "fold", "increased", "risk", "of", "participants", "in", "the", "highest", "versus", "the", "lowest", "quintile", ".", "Having", "first", "degree", "relatives", "who", "had", "a", "myocardial", "infarction", "before", "the", "age", "of", "60", "years", "was", "positively", "associated", "with", "venous", "thrombosis", "compared", "to", "not", "having", "a", "positive", "family", "history", "[", "odds", "ratio", "1.3", "(", "95", "%", "confidence", "interval", ":", "1.1", "-", "1.6", ")", "]", ".", "Subjects", "with", "blood", "pressure", "in", "the", "highest", "quintile", "had", "half", "the", "risk", "of", "developing", "venous", "thrombosis", "compared", "to", "subjects", "whose", "blood", "pressure", "was", "in", "the", "lowest", "quintile", ".", "There", "were", "no", "associations", "between", "the", "risk", "of", "venous", "thrombosis", "and", "total", "cholesterol", ",", "low", "density", "lipoprotein", "-", "cholesterol", ",", "high", "density", "lipoprotein", "-", "cholesterol", ",", "triglycerides", ",", "glucose", "or", "smoking", ".", "We", "confirmed", "the", "positive", "association", "between", "obesity", "and", "venous", "thrombosis", ".", "CONCLUSIONS", "C", "-", "reactive", "protein", "and", "a", "family", "history", "of", "myocardial", "infarction", "were", "positively", "associated", "with", "subsequent", "venous", "thrombosis", ".", "Blood", "pressure", "was", "inversely", "correlated", "to", "venous", "thrombosis", ".", "These", "findings", "should", "be", "confirmed", "by", "further", "investigations", "." ]

[ "Participant_Condition" ]

patients with venous thrombosis

41816_task2

Sentence: Arterial cardiovascular risk factors and venous thrombosis : results from a population-based , prospective study ( the HUNT 2 ) . BACKGROUND An explanation for the increased risk of myocardial infarction and stroke in patients with venous thrombosis is lacking . The objective of this study was to investigate whether risk factors for arterial cardiovascular disease also increase the risk of venous thrombosis . DESIGN AND METHODS Cases who had a first venous thrombosis ( n=515 ) and matched controls ( n=1,505 ) were identified from a population-based , nested , case-cohort study ( the HUNT 2 study ) comprising 71 % ( n=66,140 ) of the adult residents of Nord-Trøndelag County in Norway . RESULTS The age- and sex-adjusted odds ratio of venous thrombosis for subjects with concentrations of C-reactive protein in the highest quintile was 1.6 ( 95 % confidence interval : 1.2-2.2 ) compared to subjects with C-reactive protein in the lowest quintile . This association was strongest in subjects who experienced venous thrombosis within a year after blood sampling with a three-fold increased risk of participants in the highest versus the lowest quintile . Having first degree relatives who had a myocardial infarction before the age of 60 years was positively associated with venous thrombosis compared to not having a positive family history [ odds ratio 1.3 ( 95 % confidence interval : 1.1-1.6 ) ] . Subjects with blood pressure in the highest quintile had half the risk of developing venous thrombosis compared to subjects whose blood pressure was in the lowest quintile . There were no associations between the risk of venous thrombosis and total cholesterol , low density lipoprotein-cholesterol , high density lipoprotein-cholesterol , triglycerides , glucose or smoking . We confirmed the positive association between obesity and venous thrombosis . CONCLUSIONS C-reactive protein and a family history of myocardial infarction were positively associated with subsequent venous thrombosis . Blood pressure was inversely correlated to venous thrombosis . These findings should be confirmed by further investigations . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Arterial cardiovascular risk factors and venous thrombosis : results from a population-based , prospective study ( the HUNT 2 ) . BACKGROUND An explanation for the increased risk of myocardial infarction and stroke in patients with venous thrombosis is lacking . The objective of this study was to investigate whether risk factors for arterial cardiovascular disease also increase the risk of venous thrombosis . DESIGN AND METHODS Cases who had a first venous thrombosis ( n=515 ) and matched controls ( n=1,505 ) were identified from a population-based , nested , case-cohort study ( the HUNT 2 study ) comprising 71 % ( n=66,140 ) of the adult residents of Nord-Trøndelag County in Norway . RESULTS The age- and sex-adjusted odds ratio of venous thrombosis for subjects with concentrations of C-reactive protein in the highest quintile was 1.6 ( 95 % confidence interval : 1.2-2.2 ) compared to subjects with C-reactive protein in the lowest quintile . This association was strongest in subjects who experienced venous thrombosis within a year after blood sampling with a three-fold increased risk of participants in the highest versus the lowest quintile . Having first degree relatives who had a myocardial infarction before the age of 60 years was positively associated with venous thrombosis compared to not having a positive family history [ odds ratio 1.3 ( 95 % confidence interval : 1.1-1.6 ) ] . Subjects with blood pressure in the highest quintile had half the risk of developing venous thrombosis compared to subjects whose blood pressure was in the lowest quintile . There were no associations between the risk of venous thrombosis and total cholesterol , low density lipoprotein-cholesterol , high density lipoprotein-cholesterol , triglycerides , glucose or smoking . We confirmed the positive association between obesity and venous thrombosis . CONCLUSIONS C-reactive protein and a family history of myocardial infarction were positively associated with subsequent venous thrombosis . Blood pressure was inversely correlated to venous thrombosis . These findings should be confirmed by further investigations .

[ "Arterial", "cardiovascular", "risk", "factors", "and", "venous", "thrombosis", ":", "results", "from", "a", "population", "-", "based", ",", "prospective", "study", "(", "the", "HUNT", "2", ")", ".", "BACKGROUND", "An", "explanation", "for", "the", "increased", "risk", "of", "myocardial", "infarction", "and", "stroke", "in", "patients", "with", "venous", "thrombosis", "is", "lacking", ".", "The", "objective", "of", "this", "study", "was", "to", "investigate", "whether", "risk", "factors", "for", "arterial", "cardiovascular", "disease", "also", "increase", "the", "risk", "of", "venous", "thrombosis", ".", "DESIGN", "AND", "METHODS", "Cases", "who", "had", "a", "first", "venous", "thrombosis", "(", "n=515", ")", "and", "matched", "controls", "(", "n=1,505", ")", "were", "identified", "from", "a", "population", "-", "based", ",", "nested", ",", "case", "-", "cohort", "study", "(", "the", "HUNT", "2", "study", ")", "comprising", "71", "%", "(", "n=66,140", ")", "of", "the", "adult", "residents", "of", "Nord", "-", "Trøndelag", "County", "in", "Norway", ".", "RESULTS", "The", "age-", "and", "sex", "-", "adjusted", "odds", "ratio", "of", "venous", "thrombosis", "for", "subjects", "with", "concentrations", "of", "C", "-", "reactive", "protein", "in", "the", "highest", "quintile", "was", "1.6", "(", "95", "%", "confidence", "interval", ":", "1.2", "-", "2.2", ")", "compared", "to", "subjects", "with", "C", "-", "reactive", "protein", "in", "the", "lowest", "quintile", ".", "This", "association", "was", "strongest", "in", "subjects", "who", "experienced", "venous", "thrombosis", "within", "a", "year", "after", "blood", "sampling", "with", "a", "three", "-", "fold", "increased", "risk", "of", "participants", "in", "the", "highest", "versus", "the", "lowest", "quintile", ".", "Having", "first", "degree", "relatives", "who", "had", "a", "myocardial", "infarction", "before", "the", "age", "of", "60", "years", "was", "positively", "associated", "with", "venous", "thrombosis", "compared", "to", "not", "having", "a", "positive", "family", "history", "[", "odds", "ratio", "1.3", "(", "95", "%", "confidence", "interval", ":", "1.1", "-", "1.6", ")", "]", ".", "Subjects", "with", "blood", "pressure", "in", "the", "highest", "quintile", "had", "half", "the", "risk", "of", "developing", "venous", "thrombosis", "compared", "to", "subjects", "whose", "blood", "pressure", "was", "in", "the", "lowest", "quintile", ".", "There", "were", "no", "associations", "between", "the", "risk", "of", "venous", "thrombosis", "and", "total", "cholesterol", ",", "low", "density", "lipoprotein", "-", "cholesterol", ",", "high", "density", "lipoprotein", "-", "cholesterol", ",", "triglycerides", ",", "glucose", "or", "smoking", ".", "We", "confirmed", "the", "positive", "association", "between", "obesity", "and", "venous", "thrombosis", ".", "CONCLUSIONS", "C", "-", "reactive", "protein", "and", "a", "family", "history", "of", "myocardial", "infarction", "were", "positively", "associated", "with", "subsequent", "venous", "thrombosis", ".", "Blood", "pressure", "was", "inversely", "correlated", "to", "venous", "thrombosis", ".", "These", "findings", "should", "be", "confirmed", "by", "further", "investigations", "." ]

[ "Participant_Condition" ]

neoplásico is a MORFOLOGIA_NEOPLASIA, Adenocarcinoma is a MORFOLOGIA_NEOPLASIA, Hemangioma is a MORFOLOGIA_NEOPLASIA, Adenocarcinoma is a MORFOLOGIA_NEOPLASIA, M1 is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, Adenocarcinoma pobremente diferenciado is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA

211_task0

Sentence: Anamnesis Varón de 48 años. ANTECEDENTES PERSONALES: Alergia a Cefuroxima y Septrim (reacción cutánea). Fumador de 15 paquete/año y bebedor de 2 vinos a la semana. VIH + desde 1992 en control por Unidad de Enfermedades Infecciosas (UEI) con estadio C3 del CDC; en 1994 varios ingresos por neumonías de repetición (bacterianas y por Pneumocystis carinii), tuberculosis pulmonar y ganglionar. Tratamiento habitual: Raltegravir 400 1/12h, Maraviroc 150 1/12h, Ritonavir 100 1/24h, Darunavir 400 2/24h, Hierro oral antes del desayuno, Omeprazol 40 mg/24 h. ENFERMEDAD ACTUAL: En Febrero de 2011, acude a revisión en consultas de UEI y comenta la aparición de cierto grado de astenia progresiva con epigastralgia desde hace varios meses, acompañado desde el último mes de deposiciones melénicas, por lo que le realizan un análisis objetivando una hemoglobina (Hb) de 4.7, por lo que deciden ingreso para estudio. Exploración física Estable hemodinámicamente, afebril. Consciente, orientado, bien hidratado y perfundido, eupneico. Palidez cutaneo-mucosa. AC: Rítmica. AP: Murmullo vesicular conservado. Abdomen: Blando, depresible, leve dolor en región epigástrico a la palpación profunda con sensación de masa a dicho nivel. No signos de irritación peritoneal. Peristaltismo presente. Extremidades inferiores: No edemas ni signos de trombosis venosa profunda. Pruebas complementarias - ANÁLISIS (07/02/2011): Albúmina 31.2, PCR 14.4, Hb 4.7, Plaquetas 418000, Leucocitos 9380, Neutrófilos 5720. Coagulación normal. - MARCADORES TUMORALES: Antígeno Carcinoembrionario (CEA); CA 125 y Ca 19.9: Negativos. - GASTROSCOPIA: Gran masa ulcerada en la curvadura menor de aspecto neoplásico, con toma de biopsias de la zona sospechosa. - ANATOMÍA PATOLÓGICA: Biopsia gástrica positiva para Adenocarcinoma. - TAC ABDOMINO-PÉLVICO: Masa a nivel de curvadura menor del estómago, con adenopatías en ligamento gastrohepático, tronco celíaco y espacio portocava. - ECOGRAFÍA ABADOMINAL: Hemangioma hepático en segmento V. - TAC TORÁCICO: Sin evidencia de patología. Diagnóstico Adenocarcinoma gástrico localmente avanzado cT2 (dudosa M1 por adenopatías retroperitoneales por TAC). Tratamiento En el Comité de tumores Gastroesofágicos se decidió que ante la presencia de masa voluminosa y de las adenopatías, se pidiera un PET-TAC para ver el comportamiento de las adenopatías, si captaban se comenzaría con Quimioterapia paliativa por considerarse éstas como metástasis; si no captaban se comenzaría con QT neoadyuvante y tras revalorar el caso se plantearía intervención quirúrgica. - PET-TAC (02/03/2011): Se observa captación a nivel gástrico sin que capten las adenopatías retroperitoneales. El 28/02/2011 comenza tratamiento con el primer ciclo de QT Neoadyuvante con Cisplatino (75 mg/m2), Docetaxel (75 mg/m2) y 5-Fluorouracilo (750 mg/m2). Evolución A los 5 días del primer ciclo de QT presentó una importante toxicidad, con enteritis e insuficiencia renal prerrenal, anemia que precisó trasfusión y mucositis. Se realizó un análisis genético para las mutaciones de las enzimas que catabolizan el 5-Fluorouracilo (5-FU), obteniendo como resultado heterocigoto para MTHFR C677T lo que le produce una intolerancia a la administracion de 5-FU. Ante la toxicidad se cambia el esquema a CPT-11 (Irinotecan 125 mg/m2) semanal administrando 4 dosis del 1 de abril al 22 de Abril, con moderada tolerancia ya que durante la administración comienza con hiperbilirrubinemia y aumento de las enzimas hepáticas sin encontrar otra etiología que el tratamiento quimioterápico. Al mes de finalizar la QT vuelve a consultas de Oncología Médica con Análisis donde sólo se observa leve anemia con Hb de 11.1, mejoría de la función hepática y marcadores tumorales negativos, con un TAC donde se observa la masa en el estómago y las adenopatías retroperitoneales sin cambios; y el PET-TAC donde capta la masa en el estómago y no captan las adenopatías. Por todo esto se define como Enfermedad Estable, relacionando las adenopatías a su antecedente de enfermedad por el VIH y no a la enfermedad tumoral, por lo que se decide intervención quirúrgica. El 13/06/2011 le realizan gastrectomía parcial del 70%, linfadenectomía D2 y omentectomia. Con resultado de anatomía patológica de Adenocarcinoma pobremente diferenciado y áreas de moderadamente diferenciado, afectando a la capa muscular, con bordes de resección libres y con 47 ganglios libres de metástasis. Estadiaje definitivo ypT2 ypN0. Estadio IB. Ante la mala tolerancia al tratamiento quimioterápico se decide no dar quimioterapia adyuvante, y desde entonces pasa a controles. Actualmente sin evidencia de enfermedad a 5 años de la cirugía, en control anual con TAC, análisis y marcadores tumorales. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Varón de 48 años. ANTECEDENTES PERSONALES: Alergia a Cefuroxima y Septrim (reacción cutánea). Fumador de 15 paquete/año y bebedor de 2 vinos a la semana. VIH + desde 1992 en control por Unidad de Enfermedades Infecciosas (UEI) con estadio C3 del CDC; en 1994 varios ingresos por neumonías de repetición (bacterianas y por Pneumocystis carinii), tuberculosis pulmonar y ganglionar. Tratamiento habitual: Raltegravir 400 1/12h, Maraviroc 150 1/12h, Ritonavir 100 1/24h, Darunavir 400 2/24h, Hierro oral antes del desayuno, Omeprazol 40 mg/24 h. ENFERMEDAD ACTUAL: En Febrero de 2011, acude a revisión en consultas de UEI y comenta la aparición de cierto grado de astenia progresiva con epigastralgia desde hace varios meses, acompañado desde el último mes de deposiciones melénicas, por lo que le realizan un análisis objetivando una hemoglobina (Hb) de 4.7, por lo que deciden ingreso para estudio. Exploración física Estable hemodinámicamente, afebril. Consciente, orientado, bien hidratado y perfundido, eupneico. Palidez cutaneo-mucosa. AC: Rítmica. AP: Murmullo vesicular conservado. Abdomen: Blando, depresible, leve dolor en región epigástrico a la palpación profunda con sensación de masa a dicho nivel. No signos de irritación peritoneal. Peristaltismo presente. Extremidades inferiores: No edemas ni signos de trombosis venosa profunda. Pruebas complementarias - ANÁLISIS (07/02/2011): Albúmina 31.2, PCR 14.4, Hb 4.7, Plaquetas 418000, Leucocitos 9380, Neutrófilos 5720. Coagulación normal. - MARCADORES TUMORALES: Antígeno Carcinoembrionario (CEA); CA 125 y Ca 19.9: Negativos. - GASTROSCOPIA: Gran masa ulcerada en la curvadura menor de aspecto neoplásico, con toma de biopsias de la zona sospechosa. - ANATOMÍA PATOLÓGICA: Biopsia gástrica positiva para Adenocarcinoma. - TAC ABDOMINO-PÉLVICO: Masa a nivel de curvadura menor del estómago, con adenopatías en ligamento gastrohepático, tronco celíaco y espacio portocava. - ECOGRAFÍA ABADOMINAL: Hemangioma hepático en segmento V. - TAC TORÁCICO: Sin evidencia de patología. Diagnóstico Adenocarcinoma gástrico localmente avanzado cT2 (dudosa M1 por adenopatías retroperitoneales por TAC). Tratamiento En el Comité de tumores Gastroesofágicos se decidió que ante la presencia de masa voluminosa y de las adenopatías, se pidiera un PET-TAC para ver el comportamiento de las adenopatías, si captaban se comenzaría con Quimioterapia paliativa por considerarse éstas como metástasis; si no captaban se comenzaría con QT neoadyuvante y tras revalorar el caso se plantearía intervención quirúrgica. - PET-TAC (02/03/2011): Se observa captación a nivel gástrico sin que capten las adenopatías retroperitoneales. El 28/02/2011 comenza tratamiento con el primer ciclo de QT Neoadyuvante con Cisplatino (75 mg/m2), Docetaxel (75 mg/m2) y 5-Fluorouracilo (750 mg/m2). Evolución A los 5 días del primer ciclo de QT presentó una importante toxicidad, con enteritis e insuficiencia renal prerrenal, anemia que precisó trasfusión y mucositis. Se realizó un análisis genético para las mutaciones de las enzimas que catabolizan el 5-Fluorouracilo (5-FU), obteniendo como resultado heterocigoto para MTHFR C677T lo que le produce una intolerancia a la administracion de 5-FU. Ante la toxicidad se cambia el esquema a CPT-11 (Irinotecan 125 mg/m2) semanal administrando 4 dosis del 1 de abril al 22 de Abril, con moderada tolerancia ya que durante la administración comienza con hiperbilirrubinemia y aumento de las enzimas hepáticas sin encontrar otra etiología que el tratamiento quimioterápico. Al mes de finalizar la QT vuelve a consultas de Oncología Médica con Análisis donde sólo se observa leve anemia con Hb de 11.1, mejoría de la función hepática y marcadores tumorales negativos, con un TAC donde se observa la masa en el estómago y las adenopatías retroperitoneales sin cambios; y el PET-TAC donde capta la masa en el estómago y no captan las adenopatías. Por todo esto se define como Enfermedad Estable, relacionando las adenopatías a su antecedente de enfermedad por el VIH y no a la enfermedad tumoral, por lo que se decide intervención quirúrgica. El 13/06/2011 le realizan gastrectomía parcial del 70%, linfadenectomía D2 y omentectomia. Con resultado de anatomía patológica de Adenocarcinoma pobremente diferenciado y áreas de moderadamente diferenciado, afectando a la capa muscular, con bordes de resección libres y con 47 ganglios libres de metástasis. Estadiaje definitivo ypT2 ypN0. Estadio IB. Ante la mala tolerancia al tratamiento quimioterápico se decide no dar quimioterapia adyuvante, y desde entonces pasa a controles. Actualmente sin evidencia de enfermedad a 5 años de la cirugía, en control anual con TAC, análisis y marcadores tumorales.

[ "Anamnesis", "\n", "Varón", "de", "48", "años", ".", "\n\n", "ANTECEDENTES", "PERSONALES", ":", "Alergia", "a", "Cefuroxima", "y", "Septrim", "(", "reacción", "cutánea", ")", ".", "Fumador", "de", "15", "paquete", "/", "año", "y", "bebedor", "de", "2", "vinos", "a", "la", "semana", ".", "VIH", "+", "desde", "1992", "en", "control", "por", "Unidad", "de", "Enfermedades", "Infecciosas", "(", "UEI", ")", "con", "estadio", "C3", "del", "CDC", ";", "en", "1994", "varios", "ingresos", "por", "neumonías", "de", "repetición", "(", "bacterianas", "y", "por", "Pneumocystis", "carinii", ")", ",", "tuberculosis", "pulmonar", "y", "ganglionar", ".", "Tratamiento", "habitual", ":", "Raltegravir", "400", "1/12h", ",", "Maraviroc", "150", "1/12h", ",", "Ritonavir", "100", "1/24h", ",", "Darunavir", "400", "2/24h", ",", "Hierro", "oral", "antes", "del", "desayuno", ",", "Omeprazol", "40", "mg/24", "h.", "\n\n", "ENFERMEDAD", "ACTUAL", ":", "\n", "En", "Febrero", "de", "2011", ",", "acude", "a", "revisión", "en", "consultas", "de", "UEI", "y", "comenta", "la", "aparición", "de", "cierto", "grado", "de", "astenia", "progresiva", "con", "epigastralgia", "desde", "hace", "varios", "meses", ",", "acompañado", "desde", "el", "último", "mes", "de", "deposiciones", "melénicas", ",", "por", "lo", "que", "le", "realizan", "un", "análisis", "objetivando", "una", "hemoglobina", "(", "Hb", ")", "de", "4.7", ",", "por", "lo", "que", "deciden", "ingreso", "para", "estudio", ".", "\n\n", "Exploración", "física", "\n", "Estable", "hemodinámicamente", ",", "afebril", ".", "Consciente", ",", "orientado", ",", "bien", "hidratado", "y", "perfundido", ",", "eupneico", ".", "Palidez", "cutaneo", "-", "mucosa", ".", "AC", ":", "Rítmica", ".", "AP", ":", "Murmullo", "vesicular", "conservado", ".", "Abdomen", ":", "Blando", ",", "depresible", ",", "leve", "dolor", "en", "región", "epigástrico", "a", "la", "palpación", "profunda", "con", "sensación", "de", "masa", "a", "dicho", "nivel", ".", "No", "signos", "de", "irritación", "peritoneal", ".", "Peristaltismo", "presente", ".", "Extremidades", "inferiores", ":", "No", "edemas", "ni", "signos", "de", "trombosis", "venosa", "profunda", ".", "\n\n", "Pruebas", "complementarias", "\n", "-", "ANÁLISIS", "(", "07/02/2011", "):", "Albúmina", "31.2", ",", "PCR", "14.4", ",", "Hb", "4.7", ",", "Plaquetas", "418000", ",", "Leucocitos", "9380", ",", "Neutrófilos", "5720", ".", "Coagulación", "normal", ".", "\n", "-", "MARCADORES", "TUMORALES", ":", "Antígeno", "Carcinoembrionario", "(", "CEA", ")", ";", "CA", "125", "y", "Ca", "19.9", ":", "Negativos", ".", "\n", "-", "GASTROSCOPIA", ":", "Gran", "masa", "ulcerada", "en", "la", "curvadura", "menor", "de", "aspecto", "neoplásico", ",", "con", "toma", "de", "biopsias", "de", "la", "zona", "sospechosa", ".", "\n", "-", "ANATOMÍA", "PATOLÓGICA", ":", "Biopsia", "gástrica", "positiva", "para", "Adenocarcinoma", ".", "\n", "-", "TAC", "ABDOMINO", "-", "PÉLVICO", ":", "Masa", "a", "nivel", "de", "curvadura", "menor", "del", "estómago", ",", "con", "adenopatías", "en", "ligamento", "gastrohepático", ",", "tronco", "celíaco", "y", "espacio", "portocava", ".", "\n", "-", "ECOGRAFÍA", "ABADOMINAL", ":", "Hemangioma", "hepático", "en", "segmento", "V.", "\n", "-", "TAC", "TORÁCICO", ":", "Sin", "evidencia", "de", "patología", ".", "\n\n", "Diagnóstico", "\n", "Adenocarcinoma", "gástrico", "localmente", "avanzado", "cT2", "(", "dudosa", "M1", "por", "adenopatías", "retroperitoneales", "por", "TAC", ")", ".", "\n\n", "Tratamiento", "\n", "En", "el", "Comité", "de", "tumores", "Gastroesofágicos", "se", "decidió", "que", "ante", "la", "presencia", "de", "masa", "voluminosa", "y", "de", "las", "adenopatías", ",", "se", "pidiera", "un", "PET", "-", "TAC", "para", "ver", "el", "comportamiento", "de", "las", "adenopatías", ",", "si", "captaban", "se", "comenzaría", "con", "Quimioterapia", "paliativa", "por", "considerarse", "éstas", "como", "metástasis", ";", "si", "no", "captaban", "se", "comenzaría", "con", "QT", "neoadyuvante", "y", "tras", "revalorar", "el", "caso", "se", "plantearía", "intervención", "quirúrgica", ".", "\n", "-", "PET", "-", "TAC", "(", "02/03/2011", "):", "Se", "observa", "captación", "a", "nivel", "gástrico", "sin", "que", "capten", "las", "adenopatías", "retroperitoneales", ".", "\n", "El", "28/02/2011", "comenza", "tratamiento", "con", "el", "primer", "ciclo", "de", "QT", "Neoadyuvante", "con", "Cisplatino", "(", "75", "mg", "/", "m2", ")", ",", "Docetaxel", "(", "75", "mg", "/", "m2", ")", "y", "5-Fluorouracilo", "(", "750", "mg", "/", "m2", ")", ".", "\n\n", "Evolución", "\n", "A", "los", "5", "días", "del", "primer", "ciclo", "de", "QT", "presentó", "una", "importante", "toxicidad", ",", "con", "enteritis", "e", "insuficiencia", "renal", "prerrenal", ",", "anemia", "que", "precisó", "trasfusión", "y", "mucositis", ".", "Se", "realizó", "un", "análisis", "genético", "para", "las", "mutaciones", "de", "las", "enzimas", "que", "catabolizan", "el", "5-Fluorouracilo", "(", "5-FU", ")", ",", "obteniendo", "como", "resultado", "heterocigoto", "para", "MTHFR", "C677", "T", "lo", "que", "le", "produce", "una", "intolerancia", "a", "la", "administracion", "de", "5-FU", ".", "\n", "Ante", "la", "toxicidad", "se", "cambia", "el", "esquema", "a", "CPT-11", "(", "Irinotecan", "125", "mg", "/", "m2", ")", "semanal", "administrando", "4", "dosis", "del", "1", "de", "abril", "al", "22", "de", "Abril", ",", "con", "moderada", "tolerancia", "ya", "que", "durante", "la", "administración", "comienza", "con", "hiperbilirrubinemia", "y", "aumento", "de", "las", "enzimas", "hepáticas", "sin", "encontrar", "otra", "etiología", "que", "el", "tratamiento", "quimioterápico", ".", "\n", "Al", "mes", "de", "finalizar", "la", "QT", "vuelve", "a", "consultas", "de", "Oncología", "Médica", "con", "Análisis", "donde", "sólo", "se", "observa", "leve", "anemia", "con", "Hb", "de", "11.1", ",", "mejoría", "de", "la", "función", "hepática", "y", "marcadores", "tumorales", "negativos", ",", "con", "un", "TAC", "donde", "se", "observa", "la", "masa", "en", "el", "estómago", "y", "las", "adenopatías", "retroperitoneales", "sin", "cambios", ";", "y", "el", "PET", "-", "TAC", "donde", "capta", "la", "masa", "en", "el", "estómago", "y", "no", "captan", "las", "adenopatías", ".", "\n", "Por", "todo", "esto", "se", "define", "como", "Enfermedad", "Estable", ",", "relacionando", "las", "adenopatías", "a", "su", "antecedente", "de", "enfermedad", "por", "el", "VIH", "y", "no", "a", "la", "enfermedad", "tumoral", ",", "por", "lo", "que", "se", "decide", "intervención", "quirúrgica", ".", "\n", "El", "13/06/2011", "le", "realizan", "gastrectomía", "parcial", "del", "70", "%", ",", "linfadenectomía", "D2", "y", "omentectomia", ".", "Con", "resultado", "de", "anatomía", "patológica", "de", "Adenocarcinoma", "pobremente", "diferenciado", "y", "áreas", "de", "moderadamente", "diferenciado", ",", "afectando", "a", "la", "capa", "muscular", ",", "con", "bordes", "de", "resección", "libres", "y", "con", "47", "ganglios", "libres", "de", "metástasis", ".", "Estadiaje", "definitivo", "ypT2", "ypN0", ".", "Estadio", "IB", ".", "\n", "Ante", "la", "mala", "tolerancia", "al", "tratamiento", "quimioterápico", "se", "decide", "no", "dar", "quimioterapia", "adyuvante", ",", "y", "desde", "entonces", "pasa", "a", "controles", ".", "\n", "Actualmente", "sin", "evidencia", "de", "enfermedad", "a", "5", "años", "de", "la", "cirugía", ",", "en", "control", "anual", "con", "TAC", ",", "análisis", "y", "marcadores", "tumorales", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

neoplásico is a MORFOLOGIA_NEOPLASIA, Adenocarcinoma is a MORFOLOGIA_NEOPLASIA, Hemangioma is a MORFOLOGIA_NEOPLASIA, Adenocarcinoma is a MORFOLOGIA_NEOPLASIA, M1 is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA, Adenocarcinoma pobremente diferenciado is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA

211_task1

Sentence: Anamnesis Varón de 48 años. ANTECEDENTES PERSONALES: Alergia a Cefuroxima y Septrim (reacción cutánea). Fumador de 15 paquete/año y bebedor de 2 vinos a la semana. VIH + desde 1992 en control por Unidad de Enfermedades Infecciosas (UEI) con estadio C3 del CDC; en 1994 varios ingresos por neumonías de repetición (bacterianas y por Pneumocystis carinii), tuberculosis pulmonar y ganglionar. Tratamiento habitual: Raltegravir 400 1/12h, Maraviroc 150 1/12h, Ritonavir 100 1/24h, Darunavir 400 2/24h, Hierro oral antes del desayuno, Omeprazol 40 mg/24 h. ENFERMEDAD ACTUAL: En Febrero de 2011, acude a revisión en consultas de UEI y comenta la aparición de cierto grado de astenia progresiva con epigastralgia desde hace varios meses, acompañado desde el último mes de deposiciones melénicas, por lo que le realizan un análisis objetivando una hemoglobina (Hb) de 4.7, por lo que deciden ingreso para estudio. Exploración física Estable hemodinámicamente, afebril. Consciente, orientado, bien hidratado y perfundido, eupneico. Palidez cutaneo-mucosa. AC: Rítmica. AP: Murmullo vesicular conservado. Abdomen: Blando, depresible, leve dolor en región epigástrico a la palpación profunda con sensación de masa a dicho nivel. No signos de irritación peritoneal. Peristaltismo presente. Extremidades inferiores: No edemas ni signos de trombosis venosa profunda. Pruebas complementarias - ANÁLISIS (07/02/2011): Albúmina 31.2, PCR 14.4, Hb 4.7, Plaquetas 418000, Leucocitos 9380, Neutrófilos 5720. Coagulación normal. - MARCADORES TUMORALES: Antígeno Carcinoembrionario (CEA); CA 125 y Ca 19.9: Negativos. - GASTROSCOPIA: Gran masa ulcerada en la curvadura menor de aspecto neoplásico, con toma de biopsias de la zona sospechosa. - ANATOMÍA PATOLÓGICA: Biopsia gástrica positiva para Adenocarcinoma. - TAC ABDOMINO-PÉLVICO: Masa a nivel de curvadura menor del estómago, con adenopatías en ligamento gastrohepático, tronco celíaco y espacio portocava. - ECOGRAFÍA ABADOMINAL: Hemangioma hepático en segmento V. - TAC TORÁCICO: Sin evidencia de patología. Diagnóstico Adenocarcinoma gástrico localmente avanzado cT2 (dudosa M1 por adenopatías retroperitoneales por TAC). Tratamiento En el Comité de tumores Gastroesofágicos se decidió que ante la presencia de masa voluminosa y de las adenopatías, se pidiera un PET-TAC para ver el comportamiento de las adenopatías, si captaban se comenzaría con Quimioterapia paliativa por considerarse éstas como metástasis; si no captaban se comenzaría con QT neoadyuvante y tras revalorar el caso se plantearía intervención quirúrgica. - PET-TAC (02/03/2011): Se observa captación a nivel gástrico sin que capten las adenopatías retroperitoneales. El 28/02/2011 comenza tratamiento con el primer ciclo de QT Neoadyuvante con Cisplatino (75 mg/m2), Docetaxel (75 mg/m2) y 5-Fluorouracilo (750 mg/m2). Evolución A los 5 días del primer ciclo de QT presentó una importante toxicidad, con enteritis e insuficiencia renal prerrenal, anemia que precisó trasfusión y mucositis. Se realizó un análisis genético para las mutaciones de las enzimas que catabolizan el 5-Fluorouracilo (5-FU), obteniendo como resultado heterocigoto para MTHFR C677T lo que le produce una intolerancia a la administracion de 5-FU. Ante la toxicidad se cambia el esquema a CPT-11 (Irinotecan 125 mg/m2) semanal administrando 4 dosis del 1 de abril al 22 de Abril, con moderada tolerancia ya que durante la administración comienza con hiperbilirrubinemia y aumento de las enzimas hepáticas sin encontrar otra etiología que el tratamiento quimioterápico. Al mes de finalizar la QT vuelve a consultas de Oncología Médica con Análisis donde sólo se observa leve anemia con Hb de 11.1, mejoría de la función hepática y marcadores tumorales negativos, con un TAC donde se observa la masa en el estómago y las adenopatías retroperitoneales sin cambios; y el PET-TAC donde capta la masa en el estómago y no captan las adenopatías. Por todo esto se define como Enfermedad Estable, relacionando las adenopatías a su antecedente de enfermedad por el VIH y no a la enfermedad tumoral, por lo que se decide intervención quirúrgica. El 13/06/2011 le realizan gastrectomía parcial del 70%, linfadenectomía D2 y omentectomia. Con resultado de anatomía patológica de Adenocarcinoma pobremente diferenciado y áreas de moderadamente diferenciado, afectando a la capa muscular, con bordes de resección libres y con 47 ganglios libres de metástasis. Estadiaje definitivo ypT2 ypN0. Estadio IB. Ante la mala tolerancia al tratamiento quimioterápico se decide no dar quimioterapia adyuvante, y desde entonces pasa a controles. Actualmente sin evidencia de enfermedad a 5 años de la cirugía, en control anual con TAC, análisis y marcadores tumorales. Instructions: please typing these entity words according to sentence: neoplásico, Adenocarcinoma, Hemangioma, Adenocarcinoma, M1, metástasis, tumoral, Adenocarcinoma pobremente diferenciado, metástasis Options: MORFOLOGIA_NEOPLASIA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Varón de 48 años. ANTECEDENTES PERSONALES: Alergia a Cefuroxima y Septrim (reacción cutánea). Fumador de 15 paquete/año y bebedor de 2 vinos a la semana. VIH + desde 1992 en control por Unidad de Enfermedades Infecciosas (UEI) con estadio C3 del CDC; en 1994 varios ingresos por neumonías de repetición (bacterianas y por Pneumocystis carinii), tuberculosis pulmonar y ganglionar. Tratamiento habitual: Raltegravir 400 1/12h, Maraviroc 150 1/12h, Ritonavir 100 1/24h, Darunavir 400 2/24h, Hierro oral antes del desayuno, Omeprazol 40 mg/24 h. ENFERMEDAD ACTUAL: En Febrero de 2011, acude a revisión en consultas de UEI y comenta la aparición de cierto grado de astenia progresiva con epigastralgia desde hace varios meses, acompañado desde el último mes de deposiciones melénicas, por lo que le realizan un análisis objetivando una hemoglobina (Hb) de 4.7, por lo que deciden ingreso para estudio. Exploración física Estable hemodinámicamente, afebril. Consciente, orientado, bien hidratado y perfundido, eupneico. Palidez cutaneo-mucosa. AC: Rítmica. AP: Murmullo vesicular conservado. Abdomen: Blando, depresible, leve dolor en región epigástrico a la palpación profunda con sensación de masa a dicho nivel. No signos de irritación peritoneal. Peristaltismo presente. Extremidades inferiores: No edemas ni signos de trombosis venosa profunda. Pruebas complementarias - ANÁLISIS (07/02/2011): Albúmina 31.2, PCR 14.4, Hb 4.7, Plaquetas 418000, Leucocitos 9380, Neutrófilos 5720. Coagulación normal. - MARCADORES TUMORALES: Antígeno Carcinoembrionario (CEA); CA 125 y Ca 19.9: Negativos. - GASTROSCOPIA: Gran masa ulcerada en la curvadura menor de aspecto neoplásico, con toma de biopsias de la zona sospechosa. - ANATOMÍA PATOLÓGICA: Biopsia gástrica positiva para Adenocarcinoma. - TAC ABDOMINO-PÉLVICO: Masa a nivel de curvadura menor del estómago, con adenopatías en ligamento gastrohepático, tronco celíaco y espacio portocava. - ECOGRAFÍA ABADOMINAL: Hemangioma hepático en segmento V. - TAC TORÁCICO: Sin evidencia de patología. Diagnóstico Adenocarcinoma gástrico localmente avanzado cT2 (dudosa M1 por adenopatías retroperitoneales por TAC). Tratamiento En el Comité de tumores Gastroesofágicos se decidió que ante la presencia de masa voluminosa y de las adenopatías, se pidiera un PET-TAC para ver el comportamiento de las adenopatías, si captaban se comenzaría con Quimioterapia paliativa por considerarse éstas como metástasis; si no captaban se comenzaría con QT neoadyuvante y tras revalorar el caso se plantearía intervención quirúrgica. - PET-TAC (02/03/2011): Se observa captación a nivel gástrico sin que capten las adenopatías retroperitoneales. El 28/02/2011 comenza tratamiento con el primer ciclo de QT Neoadyuvante con Cisplatino (75 mg/m2), Docetaxel (75 mg/m2) y 5-Fluorouracilo (750 mg/m2). Evolución A los 5 días del primer ciclo de QT presentó una importante toxicidad, con enteritis e insuficiencia renal prerrenal, anemia que precisó trasfusión y mucositis. Se realizó un análisis genético para las mutaciones de las enzimas que catabolizan el 5-Fluorouracilo (5-FU), obteniendo como resultado heterocigoto para MTHFR C677T lo que le produce una intolerancia a la administracion de 5-FU. Ante la toxicidad se cambia el esquema a CPT-11 (Irinotecan 125 mg/m2) semanal administrando 4 dosis del 1 de abril al 22 de Abril, con moderada tolerancia ya que durante la administración comienza con hiperbilirrubinemia y aumento de las enzimas hepáticas sin encontrar otra etiología que el tratamiento quimioterápico. Al mes de finalizar la QT vuelve a consultas de Oncología Médica con Análisis donde sólo se observa leve anemia con Hb de 11.1, mejoría de la función hepática y marcadores tumorales negativos, con un TAC donde se observa la masa en el estómago y las adenopatías retroperitoneales sin cambios; y el PET-TAC donde capta la masa en el estómago y no captan las adenopatías. Por todo esto se define como Enfermedad Estable, relacionando las adenopatías a su antecedente de enfermedad por el VIH y no a la enfermedad tumoral, por lo que se decide intervención quirúrgica. El 13/06/2011 le realizan gastrectomía parcial del 70%, linfadenectomía D2 y omentectomia. Con resultado de anatomía patológica de Adenocarcinoma pobremente diferenciado y áreas de moderadamente diferenciado, afectando a la capa muscular, con bordes de resección libres y con 47 ganglios libres de metástasis. Estadiaje definitivo ypT2 ypN0. Estadio IB. Ante la mala tolerancia al tratamiento quimioterápico se decide no dar quimioterapia adyuvante, y desde entonces pasa a controles. Actualmente sin evidencia de enfermedad a 5 años de la cirugía, en control anual con TAC, análisis y marcadores tumorales.

[ "Anamnesis", "\n", "Varón", "de", "48", "años", ".", "\n\n", "ANTECEDENTES", "PERSONALES", ":", "Alergia", "a", "Cefuroxima", "y", "Septrim", "(", "reacción", "cutánea", ")", ".", "Fumador", "de", "15", "paquete", "/", "año", "y", "bebedor", "de", "2", "vinos", "a", "la", "semana", ".", "VIH", "+", "desde", "1992", "en", "control", "por", "Unidad", "de", "Enfermedades", "Infecciosas", "(", "UEI", ")", "con", "estadio", "C3", "del", "CDC", ";", "en", "1994", "varios", "ingresos", "por", "neumonías", "de", "repetición", "(", "bacterianas", "y", "por", "Pneumocystis", "carinii", ")", ",", "tuberculosis", "pulmonar", "y", "ganglionar", ".", "Tratamiento", "habitual", ":", "Raltegravir", "400", "1/12h", ",", "Maraviroc", "150", "1/12h", ",", "Ritonavir", "100", "1/24h", ",", "Darunavir", "400", "2/24h", ",", "Hierro", "oral", "antes", "del", "desayuno", ",", "Omeprazol", "40", "mg/24", "h.", "\n\n", "ENFERMEDAD", "ACTUAL", ":", "\n", "En", "Febrero", "de", "2011", ",", "acude", "a", "revisión", "en", "consultas", "de", "UEI", "y", "comenta", "la", "aparición", "de", "cierto", "grado", "de", "astenia", "progresiva", "con", "epigastralgia", "desde", "hace", "varios", "meses", ",", "acompañado", "desde", "el", "último", "mes", "de", "deposiciones", "melénicas", ",", "por", "lo", "que", "le", "realizan", "un", "análisis", "objetivando", "una", "hemoglobina", "(", "Hb", ")", "de", "4.7", ",", "por", "lo", "que", "deciden", "ingreso", "para", "estudio", ".", "\n\n", "Exploración", "física", "\n", "Estable", "hemodinámicamente", ",", "afebril", ".", "Consciente", ",", "orientado", ",", "bien", "hidratado", "y", "perfundido", ",", "eupneico", ".", "Palidez", "cutaneo", "-", "mucosa", ".", "AC", ":", "Rítmica", ".", "AP", ":", "Murmullo", "vesicular", "conservado", ".", "Abdomen", ":", "Blando", ",", "depresible", ",", "leve", "dolor", "en", "región", "epigástrico", "a", "la", "palpación", "profunda", "con", "sensación", "de", "masa", "a", "dicho", "nivel", ".", "No", "signos", "de", "irritación", "peritoneal", ".", "Peristaltismo", "presente", ".", "Extremidades", "inferiores", ":", "No", "edemas", "ni", "signos", "de", "trombosis", "venosa", "profunda", ".", "\n\n", "Pruebas", "complementarias", "\n", "-", "ANÁLISIS", "(", "07/02/2011", "):", "Albúmina", "31.2", ",", "PCR", "14.4", ",", "Hb", "4.7", ",", "Plaquetas", "418000", ",", "Leucocitos", "9380", ",", "Neutrófilos", "5720", ".", "Coagulación", "normal", ".", "\n", "-", "MARCADORES", "TUMORALES", ":", "Antígeno", "Carcinoembrionario", "(", "CEA", ")", ";", "CA", "125", "y", "Ca", "19.9", ":", "Negativos", ".", "\n", "-", "GASTROSCOPIA", ":", "Gran", "masa", "ulcerada", "en", "la", "curvadura", "menor", "de", "aspecto", "neoplásico", ",", "con", "toma", "de", "biopsias", "de", "la", "zona", "sospechosa", ".", "\n", "-", "ANATOMÍA", "PATOLÓGICA", ":", "Biopsia", "gástrica", "positiva", "para", "Adenocarcinoma", ".", "\n", "-", "TAC", "ABDOMINO", "-", "PÉLVICO", ":", "Masa", "a", "nivel", "de", "curvadura", "menor", "del", "estómago", ",", "con", "adenopatías", "en", "ligamento", "gastrohepático", ",", "tronco", "celíaco", "y", "espacio", "portocava", ".", "\n", "-", "ECOGRAFÍA", "ABADOMINAL", ":", "Hemangioma", "hepático", "en", "segmento", "V.", "\n", "-", "TAC", "TORÁCICO", ":", "Sin", "evidencia", "de", "patología", ".", "\n\n", "Diagnóstico", "\n", "Adenocarcinoma", "gástrico", "localmente", "avanzado", "cT2", "(", "dudosa", "M1", "por", "adenopatías", "retroperitoneales", "por", "TAC", ")", ".", "\n\n", "Tratamiento", "\n", "En", "el", "Comité", "de", "tumores", "Gastroesofágicos", "se", "decidió", "que", "ante", "la", "presencia", "de", "masa", "voluminosa", "y", "de", "las", "adenopatías", ",", "se", "pidiera", "un", "PET", "-", "TAC", "para", "ver", "el", "comportamiento", "de", "las", "adenopatías", ",", "si", "captaban", "se", "comenzaría", "con", "Quimioterapia", "paliativa", "por", "considerarse", "éstas", "como", "metástasis", ";", "si", "no", "captaban", "se", "comenzaría", "con", "QT", "neoadyuvante", "y", "tras", "revalorar", "el", "caso", "se", "plantearía", "intervención", "quirúrgica", ".", "\n", "-", "PET", "-", "TAC", "(", "02/03/2011", "):", "Se", "observa", "captación", "a", "nivel", "gástrico", "sin", "que", "capten", "las", "adenopatías", "retroperitoneales", ".", "\n", "El", "28/02/2011", "comenza", "tratamiento", "con", "el", "primer", "ciclo", "de", "QT", "Neoadyuvante", "con", "Cisplatino", "(", "75", "mg", "/", "m2", ")", ",", "Docetaxel", "(", "75", "mg", "/", "m2", ")", "y", "5-Fluorouracilo", "(", "750", "mg", "/", "m2", ")", ".", "\n\n", "Evolución", "\n", "A", "los", "5", "días", "del", "primer", "ciclo", "de", "QT", "presentó", "una", "importante", "toxicidad", ",", "con", "enteritis", "e", "insuficiencia", "renal", "prerrenal", ",", "anemia", "que", "precisó", "trasfusión", "y", "mucositis", ".", "Se", "realizó", "un", "análisis", "genético", "para", "las", "mutaciones", "de", "las", "enzimas", "que", "catabolizan", "el", "5-Fluorouracilo", "(", "5-FU", ")", ",", "obteniendo", "como", "resultado", "heterocigoto", "para", "MTHFR", "C677", "T", "lo", "que", "le", "produce", "una", "intolerancia", "a", "la", "administracion", "de", "5-FU", ".", "\n", "Ante", "la", "toxicidad", "se", "cambia", "el", "esquema", "a", "CPT-11", "(", "Irinotecan", "125", "mg", "/", "m2", ")", "semanal", "administrando", "4", "dosis", "del", "1", "de", "abril", "al", "22", "de", "Abril", ",", "con", "moderada", "tolerancia", "ya", "que", "durante", "la", "administración", "comienza", "con", "hiperbilirrubinemia", "y", "aumento", "de", "las", "enzimas", "hepáticas", "sin", "encontrar", "otra", "etiología", "que", "el", "tratamiento", "quimioterápico", ".", "\n", "Al", "mes", "de", "finalizar", "la", "QT", "vuelve", "a", "consultas", "de", "Oncología", "Médica", "con", "Análisis", "donde", "sólo", "se", "observa", "leve", "anemia", "con", "Hb", "de", "11.1", ",", "mejoría", "de", "la", "función", "hepática", "y", "marcadores", "tumorales", "negativos", ",", "con", "un", "TAC", "donde", "se", "observa", "la", "masa", "en", "el", "estómago", "y", "las", "adenopatías", "retroperitoneales", "sin", "cambios", ";", "y", "el", "PET", "-", "TAC", "donde", "capta", "la", "masa", "en", "el", "estómago", "y", "no", "captan", "las", "adenopatías", ".", "\n", "Por", "todo", "esto", "se", "define", "como", "Enfermedad", "Estable", ",", "relacionando", "las", "adenopatías", "a", "su", "antecedente", "de", "enfermedad", "por", "el", "VIH", "y", "no", "a", "la", "enfermedad", "tumoral", ",", "por", "lo", "que", "se", "decide", "intervención", "quirúrgica", ".", "\n", "El", "13/06/2011", "le", "realizan", "gastrectomía", "parcial", "del", "70", "%", ",", "linfadenectomía", "D2", "y", "omentectomia", ".", "Con", "resultado", "de", "anatomía", "patológica", "de", "Adenocarcinoma", "pobremente", "diferenciado", "y", "áreas", "de", "moderadamente", "diferenciado", ",", "afectando", "a", "la", "capa", "muscular", ",", "con", "bordes", "de", "resección", "libres", "y", "con", "47", "ganglios", "libres", "de", "metástasis", ".", "Estadiaje", "definitivo", "ypT2", "ypN0", ".", "Estadio", "IB", ".", "\n", "Ante", "la", "mala", "tolerancia", "al", "tratamiento", "quimioterápico", "se", "decide", "no", "dar", "quimioterapia", "adyuvante", ",", "y", "desde", "entonces", "pasa", "a", "controles", ".", "\n", "Actualmente", "sin", "evidencia", "de", "enfermedad", "a", "5", "años", "de", "la", "cirugía", ",", "en", "control", "anual", "con", "TAC", ",", "análisis", "y", "marcadores", "tumorales", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

neoplásico, Adenocarcinoma, Hemangioma, Adenocarcinoma, M1, metástasis, tumoral, Adenocarcinoma pobremente diferenciado, metástasis

211_task2

Sentence: Anamnesis Varón de 48 años. ANTECEDENTES PERSONALES: Alergia a Cefuroxima y Septrim (reacción cutánea). Fumador de 15 paquete/año y bebedor de 2 vinos a la semana. VIH + desde 1992 en control por Unidad de Enfermedades Infecciosas (UEI) con estadio C3 del CDC; en 1994 varios ingresos por neumonías de repetición (bacterianas y por Pneumocystis carinii), tuberculosis pulmonar y ganglionar. Tratamiento habitual: Raltegravir 400 1/12h, Maraviroc 150 1/12h, Ritonavir 100 1/24h, Darunavir 400 2/24h, Hierro oral antes del desayuno, Omeprazol 40 mg/24 h. ENFERMEDAD ACTUAL: En Febrero de 2011, acude a revisión en consultas de UEI y comenta la aparición de cierto grado de astenia progresiva con epigastralgia desde hace varios meses, acompañado desde el último mes de deposiciones melénicas, por lo que le realizan un análisis objetivando una hemoglobina (Hb) de 4.7, por lo que deciden ingreso para estudio. Exploración física Estable hemodinámicamente, afebril. Consciente, orientado, bien hidratado y perfundido, eupneico. Palidez cutaneo-mucosa. AC: Rítmica. AP: Murmullo vesicular conservado. Abdomen: Blando, depresible, leve dolor en región epigástrico a la palpación profunda con sensación de masa a dicho nivel. No signos de irritación peritoneal. Peristaltismo presente. Extremidades inferiores: No edemas ni signos de trombosis venosa profunda. Pruebas complementarias - ANÁLISIS (07/02/2011): Albúmina 31.2, PCR 14.4, Hb 4.7, Plaquetas 418000, Leucocitos 9380, Neutrófilos 5720. Coagulación normal. - MARCADORES TUMORALES: Antígeno Carcinoembrionario (CEA); CA 125 y Ca 19.9: Negativos. - GASTROSCOPIA: Gran masa ulcerada en la curvadura menor de aspecto neoplásico, con toma de biopsias de la zona sospechosa. - ANATOMÍA PATOLÓGICA: Biopsia gástrica positiva para Adenocarcinoma. - TAC ABDOMINO-PÉLVICO: Masa a nivel de curvadura menor del estómago, con adenopatías en ligamento gastrohepático, tronco celíaco y espacio portocava. - ECOGRAFÍA ABADOMINAL: Hemangioma hepático en segmento V. - TAC TORÁCICO: Sin evidencia de patología. Diagnóstico Adenocarcinoma gástrico localmente avanzado cT2 (dudosa M1 por adenopatías retroperitoneales por TAC). Tratamiento En el Comité de tumores Gastroesofágicos se decidió que ante la presencia de masa voluminosa y de las adenopatías, se pidiera un PET-TAC para ver el comportamiento de las adenopatías, si captaban se comenzaría con Quimioterapia paliativa por considerarse éstas como metástasis; si no captaban se comenzaría con QT neoadyuvante y tras revalorar el caso se plantearía intervención quirúrgica. - PET-TAC (02/03/2011): Se observa captación a nivel gástrico sin que capten las adenopatías retroperitoneales. El 28/02/2011 comenza tratamiento con el primer ciclo de QT Neoadyuvante con Cisplatino (75 mg/m2), Docetaxel (75 mg/m2) y 5-Fluorouracilo (750 mg/m2). Evolución A los 5 días del primer ciclo de QT presentó una importante toxicidad, con enteritis e insuficiencia renal prerrenal, anemia que precisó trasfusión y mucositis. Se realizó un análisis genético para las mutaciones de las enzimas que catabolizan el 5-Fluorouracilo (5-FU), obteniendo como resultado heterocigoto para MTHFR C677T lo que le produce una intolerancia a la administracion de 5-FU. Ante la toxicidad se cambia el esquema a CPT-11 (Irinotecan 125 mg/m2) semanal administrando 4 dosis del 1 de abril al 22 de Abril, con moderada tolerancia ya que durante la administración comienza con hiperbilirrubinemia y aumento de las enzimas hepáticas sin encontrar otra etiología que el tratamiento quimioterápico. Al mes de finalizar la QT vuelve a consultas de Oncología Médica con Análisis donde sólo se observa leve anemia con Hb de 11.1, mejoría de la función hepática y marcadores tumorales negativos, con un TAC donde se observa la masa en el estómago y las adenopatías retroperitoneales sin cambios; y el PET-TAC donde capta la masa en el estómago y no captan las adenopatías. Por todo esto se define como Enfermedad Estable, relacionando las adenopatías a su antecedente de enfermedad por el VIH y no a la enfermedad tumoral, por lo que se decide intervención quirúrgica. El 13/06/2011 le realizan gastrectomía parcial del 70%, linfadenectomía D2 y omentectomia. Con resultado de anatomía patológica de Adenocarcinoma pobremente diferenciado y áreas de moderadamente diferenciado, afectando a la capa muscular, con bordes de resección libres y con 47 ganglios libres de metástasis. Estadiaje definitivo ypT2 ypN0. Estadio IB. Ante la mala tolerancia al tratamiento quimioterápico se decide no dar quimioterapia adyuvante, y desde entonces pasa a controles. Actualmente sin evidencia de enfermedad a 5 años de la cirugía, en control anual con TAC, análisis y marcadores tumorales. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Varón de 48 años. ANTECEDENTES PERSONALES: Alergia a Cefuroxima y Septrim (reacción cutánea). Fumador de 15 paquete/año y bebedor de 2 vinos a la semana. VIH + desde 1992 en control por Unidad de Enfermedades Infecciosas (UEI) con estadio C3 del CDC; en 1994 varios ingresos por neumonías de repetición (bacterianas y por Pneumocystis carinii), tuberculosis pulmonar y ganglionar. Tratamiento habitual: Raltegravir 400 1/12h, Maraviroc 150 1/12h, Ritonavir 100 1/24h, Darunavir 400 2/24h, Hierro oral antes del desayuno, Omeprazol 40 mg/24 h. ENFERMEDAD ACTUAL: En Febrero de 2011, acude a revisión en consultas de UEI y comenta la aparición de cierto grado de astenia progresiva con epigastralgia desde hace varios meses, acompañado desde el último mes de deposiciones melénicas, por lo que le realizan un análisis objetivando una hemoglobina (Hb) de 4.7, por lo que deciden ingreso para estudio. Exploración física Estable hemodinámicamente, afebril. Consciente, orientado, bien hidratado y perfundido, eupneico. Palidez cutaneo-mucosa. AC: Rítmica. AP: Murmullo vesicular conservado. Abdomen: Blando, depresible, leve dolor en región epigástrico a la palpación profunda con sensación de masa a dicho nivel. No signos de irritación peritoneal. Peristaltismo presente. Extremidades inferiores: No edemas ni signos de trombosis venosa profunda. Pruebas complementarias - ANÁLISIS (07/02/2011): Albúmina 31.2, PCR 14.4, Hb 4.7, Plaquetas 418000, Leucocitos 9380, Neutrófilos 5720. Coagulación normal. - MARCADORES TUMORALES: Antígeno Carcinoembrionario (CEA); CA 125 y Ca 19.9: Negativos. - GASTROSCOPIA: Gran masa ulcerada en la curvadura menor de aspecto neoplásico, con toma de biopsias de la zona sospechosa. - ANATOMÍA PATOLÓGICA: Biopsia gástrica positiva para Adenocarcinoma. - TAC ABDOMINO-PÉLVICO: Masa a nivel de curvadura menor del estómago, con adenopatías en ligamento gastrohepático, tronco celíaco y espacio portocava. - ECOGRAFÍA ABADOMINAL: Hemangioma hepático en segmento V. - TAC TORÁCICO: Sin evidencia de patología. Diagnóstico Adenocarcinoma gástrico localmente avanzado cT2 (dudosa M1 por adenopatías retroperitoneales por TAC). Tratamiento En el Comité de tumores Gastroesofágicos se decidió que ante la presencia de masa voluminosa y de las adenopatías, se pidiera un PET-TAC para ver el comportamiento de las adenopatías, si captaban se comenzaría con Quimioterapia paliativa por considerarse éstas como metástasis; si no captaban se comenzaría con QT neoadyuvante y tras revalorar el caso se plantearía intervención quirúrgica. - PET-TAC (02/03/2011): Se observa captación a nivel gástrico sin que capten las adenopatías retroperitoneales. El 28/02/2011 comenza tratamiento con el primer ciclo de QT Neoadyuvante con Cisplatino (75 mg/m2), Docetaxel (75 mg/m2) y 5-Fluorouracilo (750 mg/m2). Evolución A los 5 días del primer ciclo de QT presentó una importante toxicidad, con enteritis e insuficiencia renal prerrenal, anemia que precisó trasfusión y mucositis. Se realizó un análisis genético para las mutaciones de las enzimas que catabolizan el 5-Fluorouracilo (5-FU), obteniendo como resultado heterocigoto para MTHFR C677T lo que le produce una intolerancia a la administracion de 5-FU. Ante la toxicidad se cambia el esquema a CPT-11 (Irinotecan 125 mg/m2) semanal administrando 4 dosis del 1 de abril al 22 de Abril, con moderada tolerancia ya que durante la administración comienza con hiperbilirrubinemia y aumento de las enzimas hepáticas sin encontrar otra etiología que el tratamiento quimioterápico. Al mes de finalizar la QT vuelve a consultas de Oncología Médica con Análisis donde sólo se observa leve anemia con Hb de 11.1, mejoría de la función hepática y marcadores tumorales negativos, con un TAC donde se observa la masa en el estómago y las adenopatías retroperitoneales sin cambios; y el PET-TAC donde capta la masa en el estómago y no captan las adenopatías. Por todo esto se define como Enfermedad Estable, relacionando las adenopatías a su antecedente de enfermedad por el VIH y no a la enfermedad tumoral, por lo que se decide intervención quirúrgica. El 13/06/2011 le realizan gastrectomía parcial del 70%, linfadenectomía D2 y omentectomia. Con resultado de anatomía patológica de Adenocarcinoma pobremente diferenciado y áreas de moderadamente diferenciado, afectando a la capa muscular, con bordes de resección libres y con 47 ganglios libres de metástasis. Estadiaje definitivo ypT2 ypN0. Estadio IB. Ante la mala tolerancia al tratamiento quimioterápico se decide no dar quimioterapia adyuvante, y desde entonces pasa a controles. Actualmente sin evidencia de enfermedad a 5 años de la cirugía, en control anual con TAC, análisis y marcadores tumorales.

[ "Anamnesis", "\n", "Varón", "de", "48", "años", ".", "\n\n", "ANTECEDENTES", "PERSONALES", ":", "Alergia", "a", "Cefuroxima", "y", "Septrim", "(", "reacción", "cutánea", ")", ".", "Fumador", "de", "15", "paquete", "/", "año", "y", "bebedor", "de", "2", "vinos", "a", "la", "semana", ".", "VIH", "+", "desde", "1992", "en", "control", "por", "Unidad", "de", "Enfermedades", "Infecciosas", "(", "UEI", ")", "con", "estadio", "C3", "del", "CDC", ";", "en", "1994", "varios", "ingresos", "por", "neumonías", "de", "repetición", "(", "bacterianas", "y", "por", "Pneumocystis", "carinii", ")", ",", "tuberculosis", "pulmonar", "y", "ganglionar", ".", "Tratamiento", "habitual", ":", "Raltegravir", "400", "1/12h", ",", "Maraviroc", "150", "1/12h", ",", "Ritonavir", "100", "1/24h", ",", "Darunavir", "400", "2/24h", ",", "Hierro", "oral", "antes", "del", "desayuno", ",", "Omeprazol", "40", "mg/24", "h.", "\n\n", "ENFERMEDAD", "ACTUAL", ":", "\n", "En", "Febrero", "de", "2011", ",", "acude", "a", "revisión", "en", "consultas", "de", "UEI", "y", "comenta", "la", "aparición", "de", "cierto", "grado", "de", "astenia", "progresiva", "con", "epigastralgia", "desde", "hace", "varios", "meses", ",", "acompañado", "desde", "el", "último", "mes", "de", "deposiciones", "melénicas", ",", "por", "lo", "que", "le", "realizan", "un", "análisis", "objetivando", "una", "hemoglobina", "(", "Hb", ")", "de", "4.7", ",", "por", "lo", "que", "deciden", "ingreso", "para", "estudio", ".", "\n\n", "Exploración", "física", "\n", "Estable", "hemodinámicamente", ",", "afebril", ".", "Consciente", ",", "orientado", ",", "bien", "hidratado", "y", "perfundido", ",", "eupneico", ".", "Palidez", "cutaneo", "-", "mucosa", ".", "AC", ":", "Rítmica", ".", "AP", ":", "Murmullo", "vesicular", "conservado", ".", "Abdomen", ":", "Blando", ",", "depresible", ",", "leve", "dolor", "en", "región", "epigástrico", "a", "la", "palpación", "profunda", "con", "sensación", "de", "masa", "a", "dicho", "nivel", ".", "No", "signos", "de", "irritación", "peritoneal", ".", "Peristaltismo", "presente", ".", "Extremidades", "inferiores", ":", "No", "edemas", "ni", "signos", "de", "trombosis", "venosa", "profunda", ".", "\n\n", "Pruebas", "complementarias", "\n", "-", "ANÁLISIS", "(", "07/02/2011", "):", "Albúmina", "31.2", ",", "PCR", "14.4", ",", "Hb", "4.7", ",", "Plaquetas", "418000", ",", "Leucocitos", "9380", ",", "Neutrófilos", "5720", ".", "Coagulación", "normal", ".", "\n", "-", "MARCADORES", "TUMORALES", ":", "Antígeno", "Carcinoembrionario", "(", "CEA", ")", ";", "CA", "125", "y", "Ca", "19.9", ":", "Negativos", ".", "\n", "-", "GASTROSCOPIA", ":", "Gran", "masa", "ulcerada", "en", "la", "curvadura", "menor", "de", "aspecto", "neoplásico", ",", "con", "toma", "de", "biopsias", "de", "la", "zona", "sospechosa", ".", "\n", "-", "ANATOMÍA", "PATOLÓGICA", ":", "Biopsia", "gástrica", "positiva", "para", "Adenocarcinoma", ".", "\n", "-", "TAC", "ABDOMINO", "-", "PÉLVICO", ":", "Masa", "a", "nivel", "de", "curvadura", "menor", "del", "estómago", ",", "con", "adenopatías", "en", "ligamento", "gastrohepático", ",", "tronco", "celíaco", "y", "espacio", "portocava", ".", "\n", "-", "ECOGRAFÍA", "ABADOMINAL", ":", "Hemangioma", "hepático", "en", "segmento", "V.", "\n", "-", "TAC", "TORÁCICO", ":", "Sin", "evidencia", "de", "patología", ".", "\n\n", "Diagnóstico", "\n", "Adenocarcinoma", "gástrico", "localmente", "avanzado", "cT2", "(", "dudosa", "M1", "por", "adenopatías", "retroperitoneales", "por", "TAC", ")", ".", "\n\n", "Tratamiento", "\n", "En", "el", "Comité", "de", "tumores", "Gastroesofágicos", "se", "decidió", "que", "ante", "la", "presencia", "de", "masa", "voluminosa", "y", "de", "las", "adenopatías", ",", "se", "pidiera", "un", "PET", "-", "TAC", "para", "ver", "el", "comportamiento", "de", "las", "adenopatías", ",", "si", "captaban", "se", "comenzaría", "con", "Quimioterapia", "paliativa", "por", "considerarse", "éstas", "como", "metástasis", ";", "si", "no", "captaban", "se", "comenzaría", "con", "QT", "neoadyuvante", "y", "tras", "revalorar", "el", "caso", "se", "plantearía", "intervención", "quirúrgica", ".", "\n", "-", "PET", "-", "TAC", "(", "02/03/2011", "):", "Se", "observa", "captación", "a", "nivel", "gástrico", "sin", "que", "capten", "las", "adenopatías", "retroperitoneales", ".", "\n", "El", "28/02/2011", "comenza", "tratamiento", "con", "el", "primer", "ciclo", "de", "QT", "Neoadyuvante", "con", "Cisplatino", "(", "75", "mg", "/", "m2", ")", ",", "Docetaxel", "(", "75", "mg", "/", "m2", ")", "y", "5-Fluorouracilo", "(", "750", "mg", "/", "m2", ")", ".", "\n\n", "Evolución", "\n", "A", "los", "5", "días", "del", "primer", "ciclo", "de", "QT", "presentó", "una", "importante", "toxicidad", ",", "con", "enteritis", "e", "insuficiencia", "renal", "prerrenal", ",", "anemia", "que", "precisó", "trasfusión", "y", "mucositis", ".", "Se", "realizó", "un", "análisis", "genético", "para", "las", "mutaciones", "de", "las", "enzimas", "que", "catabolizan", "el", "5-Fluorouracilo", "(", "5-FU", ")", ",", "obteniendo", "como", "resultado", "heterocigoto", "para", "MTHFR", "C677", "T", "lo", "que", "le", "produce", "una", "intolerancia", "a", "la", "administracion", "de", "5-FU", ".", "\n", "Ante", "la", "toxicidad", "se", "cambia", "el", "esquema", "a", "CPT-11", "(", "Irinotecan", "125", "mg", "/", "m2", ")", "semanal", "administrando", "4", "dosis", "del", "1", "de", "abril", "al", "22", "de", "Abril", ",", "con", "moderada", "tolerancia", "ya", "que", "durante", "la", "administración", "comienza", "con", "hiperbilirrubinemia", "y", "aumento", "de", "las", "enzimas", "hepáticas", "sin", "encontrar", "otra", "etiología", "que", "el", "tratamiento", "quimioterápico", ".", "\n", "Al", "mes", "de", "finalizar", "la", "QT", "vuelve", "a", "consultas", "de", "Oncología", "Médica", "con", "Análisis", "donde", "sólo", "se", "observa", "leve", "anemia", "con", "Hb", "de", "11.1", ",", "mejoría", "de", "la", "función", "hepática", "y", "marcadores", "tumorales", "negativos", ",", "con", "un", "TAC", "donde", "se", "observa", "la", "masa", "en", "el", "estómago", "y", "las", "adenopatías", "retroperitoneales", "sin", "cambios", ";", "y", "el", "PET", "-", "TAC", "donde", "capta", "la", "masa", "en", "el", "estómago", "y", "no", "captan", "las", "adenopatías", ".", "\n", "Por", "todo", "esto", "se", "define", "como", "Enfermedad", "Estable", ",", "relacionando", "las", "adenopatías", "a", "su", "antecedente", "de", "enfermedad", "por", "el", "VIH", "y", "no", "a", "la", "enfermedad", "tumoral", ",", "por", "lo", "que", "se", "decide", "intervención", "quirúrgica", ".", "\n", "El", "13/06/2011", "le", "realizan", "gastrectomía", "parcial", "del", "70", "%", ",", "linfadenectomía", "D2", "y", "omentectomia", ".", "Con", "resultado", "de", "anatomía", "patológica", "de", "Adenocarcinoma", "pobremente", "diferenciado", "y", "áreas", "de", "moderadamente", "diferenciado", ",", "afectando", "a", "la", "capa", "muscular", ",", "con", "bordes", "de", "resección", "libres", "y", "con", "47", "ganglios", "libres", "de", "metástasis", ".", "Estadiaje", "definitivo", "ypT2", "ypN0", ".", "Estadio", "IB", ".", "\n", "Ante", "la", "mala", "tolerancia", "al", "tratamiento", "quimioterápico", "se", "decide", "no", "dar", "quimioterapia", "adyuvante", ",", "y", "desde", "entonces", "pasa", "a", "controles", ".", "\n", "Actualmente", "sin", "evidencia", "de", "enfermedad", "a", "5", "años", "de", "la", "cirugía", ",", "en", "control", "anual", "con", "TAC", ",", "análisis", "y", "marcadores", "tumorales", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

dorzolamide is a DRUG, carbonic anhydrase inhibitors is a GROUP, salicylate is a GROUP, dorzolamide is a DRUG

Dorzolamide_ddi_task0

Sentence: Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). Therefore, the potential for such drug interactions should be considered in patients receiving dorzolamide. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, DRUG

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O" ]

Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). Therefore, the potential for such drug interactions should be considered in patients receiving dorzolamide.

[ "Although", "acid", "-", "base", "and", "electrolyte", "disturbances", "were", "not", "reported", "in", "the", "clinical", "trials", "with", "dorzolamide", ",", "these", "disturbances", "have", "been", "reported", "with", "oral", "carbonic", "anhydrase", "inhibitors", "and", "have", ",", "in", "some", "instances", ",", "resulted", "in", "drug", "interactions", "(", "e.g", ".", ",", "toxicity", "associated", "with", "high", "-", "dose", "salicylate", "therapy", ")", ".", "Therefore", ",", "the", "potential", "for", "such", "drug", "interactions", "should", "be", "considered", "in", "patients", "receiving", "dorzolamide", "." ]

[ "GROUP", "DRUG" ]

dorzolamide is a DRUG, carbonic anhydrase inhibitors is a GROUP, salicylate is a GROUP, dorzolamide is a DRUG

Dorzolamide_ddi_task1

Sentence: Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). Therefore, the potential for such drug interactions should be considered in patients receiving dorzolamide. Instructions: please typing these entity words according to sentence: dorzolamide, carbonic anhydrase inhibitors, salicylate, dorzolamide Options: GROUP, DRUG

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O" ]

Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). Therefore, the potential for such drug interactions should be considered in patients receiving dorzolamide.

[ "Although", "acid", "-", "base", "and", "electrolyte", "disturbances", "were", "not", "reported", "in", "the", "clinical", "trials", "with", "dorzolamide", ",", "these", "disturbances", "have", "been", "reported", "with", "oral", "carbonic", "anhydrase", "inhibitors", "and", "have", ",", "in", "some", "instances", ",", "resulted", "in", "drug", "interactions", "(", "e.g", ".", ",", "toxicity", "associated", "with", "high", "-", "dose", "salicylate", "therapy", ")", ".", "Therefore", ",", "the", "potential", "for", "such", "drug", "interactions", "should", "be", "considered", "in", "patients", "receiving", "dorzolamide", "." ]

[ "GROUP", "DRUG" ]

dorzolamide, carbonic anhydrase inhibitors, salicylate, dorzolamide

Dorzolamide_ddi_task2

Sentence: Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). Therefore, the potential for such drug interactions should be considered in patients receiving dorzolamide. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O" ]

Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). Therefore, the potential for such drug interactions should be considered in patients receiving dorzolamide.

[ "Although", "acid", "-", "base", "and", "electrolyte", "disturbances", "were", "not", "reported", "in", "the", "clinical", "trials", "with", "dorzolamide", ",", "these", "disturbances", "have", "been", "reported", "with", "oral", "carbonic", "anhydrase", "inhibitors", "and", "have", ",", "in", "some", "instances", ",", "resulted", "in", "drug", "interactions", "(", "e.g", ".", ",", "toxicity", "associated", "with", "high", "-", "dose", "salicylate", "therapy", ")", ".", "Therefore", ",", "the", "potential", "for", "such", "drug", "interactions", "should", "be", "considered", "in", "patients", "receiving", "dorzolamide", "." ]

[ "GROUP", "DRUG" ]

glycan is a compound, voltage - gated potassium channels is a protein

DS.d1843_task0

Sentence: Atypical sialylated N-glycan structures are attached to neuronal voltage-gated potassium channels. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O" ]

Atypical sialylated N-glycan structures are attached to neuronal voltage-gated potassium channels.

[ "Atypical", "sialylated", "N", "-", "glycan", "structures", "are", "attached", "to", "neuronal", "voltage", "-", "gated", "potassium", "channels", "." ]

[ "protein", "compound" ]

glycan is a compound, voltage - gated potassium channels is a protein

DS.d1843_task1

Sentence: Atypical sialylated N-glycan structures are attached to neuronal voltage-gated potassium channels. Instructions: please typing these entity words according to sentence: glycan, voltage - gated potassium channels Options: compound, protein

[ "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O" ]

Atypical sialylated N-glycan structures are attached to neuronal voltage-gated potassium channels.

[ "Atypical", "sialylated", "N", "-", "glycan", "structures", "are", "attached", "to", "neuronal", "voltage", "-", "gated", "potassium", "channels", "." ]

[ "protein", "compound" ]

glycan, voltage - gated potassium channels

DS.d1843_task2

Sentence: Atypical sialylated N-glycan structures are attached to neuronal voltage-gated potassium channels. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O" ]

Atypical sialylated N-glycan structures are attached to neuronal voltage-gated potassium channels.

[ "Atypical", "sialylated", "N", "-", "glycan", "structures", "are", "attached", "to", "neuronal", "voltage", "-", "gated", "potassium", "channels", "." ]

[ "protein", "compound" ]

antidepressants is a GROUP, antidepressant drugs is a GROUP, hypoglycemic agents is a GROUP, antidepressant agents is a GROUP, antidepressants is a GROUP, Imipramine is a DRUG, moclobemide is a DRUG, clonazepam is a DRUG, fluoxetine is a DRUG, sertraline is a DRUG, glucose is a DRUG, glucose is a DRUG, Imipramine is a DRUG, clonazepam is a DRUG, Fluoxetine is a DRUG, moclobemide is a DRUG, glucose is a DRUG, Sertraline is a DRUG, glucose is a DRUG, glucose is a DRUG, glucose is a DRUG, sertraline is a DRUG, glucose is a DRUG, sertraline is a DRUG, Clonazepam is a DRUG

11151029_task0

Sentence: Acute effect of different antidepressants on glycemia in diabetic and non-diabetic rats. Diabetic patients have a 20% higher risk of depression than the general population. Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents. The treatment of depression in diabetic patients must take into account variations of glycemic levels at different times and a comparison of the available antidepressant agents is important. In the present study we evaluated the interference of antidepressants with blood glucose levels of diabetic and non-diabetic rats. In a first experiment, male adult Wistar rats were fasted for 12 h. Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. After 30 min, fasting glycemia was measured. An oral glucose overload of 1 ml of a 50% glucose solution was given to rats and blood glucose was determined after 30, 60 and 90 min. Imipramine and clonazepam did not change fasting or overload glycemia. Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. Sertraline neutralized the increase of glycemia induced by oral glucose overload. In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of glucose tolerance 30 min after glucose overload. Again, sertraline neutralized the increase in glycemia after glucose overload both in diabetic and non-diabetic rats. These data raise the question of whether sertraline is the best choice for prolonged use for diabetic individuals, because of its antihyperglycemic effects. Clonazepam would be useful in cases with potential risk of hypoglycemia. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, DRUG

[ "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Acute effect of different antidepressants on glycemia in diabetic and non-diabetic rats. Diabetic patients have a 20% higher risk of depression than the general population. Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents. The treatment of depression in diabetic patients must take into account variations of glycemic levels at different times and a comparison of the available antidepressant agents is important. In the present study we evaluated the interference of antidepressants with blood glucose levels of diabetic and non-diabetic rats. In a first experiment, male adult Wistar rats were fasted for 12 h. Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. After 30 min, fasting glycemia was measured. An oral glucose overload of 1 ml of a 50% glucose solution was given to rats and blood glucose was determined after 30, 60 and 90 min. Imipramine and clonazepam did not change fasting or overload glycemia. Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. Sertraline neutralized the increase of glycemia induced by oral glucose overload. In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of glucose tolerance 30 min after glucose overload. Again, sertraline neutralized the increase in glycemia after glucose overload both in diabetic and non-diabetic rats. These data raise the question of whether sertraline is the best choice for prolonged use for diabetic individuals, because of its antihyperglycemic effects. Clonazepam would be useful in cases with potential risk of hypoglycemia.

[ "Acute", "effect", "of", "different", "antidepressants", "on", "glycemia", "in", "diabetic", "and", "non", "-", "diabetic", "rats", ".", "Diabetic", "patients", "have", "a", "20", "%", "higher", "risk", "of", "depression", "than", "the", "general", "population", ".", "Treatment", "with", "antidepressant", "drugs", "can", "directly", "interfere", "with", "blood", "glucose", "levels", "or", "may", "interact", "with", "hypoglycemic", "agents", ".", "The", "treatment", "of", "depression", "in", "diabetic", "patients", "must", "take", "into", "account", "variations", "of", "glycemic", "levels", "at", "different", "times", "and", "a", "comparison", "of", "the", "available", "antidepressant", "agents", "is", "important", ".", "In", "the", "present", "study", "we", "evaluated", "the", "interference", "of", "antidepressants", "with", "blood", "glucose", "levels", "of", "diabetic", "and", "non", "-", "diabetic", "rats", ".", "In", "a", "first", "experiment", ",", "male", "adult", "Wistar", "rats", "were", "fasted", "for", "12", "h.", "Imipramine", "(", "5", "mg", "/", "kg", ")", ",", "moclobemide", "(", "30", "mg", "/", "kg", ")", ",", "clonazepam", "(", "0.25", "mg", "/", "kg", ")", ",", "fluoxetine", "(", "20", "mg", "/", "kg", ")", "sertraline", "(", "30", "mg", "/", "kg", ")", "or", "vehicle", "was", "administered", ".", "After", "30", "min", ",", "fasting", "glycemia", "was", "measured", ".", "An", "oral", "glucose", "overload", "of", "1", "ml", "of", "a", "50", "%", "glucose", "solution", "was", "given", "to", "rats", "and", "blood", "glucose", "was", "determined", "after", "30", ",", "60", "and", "90", "min", ".", "Imipramine", "and", "clonazepam", "did", "not", "change", "fasting", "or", "overload", "glycemia", ".", "Fluoxetine", "and", "moclobemide", "increased", "blood", "glucose", "at", "different", "times", "after", "the", "glucose", "overload", ".", "Sertraline", "neutralized", "the", "increase", "of", "glycemia", "induced", "by", "oral", "glucose", "overload", ".", "In", "the", "second", "experiment", ",", "non", "-", "diabetic", "and", "streptozotocin", "-", "induced", "diabetic", "rats", "were", "fasted", ",", "and", "the", "same", "procedures", "were", "followed", "for", "estimation", "of", "glucose", "tolerance", "30", "min", "after", "glucose", "overload", ".", "Again", ",", "sertraline", "neutralized", "the", "increase", "in", "glycemia", "after", "glucose", "overload", "both", "in", "diabetic", "and", "non", "-", "diabetic", "rats", ".", "These", "data", "raise", "the", "question", "of", "whether", "sertraline", "is", "the", "best", "choice", "for", "prolonged", "use", "for", "diabetic", "individuals", ",", "because", "of", "its", "antihyperglycemic", "effects", ".", "Clonazepam", "would", "be", "useful", "in", "cases", "with", "potential", "risk", "of", "hypoglycemia", "." ]

[ "GROUP", "DRUG" ]

antidepressants is a GROUP, antidepressant drugs is a GROUP, hypoglycemic agents is a GROUP, antidepressant agents is a GROUP, antidepressants is a GROUP, Imipramine is a DRUG, moclobemide is a DRUG, clonazepam is a DRUG, fluoxetine is a DRUG, sertraline is a DRUG, glucose is a DRUG, glucose is a DRUG, Imipramine is a DRUG, clonazepam is a DRUG, Fluoxetine is a DRUG, moclobemide is a DRUG, glucose is a DRUG, Sertraline is a DRUG, glucose is a DRUG, glucose is a DRUG, glucose is a DRUG, sertraline is a DRUG, glucose is a DRUG, sertraline is a DRUG, Clonazepam is a DRUG

11151029_task1

Sentence: Acute effect of different antidepressants on glycemia in diabetic and non-diabetic rats. Diabetic patients have a 20% higher risk of depression than the general population. Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents. The treatment of depression in diabetic patients must take into account variations of glycemic levels at different times and a comparison of the available antidepressant agents is important. In the present study we evaluated the interference of antidepressants with blood glucose levels of diabetic and non-diabetic rats. In a first experiment, male adult Wistar rats were fasted for 12 h. Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. After 30 min, fasting glycemia was measured. An oral glucose overload of 1 ml of a 50% glucose solution was given to rats and blood glucose was determined after 30, 60 and 90 min. Imipramine and clonazepam did not change fasting or overload glycemia. Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. Sertraline neutralized the increase of glycemia induced by oral glucose overload. In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of glucose tolerance 30 min after glucose overload. Again, sertraline neutralized the increase in glycemia after glucose overload both in diabetic and non-diabetic rats. These data raise the question of whether sertraline is the best choice for prolonged use for diabetic individuals, because of its antihyperglycemic effects. Clonazepam would be useful in cases with potential risk of hypoglycemia. Instructions: please typing these entity words according to sentence: antidepressants, antidepressant drugs, hypoglycemic agents, antidepressant agents, antidepressants, Imipramine, moclobemide, clonazepam, fluoxetine, sertraline, glucose, glucose, Imipramine, clonazepam, Fluoxetine, moclobemide, glucose, Sertraline, glucose, glucose, glucose, sertraline, glucose, sertraline, Clonazepam Options: GROUP, DRUG

[ "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Acute effect of different antidepressants on glycemia in diabetic and non-diabetic rats. Diabetic patients have a 20% higher risk of depression than the general population. Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents. The treatment of depression in diabetic patients must take into account variations of glycemic levels at different times and a comparison of the available antidepressant agents is important. In the present study we evaluated the interference of antidepressants with blood glucose levels of diabetic and non-diabetic rats. In a first experiment, male adult Wistar rats were fasted for 12 h. Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. After 30 min, fasting glycemia was measured. An oral glucose overload of 1 ml of a 50% glucose solution was given to rats and blood glucose was determined after 30, 60 and 90 min. Imipramine and clonazepam did not change fasting or overload glycemia. Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. Sertraline neutralized the increase of glycemia induced by oral glucose overload. In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of glucose tolerance 30 min after glucose overload. Again, sertraline neutralized the increase in glycemia after glucose overload both in diabetic and non-diabetic rats. These data raise the question of whether sertraline is the best choice for prolonged use for diabetic individuals, because of its antihyperglycemic effects. Clonazepam would be useful in cases with potential risk of hypoglycemia.

[ "Acute", "effect", "of", "different", "antidepressants", "on", "glycemia", "in", "diabetic", "and", "non", "-", "diabetic", "rats", ".", "Diabetic", "patients", "have", "a", "20", "%", "higher", "risk", "of", "depression", "than", "the", "general", "population", ".", "Treatment", "with", "antidepressant", "drugs", "can", "directly", "interfere", "with", "blood", "glucose", "levels", "or", "may", "interact", "with", "hypoglycemic", "agents", ".", "The", "treatment", "of", "depression", "in", "diabetic", "patients", "must", "take", "into", "account", "variations", "of", "glycemic", "levels", "at", "different", "times", "and", "a", "comparison", "of", "the", "available", "antidepressant", "agents", "is", "important", ".", "In", "the", "present", "study", "we", "evaluated", "the", "interference", "of", "antidepressants", "with", "blood", "glucose", "levels", "of", "diabetic", "and", "non", "-", "diabetic", "rats", ".", "In", "a", "first", "experiment", ",", "male", "adult", "Wistar", "rats", "were", "fasted", "for", "12", "h.", "Imipramine", "(", "5", "mg", "/", "kg", ")", ",", "moclobemide", "(", "30", "mg", "/", "kg", ")", ",", "clonazepam", "(", "0.25", "mg", "/", "kg", ")", ",", "fluoxetine", "(", "20", "mg", "/", "kg", ")", "sertraline", "(", "30", "mg", "/", "kg", ")", "or", "vehicle", "was", "administered", ".", "After", "30", "min", ",", "fasting", "glycemia", "was", "measured", ".", "An", "oral", "glucose", "overload", "of", "1", "ml", "of", "a", "50", "%", "glucose", "solution", "was", "given", "to", "rats", "and", "blood", "glucose", "was", "determined", "after", "30", ",", "60", "and", "90", "min", ".", "Imipramine", "and", "clonazepam", "did", "not", "change", "fasting", "or", "overload", "glycemia", ".", "Fluoxetine", "and", "moclobemide", "increased", "blood", "glucose", "at", "different", "times", "after", "the", "glucose", "overload", ".", "Sertraline", "neutralized", "the", "increase", "of", "glycemia", "induced", "by", "oral", "glucose", "overload", ".", "In", "the", "second", "experiment", ",", "non", "-", "diabetic", "and", "streptozotocin", "-", "induced", "diabetic", "rats", "were", "fasted", ",", "and", "the", "same", "procedures", "were", "followed", "for", "estimation", "of", "glucose", "tolerance", "30", "min", "after", "glucose", "overload", ".", "Again", ",", "sertraline", "neutralized", "the", "increase", "in", "glycemia", "after", "glucose", "overload", "both", "in", "diabetic", "and", "non", "-", "diabetic", "rats", ".", "These", "data", "raise", "the", "question", "of", "whether", "sertraline", "is", "the", "best", "choice", "for", "prolonged", "use", "for", "diabetic", "individuals", ",", "because", "of", "its", "antihyperglycemic", "effects", ".", "Clonazepam", "would", "be", "useful", "in", "cases", "with", "potential", "risk", "of", "hypoglycemia", "." ]

[ "GROUP", "DRUG" ]

antidepressants, antidepressant drugs, hypoglycemic agents, antidepressant agents, antidepressants, Imipramine, moclobemide, clonazepam, fluoxetine, sertraline, glucose, glucose, Imipramine, clonazepam, Fluoxetine, moclobemide, glucose, Sertraline, glucose, glucose, glucose, sertraline, glucose, sertraline, Clonazepam

11151029_task2

Sentence: Acute effect of different antidepressants on glycemia in diabetic and non-diabetic rats. Diabetic patients have a 20% higher risk of depression than the general population. Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents. The treatment of depression in diabetic patients must take into account variations of glycemic levels at different times and a comparison of the available antidepressant agents is important. In the present study we evaluated the interference of antidepressants with blood glucose levels of diabetic and non-diabetic rats. In a first experiment, male adult Wistar rats were fasted for 12 h. Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. After 30 min, fasting glycemia was measured. An oral glucose overload of 1 ml of a 50% glucose solution was given to rats and blood glucose was determined after 30, 60 and 90 min. Imipramine and clonazepam did not change fasting or overload glycemia. Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. Sertraline neutralized the increase of glycemia induced by oral glucose overload. In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of glucose tolerance 30 min after glucose overload. Again, sertraline neutralized the increase in glycemia after glucose overload both in diabetic and non-diabetic rats. These data raise the question of whether sertraline is the best choice for prolonged use for diabetic individuals, because of its antihyperglycemic effects. Clonazepam would be useful in cases with potential risk of hypoglycemia. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Acute effect of different antidepressants on glycemia in diabetic and non-diabetic rats. Diabetic patients have a 20% higher risk of depression than the general population. Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents. The treatment of depression in diabetic patients must take into account variations of glycemic levels at different times and a comparison of the available antidepressant agents is important. In the present study we evaluated the interference of antidepressants with blood glucose levels of diabetic and non-diabetic rats. In a first experiment, male adult Wistar rats were fasted for 12 h. Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. After 30 min, fasting glycemia was measured. An oral glucose overload of 1 ml of a 50% glucose solution was given to rats and blood glucose was determined after 30, 60 and 90 min. Imipramine and clonazepam did not change fasting or overload glycemia. Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. Sertraline neutralized the increase of glycemia induced by oral glucose overload. In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of glucose tolerance 30 min after glucose overload. Again, sertraline neutralized the increase in glycemia after glucose overload both in diabetic and non-diabetic rats. These data raise the question of whether sertraline is the best choice for prolonged use for diabetic individuals, because of its antihyperglycemic effects. Clonazepam would be useful in cases with potential risk of hypoglycemia.

[ "Acute", "effect", "of", "different", "antidepressants", "on", "glycemia", "in", "diabetic", "and", "non", "-", "diabetic", "rats", ".", "Diabetic", "patients", "have", "a", "20", "%", "higher", "risk", "of", "depression", "than", "the", "general", "population", ".", "Treatment", "with", "antidepressant", "drugs", "can", "directly", "interfere", "with", "blood", "glucose", "levels", "or", "may", "interact", "with", "hypoglycemic", "agents", ".", "The", "treatment", "of", "depression", "in", "diabetic", "patients", "must", "take", "into", "account", "variations", "of", "glycemic", "levels", "at", "different", "times", "and", "a", "comparison", "of", "the", "available", "antidepressant", "agents", "is", "important", ".", "In", "the", "present", "study", "we", "evaluated", "the", "interference", "of", "antidepressants", "with", "blood", "glucose", "levels", "of", "diabetic", "and", "non", "-", "diabetic", "rats", ".", "In", "a", "first", "experiment", ",", "male", "adult", "Wistar", "rats", "were", "fasted", "for", "12", "h.", "Imipramine", "(", "5", "mg", "/", "kg", ")", ",", "moclobemide", "(", "30", "mg", "/", "kg", ")", ",", "clonazepam", "(", "0.25", "mg", "/", "kg", ")", ",", "fluoxetine", "(", "20", "mg", "/", "kg", ")", "sertraline", "(", "30", "mg", "/", "kg", ")", "or", "vehicle", "was", "administered", ".", "After", "30", "min", ",", "fasting", "glycemia", "was", "measured", ".", "An", "oral", "glucose", "overload", "of", "1", "ml", "of", "a", "50", "%", "glucose", "solution", "was", "given", "to", "rats", "and", "blood", "glucose", "was", "determined", "after", "30", ",", "60", "and", "90", "min", ".", "Imipramine", "and", "clonazepam", "did", "not", "change", "fasting", "or", "overload", "glycemia", ".", "Fluoxetine", "and", "moclobemide", "increased", "blood", "glucose", "at", "different", "times", "after", "the", "glucose", "overload", ".", "Sertraline", "neutralized", "the", "increase", "of", "glycemia", "induced", "by", "oral", "glucose", "overload", ".", "In", "the", "second", "experiment", ",", "non", "-", "diabetic", "and", "streptozotocin", "-", "induced", "diabetic", "rats", "were", "fasted", ",", "and", "the", "same", "procedures", "were", "followed", "for", "estimation", "of", "glucose", "tolerance", "30", "min", "after", "glucose", "overload", ".", "Again", ",", "sertraline", "neutralized", "the", "increase", "in", "glycemia", "after", "glucose", "overload", "both", "in", "diabetic", "and", "non", "-", "diabetic", "rats", ".", "These", "data", "raise", "the", "question", "of", "whether", "sertraline", "is", "the", "best", "choice", "for", "prolonged", "use", "for", "diabetic", "individuals", ",", "because", "of", "its", "antihyperglycemic", "effects", ".", "Clonazepam", "would", "be", "useful", "in", "cases", "with", "potential", "risk", "of", "hypoglycemia", "." ]

[ "GROUP", "DRUG" ]

ecstasy is a CHEMICAL

23532375_task0

Sentence: ERP evidence suggests executive dysfunction in ecstasy polydrug users. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O" ]

ERP evidence suggests executive dysfunction in ecstasy polydrug users.

[ "ERP", "evidence", "suggests", "executive", "dysfunction", "in", "ecstasy", "polydrug", "users", "." ]

[ "CHEMICAL" ]

ecstasy is a CHEMICAL

23532375_task1

Sentence: ERP evidence suggests executive dysfunction in ecstasy polydrug users. Instructions: please typing these entity words according to sentence: ecstasy Options: CHEMICAL

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O" ]

ERP evidence suggests executive dysfunction in ecstasy polydrug users.

[ "ERP", "evidence", "suggests", "executive", "dysfunction", "in", "ecstasy", "polydrug", "users", "." ]

[ "CHEMICAL" ]

ecstasy

23532375_task2

Sentence: ERP evidence suggests executive dysfunction in ecstasy polydrug users. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O" ]

ERP evidence suggests executive dysfunction in ecstasy polydrug users.

[ "ERP", "evidence", "suggests", "executive", "dysfunction", "in", "ecstasy", "polydrug", "users", "." ]

[ "CHEMICAL" ]

beta - globin is a Protein, locus is a Entity, beta - globin is a Protein, gene cluster is a Entity, upstream regulatory sequences is a Entity, locus control region is a Entity, the individual genes of the cluster is a Entity, locus control region is a Entity, gene - proximal regulatory elements is a Entity

597_task0

Sentence: Regulation of the beta-globin locus. Transcription of the human beta-globin gene cluster depends upon upstream regulatory sequences, which are collectively termed the locus control region. Recent studies have provided new insights into how the individual genes of the cluster are regulated through development. The crux of transcriptional activation is how the locus control region communicates with the gene-proximal regulatory elements. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O" ]

Regulation of the beta-globin locus. Transcription of the human beta-globin gene cluster depends upon upstream regulatory sequences, which are collectively termed the locus control region. Recent studies have provided new insights into how the individual genes of the cluster are regulated through development. The crux of transcriptional activation is how the locus control region communicates with the gene-proximal regulatory elements.

[ "Regulation", "of", "the", "beta", "-", "globin", "locus", ".", "\n", "Transcription", "of", "the", "human", "beta", "-", "globin", "gene", "cluster", "depends", "upon", "upstream", "regulatory", "sequences", ",", "which", "are", "collectively", "termed", "the", "locus", "control", "region", ".", "Recent", "studies", "have", "provided", "new", "insights", "into", "how", "the", "individual", "genes", "of", "the", "cluster", "are", "regulated", "through", "development", ".", "The", "crux", "of", "transcriptional", "activation", "is", "how", "the", "locus", "control", "region", "communicates", "with", "the", "gene", "-", "proximal", "regulatory", "elements", ".", "\n" ]

[ "Entity", "Protein" ]

beta - globin is a Protein, locus is a Entity, beta - globin is a Protein, gene cluster is a Entity, upstream regulatory sequences is a Entity, locus control region is a Entity, the individual genes of the cluster is a Entity, locus control region is a Entity, gene - proximal regulatory elements is a Entity

597_task1

Sentence: Regulation of the beta-globin locus. Transcription of the human beta-globin gene cluster depends upon upstream regulatory sequences, which are collectively termed the locus control region. Recent studies have provided new insights into how the individual genes of the cluster are regulated through development. The crux of transcriptional activation is how the locus control region communicates with the gene-proximal regulatory elements. Instructions: please typing these entity words according to sentence: beta - globin, locus, beta - globin, gene cluster, upstream regulatory sequences, locus control region, the individual genes of the cluster, locus control region, gene - proximal regulatory elements Options: Entity, Protein

[ "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O" ]

Regulation of the beta-globin locus. Transcription of the human beta-globin gene cluster depends upon upstream regulatory sequences, which are collectively termed the locus control region. Recent studies have provided new insights into how the individual genes of the cluster are regulated through development. The crux of transcriptional activation is how the locus control region communicates with the gene-proximal regulatory elements.

[ "Regulation", "of", "the", "beta", "-", "globin", "locus", ".", "\n", "Transcription", "of", "the", "human", "beta", "-", "globin", "gene", "cluster", "depends", "upon", "upstream", "regulatory", "sequences", ",", "which", "are", "collectively", "termed", "the", "locus", "control", "region", ".", "Recent", "studies", "have", "provided", "new", "insights", "into", "how", "the", "individual", "genes", "of", "the", "cluster", "are", "regulated", "through", "development", ".", "The", "crux", "of", "transcriptional", "activation", "is", "how", "the", "locus", "control", "region", "communicates", "with", "the", "gene", "-", "proximal", "regulatory", "elements", ".", "\n" ]

[ "Entity", "Protein" ]

beta - globin, locus, beta - globin, gene cluster, upstream regulatory sequences, locus control region, the individual genes of the cluster, locus control region, gene - proximal regulatory elements

597_task2

Sentence: Regulation of the beta-globin locus. Transcription of the human beta-globin gene cluster depends upon upstream regulatory sequences, which are collectively termed the locus control region. Recent studies have provided new insights into how the individual genes of the cluster are regulated through development. The crux of transcriptional activation is how the locus control region communicates with the gene-proximal regulatory elements. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O" ]

Regulation of the beta-globin locus. Transcription of the human beta-globin gene cluster depends upon upstream regulatory sequences, which are collectively termed the locus control region. Recent studies have provided new insights into how the individual genes of the cluster are regulated through development. The crux of transcriptional activation is how the locus control region communicates with the gene-proximal regulatory elements.

[ "Regulation", "of", "the", "beta", "-", "globin", "locus", ".", "\n", "Transcription", "of", "the", "human", "beta", "-", "globin", "gene", "cluster", "depends", "upon", "upstream", "regulatory", "sequences", ",", "which", "are", "collectively", "termed", "the", "locus", "control", "region", ".", "Recent", "studies", "have", "provided", "new", "insights", "into", "how", "the", "individual", "genes", "of", "the", "cluster", "are", "regulated", "through", "development", ".", "The", "crux", "of", "transcriptional", "activation", "is", "how", "the", "locus", "control", "region", "communicates", "with", "the", "gene", "-", "proximal", "regulatory", "elements", ".", "\n" ]

[ "Entity", "Protein" ]

integrin alpha5beta1 is a Gene_or_gene_product, A5 - 1 is a Gene_or_gene_product, Integrin alpha5beta1 is a Gene_or_gene_product, A5 - 1 is a Gene_or_gene_product, VILVLF is a Gene_or_gene_product, integrin alpha5beta1 is a Gene_or_gene_product, A5 - 1 is a Gene_or_gene_product, integrin is a Gene_or_gene_product, fibronectin is a Gene_or_gene_product, human umbilical vein endothelial cell is a Cell, tubular network is a Multi-tissue_structure, bFGF is a Gene_or_gene_product, chick is a Organism, chorioallantoic membrane is a Multi-tissue_structure, A5 - 1 is a Gene_or_gene_product

284_task0

Sentence: A novel integrin alpha5beta1 antagonistic peptide, A5-1, screened by Protein Chip system as a potent angiogenesis inhibitor. Integrin alpha5beta1 immobilized on a ProteoChip was used to screen new antagonistic peptides from multiple hexapeptide sub-libraries of the positional scanning synthetic peptide combinatorial library (PS-SPCL). The integrin alpha5beta1-Fibronectin interaction was demonstrated on the chip. A novel peptide ligand, A5-1 (VILVLF), with high affinity to integrin alpha5beta1 was identified from the hexapeptide libraries with this chip-based screening method on the basis of a competitive inhibition assay. A5-1 inhibits the integrin-fibronectin interaction in a dose-dependent manner (IC(50); 1.56+/-0.28 microM. In addition, it inhibits human umbilical vein endothelial cell proliferation, migration, adhesion, tubular network formation, and bFGF-induced neovascularization in a chick chorioallantoic membrane. These results suggest that A5-1 will be a potent inhibitor of neovascularization. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Multi-tissue_structure, Organism, Gene_or_gene_product, Cell

[ "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Organism", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A novel integrin alpha5beta1 antagonistic peptide, A5-1, screened by Protein Chip system as a potent angiogenesis inhibitor. Integrin alpha5beta1 immobilized on a ProteoChip was used to screen new antagonistic peptides from multiple hexapeptide sub-libraries of the positional scanning synthetic peptide combinatorial library (PS-SPCL). The integrin alpha5beta1-Fibronectin interaction was demonstrated on the chip. A novel peptide ligand, A5-1 (VILVLF), with high affinity to integrin alpha5beta1 was identified from the hexapeptide libraries with this chip-based screening method on the basis of a competitive inhibition assay. A5-1 inhibits the integrin-fibronectin interaction in a dose-dependent manner (IC(50); 1.56+/-0.28 microM. In addition, it inhibits human umbilical vein endothelial cell proliferation, migration, adhesion, tubular network formation, and bFGF-induced neovascularization in a chick chorioallantoic membrane. These results suggest that A5-1 will be a potent inhibitor of neovascularization.

[ "A", "novel", "integrin", "alpha5beta1", "antagonistic", "peptide", ",", "A5", "-", "1", ",", "screened", "by", "Protein", "Chip", "system", "as", "a", "potent", "angiogenesis", "inhibitor", ".", "\n", "Integrin", "alpha5beta1", "immobilized", "on", "a", "ProteoChip", "was", "used", "to", "screen", "new", "antagonistic", "peptides", "from", "multiple", "hexapeptide", "sub", "-", "libraries", "of", "the", "positional", "scanning", "synthetic", "peptide", "combinatorial", "library", "(", "PS", "-", "SPCL", ")", ".", "The", "integrin", "alpha5beta1-Fibronectin", "interaction", "was", "demonstrated", "on", "the", "chip", ".", "A", "novel", "peptide", "ligand", ",", "A5", "-", "1", "(", "VILVLF", ")", ",", "with", "high", "affinity", "to", "integrin", "alpha5beta1", "was", "identified", "from", "the", "hexapeptide", "libraries", "with", "this", "chip", "-", "based", "screening", "method", "on", "the", "basis", "of", "a", "competitive", "inhibition", "assay", ".", "A5", "-", "1", "inhibits", "the", "integrin", "-", "fibronectin", "interaction", "in", "a", "dose", "-", "dependent", "manner", "(", "IC(50", ")", ";", "1.56+/-0.28", "microM.", "In", "addition", ",", "it", "inhibits", "human", "umbilical", "vein", "endothelial", "cell", "proliferation", ",", "migration", ",", "adhesion", ",", "tubular", "network", "formation", ",", "and", "bFGF", "-", "induced", "neovascularization", "in", "a", "chick", "chorioallantoic", "membrane", ".", "These", "results", "suggest", "that", "A5", "-", "1", "will", "be", "a", "potent", "inhibitor", "of", "neovascularization", ".", "\n" ]

[ "Cell", "Multi-tissue_structure", "Gene_or_gene_product", "Organism" ]

integrin alpha5beta1 is a Gene_or_gene_product, A5 - 1 is a Gene_or_gene_product, Integrin alpha5beta1 is a Gene_or_gene_product, A5 - 1 is a Gene_or_gene_product, VILVLF is a Gene_or_gene_product, integrin alpha5beta1 is a Gene_or_gene_product, A5 - 1 is a Gene_or_gene_product, integrin is a Gene_or_gene_product, fibronectin is a Gene_or_gene_product, human umbilical vein endothelial cell is a Cell, tubular network is a Multi-tissue_structure, bFGF is a Gene_or_gene_product, chick is a Organism, chorioallantoic membrane is a Multi-tissue_structure, A5 - 1 is a Gene_or_gene_product

284_task1

Sentence: A novel integrin alpha5beta1 antagonistic peptide, A5-1, screened by Protein Chip system as a potent angiogenesis inhibitor. Integrin alpha5beta1 immobilized on a ProteoChip was used to screen new antagonistic peptides from multiple hexapeptide sub-libraries of the positional scanning synthetic peptide combinatorial library (PS-SPCL). The integrin alpha5beta1-Fibronectin interaction was demonstrated on the chip. A novel peptide ligand, A5-1 (VILVLF), with high affinity to integrin alpha5beta1 was identified from the hexapeptide libraries with this chip-based screening method on the basis of a competitive inhibition assay. A5-1 inhibits the integrin-fibronectin interaction in a dose-dependent manner (IC(50); 1.56+/-0.28 microM. In addition, it inhibits human umbilical vein endothelial cell proliferation, migration, adhesion, tubular network formation, and bFGF-induced neovascularization in a chick chorioallantoic membrane. These results suggest that A5-1 will be a potent inhibitor of neovascularization. Instructions: please typing these entity words according to sentence: integrin alpha5beta1, A5 - 1, Integrin alpha5beta1, A5 - 1, VILVLF, integrin alpha5beta1, A5 - 1, integrin, fibronectin, human umbilical vein endothelial cell, tubular network, bFGF, chick, chorioallantoic membrane, A5 - 1 Options: Multi-tissue_structure, Organism, Gene_or_gene_product, Cell

[ "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Organism", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A novel integrin alpha5beta1 antagonistic peptide, A5-1, screened by Protein Chip system as a potent angiogenesis inhibitor. Integrin alpha5beta1 immobilized on a ProteoChip was used to screen new antagonistic peptides from multiple hexapeptide sub-libraries of the positional scanning synthetic peptide combinatorial library (PS-SPCL). The integrin alpha5beta1-Fibronectin interaction was demonstrated on the chip. A novel peptide ligand, A5-1 (VILVLF), with high affinity to integrin alpha5beta1 was identified from the hexapeptide libraries with this chip-based screening method on the basis of a competitive inhibition assay. A5-1 inhibits the integrin-fibronectin interaction in a dose-dependent manner (IC(50); 1.56+/-0.28 microM. In addition, it inhibits human umbilical vein endothelial cell proliferation, migration, adhesion, tubular network formation, and bFGF-induced neovascularization in a chick chorioallantoic membrane. These results suggest that A5-1 will be a potent inhibitor of neovascularization.

[ "A", "novel", "integrin", "alpha5beta1", "antagonistic", "peptide", ",", "A5", "-", "1", ",", "screened", "by", "Protein", "Chip", "system", "as", "a", "potent", "angiogenesis", "inhibitor", ".", "\n", "Integrin", "alpha5beta1", "immobilized", "on", "a", "ProteoChip", "was", "used", "to", "screen", "new", "antagonistic", "peptides", "from", "multiple", "hexapeptide", "sub", "-", "libraries", "of", "the", "positional", "scanning", "synthetic", "peptide", "combinatorial", "library", "(", "PS", "-", "SPCL", ")", ".", "The", "integrin", "alpha5beta1-Fibronectin", "interaction", "was", "demonstrated", "on", "the", "chip", ".", "A", "novel", "peptide", "ligand", ",", "A5", "-", "1", "(", "VILVLF", ")", ",", "with", "high", "affinity", "to", "integrin", "alpha5beta1", "was", "identified", "from", "the", "hexapeptide", "libraries", "with", "this", "chip", "-", "based", "screening", "method", "on", "the", "basis", "of", "a", "competitive", "inhibition", "assay", ".", "A5", "-", "1", "inhibits", "the", "integrin", "-", "fibronectin", "interaction", "in", "a", "dose", "-", "dependent", "manner", "(", "IC(50", ")", ";", "1.56+/-0.28", "microM.", "In", "addition", ",", "it", "inhibits", "human", "umbilical", "vein", "endothelial", "cell", "proliferation", ",", "migration", ",", "adhesion", ",", "tubular", "network", "formation", ",", "and", "bFGF", "-", "induced", "neovascularization", "in", "a", "chick", "chorioallantoic", "membrane", ".", "These", "results", "suggest", "that", "A5", "-", "1", "will", "be", "a", "potent", "inhibitor", "of", "neovascularization", ".", "\n" ]

[ "Cell", "Multi-tissue_structure", "Gene_or_gene_product", "Organism" ]

integrin alpha5beta1, A5 - 1, Integrin alpha5beta1, A5 - 1, VILVLF, integrin alpha5beta1, A5 - 1, integrin, fibronectin, human umbilical vein endothelial cell, tubular network, bFGF, chick, chorioallantoic membrane, A5 - 1

284_task2

Sentence: A novel integrin alpha5beta1 antagonistic peptide, A5-1, screened by Protein Chip system as a potent angiogenesis inhibitor. Integrin alpha5beta1 immobilized on a ProteoChip was used to screen new antagonistic peptides from multiple hexapeptide sub-libraries of the positional scanning synthetic peptide combinatorial library (PS-SPCL). The integrin alpha5beta1-Fibronectin interaction was demonstrated on the chip. A novel peptide ligand, A5-1 (VILVLF), with high affinity to integrin alpha5beta1 was identified from the hexapeptide libraries with this chip-based screening method on the basis of a competitive inhibition assay. A5-1 inhibits the integrin-fibronectin interaction in a dose-dependent manner (IC(50); 1.56+/-0.28 microM. In addition, it inhibits human umbilical vein endothelial cell proliferation, migration, adhesion, tubular network formation, and bFGF-induced neovascularization in a chick chorioallantoic membrane. These results suggest that A5-1 will be a potent inhibitor of neovascularization. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Organism", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A novel integrin alpha5beta1 antagonistic peptide, A5-1, screened by Protein Chip system as a potent angiogenesis inhibitor. Integrin alpha5beta1 immobilized on a ProteoChip was used to screen new antagonistic peptides from multiple hexapeptide sub-libraries of the positional scanning synthetic peptide combinatorial library (PS-SPCL). The integrin alpha5beta1-Fibronectin interaction was demonstrated on the chip. A novel peptide ligand, A5-1 (VILVLF), with high affinity to integrin alpha5beta1 was identified from the hexapeptide libraries with this chip-based screening method on the basis of a competitive inhibition assay. A5-1 inhibits the integrin-fibronectin interaction in a dose-dependent manner (IC(50); 1.56+/-0.28 microM. In addition, it inhibits human umbilical vein endothelial cell proliferation, migration, adhesion, tubular network formation, and bFGF-induced neovascularization in a chick chorioallantoic membrane. These results suggest that A5-1 will be a potent inhibitor of neovascularization.

[ "A", "novel", "integrin", "alpha5beta1", "antagonistic", "peptide", ",", "A5", "-", "1", ",", "screened", "by", "Protein", "Chip", "system", "as", "a", "potent", "angiogenesis", "inhibitor", ".", "\n", "Integrin", "alpha5beta1", "immobilized", "on", "a", "ProteoChip", "was", "used", "to", "screen", "new", "antagonistic", "peptides", "from", "multiple", "hexapeptide", "sub", "-", "libraries", "of", "the", "positional", "scanning", "synthetic", "peptide", "combinatorial", "library", "(", "PS", "-", "SPCL", ")", ".", "The", "integrin", "alpha5beta1-Fibronectin", "interaction", "was", "demonstrated", "on", "the", "chip", ".", "A", "novel", "peptide", "ligand", ",", "A5", "-", "1", "(", "VILVLF", ")", ",", "with", "high", "affinity", "to", "integrin", "alpha5beta1", "was", "identified", "from", "the", "hexapeptide", "libraries", "with", "this", "chip", "-", "based", "screening", "method", "on", "the", "basis", "of", "a", "competitive", "inhibition", "assay", ".", "A5", "-", "1", "inhibits", "the", "integrin", "-", "fibronectin", "interaction", "in", "a", "dose", "-", "dependent", "manner", "(", "IC(50", ")", ";", "1.56+/-0.28", "microM.", "In", "addition", ",", "it", "inhibits", "human", "umbilical", "vein", "endothelial", "cell", "proliferation", ",", "migration", ",", "adhesion", ",", "tubular", "network", "formation", ",", "and", "bFGF", "-", "induced", "neovascularization", "in", "a", "chick", "chorioallantoic", "membrane", ".", "These", "results", "suggest", "that", "A5", "-", "1", "will", "be", "a", "potent", "inhibitor", "of", "neovascularization", ".", "\n" ]

[ "Cell", "Multi-tissue_structure", "Gene_or_gene_product", "Organism" ]

monoamine oxidase type A is a GENE-Y

10027835_task0

Sentence: Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y

[ "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.

[ "Inhibition", "of", "monoamine", "oxidase", "type", "A", ",", "but", "not", "type", "B", ",", "is", "an", "effective", "means", "of", "inducing", "anticonvulsant", "activity", "in", "the", "kindling", "model", "of", "epilepsy", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

monoamine oxidase type A is a GENE-Y

10027835_task1

Sentence: Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. Instructions: please typing these entity words according to sentence: monoamine oxidase type A Options: GENE-Y

[ "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.

[ "Inhibition", "of", "monoamine", "oxidase", "type", "A", ",", "but", "not", "type", "B", ",", "is", "an", "effective", "means", "of", "inducing", "anticonvulsant", "activity", "in", "the", "kindling", "model", "of", "epilepsy", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

monoamine oxidase type A

10027835_task2

Sentence: Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.

[ "Inhibition", "of", "monoamine", "oxidase", "type", "A", ",", "but", "not", "type", "B", ",", "is", "an", "effective", "means", "of", "inducing", "anticonvulsant", "activity", "in", "the", "kindling", "model", "of", "epilepsy", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

Fallberichten is an umlsterm, Therapie is an umlsterm, Harnleiterobstruktion is an umlsterm, Harnleiterschiene is an umlsterm, Harnleiters is an umlsterm, Nierenbeckenkelchsystems is an umlsterm, Technik is an umlsterm, Urinfluss is an umlsterm, Urinpassage is an umlsterm, Harnleiterschienen is an umlsterm, Harnleiterkompression is an umlsterm, Schiene is an umlsterm, Therapiealternative is an umlsterm, Patienten is an umlsterm

DerUrologeA.90380150.ger.abstr_task0

Sentence: Anhand von 5 Fallberichten wird ueber die Therapie der extrinsischen Harnleiterobstruktion durch die Einlage von 2 ipsilateralen inneren Doppel-J-Harnleiterschienen berichtet , nachdem die Einlage einer singulaeren inneren Harnleiterschiene trotz korrekter Lage zu keiner suffizienten Entstauung des Harnleiters und Nierenbeckenkelchsystems gefuehrt hatte . Durch die erhoehte Festigkeit von 2 parallelen inneren Schienen konnten Obstruktion und Kinking vermindert und eine Rueckbildung der Stauung des proximalen Hohlsystems erzielt werden . Ferner ermoeglicht diese Technik neben dem Urinfluss innerhalb der Schienen einen vermehrten Fluss zwischen den Schienen , der als entscheidender Mechanismus der Urinpassage bei liegenden Harnleiterschienen angesehen wird . In Faellen extrinsischer Harnleiterkompression , in denen durch die Einlage einer singulaeren inneren Schiene keine suffiziente Rueckbildung der Ektasie des vorgeschalteten intra- und extrarenalen Hohlraumsystems erreicht werden kann , sollte die simultane Einlage von 2 ipsilateralen inneren Doppel-J-Harnleiterschienen als technisch einfache , komplikationsarme Therapiealternative in Betracht gezogen werden , die einigen Patienten die Einlage eines perkutanen Nephrostomiekatheters oder invasivere Massnahmen ersparen kann . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anhand von 5 Fallberichten wird ueber die Therapie der extrinsischen Harnleiterobstruktion durch die Einlage von 2 ipsilateralen inneren Doppel-J-Harnleiterschienen berichtet , nachdem die Einlage einer singulaeren inneren Harnleiterschiene trotz korrekter Lage zu keiner suffizienten Entstauung des Harnleiters und Nierenbeckenkelchsystems gefuehrt hatte . Durch die erhoehte Festigkeit von 2 parallelen inneren Schienen konnten Obstruktion und Kinking vermindert und eine Rueckbildung der Stauung des proximalen Hohlsystems erzielt werden . Ferner ermoeglicht diese Technik neben dem Urinfluss innerhalb der Schienen einen vermehrten Fluss zwischen den Schienen , der als entscheidender Mechanismus der Urinpassage bei liegenden Harnleiterschienen angesehen wird . In Faellen extrinsischer Harnleiterkompression , in denen durch die Einlage einer singulaeren inneren Schiene keine suffiziente Rueckbildung der Ektasie des vorgeschalteten intra- und extrarenalen Hohlraumsystems erreicht werden kann , sollte die simultane Einlage von 2 ipsilateralen inneren Doppel-J-Harnleiterschienen als technisch einfache , komplikationsarme Therapiealternative in Betracht gezogen werden , die einigen Patienten die Einlage eines perkutanen Nephrostomiekatheters oder invasivere Massnahmen ersparen kann .

[ "Anhand", "von", "5", "Fallberichten", "wird", "ueber", "die", "Therapie", "der", "extrinsischen", "Harnleiterobstruktion", "durch", "die", "Einlage", "von", "2", "ipsilateralen", "inneren", "Doppel", "-", "J", "-", "Harnleiterschienen", "berichtet", ",", "nachdem", "die", "Einlage", "einer", "singulaeren", "inneren", "Harnleiterschiene", "trotz", "korrekter", "Lage", "zu", "keiner", "suffizienten", "Entstauung", "des", "Harnleiters", "und", "Nierenbeckenkelchsystems", "gefuehrt", "hatte", ".", "Durch", "die", "erhoehte", "Festigkeit", "von", "2", "parallelen", "inneren", "Schienen", "konnten", "Obstruktion", "und", "Kinking", "vermindert", "und", "eine", "Rueckbildung", "der", "Stauung", "des", "proximalen", "Hohlsystems", "erzielt", "werden", ".", "Ferner", "ermoeglicht", "diese", "Technik", "neben", "dem", "Urinfluss", "innerhalb", "der", "Schienen", "einen", "vermehrten", "Fluss", "zwischen", "den", "Schienen", ",", "der", "als", "entscheidender", "Mechanismus", "der", "Urinpassage", "bei", "liegenden", "Harnleiterschienen", "angesehen", "wird", ".", "In", "Faellen", "extrinsischer", "Harnleiterkompression", ",", "in", "denen", "durch", "die", "Einlage", "einer", "singulaeren", "inneren", "Schiene", "keine", "suffiziente", "Rueckbildung", "der", "Ektasie", "des", "vorgeschalteten", "intra-", "und", "extrarenalen", "Hohlraumsystems", "erreicht", "werden", "kann", ",", "sollte", "die", "simultane", "Einlage", "von", "2", "ipsilateralen", "inneren", "Doppel", "-", "J", "-", "Harnleiterschienen", "als", "technisch", "einfache", ",", "komplikationsarme", "Therapiealternative", "in", "Betracht", "gezogen", "werden", ",", "die", "einigen", "Patienten", "die", "Einlage", "eines", "perkutanen", "Nephrostomiekatheters", "oder", "invasivere", "Massnahmen", "ersparen", "kann", "." ]

[ "umlsterm" ]

Fallberichten is an umlsterm, Therapie is an umlsterm, Harnleiterobstruktion is an umlsterm, Harnleiterschiene is an umlsterm, Harnleiters is an umlsterm, Nierenbeckenkelchsystems is an umlsterm, Technik is an umlsterm, Urinfluss is an umlsterm, Urinpassage is an umlsterm, Harnleiterschienen is an umlsterm, Harnleiterkompression is an umlsterm, Schiene is an umlsterm, Therapiealternative is an umlsterm, Patienten is an umlsterm

DerUrologeA.90380150.ger.abstr_task1

Sentence: Anhand von 5 Fallberichten wird ueber die Therapie der extrinsischen Harnleiterobstruktion durch die Einlage von 2 ipsilateralen inneren Doppel-J-Harnleiterschienen berichtet , nachdem die Einlage einer singulaeren inneren Harnleiterschiene trotz korrekter Lage zu keiner suffizienten Entstauung des Harnleiters und Nierenbeckenkelchsystems gefuehrt hatte . Durch die erhoehte Festigkeit von 2 parallelen inneren Schienen konnten Obstruktion und Kinking vermindert und eine Rueckbildung der Stauung des proximalen Hohlsystems erzielt werden . Ferner ermoeglicht diese Technik neben dem Urinfluss innerhalb der Schienen einen vermehrten Fluss zwischen den Schienen , der als entscheidender Mechanismus der Urinpassage bei liegenden Harnleiterschienen angesehen wird . In Faellen extrinsischer Harnleiterkompression , in denen durch die Einlage einer singulaeren inneren Schiene keine suffiziente Rueckbildung der Ektasie des vorgeschalteten intra- und extrarenalen Hohlraumsystems erreicht werden kann , sollte die simultane Einlage von 2 ipsilateralen inneren Doppel-J-Harnleiterschienen als technisch einfache , komplikationsarme Therapiealternative in Betracht gezogen werden , die einigen Patienten die Einlage eines perkutanen Nephrostomiekatheters oder invasivere Massnahmen ersparen kann . Instructions: please typing these entity words according to sentence: Fallberichten, Therapie, Harnleiterobstruktion, Harnleiterschiene, Harnleiters, Nierenbeckenkelchsystems, Technik, Urinfluss, Urinpassage, Harnleiterschienen, Harnleiterkompression, Schiene, Therapiealternative, Patienten Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anhand von 5 Fallberichten wird ueber die Therapie der extrinsischen Harnleiterobstruktion durch die Einlage von 2 ipsilateralen inneren Doppel-J-Harnleiterschienen berichtet , nachdem die Einlage einer singulaeren inneren Harnleiterschiene trotz korrekter Lage zu keiner suffizienten Entstauung des Harnleiters und Nierenbeckenkelchsystems gefuehrt hatte . Durch die erhoehte Festigkeit von 2 parallelen inneren Schienen konnten Obstruktion und Kinking vermindert und eine Rueckbildung der Stauung des proximalen Hohlsystems erzielt werden . Ferner ermoeglicht diese Technik neben dem Urinfluss innerhalb der Schienen einen vermehrten Fluss zwischen den Schienen , der als entscheidender Mechanismus der Urinpassage bei liegenden Harnleiterschienen angesehen wird . In Faellen extrinsischer Harnleiterkompression , in denen durch die Einlage einer singulaeren inneren Schiene keine suffiziente Rueckbildung der Ektasie des vorgeschalteten intra- und extrarenalen Hohlraumsystems erreicht werden kann , sollte die simultane Einlage von 2 ipsilateralen inneren Doppel-J-Harnleiterschienen als technisch einfache , komplikationsarme Therapiealternative in Betracht gezogen werden , die einigen Patienten die Einlage eines perkutanen Nephrostomiekatheters oder invasivere Massnahmen ersparen kann .

[ "Anhand", "von", "5", "Fallberichten", "wird", "ueber", "die", "Therapie", "der", "extrinsischen", "Harnleiterobstruktion", "durch", "die", "Einlage", "von", "2", "ipsilateralen", "inneren", "Doppel", "-", "J", "-", "Harnleiterschienen", "berichtet", ",", "nachdem", "die", "Einlage", "einer", "singulaeren", "inneren", "Harnleiterschiene", "trotz", "korrekter", "Lage", "zu", "keiner", "suffizienten", "Entstauung", "des", "Harnleiters", "und", "Nierenbeckenkelchsystems", "gefuehrt", "hatte", ".", "Durch", "die", "erhoehte", "Festigkeit", "von", "2", "parallelen", "inneren", "Schienen", "konnten", "Obstruktion", "und", "Kinking", "vermindert", "und", "eine", "Rueckbildung", "der", "Stauung", "des", "proximalen", "Hohlsystems", "erzielt", "werden", ".", "Ferner", "ermoeglicht", "diese", "Technik", "neben", "dem", "Urinfluss", "innerhalb", "der", "Schienen", "einen", "vermehrten", "Fluss", "zwischen", "den", "Schienen", ",", "der", "als", "entscheidender", "Mechanismus", "der", "Urinpassage", "bei", "liegenden", "Harnleiterschienen", "angesehen", "wird", ".", "In", "Faellen", "extrinsischer", "Harnleiterkompression", ",", "in", "denen", "durch", "die", "Einlage", "einer", "singulaeren", "inneren", "Schiene", "keine", "suffiziente", "Rueckbildung", "der", "Ektasie", "des", "vorgeschalteten", "intra-", "und", "extrarenalen", "Hohlraumsystems", "erreicht", "werden", "kann", ",", "sollte", "die", "simultane", "Einlage", "von", "2", "ipsilateralen", "inneren", "Doppel", "-", "J", "-", "Harnleiterschienen", "als", "technisch", "einfache", ",", "komplikationsarme", "Therapiealternative", "in", "Betracht", "gezogen", "werden", ",", "die", "einigen", "Patienten", "die", "Einlage", "eines", "perkutanen", "Nephrostomiekatheters", "oder", "invasivere", "Massnahmen", "ersparen", "kann", "." ]

[ "umlsterm" ]